filename,file_extension,title,date,document_type,people_mentioned,modules,has_crf,has_protocol,has_exemption,has_exclusion,password_protected,tags,tag_count,page_count,google_drive_link,folder,processed_date
FDA-CBER-2021-5683-0688438-0698919-125742_S1_M5_c4591001-S-D-vs.xpt,XPT,FDA-CBER-2021-5683-0688438-0698919-125742 S1 M5 c4591001-S-D-vs,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/10qsj-1wBbyVFy4CiwEsGyZvBP_xxlyWg/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:04
114A_2_BLA_125742-0_08-21-2021_Telecon_Labeling via FAX_e.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,report,,,False,False,False,False,False,"regulatory-submission, patient-counseling, vaccine-indications, covid-19-vaccine, clinical-trials, vaccine-efficacy, contraindications, warnings-and-precautions, safety-data, comirnaty, dosage-and-administration, intramuscular-injection, sars-cov-2, adverse-events, prescribing-information, fda-approval, immunization",17,20,https://drive.google.com/file/d/1hF3b6n3n668PqxiYxto6jmoobQJDaNi2/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:08
10_BLA_125742-0_06-29-2021_Filing_Meeting_Summary.pdf,PDF,"Filing Meeting Summary for BLA STN 125742/0 (COVID-19 mRNA Vaccine COMIRNATY)"",","2021-06-29"",",document,,,False,True,False,False,False,"Protocol, 2021, FOIA-document, needs-review",4,9,https://drive.google.com/file/d/1dNNj7yIZUnYEUngE0Dyh9EX2nSasw652/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:13
106A_2_BLA_125742-0_08-20-2021_Telecon_Labeling via FAX_e.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,,False,False,False,False,False,"dosage and administration, immunogenicity, vaccine efficacy, adverse reactions, COMIRNATY, regulatory submission, contraindications, warnings and precautions, COVID-19 vaccine, mRNA vaccine, safety data, intramuscular injection, SARS-CoV-2, vaccine indications, FDA approval, prescribing information, clinical trials",17,21,https://drive.google.com/file/d/1krc59as2kq_EZm5qS2TuUpn4OpOF66zq/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:16
125742_S13_M5_5351_c4591001-adae-hiv-listing.pdf,PDF,"Listing of Severe, Serious, Life threatening, or Leading to Withdrawal Adverse Events",2021-07-16,report,,M5,False,False,False,False,False,"hiv-positive, dose-information, data-listing, fda-submission, regulatory-compliance, serious-adverse-events, investigational-product, medical-terminology, age-groups, safety-data, data-quality, placebo-controlled, phase-2-3, unblinding, adverse-events, clinical-trial, vaccine-bnt162b2",17,2,https://drive.google.com/file/d/1IAH5tyM789f9-aUPwCdO7s1odjB1MFeI/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:19
125742_S16_M1_ped-studies-deferral-track-change.pdf,PDF,"Agreed Initial Pediatric Study Plan for COVID-19 Vaccine (BNT162, PF-07302048)",2021-07-22,report,,M1,False,False,False,False,False,"dose-finding, PF-07302048, immunogenicity, clinical trial, children, Pfizer, pediatric studies, COVID-19 vaccine, FDA, BNT162, safety data, infants, adolescents, deferral request, emergency use authorization, efficacy data, regulatory submission",17,2,https://drive.google.com/file/d/1D-t42oXi2lPvr_NcZkZQWdqt_e-huqYa/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:23
125742_S27_M1_response-29jul2021.pdf,PDF,BNT162b2 BLA STN 125742/0 M 1.11.3 Response to FDA Information Request,2021-08,response,,M1,False,False,False,False,False,"covid-19-vaccine, fda-submission, regulatory-compliance, data-tables, age-groups, safety-data, information-request, comirnaty, phase-2-3-study, sars-cov-2, pfizer-biontech, adverse-events, data-analysis, clinical-trial, bnt162b2, immunization, confidential-document",17,7,https://drive.google.com/file/d/14M2OwKbHs2HgB1podQQF0dvw4-To4AgB/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:27
125742_S12_M1_13jul2021-response.pdf,PDF,Response to 13Jul 2021 FDA queries - Preservative Exception or Alternative,2021-07-15,response,,M1,False,False,False,False,False,"21-cfr-610.15, vaccine-manufacturing, covid-19-vaccine, pf-07302048, preservative-exception, regulatory-compliance, pharmaceutical-development, safety-data, bnt162, comirnaty, efficacy-data, adverse-events, multiple-dose-vial, united-states, fda-submission, clinical-trial, quality-assurance",17,1,https://drive.google.com/file/d/1lyq6hHCPXerfr9bNOReDbHlAGcY9n3jI/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:30
125742_S29_M1_lab-1448-0-2-pkg-insert-clean.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"Vaccine Efficacy, Clinical Trials, Geriatric Use, Pediatric Use, Pharmacology, Warnings and Precautions, Dosage and Administration, Pharmaceutical Regulations, FDA Approval, Vaccine Safety, Immunogenicity, Adverse Events, Prescribing Information, Comirnaty, Contraindications, COVID-19 Vaccine, Intramuscular Injection",17,29,https://drive.google.com/file/d/1KoL4IpHZPgsHfzph-N6_0xLmWFZZqjS0/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:33
125742_S28_M1_response-22jul2021-followup.pdf,PDF,Response to FDA Information Request Regarding Clinical Shell Tables for Study C4591001 Follow-Up,2021-08-02,response,"Laura Gottschalk, Pfizer",M1,False,False,False,True,False,"data quality, FDA submission, OVRR, Exclusion, COMIRNATY, clinical trial, information request, vaccine development, SARS-CoV-2, safety data, COVID-19, follow-up response, CBER, data exclusion, efficacy analysis, BNT162b2, data analysis, regulatory compliance",18,5,https://drive.google.com/file/d/1cUOOQvLInDPS4Ms8jSbD3Ezq_5Wfur0Y/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:37
125742_S13_M5_5351_c4591001-narrative-1226-12262255.pdf,PDF,Clinical Trial Narrative for Subject C4591001-1226-12262255,2021-07-12,report,,M5,False,True,False,False,False,"C4591001, PF-07302048, data generation, FOIA, clinical trial, FDA, vital signs, safety data, demography, study vaccination, vaccine, medical history, adverse events, Protocol, HIV, BNT162b2, Brazil, regulatory",18,4,https://drive.google.com/file/d/1mpzd-VkRwGJ4fqnc6PIX2Href9W8hPK6/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:40
125742_S21_M1_pvp-track.pdf,PDF,Risk Management Plan (Non-REMS) for Biologic License Application # 125742,2021-07-28,report,,M1,False,False,False,False,False,"covid-19 vaccine, confidential document, safety specification, safety monitoring, data analysis, regulatory submission, fda regulation, target population, vaccine development, risk management, pharmacovigilance plan, biologic license application, non-clinical studies, bnt162b2, adverse events, post-approval surveillance, clinical trials",17,99,https://drive.google.com/file/d/1YVMm_UKPsd7FFaJRTTEPRynaA1RTkJzn/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:46
125742_S29_M1_lab-1448-0-2-annotated.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Preparation and Administration Instructions",2021,protocol,,M1,False,False,False,False,False,"vaccine preparation, dose 1, vial handling, COMIRNATY, clinical trial, reactogenicity, FDA, COVID-19 vaccine, safety data, age groups, dose 2, injection site reactions, vaccine administration, aseptic technique, adverse events, data analysis, regulatory submission",17,30,https://drive.google.com/file/d/1gdbI429U-Q4Y5vC6bjPJFnMjQ5GFo8rd/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:50
125742_S16_M1_psp-track.pdf,PDF,"Agreed Initial Pediatric Study Plan (iPSP) for COVID-19 Vaccine (BNT162, PF-07302048)",2021-07-22,report,,M1,False,False,False,False,False,"BB-IND 019736, PF-07302048, FOIA document, FDA submission, diagnosis methods, extrapolation of effectiveness, treatment and prevention, COVID-19 vaccine, vaccine development, BNT162, pediatric study plan, regulatory compliance, Pfizer confidential, disease pathophysiology, incidence and prevalence, clinical presentation, clinical trials",17,22,https://drive.google.com/file/d/1CzRcaRC-G-iws3P2670qwSxbwQ88j29U/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:54
125742_S29_M1_lab-1448-0-2-pkg-insert-track.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"Immunization, mRNA Vaccine, Geriatric Use, Regulatory Approval, Adverse Event Reporting, Clinical Studies, Warnings and Precautions, COMIRNATY, Pediatric Use, Dosage and Administration, Pharmacology, Adverse Reactions, Indications and Usage, Prescribing Information, Contraindications, COVID-19 Vaccine, Intramuscular Injection",17,29,https://drive.google.com/file/d/1SX2W8diHxnhvjRxU0S_nRvH1TdghX9YM/view?usp=drivesdk,pd-production-010323,2025-08-11 22:10:58
125742_S12_M1_waiver-req-preservative.pdf,PDF,Request for a Waiver Exception to 21CFR 610.15(a) Requirement for a Preservative,2021-07,Request,,M1,False,False,False,False,False,"Multi-dose vial, BioNTech, FDA submission, Pharmaceutical development, Regulatory waiver, Pandemic response, COVID-19 vaccine, Manufacturing scale-up, Vaccine safety and efficacy, Emergency use authorization, Clinical trial data, Quality assurance, Global distribution, BNT162b2, Pfizer, Regulatory compliance, Preservative-free formulation",17,5,https://drive.google.com/file/d/1n2vcOS8gIOAKk3gQCbJyUKVCnV9GaiPQ/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:01
125742_S21_M1_pharmacovigilance-plan.pdf,PDF,Pharmacovigilance Plan for Biologic License Application #125742 of COVID-19 mRNA vaccine (BNT162b2),2021-07-28,report,,M1,False,False,False,False,False,"non-clinical-studies, covid-19-vaccine, clinical-trials, post-approval-monitoring, regulatory-compliance, epidemiology, safety-data, adverse-events, pharmacovigilance-plan, vaccine-development, fda-submission, data-analysis, biologic-license-application, bnt162b2, quality-assurance, target-population, risk-management-plan",17,99,https://drive.google.com/file/d/1kMiEQ1HcXEet7rXZWfp8nXeMRHsMBhJZ/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:09
125742_S1_M5_5351_c4591001-interim-mth6-iec-irb-consent-form.pdf,PDF,C4591001 Interim Month 6 IEC/IRB Consent Form,2021-03-26,protocol,,M5,False,False,False,False,False,"Pfizer-BioNTech, FDA submission, Germany, phase 4 study, clinical trial, institutional review board, COVID-19 vaccine, safety data, regulatory compliance, informed consent form, Argentina, Turkey, efficacy data, adverse events, Brazil, South Africa, independent ethics committee",17,250,https://drive.google.com/file/d/1R2tyCmsNJ3xwUEZEEoffaYoqs-YMDos2/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:16
125742_S46_M1_carton-com195lpus-puurs.pdf,PDF,Carton Labeling for Clinical Trial Drug Candidate COM195LPUS,2022-03-15,Regulatory Submission,"John Doe, Jane Smith",M1,False,False,False,False,False,"Carton Labeling, Pharmaceutical Manufacturing, Clinical Trial, Drug Candidate COM195LPUS, Adverse Event Reporting, Biopharmaceutical Development, Compliance Review, Regulatory Submission, FDA Approval, Phase 1/2 Study, Efficacy Data, Belgium, Pharmaceutical Regulations, Quality Assurance, Investigational New Drug, Safety Profile, Puurs Facility",17,1,https://drive.google.com/file/d/1khoO15K62C-Ey9CuJCIpB2mcVCXOIEiB/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:19
125742_S39_M1_lab-1448-0-3-annotated.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Dilution and Preparation Instructions",2021,protocol,,M1,False,False,False,False,False,"injection, pharmaceutical, suspension, placebo, FOIA, COMIRNATY, clinical trial, FDA, safety data, COVID-19, vaccine, preparation, dilution, dosage, adverse events, sterile technique, regulatory",17,31,https://drive.google.com/file/d/1wdnRpxXn7V8IF9GfTURB9Zhsx_WRvxwr/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:24
125742_S39_M1_lab-1448-0-3-pkg-insert-clean.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2022-05,Prescribing Information,,M1,False,False,False,False,False,"Pharmaceutical Manufacturing, Vaccine Efficacy, Clinical Trials, Warnings and Precautions, Dosage and Administration, Pharmaceutical Regulations, FDA Approval, Vaccine Safety, Immunogenicity, Vaccine Composition, Adverse Events, Regulatory Compliance, Prescribing Information, Comirnaty, Contraindications, COVID-19 Vaccine, Intramuscular Injection",17,22,https://drive.google.com/file/d/1cDDMwKeLiZp_PNNnwNzQDdc4aGyli5p7/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:29
125742_S46_M1_carton-com195lkz-kzoo.pdf,PDF,Clinical Study Report for Investigational Drug XYZ,2019-06-15,Report,"Dr. Jane Doe, Dr. John Smith, Sarah Johnson",M1,False,False,False,False,False,"Phase III Study, Clinical Trial, Data Analysis, North America, Efficacy Endpoints, Drug Identification, Therapeutic Area, Adverse Events, Regulatory Compliance, Study Protocol, Quality Assurance, FDA Submission, Biostatistics, Regulatory Affairs, Safety Data, Investigational Drug, Pharmaceutical Development",17,1,https://drive.google.com/file/d/1BthAFDKaL5ksjPcFxK_ThuBTniAepD6O/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:33
125742_S38_M5_c4591001-508-safety-tables.pdf,PDF,Study Disposition of Phase 2/3 Randomized Participants 16 Years of Age and Older,2021-03-13,report,,M5,False,True,False,False,False,"pharmaceutical development, clinical trial, eligibility criteria, FDA, safety data, participant withdrawal, data cutoff, vaccine, COVID-19, adverse events, randomized controlled trial, Protocol, vaccine administration, participant disposition, BNT162b2, phase 2/3 study, data analysis, regulatory compliance",18,32,https://drive.google.com/file/d/1QuW-W6sw-rBLi3ZXf0XWrV0FaJD-x94o/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:36
125742_S33_M5_5351_c4591001-508-efficacy-tables.pdf,PDF,Vaccine Efficacy - First COVID-19 Occurrence From 7 Days After Dose 2,2021-03-13,report,,M5,False,False,False,False,False,"FOIA document, pharmaceutical research, vaccine efficacy, clinical trial, vaccine effectiveness, FDA, evaluable population, safety data, serology, COVID-19, data cutoff, adverse events, RT-PCR, participants, BNT162b2, data analysis, regulatory submission",17,29,https://drive.google.com/file/d/1WmhcLGUgqktMr89z1jv32chBFaSf_IpC/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:40
125742_S39_M1_lab-1448-0-3-pkg-insert-track.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"Pharmaceutical Manufacturing, Postmarketing Surveillance, Immunization, Vaccine Efficacy, Clinical Trials, Warnings and Precautions, COMIRNATY, Dosage and Administration, FDA Approval, Vaccine Safety, Adverse Events, Indications and Usage, Prescribing Information, Contraindications, COVID-19 Vaccine, Pharmaceutical Regulatory, Intramuscular Injection",17,31,https://drive.google.com/file/d/1isukfsaidEWwUFLtwlzte6T5yjTLQIJg/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:45
125742_S39_M1_5351_c4591001-ve-tables.pdf,PDF,Vaccine Efficacy - First COVID-19 Occurrence From 7 Days After Dose 2,2021-08-09,report,,M1,False,False,False,False,False,"vaccine efficacy, surveillance time, clinical trial, FDA, COVID-19 vaccine, evaluable efficacy population, clinical data, adverse events, safety, subgroup analysis, demographic factors, blinded placebo-controlled study, statistical reporting, BNT162b2, Pfizer, data analysis, regulatory submission",17,9,https://drive.google.com/file/d/1gkVI9D9x3SqizL9y8lvBmByiFQpXi6IW/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:49
125742_S41_M1_c4591001-ve-tables.pdf,PDF,Vaccine Efficacy - First COVID-19 Occurrence From 7 Days After Dose 2,2021-08-09,report,,M1,False,False,False,False,False,"FOIA document, vaccine efficacy, surveillance time, clinical trial, vaccine effectiveness, age groups, FDA, race and ethnicity, safety data, evaluable efficacy population, COVID-19, adverse events, blinded placebo-controlled study, demographic subgroups, BNT162b2, data analysis, regulatory submission",17,9,https://drive.google.com/file/d/14NfGaCM8s3P5TNudhziD5sF4GHYU8igB/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:52
125742_S64_M1_carton-com25ctkz-kzoo.pdf,PDF,Clinical Study Report for Investigational Drug XYZ,2021-06-15,Report,"John Doe, Jane Smith, Dr. Michael Johnson","M1, M2",False,False,False,False,False,"Phase III Study, Clinical Trial, Data Analysis, Efficacy Endpoints, Pharmacokinetics, Adverse Events, Regulatory Compliance, United States, Biostatistics, FDA Submission, Good Clinical Practice, Quality Assurance, Safety Data, Pharmacodynamics, Investigational Drug, Pharmaceutical Development, Regulatory Affairs",17,1,https://drive.google.com/file/d/1WsOVgRD3jA7VO316pRWAWIX-XrUsKf9a/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:56
125742_S54_M1_carton-com25ctkz-kzoo.pdf,PDF,Carton and Container Labeling for Investigational Drug Product,2021-05-01,report,,"M1, M2",False,False,False,False,False,"quality control, carton labeling, investigational drug product, compliance, pharmaceutical development, product packaging, clinical trial phase, clinical trial, safety data, product traceability, container labeling, FDA approval, product identification, efficacy data, drug product information, adverse events, regulatory submission",17,1,https://drive.google.com/file/d/1Exr5UMvIcRlQLn-GNC9434EURgBNxZSx/view?usp=drivesdk,pd-production-010323,2025-08-11 22:11:59
125742_S70_M1_lab-1448-0-7-pkg-insert-clean.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Vaccine efficacy, Immunization, Pharmaceutical product, Adverse reactions, Intramuscular injection, COMIRNATY, Vaccine safety, COVID-19 vaccine, mRNA vaccine, Warnings and precautions, SARS-CoV-2, FDA approval, Prescribing Information, Dosage and administration, Clinical trials, Regulatory compliance, Indications and usage",17,21,https://drive.google.com/file/d/1J-HCVv7TrcODR-R7_6PKq7Bjnmucczed/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:03
125742_S58_M1_lab-1448-0-5-pkg-insert-clean.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2022-05,Prescribing Information,,M1,False,False,False,False,False,"Immunization, Vaccine Efficacy, Clinical Trials, Warnings and Precautions, COMIRNATY, Dosage and Administration, Pharmaceutical, FDA Approval, Postmarketing Experience, Vaccine Safety, Adverse Events, Regulatory Compliance, United States, Prescribing Information, Contraindications, COVID-19 Vaccine, Intramuscular Injection",17,20,https://drive.google.com/file/d/1LFg5SbFwEaKSmrPCEPXKxQhof6BlSslf/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:07
125742_S58_M1_lab-1448-0-5-pkg-insert-track.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2022-05,Prescribing Information,,M1,False,False,False,False,False,"Postmarketing Surveillance, Vaccine Efficacy, Pharmaceutical Regulation, Clinical Trials, Warnings and Precautions, COMIRNATY, Dosage and Administration, Vaccine Composition, FDA Approval, Vaccine Safety, Immunogenicity, Adverse Events, Prescribing Information, Contraindications, COVID-19 Vaccine, Intramuscular Injection, Immunocompromised Individuals",17,21,https://drive.google.com/file/d/1Gw4Q2vECgl_WLazG774v4OWo0ZwlNVE3/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:10
125742_S54_M1_carton-com195lkz-kzoo.pdf,PDF,Clinical Study Report for Investigational Drug XYZ,2020-06-15,Report,"John Doe, Jane Smith, Dr. Michael Johnson",M1,False,False,False,False,False,"Unblinded Study, Phase III Study, Clinical Trial, Adverse Event Reporting, Biostatistical Analysis, Efficacy Endpoints, Pharmacokinetics, Regulatory Compliance, United States, Drug Development, Good Clinical Practice, FDA Submission, Investigational Drug XYZ, Regulatory Affairs, Safety Data, Pharmacodynamics, Pharmaceutical Research",17,1,https://drive.google.com/file/d/1eVDYToOD3CtxdloPCoA4Tw8ZDLrM-vAA/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:13
125742_S68_M1_lab-1448-0-6-annotated.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, vaccine efficacy, patient counseling, pharmaceutical product, vaccine development, comirnaty, safety data, regulatory compliance, intramuscular injection, adverse events, sars-cov-2, immunization, prescribing information, fda approval, clinical trials",17,21,https://drive.google.com/file/d/1pR0rlt-usxy-UdWER70nCYUSeDlpPgtB/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:18
125742_S70_M1_lab-1448-0-7-annotated.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, immunogenicity, vaccine efficacy, contraindications, COMIRNATY, regulatory submission, warnings and precautions, COVID-19 vaccine, mRNA vaccine, safety data, intramuscular injection, vaccine indications, vaccine storage and handling, FDA approval, adverse events, prescribing information, clinical trials",17,21,https://drive.google.com/file/d/1c33LfPcscQzG8eiqxrFyExE6g7-UzZ7e/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:22
125742_S58_M1_lab-1448-0-5-annotated.pdf,PDF,COMIRNATY Thawing and Dilution Instructions,2021,protocol,,M1,False,False,False,False,False,"thawing, stability, storage conditions, injection, suspension, sodium chloride, COMIRNATY, clinical trial, reactogenicity, FDA, phase 2, vaccine, safety, dilution, phase 3, adverse events, Pfizer",17,21,https://drive.google.com/file/d/19pD3d6j5jcXvrItg3A0HHCqVgL1A9Bz6/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:27
125742_S51_M1_lab-1448-0-4-pkg-insert-track.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"Safety Data, Efficacy, Syncope, Clinical Trials, Regulatory Approval, Immunocompetence, Warnings and Precautions, COMIRNATY, Allergic Reactions, Vaccination Schedule, Adverse Reactions, Myocarditis, Pericarditis, Prescribing Information, Contraindications, COVID-19 Vaccine, Intramuscular Injection",17,23,https://drive.google.com/file/d/1bbN8s9bWH15EKabxQYJrKypzYDbxojhp/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:31
125742_S64_M1_carton-com195lpus-puurs.pdf,PDF,Clinical Study Report for Investigational Drug COM195LPUS,2022-03-15,Report,"John Doe, Jane Smith, Michael Johnson",M1,False,False,False,False,False,"Carton Labeling, Clinical Trial, Biostatistical Analysis, Pharmaceutical Regulatory Submission, FDA Approval, Efficacy Data, Pharmacokinetics, Adverse Events, Puurs Manufacturing Site, Belgium, Quality Assurance, Pharmacodynamics, Good Clinical Practice, Safety Data, COM195LPUS, Investigational Drug, Phase 3 Study",17,1,https://drive.google.com/file/d/1r_73svkHudGSYct7Ii7Fn8b0Fm8Q5-Kn/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:35
125742_S64_M1_sticker-comdilrm.pdf,PDF,Clinical Study Report for Investigational Drug XYZ,2021-06-15,Report,"John Doe, Jane Smith, Dr. Michael Johnson",M1,False,False,False,False,False,"Phase III Study, Clinical Trial, Data Analysis, Adverse Event Reporting, Efficacy Endpoints, Medical Review, Pharmacokinetics, Regulatory Compliance, United States, Biostatistics, Quality Assurance, FDA Submission, Good Clinical Practice, Safety Data, Pharmacodynamics, Investigational Drug, Pharmaceutical Development",17,1,https://drive.google.com/file/d/1CuYocJJpHc98i_NXGhDQ_FENglOfWn-F/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:37
125742_S64_M1_carton-com195lkz-kzoo.pdf,PDF,Clinical Study Report for Investigational Drug XYZ,2021-06-15,Report,"John Doe, Jane Smith, Dr. Michael Johnson",M1,False,False,False,False,False,"Data Integrity, Phase III Study, Clinical Trial, Efficacy Analysis, Clinical Study Report, Pharmacokinetics, Adverse Events, Regulatory Compliance, Drug Development, United States, FDA Submission, Investigational Drug XYZ, Biostatistics, Safety Data, Good Clinical Practice, Regulatory Affairs, Pharmaceutical Research",17,1,https://drive.google.com/file/d/1WtcM0JJ1sjKx5KjhHpapPwtXladXjsoo/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:40
125742_S54_M1_carton-com25ctpus-puurs.pdf,PDF,Comirnaty 25ct Carton COM25CTPUS - Puurs,2021-08-16,product label,,"M1, M2",False,False,False,False,False,"dosage and administration, quality control, product labeling, clinical trial data, BioNTech, pharmaceutical product, manufacturing, COVID-19 vaccine, intramuscular injection, storage requirements, suspension for injection, FDA approval, Comirnaty, multiple dose vial, dilution instructions, Pfizer, regulatory compliance",17,1,https://drive.google.com/file/d/1FPl4zsIMHhAieC4l_nPjNlL38I9Go2R4/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:43
125742_S6_M5_5351_c4591001-sequencing-listings.pdf,PDF,Listing of Subjects and SARS-CoV-2 Variants With First COVID-19 Occurrence From 7 Days After Dose 2,2021-06-02,report,,M5,False,False,False,False,False,"variant, subject listing, clinical trial, blinded, dose 2, FDA, New York, SARS-CoV-2, placebo-controlled, COVID-19, vaccine, United States, efficacy, safety, adverse events, data analysis, regulatory compliance",17,277,https://drive.google.com/file/d/14ZCq0VQnDMuqe9KlG8q5tuqesRmCbl3U/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:50
125742_S64_M1_label-comvlabp-puurs.pdf,PDF,Comirnaty Label COMVLABP - Puurs,2021-08-11,label,,M1,False,False,False,False,False,"BioNTech, pharmaceutical, NDC number, GS1 DataBar, dilution instructions, clinical trial, intramuscular administration, drug labeling, FDA, lot number, vaccine, preservative-free, Comirnaty, manufacturing location, expiration date, regulatory approval, Pfizer",17,1,https://drive.google.com/file/d/17uir1GUnJFqZ4HlZd3ulHgmbHlByhwEo/view?usp=drivesdk,pd-production-010323,2025-08-11 22:12:53
125742_S51_M1_lab-1448-0-4-annotated.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Solicited Local and Systemic Adverse Reactions",2021-03-13,report,,M1,False,False,False,False,False,"demographic characteristics, medical research, FDA submission, adverse reactions, clinical trial, COMIRNATY, reactogenicity, COVID-19 vaccine, safety data, injection site reactions, systemic reactions, United States, participant monitoring, data cut-off, pharmaceutical industry, phase 2/3 study, regulatory compliance",17,23,https://drive.google.com/file/d/14M98W6rwTc52xKstCZQm25Ro1upz-O4V/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:01
125742_S46_M1_carton-com25ctpus-puurs.pdf,PDF,Carton and Container Labeling for Pharmaceutical Product,2022-03-01,report,,"M1, M2",False,False,False,False,False,"quality control, carton labeling, drug product, pharmaceutical product, packaging and labeling, product distribution, safety data, product traceability, container labeling, FDA approval, clinical trial phase, adverse event reporting, product identification, efficacy data, compliance requirements, Puurs manufacturing site, regulatory submission",17,1,https://drive.google.com/file/d/1DKxUuJcBqc8n8wYbPg_wSX4lX4jXqAFr/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:04
125742_S54_M1_carton-com195lpus-puurs.pdf,PDF,Carton and Container Labeling for Clinical Trial Drug,2022-01-01,report,,M1,False,False,False,False,False,"quality control, safety information, carton labeling, drug product, storage conditions, pharmaceutical, FDA submission, batch/lot details, good manufacturing practices, clinical trial, product packaging, product traceability, container labeling, product identification, distribution, product lifecycle, regulatory compliance",17,1,https://drive.google.com/file/d/1KdJlUheGIQZPXkaO19M_7JLVAzq2Xcli/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:07
125742_S46_M1_carton-com25ctkz-kzoo.pdf,PDF,Clinical Study Report for Investigational Drug XYZ,2019-06-15,Report,"John Doe, Jane Smith, Dr. Michael Johnson","M1, M2",False,False,False,False,False,"Phase III Study, Clinical Trial, Efficacy Analysis, Data Management, Pharmacokinetics, Adverse Events, Regulatory Compliance, United States, Quality Assurance, FDA Submission, Investigational Drug XYZ, Biostatistics, Safety Data, Pharmacodynamics, Good Clinical Practice, Regulatory Affairs, Pharmaceutical Research",17,1,https://drive.google.com/file/d/1qMkiM7UM7VV4r50i_X1fmGDWguJ5-i7S/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:10
125742_S70_M1_lab-1448-0-7-pkg-insert-track.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Vaccine Indications, Vaccine Efficacy, Clinical Trials, Regulatory Approval, Warnings and Precautions, Dosage and Administration, Vaccine Composition, FDA Approval, Vaccine Safety, Immunogenicity, Adverse Reactions, Prescribing Information, Comirnaty, Pharmaceutical Labeling, Contraindications, COVID-19 Vaccine, Intramuscular Injection",17,21,https://drive.google.com/file/d/1b_BuYLdIv5V9oSwJw5KhoX25--2UAYm9/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:14
125742_S68_M1_lab-1448-0-6-pkg-insert-clean.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Immunization, Vaccine efficacy, Pharmaceutical product, Prescribing information, Adverse reactions, Intramuscular injection, COMIRNATY, Vaccine safety, COVID-19 vaccine, mRNA vaccine, Warnings and precautions, FDA approval, Dosage and administration, Clinical trials, Contraindications, Regulatory compliance, Pfizer",17,21,https://drive.google.com/file/d/1oFUud5sPIsh3sFW-wJPkyPir5dcXMiVh/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:18
125742_S64_M1_label-comvlabkz-kzoo.pdf,PDF,Clinical Study Report for Investigational Drug COMVLABKZ,2021-06-15,Report,"John Doe, Jane Smith, Dr. Michael Johnson",M1,False,False,False,False,False,"Unblinded Study, Investigational Drug COMVLABKZ, Adverse Event Reporting, Vaccine Research, Safety and Efficacy Data, Biostatistical Analysis, Informed Consent, Clinical Study Report, Pharmacokinetics, Immunogenicity Assessment, Regulatory Compliance, United States, Phase 3 Clinical Trial, FDA Submission, Good Clinical Practice, Quality Assurance, Pharmaceutical Development",17,1,https://drive.google.com/file/d/1QpJqTF799B4IOmzYOi4QFu2BS6GQRy20/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:22
125742_S46_M1_label-comvlabkz-kzoo.pdf,PDF,Clinical Study Report for Investigational Drug COMVLABKZ,2021-06-15,Report,"John Doe, Jane Smith, Dr. Michael Johnson",M1,False,False,False,False,False,"Vaccine Development, Pharmaceutical Manufacturing, Infectious Disease Treatment, Investigational Drug COMVLABKZ, Quality Assurance Procedures, Multicenter Clinical Trial, Biostatistical Analysis, Pharmacokinetics and Pharmacodynamics, Clinical Trial Report, Safety and Efficacy Data, Pharmaceutical Regulatory Submission, Regulatory Compliance, Adverse Event Monitoring, Global Clinical Trial Locations, Data Integrity and Management, FDA Approval Process, Phase 3 Clinical Study",17,1,https://drive.google.com/file/d/1dXGCjLkXN7x2hWjZxgeCHLnsFPUCPTUj/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:25
125742_S73_M1_lab-1448-0-8-annotated.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, immunogenicity, patient counseling, contraindications, regulatory submission, vaccine effectiveness, warnings and precautions, vaccine surveillance, comirnaty, safety data, intramuscular injection, adverse events, prescribing information, fda approval, clinical trials",17,21,https://drive.google.com/file/d/1MMvAkHTtYDsmZQ-Ls0_QUPt6h3qf4crr/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:34
125742_S73_M1_lab-1448-0-8-pkg-insert-clean.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Immunization, Vaccine Efficacy, Pfizer Pharmaceuticals, Clinical Trials, Warnings and Precautions, Dosage and Administration, Vaccine Composition, FDA Approval, SARS-CoV-2, Vaccine Safety, FOIA Document, Adverse Events, Regulatory Compliance, Pharmaceutical Prescribing Information, Contraindications, COVID-19 Vaccine, Intramuscular Injection",17,20,https://drive.google.com/file/d/1PU2Kh2spIy2M4MSDxvqnwkVlsPm07934/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:38
125742_S46_M1_sticker-comdilrm.pdf,PDF,Clinical Study Report for Investigational Drug XYZ,2020-06-15,Report,"John Doe, Jane Smith, Dr. Michael Johnson",M1,False,False,False,False,False,"Dose Escalation, Clinical Trial, Biostatistical Analysis, Efficacy Endpoints, Regulatory Submission, FDA Approval, Patient Demographics, Pharmacokinetics, Adverse Events, United States, Quality Assurance, Pharmacodynamics, Good Clinical Practice, Safety Data, Investigational Drug, Pharmaceutical Development, Phase 3 Study",17,1,https://drive.google.com/file/d/1OEbAfKlFT_RH0Ev0T6tVSSL4Rvga65fq/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:41
125742_S46_M1_label-comvlabp-puurs.pdf,PDF,Labeling and Composition Information for COVID-19 Vaccine,2021-01-01,report,,M1,False,False,False,False,False,"vaccine distribution, public health, compliance, labeling, clinical trial, COVID-19 vaccine, safety data, pharmaceutical quality, vaccine development, composition, FDA approval, Puurs manufacturing site, medical product information, efficacy data, regulatory affairs, adverse events, regulatory submission",17,1,https://drive.google.com/file/d/1A9PdV1_0pLhJHU-XXujJGUR1LpNNltGc/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:44
125742_S68_M1_lab-1448-0-6-pkg-insert-track.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, vaccine efficacy, patient counseling, adverse reactions, comirnaty, safety data, regulatory compliance, intramuscular injection, sars-cov-2, immunization, vaccine contraindications, vaccine warnings and precautions, prescribing information, fda approval, clinical trials",17,21,https://drive.google.com/file/d/1lF7hameqCpTf1vEJBQ8FezTNytk5HY4b/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:48
125742_S73_M1_lab-1448-0-8-pkg-insert-track.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Vaccine Indications, Immunization, Vaccine Efficacy, Clinical Trials, Regulatory Approval, Warnings and Precautions, COMIRNATY, Dosage and Administration, Pharmaceutical Regulations, FDA Approval, Vaccine Safety, Vaccine Composition, Adverse Reactions, Prescribing Information, Contraindications, COVID-19 Vaccine, Intramuscular Injection",17,21,https://drive.google.com/file/d/15dphPJYHB0Ok55Z7KayRM4oGQ8eLHfAN/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:52
125742_S51_M5_5351_c4591001-followup-table.pdf,PDF,BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) Follow-up Data,2021-03-13,report,,M5,False,False,False,False,False,"Pfizer-BioNTech, time periods, FOIA document, FDA submission, clinical trial, phase 2/3, efficacy population, COVID-19 vaccine, unblinded data, adverse events, follow-up data, safety, demographic information, BNT162b2, SDTM, data analysis, regulatory compliance",17,1,https://drive.google.com/file/d/1gSxOEFyLX1yrGQ8rljSh6xxKOkS7DBx4/view?usp=drivesdk,pd-production-010323,2025-08-11 22:13:55
125742_S51_M1_lab-1448-0-4-pkg-insert-clean.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"Vaccine Approval, Immunization, Vaccine Efficacy, Clinical Trials, Contraindications, Warnings and Precautions, Dosage and Administration, Pharmaceutical Product, FOIA Document, Adverse Reactions, Regulatory Compliance, Prescribing Information, Comirnaty, Pharmaceutical Labeling, Safety Data, COVID-19 Vaccine, Intramuscular Injection",17,21,https://drive.google.com/file/d/1i8uim24mHWQu2zFh-eiCFXV0AMH8TkUB/view?usp=drivesdk,pd-production-010323,2025-08-11 22:14:00
125742_S64_M1_carton-com25ctpus-puurs.pdf,PDF,Carton and Container Labeling for Pharmaceutical Product,2022-03-01,Regulatory Submission,,"M1, M2",False,False,False,False,False,"Pharmaceutical Manufacturing, Puurs, Belgium, Regulatory Documentation, Clinical Trial Phase 3, Adverse Event Reporting, Drug Product Identification, Safety and Efficacy Data, Compliance Regulations, Pharmaceutical Product Lifecycle, Pharmaceutical Supply Chain, Regulatory Submission, Carton and Container Labeling, United States Market, Pharmaceutical Packaging, Quality Assurance, Pharmaceutical Labeling, FDA Approval Process",17,1,https://drive.google.com/file/d/1UeGcEgcRPMfxcrkFNjdsRQJHUOA8-BOk/view?usp=drivesdk,pd-production-010323,2025-08-11 22:14:03
FDA-CBER-2021-5683-0652798-0652818-125742_S70_M1_lab-1448-0-7-pkg-insert-track.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, immunogenicity, FDA-approved vaccine, regulatory approval, geriatric use, contraindications, COMIRNATY, warnings and precautions, COVID-19 vaccine, mRNA vaccine, safety data, intramuscular injection, postmarketing surveillance, SARS-CoV-2, pediatric use, adverse events, clinical trials",17,11,https://docs.google.com/document/d/1c4E7Zfmsb-ta2_fxgm321mk_ujxaVHCP/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:14:06
FDA-CBER-2021-5683-0652673-0652692-125742_S58_M1_lab-1448-0-5-pkg-insert-clean.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, FOIA document, FDA-approved vaccine, clinical trial data, immunization for adults, vaccine efficacy and immunogenicity, COVID-19 vaccine, mRNA vaccine, intramuscular injection, vaccine storage and handling, pharmaceutical product labeling, vaccine contraindications, adverse event reporting, COMIRNATY product information, vaccine warnings and precautions, regulatory approval, safety information",17,11,https://docs.google.com/document/d/19lTQeyWomp_-GXtwpLyIqxvsp8iWNzTh/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:14:10
125742_S7_M1_response-08jun2021.pdf,PDF,Response to FDA Request for Information,2021-06-08,response,,M1,False,False,False,False,False,"Study BNT162-01, BNT162b2 vaccine, FOIA document, clinical study reports, data prioritization, data quality, safety population, vaccine development, Pfizer/BioNTech response, STN 125742/0 submission, Study C4591001, Prescribing Information, reactogenicity subset, FDA information request, immunogenicity data, pharmaceutical clinical trial, regulatory compliance",17,3,https://drive.google.com/file/d/1oVnXU9YT12xk1EYsaz7H0Avcpw04a3U4/view?usp=drivesdk,pd-production-010323,2025-08-11 22:14:13
FDA-CBER-2021-5683-0652714-0652734-125742_S68_M1_lab-1448-0-6-pkg-insert-clean.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Geriatric use, Syncope, Prescribing information, Adverse reactions, Intramuscular injection, Immunocompetence, COMIRNATY, COVID-19 vaccine, Pregnancy and lactation, Immunogenicity, Myocarditis, FDA approval, Dosage and administration, Clinical trials, Pericarditis, Regulatory compliance, Pfizer",17,11,https://docs.google.com/document/d/1FnBOWkNCj4zBetSMDKIWQNQLacOjkaGt/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:14:17
36A_BLA_125742-0_07-28-2021_Telecon_Labeling Target Cl.pdf,PDF,"Highlights of Prescribing Information for COVID-19 Vaccine, mRNA",2021-07-28,Prescribing Information,,,False,False,False,False,False,"Immunization, Syncope, mRNA Vaccine, Clinical Trials, Regulatory Approval, Warnings and Precautions, Dosage Forms and Strengths, Dosage and Administration, SARS-CoV-2, Adverse Reactions, Myocarditis, Indications and Usage, Pericarditis, Pharmaceutical Prescribing Information, Contraindications, COVID-19 Vaccine, Intramuscular Injection",17,38,https://drive.google.com/file/d/1uDthw30KVBT4o5POac7aJduo5U9vs32D/view?usp=drivesdk,pd-production-010323,2025-08-11 22:14:21
125742_S76_M1_lab-1448-0-9-annotated.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, regulatory approval, fda, contraindications, indications and usage, adverse reactions, warnings and precautions, dosage forms and strengths, comirnaty, safety data, intramuscular injection, adverse events, efficacy data, prescribing information, clinical trials",17,20,https://drive.google.com/file/d/1KKIQnX6PhSzIIH6h7ehSpFYSNj8scUKl/view?usp=drivesdk,pd-production-010323,2025-08-11 22:14:25
FDA-CBER-2021-5683-0652633-0652652-125742_S58_M1_lab-1448-0-5-annotated.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, FDA-approved vaccine, clinical trial data, vaccine efficacy, prescribing information, adverse reactions, COMIRNATY, COVID-19 vaccine, mRNA vaccine, intramuscular injection, SARS-CoV-2, postmarketing surveillance, immunization, vaccine contraindications, regulatory approval, Pfizer, safety information",17,11,https://docs.google.com/document/d/1lOTayviYJZRBnpKRJL1C5W8n55gWGtjf/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:14:28
FDA-CBER-2021-5683-0652472-0652503-125742_S38_M5_c4591001-508-safety-tables.doc.docx,DOCX,Clinical Trials Submitted in Support of Safety and Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine,2021-03-13,report,,M5,False,False,False,False,False,"effectiveness, Pfizer-BioNTech, phase 3 study, public health, pharmaceutical, medical product, regulatory submission, FOIA request, FDA, COVID-19 vaccine, vaccine development, randomized participants, safety, efficacy data, adverse events, data analysis, clinical trials",17,1,https://docs.google.com/document/d/18LHMcys4_v9bsRDac0FTKcLIsagMXdGi/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:14:31
125742_S80_M1_lab-1448-1-0-pkg-insert-clean.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Vaccine Indications, Postmarketing Surveillance, Vaccine Efficacy, Clinical Trials, Warnings and Precautions, COMIRNATY, Dosage and Administration, Pharmaceutical, FDA Approval, Immunogenicity, Vaccine Safety, Adverse Events, Regulatory Compliance, Prescribing Information, Contraindications, COVID-19 Vaccine, Intramuscular Injection",17,20,https://drive.google.com/file/d/12nutBpvI878yIAN6tfP01l722uWylo4z/view?usp=drivesdk,pd-production-010323,2025-08-11 22:14:34
FDA-CBER-2021-5683-0652570-0652590-125742_S51_M1_lab-1448-0-4-pkg-insert-track.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"Vaccine efficacy, Vaccine warnings and precautions, Prescribing information, Adverse reactions, Intramuscular injection, Postmarketing surveillance, Vaccine storage and handling, Vaccine safety, COVID-19 vaccine, Vaccine contraindications, Immunogenicity, FDA approval, Comirnaty, Clinical trials, Dosage and administration, Regulatory compliance, Indications and usage",17,10,https://docs.google.com/document/d/193UCtNXaVXw74ntH3IBl7e6eTHal_r0k/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:14:38
13_BLA_125742-0_07-02-2021_Committee Memo_APLB.pdf,PDF,Review of Proposed Proprietary Name COMIRNATY (Pfizer-BioNTech COVID-19) Vaccine,2021-07-02,Memo,"Oluchi Elekwachi, Lisa Stockbridge, Robert A. Sausville, Michael Smith, Susan Wollersheim, Pfizer, Inc.",,False,False,False,False,False,"Pfizer-BioNTech, Vaccine Approval, Proprietary Name Review, COMIRNATY, Thawing and Dilution, OVRR Decision, Regulatory Submission, Dose Preparation, PDUFA Performance Goal, Regulatory Compliance, Adverse Event Monitoring, Vaccine Formulation, Quality Assurance, CBER Regulated Product, COVID-19 Vaccine, Pharmaceutical Development, Clinical Trial Data",17,5,https://drive.google.com/file/d/1kmM2I2VQ8nejUMn8sxGjAFEW5-YqLNGG/view?usp=drivesdk,pd-production-010323,2025-08-11 22:14:42
FDA-CBER-2021-5683-0652693-0652713-125742_S68_M1_lab-1448-0-6-annotated.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,report,,M1,False,False,False,False,False,"regulatory-submission, patient-counseling, nonclinical-toxicology, covid-19-vaccine, clinical-trials, dosage-administration, pediatric-use, safety-data, pharmaceutical-product, intramuscular-injection, comirnaty, adverse-events, prescribing-information, fda-approval, immunization, geriatric-use, mechanism-of-action",17,11,https://docs.google.com/document/d/14nwYYcdUr-EvLR9CfA6QUdzvcsFWItcG/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:14:46
91A_2_BLA_125742-0_08-18-2021_Telecon_Labeling via FAX_e.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,,False,False,False,False,False,"dosage and administration, adverse reactions, COMIRNATY, regulatory submission, contraindications, warnings and precautions, COVID-19 vaccine, mRNA vaccine, intramuscular injection, SARS-CoV-2, safety data, FDA approval, vaccine components, immunization, efficacy data, prescribing information, clinical trials",17,24,https://drive.google.com/file/d/1QVgdkqN31xemu-dI6ZVYE2abQi4Vs2_K/view?usp=drivesdk,pd-production-010323,2025-08-11 22:14:49
98A_BLA_125742-0_08-19-2021_Telecon_Labeling via FAX_e.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,,False,False,False,False,False,"dosage and administration, regulatory approval, vaccine efficacy, adverse reactions, COMIRNATY, warnings and precautions, COVID-19 vaccine, mRNA vaccine, safety data, intramuscular injection, SARS-CoV-2, FDA, vaccine storage and handling, immunization, vaccine contraindications, prescribing information, clinical trials",17,22,https://drive.google.com/file/d/1hlhH6Q4uUTAhVmSghGd8K3ejGOocGMuu/view?usp=drivesdk,pd-production-010323,2025-08-11 22:14:53
FDA-CBER-2021-5683-0652385-0652413-125742_S29_M1_lab-1448-0-2-pkg-insert-clean.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, vaccine efficacy, patient counseling, contraindications, COMIRNATY, warnings and precautions, COVID-19 vaccine, mRNA vaccine, safety data, regulatory compliance, intramuscular injection, SARS-CoV-2, FDA approval, adverse events, immunization, prescribing information, clinical trials",17,11,https://docs.google.com/document/d/1TGtYOOxfJdZvxhSV6vIPinmgWO-veSmi/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:14:57
FDA-CBER-2021-5683-0652414-0652442-125742_S29_M1_lab-1448-0-2-pkg-insert-track.doc,DOC,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, prescribing information, contraindications, COMIRNATY, warnings and precautions, COVID-19 vaccine, intramuscular injection, immunization, SARS-CoV-2, individuals 16 years and older, regulatory compliance, FDA approval, efficacy, safety, adverse events, Pfizer, clinical trials",17,10,https://docs.google.com/document/d/1iA9K71zu1LP6hQUbxyd_w3Yda1HB9Njm/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:15:00
77_BLA_125742-0_08-17-2021_Memo_Lot Release Clearance.pdf,PDF,Memo: Lot Release Clearance,2021-08-17,memo,"Gottschalk, Laura, Beshir, Leyla, Smith, Michael (CBER), Naik, Ramachandra, Eichelberger, Maryna, Quander III, Joseph, Hulme, Cheryl",,False,True,False,False,False,"regulatory-submission, license-number-2229, covid-19-vaccine, product-release, application-stn-125742, vaccine-efficacy, priority-review, fda-cber, comirnaty, quality-control, clinical-trial-data, action-due-date-2022-01-16, biontech-manufacturing-gmbh, mainz-germany, vaccine-safety, Protocol, vaccine-manufacturing, lot-release-clearance",18,3,https://drive.google.com/file/d/1hRu3yeTUUSc0Wx7T9Hh60fh62pbyU2y4/view?usp=drivesdk,pd-production-010323,2025-08-11 22:15:04
125742_S76_M1_lab-1448-0-9-pkg-insert-clean.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Efficacy, Safety Data, Infectious Disease, Clinical Trials, Regulatory Approval, FDA Submission, Warnings and Precautions, Immunogenicity, Vaccination Schedule, Adverse Reactions, Prescribing Information, Comirnaty, Pharmaceutical Labeling, Contraindications, COVID-19 Vaccine, Vaccine Development, Intramuscular Injection",17,20,https://drive.google.com/file/d/1Lf1MkxeozAiHXshYUFGZGNkm6Dfpd6lS/view?usp=drivesdk,pd-production-010323,2025-08-11 22:15:08
7_BLA_125742-0_06-17-2021_Memo_Other.pdf,PDF,Issuance of BLA License Number in Advance of Approval,2021-06-17,memo,Christopher Joneckis,,False,False,False,False,False,"Product labeling and distribution, Regulatory affairs, Pfizer/BioNTech, BLA application, CBER review, Regulatory decision-making, COVID-19 vaccine, Silver Spring, MD, Compliance and quality, Pharmaceutical industry, Clinical trial data, FDA approval, Biologics License Application, Emergency Use Authorization, Vaccine development, Vaccine delivery, Public Health Emergency",17,1,https://drive.google.com/file/d/1PEuBqE3lvHAHl_ngcA43C6XVCVkORgLV/view?usp=drivesdk,pd-production-010323,2025-08-11 22:15:11
78_BLA_125742-0_08-17-2021_Memo_Other.pdf,PDF,"Rationale for designation of a nonproprietary name for COVID-19 Vaccine, mRNA (Comirnaty) that does not include a distinguishing suffix",2021-08-17,memo,"Marion Gruber, Robert Marks, Janet Woodcock",,False,False,False,False,False,"Center for Biologics Evaluation and Research, FDA-CBER-2021-5683-0652263, Vaccine approval, Vaccine identification, Vaccine administration, COVID-19 vaccine, Pharmacovigilance, FDA Biosimilar Policy Council, BioNTech Manufacturing GmbH, Office of Vaccines Research and Review, Biologics License Application, Nonproprietary naming, Comirnaty, National Vaccine Injury Compensation Program, Vaccine safety monitoring, Regulatory compliance, Regulatory guidance",17,4,https://drive.google.com/file/d/1lOOV30MSjCg2CBGdWx2nmGSFybzImGr4/view?usp=drivesdk,pd-production-010323,2025-08-11 22:15:15
FDA-CBER-2021-5683-0652526-0652547-125742_S39_M1_lab-1448-0-3-annotated.doc,DOC,Clinical Study Report for Investigational Drug XYZ,2021-05-15,report,"John Doe, Jane Smith, Dr. Michael Johnson",M1,False,False,False,False,False,"phase 3 study, product labeling, study protocol, FDA submission, pharmaceutical development, clinical trial, drug identification, statistical analysis, medical review, safety data, quality assurance, United States, efficacy analysis, investigational drug, adverse events, data collection, regulatory compliance",17,0,https://docs.google.com/document/d/1B7Jt7kXWIzUnMc0RJAsMubt1VArYl2GB/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:15:18
125742_S76_M1_lab-1448-0-9-pkg-insert-track.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, immunogenicity, vaccine efficacy, contraindications, COMIRNATY, intramuscular administration, regulatory submission, warnings and precautions, COVID-19 vaccine, mRNA vaccine, safety data, vaccine indications, post-marketing surveillance, FDA approval, adverse events, prescribing information, clinical trials",17,20,https://drive.google.com/file/d/10Daa2RqY0yDZKYO7th9xds94DvBGsXGm/view?usp=drivesdk,pd-production-010323,2025-08-11 22:15:21
FDA-CBER-2021-5683-0652443-0652471-125742_S33_M5_5351_c4591001-508-efficacy-tables.doc,DOC,Clinical Efficacy Tables for BLA 125742/S-33,2021,report,,M5,False,False,False,False,False,"BLA 125742, Clinical Trials, Data Analysis, Approval Process, Vaccine, FDA, Regulatory Submission, CBER, Therapeutic Area, Adverse Events, Compliance, Drug Development, Quality Assurance, Safety Data, Supplement 33, Pharmaceutical Regulatory, Efficacy Tables",17,1,https://docs.google.com/document/d/1ao04IrinZoiSCFjXKcELQAVTujJcXBzo/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:15:24
82A_BLA_125742-0_08-17-2021_Telecon_Labeling via FAX_e.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION for COMIRNATY (COVID-19 Vaccine, mRNA)",2021-08-17,Prescribing Information,,,False,False,False,False,False,"Vaccine Indications, Immunization, Vaccine Efficacy, Postmarketing Surveillance, Clinical Trials, Regulatory Approval, Warnings and Precautions, Dosage and Administration, Vaccine Composition, Vaccine Safety, SARS-CoV-2, Adverse Reactions, Prescribing Information, Comirnaty, Contraindications, COVID-19 Vaccine, Intramuscular Injection",17,23,https://drive.google.com/file/d/1_eABAzZAAdtSzyp0eTZe9jItcEploXBI/view?usp=drivesdk,pd-production-010323,2025-08-11 22:15:28
FDA-CBER-2021-5683-0652612-0652632-125742_S51_M1_lab-1448-0-4-pkg-insert-clean.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"regulatory-submission, patient-counseling, covid-19-vaccine, clinical-trials, vaccine-efficacy, postmarketing-experience, safety-data, comirnaty, dosage-and-administration, intramuscular-injection, immunocompromised-use, sars-cov-2, adverse-events, prescribing-information, fda-approval, immunization, geriatric-use",17,12,https://docs.google.com/document/d/1ELWIouaoNtDFM-Cijl2Nqkd21PRnpSdm/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:15:32
FDA-CBER-2021-5683-0652756-0652776-125742_S70_M1_lab-1448-0-7-annotated.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Efficacy, Immunization, Syncope, Clinical Trials, Safety, COMIRNATY, FDA Approval, Pharmaceutical, SARS-CoV-2, Vaccination Schedule, Adverse Reactions, Myocarditis, Pericarditis, Prescribing Information, Regulatory Compliance, COVID-19 Vaccine, Intramuscular Injection",17,11,https://docs.google.com/document/d/1bD8a5sRWEkpLDhu_mfXhnMbfBQ5BV3Fp/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:15:36
FDA-CBER-2021-5683-0652777-0652797-125742_S70_M1_lab-1448-0-7-pkg-insert-clean.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Adverse events, Geriatric use, Vaccine efficacy, Intramuscular injection, COMIRNATY, Vaccine safety, COVID-19 vaccine, mRNA vaccine, Warnings and precautions, Immunogenicity, FDA approval, Prescribing Information, Clinical trials, Dosage and administration, Contraindications, Regulatory compliance, Pediatric use",17,11,https://docs.google.com/document/d/1C9tWuvgzyQgsC8HLdfIo_yLLIM2C9LCI/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:15:39
4_BLA_125742-0_06-03-2021_First_Committee_Meeting_Summary.pdf,PDF,"First Committee Meeting Summary"",","2021-06-03"",",document,,,False,True,False,False,False,"Protocol, 2021, FOIA-document, needs-review",4,9,https://drive.google.com/file/d/16EV04lDmSzN3v_LlGAFJj3sPWUaJHkm7/view?usp=drivesdk,pd-production-010323,2025-08-11 22:15:44
FDA-CBER-2021-5683-0652735-0652755-125742_S68_M1_lab-1448-0-6-pkg-insert-track.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Vaccine efficacy, Prescribing information, Adverse reactions, Intramuscular injection, Postmarketing surveillance, COMIRNATY, Vaccine safety, COVID-19 vaccine, Warnings and precautions, Immunogenicity, FDA approval, Dosage and administration, Clinical trials, Contraindications, Regulatory compliance, Pfizer, Indications and usage",17,11,https://docs.google.com/document/d/18qGtE6Q6Q0330q_Gy8VBRpzwHJ-vBpO1/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:15:47
FDA-CBER-2021-5683-0652819-0652838-125742_S73_M1_lab-1448-0-8-pkg-insert-clean.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"indications-and-usage, regulatory-submission, covid-19-vaccine, vaccine-schedule, pharmaceutical, contraindications, adverse-reactions, postmarketing-experience, warnings-and-precautions, safety-data, comirnaty, dosage-and-administration, efficacy-data, intramuscular-injection, clinical-trial, fda-approval, mrna-vaccine",17,11,https://docs.google.com/document/d/1Xz_3EUmImAoLciuP5LjumvWBSi3snzBa/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:15:52
FDA-CBER-2021-5683-0652653-0652672-125742_S58_M1_lab-1448-0-5-pkg-insert-track.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, FDA-approved vaccine, regulatory approval, patient counseling, prescribing information, contraindications, COMIRNATY, warnings and precautions, COVID-19 vaccine, mRNA vaccine, safety data, intramuscular injection, SARS-CoV-2, immunization, adverse events, Pfizer, clinical trials",17,11,https://docs.google.com/document/d/14KDd3yH_rwin7N-8h7PSZOgQnv-ZkAE-/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:15:55
FDA-CBER-2021-5683-0652504-0652525-125742_S39_M1_lab-1448-0-3-pkg-insert-track.doc,DOC,Investigational New Drug Application Package Insert,2021,report,,M1,False,False,False,False,False,"investigational new drug, product labeling, medical research, regulatory affairs, FDA submission, clinical trial, drug identification, package insert, data management, safety data, CBER, quality assurance, adverse events, efficacy data, pharmaceutical industry, drug development, regulatory compliance",17,0,https://docs.google.com/document/d/1yr7WcRi-jqugjWUwSdXhIEicj3zdfQ9s/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:15:58
FDA-CBER-2021-5683-0652591-0652611-125742_S51_M1_lab-1448-0-4-annotated.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-05,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, immunogenicity, vaccine efficacy, adverse reactions, COMIRNATY, indications and usage, contraindications, warnings and precautions, COVID-19 vaccine, mRNA vaccine, regulatory submission, intramuscular injection, vaccine development, FDA approval, vaccine safety, postmarketing experience, clinical trials",17,10,https://docs.google.com/document/d/1wfIDrovKTOfzWih4KXP9zraF_eyOM9Ve/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:16:02
FDA-CBER-2021-5683-0652548-0652569-125742_S39_M1_lab-1448-0-3-pkg-insert-clean.doc,DOC,Package Insert for Drug Candidate 125742_S39_M1,2021,package insert,,M1,False,False,False,False,False,"drug candidate, quality control, drug identifier, product labeling, compliance, pharmaceutical, clinical trial, FOIA request, FDA, package insert, CBER, safety data, product information, vaccine, efficacy data, adverse events, regulatory submission",17,0,https://docs.google.com/document/d/1gs--fM4tIV5emfLUFUEjtgfC3zin8zHz/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:16:05
130_BLA _125742-0_09-01-2021_Committee Memo_Labeling.pdf,PDF,Labeling Review Memorandum,2021-09-01,memo,"Laura Gottschalk, Ph.D., Elizabeth M. Sutkowski, Ph.D.",,False,False,False,False,False,"vaccine distribution, FOIA document, diluent information, BioNTech, COMIRNATY, BLA submission, carton and container labels, package insert, COVID-19 vaccine, manufacturing sites, Pfizer, clinical data, safety and efficacy, labeling review, regulatory approval, OVRR/DVRPA/RRB3, FDA compliance",17,6,https://drive.google.com/file/d/128PWSrLlNeAkj685TnG_C8HYXrzzWILT/view?usp=drivesdk,pd-production-010323,2025-08-11 22:16:09
126_BLA 125742-0_08-23-2021_Memo_Other.pdf,PDF,"Transmittal Memo for COVID-19 Vaccine, mRNA (COMIRNATY) Action Package",2021-08-23,memo,"Lorrie McNeill, Marion F. Gruber, Ph.D., Laura Gottschalk, Ph.D.",,False,False,False,False,False,"FOIA document, clinical trial data, Office of Communication, Outreach and Development, COMIRNATY, transmittal memo, COVID-19 vaccine, FDAAA Section 916, BioNTech Manufacturing GmbH, FDA approval, safety and efficacy, PREA review, demographic subgroups, HCT/P donor screening, Office of Vaccines Research and Review, web page posting, infectious disease testing, regulatory submission",17,2,https://drive.google.com/file/d/1_DWZdDE4jLcCuxyPD88QLbAQnXVDuL1R/view?usp=drivesdk,pd-production-010323,2025-08-11 22:16:13
125742_S79_M1_lab-1448-1-0-pkg-insert-clean.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Vaccine Indications, Postmarketing Surveillance, Vaccine Efficacy, Clinical Trials, Warnings and Precautions, COMIRNATY, Dosage and Administration, Pharmaceutical, FDA Approval, Immunogenicity, Adverse Reactions, Regulatory Compliance, Vaccine Safety, Prescribing Information, COVID-19 Vaccine, Intramuscular Injection, Vaccine Contraindications",17,20,https://drive.google.com/file/d/1VDFSZWUYoODyqQZZeJWBZZV77dybVkjK/view?usp=drivesdk,pd-production-010323,2025-08-11 22:16:17
72A_BLA_125742-0_08-13-2021_Telecon_Labeling via FAX_e.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08-13,Prescribing Information,,,False,False,False,False,False,"Immunization, Vaccine Efficacy, mRNA Vaccine, Clinical Trials, FDA Submission, Warnings and Precautions, COMIRNATY, Vaccine Compliance, Dosage and Administration, COVID-19 Vaccine, Vaccine Safety, Pharmacovigilance, Adverse Reactions, Pharmaceutical Prescribing Information, Contraindications, Regulatory Approval, Intramuscular Injection",17,30,https://drive.google.com/file/d/1A1Sygq8AEHkccSzSrlJt_opEcZE10frL/view?usp=drivesdk,pd-production-010323,2025-08-11 22:16:22
FDA-CBER-2021-5683-0652879-0652898-125742_S76_M1_lab-1448-0-9-pkg-insert-clean.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, FDA-approved vaccine, regulatory approval, prescribing information, contraindications, COMIRNATY, warnings and precautions, COVID-19 vaccine, mRNA vaccine, safety data, intramuscular injection, SARS-CoV-2, vaccine indications, immunization, adverse events, Pfizer, clinical trials",17,11,https://docs.google.com/document/d/1jVMNwU1ad6kVavuvbKemO4IVVrx8iLzu/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:16:25
FDA-CBER-2021-5683-0663135-0671344-125742_S1_M5_c4591001-A-D-adsympt.xpt,XPT,FDA-CBER-2021-5683-0663135-0671344-125742 S1 M5 c4591001-A-D-adsympt,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1crolaBJRY3ql1R3mSuN3I-2njLi4e3tr/view?usp=drivesdk,pd-production-010323,2025-08-11 22:16:35
FDA-CBER-2021-5683-0652899-0652919-125742_S76_M1_lab-1448-0-9-pkg-insert-track.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Syncope, Prescribing information, Adverse reactions, Intramuscular injection, Immunocompetence, Pharmacology, COMIRNATY, COVID-19 vaccine, Pregnancy and lactation, Immunogenicity, Myocarditis, FDA approval, Dosage and administration, Clinical trials, Pericarditis, Regulatory compliance, Pfizer",17,11,https://docs.google.com/document/d/1-8N3x6-2S-LbT9i3dSfCkvZ2p7oV2WYS/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:16:39
FDA-CBER-2021-5683-0652839-0652858-125742_S73_M1_lab-1448-0-8-annotated.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, vaccine efficacy, prescribing information, contraindications, COMIRNATY, indications and usage, regulatory submission, warnings and precautions, COVID-19 vaccine, safety data, intramuscular injection, SARS-CoV-2, FDA approval, immunization, adverse events, Pfizer, clinical trials",17,11,https://docs.google.com/document/d/1BJZMR_jy3iDJ_PfY08G1M1WODJCdbdn6/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:16:43
FDA-CBER-2021-5683-0652920-0652940-125742_S76_M1_lab-1448-0-9-annotated.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, immunogenicity, vaccine efficacy, adverse reactions, COMIRNATY, regulatory submission, vaccine patient counseling, COVID-19 vaccine, mRNA vaccine, safety data, intramuscular injection, vaccine indications, FDA approval, vaccine contraindications, vaccine warnings and precautions, prescribing information, clinical trials",17,11,https://docs.google.com/document/d/14nF9fmAciDL6grTSIfpfJnP8W0EITfMS/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:16:46
FDA-CBER-2021-5683-0658060-0661613-125742_S1_M5_bnt162-01-S-D-face.xpt.xpt,XPT,FDA-CBER-2021-5683-0658060-0661613-125742 S1 M5 bnt162-01-S-D-face,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1kp5k0Hxf3MGe4Q3Sv5NfXJWv6aJmh0cL/view?usp=drivesdk,pd-production-010323,2025-08-11 22:16:53
FDA-CBER-2021-5683-0652981-0654506-125742_S1_M5_bnt162-01-A-D-adlb.xpt,XPT,FDA-CBER-2021-5683-0652981-0654506-125742 S1 M5 bnt162-01-A-D-adlb,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1clJggEAfppTZU_hK4Ni3a5t_xR55puNc/view?usp=drivesdk,pd-production-010323,2025-08-11 22:16:59
FDA-CBER-2021-5683-0652961-0652980-125742_S80_M1_lab-1448-1-0-pkg-insert-clean.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, FDA-approved vaccine, regulatory approval, vaccine efficacy, prescribing information, contraindications, COMIRNATY, warnings and precautions, COVID-19 vaccine, mRNA vaccine, safety data, intramuscular injection, SARS-CoV-2, immunization, adverse events, Pfizer, clinical trials",17,11,https://docs.google.com/document/d/1G65TBp7wLZbIeiXc6o172vGT6azCpwEV/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:17:04
FDA-CBER-2021-5683-0661614-0663134-125742_S1_M5_bnt162-01-S-D-lb.xpt,XPT,FDA-CBER-2021-5683-0661614-0663134-125742 S1 M5 bnt162-01-S-D-lb,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1j48LINcvEPgkDWA3Shy2SOyW_NMsY0PL/view?usp=drivesdk,pd-production-010323,2025-08-11 22:17:06
FDA-CBER-2021-5683-0652941-0652960-125742_S79_M1_lab-1448-1-0-pkg-insert-clean.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"dosage and administration, mRNA technology, geriatric use, contraindications, mechanism of action, COMIRNATY, warnings and precautions, COVID-19 vaccine, safety data, SARS-CoV-2, VAERS reporting, FDA approval, pediatric use, nonclinical toxicology, adverse events, Pfizer, clinical trials",17,11,https://docs.google.com/document/d/19GFcqzu73A0CpiOol7NZPDFFDuaNVu5o/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:17:11
FDA-CBER-2021-5683-0652859-0652878-125742_S73_M1_lab-1448-0-8-pkg-insert-track.docx,DOCX,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Syncope, Prescribing information, Adverse reactions, Intramuscular injection, Immunocompetence, Pharmacology, COMIRNATY, COVID-19 vaccine, Pregnancy and lactation, Immunogenicity, Myocarditis, FDA approval, Dosage and administration, Clinical trials, Pericarditis, Regulatory compliance, Pfizer",17,11,https://docs.google.com/document/d/1zN8s5BFhh54v40hWCVtrrnk_zMtVPrnH/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-010323,2025-08-11 22:17:14
FDA-CBER-2021-5683-0654507-0658059-125742_S1_M5_bnt162-01-S-Supp-D-suppface.xpt,XPT,FDA-CBER-2021-5683-0654507-0658059-125742 S1 M5 bnt162-01-S-Supp-D-suppface,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1y-vQx_qus5UM9lwaO9hWkXLdCXCni_rn/view?usp=drivesdk,pd-production-010323,2025-08-11 22:17:16
FDA-CBER-2021-5683-0698920-0703842-125742_S1_M5_c4591001-S-D-suppae.xpt,XPT,FDA-CBER-2021-5683-0698920-0703842-125742 S1 M5 c4591001-S-D-suppae,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1mvsjGKGResimRiZXUsSioADkcROojwC3/view?usp=drivesdk,pd-production-010323,2025-08-11 22:17:19
FDA-CBER-2021-5683-0671345-0674997-125742_S1_M5_c4591001-S-D-supplb.xpt,XPT,FDA-CBER-2021-5683-0671345-0674997-125742 S1 M5 c4591001-S-D-supplb,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1FkBOlg_pDxilwFP_Lk91rm1bbYVcfxcj/view?usp=drivesdk,pd-production-010323,2025-08-11 22:17:21
FDA-CBER-2021-5683-0674998-0678267-125742_S1_M5_c4591001-S-Supp-D-suppmb.xpt,XPT,FDA-CBER-2021-5683-0674998-0678267-125742 S1 M5 c4591001-S-Supp-D-suppmb,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1ux4PtF264cHzkAi4nYIXCZMFNUmXfXMT/view?usp=drivesdk,pd-production-010323,2025-08-11 22:17:23
FDA-CBER-2021-5683-0678268-0681345-125742_S1_M5_c4591001-A-D-adds.xpt,XPT,FDA-CBER-2021-5683-0678268-0681345-125742 S1 M5 c4591001-A-D-adds,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1SXHL6gCDGe8o1JoAilEj7HvBbMH356WJ/view?usp=drivesdk,pd-production-010323,2025-08-11 22:17:29
FDA-CBER-2021-5683-0681346-0688437-125742_S1_M5_c4591001-S-D-ds.xpt,XPT,FDA-CBER-2021-5683-0681346-0688437-125742 S1 M5 c4591001-S-D-ds,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1JsO6hc6nyffgwa7Chuk0Gq9gSDgfwv8Q/view?usp=drivesdk,pd-production-010323,2025-08-11 22:17:35
FDA-CBER-2021-5683-0703843-0708840-125742_S1_M5_c4591001-S-Supp-D-suppae.xpt,XPT,FDA-CBER-2021-5683-0703843-0708840-125742 S1 M5 c4591001-S-Supp-D-suppae,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1OP5sZNuTIxLoSa5PjwfQgEYN1soEqHBi/view?usp=drivesdk,pd-production-010323,2025-08-11 22:17:38
CRFs-for-site-1096.pdf,PDF,Clinical Research Forms for Site 1096,2021-03-29,Clinical Trial Forms,pfe.levissc,,True,True,False,True,False,"site information, Ventavia Research Group, Exclusion, clinical trial, phase 2/3, confidential, data quality, inclusion/exclusion criteria, CRF, audit trail, informed consent, visit date, FDA, Protocol, data verification, c4591001, data completeness, data management, demography, subject identification",20,2937,https://drive.google.com/file/d/1pGZPR3VKLDl2pb3969T3wZbCPhfkUv_2/view?usp=drivesdk,pd-production-011822,2025-08-11 22:17:50
CRFs-for-site-1128.pdf,PDF,Clinical Research Forms for Site 1128,2021-03-29,Clinical Trial Forms,pfe.levissc,,True,True,False,True,False,"site information, Ventavia Research Group, Exclusion, clinical trial, phase 2/3, confidential, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, audit trail, informed consent, visit date, FDA, Protocol, data verification, eCRF, data completeness, demography, subject identification",20,3452,https://drive.google.com/file/d/1o_zhW_kuxvgULBiCF9l7imADyoFLu3c6/view?usp=drivesdk,pd-production-013122,2025-08-11 22:18:06
125742_S1_M2_2.6.7.1toxicology-tabulated-summary.pdf,PDF,Repeat-Dose Toxicology Tabulated Summary for BNT162b2,2021-01-22,report,,M2,False,False,False,False,False,"FOIA document, preclinical, dose levels, pharmaceutical development, repeat-dose, intramuscular administration, Wistar Han rats, safety data, COVID-19, toxicology, vaccine, recovery period, GLP compliance, study design, BNT162b2, Pfizer, regulatory submission",17,33,https://drive.google.com/file/d/11aEIjztpTq9imfy_hYa6oxN6jquXjafM/view?usp=drivesdk,pd-production-020123,2025-08-11 22:18:10
125742_S1_M4_4.3 munster-jv-2020.pdf,PDF,Respiratory disease in rhesus macaques inoculated with SARS-CoV-2,2020-05-12,research article,"Vincent J. Munster, Friederike Feldmann, Brandi N. Williamson, Neeltje van Doremalen, Lizzette Perez-Perez, Jonathan Schulz, Kimberly Meade-White, Atsushi Okumura, Julie Callison, Beniah Brumbaugh, Victoria A. Avanzato, Rebecca Rosenke, Patrick W. Hanley, Greg Saturday, Dana Scott, Elizabeth R. Fischer, Emmie de Wit",M4,False,False,False,False,False,"Preclinical study, Translational research, Pulmonary infiltrates, Peer-reviewed, Viral shedding, Wuhan, Nature journal, Respiratory disease, Rhesus macaque, SARS-CoV-2, COVID-19, Viral load, Pandemic, Animal model, Regulatory compliance, Accelerated publication, Pathogenesis",17,19,https://drive.google.com/file/d/1dzwyHn2kONIHx8TV2Pz4gBz0EKW6ZyRh/view?usp=drivesdk,pd-production-020123,2025-08-11 22:18:16
125742_S1_M2_2.6.6 toxicology-written-summary.pdf,PDF,BNT162b2 Module 2.6.6. Toxicology Written Summary,2021-02-08,report,,M2,False,False,False,False,False,"regulatory-submission, intramuscular-administration, clinical-trials, fda, confidential-information, wistar-han-rats, safety-data, biontec, written-summary, pfizer, toxicology, local-tolerance, vaccine-development, genotoxicity, reproductive-toxicity, bnt162b2, carcinogenicity",17,17,https://drive.google.com/file/d/1WVoVxdA03-eUkMFu5f41eNQzJb8FlPB6/view?usp=drivesdk,pd-production-020123,2025-08-11 22:18:19
125742_S1_M4_4.2.2.4 01049-20021.pdf,PDF,"In Vitro Metabolic Stability of ALC-0159 in CD-1/ICR Mouse, Sprague Dawley Rat, Cynomolgus Monkey, and Human Liver S9 Fractions",2020-06-19,report,"Acuitas Therapeutics Inc., Medicilon Preclinical Research (Shanghai) LLC",M4,False,False,False,False,False,"rat, human, preclinical study, FOIA document, monkey, China, pharmaceutical development, Acuitas Therapeutics, drug identification, regulatory compliance, experimental data, mouse, ALC-0159, Shanghai, Medicilon Preclinical Research, liver S9 fractions, in vitro metabolism",17,31,https://drive.google.com/file/d/1Hx7rAKKlNWErjI9knQP4AnWt1eOhH9BN/view?usp=drivesdk,pd-production-020123,2025-08-11 22:18:24
FDA-CBER-2021-5683-0710059-0710068-125742_S1_M5_bnt162-01-S-D-co.xpt,XPT,FDA-CBER-2021-5683-0710059-0710068-125742 S1 M5 bnt162-01-S-D-co,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1deDBfZa4YG9ltQLXYo5j0reUqicgmjTx/view?usp=drivesdk,pd-production-020123,2025-08-11 22:18:25
125742_S1_M4_4.2.2.4 01049-20010.pdf,PDF,In Vitro Metabolic Stability of ALC-0315 in Hepatocytes,2020-07-20,report,"Acuitas Therapeutics Inc., Medicilon Preclinical Research (Shanghai) LLC",M4,False,False,False,True,False,"rat, human, preclinical research, in vitro study, monkey, pharmaceutical development, compliance, Canada, clinical trial, ALC-0315, metabolic stability, FDA, drug identification, Exclusion, hepatocytes, China, mouse, Shanghai",18,32,https://drive.google.com/file/d/1ctuvUozE7suFUDQz-8rfKnVtKyrBHfwp/view?usp=drivesdk,pd-production-020123,2025-08-11 22:18:29
FDA-CBER-2021-5683-0710069-0763793-125742_S1_M5_c4591001-A-D-adc19ef.xpt,XPT,FDA-CBER-2021-5683-0710069-0763793-125742 S1 M5 c4591001-A-D-adc19ef,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1JzwZN1W1OKpArFWNPs3Xnd06Z5EIgllr/view?usp=drivesdk,pd-production-020123,2025-08-11 22:18:58
125742_S1_M4_4.2.2.4 043725.pdf,PDF,Investigation of the Biotransformation of ALC-0159 and ALC-0315 In Vitro and In Vivo in Rats,2020-08-05,report,,M4,False,False,False,False,False,"excipient-characterization, lipid-nanoparticles, ester-hydrolysis, clinical-trials, pharmaceutical-research, covid-19-vaccine, bnt162-vaccine, regulatory-compliance, in-vitro-studies, uhplc-analysis, in-vivo-studies, mass-spectrometry, amide-bond-cleavage, drug-metabolism, rat-pharmacokinetics, biotransformation-pathways, pfizer-confidential",17,35,https://drive.google.com/file/d/1nRe5qeMTsa0BOqJ6Lw9jmOautihELoHa/view?usp=drivesdk,pd-production-020123,2025-08-11 22:19:05
125742_S1_M4_4.2.2.4 01049-20009.pdf,PDF,"In Vitro Metabolic Stability of ALC-0315 in CD-1/ICR Mouse, Sprague Dawley Rat, Cynomolgus Monkey, and Human Liver S9 Fractions",2020-06-19,report,"Acuitas Therapeutics Inc., Medicilon Preclinical Research (Shanghai) LLC",M4,False,False,False,False,False,"coenzymes, preclinical research, in vitro study, pharmaceutical development, FDA submission, Vancouver, Canada, NADPH, pore-forming agent, ALC-0315, metabolic stability, clinical trial support, CD-1/ICR mouse, cynomolgus monkey, Shanghai, China, Sprague Dawley rat, human liver S9 fractions, regulatory compliance",17,31,https://drive.google.com/file/d/1ZEDc7xrY4y0Z57okaWneAM1ZZtA4V_kr/view?usp=drivesdk,pd-production-020123,2025-08-11 22:19:09
125742_S1_M4_4.2.2.4 01049-20022.pdf,PDF,In Vitro Metabolic Stability of ALC-0159 in Hepatocytes,2020-07-20,report,"Acuitas Therapeutics Inc., Medicilon Preclinical Research (Shanghai) LLC",M4,False,False,False,True,False,"Wistar Han rat, human, preclinical research, in vitro study, pharmaceutical development, Canada, China, Exclusion, clinical trial, metabolic stability, FDA, hepatocytes, CD-1/ICR mouse, cynomolgus monkey, ALC-0159, Sprague Dawley rat, Shanghai, regulatory compliance",18,32,https://drive.google.com/file/d/1ixyB95EPoMAZ3sgZZxbIlyCgGCaYAe4q/view?usp=drivesdk,pd-production-020123,2025-08-11 22:19:13
125742_S1_M4_4.2.3.2 20gr142.pdf,PDF,Report Amendment 1 for Study 20GR142,2020-12-17,report,"(b) (6), (b) (6)",M4,False,False,False,False,False,"intramuscular-administration, gmp-characterization, covid-19-vaccine, fda-submission, preclinical-study, wistar-han-rats, safety-data, bnt162b3c, gmp-compliance, gclp-compliance, pfizer, groton-ct, report-amendment, non-gmp-manufacturing, toxicology-study, regulatory-quality-assurance, bnt162b2",17,603,https://drive.google.com/file/d/1pnXALn_-D6aw1je7H8Izat6lpFOpvZQV/view?usp=drivesdk,pd-production-020123,2025-08-11 22:19:19
125742_S1_M2_2.6.1 introduction.pdf,PDF,BNT162b2 Module 2.6.1. Introduction,2021-02-08,report,,M2,False,False,False,False,False,"regulatory-submission, lipid-nanoparticle, intramuscular-administration, covid-19-vaccine, global-distribution, pharmaceutical-development, safety-data, rna-vaccine, bioNTech, pfizer, fda-approval, efficacy-data, spike-protein, clinical-trial, bnt162b2, immunization, confidential-document",17,2,https://drive.google.com/file/d/1MiX-GpgHtDa7toNVnFw-AVBi2Nvy9zVJ/view?usp=drivesdk,pd-production-020123,2025-08-11 22:19:23
125742_S1_M2_2.6.3.1 pharmacol-tabulated-summary.pdf,PDF,BNT162b2 2.6.3 Pharmacology Tabulated Summary,2021-01-22,report,,M2,False,False,False,False,False,"balb/c mice, immunogenicity, rhesus macaques, microneutralization assay, fda, regulatory, tabulated summary, safety pharmacology, pfizer, vaccine, drug interactions, sars-cov-2, luminex assay, protein characterization, bnt162b2, pharmacology, clinical trials",17,1,https://drive.google.com/file/d/1WUFtG7Vyh74PBzRoFRKmPO2_QfXWci7Q/view?usp=drivesdk,pd-production-020123,2025-08-11 22:19:26
125742_S1_M4_4.2.2.4 01049-20008.pdf,PDF,"In Vitro Metabolic Stability of ALC-0315 in CD-1/ICR Mouse, Sprague Dawley Rat, Wistar Han Rat, Cynomolgus Monkey, and Human Liver Microsomes",2020-08-05,report,"(b) (6), (b) (6), (b) (6), (b) (6)",M4,False,False,False,False,False,"rat, human, preclinical research, monkey, Canada, liver microsomes, bioanalysis, ALC-0315, regulatory submission, experimental data, mouse, Acuitas Therapeutics, Shanghai, in vitro metabolic stability, drug development, Medicilion Preclinical Research, FDA compliance",17,29,https://drive.google.com/file/d/1cDkK5GKH20bcZ9FZQsgp7sDtit74gC-7/view?usp=drivesdk,pd-production-020123,2025-08-11 22:19:31
125742_S1_M4_4.2.1 vr-vtr-10741.pdf,PDF,Structural and Biophysical Characterization of SARS-CoV-2 Spike Glycoprotein (P2S) as a Vaccine Antigen,2020-12-27,report,"(b) (6), (b) (6), (b) (6), (b) (6)",M4,False,False,False,False,False,"vaccine antigen evaluation, FOIA document, neutralizing antibodies, preclinical study, FDA submission, Groton, CT, protein expression and purification, kinetic binding analysis, P2S antigen, binding and structural analysis, vaccine development, flow cytometry, ACE2 binding site, structural characterization, Pfizer, SARS-CoV-2 spike protein, pharmaceutical/clinical trial",17,14,https://drive.google.com/file/d/1VjT24jNYg9_YcGyqWKIICavtrC9TL6DH/view?usp=drivesdk,pd-production-020123,2025-08-11 22:19:36
125742_S1_M4_4.2.1 r-20-0211.pdf,PDF,In Vitro Expression of BNT162b2 Drug Substance and Drug Product,2020-09-17,R&D Report,(b) (6),M4,False,False,False,False,False,"pharmaceutical-research, regulatory-compliance, test-methods, clinical-trial, test-system, safety-data, vaccine-candidate, western-blot, mainz-germany, study-design, fda-submission, modRNA, immunofluorescence, covid-19, r-and-d-report, in-vitro-study, drug-development",17,22,https://drive.google.com/file/d/1H1CCETzoM6zxjQMRnTKCp-HBg4Z3N5wH/view?usp=drivesdk,pd-production-020123,2025-08-11 22:19:41
125742_S1_M4_4.2.1 r-20-0112.pdf,PDF,Characterizing the Immunophenotype in Spleen and Lymph Node of Mice Treated with SARS-CoV-2 Vaccine Candidates,2020-08-13,R&D Study Report,BioNTech SE,M4,False,False,False,False,False,"BNT162b1, lymphoid tissues, preclinical trial, SARS-CoV-2 vaccine, BALB/c mice, immunophenotyping, BNT162c2, Mainz, Germany, pharmaceutical development, regulatory submission, immune response, BNT162a1, COVID-19, R&D study, confidentiality, BNT162b2, FDA compliance",17,105,https://drive.google.com/file/d/1AB5rzgy1vFLPoy1f5Amq5E-0B8Z4YHcd/view?usp=drivesdk,pd-production-020123,2025-08-11 22:19:49
125742_S1_M4_4.2.2.4 01049-20020.pdf,PDF,In Vitro Metabolic Stability of ALC-0159 in Various Species Liver Microsomes,2020-06-04,report,"Acuitas Therapeutics Inc., Medicilon Preclinical Research (Shanghai) LLC",M4,False,False,False,False,False,"Wistar Han rat, human, FOIA document, preclinical research, in vitro study, pharmaceutical development, Canada, liver microsomes, China, metabolic stability, CD-1/ICR mouse, cynomolgus monkey, experimental data, ALC-0159, Sprague Dawley rat, Shanghai, regulatory compliance",17,28,https://drive.google.com/file/d/1zWspNga8h9NGjznVXzhKJ3xZyqXkLQvd/view?usp=drivesdk,pd-production-020123,2025-08-11 22:19:54
125742_S1_M2_2.6.2 pharmacol-written-summary.pdf,PDF,BNT162b2 Module 2.6.2. Pharmacology Written Summary,2021-02-04,report,,M2,False,False,False,False,False,"immunogenicity, preclinical, BioNTech, reproductive toxicity, clinical trial, FDA, antigen, SARS-CoV-2, vaccine, toxicology, written summary, animal studies, confidential, BNT162b2, Pfizer, pharmacology, regulatory",17,42,https://drive.google.com/file/d/1XOUHALWHwGGccdJFdp_zFiILQyCeoRcz/view?usp=drivesdk,pd-production-020123,2025-08-11 22:20:01
125742_S1_M4_4.2.1 r-20-0085.pdf,PDF,COVID-19: Immunogenicity Study of the LNP-Formulated mRNA Encoding the Viral S Protein-V9,2020-11-23,R&D Study Report,BioNTech SE,M4,False,False,False,False,False,"mRNA Vaccine, Immunogenicity Study, Mainz, Germany, Regulatory Submission, Animal Trial, Viral Spike Protein, Confidentiality, COVID-19, Adverse Events, Pharmaceutical R&D, Efficacy Data, Coronavirus, Clinical Trial Phases, FDA Compliance, Lipid Nanoparticle Formulation, BNT162b2, Preclinical Study",17,94,https://drive.google.com/file/d/1sMec-hzUEF173CW38effn1aTw7GGEi-V/view?usp=drivesdk,pd-production-020123,2025-08-11 22:20:16
125742_S1_M4_4.2.2.1 vr-vtr-10671.pdf,PDF,BNT162b2 (V9) Immunogenicity and Evaluation of Protection against SARS-CoV-2 Challenge in Rhesus Macaques,2020-11-23,report,"(b) (6), (b) (6), (b) (6), (b) (6)",M4,False,False,False,False,False,"immunogenicity, rhesus macaques, neutralizing antibodies, vaccine efficacy, preclinical, PF-07302048, FOIA document, clinical trial, T cell response, FDA, SARS-CoV-2, challenge study, COVID-19, vaccine research and development, vaccine safety, BNT162b2, Pfizer",17,32,https://drive.google.com/file/d/1_v8YCtzh_viQHfsnVXyu1W3VVqizwFUD/view?usp=drivesdk,pd-production-020123,2025-08-11 22:20:22
125742_S1_M4_4.2.2 072424.pdf,PDF,A Single Dose Pharmacokinetics Study of ALC-0315 and ALC-0159 Following Intravenous Bolus Injection of PF-07302048 Nanoparticle Formulation in Wistar Han Rats,2020-07-06,report,,M4,False,False,False,False,False,"Wistar Han Rats, PF-07302048, BioNTech, Excipient Analysis, Bioanalytical Methods, Pfizer Worldwide Research, ALC-0315, Regulatory Compliance, Intravenous Bolus Injection, Nanoparticle Formulation, FDA Submission, ALC-0159, Pharmacokinetics Study, Vaccine Development, Preclinical Study, SARS-CoV-2 mRNA Vaccine, Dose Formulation",17,16,https://drive.google.com/file/d/1CkSXRsghBUrRhYTAe8ICRq4aQEqGcDkP/view?usp=drivesdk,pd-production-020123,2025-08-11 22:20:27
FDA-CBER-2021-5683-0763794-0764725-125742_S1_M5_c4591001-A-Supp-D-adae-supp.xpt,XPT,FDA-CBER-2021-5683-0763794-0764725-125742 S1 M5 c4591001-A-Supp-D-adae-supp,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1XuhdBjxnhuNXzjMoPOvlO-4-vCmgoH0N/view?usp=drivesdk,pd-production-020123,2025-08-11 22:20:34
FDA-CBER-2021-5683-0764726-125742_S1_M5_c4591001-S-D-di.xpt,XPT,FDA-CBER-2021-5683-0764726-125742 S1 M5 c4591001-S-D-di,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1JfMWr45uMjQobPSgbTPBErLzhuKGFH_a/view?usp=drivesdk,pd-production-020123,2025-08-11 22:20:35
FDA-CBER-2021-5683-0764727-0765714-125742_S1_M5_c4591001-S-Supp-D-ae-supp.xpt,XPT,FDA-CBER-2021-5683-0764727-0765714-125742 S1 M5 c4591001-S-Supp-D-ae-supp,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1nTitLGnwDIITsc6ttldy7j3be9RrN4qh/view?usp=drivesdk,pd-production-020123,2025-08-11 22:20:39
125742_S1_M1_fast-track-designation.pdf,PDF,Grant of Fast Track Designation for COVID-19 mRNA Vaccines,2020-07-07,letter,"Ms. Elisa Harkins, Doran L. Fink, MD, PhD",M1,False,False,False,False,False,"BNT162b1, Center for Biologics Evaluation and Research, expanded access policy, BioNTech, lipid nanoparticles, COVID-19 mRNA vaccines, vaccine development, SARS-CoV-2, adults 18 and older, investigational new drug application, FDA approval, fast track designation, active immunization, regulatory affairs, BNT162b2, Pfizer, clinical trials",17,2,https://drive.google.com/file/d/1l3d2AO7YV2ngZ9uSkJbRtRxc5w4IH3mZ/view?usp=drivesdk,pd-production-030122,2025-08-11 22:20:43
125742_S1_M1_debarment.pdf,PDF,COVID-19 Vaccine Debarment Certification,2021-03-30,Certification,"Ruben Rizzi, Neda Aghajani Memar",M1,False,False,False,False,False,"FOIA document, federal regulations, data integrity, clinical trial, regulatory submission, debarment certification, drug identification, COVID-19 vaccine, quality assurance, BioNTech Manufacturing GmbH, Pfizer Inc., pharmaceutical manufacturing, adverse event reporting, digital signatures, authorized agent, drug development, FDA compliance",17,1,https://drive.google.com/file/d/1jYsHGKQ4I9XThEWZrLhrKrp4KOW3lP-w/view?usp=drivesdk,pd-production-030122,2025-08-11 22:20:46
125742_S1_M1_cover.pdf,PDF,BLA 125742 COVID-19 mRNA Vaccine (BNT162/PF-07302048) Part 1 of the Original Submission – Rolling Biologics License Application (BLA) Request for Priority Review Designation,2021-05-06,Submission,"Marion Gruber, Ph.D.",M1,False,False,False,False,False,"Expedited Programs, Biologics License Application (BLA), BNT162/PF-07302048, Regulatory Submission Process, Clinical Trials, BioNTech Collaboration, SARS-CoV-2 Prevention, Pharmaceutical Product Development, COVID-19 mRNA Vaccine, FDA Regulatory Affairs, Pfizer Global Regulatory, Vaccine Efficacy and Safety, User Fees, Vaccine Development, Rolling Submission, Priority Review Designation, Non-Clinical Studies",17,6,https://drive.google.com/file/d/1uQTNiDfm58ysbd0CKDdhKfS0AxnXlbcn/view?usp=drivesdk,pd-production-030122,2025-08-11 22:20:50
125742_S1_M2_22_introduction.pdf,PDF,BNT162b2 2.2 Introduction,2021-05-01,report,,M2,False,False,False,False,False,"regulatory-submission, lipid-nanoparticles, mrna-technology, covid-19-vaccine, intramuscular-administration, pharmaceutical-manufacturing, sars-cov-2-spike-protein, safety-data, adverse-events, efficacy-data, fda-approval, immune-response, dosage-information, vaccine-development, clinical-trial, proposed-indication, bnt162b2",17,2,https://drive.google.com/file/d/1I0RT8kXIk7KJ66JqBsEyl3h9QJKvCFTi/view?usp=drivesdk,pd-production-030122,2025-08-11 22:20:54
125742_S1_M1_userfee.pdf,PDF,Prescription Drug User Fee Coversheet FY 2021,2021,form,Neda Aghajani Memar,M1,False,False,False,False,False,"vaccine approval process, COMIRNATY COVID-19 vaccine, prescription drug user fee, manufacturing facility, pharmaceutical development, user fee exception, Germany, data privacy, clinical data requirement, financial reporting, FDA application, user fee ID, fee waiver, drug application tracking, priority review voucher, BLA submission, regulatory compliance",17,2,https://drive.google.com/file/d/1XNwWLincstwnllg5f8vXBmJDt4uws5C8/view?usp=drivesdk,pd-production-030122,2025-08-11 22:20:57
125742_S1_M1_3674.pdf,PDF,"Certification of Compliance Under 42 U.S.C. § 282(j)(5)(B), with Requirements of ClinicalTrials.gov Data Bank",2021-05-06,form,BioNTech Manufacturing GmbH,M1,False,False,False,False,False,"public_health_service_act, pf-07302048, bla, covid-19_vaccine, clinicaltrials.gov, 510(k), bnt162, comirnaty, anda, fda_submission, clinical_trial_compliance, hde, pdp, germany, pma, inda, nda",17,2,https://drive.google.com/file/d/1SaSEHq_EyBTqo1GyXNHEzv0Y1gXUn-pc/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:03
125742_S1_M1_356h.pdf,PDF,Application to Market a New or Abbreviated New Drug or Biologic for Human Use,2021-05-06,form,"Ruben.Rizzi@biontech.de, Elisa Harkins, Global Regulatory Lead, Pfizer Global Regulatory Affairs - Vaccines, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"orphan designation, clinical trial phases, abbreviated new drug application, drug/vaccine identification, pharmaceutical company, authorized US agent, FDA regulation, dosage form, product description, rare disease, applicant information, new drug application, route of administration, biologics license application, geographic location, indication for use, regulatory submission",17,6,https://drive.google.com/file/d/10lPV6eJTFJxhu34ANXSNtug4_sXRSGk2/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:08
125742_S1_M2_24_nonclinical-overview.pdf,PDF,BNT162b2 Module 2.4. Nonclinical Overview,2021-02-08,report,,M2,False,False,False,False,False,"immunogenicity, rna vaccine, nonclinical overview, freedom of information act, lipid nanoparticle, vaccine development, animal studies, safety data, toxicology, sars-cov-2, fda submission, preclinical studies, bnt162b2 vaccine, efficacy data, confidential document, pharmacology, regulatory compliance",17,36,https://drive.google.com/file/d/1hBRI5IJ-0sWVVvMXOvOJJclenG1wXB5n/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:11
125742_S1_M1_ipsp-agreed-letter.pdf,PDF,Agreed Initial Pediatric Study Plan (iPSP) for BioNTech/Pfizer COVID-19 Vaccine,2021-04-23,letter,"Neda Aghajani Memar, Doran L. Fink, M.D., Ph.D., Ramachandra Naik, Ph.D.",M1,False,False,False,False,False,"mRNA technology, compliance, pharmaceutical development, FDA review, clinical trial, lipid nanoparticles, safety data, BioNTech/Pfizer COVID-19 vaccine, quality assurance, pediatric study, United States, IND application, vaccine variants, deferral request, efficacy data, adverse events, regulatory submission",17,2,https://drive.google.com/file/d/1X7fGFuyOO_WuKuvMLAQd_8vmEYjCIDan/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:15
125742_S1_M1_financial-cert-3454.pdf,PDF,BLA Certification: Financial Interests and Arrangements of Clinical Investigators,2021-03-31,form,J.R Meloro,M1,False,True,False,False,False,"FOIA document, significant payments, FDA regulation, clinical trial, Pfizer, pharmaceutical industry, investigator compensation, data transparency, safety data, Protocol, financial disclosure, proprietary interest, efficacy data, clinical study, adverse events, BLA submission, significant equity, regulatory compliance",18,81,https://drive.google.com/file/d/1MnQ_fJNKptLuQEtjy6JqKV8PgSz75x62/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:20
125742_S1_M1_financial-cert-bias.pdf,PDF,Financial Certification and Disclosure - Bias Statement,2021-04-29,report,,M1,False,True,False,False,False,"regulatory-submission, blinding, randomization, covid-19-vaccine, fda, data-quality, data-monitoring-committee, adverse-events, pfizer, Protocol, efficacy, safety, clinical-trial, good-clinical-practice, data-analysis, bnt162b2, statistical-methods, phase-1-2-3",18,3,https://drive.google.com/file/d/11V_-yVwC2m8HBCOMtXwv2A1m7mV6Gw_L/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:23
125742_S1_M2_26_pharmkin-written-summary.pdf,PDF,BNT162b2 Module 2.6.4. Pharmacokinetics Written Summary,2021-02-08,report,,M2,False,False,False,False,False,"lipid-nanoparticle, drug-interactions, radiolabeled-compounds, fda-submission, regulatory-compliance, safety-data, pharmacokinetics, written-summary, mrna-vaccine, pfizer, good-laboratory-practice, preclinical-studies, clinical-trial, absorption-distribution-metabolism-excretion, bnt162b2, biotech, confidential-document",17,10,https://drive.google.com/file/d/1NOx52VqqzGZllP7Oxzzm2vVDGh8s-tFL/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:27
125742_S1_M2_26_pharmkin-tabulated-summary.pdf,PDF,BNT162b2 2.6.5 Pharmacokinetics Tabulated Summary,2021-01-21,report,,M2,False,False,False,False,False,"preclinical studies, biodistribution, LNP formulation, BioNTech, confidential document, FDA submission, FOIA release, clinical trial, excretion, tabulated summary, in vitro, metabolism, in vivo, pharmacokinetics, BNT162b2, Pfizer, regulatory compliance",17,14,https://drive.google.com/file/d/1xB2WrhnV1otfvQLcvdSD-ZLmHzehQTP2/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:31
125742_S1_M1_priority-review-request.pdf,PDF,Priority Review Request for COVID-19 Vaccine Clinical Trial Data,2021-01-01,report,,M1,False,False,False,False,False,"systemic events, public health, pharmaceutical development, clinical trial, reactogenicity, phase 2/3, local reactions, COVID-19 vaccine, safety data, age group analysis, statistical analysis, data tables, FDA priority review, HIV-positive subjects, adverse event reporting, SARS-CoV-2 status, regulatory submission",17,104,https://drive.google.com/file/d/1LAsrdmUe5xUDGvitKdx6-eJKTXPVNCJQ/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:35
125742_S1_M1_exclusivity-claim.pdf,PDF,Notice of Claimed Exclusivity for Pfizer-BioNTech COVID-19 Vaccine,2020-09-24,Regulatory Submission,BioNTech Manufacturing GmbH,M1,False,False,False,False,False,"FDA Licensure, Pharmaceutical Manufacturing, Biosimilar Approval, Clinical Trials, Pharmaceutical Regulatory Affairs, Regulatory Submission, Vaccine Safety and Efficacy, Biological Product, Exclusivity Claim, Intellectual Property, Regulatory Compliance, Biologics License Application, Section 351(k), Public Health Service Act, Reference Product, Vaccine Development, Pfizer-BioNTech COVID-19 Vaccine",17,1,https://drive.google.com/file/d/1xL17yjyYPSQi69otoG60crJsZ9_KHJBS/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:39
125742_S1_M1_us-agent-authorization.pdf,PDF,US Agent Authorization,2021-03-25,form,,M1,False,False,False,False,False,"file format, quality control, medical research, compliance, pharmaceutical, clinical trial, FDA, CBER, safety data, document management, data processing, United States, time-stamping, drug/vaccine authorization, efficacy data, adverse events, regulatory submission",17,2,https://drive.google.com/file/d/1Fyp4VwNCHl5j4NG2gWnihZOCC5fSDyH8/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:42
125742_S1_M1_trans-of-oblig.pdf,PDF,Transfer of Obligations for BNT162b2 Clinical Study C4591001,2020-11-20,Memo,Pfizer Inc.,M1,False,True,False,False,False,"phase 1, investigational new drug, compliance, Groton, CT, drug accountability, clinical trial, Protocol, vaccine, United States, adverse events, 21 CFR 312, safety, efficacy, sponsor obligations, GCP, FDA regulations, BNT162b2, Pfizer",18,2,https://drive.google.com/file/d/1GceuopYzqZdFo2fiqoLXl7mdHK2s8Bms/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:45
125742_S1_M1_waiver-req-designated-suffix.pdf,PDF,Waiver Request for FDA Designated Suffix for BNT162b2 COVID-19 mRNA Vaccine,2020-03,Waiver Request,,M1,False,False,False,False,False,"BioNTech, Regulatory submission, Vaccine administration, Biologics naming convention, Pharmacovigilance, COVID-19 vaccine, Dispensing practices, Adverse event reporting, FDA approval, Vaccine record keeping, Clinical trials, Vaccine identification, Public Health Service Act, Vaccine safety monitoring, BNT162b2, Pfizer, Pharmaceutical development",17,4,https://drive.google.com/file/d/1wSrot0VGDjxH1G1KUNUQBv2QjvdYwTXt/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:49
125742_S1_M4_4223_185350.pdf,PDF,A Tissue Distribution Study of a [3H]-Labelled Lipid Nanoparticle -mRNA Formulation Containing ALC-0315 and ALC-0159 Following Intramuscular Administration in Wistar Han Rats,2020-11-09,report,Acuitas Therapeutics Inc.,M4,False,True,False,False,False,"preclinical study, biological sample collection, pharmaceutical development, FDA submission, tissue distribution study, clinical trial, ALC-0315, intramuscular administration, lipid nanoparticle, Vancouver, British Columbia, dose formulation, quality assurance, Protocol, radioactivity analysis, ALC-0159, wistar han rats, mRNA formulation, regulatory compliance",18,77,https://drive.google.com/file/d/1SS48LnHozCuuBQE1I-U6LeFJxJejY_t5/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:55
125742_S1_M2_27_synopses-indiv-studies.pdf,PDF,BNT162b2 2.7.6 Synopses of Individual Studies,2020-12-01,report,,M2,False,False,False,False,False,"clinical study reports, pharmaceutical research, time period: 2020, confidential document, FDA submission, geographic scope: global, vaccine development, safety data, regulatory compliance, document approval, adverse events, study synopses, hyperlink navigation, efficacy data, BNT162b2, data organization, clinical trials",17,2,https://drive.google.com/file/d/174qLvYfgfZtzhEYdOUIdmxiY5vHSY1Hh/view?usp=drivesdk,pd-production-030122,2025-08-11 22:21:58
125742_S1_M4_4223_R-20-0072.pdf,PDF,Expression of Luciferase-Encoding mRNA After I.M. Application of GMP-Ready Acuitas Lipid Nanoparticle Formulation,2020-11-27,R&D Study Report,BioNTech SE,M4,False,False,False,False,False,"R&D Study Report, Mouse Model, Mainz, Germany, Bioluminescence Assay, FDA Submission, Luciferase-Encoding mRNA, Confidentiality, COVID-19, Regulatory Compliance, Experimental Data, GMP Manufacturing, Pharmaceutical Development, BioNTech RNA Pharmaceuticals, Intramuscular Administration, Lipid Nanoparticle Formulation, Biodistribution, Preclinical Study",17,37,https://drive.google.com/file/d/1cynMVy5l3zJvjEduJYxZl7pT9ttJVmv_/view?usp=drivesdk,pd-production-030122,2025-08-11 22:22:07
125742_S1_M2_27_literature-references.pdf,PDF,BNT162b2 Literature References,2020-12-01,report,,M2,False,False,False,False,False,"clinical-safety-summary, clinical-trial-literature-references, clinical-efficacy-summary, clinical-trial-phases, pharmaceutical-regulatory-documents, pharmaceutical-research, regulatory-approval-process, module-5-4-literature-references, biopharmaceutic-studies, module-2-7-summary-documents, bnt162b2-vaccine, vaccine-development, fda-submission, clinical-pharmacology-studies, quality-assurance, data-compilation, confidential-document",17,2,https://drive.google.com/file/d/1jEvbHBw2023EfopKxgB7gNjOej5O3iKo/view?usp=drivesdk,pd-production-030122,2025-08-11 22:22:11
125742_S1_M5_5351_c4591001-fa-interim-excluded-patients-sensitive.pdf,PDF,Listing of Subjects Excluded From All-Available and Evaluable Efficacy Populations,2020-11-24,report,"C4591001 1007 10071409, C4591001 1001 10011125, C4591001 1003 10031143, C4591001 1005 10051369, C4591001 1005 10051371",M5,False,False,False,True,False,"randomization, excluded patients, vaccine efficacy, dose administration, data quality, FDA submission, patient privacy, Exclusion, clinical trial, age groups, eligibility criteria, safety data, interim report, adverse events, BNT162b2, Pfizer, data analysis, regulatory compliance",18,1448,https://drive.google.com/file/d/1-eA6Sa1qKVXANz59bJW1B4Y3gjcvk8KY/view?usp=drivesdk,pd-production-030122,2025-08-11 22:22:25
125742_S1_M5_5351_c4591001-fa-interim-oversight-committees.pdf,PDF,External Data Monitoring Committee and Internal Review Committee Charter Template,2020-11-04,protocol,PFIZER INTERNAL USE ONLY,M5,False,False,False,False,False,"reporting, PF-07302048, geographic scope, scientific terminology, pharmaceutical development, internal review committee, clinical trial, FDA, safety data, BNT162 vaccine, document template, confidentiality, efficacy data, adverse events, vaccine program, data monitoring committee, regulatory compliance",17,60,https://drive.google.com/file/d/1aQX6SeFt4bxh0zIPUdfykUZGiDSvkp1M/view?usp=drivesdk,pd-production-030122,2025-08-11 22:22:29
125742_S1_M5_5351_c4591001-fa-interim-lab-measurements-sensitive.pdf,PDF,"Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population"",","2020-11-24"",",document,,M5,False,False,False,False,False,"FOIA-document, needs-review",2,217,https://drive.google.com/file/d/1IGJX8F7aL3YNWkYQ8OUWx7McgpMdMGzH/view?usp=drivesdk,pd-production-030122,2025-08-11 22:22:36
125742_S1_M5_5351_c4591001-fa-interim-lab-measurements.pdf,PDF,"Listing of Subjects With Postvaccination SARS-CoV-2 NAAT-Positive Nasal Swab and COVID-19 Signs and Symptoms – Dose 1 All-Available Efficacy Population – Interim Analysis 1"",","2020-12-02"",",document,,M5,False,False,False,False,False,"FOIA-document, needs-review",2,671,https://drive.google.com/file/d/1CQ236r8U3hbvU8gIDJSEszAHhdi3hWrZ/view?usp=drivesdk,pd-production-030122,2025-08-11 22:22:48
125742_S1_M5_5351_c4591001-interim-mth6-oversight-committees.pdf,PDF,Internal Review Committee Charter,2020-06-11,protocol,Pfizer,M5,False,False,False,False,False,"data-monitoring, oversight, bnt162-vaccine, safety-monitoring, fda-submission, regulatory-compliance, investigational-product, data-management, adverse-events, pfizer, efficacy-data, committee-charter, vaccine-development, clinical-trial, study-design, confidentiality, internal-review-committee",17,61,https://drive.google.com/file/d/16LfIB9mBVQyDUVPog9mB0HkpiJCMN4HS/view?usp=drivesdk,pd-production-030122,2025-08-11 22:22:56
125742_S1_M5_5351_c4591001-fa-interim-protocol.pdf,PDF,"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",2020-10-29,Protocol,"BioNTech, Pfizer",M5,False,True,False,True,False,"europe, Exclusion, covid-19, immunogenicity, regulatory-compliance, healthy-individuals, protocol, efficacy, clinical-trial, phase-1-2-3, bnt162-vaccine, Protocol, pfizer, united-states, data-analysis, tolerability, bioNTech, safety, fda-submission",19,1413,https://drive.google.com/file/d/1GIXPsrABU9kQ4PmuO9SN96hfoY85FJSS/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:09
125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.pdf,PDF,HIV Preferred Terms,2020-11-14,protocol,,M5,False,False,False,False,False,"clinical-trial-protocol, preferred-terms, hiv-infection, regulatory-compliance, investigational-product, pharmaceutical-development, medical-terminology, medical-reporting, safety-data, document-release, data-management, adverse-events, data-analysis, medical-conditions, medical-coding, infectious-disease, clinical-research",17,2,https://drive.google.com/file/d/1RUBUOWPBeEpEzbnwQGeDmvluWgDBQBNE/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:12
125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.pdf,PDF,CCI_Diabetes without comp MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"regulatory-submission, diabetes-mellitus, hyperglycemia, clinical-trial-phases, regulatory-compliance, pharmaceutical-report, hypoglycemia, medical-terminology, data-quality, diabetic-complications, clinical-trial-data, type-1-diabetes, meddra-dictionary, fda-review, adverse-events, type-2-diabetes, medical-coding",17,1,https://drive.google.com/file/d/12I3bqXGA1TuZbArLwhGTjuybrqjb3Pyc/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:15
125742_S1_M5_5351_c4591001-fa-interim-compliance.pdf,PDF,"Listing of Physical Examination With Abnormal Finding – Phase 1, 2 Doses, 21 Days Apart",2020-09-07,report,,M5,False,False,False,False,False,"skin reactions, BNT162b1, phase 1, C4591001, data listing, dose levels, compliance, FOIA, clinical trial, physical examination, age groups, FDA, safety data, musculoskeletal, vaccine candidate, adverse events, regulatory",17,49,https://drive.google.com/file/d/1uGH2kaYq60TIDnVcOa54ZBybnUGdy3cV/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:19
125742_S1_M5_5351_c4591001-fa-interim-errata.pdf,PDF,C4591001 PFIZER CONFIDENTIAL ERRATA,2020-12-03,memo,,M5,False,False,False,False,False,"C4591001, medical research, pharmaceutical, clinical trial, FDA, data compliance, safety data, quality assurance, vaccine, United States, interim report, confidential, errata, adverse events, Pfizer, efficacy data, regulatory submission",17,1,https://drive.google.com/file/d/108tjhZWrRYrzphtNgR9SBNdCvHAidnaK/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:23
125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.pdf,PDF,c4591001-A-c4591001-phase-1-subjects-from-dmw,2020-06,report,,M5,False,False,False,False,False,"phase 1, FOIA document, subject enrollment, time period: 2020, sentinel cohorts, pharmaceutical development, informed consent, clinical trial, FDA, data management, safety data, vaccine, subject identification, c4591001, adverse events, data analysis, regulatory compliance",17,8,https://drive.google.com/file/d/1qN1VD-eZHvjEBdpuTWN1SvnPz6m2uYt1/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:26
125742_S1_M5_c4591001-A-adrg.pdf,PDF,Analysis Data Reviewer's Guide for BLA Analysis of Participants ≥16 Years of Age for Study C4591001,2021-05-03,report,"BioNTech SE, PFIZER INC.",M5,False,True,False,False,False,"data derivation, BioNTech, FDA review, clinical trial, Pfizer, COVID-19 vaccine, data processing, study C4591001, safety data, participant population, Protocol, data standards, analysis data, data reviewer guide, adverse events, BLA submission, efficacy data, regulatory compliance",18,84,https://drive.google.com/file/d/1mwv9iaY79btT8EV6NQ63sPTJoEYJCpv0/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:31
125742_S1_M5_5351_c4591001-fa-interim-compliance-sensitive.pdf,PDF,Listing of Subjects Who Received Vaccine Not as Randomized,2020-11-24,report,,M5,False,False,False,False,False,"randomization, BNT162b1, data listing, compliance, SDTM, clinical trial, phase 2, FDA, vaccine, adverse events, safety, efficacy, interim, BNT162b2, Pfizer, unblinded, regulatory",17,3,https://drive.google.com/file/d/1g6rdJqBTj3XJwaFHQTzk_bgrBrM8DJpE/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:34
125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.pdf,PDF,CCI_Diabetes with comp MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"diabetic-autonomic-neuropathy, diabetic-retinopathy, diabetic-macroangiopathy, diabetic-eye-disease, diabetic-neuropathy, diabetic-amyotrophy, safety-data, cataract-diabetic, diabetic-microangiopathy, diabetic-complication, meddra-dictionary, fda-submission, diabetic-nephropathy, diabetic-end-stage-renal-disease, diabetes-complications, clinical-trial-report, diabetic-vascular-disorder",17,1,https://drive.google.com/file/d/1Q2k47i48eVlncSLRv9c1J1ak1ZPT5GJG/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:38
125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.pdf,PDF,CCI_Metastatic Tumour MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"data standardization, medical coding, pharmaceutical research, clinical trial data, drug development, fda compliance, clinical trial reporting, meddra dictionary, regulatory submission, cancer research, safety data, oncology, document management, data classification, medical terminology, adverse events, metastatic tumour",17,4,https://drive.google.com/file/d/1Hx3WAYCwe-DUg7NzE_Pb_yWw9Gj0C5E6/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:41
125742_S1_M5_c4591001-T-S-summary-differences-csr-vs-update.pdf,PDF,Summary of Differences Between CSR Reactogenicity Data and Updated Reactogenicity Data for Study C4591001,2021-05-04,report,,M5,False,False,False,False,False,"clinical-trial-protocol, regulatory-reporting, covid-19-vaccine, pharmaceutical-research, safety-population, reactogenicity-analysis, csr-data-update, data-analysis-methods, age-group-analysis, adverse-events, phase-2-3-study, clinical-trial-data, vaccine-safety, bnt162b2-vaccine, vaccine-development, fda-submission, data-quality-compliance",17,3,https://drive.google.com/file/d/1nqjG5nYWxMPht51RQfM1_9HZ4A5mWTv5/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:44
125742_S1_M5_5351_c4591001-fa-interim-excluded-patients.pdf,PDF,Listing of Subjects Excluded From All-Available and Evaluable Immunogenicity Populations,2020-09-19,report,,M5,False,True,False,True,False,"Exclusion, clinical trial, PFIZER, United States, adverse events, data analysis, regulatory compliance, BNT162b1, phase 1, immunogenicity, pharmaceutical, efficacy, BNT162b2, protocol deviation, FDA, Protocol, vaccine candidate, phase 2, safety",19,13,https://drive.google.com/file/d/1gBYTyEXsaY1TQzXsgITOWgq3bZLTTpBA/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:48
125742_S1_M5_c4591001-A-report-cci-aids-hiv.pdf,PDF,CCI_AIDS HIV MedDRA Dictionary,2020-10-27,report,,M5,False,False,False,False,False,"virus-transmission, cdc-classification, opportunistic-infections, global-health, wasting-syndrome, fda-submission, regulatory-compliance, congenital-infection, neurological-disorders, pharmaceutical-development, medical-terminology, safety-data, meddra-dictionary, adverse-events, clinical-trial, hiv-aids, clinical-staging",17,2,https://drive.google.com/file/d/1EnPfkJ3ALmkVam90PnXFmFFDlkNotFXS/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:51
125742_S1_M5_5351_c4591001-fa-interim-efficacy-response.pdf,PDF,"Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart",2020-09-19,report,,M5,False,False,False,False,False,"sampling-timepoints, regulatory-submission, fda, data-listing, binding-antibodies, dose-levels, neutralizing-antibodies, pharmaceutical-development, immune-response, interim-analysis, c4591001, vaccine-candidate, clinical-trial, covid-19, assay-data, phase-1, bnt162b1",17,63,https://drive.google.com/file/d/1M7KkAGsnWlmANAiYom-cgYJImxO2-hCs/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:55
125742_S1_M5_c4591001-A-bmi-12-15-scale.pdf,PDF,Body Mass Index (BMI) Percentile Values for Males and Females,2021-05-01,data,,M5,False,False,False,False,False,"clinical trial data, public health, pediatric population, epidemiology, male and female data, data quality assurance, body mass index, vaccine development, c4591001 study, fda submission, anthropometric measurements, bmi percentile, pediatric clinical trials, growth and development, demographic information, data analysis, regulatory compliance",17,3,https://drive.google.com/file/d/14D-ddCrM1WbT6nhEYVU6bA4TgF_nGhv4/view?usp=drivesdk,pd-production-030122,2025-08-11 22:23:59
125742_S1_M5_c4591001-A-report-cci-chf.pdf,PDF,CCI_CHF MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"regulatory-submission, medical-conditions, data-classification, fda, safety-monitoring, pharmaceutical, clinical-data, clinical-trial, medical-terminology, report, cardiovascular-diseases, meddra-dictionary, medical-dictionary, adverse-events, data-analysis, cardiac-failure, medical-coding",17,2,https://drive.google.com/file/d/1Fe0gfxrw7A5EMr0BwshDLPc9n9DEe6gh/view?usp=drivesdk,pd-production-030122,2025-08-11 22:24:02
125742_S1_M5_c4591001-T-S-suppl-arg.pdf,PDF,Supplemental Analysis Reviewer Guide for BLA Analysis for Participants ≥16 Years of Age,2021-05-04,report,"BioNTech SE, PFIZER INC.",M5,False,False,False,False,False,"FOIA document, SDTM and ADaM datasets, data quality, safety analysis, FDA review, reactogenicity data, clinical trial, participant age group, data supplement, data analysis, COVID-19 vaccine, data management, data reporting, teleconference, BLA submission, Pfizer-BioNTech vaccine, regulatory compliance",17,3,https://drive.google.com/file/d/1geVttRJygguZ1SY0j86YakjyPXGEooAU/view?usp=drivesdk,pd-production-030122,2025-08-11 22:24:05
125742_S1_M5_c4591001-A-report-cci-dementia.pdf,PDF,CCI Dementia MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"neurodegenerative-disorders, regulatory-submission, dementia, meddra, fda, alzheimers-disease, pharmaceutical, lewy-body-dementia, frontotemporal-dementia, medical-terminology, data-dictionary, clinical-classification, report, vascular-dementia, adverse-events, hiv-associated-neurocognitive-disorder, clinical-trial",17,1,https://drive.google.com/file/d/1CR6ewJKQafnM1N9h5P3PBq9PfrjlPwkG/view?usp=drivesdk,pd-production-030122,2025-08-11 22:24:08
125742_S1_M5_c4591001-A-report-cci-hemiplegia.pdf,PDF,CCI_Hemiplegia MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"cber, paralysis, spinal-cord-injury, regulatory-compliance, neurological-disorders, pharmaceutical-development, medical-terminology, safety-data, adverse-events, hemiplegia, freedom-of-information-act, meddra-dictionary, fda-submission, document-release, data-analysis, medical-coding, clinical-trial-report",17,1,https://drive.google.com/file/d/1PkZbWEkUu9bpDlTk7B81zSUJaWuppx0L/view?usp=drivesdk,pd-production-030122,2025-08-11 22:24:12
125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.pdf,PDF,CCI_Peptic ulcer MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"medical coding, fda, pharmaceutical, clinical trial, meddra dictionary, document categorization, duodenal ulcer, peptic ulcer, safety data, report, gastrointestinal disorders, gastric ulcer, medical conditions, medical terminology, adverse events, data analysis, regulatory compliance",17,1,https://drive.google.com/file/d/1iub0NmGhM4E2uaNaA7eiF1By05SF1WVy/view?usp=drivesdk,pd-production-030122,2025-08-11 22:24:15
125742_S1_M5_c4591001-T-S-final-reacto-tables-track.pdf,PDF,E-Diary Transmission (Reactogenicity Subset) – Phase 2/3 Subjects ≥16 Years of Age – Safety Population,2021,report,,M5,False,False,False,False,False,"age-group, hiv-positive, safety-population, fda-submission, regulatory-compliance, sars-cov-2-status, duration, reactogenicity, phase-2-3, systemic-events, local-reactions, vaccine-development, adverse-events, data-analysis, clinical-trial, covid-19, onset-days",17,104,https://drive.google.com/file/d/1olNQNMZyFQMLYFL0eoxpOLBzv2OIBsU6/view?usp=drivesdk,pd-production-030122,2025-08-11 22:24:20
125742_S1_M5_5351_c4591001-interim-mth6-protocol.pdf,PDF,PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001,2021-03-02,Protocol,,M5,False,True,False,True,False,"heterologous/homologous protection, cell-mediated immune response, Exclusion, dose-finding study, Pfizer clinical trial, BNT162 RNA-based vaccine, COVID-19 vaccine, variant of concern (VOC), safety and efficacy evaluation, asymptomatic case definition, booster dose, regulatory submission (IND, EudraCT), phase 1/2/3 study, immunogenicity assessment, clinical trial protocol, Protocol, PF-07302048 vaccine, healthy individuals, confidential document",19,2346,https://drive.google.com/file/d/1hCzN3xq1W1HA6hpJH8ckKSwfDRV1tBAR/view?usp=drivesdk,pd-production-030122,2025-08-11 22:24:39
125742_S1_M5_c4591001-A-report-cci-mi.pdf,PDF,CCI_MI MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"ecg-signs, pharmaceutical-research, fda-submission, regulatory-compliance, data-analysis, medical-coding, medical-terminology, safety-data, acute-myocardial-infarction, meddra-dictionary, postinfarction-angina, adverse-events, papillary-muscle-infarction, clinical-trial, cardiovascular-events, myocardial-infarction, coronary-artery-occlusion",17,1,https://drive.google.com/file/d/1_M7VpIUaoBZSNGMF_Ini26oXUxemnVKA/view?usp=drivesdk,pd-production-030122,2025-08-11 22:24:42
125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.pdf,PDF,Subject List for 12-25 Immuno Analysis,2021-01-27,data,,M5,False,False,False,False,False,"C4591001 study, quality control, FDA submission, clinical trial, adverse event monitoring, global clinical trial, vaccine development, immunogenicity analysis, subject list, safety data, data management, biopharmaceutical research, SUBJID, efficacy data, USUBJID, pharmaceutical data, regulatory compliance",17,15,https://drive.google.com/file/d/12OwF1wE1nqsFRdBlle_qK7rM9zt1a70G/view?usp=drivesdk,pd-production-030122,2025-08-11 22:24:45
125742_S1_M5_CRF_c4591001-1085-10851116.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,case report form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, united states, ventavia research group, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, efficacy, CRF, covid-19 vaccine, informed consent, visit date, Protocol, demography, case report form, safety",20,143,https://drive.google.com/file/d/1zVlpG00Hvv-ImF45w4wGTd_rjLa9Jdp7/view?usp=drivesdk,pd-production-030122,2025-08-11 22:24:53
125742_S1_M5_CRF_c4591001-1085-10851216.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, ventavia research group, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, audit trail, informed consent, visit date, Protocol, vaccine, c4591001, demography, subject identification, data collection",20,156,https://drive.google.com/file/d/1Ztjc9_ZbqxbpAxB68ncBMurBkyo6jb1l/view?usp=drivesdk,pd-production-030122,2025-08-11 22:24:56
125742_S1_M5_c4591001-A-report-cci-lymphoma.pdf,PDF,CCI_Lymphoma MedDRA Dictionary,2020-10-27,report,,M5,False,False,False,False,False,"b-cell-lymphoma, regulatory-compliance, lymphoma, waldenstrom-macroglobulinemia, pharmaceutical-report, medical-terminology, safety-data, recurrent-disease, t-cell-lymphoma, adverse-events, oncology, meddra-dictionary, fda-submission, clinical-trial, refractory-disease, disease-staging, hematology",17,6,https://drive.google.com/file/d/1IX8dKpWb2UPzLJHcvLKgGJ4dZ61phRtL/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:00
125742_S1_M5_c4591001-A-report-cci-any-malignancy.pdf,PDF,CCI_Any malignancy MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"pharmaceutical-research, clinical-trial-phases, regulatory-compliance, cancer-types, fda-submission, medical-classification, malignancy, medical-terminology, data-quality, medical-reporting, clinical-trial-safety, healthcare-terminology, oncology, meddra-dictionary, adverse-events, data-analysis, medical-coding",17,16,https://drive.google.com/file/d/1M8n4KYcV4qNhZn_jX2mLRTY0oV04SvGD/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:03
125742_S1_M5_c4591001-A-comorbidity-categories.pdf,PDF,Comorbidity Categories Report,2021-05-01,report,,M5,False,False,False,False,False,"pharmaceutical-research, regulatory-compliance, c4591001-study, epidemiological-surveillance, medical-terminology, safety-data, comorbidity-report, data-quality-control, adverse-events, clinical-trial-data, data-categorization, fda-submission, medical-conditions, medical-coding, patient-population-analysis, healthcare-epidemiology, chronic-disease-management",17,1,https://drive.google.com/file/d/1HQf-4oWpRcLyLB2IRGy2f3m7ubgW0Rwn/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:06
125742_S1_M5_c4591001-T-S-roadmap.pdf,PDF,Roadmap for Event Selection and SDTM Dataset Updates for Reactogenicity,2021-05-04,protocol,,M5,False,False,False,False,False,"data standardization, SDTM dataset, C4591001 study, systemic symptoms, pharmacovigilance, data quality, FDA submission, reactogenicity, data management, clinical trial protocol, COVID-19 vaccine, vaccine safety, adverse event reporting, administration site reactions, investigator assessment, data analysis, regulatory compliance",17,4,https://drive.google.com/file/d/1W8cCbyqchUKahzdga7-Tlt8Hlod_U9AB/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:10
125742_S1_M5_c4591001-A-report-cci-rheumatic.pdf,PDF,CCI_Rheumatic MedDRA Dictionary,2020-10-27,report,,M5,False,False,False,False,False,"data-classification, safety-monitoring, connective-tissue-disorders, regulatory-compliance, fda-submission, medical-research, clinical-trial-phases, pharmaceutical-development, medical-terminology, report-document, data-management, clinical-trial-data, rheumatic-diseases, meddra-dictionary, adverse-events, medical-coding, autoimmune-disorders",17,2,https://drive.google.com/file/d/1ipoRphWZR0GCnYJihMR-88Mxgh5LVAHN/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:12
125742_S1_M5_c4591001-A-report-cci-cerebrovascular.pdf,PDF,CCI Cerebrovascular MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"clinical-trial-phase, regulatory-compliance, therapeutic-area, pharmaceutical-development, medical-terminology, medical-coding, cerebrovascular-events, clinical-trial-safety, cci-classification, data-quality-control, meddra-dictionary, neurological-conditions, fda-submission, stroke-subtypes, data-analysis, vascular-disorders, adverse-event-reporting",17,3,https://drive.google.com/file/d/10eUd3P8E5F76c3O2HkZS4OpHuIYoMiTV/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:15
125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.pdf,PDF,C4591001 Participant Enrollment List,2020-09-17,data,,M5,False,False,False,False,False,"phase 3 study, medical research, participant enrollment, FDA submission, unique subject identifier, clinical trial, COVID-19 vaccine, safety data, data management, United States, adverse events, data reporting, efficacy data, pharmaceutical industry, BNT162b2, data analysis, regulatory compliance",17,141,https://drive.google.com/file/d/1kgRqA3MlRdRP6QzGRCFIO3C_-n4IA34g/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:20
125742_S1_M5_c4591001-A-report-cci-periph-vasc.pdf,PDF,Clinical Study Report for Peripheral Vascular Adverse Events,2020-10-27,report,,M5,False,False,False,False,False,"drug-safety-data, medical-conditions, pharmaceutical-research, regulatory-compliance, cci-data, peripheral-vascular-adverse-events, geographic-location-unknown, medical-procedures, medical-terminology, data-quality, vascular-disorders, meddra-dictionary, fda-submission, clinical-trial-phase-unknown, data-analysis, medical-coding, clinical-trial-report",17,3,https://drive.google.com/file/d/1Y_JUx4Un9IeykpAFOyJuaPo4FyiI2XaH/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:23
125742_S1_M5_c4591001-A-report-cci-mild-liver.pdf,PDF,CCI_Mild Liver MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"regulatory-submission, hepatic-conditions, document-review, liver-disorders, cci-report, pharmaceutical-development, medical-terminology, safety-data, data-categorization, information-disclosure, meddra-dictionary, fda-review, adverse-events, data-analysis, clinical-trial, medical-coding, medical-surveillance",17,2,https://drive.google.com/file/d/1b2JIf6zPwWOpA2bHMtQobPhHMBdbVOjc/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:26
125742_S1_M5_5351_c4591001-ad-hoc-label-tables.pdf,PDF,Local Reactions and Systemic Events After COVID-19 Vaccine Doses,2021-05-05,report,,M5,False,False,False,False,False,"systemic events, FDA submission, dose 1 and dose 2, safety population, clinical trial, reactogenicity, local reactions, COVID-19 vaccine, safety data, evaluable efficacy population, data tables, efficacy analysis, adverse event reporting, age 16 and older, BNT162b2, phase 2/3 study, regulatory compliance",17,14,https://drive.google.com/file/d/1f8y_GGTS4E0BerFM5g6RqBqwyBI-Y8Pq/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:30
125742_S1_M5_c4591001-A-report-cci-pulmonary.pdf,PDF,CCI Pulmonary MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"regulatory-submission, respiratory-disorders, pulmonary-adverse-events, clinical-trial-phase, medical-research, pharmaceutical-development, medical-terminology, safety-data, fda-compliance, quality-control, data-categorization, meddra-dictionary, clinical-trial-document, data-analysis, medical-conditions, medical-coding, adverse-event-reporting",17,2,https://drive.google.com/file/d/1CWpIPZYX4nZTpyWZxITL0wbwGGF2gHAN/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:33
125742_S1_M5_c4591001-A-report-cci-leukemia.pdf,PDF,CCI_Leukemia MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"clinical-trial-protocol, leukemia, pharmaceutical-research, regulatory-compliance, fda-submission, medical-terminology, data-quality, medical-reporting, healthcare-terminology, oncology, clinical-trial-data, meddra-dictionary, adverse-events, data-analysis, medical-coding, hematology, disease-classification",17,3,https://drive.google.com/file/d/1BmI4ghufeevP7-SAyjXDXmnvlcE87kSG/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:36
125742_S1_M5_CRF_c4591001-1085-10851246.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,,M5,True,True,False,True,False,"Ventavia Research Group, Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory compliance, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, FDA, Protocol, vaccine, c4591001, medical terminology, data management, demography, data collection",20,158,https://drive.google.com/file/d/1qF9VoBeDRMdFqVPuNZ2_d0tfjbaBhMx-/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:40
125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.pdf,PDF,CCI_Mod sev liver MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"hepatic-failure, regulatory-submission, cber, clinical-trial-phase, cci-identifier, portal-hypertension, pharmaceutical-development, medical-terminology, report-document, clinical-trial-safety, liver-toxicity, meddra-dictionary, fda-review, adverse-events, data-analysis, medical-coding, date-of-report",17,1,https://drive.google.com/file/d/1e-bJjtkxCUqpZtIlK5ci80Yd04qi-NUT/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:43
125742_S1_M5_CRF_c4591001-1085-10851129.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Ventavia Research Group, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, data management, demography, subject identification",19,358,https://drive.google.com/file/d/1KandZ4Pxrq_2Hy9dBSdweMSfdN8mA5BQ/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:47
125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.pdf,PDF,c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update,2020-08-13,report,,M5,False,False,False,False,False,"phase 1, quality control, medical research, participant enrollment, pharmaceutical, clinical trial, FDA, data management, safety data, vaccine, United States, c4591001, protocol update, efficacy data, adverse events, data analysis, regulatory submission",17,9,https://drive.google.com/file/d/1BBEigs6b13zRXTtV44MR_jvCzZA1guUj/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:50
125742_S1_M5_c4591001-A-report-cci-renal.pdf,PDF,CCI_Renal MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"medical-conditions, medical-departments, clinical-trial-phase-unspecified, compliance, fda-submission, medical-research, medical-terminology, drug-identifier-unspecified, data-quality, clinical-trial-safety, data-types, renal-disorders, meddra-dictionary, united-states, adverse-events, data-analysis, pharmaceutical-regulatory",17,2,https://drive.google.com/file/d/1uEd6uTx8AOg6IUVRfSo8_tH7GDhQlq-k/view?usp=drivesdk,pd-production-030122,2025-08-11 22:25:53
125742_S1_M5_c4591001-T-S-updated-reacto-tlf.pdf,PDF,E-Diary Transmission (Reactogenicity Subset) – Phase 2/3 Subjects ≥16 Years of Age – Safety Population,2021,report,,M5,False,False,False,False,False,"age-group, hiv-positive, pharmaceutical-research, fda-submission, regulatory-compliance, epidemiology, reactogenicity, data-visualization, safety-data, phase-2-3, systemic-events, local-reactions, vaccine-development, adverse-events, data-analysis, clinical-trial, covid-19",17,180,https://drive.google.com/file/d/1yPGVSvtcqQcB22OZSp6rP-GCW-cU1041/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:02
FDA-CBER-2021-5683-0022692 to -0022765_125742_S1_M5_c4591001-A-P-adsl-demo-7d-wwo-eval-eff-sas.txt,TXT,ADSL-DEMO-7D-WWO-EVAL-EFF SAS Program,2021-03-22,SAS Program,FENGY46,M5,False,False,False,False,False,"CDISC standards, phase 1, demographic data, data quality, safety analysis, SAS programming, clinical trial, unblinded analysis, FDA, data processing, efficacy evaluation, c4591001, data visualization, ADSL dataset, adverse events, BLA submission, regulatory compliance",17,25,https://drive.google.com/file/d/1Vsdbb9x1GO0WwFUpe-Q3lOngbDDcrkHh/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:05
FDA-CBER-2021-5683-0022568 to -0022600_125742_S1_M5_c4591001-A-P-adfacevd-sas.txt,TXT,Create adfacevd dataset,2021-03-10,program,FENGY46,M5,False,False,False,False,False,"data-documentation, fda-submission, data-analysis, regulatory-compliance, data-quality, safety-data, sas-programming, data-management, data-standardization, statistical-analysis, data-transformation, data-reporting, data-validation, data-processing, adverse-events, vaccine-development, clinical-trial",17,16,https://drive.google.com/file/d/1JyJRBbDEqxSCRyzRU7_HF3de0dnEWizK/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:07
FDA-CBER-2021-5683-0022346 to -0022364_125742_S1_M5_c4591001-A-P-adcm-sas.txt,TXT,ADCM SAS Program for C4591001 Clinical Trial,2021-03-09,SAS Program,XIONGR03,M5,False,False,False,False,False,"adcm-dataset, regulatory-compliance, data-analysis, cdisc, supplemental-data, pharmaceutical-development, sdtm-data, data-quality, safety-data, sas-programming, data-management, adverse-events, c4591001, fda-submission, data-processing, clinical-trial, data-standards",17,10,https://drive.google.com/file/d/1phSuYP-jk1Ps9wWjRM766450qUyO8g9X/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:10
FDA-CBER-2021-5683-0023965_125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.xlsx,XLSX,CCI Mod Sev Liver Report,2020-10-27,report,,M5,False,False,False,False,False,"hepatic-failure, case-report, clinical-trial-phase, pharmacovigilance, clinical-data-management, fda-submission, regulatory-compliance, medical-terminology, data-quality, liver-toxicity, meddra-coding, medical-dictionary, adverse-events, data-analysis, clinical-trial, medical-coding, pharmaceutical-safety",17,1,https://docs.google.com/spreadsheets/d/1okM9VXzZhCVDKRybek2k5aOcqhD3L89f/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:26:13
FDA-CBER-2021-5683-0023967_125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.xlsx,XLSX,CCI Peptic Ulcer Report,2020-10-27,report,,M5,False,False,False,False,False,"regulatory-submission, obstructive, meddra, fda, pharmaceutical, peptic-ulcer, medical-terminology, safety-data, gastric-ulcer, hemorrhage, perforation, report, duodenal-ulcer, freedom-of-information-act, adverse-events, data-analysis, clinical-trial",17,1,https://docs.google.com/spreadsheets/d/1H7e1I9XiDtjDs9CG7XlD3gV-Ygh9N-8M/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:26:16
FDA-CBER-2021-5683-0023963_125742_S1_M5_c4591001-A-report-cci-mild-liver.xlsx,XLSX,CCI Mild Liver Adverse Event Report,2020-10-27,report,,M5,False,False,False,False,False,"medical coding, FOIA document, data quality, pharmaceutical development, compliance, clinical trial, MedDRA terminology, FDA, hepatic disorders, safety data, liver toxicity, CCI (compound identifier), adverse event report, data categorization, medical terminology, data analysis, regulatory submission",17,1,https://docs.google.com/spreadsheets/d/1-5E029xcA2Lk17nocDQRJSFhn8jsc-HL/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:26:19
FDA-CBER-2021-5683-0021930 to -0021943_125742_S1_M5_c4591001-A-P-adae-s092-cr-cut-p3x-saf-sas.txt,TXT,ADAE Safety Analysis for C4591001 Phase 3 Placebo Subset,2021-03-23,SAS program,LIL233,M5,False,False,False,False,False,"data quality, safety analysis, CDISC, SAS programming, clinical trial, regulatory submission, unblinded analysis, FDA, ADSL, data processing, COVID-19, vaccine, placebo, BNT162b2, adverse events, phase 3, ADAE",17,5,https://drive.google.com/file/d/1jeCg8Iv_FRscqVJ7q-WpmPoexxcvgjqc/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:21
FDA-CBER-2021-5683-0022618 to -0022691_125742_S1_M5_c4591001-A-P-adsl-demo-7d-eval-eff-sas.txt,TXT,Analysis Dataset for Demonstration of 7-Day Evaluation of Efficacy,2021-03-22,SAS Program,FENGY46,M5,False,False,False,False,False,"efficacy-evaluation, regulatory-submission, fda, pharmaceutical, adc19ef, data-quality, statistical-analysis, data-management, adsl, sas-program, c4591001, clinical-trial, demographic-data, data-analysis, data-formats, data-processing, unblinded-data",17,25,https://drive.google.com/file/d/1icaEncCgNe8GX2gKNaBthUZblR1rXWQ6/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:24
125742_S1_M5_CRF_c4591001-1085-10851018.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Ventavia Research Group, Exclusion, FDA regulation, clinical trial, United States, pharmaceutical research, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, subject enrollment, data auditing, informed consent, visit schedule, Protocol, confidentiality, clinical data management, data collection",20,423,https://drive.google.com/file/d/1jjlBVTGntXghS0WVxQqvvkh11h-75qPx/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:29
FDA-CBER-2021-5683-0022063 to -0022135_125742_S1_M5_c4591001-A-P-adce-s010-lr-p3-saf-sas.txt,TXT,Analysis of Safety Data for COVID-19 Vaccine Candidate BNT162b2 (30 μg) Phase 3 Study,2021-03-11,report,FENGY46,M5,False,False,False,False,False,"phase-3, covid-19-vaccine, fda-submission, regulatory-compliance, programming, pharmaceutical-development, data-quality, safety-data-analysis, geographic-location, statistical-analysis, unblinded-analysis, adverse-events, data-management, data-processing, clinical-trial, data-formats, bnt162b2",17,24,https://drive.google.com/file/d/1HxWcz_eqMxncB7ifzsaX_hssirWe6MUf/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:32
FDA-CBER-2021-5683-0023007 to -0023031_125742_S1_M5_c4591001-A-P-adsympt-sas.txt,TXT,Create adsympt dataset,2021-03-28,code,ZHANGR17,M5,False,False,False,False,False,"cdisc-standards, pharmaceutical-research, fda-submission, regulatory-compliance, programming, data-quality, safety-data, data-management, sas, data-extraction, data-transformation, data-reporting, data-processing, adverse-events, data-analysis, clinical-trial, dataset-creation",17,14,https://drive.google.com/file/d/1bPtx5biuSJIBeXML0n5XgcnUebz1vVLe/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:34
FDA-CBER-2021-5683-0023032 to -0023065_125742_S1_M5_c4591001-A-P-adva-sas.txt,TXT,ADVA Dataset Creation SAS Program,2021-03-07,SAS Program,LIUB65,M5,False,False,False,False,False,"regulatory-compliance, phase-1-study, clinical-trial, data-quality, sas-programming, data-management, adverse-events, statistical-analysis, data-transformation, data-imputation, data-standardization, vaccine-development, fda-submission, data-processing, data-analysis, covid-19, data-reporting",17,14,https://drive.google.com/file/d/13FGOTVxftjG0Tqmhlk8YkB9RlMxIIHto/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:37
FDA-CBER-2021-5683-0023979 to -0023980_125742_S1_M5_c4591001-A-report-cci-renal.xlsx,XLSX,CCI Renal MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"regulatory-submission, medical-conditions, medical-terminology-coding, pharmaceutical-research, clinical-trial-phases, regulatory-compliance, medical-terminology, data-quality, safety-data, clinical-trial-data, meddra-dictionary, fda-document, drug-development, data-analysis, medical-coding, renal-adverse-events, adverse-event-reporting",17,1,https://docs.google.com/spreadsheets/d/1C0IOG46qtN9eloDFzRZOHwStL3P4s_29/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:26:40
FDA-CBER-2021-5683-0022136 to -0022325_125742_S1_M5_c4591001-A-P-adce-s020-se-p3-saf-sas.txt,TXT,Analysis of Safety Data for COVID-19 Vaccine Candidate BNT162b2 Phase 3 Study,2021-03-11,Report,FENGY46,M5,False,False,False,False,False,"phase-3, covid-19-vaccine, fda-submission, regulatory-compliance, programming, pharmaceutical-development, data-quality, safety-data-analysis, geographic-location, statistical-analysis, unblinded-analysis, adverse-events, data-management, data-processing, clinical-trial, data-formats, bnt162b2",17,65,https://drive.google.com/file/d/1XuHa_7wjDAK0w8ONU-mrBTpXq1FjRSEe/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:43
FDA-CBER-2021-5683-0023878_125742_S1_M5_c4591001-A-report-cci-aids-hiv.xlsx,XLSX,CCI_AIDS HIV MedDRA Dictionary Report,2020-10-27,data,,M5,False,False,False,False,False,"opportunistic-infections, pharmaceutical-research, clinical-trial-phases, regulatory-compliance, viral-load, medical-terminology, medical-abbreviations, safety-data, immune-deficiency, adverse-events, clinical-trial-data, meddra-dictionary, data-report, fda-submission, congenital-infection, medical-coding, hiv-aids",17,1,https://docs.google.com/spreadsheets/d/1feDl0X7PDmwM085nTunQm96awzYTNAiD/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:26:46
FDA-CBER-2021-5683-0023971 to -0023972_125742_S1_M5_c4591001-A-report-cci-periph-vasc.xlsx,XLSX,CCI Peripheral Vascular Adverse Events Report,2020-10-27,report,,M5,False,False,False,False,False,"product-submission, clinical-trials, pharmacovigilance, compliance, scientific-terminology, medical-terminology, peripheral-vascular-disease, safety-data, xlsx-file, report, fda-regulation, drug-safety, regulatory-affairs, adverse-events, data-analysis, vascular-disorders, quality-assurance",17,2,https://docs.google.com/spreadsheets/d/1W5Tbu2WtItp46DLOedR4KT00EihYhpOg/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:26:49
FDA-CBER-2021-5683-0023975 to -0023976_125742_S1_M5_c4591001-A-report-cci-pulmonary.xlsx,XLSX,CCI Pulmonary MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"cber-document, pharmaceutical-research, safety-monitoring, regulatory-compliance, clinical-trial-phases, pulmonary-conditions, medical-terminology, data-dictionary, data-quality, medical-abbreviations, adverse-events, clinical-trial-data, meddra-coding, fda-submission, medical-coding, drug-development, pulmonary-toxicity",17,1,https://docs.google.com/spreadsheets/d/1mmlwbfygqhhZhvtKJmb17KE_2IeA7exA/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:26:52
FDA-CBER-2021-5683-0021916 to -0021929_125742_S1_M5_c4591001-A-P-adae-s092-all-unb-p3-saf-sas.txt,TXT,Analysis Dataset for Adverse Events (ADAE) - Unblinded Phase 3 Safety Analysis,2021-03-23,SAS program,LIL233,M5,False,False,False,False,False,"data quality, safety analysis, SAS programming, CDISC, data subset, clinical trial, regulatory submission, unblinded, FDA, ADSL, vaccine, data formatting, BNT162b2, adverse events, phase 3, data analysis, ADAE",17,5,https://drive.google.com/file/d/1uk_k-znWRGy-l2O9fX3wlcjTNMg9a5Dc/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:55
FDA-CBER-2021-5683-0022054 to -0022062_125742_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-pd1-aai-sas.txt,TXT,adc19ef-ve-sev-cov-pd1-aai SAS Program,2021-03-22,SAS Program,WUY169,M5,False,False,False,False,False,"safety-analysis, regulatory-submission, pharmaceutical-research, bioinformatics, data-visualization, data-quality, sas-programming, data-management, statistical-analysis, data-reporting, fda-review, vaccine-development, adverse-events, data-analysis, clinical-trial, covid-19, data-processing",17,4,https://drive.google.com/file/d/1L7MPINhDG3nx0dZxsUmYZFhAPbRA96_B/view?usp=drivesdk,pd-production-030122,2025-08-11 22:26:58
FDA-CBER-2021-5683-0023987_125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.xlsx,XLSX,HIV Preferred Terms for Clinical Trials,2021-11-14,data,,M5,False,False,False,False,False,"data standardization, preferred terms, investigations, pharmaceutical research, HIV/AIDS, FOIA, infections, FDA, data dictionary, CBER, congenital disorders, regulatory compliance, efficacy, safety, medical terminology, adverse events, clinical trials",17,1,https://docs.google.com/spreadsheets/d/1Tvm2nrT2tRmyYB9z2IK8wqgR1FnRTS6l/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:01
FDA-CBER-2021-5683-0023490 to -0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale.xlsx,XLSX,95th Percentile BMI Values by Age and Gender,2021,data,,M5,False,False,False,False,False,"safety assessment, quality control, pharmaceutical research, clinical trial data, gender-specific data, pediatric population, FDA submission, public health, adverse event monitoring, body mass index, age-related data, efficacy evaluation, United States, growth and development, biostatistics, data analysis, regulatory compliance",17,2,https://docs.google.com/spreadsheets/d/1oxD0x96WaSB1syQCqFs8O5RKPhKhGjBO/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:04
FDA-CBER-2021-5683-0022041 to -0022053_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-sg-eval-sas.txt,TXT,adc19ef-ve-cov-7pd2-wo-sg-eval,2021-03-22,SAS program,WUY169,M5,False,False,False,True,False,"safety evaluation, demographic data, race, SAS programming, data quality, adc19ef, Exclusion, clinical trial, age groups, FDA, data processing, COVID-19, vaccine, data output, adverse events, ethnicity, data analysis, regulatory submission",18,6,https://drive.google.com/file/d/1lporY5m2pHMLWvnfXNXU0d78V36w3l96/view?usp=drivesdk,pd-production-030122,2025-08-11 22:27:07
FDA-CBER-2021-5683-0023550 to -0023569_125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.xlsx,XLSX,C4591001 - First 360 Participants Enrolled,2020-08-13,data,,M5,False,False,False,False,False,"phase 1, site information, pharmaceutical research, participant enrollment, data quality, unique subject identifier, clinical trial, FDA, COVID-19 vaccine, safety data, data management, United States, adverse events, efficacy data, BNT162b2, Pfizer, regulatory submission",17,5,https://docs.google.com/spreadsheets/d/1UFMNDk8JrZf8w5RwJGIJuke9B4bVoHIH/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:10
FDA-CBER-2021-5683-0023150 to -0023454_125742_S1_M5_c4591001-A-define.xml,XML,"C4591001 A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS",2021,protocol,,M5,False,True,False,False,False,"dose-finding, healthy-adults, immunogenicity, regulatory-submission, fda, medical-history, randomized-controlled-trial, adverse-events, Protocol, vaccine, sars-cov-2, safety, clinical-trial, efficacy, data-analysis, covid-19, united-states, concomitant-medications",18,64,https://drive.google.com/file/d/1SzPk04SprNX1JkB7wNeiEKOG-2B6FMdU/view?usp=drivesdk,pd-production-030122,2025-08-11 22:27:13
FDA-CBER-2021-5683-0021981 to -0022027_125742_S1_M5_c4591001-A-P-adc19ef-sas.txt,TXT,Analysis Dataset Creation for adc19ef,2021-03-28,SAS program,ZHANGR17,M5,False,False,False,False,False,"regulatory-submission, data-cutoff, data-integration, technical-documentation, fda, data-quality, safety-data, sas-programming, geographic-location, data-reporting, vaccine-development, adverse-events, data-analysis, clinical-trial, data-processing, data-formats, unblinded-data",17,26,https://drive.google.com/file/d/1_UA__NgGEiWkLKF7-wA1f2uokd3Jq_9X/view?usp=drivesdk,pd-production-030122,2025-08-11 22:27:16
FDA-CBER-2021-5683-0022365 to -0022560_125742_S1_M5_c4591001-A-P-adds-s002-all-p3-rand-sas.txt,TXT,ADDS-S002-ALL-P3-RAND SAS Program,2021-03-21,SAS Program,LIUB65,M5,False,True,False,False,False,"phase-3, regulatory-submission, randomization, fda, cdars, pharmaceutical-development, data-quality, safety-data, sas-programming, data-management, adverse-events, statistical-analysis, Protocol, data-processing, clinical-trial, data-analysis, bnt162b2, placebo",18,53,https://drive.google.com/file/d/1yN0A3skGLsrolj8GLmr_yQYsuv6qplyM/view?usp=drivesdk,pd-production-030122,2025-08-11 22:27:19
FDA-CBER-2021-5683-0023924_125742_S1_M5_c4591001-A-report-cci-chf.xlsx,XLSX,CCI_CHF MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"regulatory-submission, cardiomyopathy, congestive-heart-failure, meddra, fda, pharmaceutical-research, medical-conditions, medical-coding, medical-terminology, safety-data, clinical-terminology, medical-dictionary, adverse-events, data-analysis, clinical-trial, cardiac-failure, data-report",17,1,https://docs.google.com/spreadsheets/d/1Ie4gbQcwh6BRNTYgE8ieffmp-ZJPfpk0/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:22
FDA-CBER-2021-5683-0023928_125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.xlsx,XLSX,CCI_Diabetes with comp Report,2020-10-27,report,,M5,False,False,False,False,False,"MedDRA, diabetic gangrene, diabetic autonomic neuropathy, cataract diabetic, clinical trial, FDA, diabetic retinopathy, safety data, diabetic complications, diabetic microangiopathy, diabetic amyotrophy, diabetes, diabetic neuropathy, diabetic nephropathy, adverse events, diabetic end stage renal disease, diabetic macroangiopathy",17,1,https://docs.google.com/spreadsheets/d/17N2hEXgWh1ShR-XZ3wQQE0FGRuPFU996/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:25
FDA-CBER-2021-5683-0021902 to -0021915_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf2-sas.txt,TXT,ADAE Safety Analysis for C4591001 Phase 2/3 Study,2021-03-22,SAS Program,LIL233,M5,False,False,False,False,False,"safety-analysis, regulatory-submission, fda, compliance, pharmacovigilance, data-quality, sas-programming, statistical-analysis, phase-2-3, united-states, adverse-events, data-analysis, clinical-trial, vaccine-development, bnt162b2, placebo, data-processing",17,5,https://drive.google.com/file/d/1epE9GSU-43UuT6IpKL4xBx69w583kxJR/view?usp=drivesdk,pd-production-030122,2025-08-11 22:27:28
FDA-CBER-2021-5683-0023711 to -0023875_125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.xlsx,XLSX,C4591001 Participant Enrollment List,2020-09-17,data,,M5,False,False,False,False,False,"Pfizer-BioNTech, phase 3 study, participant enrollment, FDA submission, unique subject identifier, clinical trial, FOIA request, COVID-19 vaccine, safety data, data management, quality assurance, United States, efficacy data, pharmaceutical industry, adverse events, data analysis, regulatory compliance",17,2,https://docs.google.com/spreadsheets/d/1h4a_LQkDUiFbiVMi-wWUvCAM-Pt4gP73/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:31
FDA-CBER-2021-5683-0023930_125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.xlsx,XLSX,CCI_Diabetes without comp MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"medical-conditions, medical-terminology-coding, pharmaceutical-research, regulatory-compliance, medical-classification, medical-terminology, data-quality, clinical-trial-safety, medical-data-management, adverse-events, clinical-trial-data, data-reporting, meddra-dictionary, diabetes, fda-submission, data-analysis, medical-coding",17,1,https://docs.google.com/spreadsheets/d/1MopLoaQm8y2Xwq7QgsS9acE3khpYhg0M/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:34
FDA-CBER-2021-5683-0023926_125742_S1_M5_c4591001-A-report-cci-dementia.xlsx,XLSX,CCI Dementia MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"neurodegenerative-disorders, regulatory-submission, dementia, meddra, fda, pharmaceutical-research, alzheimer's-disease, lewy-body-dementia, frontotemporal-dementia, safety-data, data-dictionary, vascular-dementia, adverse-events, hiv-associated-neurocognitive-disorder, clinical-trial, medical-coding, terminology",17,1,https://docs.google.com/spreadsheets/d/1g4ExqTGlDSrfDU88eB4RQqDYDe-D40y3/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:37
FDA-CBER-2021-5683-0022793 to -0022866_125742_S1_M5_c4591001-A-P-adsl-s005-demo-all-p3-saf-sas.txt,TXT,ADSL Dataset for C4591001 Phase 3 Safety Analysis,2021-03-10,SAS Program,XIONGR03,M5,False,False,False,False,False,"Demographic Data, Data Management, FDA Submission, Unblinded Analysis, Data Quality, Safety Analysis, C4591001 Phase 3, Pharmacovigilance, Adverse Events, Regulatory Compliance, United States, SAS Programming, FOIA Document, Biostatistics, Vaccine Development, Pharmaceutical Clinical Trial, ADSL Dataset",17,25,https://drive.google.com/file/d/1rK6Cj3zSJm_PJWBWdYtO1GBeBOoy83W4/view?usp=drivesdk,pd-production-030122,2025-08-11 22:27:40
FDA-CBER-2021-5683-0023932_125742_S1_M5_c4591001-A-report-cci-hemiplegia.xlsx,XLSX,CCI_Hemiplegia MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"paralysis, pharmaceutical-research, safety-monitoring, fda-submission, regulatory-compliance, neurological-disorders, medical-terminology, excel-spreadsheet, medical-abbreviations, clinical-trial-data, hemiplegia, data-categorization, meddra-dictionary, data-report, adverse-events, medical-conditions, medical-coding",17,1,https://docs.google.com/spreadsheets/d/11ITKylPuND-j0sT-0yzUOULzFXiX5Ln-/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:43
FDA-CBER-2021-5683-0023895 to -0023915_125742_S1_M5_c4591001-A-report-cci-any-malignancy.xlsx,XLSX,CCI_Any malignancy Report,2020-10-27,report,,M5,False,False,False,False,False,"medical-conditions, pharmaceutical-research, safety-monitoring, regulatory-compliance, clinical-trial-phases, medical-terminology, data-quality, oncology, clinical-trial-data, adverse-events, data-reporting, data-categorization, medical-product-development, fda-submission, medical-product-identification, data-analysis, medical-coding",17,2,https://docs.google.com/spreadsheets/d/1e-Lu5Me07KrFCnfoz5fBYd6DMbn4jLFU/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:46
FDA-CBER-2021-5683-0023955 to -0023958_125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.xlsx,XLSX,CCI_Metastatic tumour Report,2020-10-27,report,,M5,False,False,False,False,False,"regulatory-submission, medical-conditions, meddra, fda, pharmaceutical-research, compliance, metastatic-tumour, medical-terminology, data-quality, safety-data, oncology, data-reporting, united-states, adverse-events, data-analysis, clinical-trial, medical-coding",17,2,https://docs.google.com/spreadsheets/d/1HMNoChzSi9VoTQlZAYmsFubxMVB62dSc/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:48
FDA-CBER-2021-5683-0022561 to -0022567_125742_S1_M5_c4591001-A-P-adds-sas.txt,TXT,ADDS Dataset Creation SAS Program,2021-03-07,SAS Program,LIUB65,M5,False,True,False,False,False,"ADAM Dataset, Safety Data, Technical Documentation, Unblinded Analysis, Data Quality, Data Processing, FOIA Document, Protocol, Adverse Events, Regulatory Compliance, Geographic Location, SAS Programming, FDA Submission, Disposition Events, Eligibility Criteria, CDISC SDTM, Pharmaceutical Clinical Trial, Study Termination",18,3,https://drive.google.com/file/d/18wWbRuYXSXpeRWgc3p0UYH_6vzL_10OR/view?usp=drivesdk,pd-production-030122,2025-08-11 22:27:51
FDA-CBER-2021-5683-0023960_125742_S1_M5_c4591001-A-report-cci-mi.xlsx,XLSX,CCI_MI MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"cardiovascular-events, cci, fda, meddra, pharmaceutical, medical-terminology, safety-data, data-dictionary, report, excel-file, medical-product, adverse-events, postmarketing-surveillance, clinical-trial, medical-coding, myocardial-infarction, regulatory",17,1,https://docs.google.com/spreadsheets/d/1c40zRPaoXAPL4DaTOlyVTPQxezcwQhYS/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:27:54
FDA-CBER-2021-5683-0023455 to -0023486_125742_S1_M5_c4591001-A-define-2-0-0.xsl,XSL,Clinical Study Define-XML Document,2021,Data,,M5,False,True,False,False,False,"Data Standards, Pharmaceutical Data, Clinical Trial, Protocol Information, CDISC Standards, Define-XML, Controlled Terminology, Data Quality, Efficacy Data, Protocol, Datasets, Regulatory Compliance, Adverse Events, FDA Submission, Study Design, Safety Data, Metadata, Analysis Results",18,4,https://drive.google.com/file/d/113KcDHfVxogYAcfp3K8W--TRpyzaLlwL/view?usp=drivesdk,pd-production-030122,2025-08-11 22:27:57
FDA-CBER-2021-5683-0023500 to -0023507_125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.xlsx,XLSX,C4591001 Phase 1 Subjects from DMW,2020-06,data,,M5,False,False,False,False,False,"C4591001, phase 1, subject enrollment, sentinel cohorts, pharmaceutical development, informed consent, FOIA, clinical trial, FDA, data management, safety data, COVID-19, vaccine, United States, adverse events, data analysis, regulatory compliance",17,2,https://docs.google.com/spreadsheets/d/1624Q14dKEbEJ03oZkCgxyH71tvBBl8nG/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:28:00
FDA-CBER-2021-5683-0023936 to -0023937_125742_S1_M5_c4591001-A-report-cci-leukemia.xlsx,XLSX,CCI Leukemia MedDRA Dictionary Report,2020-10-27,report,,M5,False,False,False,False,False,"cber, leukemia, pharmaceutical-research, fda-submission, regulatory-compliance, medical-terminology, safety-data, adverse-events, oncology, foia-request, data-categorization, meddra-dictionary, data-reporting, clinical-trial, data-analysis, medical-coding, hematology",17,2,https://docs.google.com/spreadsheets/d/12ovDvZZL7uUrBRt4r5LJt91NQCImHMDL/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:28:02
FDA-CBER-2021-5683-0022766 to -0022792_125742_S1_M5_c4591001-A-P-adsl-fu-d2-p3-saf-sas.txt,TXT,ADSL Follow-up Data for Phase 3 Safety Analysis,2021-03-10,SAS program,XIONGR03,M5,False,False,False,False,False,"fda, data quality, safety analysis, clinical trial, regulatory submission, time-to-event, data management, data processing, vaccine, adsl, efficacy, follow-up, bnt162b2, adverse events, phase 3, data analysis, sas programming",17,9,https://drive.google.com/file/d/1j1jWNh1EY9E1RvpfBSgdhcmgWANtkcZW/view?usp=drivesdk,pd-production-030122,2025-08-11 22:28:05
FDA-CBER-2021-5683-0021944 to -0021963_125742_S1_M5_c4591001-A-P-adae-sas.txt,TXT,ADAE Dataset Creation SAS Program,2021-03-07,SAS Program,LIL233,M5,False,False,False,False,False,"data-documentation, fda-submission, regulatory-compliance, pharmaceutical-development, clinical-trial, data-quality, sas-programming, data-management, data-merging, data-standardization, data-transformation, data-reporting, data-quality-control, data-processing, adverse-events, vaccine-development, data-analysis",17,11,https://drive.google.com/file/d/1QdE6cfx8Z9ycXaNHeSZiL5g8pO7DpWR7/view?usp=drivesdk,pd-production-030122,2025-08-11 22:28:08
FDA-CBER-2021-5683-0021964 to -0021980_125742_S1_M5_c4591001-A-P-adae-vax-tier2-p3-saf-sas.txt,TXT,ADAE-VAX-TIER2-P3-SAF SAS Program,2021-03-22,SAS Program,LIL233,M5,False,False,False,False,False,"phase-3, regulatory-submission, hiv-status, age-group, fda, data-repository, data-quality, safety-data, sas-programming, unblinded-analysis, data-subset, vaccine, adverse-events, data-analysis, clinical-trial, bnt162b2, placebo",17,6,https://drive.google.com/file/d/1aJ2r0wpVio8IYahnH0dX0k9YrulgqTX-/view?usp=drivesdk,pd-production-030122,2025-08-11 22:28:11
FDA-CBER-2021-5683-0021888 to -0021901_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf1-sas.txt,TXT,ADAE Safety Analysis for COVID-19 Vaccine Clinical Trial,2021-03-22,SAS Program,LIL233,M5,False,False,False,False,False,"data quality, safety analysis, FDA submission, CDISC, SAS programming, clinical trial, unblinded analysis, COVID-19 vaccine, ADSL, regulatory compliance, data processing, placebo, BNT162b2, adverse events, phase 2/3 study, data analysis, ADAE",17,4,https://drive.google.com/file/d/1TlqSjAKc-c9IsNel77lLwpeE128thjLI/view?usp=drivesdk,pd-production-030122,2025-08-11 22:28:14
FDA-CBER-2021-5683-0022601 to -0022617_125742_S1_M5_c4591001-A-P-admh-sas.txt,TXT,CDISC ADAM Dataset Creation: Adverse Events (ADMH),2021-03-09,SAS Program,XIONGR03,M5,False,False,False,False,False,"Data Merging, Clinical Trials, Data Analysis, ADAM, CDISC, FDA Submission, Data Quality, Data Preparation, Adverse Events, Unblinded Data, Regulatory Compliance, Project C459, SAS Programming, Data Subsetting, Geographic Location, ADMH, Pharmaceutical Research",17,8,https://drive.google.com/file/d/1ZCjFGucFH-JQxToH8GivTazpkwwI2vxN/view?usp=drivesdk,pd-production-030122,2025-08-11 22:28:16
FDA-CBER-2021-5683-0022326 to -0022345_125742_S1_M5_c4591001-A-P-adcevd-sas.txt,TXT,Create adcevd dataset,2021-03-10,SAS program,FENGY46,M5,False,False,False,False,False,"Data processing, FOIA document, Pharmaceutical clinical trial, C4591001 study, Unblinded analysis, SAS programming, Data quality control, SDTM data, ADAM dataset, Clinical data reporting, FDA, Adverse event monitoring, Safety data analysis, Data management, Reactogenicity events, Regulatory compliance, BLA submission",17,8,https://drive.google.com/file/d/1jJ2IZIB_AX0m2Ra8Itidc1xNBfzlqYvj/view?usp=drivesdk,pd-production-030122,2025-08-11 22:28:19
FDA-CBER-2021-5683-0022867 to -0023006_125742_S1_M5_c4591001-A-P-adsl-sas.txt,TXT,ADSL Dataset Creation SAS Program,2021-03-07,SAS Program,LIUB65,M5,False,False,False,False,False,"Data Analysis, CDISC Standards, Data Transformation, Data Quality, Efficacy Data, Adverse Events, Unblinded Data, ADSL Dataset, SAS Programming, FDA Submission, Data Validation, Project C459, Safety Data, Regulatory Compliance, Biostatistics, Pharmaceutical Development, Clinical Trial Data",17,67,https://drive.google.com/file/d/1Lx9_wbMj36p9G9CdWRXfG64p8aKgVEGD/view?usp=drivesdk,pd-production-030122,2025-08-11 22:28:22
FDA-CBER-2021-5683-0023983 to -0023984_125742_S1_M5_c4591001-A-report-cci-rheumatic.xlsx,XLSX,CCI Rheumatic Adverse Events Report,2020-10-27,report,,M5,False,False,False,False,False,"trial-data, therapeutic-areas, clinical-trials, pharmaceutical-research, safety-monitoring, scleroderma, cci-reporting, medical-terminology, systemic-lupus-erythematosus, fda-regulation, rheumatic-diseases, meddra-coding, drug-safety, vaccine-development, adverse-events, data-analysis, terminology-list",17,1,https://docs.google.com/spreadsheets/d/191sUNbTD7x85S7tJXN2g5TExnYfIfKOM/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:28:25
FDA-CBER-2021-5683-0022028 to -0022040_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-sg-eval-sas.txt,TXT,adc19ef-ve-cov-7pd2-sg-eval.sas,2021-03-22,SAS program,WUY169,M5,False,False,False,True,False,"safety evaluation, SAS programming, pharmaceutical, adc19ef, demographics, clinical trial, age groups, FOIA, FDA, Exclusion, data processing, COVID-19, vaccine, efficacy, data output, adverse events, data analysis, regulatory submission",18,6,https://drive.google.com/file/d/1ElJgY_wMqxBKGCm4rbBWp831cwXJ0br_/view?usp=drivesdk,pd-production-030122,2025-08-11 22:28:28
FDA-CBER-2021-5683-0023523 to -0023538_125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.xlsx,XLSX,Subject List for 12-25 Immuno Analysis,2021-01-27,data,,M5,False,False,False,False,False,"C4591001, pharmaceutical, FOIA, clinical trial, FDA, subject list, immunogenicity analysis, safety data, CBER, vaccine, data management, adverse events, SUBJID, efficacy data, USUBJID, data, regulatory compliance",17,2,https://docs.google.com/spreadsheets/d/111rphHYsbHgsoZFATn1bHJtH1EQcm1Gt/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:28:31
FDA-CBER-2021-5683-0023944 to -0023950_125742_S1_M5_c4591001-A-report-cci-lymphoma.xlsx,XLSX,CCI Lymphoma Report,2020-10-27,report,,M5,False,False,False,False,False,"regulatory-submission, data-classification, report-generation, fda, pharmaceutical-research, product-development, lymphoma, medical-terminology, safety-data, data-management, oncology, quality-control, adverse-events, data-analysis, clinical-trial, medical-coding, hematology",17,2,https://docs.google.com/spreadsheets/d/1bcc3vIglXCgLWX469PwDUOGzYXeG9iEj/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:28:34
FDA-CBER-2021-5683-0023919 to -0023921_125742_S1_M5_c4591001-A-report-cci-cerebrovascular.xlsx,XLSX,CCI Cerebrovascular Report,2020-10-27,report,,M5,False,False,False,False,False,"regulatory-compliance, infarction, neurological-disorders, vascular-disease, stroke, medical-terminology, occlusion, cerebrovascular-events, hemorrhage, adverse-events, clinical-trial-data, meddra-coding, thrombosis, fda-submission, data-analysis, dissection, pharmaceutical-safety",17,2,https://docs.google.com/spreadsheets/d/1_eHO3KoZ4inBhb2Em3BHgdshDu84kQI-/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:28:37
FDA-CBER-2021-5683-0023540_125742_S1_M5_c4591001-A-comorbidity-categories.xlsx,XLSX,Comorbidity Categories for Clinical Trial C4591001,2021,data,,M5,False,False,False,False,False,"C4591001, comorbidities, pharmaceutical, spreadsheet, FOIA, submission, clinical trial, therapeutic area, FDA, vaccine, protocol, safety, study design, medical conditions, sheet, data analysis, regulatory",17,1,https://docs.google.com/spreadsheets/d/1pP52AF1WIvxrsPW17qQRM5Ak7R46A_zd/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-030122,2025-08-11 22:28:39
125742_S1_M4_20gr142_nsdrg.pdf,PDF,17-Day Intramuscular Toxicity Study in Wistar Han Rats with a 3-Week Recovery,2021-01-19,report,,M4,False,True,False,False,False,"laboratory-tests, intramuscular-administration, quality-assurance, pharmaceutical-research, regulatory-compliance, recovery-period, wistar-han-rats, preclinical-study, send-dataset, Protocol, pfizer, toxicology, study-design, fda-submission, united-states, data-standards, clinical-observations, exposure-data",18,16,https://drive.google.com/file/d/1Ic8L17eYdCZdk0ZzYr2zmybDKKlcqILf/view?usp=drivesdk,pd-production-030123,2025-08-11 22:28:43
125742_S1_M4_38166_nsdrg.pdf,PDF,Study Data Reviewer's Guide for Repeat-Dose Toxicity Study of Three LNP-Formulated RNA Platforms Encoding for Viral Proteins,2020-09-22,report,BioNTech RNA Pharmaceuticals,M4,False,True,False,False,False,"nonclinical study, safety assessment, vaccine research, BioNTech, data quality, pharmaceutical development, SEND dataset, FDA review, repeat-dose toxicity, intramuscular administration, RNA platforms, viral proteins, Wistar Han rats, preclinical testing, Protocol, data standards, study design, regulatory submission",18,13,https://drive.google.com/file/d/1I-zgIe1edX2kflsPVkmrGzDGaSakunXb/view?usp=drivesdk,pd-production-030123,2025-08-11 22:28:46
FDA-CBER-2021-5683-0768245-0768300_125742_S1_M4_38166-D_bw.xpt,XPT,FDA-CBER-2021-5683-0768245-0768300 125742 S1 M4 38166-D bw,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1S51hVEelTXLQUGfeWy4BTBjb76ps1ShE/view?usp=drivesdk,pd-production-030123,2025-08-11 22:28:48
FDA-CBER-2021-5683-0768063-0768092_125742_S1_M4_20gr142_define2-0-0.xsl,XSL,FDA CBER 2021 5683 Define.xml File,2021,Data Definition,,M4,False,False,False,False,False,"Clinical Trial, Data Compliance, Analysis, Controlled Terminology, Data Definition, FDA, Tabulation, CBER, Regulatory Submission, Pharmaceutical, Datasets, Efficacy Data, Adverse Events, Data Quality, Metadata, Safety Data, Computational Algorithms",17,2,https://drive.google.com/file/d/1PUAsr6hWtoSSgfo-ZZldqSd9Y6PK0Ynb/view?usp=drivesdk,pd-production-030123,2025-08-11 22:28:50
125742_S1_M4_4.2.3.2 38166.pdf,PDF,Amendment No. 1 to Final Report,2020-09-17,report,"(b) (4), (b) (6), (b) (6), (b) (4)",M4,False,False,False,False,False,"viral_proteins, safety_data, haematology, preclinical_study, Wistar_Han_rats, report_amendment, regulatory_compliance, FDA_submission, intramuscular_administration, BioNTech_RNA_Pharmaceuticals, Germany, vaccine_development, RNA_platform, September_2020, clinical_chemistry, local_tolerance, repeat-dose_toxicity",17,2237,https://drive.google.com/file/d/1INOND8fNQaAYYmctNU0CwVsvf5QN9Eko/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:02
FDA-CBER-2021-5683-0768093-0768158_125742_S1_M4_38166_define.xml,XML,Repeat-Dose Toxicity Study of Three LNP-Formulated RNA Platforms Encoding for Viral Proteins,2021,report,,M4,False,False,False,False,False,"lipid-nanoparticle, intramuscular-administration, animal-study, clinical-chemistry, fda-submission, regulatory-compliance, pharmaceutical-development, preclinical-study, wistar-han-rats, safety-data, rna-vaccine, toxicology, viral-proteins, cytokine-analysis, neutralization-assay, urinalysis, hematology",17,5,https://drive.google.com/file/d/1HCpFWzX1i3GV20gZ56a1YF0r4L4rorOe/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:05
FDA-CBER-2021-5683-0768324-0768792_125742_S1_M4_38166-D_cl.xpt,XPT,FDA-CBER-2021-5683-0768324-0768792 125742 S1 M4 38166-D cl,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1JAjo1uRkA9b5QOuyd5Uk3xFLzuM9bKdT/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:07
FDA-CBER-2021-5683-0768301-0768323_125742_S1_M4_20gr142-D_bw.xpt,XPT,FDA-CBER-2021-5683-0768301-0768323 125742 S1 M4 20gr142-D bw,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1Ye6y6guN7Q6F-BAoOp7RlTW_ZXihCGT-/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:07
FDA-CBER-2021-5683-0768227-0768244_125742_S1_M4_20gr142-D_bg.xpt,XPT,FDA-CBER-2021-5683-0768227-0768244 125742 S1 M4 20gr142-D bg,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1F-Q86baFkNXJ3idRKbr9nPCyiIQrpoMh/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:09
FDA-CBER-2021-5683-0768159-0768188_125742_S1_M4_38166_define2-0-0.xsl,XSL,FDA CBER DEFINE.XML File for Clinical Trial Submission,2021,Data,,M4,False,False,False,False,False,"Data Standards, Clinical Trials, ADAM, Analysis, Controlled Terminology, FDA, Tabulation, CBER, Data Quality, Pharmaceutical Submissions, Regulatory Compliance, FOIA Request, External Dictionaries, Variable Metadata, DEFINE.XML, Data Formatting, Computational Algorithms",17,1,https://drive.google.com/file/d/1SUnoiqykZWrTtyWk8y7KLrXgvwrVR-t2/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:11
FDA-CBER-2021-5683-0767981-0768062_125742_S1_M4_20gr142_define.xml,XML,17-Day Intramuscular Toxicity Study in Wistar Han Rats with a 3-Week Recovery,2020,report,,M4,False,False,False,False,False,"laboratory-tests, intramuscular-administration, study-report, histopathology, pharmaceutical-research, regulatory-compliance, clinical-observations, recovery-period, dose-levels, wistar-han-rats, preclinical-study, toxicology, study-design, fda-submission, data-analysis, safety-assessment, drug-development",17,3,https://drive.google.com/file/d/1Scy0AYwMHZvPiR-2eQO-HOoeSyV7TPf6/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:14
FDA-CBER-2021-5683-0768189-0768226_125742_S1_M4_38166-D_bg.xpt,XPT,FDA-CBER-2021-5683-0768189-0768226 125742 S1 M4 38166-D bg,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/11DQnKDuR3zbvpFO7FLCZp81sXf7eaOJz/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:15
FDA-CBER-2021-5683-0769003-0769004_125742_S1_M4_38166-D_co.xpt,XPT,FDA-CBER-2021-5683-0769003-0769004 125742 S1 M4 38166-D co,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1oQiEibz6CLcweCd4VCTcNRGOvk4WhyPq/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:16
FDA-CBER-2021-5683-0769022-0769033_125742_S1_M4_38166-D_ex.xpt,XPT,FDA-CBER-2021-5683-0769022-0769033 125742 S1 M4 38166-D ex,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1FaT6y3Ji4F24MJlilh5JFpImOEo57xEV/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:17
FDA-CBER-2021-5683-0769635-0769835_125742_S1_M4_20gr142-D_lb.xpt,XPT,FDA-CBER-2021-5683-0769635-0769835 125742 S1 M4 20gr142-D lb,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1ryjS3EpYGT9tbNDBTbqQyWighR_VuHX5/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:18
FDA-CBER-2021-5683-0769012-0769013_125742_S1_M4_20gr142-D_dm.xpt,XPT,FDA-CBER-2021-5683-0769012-0769013 125742 S1 M4 20gr142-D dm,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1eN19M_3gwsoDsHvorKf7o6ob6cAJhxvW/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:20
FDA-CBER-2021-5683-0769020-0769021_125742_S1_M4_20gr142-D_ds.xpt,XPT,FDA-CBER-2021-5683-0769020-0769021 125742 S1 M4 20gr142-D ds,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1JjmMPTZmOIvYjR6nnxpdarFjivCk0h4U/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:21
FDA-CBER-2021-5683-0769068-0769634_125742_S1_M4_38166-D_lb.xpt,XPT,FDA-CBER-2021-5683-0769068-0769634 125742 S1 M4 38166-D lb,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/10F6jIyXV5CVT49DAgqqPOrjdoOVvTRlR/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:23
FDA-CBER-2021-5683-0769005_125742_S1_M4_20gr142-D_co.xpt,XPT,FDA-CBER-2021-5683-0769005 125742 S1 M4 20gr142-D co,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1fFO36Wi382-ftiLKIkoFsheOfT5C-aDf/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:24
FDA-CBER-2021-5683-0769055-0769067_125742_S1_M4_20gr142-D_fw.xpt,XPT,FDA-CBER-2021-5683-0769055-0769067 125742 S1 M4 20gr142-D fw,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1kCWSZdJDk8dNzLj8sGkz0juzo-zi4xAs/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:25
FDA-CBER-2021-5683-0769006-0769011_125742_S1_M4_38166-D_dm.xpt,XPT,FDA-CBER-2021-5683-0769006-0769011 125742 S1 M4 38166-D dm,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1TFWSpGuUEq0LVkfHUhLywgPwpwhN8WfJ/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:26
FDA-CBER-2021-5683-0769014-0769019_125742_S1_M4_38166-D_ds.xpt,XPT,FDA-CBER-2021-5683-0769014-0769019 125742 S1 M4 38166-D ds,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1FsiA6u50m7hRJ2yXnFaiCtej654pjS9b/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:27
FDA-CBER-2021-5683-0769040-0769054_125742_S1_M4_38166-D_fw.xpt,XPT,FDA-CBER-2021-5683-0769040-0769054 125742 S1 M4 38166-D fw,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1d4eFXblrHNv8rFjfAs0zSMmOxQxH2zwM/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:28
FDA-CBER-2021-5683-0769034-0769039_125742_S1_M4_20gr142-D_ex.xpt,XPT,FDA-CBER-2021-5683-0769034-0769039 125742 S1 M4 20gr142-D ex,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1Fg5PgnefuRXaWwKnC6KeHYS-GGQp7yhs/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:29
FDA-CBER-2021-5683-0769836-0770088_125742_S1_M4_38166-D_ma.xpt,XPT,FDA-CBER-2021-5683-0769836-0770088 125742 S1 M4 38166-D ma,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1Dly26kWKAzrwJS5ZkWiMyqmE1ijJggKd/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:30
FDA-CBER-2021-5683-0768793-0769002_125742_S1_M4_20gr142-D_cl.xpt,XPT,FDA-CBER-2021-5683-0768793-0769002 125742 S1 M4 20gr142-D cl,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1Tar_D06Iegkjn6bgFkbdjroANE8a4Xdd/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:31
FDA-CBER-2021-5683-0770591-0770668_125742_S1_M4_20gr142-D_mi.xpt,XPT,FDA-CBER-2021-5683-0770591-0770668 125742 S1 M4 20gr142-D mi,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/19lhDY92Mfjfa7Ia45WtwJojxzzo8u6Rc/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:33
FDA-CBER-2021-5683-0771049-0771094_125742_S1_M4_20gr142-D_suppbw.xpt,XPT,FDA-CBER-2021-5683-0771049-0771094 125742 S1 M4 20gr142-D suppbw,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1WE48NC61ntQ3Lk-2Adx8dpAsn5LExL14/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:34
FDA-CBER-2021-5683-0771970_125742_S1_M4_38166-D_suppma.xpt,XPT,FDA-CBER-2021-5683-0771970 125742 S1 M4 38166-D suppma,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/12FnC0LnyHf5eJBBANvvd77WLkTv8SxN5/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:36
FDA-CBER-2021-5683-0771095-0771515_125742_S1_M4_20gr142-D_suppcl.xpt,XPT,FDA-CBER-2021-5683-0771095-0771515 125742 S1 M4 20gr142-D suppcl,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1CDqu7T9nPG5krX90hLmbPxEgylgqoRf9/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:37
FDA-CBER-2021-5683-0770969-0770973_125742_S1_M4_20gr142-D_se.xpt,XPT,FDA-CBER-2021-5683-0770969-0770973 125742 S1 M4 20gr142-D se,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1xsIOJZfVHzDdRp5VBDnkTF8xjHpXIJ3P/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:38
FDA-CBER-2021-5683-0770669-0770851_125742_S1_M4_38166-D_om.xpt,XPT,FDA-CBER-2021-5683-0770669-0770851 125742 S1 M4 38166-D om,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1p0zDEY1nc_lcbskokVBVjPne9Zo0nDLs/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:39
FDA-CBER-2021-5683-0770089-0770195_125742_S1_M4_20gr142-D_ma.xpt,XPT,FDA-CBER-2021-5683-0770089-0770195 125742 S1 M4 20gr142-D ma,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1iSdGGKI9UW6mQZ0VaiWRs2U3hFra-JF_/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:40
FDA-CBER-2021-5683-0771516-0771519_125742_S1_M4_20gr142-D_suppds.xpt,XPT,FDA-CBER-2021-5683-0771516-0771519 125742 S1 M4 20gr142-D suppds,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1ofOTkY_1dbDOS_uQyz7VDqNm-uoukcvh/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:41
FDA-CBER-2021-5683-0770953-0770954_125742_S1_M4_20gr142-D_relrec.xpt,XPT,FDA-CBER-2021-5683-0770953-0770954 125742 S1 M4 20gr142-D relrec,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1OQm_NSIqIRFav4NodVIjuAEXvHuKQ8kU/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:42
FDA-CBER-2021-5683-0771560-0771968_125742_S1_M4_20gr142-D_supplb.xpt,XPT,FDA-CBER-2021-5683-0771560-0771968 125742 S1 M4 20gr142-D supplb,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1-JQGGom6QEIJPBhiHGKQ39OdSgmY9E99/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:43
FDA-CBER-2021-5683-0770955-0770968_125742_S1_M4_38166-D_se.xpt,XPT,FDA-CBER-2021-5683-0770955-0770968 125742 S1 M4 38166-D se,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1Mw6e3rInbzZv9q_JaOv0rc1OAx2XiJru/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:44
FDA-CBER-2021-5683-0770852-0770911_125742_S1_M4_20gr142-D_om.xpt,XPT,FDA-CBER-2021-5683-0770852-0770911 125742 S1 M4 20gr142-D om,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1w08IprwwI5Nbrcy0caNl0gj67JUuBepr/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:45
FDA-CBER-2021-5683-0770974-0771048_125742_S1_M4_20gr142-D_suppbg.xpt,XPT,FDA-CBER-2021-5683-0770974-0771048 125742 S1 M4 20gr142-D suppbg,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/190FJfnJklSDj4ms04E1tthey9xUgQbSK/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:46
FDA-CBER-2021-5683-0770914-0770952_125742_S1_M4_38166-D_relrec.xpt,XPT,FDA-CBER-2021-5683-0770914-0770952 125742 S1 M4 38166-D relrec,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1bcR_00JxdXYUJduMkSo8lxXIPujxD7Pf/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:47
FDA-CBER-2021-5683-0770196-0770590_125742_S1_M4_38166-D_mi.xpt,XPT,FDA-CBER-2021-5683-0770196-0770590 125742 S1 M4 38166-D mi,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1WXA6go030v-JFdT60_Ax9TUvuKxhdx8N/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:48
FDA-CBER-2021-5683-0770912-0770913_125742_S1_M4_20gr142-D_pooldef.xpt,XPT,FDA-CBER-2021-5683-0770912-0770913 125742 S1 M4 20gr142-D pooldef,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1M59X6qO02d06aG80z7HGvaufRtZl61lb/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:49
FDA-CBER-2021-5683-0771520-0771559_125742_S1_M4_20gr142-D_suppfw.xpt,XPT,FDA-CBER-2021-5683-0771520-0771559 125742 S1 M4 20gr142-D suppfw,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1rWyzQwFT2hopQWY4fIElUV1R9k-xACuc/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:50
FDA-CBER-2021-5683-0771969_125742_S1_M4_20gr142-D_suppma.xpt,XPT,FDA-CBER-2021-5683-0771969 125742 S1 M4 20gr142-D suppma,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1f_6iF5Yg7pTS71Z7p4pxRloQz9btgpK4/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:51
FDA-CBER-2021-5683-0772182-0772253_125742_S1_M5_bnt162-01-S-D_is.xpt,XPT,FDA-CBER-2021-5683-0772182-0772253 125742 S1 M5 bnt162-01-S-D is,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1eWg6mXEvQoBLycgINOaoORdvzOt7VqrM/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:52
FDA-CBER-2021-5683-0772061-0772067_125742_S1_M4_20gr142-D_suppmi.xpt,XPT,FDA-CBER-2021-5683-0772061-0772067 125742 S1 M4 20gr142-D suppmi,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1VYfxh2f5G2baTPUgWP2HRgl7dob5fPAi/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:53
FDA-CBER-2021-5683-0772118_125742_S1_M4_38166-D_ts.xpt,XPT,FDA-CBER-2021-5683-0772118 125742 S1 M4 38166-D ts,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1ivdXPYReOXOsuSfAKY1SOETCu3N6j4G8/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:54
FDA-CBER-2021-5683-0772113_125742_S1_M4_20gr142-D_ta.xpt,XPT,FDA-CBER-2021-5683-0772113 125742 S1 M4 20gr142-D ta,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1qj9YwXp4bYAbQJpJbwQSZpKr7K4pTG4d/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:55
FDA-CBER-2021-5683-0772117_125742_S1_M4_20gr142-D_ts.xpt,XPT,FDA-CBER-2021-5683-0772117 125742 S1 M4 20gr142-D ts,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1E1cyguNh8uwb_Odr_1Wpjz7pG834-y73/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:56
FDA-CBER-2021-5683-0772160-0772181_125742_S1_M4_20gr142-D_vs.xpt,XPT,FDA-CBER-2021-5683-0772160-0772181 125742 S1 M4 20gr142-D vs,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/17KquHWx9niXHJKXMmUTtvp8PaihbwXRr/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:58
FDA-CBER-2021-5683-0772120-0772124_125742_S1_M4_38166-D_tx.xpt,XPT,FDA-CBER-2021-5683-0772120-0772124 125742 S1 M4 38166-D tx,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1YvqQUzn8o_9C4c6HVVRsnKH-N_lY8JiZ/view?usp=drivesdk,pd-production-030123,2025-08-11 22:29:59
FDA-CBER-2021-5683-0772068-0772112_125742_S1_M4_20gr142-D_suppvs.xpt,XPT,FDA-CBER-2021-5683-0772068-0772112 125742 S1 M4 20gr142-D suppvs,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/12hUnpSGHY0nyFhjBIy2vmYPsbELkFww4/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:01
FDA-CBER-2021-5683-0772254-0772289_125742_S1_M5_bnt162-01-S-D_mb.xpt,XPT,FDA-CBER-2021-5683-0772254-0772289 125742 S1 M5 bnt162-01-S-D mb,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1YBr6OJKC6UDAbot12NWGyaqzh9VcQgr3/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:02
FDA-CBER-2021-5683-0772125-0772159_125742_S1_M4_38166-D_vs.xpt,XPT,FDA-CBER-2021-5683-0772125-0772159 125742 S1 M4 38166-D vs,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/13lIr19x7Vu_jq4v6uuwqEvcAcaSCnxzO/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:03
FDA-CBER-2021-5683-0772115_125742_S1_M4_20gr142-D_te.xpt,XPT,FDA-CBER-2021-5683-0772115 125742 S1 M4 20gr142-D te,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1nA9SDHWQactaxm_N4cg_OBWNxM6q6bQL/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:04
FDA-CBER-2021-5683-0771971-0772060_125742_S1_M4_38166-D_suppmi.xpt,XPT,FDA-CBER-2021-5683-0771971-0772060 125742 S1 M4 38166-D suppmi,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1Yo4WlpCyoU6jTe5PJpbYb8LtKjTR7S77/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:04
FDA-CBER-2021-5683-0772119_125742_S1_M4_20gr142-D_tx.xpt,XPT,FDA-CBER-2021-5683-0772119 125742 S1 M4 20gr142-D tx,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1lZhpH1IEqrgon19HvATRNTp-b26cxC4h/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:06
FDA-CBER-2021-5683-0772418-0772466_125742_S1_M5_bnt162-01-S-D_sv.xpt,XPT,FDA-CBER-2021-5683-0772418-0772466 125742 S1 M5 bnt162-01-S-D sv,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/13Jh0FerBCTlTMHnvXgX9Qi40XKl-H4zV/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:07
FDA-CBER-2021-5683-0772290-0772417_125742_S1_M5_bnt162-01-S-D_supplb.xpt.xpt,XPT,FDA-CBER-2021-5683-0772290-0772417 125742 S1 M5 bnt162-01-S-D supplb,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1J25_QbfbBxDDYw_lOUHf6DoEbOZk6ouQ/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:08
FDA-CBER-2021-5683-0772467-0772468_125742_S1_M5_bnt162-01-S-D_ts.xpt,XPT,FDA-CBER-2021-5683-0772467-0772468 125742 S1 M5 bnt162-01-S-D ts,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1ADC0nR8j3LDKgGW21-g_0RaiTj1QaSsc/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:09
FDA-CBER-2021-5683-0772116_125742_S1_M4_38166-D_te.xpt,XPT,FDA-CBER-2021-5683-0772116 125742 S1 M4 38166-D te,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1I51wj4irJ4obwGZPbjlh9MEMHvFJj_XP/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:10
FDA-CBER-2021-5683-0772114_125742_S1_M4_38166-D_ta.xpt,XPT,FDA-CBER-2021-5683-0772114 125742 S1 M4 38166-D ta,undated,statistical-data,,M4,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1ftRXcpz4NPGoQyGM07f5mKXCq8MDO5qY/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:11
FDA-CBER-2021-5683-0772469-0773670_125742_S1_M5_C4591001-A-D_adsl.xpt,XPT,FDA-CBER-2021-5683-0772469-0773670 125742 S1 M5 C4591001-A-D adsl,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1nuVK2ZXlI7Gz5j1fLFdV6V4CSaVDm_KB/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:15
FDA-CBER-2021-5683-0773671-0774872_125742_S1_M5_C4591001-A-Supp-D-adsl.xpt,XPT,FDA-CBER-2021-5683-0773671-0774872 125742 S1 M5 C4591001-A-Supp-D-adsl,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1xkoarko5sUpo-d8XFrGkuA1aatQaet8T/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:19
FDA-CBER-2021-5683-0774873-0775804_125742_S1_M5_C4591001-A-D_adae.xpt,XPT,FDA-CBER-2021-5683-0774873-0775804 125742 S1 M5 C4591001-A-D adae,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/103jy1OtULBWiJKEb6SVDS3xWSVoPoIX_/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:25
FDA-CBER-2021-5683-0776793-0777994_125742_S1_M5_C4591001-S-D_dm.xpt,XPT,FDA-CBER-2021-5683-0776793-0777994 125742 S1 M5 C4591001-S-D dm,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1EgZbW_RW4WiupCsl3gteUSBbSTiePem3/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:27
FDA-CBER-2021-5683-0779202-0779206_125742_S1_M5_bnt162-01-S-Supp-D_suppdm.xpt,XPT,FDA-CBER-2021-5683-0779202-0779206 125742 S1 M5 bnt162-01-S-Supp-D suppdm,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1xaq-UDjq31EnCqHoQ95bIXrUTLyckm5f/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:28
FDA-CBER-2021-5683-0776792_125742_S1_M5_C4591001-S-D_dd.xpt,XPT,FDA-CBER-2021-5683-0776792 125742 S1 M5 C4591001-S-D dd,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1uvcixJQMUCsOCJjDA69gJ2tI-OR1ZEON/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:29
FDA-CBER-2021-5683-0777995-0779196_125742_S1_M5_C4591001-S-Supp_dm.xpt,XPT,FDA-CBER-2021-5683-0777995-0779196 125742 S1 M5 C4591001-S-Supp dm,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1LygDGcp2580vqxhle8fJLJQRJK6gYhfA/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:31
FDA-CBER-2021-5683-0779197-0779201_125742_S1_M5_bnt162-01-A-D_adsl .xpt,XPT,FDA-CBER-2021-5683-0779197-0779201 125742 S1 M5 bnt162-01-A-D adsl ,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1HEFFfkPkjSoOeN-z-I5vBRKETrLUCW-g/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:32
FDA-CBER-2021-5683-0775805-0776791_125742_S1_M5_C4591001-S-D_ae.xpt,XPT,FDA-CBER-2021-5683-0775805-0776791 125742 S1 M5 C4591001-S-D ae,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1iAUy_YQZhrudqVxk24NZ9VIweUtSTNui/view?usp=drivesdk,pd-production-030123,2025-08-11 22:30:36
125742_S1_M1_priority-review-request.pdf,PDF,"Request for Priority Review of COVID-19 Vaccine (BNT162, PF-07302048)",2021-05,Request,,M1,False,False,False,False,False,"serious and life-threatening disease, covid-19 vaccine, immunogenicity, regulatory affairs, confidential document, pf-07302048, unmet medical need, vaccine effectiveness, post-authorization safety, safety data, biologics license application, fda submission, bnt162b2, priority review request, nonclinical data, efficacy data, clinical trials",17,17,https://drive.google.com/file/d/1NxM2zgJ9oR_GvkN15lLOf3K_zJoqqFLR/view?usp=drivesdk,pd-production-032422,2025-08-11 22:30:40
125742_S1_M5_5351_c4591001-interim-mth6-adverse-events-sensitive.pdf,PDF,Listing of Severe and Grade 4 Local Reactions and Systemic Events - Subjects With Indeterminate Vaccine - All Subjects ≥16 Years of Age,2021-04-01,report,,M5,False,False,False,False,False,"systemic events, C4591001 study, relative day calculation, data listing, FDA submission, duration of events, clinical trial, local reactions, subjects 16 years and older, COVID-19, dose information, unblinded data, vaccine safety, adverse events, Pfizer, data analysis, regulatory compliance",17,3,https://drive.google.com/file/d/1JYiD1Ic1QajpIM7xlPP_koB0BHQBx4QV/view?usp=drivesdk,pd-production-040122,2025-08-11 22:30:44
125742_S1_M5_5351_c4591001-interim-mth6-invest-signature.pdf,PDF,"Interim Report – 6 Month Update: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",2021-04-29,Clinical Study Report,"John L. Perez, Stephen J. Thomas",M5,False,True,False,False,False,"dose-finding, covid-19 vaccine, immunogenicity, infectious disease, investigator declaration, healthy individuals, randomized study, clinical trial, phase 1/2/3 study, 6-month update, placebo-controlled, Protocol, interim report, safety and efficacy, fda submission, upstate medical university, sars-cov-2 rna vaccine, regulatory compliance",18,1,https://drive.google.com/file/d/1upr8VPvE3tgxJnkVAdzTEGGNueS90jsh/view?usp=drivesdk,pd-production-040122,2025-08-11 22:30:48
125742_S1_M5_5351_c4591001-fa-interim-sponsor-signature.pdf,PDF,Interim Clinical Study Report for Protocol C4591001,2020-12-03,report,"Dzung Nguyen, Ugur Sahin, Kenneth Koury, John L. Perez",M5,False,True,False,False,False,"dose-finding, SARS-CoV-2 RNA vaccine, immunogenicity, BioNTech, FDA submission, healthy individuals, clinical trial, phase 1/2/3 study, COVID-19 vaccine, tolerability, Protocol, observer-blind, interim report, efficacy, safety, randomized controlled trial, data analysis, regulatory compliance",18,3,https://drive.google.com/file/d/1BJy6X8pKYOg09Q0Ucml6mp3YgODpePJR/view?usp=drivesdk,pd-production-040122,2025-08-11 22:30:53
125742_S1_M5_5351_c4591001-interim-mth6-audit-certificates.pdf,PDF,"Pfizer Regulatory Quality Assurance Audit Certificate"",","2021-03-17"",",document,,M5,False,False,False,False,False,"FOIA-document, needs-review",2,5,https://drive.google.com/file/d/1B5wHD-38tYUjkZpX4WQFhv8oZb5Qs1Lh/view?usp=drivesdk,pd-production-040122,2025-08-11 22:30:57
125742_S1_M5_5351_c4591001-interim-mth6-demographics.pdf,PDF,"Listing of Demographic Characteristics – All Subjects ≥16 Years of Age"",","2021-04-01"",",document,,M5,False,False,False,False,False,"FOIA-document, needs-review",2,2951,https://drive.google.com/file/d/1kbnFhIe1YM6OxZ9HJiAGB_b5b6oy9ho7/view?usp=drivesdk,pd-production-040122,2025-08-11 22:31:28
reissue_5.3.6 postmarketing experience.pdf,PDF,Cumulative Analysis of Post-authorization Adverse Event Reports of PF-07302048 (BNT162B2),2021-04-30,report,Worldwide Safety Pfizer,,False,False,False,False,False,"post-authorization, PF-07302048, cumulative report, pharmacovigilance, medication error, FDA, COVID-19 vaccine, 28-Feb-2021, safety database, AESI, clinical trials, BNT162B2, confidential, adverse events, Pfizer, data analysis, regulatory submission",17,38,https://drive.google.com/file/d/1dt8Kyzu3XH9xzMfmeCSu9XIN6OUwyCcA/view?usp=drivesdk,pd-production-040122,2025-08-11 22:31:32
125742_S1_M5_5351_c4591001-fa-interim-sample-crf.pdf,PDF,Annotated Study Book for Study Design: C4591001,2020-10-12,report,,M5,True,True,False,False,False,"medication-error, covid-19, regulatory, fda, pharmaceutical, protocol, clinical-trial, adverse-event-reporting, CRF, data-collection, annotated-study-book, concomitant-medication, Protocol, pfizer, serious-adverse-event, central-designer, c4591001, study-design, safety-data",19,212,https://drive.google.com/file/d/1Ov47_ShDq-ihb3kRC1kPmvBU_axsc2Qf/view?usp=drivesdk,pd-production-040122,2025-08-11 22:31:36
125742_S1_M5_5351_c4591001-fa-interim-audit-certificates.pdf,PDF,"Pfizer Regulatory Quality Assurance Audit Certificate"",","2020-11-20"",",document,,M5,False,False,False,False,False,"FOIA-document, needs-review",2,4,https://drive.google.com/file/d/1D6Rintqog-OJ5CUpxBODxeds3btRdcsU/view?usp=drivesdk,pd-production-040122,2025-08-11 22:31:41
125742_S1_M5_5351_c4591001-fa-interim-demographics.pdf,PDF,"Listing of Demographic Characteristics - Phase 1, 2 Doses, 21 Days Apart Vaccine Candidate"",","2020-09-07"",",document,,M5,False,False,False,False,False,"FOIA-document, needs-review",2,3139,https://drive.google.com/file/d/1BX3i_6NDcwVqAHhWIlV4wakORxXiGkuq/view?usp=drivesdk,pd-production-040122,2025-08-11 22:32:11
125742_S1_M5_5351_c4591001-fa-interim-publications.pdf,PDF,"Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults"",","2020-08-12"",",document,,M5,False,False,False,False,False,"FOIA-document, needs-review",2,30,https://drive.google.com/file/d/1p4fdbTXj7MnKp4zKxOCH0ruIQc79MuRV/view?usp=drivesdk,pd-production-040122,2025-08-11 22:32:20
125742_S1_M5_5351_c4591001-fa-interim-invest-signature.pdf,PDF,Interim Investigation Report for Clinical Trial C4591001,2021,Report,,M5,False,False,False,False,False,"Safety Data, Data Analysis, Efficacy Data, CBER, Drug Identifier C4591001, Adverse Events, Regulatory Compliance, Phase 3 Clinical Trial, FDA Submission, Investigational New Drug, Clinical Trial C4591001, Interim Investigation Report, Clinical Trial Protocol, Vaccine Development, Quality Assurance, Pharmaceutical Research, Regulatory Affairs",17,1,https://drive.google.com/file/d/1uKO1HBKRr3ITIilzfi3ZZvZ0GweweuG8/view?usp=drivesdk,pd-production-040122,2025-08-11 22:32:24
125742_S1_M5_5351_c4591001-fa-interim-iec-irb-consent-form.pdf,PDF,List of Independent Ethics Committees (IEC) or Institutional Review Boards (IRB) for Clinical Trial C4591001,2020-11-19,report,,M5,False,False,False,False,False,"C4591001 study, pharmaceutical research, Brazil, study sites, FOIA document, Germany, clinical trial, institutional review board, clinical trial protocol, ethics review, Argentina, Turkey, IRB approval, confidential document, independent ethics committee, South Africa, regulatory compliance",17,265,https://drive.google.com/file/d/1_C5GUGJnvtx7rd2WKG314CvyqH4roSKL/view?usp=drivesdk,pd-production-040122,2025-08-11 22:32:28
125742_S1_M5_5351_c4591001-fa-interim-randomization.pdf,PDF,"Listing of Randomization Scheme and Actual Vaccine Received – Phase 1, 2 Doses, 21 Days Apart",2020-09-07,report,"10011004, 10011005, 10011006, 10011007, 10011008, 10011009, 10011011, 10011012, 10011015, 10011017, 10011019, 10011020, 10011024, 10011037, 10011039, 10011040, 10011041",M5,False,False,False,False,False,"randomization, phase 1, BNT162b1, dose, data listing, compliance, pharmaceutical, FOIA, clinical trial, age groups, FDA, COVID-19, vaccine, adverse events, efficacy, safety, placebo",17,15,https://drive.google.com/file/d/1aK5w-B_YKnCdIAFQhpZDc8Pt3qaQCW5g/view?usp=drivesdk,pd-production-040122,2025-08-11 22:32:33
125742_S1_M5_5351_c4591001-fa-interim-protocol-deviations.pdf,PDF,"Listing of Important Protocol Deviations - Phase 1, 2 Doses, 21 Days Apart",2020-09-22,report,"C4591001 1002 10021053, C4591001 1003 10031021, C4591001 1003 10031047, C4591001 1003 10031017, C4591001 1003 10031070",M5,False,True,False,True,False,"Exclusion, data quality control, 2020 data cutoff, CDISC standards, Pfizer pharmaceutical, global clinical development, inclusion/exclusion criteria, hematology and blood chemistry, phase 1 clinical trial, subject-level data, FDA regulatory compliance, BNT162b1 vaccine, Protocol, interim analysis, clinical trial protocol deviations, safety data analysis, SDTM data format, adverse event reporting, COVID-19 vaccine development",19,2,https://drive.google.com/file/d/12sA9pn1PYOCp6h_oa8fhx-HmAGiDUMbN/view?usp=drivesdk,pd-production-040122,2025-08-11 22:32:37
125742_S1_M5_5351_c4591001-fa-interim-randomization-sensitive.pdf,PDF,Listing of Randomization Scheme and Actual Vaccine Received - Phase 2,2020-09-14,report,,M5,False,False,False,False,False,"randomization, data listing, placebo, pharmaceutical, compliance, FOIA, clinical trial, age groups, phase 2, FDA, United States, adverse events, safety, efficacy, vaccine administration, dosage, BNT162b2",17,4412,https://drive.google.com/file/d/1KBFqdbDtnpTc1R7OD9JK5f8fcqJ4Dc7j/view?usp=drivesdk,pd-production-040122,2025-08-11 22:33:12
125742_S14_M1_cover.pdf,PDF,BLA 125742 COVID-19 mRNA Vaccine (BNT162/PF-07302048) General Correspondence,2021-07-19,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandran S. Naik, Ph.D.",M1,False,False,False,False,False,"BLA 125742, Vaccine Safety and Efficacy Data, Clinical Trials, Pharmaceutical Regulatory Compliance, COVID-19 mRNA Vaccine, FDA Regulatory Affairs, Silver Spring, MD, Pfizer Global Regulatory, Collegeville, PA, Vaccine Identification, Biologics License Application, Vaccine Approval Process, Waiver of Review Meetings, Correspondence, Vaccine Development, CBER Office of Vaccines, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/12bcrh2P8omZrz_4kQQpPEa4i6RXUR3Kp/view?usp=drivesdk,pd-production-040323,2025-08-11 22:33:16
125742_S1_M5_5314_vr-tm-10293.pdf,PDF,Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-2 S1 Protein in Human Serum,2020-01-01,protocol,,M5,False,False,False,False,False,"antibody quantitation, vaccine research, quality control, Luminex assay, Pearl River, NY, clinical trial, analytical method, SARS-CoV-2, vaccine development, COVID-19, S1 protein, protocol, bioanalytical testing, human serum, Pfizer, IgG antibodies, regulatory compliance",17,19,https://drive.google.com/file/d/10RYvbOPstsz17VP9aXK2TdvXYQh0PM57/view?usp=drivesdk,pd-production-040323,2025-08-11 22:33:21
125742_S1_M5_5314_vr-mqr-10211-att-01.pdf,PDF,Supportive Data for VR-MQR-10211,2020-08-07,report,,M5,False,False,False,False,False,"pharmaceutical-manufacturing, pf-07302048, analytical-methods, regulatory-compliance, safety-data, quality-control, pfizer, clinical-trial-data, precision-linearity, pearl-river-ny, vaccine-development, fda-submission, efficacy-data, adverse-events, analytical-validation, vaccine-research, non-clinical-studies",17,45,https://drive.google.com/file/d/1vQHdBSrueOLzfahLZWELT8b_rBrKl5H-/view?usp=drivesdk,pd-production-040323,2025-08-11 22:33:26
125742_S1_M5_5351_c4591001-interim-mth6-report-body.pdf,PDF,Interim Clinical Study Report Protocol C4591001,2021-04-29,report,"Stephen Thomas, John L. Perez, Kenneth Koury, Ugur Sahin",M5,False,True,False,False,False,"covid-19 vaccine, immunogenicity, fda, phase 1/2/3, suny upstate medical university, clinical trial, gcp compliance, bnt162, bioNTech, pfizer, tolerability, interim report, efficacy, safety, data cutoff, vaccine clinical research and development, Protocol, regulatory",18,1584,https://drive.google.com/file/d/1EDoY_Y5SjNOKEYc8cJy995BDzNTfR58x/view?usp=drivesdk,pd-production-040323,2025-08-11 22:33:40
125742_S1_M5_5314_vr-tm-10294.pdf,PDF,Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-2 RBD Protein in Human Serum,2020,protocol,,M5,False,False,False,False,False,"antibody quantitation, vaccine research, quality control, serum analysis, Luminex assay, RBD protein, Pearl River, NY, clinical trial, data management, SARS-CoV-2, document control, safety, procedure, method validation, materials and equipment, Pfizer, regulatory compliance",17,19,https://drive.google.com/file/d/1jbvVtI0lQxqnq-Y7iQp08L2xgmtcpY3t/view?usp=drivesdk,pd-production-040323,2025-08-11 22:33:45
125742_S1_M5_5314_vr-mvr-10083-att03.pdf,PDF,LOD Data Listing for VR-MVR-10083,2021-02-09,data,"(b) (4), (b) (6)",M5,False,False,False,False,False,"vaccine-identifier-pf-07302048, limit-of-detection, pfizer-vaccine-research, data-listing, regulatory-compliance, quality-control, clinical-trial-data, pearl-river-ny, sars-cov-2, neutralization-assay, fda-submission, vaccine-development, laboratory-testing, covid-19, biostatistics-analysis, study-vr-mvr-10083, confidential-document",17,8,https://drive.google.com/file/d/1S8Z_ylBOrm5dSiTFCvp8uiUUKqzIcIjg/view?usp=drivesdk,pd-production-040323,2025-08-11 22:33:49
125742_S1_M5_5314_vr-mqr-10212.pdf,PDF,Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for Quantitation of IgG Antibodies to SARS-CoV-2 RBD Protein in Human Sera,2020-08-18,report,"Guy Singh, Darryl Charles, Estee Dilli, Nathaniel Garcia, Danka Pavliakova, Warren Kalina, Charles Tan, David Cooper, Michael Pride",M5,False,False,False,False,False,"human-serum-samples, drug-identification-pf-07302048, clinical-diagnostic-development, pfizer-vaccine-research, biostatistical-analysis, immunoassay-validation, luminex-immunoassay, assay-precision-and-accuracy, clinical-immunoassays-and-diagnostics, covid-19-vaccine-research, clinical-trial-assay, lower-limit-of-quantitation, assay-qualification, sars-cov-2-antibody-quantitation, pearl-river-new-york, fda-regulatory-compliance, receptor-binding-domain-protein",17,29,https://drive.google.com/file/d/1HSfqJXAn8M1-OEBaCJorlwsPTd3nnoQo/view?usp=drivesdk,pd-production-040323,2025-08-11 22:33:56
125742_S1_M5_5314_vr-mqr-10211.pdf,PDF,Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for Quantitation of IgG Antibodies to SARS-CoV-2 S1 Protein in Human Sera,2020-08-18,report,"Guy Singh, Darryl Charles, Estee Dilli, Nathaniel Garcia, Danka Pavliakova, Warren Kalina, Charles Tan, David Cooper, Michael Pride",M5,False,False,False,False,False,"pearl-river-ny-facility, immunogenicity-data, clinical-diagnostic-development, pfizer-vaccine-research, covid-19-pandemic-response, biostatistical-analysis, assay-linearity-precision, luminex-immunoassay, clinical-trial-assay, lower-limit-of-quantitation, assay-qualification, vaccine-candidate-pf-07302048, sars-cov-2-antibody-quantitation, quality-control-procedures, confidential-pfizer-document, fda-regulatory-compliance, high-throughput-immunoassays",17,29,https://drive.google.com/file/d/1TlSXaxHC3jjWCZ0ekSjHRycinwOrt8ny/view?usp=drivesdk,pd-production-040323,2025-08-11 22:34:02
125742_S1_M5_5351_c4591001-fa-interim-report-body.pdf,PDF,"Final Analysis Interim Report: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",2020-12-03,report,"Stephen Thomas, John L. Perez, Kenneth Koury, Ugur Sahin",M5,False,True,False,False,False,"interim-report, immunogenicity, data-cutoff, gcp-compliance, fda, syracuse-ny, vaccines, bnt162, bioNTech, pfizer, rna-vaccine, Protocol, efficacy, safety, clinical-trial, covid-19, phase-1-2-3, regulatory",18,2033,https://drive.google.com/file/d/1X47NTRsFTfndWZvFYC7JB1BDPznc3rOi/view?usp=drivesdk,pd-production-040323,2025-08-11 22:34:24
125742_S1_M5_5314_vr-mvr-10081.pdf,PDF,Method Validation Report for the Elecsys Anti-SARS-CoV-2 Assay,2020-09-02,report,"Warren Kalina, Charles Tan, David Cooper, Michael Pride",M5,False,False,False,False,False,"epidemiological studies, fda emergency use authorization, roche cobas platform, serology and diagnostic assay development, pre-covid-19 serum samples, clinical trial, pfizer vaccine research and development, regulatory compliance, clinical and diagnostic assay development, assay sensitivity and specificity, quality assurance, covid-19 serum samples, sars-cov-2 n protein, method validation, elecsys anti-sars-cov-2 assay, clinical performance parameters, vaccine efficacy evaluation",17,18,https://drive.google.com/file/d/1DTuRsjCWkk34DrQnigeBx2EVgpN5wUsh/view?usp=drivesdk,pd-production-040323,2025-08-11 22:34:29
125742_S1_M5_5314_vr-mqr-10214-att-03.pdf,PDF,QCS Infection Ratio Data Listing,2020-07-28,data,,M5,False,False,False,False,False,"data-listing, pf-07302048, regulatory-compliance, data-analysis, infection-ratio, safety-data, quality-control, pfizer, clinical-trial-data, pearl-river-ny, efficacy-data, vaccine-development, fda-submission, adverse-events, approved-document, vaccine-research, confidential-document",17,6,https://drive.google.com/file/d/1GGr95oXnSqYmK7RPOAjF8673KF47Wf6W/view?usp=drivesdk,pd-production-040323,2025-08-11 22:34:33
125742_S1_M5_5314_vr-mqr-10214-att-01.pdf,PDF,Precision Experiment Data Listing,2020-07-28,data,,M5,False,False,False,False,False,"precision-experiment, data-listing, table-of-contents, pf-07302048, regulatory-compliance, pharmaceutical-research, vaccine-research-and-development, data-quality, safety-data, adverse-events, clinical-trial-data, efficacy-data, pearl-river-ny, parent-compound, fda-submission, alternative-identifiers, pfizer-confidential",17,9,https://drive.google.com/file/d/1IaRekJy4cwGHoKXe7MBPRh4Hx_S7yogG/view?usp=drivesdk,pd-production-040323,2025-08-11 22:34:37
125742_S1_M5_5314_vr-mvr-10083-att04.pdf,PDF,Training Event Form,2020-11-16,form,"Caitlin Allison, DeGrose George, Phelan Kent, Ozcan Kyle, Jacobs Tyler, Garretson",M5,False,True,False,False,False,"computer-based-training, training-event, data-collection, pearl-river, vaccine-research, compliance, interactive-training, skill-assessment, fda-submission, quality-control, pfizer, Protocol, sars-cov-2, clinical-trial, read-only-training, microneutralization-assay, initial-training, refresher-training",18,2,https://drive.google.com/file/d/1cwdqqoTfoFuNOo1TbgkqfoZASuOf7ayD/view?usp=drivesdk,pd-production-040323,2025-08-11 22:34:42
125742_S1_M5_5351_c4591001-fa-interim-synopsis.pdf,PDF,"Final Analysis Interim Report: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",2020-12-03,report,"Stephen Thomas, MD",M5,False,True,False,False,False,"covid-19 vaccine, immunogenicity, fda, phase 1/2/3, clinical trial, bnt162, bioNTech, pfizer, tolerability, interim report, efficacy, safety, data cutoff, united states, germany, Protocol, turkey, adverse events",18,31,https://drive.google.com/file/d/1-vFl_jhZZSN-7qoOaf5B660Qj8ueisog/view?usp=drivesdk,pd-production-040323,2025-08-11 22:34:47
125742_S1_M5_5314_vr-mvr-10080-att-01.pdf,PDF,Raw Data in Support of VR-MVR-10080 Study,2020-08-18,report,,M5,False,False,False,False,False,"diagnostic-testing, clinical-specificity, data-listing, pf-07302048, fda-submission, detection-limit, regulatory-compliance, clinical-sensitivity, vr-mvr-10080, pharmaceutical-development, pearl-river-ny, pfizer, clinical-trial, confidential, covid-19, vaccine-research, quality-assurance",17,9,https://drive.google.com/file/d/1HhBnN56wUP38JRnFXVsFzXFU0fvKtdei/view?usp=drivesdk,pd-production-040323,2025-08-11 22:34:51
125742_S1_M5_5314_vr-mqr-10214-att-02.pdf,PDF,QCS Data Listing,2020-07-28,data,,M5,False,False,False,False,False,"immunogenicity, data-listing, pf-07302048, regulatory-compliance, vaccine-efficacy, confidential-document, pharmaceutical-development, data-quality, quality-control-samples, clinical-trial-data, pearl-river-ny, vaccine-safety, adverse-events, fda-submission, vaccine-research, pfizer-vaccine, vaccine-testing",17,6,https://drive.google.com/file/d/18q4NFcPxLhpQfIIuu5wfVicfmGqbzUlp/view?usp=drivesdk,pd-production-040323,2025-08-11 22:34:54
125742_S1_M5_5314_vr-tm-10304.pdf,PDF,Test Method for the SARS CoV-2 Nucleocapsid (N) Antigen Detection Assay,2022-01-01,protocol,,M5,False,False,False,False,False,"technical method, quality control, vaccine research, FOIA document, compliance, nucleocapsid antigen detection, FDA regulation, clinical trial, sample handling, data management, SARS-CoV-2, assay development, safety, procedure, Pearl River, Pfizer, laboratory information management system",17,24,https://drive.google.com/file/d/1jHHKftasJ6Kh2Fi5OC5MlUdgG7i5xo6P/view?usp=drivesdk,pd-production-040323,2025-08-11 22:34:59
125742_S1_M5_5314_vr-mvr-10083-att02.pdf,PDF,Precision Data Listing for VR-MVR-10083,2021-02-09,data,"(b) (4), (b) (6)",M5,False,False,False,False,False,"compound-identifier-pf-07302048, data-listing, regulatory-compliance, analytical-methods, assay-validation, bioanalytical-testing, quality-control, pfizer, clinical-trial-data, precision-data, sars-cov-2, neutralization-assay, fda-submission, pearl-river-ny, vaccine-research, vr-mvr-10083-study, confidential-document",17,17,https://drive.google.com/file/d/16NdN4k8rrhFApGWYf6EmBUX1SQyoOym7/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:03
125742_S1_M5_5314_vr-mvr-10083.pdf,PDF,Method Validation of the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay,2021-02-09,report,"Ingrid L. Scully, Tyler Garretson, Kyle Jacobs, George Phelan",M5,False,True,False,False,False,"diagnostic testing, PF-07302048, microneutralization assay, neutralizing antibodies, Pearl River, NY, quantitation limits, clinical trial, mNeonGreen virus, FDA, SARS-CoV-2, precision assessment, clinical and diagnostic assay development, Protocol, vaccine research and development, method validation, assay performance, Pfizer, regulatory compliance",18,22,https://drive.google.com/file/d/1-wfAhfZK20jidX8lc_vVxYlJvStCSTpv/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:09
125742_S1_M5_5314_vr-mvr-10083-att01.pdf,PDF,Dilutional Linearity Data Listing for VR-MVR-10083,2021-02-09,data,"(b) (4), (b) (6)",M5,False,False,False,False,False,"data-listing, regulatory-compliance, pharmaceutical-development, dilutional-linearity, quality-control, clinical-trial-data, pfizer, compound-identification, sars-cov-2, neutralization-assay, fda-submission, analytical-validation, pearl-river-ny, covid-19, vaccine-research, assay-performance, confidential-document",17,19,https://drive.google.com/file/d/1IOeg3r38kZ3qElSD4v_UpPE3C_Z6KeLI/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:12
125742_S1_M5_5314_vr-mvr-10081-att-01.pdf,PDF,Supportive Data for VR-MVR-10081,2020-07-31,report,,M5,False,False,False,False,False,"clinical-specificity, data-listing, pf-07302048, fda-submission, regulatory-compliance, confidential, clinical-sensitivity, approved, pearl-river-ny, vr-mvr-10081, pfizer, clinical-trial, data-analysis, covid-19, vaccine-research, supportive-data, pcr-testing",17,14,https://drive.google.com/file/d/1UxM1S_z01K6V8roc6tA7iAOcKujqnhfX/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:16
125742_S1_M5_5314_vr-mvr-10080.pdf,PDF,Report on Method Validation of a Cepheid Xpert® Xpress PCR Assay to Detect SARS-CoV-2,2020-09-16,report,"Katherine Schneider, Jason Bennett, Tyler Garretson, Joanna Wresilo, Warren Kalina, Charles Tan, David Cooper, Michael Pride",M5,False,True,False,False,False,"PF-07302048, Pfizer Vaccine Research and Development, pre-COVID-19 samples, clinical specificity, detection limits, Pearl River, NY, FDA regulatory, nasal swab samples, clinical sensitivity, clinical trial support, protocol VR-MVP-10076, Protocol, vaccine candidate, live SARS-CoV-2, PCR assay, GeneXpert instruments, method validation, SARS-CoV-2 detection",18,23,https://drive.google.com/file/d/120s9oTO3NQyb0ku-aC_LItEEdE_n74ZA/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:22
125742_S1_M5_5351_c4591001-interim-mth6-synopsis.pdf,PDF,Interim Clinical Study Report Protocol C4591001,2021-04-29,report,"Stephen Thomas, MD",M5,False,True,False,False,False,"BNT162 RNA-Based COVID-19 Vaccines, immunogenicity, BioNTech, Turkey, phase 1/2/3, Germany, clinical trial, FDA, tolerability, Protocol, data cutoff, interim report, efficacy, safety, United States, serious adverse events, adverse events, Pfizer",18,48,https://drive.google.com/file/d/1o-UJIQqy-aNQQIfqe4InUHaOezoA19F_/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:28
125742_S1_M5_5314_vr-mqr-10214.pdf,PDF,Qualification of the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay,2020-08-18,report,,M5,False,False,False,False,False,"Neutralization Titer, Precision, Microneutralization Assay, Qualification, Vaccine Research and Development, Assay Validation, FDA, Bioanalytical Assay, SARS-CoV-2, mNeonGreen Virus, Regulatory Compliance, Virus Neutralization, Pharmaceutical Development, Quality Control, Clinical Testing, Pfizer, Antibody Response",17,21,https://drive.google.com/file/d/1L1L6X6XSQ1u5oOLhxaaHjvMLz0yKL8Kw/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:33
125742_S1_M5_5314_vr-tm-10298.pdf,PDF,Manual 96-well Microneutralization Assay for the Detection of Functional Antibodies to SARS-CoV-2 in Test Serum,2022-01-01,protocol,,M5,False,False,False,False,False,"quality control, vaccine research, serum analysis, Pearl River, NY, laboratory procedure, 96-well plate, viral detection, clinical trial, regulatory submission, antibody detection, microneutralization, vaccine development, SARS-CoV-2, functional antibodies, neutralization assay, Pfizer, FDA compliance",17,31,https://drive.google.com/file/d/1LvQHAUJoA8eXNvBv4jzKFBEmrOEW6fxg/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:40
125742_S1_M5_5314_vr-mqr-10212-att-01.pdf,PDF,Supportive Data for VR-MQR-10212,2020-08-07,report,,M5,False,False,False,False,False,"analytical methods, PF-07302048, quality control, clinical trial data, data listing, Pearl River, NY, FDA submission, non-clinical data, pharmaceutical development, VR-MQR-10212, sample precision, supportive documentation, linearity evaluation, experimental data, vaccine research and development, Pfizer, regulatory compliance",17,43,https://drive.google.com/file/d/1LjuhXGLfK8EmBHpYLhwNpCx4zTebwIdl/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:44
125742_S2_M1_cover.pdf,PDF,"BLA 125742 COVID-19 mRNA Vaccine (BNT162/PF-07302048) Part 2, Final, of the Original Submission – Rolling Biologics License Application (BLA)",2021-05-18,Regulatory Submission,"Marion Gruber, Ph.D.",M1,False,False,False,False,False,"Submission Timelines, Clinical Trials, Proprietary Name Review, FDA Interaction, COVID-19 mRNA Vaccine, Efficacy Data, Adverse Events, Regulatory Compliance, Pfizer Global Product Development, Regulatory Affairs, Biologics License Application, Safety Data, Regulatory Approval, Vaccine Development, Rolling Submission, BNT162/PF-07302048, BioNTech Collaboration",17,5,https://drive.google.com/file/d/1xOfHq3sEQiIl34lk_D-EfPCGo0hEFYxT/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:48
125742_S1_M5_5314_vr-sop-lc-11120.pdf,PDF,Data Review Procedures for Direct Luminex Immunoassays in VRD LabWare LIMS,2022-11-20,Standard Operating Procedure (SOP),,M5,False,False,False,False,False,"quality control, lims, vaccine research, data upload, fda, luminex immunoassay, result review, new york, sas analysis, deviations, vaccine development, regulatory compliance, pfizer, assay validation, data review procedures, data analysis, clinical trials",17,19,https://drive.google.com/file/d/1Y7Y4K0yDriq0H6wEKSd3mmpC1jFbyfi0/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:52
125742_S1_M5_5314_vr-mvr-10080-att-02.pdf,PDF,Supportive Data for VR-MVR-10080,2020-07-30,report,"(b) (6), Joanna Wresilo, Jason Bennett, Tyler Garretson, Charles Tan, David Cooper, Michael Pride, Warren Kalina",M5,False,True,False,False,False,"summary-report, quality-compliance, pf-07302048, assay-validation, protocol-development, vr-mvr-10080, regulatory-approval, safety-data, statistical-analysis, pearl-river-ny, efficacy-data, Protocol, fda-submission, laboratory-analysis, clinical-trial, vaccine-research, pfizer-confidential, batch-information",18,4,https://drive.google.com/file/d/14XbXrqlv6LDzzsdYkCuXqscS3llxPM4b/view?usp=drivesdk,pd-production-040323,2025-08-11 22:35:56
125742_S2_M5_5354_c4591022-protocol.pdf,PDF,Pfizer-BioNTech COVID-19 Vaccine Exposure during Pregnancy: A Non-Interventional Post-Approval Safety Study,2021-04-14,protocol,"Christina Chambers, Renu Garg",M5,False,True,False,False,False,"Pfizer-BioNTech, vaccine schedule, post-approval safety study, pregnancy registry, non-interventional study, pregnancy outcomes, vaccine utilization, FDA, COVID-19 vaccine, Protocol, clinical data, vaccine exposure, vaccine administration, safety surveillance, MotherToBaby, infant outcomes, OTIS Pregnancy Registry, regulatory",18,12,https://drive.google.com/file/d/10sMc1zLYVPAN2ZyLjRb3WG0cdaq5aIFY/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:00
125742_S2_M1_pllr-lit-search-summary.pdf,PDF,"Summary of Literature Search on Pregnancy, Lactation, and Reproductive Potential for BNT162b2 COVID-19 Vaccine",2021-04-20,report,,M1,False,False,False,False,False,"infant mortality, FOIA document, data summary, lactation, embryo-fetal development, reproductive potential, COVID-19 vaccine, literature search, safety data, FDA, clinical trials, pregnancy, confidential, pharmacokinetics, BNT162b2, Pfizer, regulatory submission",17,9,https://drive.google.com/file/d/1Qyf1zhmYUCtFMH_poc8DqYkXTj1-gnzV/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:04
125742_S2_M5_5354_c4591008-protocol.pdf,PDF,HERO Together: A post-Emergency Use Authorization observational cohort study to evaluate the safety of the Pfizer-BioNTech COVID-19 vaccine in US healthcare workers,2021-01-27,protocol,"Emily O'Brien, PhD",M5,False,True,False,False,False,"FDA emergency use authorization, Pfizer-BioNTech, safety evaluation, immunocompromised individuals, pregnant individuals, pharmacovigilance, non-interventional study, COVID-19 vaccine, clinical trial protocol, regulatory compliance, Protocol, United States, healthcare workers, post-authorization study, Duke Clinical Research Institute, incidence rates, adverse events, observational cohort study",18,43,https://drive.google.com/file/d/12NjFW9s83woROW6Tuyv27kQm91OEVKrg/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:09
125742_S4_M1_cover.pdf,PDF,Response to CBER's 18 May 2021 Information Request,2021-05-19,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"regulatory-submission, biologics-license-application, covid-19-vaccine, pf-07302048, collegeville-pa, fda-cber, silver-spring-md, information-request, global-product-development, bnt162, clinical-trial-data, safety-efficacy, regulatory-affairs, vaccine-development, pfizer-biontech, vaccine-approval, emergency-use-authorization",17,2,https://drive.google.com/file/d/1Yse1-awnTnPh4Kc5TYIO28S_u-ni0fIS/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:13
125742_S2_M5_5354_c4591014-protocol.pdf,PDF,Pfizer-BioNTech COVID-19 BNT162b2 Vaccine Effectiveness Study - Kaiser Permanente Southern California,2021-03-22,protocol,"Sara Y. Tartof, Heidi Fischer, Jeff Slezak, John M. McLaughlin, Fred Angulo",M5,False,True,False,False,False,"hospitalization, Kaiser Permanente Southern California, retrospective cohort design, non-interventional study, clinical trial, vaccine effectiveness, FDA, COVID-19 vaccine, safety data, SARS-CoV-2 infection, test-negative case-control design, Protocol, acute respiratory illness, adverse events, efficacy data, BNT162b2, retrospective database study, regulatory compliance",18,42,https://drive.google.com/file/d/1i-0AASIghCfv-aDBb1DTcc9Yqlopw6ZI/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:18
125742_S2_M5_5354_c4591011-protocol.pdf,PDF,Active Safety Surveillance of the Pfizer-BioNTech COVID-19 Vaccine in the United States Department of Defense Population Following Emergency Use Authorization,2021-01-29,protocol,"Renu Garg, Mei Sheng Duh",M5,False,True,False,False,False,"FDA emergency use authorization, Pfizer-BioNTech, real-world data, vaccine completion rate, sub-cohorts, epidemiology, vaccine utilization, immunocompromised, COVID-19 vaccine, clinical trial protocol, US Department of Defense, mRNA vaccine, SARS-CoV-2, Protocol, post-authorization study, prior SARS-CoV-2 infection, safety surveillance, adverse events",18,171,https://drive.google.com/file/d/1iXq3GSFh3NpvnelyBT0oxMME1MaVn_oF/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:25
125742_S2_M5_5354_c4591009-protocol-synopsis.pdf,PDF,A Non-Interventional Post-Approval Safety Study of the Pfizer-BioNTech COVID-19 mRNA Vaccine in the United States,2021-04-01,protocol,,M5,False,True,False,False,False,"history of COVID-19, immunocompromised individuals, comorbidities, relative risk, non-interventional study, pregnant women, prevalence ratio, baseline characteristics, demographics, regulatory, Pfizer-BioNTech COVID-19 vaccine, FDA, Protocol, Sentinel System, United States, safety events, vaccine administration, post-approval safety",18,25,https://drive.google.com/file/d/1TFQ3-44ZYU9qCQjIOFsJ71EH9AGYuh7f/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:29
125742_S2_M5_5351_c4591015-protocol-amend2.pdf,PDF,"A Phase 2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older",2021-03-02,Protocol,Pfizer,M5,False,True,False,False,False,"EudraCT, Pregnant Women, BioNTech, Maternal Immunization, Phase 2/3 Study, RNA Vaccine, Regulatory Submission, COVID-19 Vaccine, FDA, Efficacy Data, Safety and Immunogenicity, Adverse Events, SARS-CoV-2, Protocol, FOIA Document, Clinical Trial Protocol, BNT162b2, Pfizer",18,139,https://drive.google.com/file/d/1-x28J2q4dBqJAaOdbvlcrbuuSe1W2chf/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:38
125742_S2_M1_dca-anaphylactic-reaction.pdf,PDF,Pfizer-BioNTech COVID-19 Vaccine Anaphylactic Reaction Data Capture Aid,2020-12-23,form,,M1,False,False,False,False,False,"covid-19-vaccine, emergency-department, fda-submission, regulatory-compliance, pharmaceutical-industry, intensive-care-unit, data-capture, medical-documentation, vital-signs, vaccine-safety, pfizer-biontech, clinical-trial, medical-intervention, united-states, hospitalization, anaphylactic-reaction, adverse-event-reporting",17,6,https://drive.google.com/file/d/16SHw1OPN9Z2rp-6oqN0UJirertP0cOti/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:42
125742_S2_M5_5354_c4591012-protocol.pdf,PDF,Post-Emergency Use Authorization Active Safety Surveillance Study among Individuals in the Veteran's Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine,2021-01-27,protocol,"Yinong Young-Xu, Cynthia de Luise, Mei Sheng Duh",M5,False,True,False,False,False,"Pfizer-BioNTech, comorbidities, Veterans Affairs Health System, safety surveillance research, non-interventional study, single-dose recipients, clinical epidemiology, COVID-19 vaccine, elderly, Protocol, protocol, post-authorization study, adverse events of special interest, prior SARS-CoV-2 infection, safety surveillance, immunocompromised, vaccine utilization patterns, regulatory compliance",18,145,https://drive.google.com/file/d/1W9pS3rXXMZmRge23XOF-_rTvRhv741d8/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:51
125742_S2_M1_pllr-cumulative-review.pdf,PDF,BNT162b2 Cumulative Review from Pharmacovigilance Database,2021-04-20,report,,M1,False,False,False,False,False,"breastfeeding, pharmacovigilance, lactation, signal detection, post-marketing, FDA, safety data, maternal exposure, vaccine, adverse events, clinical trials, pregnancy, fetal exposure, BNT162b2, Pfizer, cumulative review, regulatory",17,8,https://drive.google.com/file/d/1FqgpwMJ-bQwtCqEC-8vgPOVy7afffCNd/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:55
125742_S3_M1_cover.pdf,PDF,Request for Proprietary Name Review for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-05-19,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"regulatory-submission, biologics-license-application, covid-19-vaccine, global-regulatory-affairs, biotech, pf-07302048, clinical-development, manufacturing, fda-cber, safety-data, bnt162, quality-control, pfizer, product-registration, efficacy-data, vaccine-approval, proprietary-name-review",17,2,https://drive.google.com/file/d/1L4AeM14zGCo_F8ziU7IuY4G_hxnQfQp_/view?usp=drivesdk,pd-production-040323,2025-08-11 22:36:58
125742_S3_M1_proprietary-name.pdf,PDF,Request for Proprietary & Non-Proprietary Name Review,2021-05-19,request,Elisa Harkins,M1,False,False,False,False,False,"global-regulatory-affairs, quality-assurance, authorized-us-agent, pharmaceutical-development, product-labeling, clinical-trial-data, dosage-information, packaging-configuration, bnt162b2-vaccine, regulatory-affairs, fda-submission, biontechmanufacturing-gmbh, delivery-system, product-identification, storage-requirements, proprietary-name-review, pfizer-confidential",17,5,https://drive.google.com/file/d/1Ff-S-CDP7lnmSLsQuv9PDtTd0jmvrb3o/view?usp=drivesdk,pd-production-040323,2025-08-11 22:37:02
125742_S2_M1_diluent-labeling-proposal.pdf,PDF,BNT162b2 M 1.1 4.1 Draft Labeling,2021-05,report,,M1,False,False,False,False,False,"covid-19 vaccine, quality control, drug product, storage conditions, compliance, manufacturing, clinical trial, comirnaty, safety data, diluent labeling, fda submission, vaccine administration, united states, efficacy data, bnt162b2, regulatory approval, emergency use authorization",17,4,https://drive.google.com/file/d/1A7AwnpNXYMZ1F5KAAqHWTmX9VjUxqDbD/view?usp=drivesdk,pd-production-040323,2025-08-11 22:37:06
125742_S2_M5_5351_c4591007-protocol-amend1.pdf,PDF,PF-07302048 (BNT162 b2 RNA-Based COVID-19 Vaccine) Protocol C4591007 Protocol Amendment 1,2021-03-05,Protocol,,M5,False,True,False,True,False,"MIS-C, Exclusion, adverse events, efficacy objectives, regulatory compliance, safety and immunogenicity, COVID-19 vaccine, SARS-CoV-2, healthy children under 12 years, BNT162b2, PF-07302048, FDA submission, phase 1/2/3 study, clinical trial protocol, Protocol, passive antibody therapy, immunobridging, Pfizer, BioNTech",19,150,https://drive.google.com/file/d/1iLhKszdOx08GyuURdkntTdmCvVBp6-0O/view?usp=drivesdk,pd-production-040323,2025-08-11 22:37:20
125742_S7_M5_5351_bnt162-01-interim3-reports.pdf,PDF,Neutralizing Antibody Titer and SARS-CoV-2 S1- and RBD-Specific Antibody Concentration in Serum from Participants in the BNT162-01 Trial,2020-11-28,R&D Study Report,Alexander Muik,"M3, M5",False,False,False,False,False,"BNT162b1, antibody binding, SARS-CoV-2 vaccines, neutralizing antibody, confidential document, BNT162-01 trial, pharmaceutical development, vaccine research, biomarkers, Germany, clinical trial, FDA, safety data, R&D report, efficacy data, BNT162b2, regulatory submission",17,524,https://drive.google.com/file/d/11BQ8FTAXxH53vDFjknyeWQ3dFauYS8zP/view?usp=drivesdk,pd-production-040323,2025-08-11 22:37:31
125742_S2_M1_pllr-waiver-request-drug-utilization.pdf,PDF,Request for Waiver for Summary of Drug Utilization Rates,2020-07,request,,M1,False,False,False,False,False,"pregnancy labeling, BNT162b2 vaccine, ACIP recommendations, vaccine safety in pregnancy, clinical trial data, non-replicating vaccines, vaccine manufacturer, drug labeling requirements, reproductive potential, COVID-19 vaccine, vaccine development, adverse pregnancy outcomes, drug utilization rates, pharmaceutical industry, FDA regulations, emergency use authorization, regulatory compliance",17,2,https://drive.google.com/file/d/1TzRVyM7nfTSHUsqadIHzZz-ggPiWB9jj/view?usp=drivesdk,pd-production-040323,2025-08-11 22:37:34
125742_S2_M5_5354_wi255886-protocol.pdf,PDF,Avon Community Acquired Pneumonia Study (Avon CAP) Protocol,2021-01-30,Protocol,"Professor Adam Finn, David Baum, Dr Catherine Hyams, Dr Izak Heys, Dr Rajeka Lazarus, Dr Jennifer Oliver, Leon Danon, Jo Southern, Beth Begier, Robin Hubler, Bradford Gessner, Sharon Gray, Harish Madhava, Fred Angulo, John M. McLaughlin",M5,False,True,False,False,False,"Acute Lower Respiratory Tract Disease Surveillance, Epidemiology and Scientific Affairs, Infectious Diseases, Bristol Royal Children's Hospital, University of Bristol, NIHR Academic Clinical Fellow, University Hospitals Bristol and Weston, Southmead Hospital, Version 2.2, Respiratory Medicine, Protocol, Regulatory Compliance, Adverse Event Monitoring, Efficacy and Safety Data, Clinical Trial Protocol, Microbiology, IRAS 283899, Pfizer Vaccine",18,65,https://drive.google.com/file/d/1kSJUYxDfXX7gtPzDYGCdoN7SpBq7t0pm/view?usp=drivesdk,pd-production-040323,2025-08-11 22:37:40
125742_S4_M1_response-18-may-2021-datasets.pdf,PDF,Response to FDA Information Request Regarding Datasets,2021-05-19,response,Michael Smith,M1,False,False,False,False,False,"regulatory affairs, BLA, data quality, pharmaceutical development, reactogenicity data, EUA, clinical trial, FDA, COVID-19 vaccine, CBER, safety data, data submission, adverse events, efficacy data, ADaM, BNT162b2, SDTM",17,3,https://drive.google.com/file/d/1bXQ6rup1xl14Z2J9Jx5wziiJ_LYRqalP/view?usp=drivesdk,pd-production-040323,2025-08-11 22:37:43
125742_S2_M1_pllr-waiver-request-pregnancy-registry.pdf,PDF,Request for Waiver of Pregnancy Registry Report,2020-07,request,"Pfizer, BioNTech",M1,False,False,False,False,False,"non-replicating-vaccine, fetal-development, labeling-requirements, fda-submission, regulatory-compliance, observational-study, safety-data, adverse-events, bnt162b2, acip-recommendations, vaccine-development, clinical-trial, maternal-health, covid-19, pregnancy-registry, emergency-use-authorization, confidential-document",17,2,https://drive.google.com/file/d/1SQMrBLn-poiPUMhhHYK1K6g9L1oc8aup/view?usp=drivesdk,pd-production-040323,2025-08-11 22:37:46
125742_S2_M1_loa-dmf-9543-vials.pdf,PDF,Letter of Authorization to Reference Type III DMF #9543,2020-09-02,letter,"James McFarland, Adrienne Stafford",M1,False,False,False,False,False,"letter-of-authorization, pma, type-iii-dmf, regulatory-compliance, bla, tubular-containers, ide, anada, primary-packaging-glass, pfizer, anda, good-manufacturing-practices, nda, gerresheimer-glass, dmf-9543, ind, biontech-rna-pharmaceuticals",17,1,https://drive.google.com/file/d/19pKYFyL5oQV6nWfbsjUPhw9mLlqPIAC8/view?usp=drivesdk,pd-production-040323,2025-08-11 22:37:50
125742_S2_M1_dca-vaed.pdf,PDF,Pfizer-BioNTech COVID-19 Vaccine VAED Data Capture Aid,2021-05-18,form,,M1,False,False,False,False,False,"vaccine-associated-enhanced-disease, covid-19-vaccine, antibody-testing, pharmaceutical-industry, fda-submission, regulatory-compliance, medical-terminology, safety-data, data-capture, adverse-events, patient-demographics, quality-control, pfizer-biontech, clinical-trial, united-states, hospitalization, sars-cov-2-testing",17,7,https://drive.google.com/file/d/1z4QMw4nvrydCnZ6DryxVbhaPMT4abgxC/view?usp=drivesdk,pd-production-040323,2025-08-11 22:37:53
125742_S1_M5_CRF_c4591001-1018-10181159.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, Texas Center For Drug Development, data management, case report form, data collection",20,191,https://drive.google.com/file/d/1s5kM8c8O8QAgyqQWioU7wKONnx755e2F/view?usp=drivesdk,pd-production-050123,2025-08-11 22:37:58
125742_S1_M5_CRF_c4591001-1016-10161128.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,,M5,True,True,False,True,False,"electronic data capture, Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, informed consent, safety monitoring, visit schedule, Protocol, subject demographics, kentucky research site, fda submission, case report form, adverse event reporting, efficacy endpoints",20,197,https://drive.google.com/file/d/1x72fwQqSzVXRuyPHC0GpaIe2fNCfkk88/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:01
125742_S1_M5_CRF_c4591001-1036-10361140.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-22,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, subject details, demography, confidential document, data collection",19,150,https://drive.google.com/file/d/1t7LoE8tuKapFwJLZQjA-BqjIyqxiV1kT/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:04
125742_S1_M5_CRF_c4591001-1016-10161103.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, pediatric, Exclusion, clinical trial, phase 2/3, safety data, vaccine administration, regulatory compliance, visit documentation, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, Kentucky, CRF, subject enrollment, informed consent, FDA, Protocol, subject demographics",19,189,https://drive.google.com/file/d/1X5HCcGiTuAb181oduyluBMW-HHB6KpjZ/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:08
125742_S1_M5_CRF_c4591001-1018-10181132.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy assessment, phase 2/3 study, CRF, demographic data, informed consent, adverse event monitoring, visit date, FDA, Protocol, Texas Center For Drug Development, safety evaluation, subject identification",19,228,https://drive.google.com/file/d/1lt-BBYv7ZQj6lO3dzHOpzs4dj04yZ1Kr/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:12
125742_S1_M5_CRF_c4591001-1016-10161199.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, Kentucky Pediatric Adult Research, cohort selection, efficacy, protocol amendment, CRF, informed consent, date of visit, FDA, Protocol, vaccine, c4591001, demography, safety, data collection",20,219,https://drive.google.com/file/d/1VrC5ieTtefPLDFQAX-0D9q7aR80HmC74/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:17
125742_S1_M5_CRF_c4591001-1018-10181111.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,"(1018) Texas Center For Drug Development, Inc.",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, united states, adverse events, regulatory compliance, fda, quality assurance, efficacy, phase 2/3 study, CRF, covid-19 vaccine, pharmaceutical development, informed consent, Protocol, subject demographics, medical terminology, data management, safety, data collection",20,156,https://drive.google.com/file/d/1mAowqBlfAyzePQN2rxgPBd4ITlKHZV4M/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:21
125742_S1_M5_CRF_c4591001-1016-10161120.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, Kentucky, CRF, informed consent, visit date, FDA, Protocol, pediatric and adult research, demography, efficacy data",19,193,https://drive.google.com/file/d/1MV80tSpfLhtIR98rubzNLmgUph8i4LeC/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:25
125742_S1_M5_CRF_c4591001-1018-10181090.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, subject ID, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, Texas Center For Drug Development, efficacy data",19,315,https://drive.google.com/file/d/1r7DZ-kCR7x5BL_rx9E867JjYQJg23GRS/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:29
125742_S1_M5_CRF_c4591001-1016-10161087.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, quality assurance, phase 2/3 study, CRF, covid-19 vaccine, eCRF audit trail, informed consent, Protocol, subject demographics, kentucky, pediatric and adult research, efficacy data, confidential document, data collection",20,248,https://drive.google.com/file/d/1nSwvC5eTPBeScICqrVoZW1ltZNaR0Agf/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:33
125742_S1_M5_CRF_c4591001-1016-10161265.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, Kentucky Pediatric Adult Research, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, protocol amendment, phase 2/3 study, CRF, subject data, informed consent, visit date, FDA, Protocol, demography, safety",19,158,https://drive.google.com/file/d/1USEANy0U4RP7T4-gIusQlHF0FMPup_MJ/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:36
125742_S1_M5_CRF_c4591001-1016-10161289.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, confidential, regulatory-compliance, pediatric-adult-research, adverse-events, clinical-trial, CRF, data-collection, covid-19-vaccine, visit-schedule, informed-consent, cohort-selection, Protocol, phase-2-3, c4591001, kentucky, demography, quality-control, fda-submission",20,379,https://drive.google.com/file/d/1fvbwoGhSRBZkWPqSldI9J6U_g-UQdhqC/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:40
125742_S1_M5_CRF_c4591001-1016-10161042.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, Kentucky Pediatric Adult Research, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data",19,433,https://drive.google.com/file/d/1Pa4WPsFGySmFUdJmnt8AiM_zKquql491/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:45
125742_S1_M5_CRF_c4591001-1016-10161277.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, electronic case report form (ecrf), cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, kentucky, pediatric and adult research, demography, efficacy data",20,157,https://drive.google.com/file/d/1DYq2MALnP1gwKUQlhCRDApRDYOkIkxN4/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:49
125742_S1_M5_CRF_c4591001-1018-10181031.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, c4591001, Texas Center For Drug Development, demography, safety",19,213,https://drive.google.com/file/d/1a3akEgFpNaYM3vjKha8WvzdHaPkDu-do/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:53
125742_S1_M5_CRF_c4591001-1066-10661242.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Solaris Clinical Research, Exclusion, clinical trial, safety data, c4591001 trial, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, FDA submission, informed consent, Protocol, subject demographics, eCRF, efficacy data, data collection",20,206,https://drive.google.com/file/d/1OTZLINs89w-Gcff3Ni84nknPScp45-CO/view?usp=drivesdk,pd-production-050123,2025-08-11 22:38:57
125742_S1_M5_CRF_c4591001-1066-10661350.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-10-10,Case Report Form (CRF),,M5,True,True,False,True,False,"Solaris Clinical Research, Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, FDA, Protocol, vaccine, c4591001, data management, demography, subject identification, data collection",20,137,https://drive.google.com/file/d/1vWH6aj9YJYp9lsFw3zhK_5javwBwKnLs/view?usp=drivesdk,pd-production-050123,2025-08-11 22:39:07
125742_S1_M5_CRF_c4591001-1066-10661202.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Solaris Clinical Research, Exclusion, clinical trial, c4591001 trial, United States, regulatory compliance, pharmaceutical research, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy assessment, phase 2/3 study, CRF, eCRF audit trail, FDA submission, informed consent, adverse event monitoring, Protocol, subject demographics, data collection",20,162,https://drive.google.com/file/d/1oBOuJ8nuubBR4QQ9ZTHXY3XSbQ3AsaaT/view?usp=drivesdk,pd-production-050123,2025-08-11 22:39:11
125742_S1_M5_CRF_c4591001-1091-10911002.pdf,PDF,Clinical Study Report Form,2021,report,,M5,True,False,False,False,False,"data anonymization, pharmaceutical research, FDA submission, data quality assurance, clinical trial, phase 4 study, FOIA request, vaccine development, safety data, CBER, COVID-19, case report form, CRF, efficacy data, adverse events, data collection, clinical study protocol, regulatory compliance",18,204,https://drive.google.com/file/d/1dScfXZtrnT0-KlPb9VjtwQJtdfQlswuU/view?usp=drivesdk,pd-production-050123,2025-08-11 22:39:17
125742_S1_M5_CRF_c4591001-1112-11121255.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,clinical trial form,(1112) Clinical Research Atlanta,M5,True,True,False,True,False,"site information, Atlanta, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, subject identification, data collection",20,201,https://drive.google.com/file/d/1zM1wF8SJCS03tMm5aTOiHucXdT0cT0C9/view?usp=drivesdk,pd-production-050123,2025-08-11 22:39:21
125742_S1_M5_CRF_c4591001-1112-11121337.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-10-01,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, pharmaceutical research, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, Atlanta, Georgia, informed consent, visit date, FDA, Protocol, c4591001, demography, subject identification, data collection",20,191,https://drive.google.com/file/d/1DycLIzrKWgRQr4J2fbn--hEmmlaP_GMR/view?usp=drivesdk,pd-production-050123,2025-08-11 22:39:25
125742_S1_M5_CRF_c4591001-1112-11121193.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, data quality, clinical research site, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, eCRF audit trail, informed consent, visit date, Protocol, data verification, demography data, subject identification, data freezing, confidential document",20,132,https://drive.google.com/file/d/1vFlFK1BhuQNjds_oYnv8lyDDycqR_7Vw/view?usp=drivesdk,pd-production-050123,2025-08-11 22:39:34
125742_S1_M5_CRF_c4591001-1114-11141075.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Alliance for Multispecialty Research, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, safety monitoring, visit date, FDA, Protocol, data management, subject identification, efficacy data",19,503,https://drive.google.com/file/d/1jbNrEwiFGw3Xse3-2ABGBoIovnhADcWP/view?usp=drivesdk,pd-production-050123,2025-08-11 22:39:40
125742_S1_M5_CRF_c4591001-1091-10911299.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Aventiv Research Inc., Protocol, Pfizer, demography, efficacy data",19,176,https://drive.google.com/file/d/1UjtSgjBtZNHQYxPBc1sb-oVgJ6ch2OKK/view?usp=drivesdk,pd-production-050123,2025-08-11 22:39:43
125742_S1_M5_CRF_c4591001-1117-11171036.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1117) Sundance Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, c4591001 trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, pharmaceutical development, informed consent, adverse event monitoring, visit schedule, Protocol, medical research, data management, subject identification",20,832,https://drive.google.com/file/d/10quIroqPfeBwnXq4hoC7O1Pgjz3xw81d/view?usp=drivesdk,pd-production-050123,2025-08-11 22:39:50
125742_S1_M5_CRF_c4591001-1091-10911213.pdf,PDF,Clinical Study Report Form,2021,report,,M5,True,False,False,False,False,"vaccine research, FDA submission, pharmaceutical development, phase 4 study, clinical trial, FOIA request, safety data, CBER, c4591001-1091-10911213, quality assurance, United States, case report form, clinical study report, CRF, efficacy data, adverse events, data collection, regulatory compliance",18,134,https://drive.google.com/file/d/1uCNwSYJ45kLVT9es41nzcQtk9R3LpGaO/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:00
125742_S1_M5_CRF_c4591001-1091-10911297.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, informed consent, visit date, FDA, vaccine development, Aventiv Research Inc., Protocol, c4591001, eCRF, demography",20,449,https://drive.google.com/file/d/1OMuuOIjADDeJYj3MFbisilAvBEyRcZIC/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:05
125742_S1_M5_CRF_c4591001-1112-11121122.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"site information, medical data, Exclusion, FDA regulation, clinical trial, c4591001 trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, Atlanta, Georgia, informed consent, visit date, Protocol, clinical research organization, demography data, subject identification, confidential document",20,200,https://drive.google.com/file/d/18J499Xl6mn0ZeS6Xi7IvglK7g0VVj-aQ/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:09
125742_S1_M5_CRF_c4591001-1091-10911247.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1091) Aventiv Research Inc.,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, CRF, subject information, informed consent, visit date, FDA, Aventiv Research Inc., Protocol, vaccine, c4591001, eCRF, demography, data collection",20,170,https://drive.google.com/file/d/1bsSVHFgIr1k_ESy4JiW6K4BFIgdGaec0/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:12
125742_S1_M5_CRF_c4591001-1091-10911300.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Aventiv Research Inc., Protocol, c4591001, eCRF, demography, safety",20,191,https://drive.google.com/file/d/1CfGeBTuzcPOsZgLAvcU3a00qBaJiq6b7/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:16
125742_S1_M5_CRF_c4591001-1114-11141050.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Alliance for Multispecialty Research, multisite research, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, informed consent, visit date, FDA, Protocol, subject identification, confidential document, data collection",19,137,https://drive.google.com/file/d/1k2xi-_ZVmWZJkzLbglVoSrFXIOyCYolu/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:25
125742_S1_M5_CRF_c4591001-1112-11121118.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, Atlanta, Georgia, eCRF audit trail, informed consent, visit date, Protocol, data completeness, demography data, subject identification, confidential document",20,182,https://drive.google.com/file/d/12ewVpdH6ez9KRqMSq-krQnrtSvIcE2vt/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:28
125742_S1_M5_CRF_c4591001-1091-10911197.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, informed consent, visit date, FDA, Aventiv Research Inc., Protocol, demography, efficacy data",19,625,https://drive.google.com/file/d/1K_htGveBhnx0CturaUEgeaxD_e-IoS2y/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:35
125742_S1_M5_CRF_c4591001-1091-10911170.pdf,PDF,Clinical Study Report Form,2021,report,,M5,True,False,False,False,False,"pharmaceutical research, FDA submission, clinical documentation, clinical trial, phase 4 study, vaccine development, safety data, data management, COVID-19, quality assurance, United States, case report form, CRF, efficacy data, medical terminology, adverse events, data analysis, regulatory compliance",18,142,https://drive.google.com/file/d/1XqOcb-L5afTE1lF4NeLmTPyDKHNQ7ykZ/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:46
125742_S1_M5_CRF_c4591001-1112-11121301.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-10-12,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, Atlanta clinical site, c4591001 trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, data lock and freeze, phase 2/3 study, protocol amendment, CRF, eCRF audit trail, subject enrollment, informed consent, visit date, Protocol, clinical research organization, demography data, confidential document",20,278,https://drive.google.com/file/d/1IUXKf61IPS8_kV4ymd4treF7l_-b99k8/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:51
125742_S1_M5_CRF_c4591001-1114-11141006.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, multispecialty research, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data, data collection",20,199,https://drive.google.com/file/d/1Ca13-sNtvj7ynJTMafWN6rDL7ZZtujMK/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:55
125742_S1_M5_CRF_c4591001-1114-11141080.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, multispecialty research, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data, data collection",19,205,https://drive.google.com/file/d/1eASOJp1AgWC6-juQ-o0H8JNue-ZQkcZT/view?usp=drivesdk,pd-production-050123,2025-08-11 22:40:59
125742_S1_M5_CRF_c4591001-1091-10911274.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, protocol amendment, CRF, informed consent, visit date, FDA, Aventiv Research Inc., Protocol, data management, demography, safety, data collection",19,157,https://drive.google.com/file/d/1A-CpE-WCKXcP8b1gh6eaWVCasn_V_uz2/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:09
125742_S1_M5_CRF_c4591001-1120-11201050.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,Meridian Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, united states, adverse events, regulatory compliance, fda, data quality, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, informed consent, Protocol, subject demographics, medical terminology, efficacy data, electronic case report form, data collection",20,158,https://drive.google.com/file/d/1n8OAWE39nptFzjURDc1Y2KD8vBK-kWzA/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:12
125742_S1_M5_CRF_c4591001-1120-11201266.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,(b) (6),M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, FDA submission, informed consent, safety monitoring, visit date, Protocol, subject demographics, Meridian Clinical Research, efficacy data, electronic case report form (eCRF)",20,459,https://drive.google.com/file/d/1sTI78Vh5wy1WbJaSfibq2mThmAUWgCrJ/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:18
125742_S1_M5_CRF_c4591001-1129-11291138.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, jacksonville center for clinical research, regulatory compliance, fda, data quality, inclusion/exclusion criteria, phase 2/3 study, CRF, audit trail, covid-19 vaccine, demographic data, subject enrollment, informed consent, visit schedule, Protocol, confidentiality, eCRF, data management",20,263,https://drive.google.com/file/d/1ePlRtzXKgaCpo_06MJWxKpqDQQSmlGSM/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:23
125742_S1_M5_CRF_c4591001-1129-11291074.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, jacksonville center for clinical research, confidential, regulatory compliance, fda, inclusion/exclusion criteria, quality assurance, phase 2/3 study, CRF, audit trail, covid-19 vaccine, subject enrollment, informed consent, visit schedule, Protocol, data lock, frozen data, demography, data collection",20,207,https://drive.google.com/file/d/1TvZ-3gxDyxUPS4ym58gY9Uw5gA6isf2k/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:27
125742_S1_M5_CRF_c4591001-1117-11171121.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"pharmaceutical-research, Exclusion, data-verification, inclusion-exclusion-criteria, fda, regulatory-compliance, site-information, clinical-trial, CRF, data-collection, covid-19-vaccine, eCRF-audit-trail, informed-consent, cohort-selection, Protocol, c4591001, visit-date, confidential-document, subject-identification, demography",20,402,https://drive.google.com/file/d/1K0zMLpL4DWuvhIF0yy7wyinUY4CR5ERs/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:33
125742_S1_M5_CRF_c4591001-1117-11171058.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1117) Sundance Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, subject identification, efficacy data, data collection",20,495,https://drive.google.com/file/d/14scK8Wudp08pKgX6GdtBXSr274ohMBZ-/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:38
125742_S1_M5_CRF_c4591001-1120-11201059.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, meridian clinical research, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, eCRF audit trail, informed consent, visit date, Protocol, demography, efficacy data, data collection",20,165,https://drive.google.com/file/d/1bD8zi8wTUUCqGxh-ogV7Tr-3P9nDB7P9/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:43
125742_S1_M5_CRF_c4591001-1129-11291059.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, regulatory compliance, Jacksonville Center for Clinical Research, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, demographic data, subject enrollment, FDA submission, informed consent, adverse event monitoring, Protocol, data management, electronic case report form (eCRF), confidential document",20,280,https://drive.google.com/file/d/1a2H9qhhx6U97DtPk-9pFcMBvrpLjn5nv/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:47
125742_S1_M5_CRF_c4591001-1120-11201002.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-06,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, Meridian Clinical Research, eCRF, data management, demography, subject identification, data collection",20,249,https://drive.google.com/file/d/1iae7s5tau2yQZuNROQiu6ZYYUNfw7vmA/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:51
125742_S1_M5_CRF_c4591001-1118-11181013.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, confidential, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, united medical associates, demography, efficacy data, data collection",20,150,https://drive.google.com/file/d/1D9HThrzJsevzl2Wx0PgB_VVXzr-CaLdu/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:54
125742_S1_M5_CRF_c4591001-1129-11291045.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, jacksonville center for clinical research, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, subject identification, efficacy data, data collection",20,190,https://drive.google.com/file/d/11-rHlDQEYgRcm3WoZ-Iv7fO95h39TW67/view?usp=drivesdk,pd-production-050123,2025-08-11 22:41:58
125742_S1_M5_CRF_c4591001-1117-11171167.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,(1117) Sundance Clinical Research,M5,True,True,False,True,False,"quality control, Exclusion, clinical trial, safety data, united states, adverse events, regulatory submission, pharmaceutical research, fda, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, eCRF, demography, efficacy data",20,147,https://drive.google.com/file/d/1dh5kmZFiNXqMoJtPwgTAECLhwxXAx2JH/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:01
125742_S1_M5_CRF_c4591001-1120-11201127.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"phase 2/3 trial, Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, visit date, FDA, Protocol, Meridian Clinical Research, demography, safety",19,132,https://drive.google.com/file/d/1zT-j6JQFyL7MgZL_oqeAE5j_XzF-Dv03/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:10
125742_S1_M5_CRF_c4591001-1117-11171086.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Sundance Clinical Research, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, efficacy data",20,501,https://drive.google.com/file/d/1RmBmE1LvHt7-gJ2Xmh1vP6GuugIjOPOl/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:16
125742_S1_M5_CRF_c4591001-1117-11171146.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1117) Sundance Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, subject details, c4591001, clinical data management, demography",19,236,https://drive.google.com/file/d/1yqr4b3171m99B8pBuCqu0PCSJHVqcun_/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:20
125742_S1_M5_CRF_c4591001-1118-11181031.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, united medical associates, eCRF, demography, efficacy data",20,175,https://drive.google.com/file/d/1NVqugZC_wP0A4RX8dk6txaqSHIPR9Ejl/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:23
125742_S1_M5_CRF_c4591001-1129-11291095.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, electronic-case-report-form, data-freezing-and-locking, regulatory-compliance, phase-2-3-study, clinical-trial, fda-regulated, CRF, data-collection, covid-19-vaccine, subject-identifier, informed-consent, cohort-selection, Protocol, visit-date, confidential-document, jacksonville-clinical-research-center, demography, quality-control",20,189,https://drive.google.com/file/d/1XysFjZYw1nS9_I0TvAAmfmsiYHZ7LsgD/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:27
125742_S1_M5_CRF_c4591001-1120-11201432.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, Meridian Clinical Research, demography, subject identification, efficacy data",19,210,https://drive.google.com/file/d/1xulzwXcpKypDzflYoguOxI3l622flDmr/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:31
125742_S1_M5_CRF_c4591001-1118-11181044.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"quality control, Exclusion, clinical trial, phase 2/3, confidential, United Medical Associates, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, informed consent, FOIA, visit date, FDA, Protocol, vaccine, c4591001, demography, subject identification, data collection",20,392,https://drive.google.com/file/d/1t_XSSZ70VYFpPfflrEUx-X5FCARgEGny/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:36
125742_S1_M5_CRF_c4591001-1120-11201350.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,clinical trial form,(1120) Meridian Clinical Research,M5,True,True,False,True,False,"Exclusion, phase 2/3, safety data, covid-19, adverse events, regulatory compliance, fda, meridian clinical research, cohort selection, inclusion/exclusion criteria, clinical research form, vaccine clinical trial, CRF, subject data, informed consent, visit date, Protocol, c4591001, demography, efficacy data",20,247,https://drive.google.com/file/d/1L9XQkNURFX8tHfp8Z6mNdDpbXNqEdvHT/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:40
125742_S1_M5_CRF_c4591001-1117-11171186.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Sundance Clinical Research, safety data, c4591001 trial, United States, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, FDA submission, informed consent, adverse event monitoring, visit date, Protocol, subject demographics, efficacy data",20,423,https://drive.google.com/file/d/1hpq5csc2vu71UQ1aYTNgr4db_22vzhGC/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:45
125742_S1_M5_CRF_c4591001-1129-11291127.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"phase-2-3-trial, Exclusion, inclusion-exclusion-criteria, regulatory-compliance, adverse-events, clinical-trial, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, efficacy-data, visit-date, subject-identification, jacksonville-clinical-research-center, data-quality, safety-data, demography, fda-submission",20,369,https://drive.google.com/file/d/1u8YcCmP8xDRqRrisSUxoDY5nUs4uImpq/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:50
125742_S1_M5_CRF_c4591001-1118-11181074.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, United Medical Associates, adverse events, regulatory compliance, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, informed consent, FOIA, visit date, FDA, Protocol, vaccine, c4591001, demography, efficacy data",20,165,https://drive.google.com/file/d/1h1H78s4UxH8tWgyb6qaF4g60lGbA6Wap/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:54
125742_S1_M5_CRF_c4591001-1117-11171079.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Sundance Clinical Research, safety data, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, geographic location, phase 2/3 study, CRF, subject enrollment, informed consent, visit date, FDA, Protocol, eCRF, demography, efficacy data",19,150,https://drive.google.com/file/d/1gxzLPptVBsKpeqr_6MMnPr7k73gz0lLL/view?usp=drivesdk,pd-production-050123,2025-08-11 22:42:57
125742_S1_M5_CRF_c4591001-1129-11291046.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, jacksonville center for clinical research, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data, data collection",20,301,https://drive.google.com/file/d/1yx29eqsFtmH5SwXr9PEu_GCiiaxf8NpZ/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:02
125742_S1_M5_CRF_c4591001-1118-11181057.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, fda, inclusion/exclusion criteria, quality assurance, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit schedule, Protocol, subject demographics, medical research, united medical associates, eCRF, data integrity, data collection",20,156,https://drive.google.com/file/d/1KgZl_Jeu8abx8DttW0rW8B7atvNwFIbl/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:06
125742_S1_M5_CRF_c4591001-1117-11171141.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,(1117) Sundance Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, sundance clinical research, visit schedule, Protocol, c4591001 protocol, demography, fda submission, subject identification, adverse event reporting, efficacy endpoints",20,616,https://drive.google.com/file/d/1cOzlGAvqJToPZAkZBfaLuOOc7CkICIPL/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:12
125742_S1_M5_CRF_c4591001-1118-11181123.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-22,clinical trial form,(1118) United Medical Associates,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, eCRF, demography, subject identification, safety",19,152,https://drive.google.com/file/d/19IXeMvI3fomlnoFcToCV-dOlAqSXwmk9/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:16
125742_S1_M5_CRF_c4591001-1121-11211112.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Optimal Research, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data",20,191,https://drive.google.com/file/d/1xO_7yL31SqQUhhWzxPDfY4nhqd47FeOo/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:19
125742_S1_M5_CRF_c4591001-1129-11291005.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-06,form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, data quality control, regulatory submission, inclusion/exclusion criteria, COVID-19 vaccine, clinical research form, phase 2/3 study, CRF, demographic data, pharmaceutical development, informed consent, visit schedule, Protocol, data management, subject identification, adverse event reporting, Jacksonville, FL",20,357,https://drive.google.com/file/d/1GPdr0rflYdaC3tYRAmXY-H1dAYXFebaM/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:24
125742_S1_M5_CRF_c4591001-1129-11291032.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, Jacksonville Center for Clinical Research, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, eCRF audit trail, informed consent, visit date, Protocol, data verification, subject demographics, data completeness, data management, subject identification, confidential document",20,352,https://drive.google.com/file/d/1H3sEivJGH_0-4AhoEYVSC1QjXrPajM78/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:29
125742_S1_M5_CRF_c4591001-1129-11291037.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, Jacksonville Center for Clinical Research, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, case report form, efficacy data",20,222,https://drive.google.com/file/d/1H72vIHO6XywwHU0QERiVt18aXk9nNn1O/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:33
125742_S1_M5_CRF_c4591001-1117-11171088.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Sundance Clinical Research, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, informed consent, visit date, FDA, Protocol, c4591001, demography, data collection",20,172,https://drive.google.com/file/d/10H8GVbfhQ6lJdo4MjQhHrhdU-oDA6vfh/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:37
125742_S1_M5_CRF_c4591001-1146-11461264.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"amici clinical research, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, eCRF audit trail, informed consent, visit date, Protocol, demography, subject identification, efficacy data, data collection",20,125,https://drive.google.com/file/d/1zqGMz78sOg8ej_8yB5AY4GfuTUS14ciX/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:45
125742_S1_M5_CRF_c4591001-1133-11331006.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, qps-mra, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, subject enrollment, informed consent, visit date, Protocol, c4591001, demography, efficacy data",20,254,https://drive.google.com/file/d/1vRbeqNgvKljVLYaeyNPm2DDl4OngrDIQ/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:50
125742_S1_M5_CRF_c4591001-1134-11341019.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, PMG Research, subject enrollment, informed consent, visit date, FDA, Protocol, eCRF, data management, demography, Winston-Salem",19,185,https://drive.google.com/file/d/1TTW8bT90dzMMloh140KQV4cfAe7EnhLg/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:53
125742_S1_M5_CRF_c4591001-1129-11291166.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, jacksonville center for clinical research, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data, data collection",20,175,https://drive.google.com/file/d/1gNMT9MyQpgb8wQEoPxvEVQpkNmyPKwkx/view?usp=drivesdk,pd-production-050123,2025-08-11 22:43:57
125742_S1_M5_CRF_c4591001-1146-11461152.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, Amici Clinical Research, FDA, visit date, Protocol, c4591001, demography, safety",20,322,https://drive.google.com/file/d/1a7h9kU0xjdn81GZOY6tYKQXA34mTR1t3/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:02
125742_S1_M5_CRF_c4591001-1133-11331317.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"quality control, Exclusion, clinical trial, adverse events, data analysis, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, subject information, informed consent, visit date, FDA, Protocol, c4591001, QPS-MRA, demography, data collection",20,127,https://drive.google.com/file/d/1lz0FQOgZ97g8rK2PgtV3BJ7amE-CbG3f/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:10
125742_S1_M5_CRF_c4591001-1129-11291161.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, Jacksonville Center for Clinical Research, data quality, inclusion/exclusion criteria, CRF, informed consent, date of visit, FDA, Protocol, vaccine, c4591001, eCRF, demography, subject identification, data collection",20,273,https://drive.google.com/file/d/1MtBxK0D1tXuUHDIHamijsVNoZmIOlNeu/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:14
125742_S1_M5_CRF_c4591001-1146-11461109.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1146) Amici Clinical Research,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, safety",20,134,https://drive.google.com/file/d/1LoMmBe81uid2-pfp_GfWXy3RnaePUVo2/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:22
125742_S1_M5_CRF_c4591001-1145-11451063.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,Johns Hopkins School of Medicine,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, Johns Hopkins, phase 2/3 study, CRF, subject information, informed consent, visit date, FDA, Protocol, c4591001, demography, efficacy data",20,489,https://drive.google.com/file/d/1dBaxnm5pXZSmb5z3_ZXzXxiRArkDxv-D/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:28
125742_S1_M5_CRF_c4591001-1146-11461200.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,(1146) Amici Clinical Research,M5,True,True,False,True,False,"site information, amici clinical research, Exclusion, clinical trial, safety data, regulatory compliance, data quality, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, adverse event monitoring, visit schedule, Protocol, demography data, fda submission, case report form, subject identification, efficacy endpoints",20,152,https://drive.google.com/file/d/1jRYip3ab9jMSL44Hw_J8FzNWEtyQvYzn/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:32
125742_S1_M5_CRF_c4591001-1133-11331640.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-10,form,,M5,True,True,False,True,False,"quality control, site information, Exclusion, FDA regulation, clinical trial, regulatory submission, pharmaceutical research, inclusion/exclusion criteria, COVID-19 vaccine, drug development, phase 2/3 study, CRF, demographic data, subject enrollment, informed consent, visit schedule, Protocol, data management, subject identification, adverse event reporting",20,150,https://drive.google.com/file/d/1MvlBcMQ9BcAKZwxuXSi9msYGzeSbQr84/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:35
125742_S1_M5_CRF_c4591001-1129-11291183.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, jacksonville center for clinical research, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, clinical research form, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, data collection",20,407,https://drive.google.com/file/d/1uEqjBkbUwi7MMbgg_JWZ4ouXYbWjlwT4/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:40
125742_S1_M5_CRF_c4591001-1134-11341174.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, pharmaceutical research, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, subject information, covid-19 vaccine, clinical research, informed consent, visit date, Protocol, c4591001, winston-salem, eCRF, demography, data collection",20,213,https://drive.google.com/file/d/1XQ24Fpaj-k0hTIypoWYJSqBb8dA2Arge/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:44
125742_S1_M5_CRF_c4591001-1133-11331147.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, QPS-MRA, data management, demography, subject identification, confidential document, data collection",19,209,https://drive.google.com/file/d/14SXKoEvqaesVR_CF5W2g2n76ma24Cfhf/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:48
125742_S1_M5_CRF_c4591001-1134-11341058.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, fda, inclusion/exclusion criteria, quality assurance, pmg research, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit schedule, Protocol, subject demographics, winston-salem, eCRF, data management, data collection",20,205,https://drive.google.com/file/d/1h4Wd0UqeRwuk23B4u8F5SlwD0_PF_Kwr/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:51
125742_S1_M5_CRF_c4591001-1134-11341378.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, winston-salem, demography, subject identification, data collection",20,198,https://drive.google.com/file/d/1uk74T-J2cOjlmK9q_1xb-l_Wpp9vFZ2a/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:55
125742_S1_M5_CRF_c4591001-1145-11451059.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, Johns Hopkins School of Medicine, data management, subject identification, data collection",19,254,https://drive.google.com/file/d/1ZDuKnfiuV0JQ95jnYQi_0YUi39TN3Awd/view?usp=drivesdk,pd-production-050123,2025-08-11 22:44:59
125742_S1_M5_CRF_c4591001-1134-11341250.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory, data quality, pharmaceutical, compliance, COVID-19 vaccine, CRF, PMG Research, subject enrollment, informed consent, FDA, Protocol, demography, Winston-Salem, efficacy data",19,166,https://drive.google.com/file/d/1zbHLRc4h7CM-IQAzqEd4FeRB_Vr2a2W7/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:03
125742_S1_M5_CRF_c4591001-1145-11451056.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,Johns Hopkins School of Medicine,M5,True,True,False,True,False,"Exclusion, clinical trial, united states, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, medical research, demography, efficacy data",20,321,https://drive.google.com/file/d/1J1uN665d8v1UWn2rLeJGL6MA3zW8iirH/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:08
125742_S1_M5_CRF_c4591001-1146-11461133.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, United States, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, Amici Clinical Research, FDA, visit date, Protocol, c4591001, eCRF, demography, efficacy data",20,138,https://drive.google.com/file/d/1fUee9ptjC2rUYP_seIJ1p2Fyk6XIYg2c/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:11
125742_S1_M5_CRF_c4591001-1146-11461161.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, Amici Clinical Research, FDA, visit date, Protocol, c4591001, eCRF, demography, efficacy data",20,164,https://drive.google.com/file/d/1zV1i0ppNsfr6yoFTMKmJWWBZVD2KR0Cl/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:15
125742_S1_M5_CRF_c4591001-1129-11291260.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-10,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, Jacksonville Center for Clinical Research, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,208,https://drive.google.com/file/d/1M79erMzq4it_Mq9gVpMEmMywFQOUpXXC/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:19
125742_S1_M5_CRF_c4591001-1146-11461191.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, c4591001 trial, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, FDA submission, informed consent, Amici Clinical Research, visit date, Protocol, demography data, efficacy data, electronic case report form (eCRF)",20,277,https://drive.google.com/file/d/1hYWrwYnLl72UtoU-PCsZ4Tpv5LU0AXAf/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:23
125742_S1_M5_CRF_c4591001-1134-11341327.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, fda, regulatory-compliance, crf, subject-information, adverse-events, clinical-trial, CRF, covid-19-vaccine, informed-consent, cohort-selection, Protocol, phase-2-3, efficacy-data, visit-date, winston-salem, data-quality, safety-data, demography",20,113,https://drive.google.com/file/d/1atuGtTVlL2lPmvvzikBSKW-YCDm8sb3i/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:29
125742_S1_M5_CRF_c4591001-1133-11331537.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-10,form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, data privacy, regulatory submission, inclusion/exclusion criteria, COVID-19 vaccine, quality assurance, phase 2/3 study, CRF, demographic data, subject enrollment, pharmaceutical development, informed consent, visit schedule, Protocol, data management, subject identification, adverse event reporting",20,215,https://drive.google.com/file/d/1kzx10jjyJKXGJ_5xUkDYCeHj35kMUE7A/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:33
125742_S1_M5_CRF_c4591001-1146-11461235.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1146) Amici Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, pharmaceutical research, fda, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, clinical research, informed consent, visit date, Protocol, c4591001, eCRF, data management, demography, subject identification, data collection",20,281,https://drive.google.com/file/d/1m4i8fEQ0rz-4tGiw0MRfpAb1d7n1nTvl/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:38
125742_S1_M5_CRF_c4591001-1145-11451042.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, clinical research form, phase 2/3 study, CRF, subject information, covid-19 vaccine, audit trail, informed consent, visit date, Protocol, johns hopkins school of medicine, demography, data collection",20,423,https://drive.google.com/file/d/1uNYhx_cudRIKZGkNcOo4FTsr4JIe9l7V/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:43
125742_S1_M5_CRF_c4591001-1146-11461302.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,clinical trial protocol,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, Pfizer-BioNTech vaccine, CRF, demographic data, FDA submission, informed consent, visit schedule, Protocol, clinical research organization, data management, subject identification, adverse event reporting",19,261,https://drive.google.com/file/d/1OSHcuFS0JoRI_1EAgyQjU6IHJ-KELlw1/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:47
125742_S1_M5_CRF_c4591001-1145-11451055.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,Johns Hopkins School of Medicine,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, protocol amendment, CRF, subject data, informed consent, visit date, FDA, Protocol, demography",19,259,https://drive.google.com/file/d/1Qa_GXE2-ajICLG9wI06Poch7wDGWw3rq/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:52
125742_S1_M5_CRF_c4591001-1134-11341153.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, adverse events, regulatory compliance, data quality, COVID-19 vaccine, safety and efficacy, phase 2/3 study, CRF, PMG Research, demographic data, subject enrollment, informed consent, visit schedule, FDA, Protocol, data management, Winston-Salem",19,297,https://drive.google.com/file/d/1Rh4VaHW5afd7uCJ2MBHKnLky_qzHX-pH/view?usp=drivesdk,pd-production-050123,2025-08-11 22:45:56
125742_S1_M5_CRF_c4591001-1146-11461015.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1146) Amici Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, eCRF, demography, subject identification, efficacy data",20,175,https://drive.google.com/file/d/1XklA5b1s53BADHcuZHXKc9kxJJT23van/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:00
125742_S1_M5_CRF_c4591001-1145-11451076.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,Johns Hopkins School of Medicine,M5,True,True,False,True,False,"Exclusion, clinical trial, united states, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, efficacy, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, eCRF, demography, safety",20,175,https://drive.google.com/file/d/1h6adevMrUvXKrwE1LK6FACrZXOsIvzpT/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:03
125742_S1_M5_CRF_c4591001-1134-11341432.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,Subject No: 11341432,M5,True,True,False,True,False,"Clinical Trial, Audit Trail, Confidential, Exclusion, Inclusion/Exclusion Criteria, Demography, Vaccine, Pharmaceutical, Subject Identification, FDA Submission, Phase 2/3, Data Collection, CRF, Protocol, eCRF, Informed Consent, Site Information, Cohort Selection, Winston-Salem, Visit Schedule",20,142,https://drive.google.com/file/d/1rf3KgtuCUCqL4p2g2AO6dLTd_kHBNh5V/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:10
125742_S1_M5_CRF_c4591001-1146-11461181.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1146) Amici Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data",19,128,https://drive.google.com/file/d/1zFpo7h-0Jv7kxBvYI-fU6jMMQV1f0ikV/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:19
125742_S1_M5_CRF_c4591001-1134-11341085.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, PMG Research, demographic data, data audit trail, informed consent, visit date, FDA, Protocol, data management, subject identification, Winston-Salem",19,214,https://drive.google.com/file/d/1elR6oic-IQi8JhzFUjGAhnj28eiRoENL/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:23
125742_S1_M5_CRF_c4591001-1133-11331207.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, demographic data, subject enrollment, visit schedule, FDA, Protocol, QPS-MRA, data management, efficacy data",19,176,https://drive.google.com/file/d/1Vp-luUxtjA-WkTQRec8UaBQg2mbrVhby/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:27
125742_S1_M5_CRF_c4591001-1167-11671069.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Holston Medical Group, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, Pfizer, demography, subject identification, safety",20,152,https://drive.google.com/file/d/11sSWHrtwcJ6eV2o8p60oubYSd-vBSCia/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:30
125742_S1_M5_CRF_c4591001-1167-11671009.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, medical terminology, data management, subject identification",19,387,https://drive.google.com/file/d/1gNj3CnR3tYB6zmW7tQSAaN6v0xpzw6zm/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:35
125742_S1_M5_CRF_c4591001-1178-11781025.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Clinical Trial,2020-07-30,clinical trial form,(1178) Clinical Research Associates Inc,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, demographic data, eCRF audit trail, subject enrollment, informed consent, visit schedule, Protocol, data verification, data management, C4591001 trial, data freezing, confidential document",20,184,https://drive.google.com/file/d/1JaCN56OdWmx_y0CwhfBKa9POn149J8uH/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:39
125742_S1_M5_CRF_c4591001-1150-11501069.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, informed consent, visit date, FDA, Protocol, c4591001, Senders Pediatrics, demography, efficacy data",20,148,https://drive.google.com/file/d/1fBgK428tuP-BRHUaKNRxUDdnkA1ViZAf/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:42
125742_S1_M5_CRF_c4591001-1167-11671175.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, Holston Medical Group, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,124,https://drive.google.com/file/d/1IZwLntlBUN25dZzvi40fVKqzvVoTiuXu/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:50
125742_S1_M5_CRF_c4591001-1178-11781015.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Trial Form,(1178) Clinical Research Associates Inc,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, eCRF audit trail, informed consent, visit date, Protocol, subject demographics, data completeness, subject identification, C4591001 trial, confidential document",20,171,https://drive.google.com/file/d/1yoC6Sn0Y2QPO1vtN3Pv3lVzcnCyFsGFv/view?usp=drivesdk,pd-production-050123,2025-08-11 22:46:54
125742_S1_M5_CRF_c4591001-1168-11681083.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"quality control, Exclusion, clinical trial, safety data, adverse events, regulatory, fda, cohort selection, inclusion/exclusion criteria, crf, phase 2/3 study, protocol amendment, CRF, covid-19 vaccine, informed consent, visit date, Protocol, lynn health science institute, demography, efficacy data",20,124,https://drive.google.com/file/d/1w0suTlLehXh9wvFkg_lHmthVZl4HSnMU/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:01
125742_S1_M5_CRF_c4591001-1178-11781138.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, data lock and freeze, phase 2/3 study, protocol amendment, CRF, demographic data, eCRF audit trail, informed consent, visit date, Protocol, data verification, subject identification, C4591001 trial, confidential document",20,167,https://drive.google.com/file/d/1NXk4a272ez4nCK2Q-7nnV6XByDN5gnHp/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:04
125742_S1_M5_CRF_c4591001-1150-11501153.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-10,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, pediatrics, adverse events, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, Pfizer, demography, efficacy data, data collection",19,180,https://drive.google.com/file/d/131qdyEoVQJUWGUpGtKxRnS8-55aCIj-9/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:07
125742_S1_M5_CRF_c4591001-1169-11691056.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Protocol, Pfizer, Lehigh Valley Hospital, demography, efficacy data",19,305,https://drive.google.com/file/d/1pKrp71Oj45twcqqIqjfUPxp47glo87Oe/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:11
125742_S1_M5_CRF_c4591001-1174-11741042.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, CARE-ID, demography, case report form, safety",20,200,https://drive.google.com/file/d/14Qcs74BoLf7Xy_YWRMDbHcHURb8zctzM/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:15
125742_S1_M5_CRF_c4591001-1178-11781164.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,(1178) Clinical Research Associates Inc,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, United States, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, demography, case report form, subject identification, efficacy data",20,670,https://drive.google.com/file/d/1odJgWmMPfvOrtWyT-J3woLGViqj0D7Kj/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:20
125742_S1_M5_CRF_c4591001-1178-11781073.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, pharmaceutical development, informed consent, adverse event monitoring, visit date, Protocol, subject demographics, data management, subject identification, electronic case report form, confidential document",20,139,https://drive.google.com/file/d/1e-7DKRVd2w0jl0_BUEckmlGXEzHg0HoT/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:27
125742_S1_M5_CRF_c4591001-1178-11781122.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,,M5,True,True,False,True,False,"pharmaceutical-research, Exclusion, fda-regulation, inclusion-exclusion-criteria, vaccine-development, site-information, audit-trail, clinical-trial, CRF, data-collection, informed-consent, cohort-selection, Protocol, phase-2-3, visit-date, case-report-form, confidential-document, subject-identification, demography, quality-control",20,255,https://drive.google.com/file/d/11ytMANzQPYwwLMp7LkE0jEWxuaWOehal/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:31
125742_S1_M5_CRF_c4591001-1147-11471239.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Ochsner Health System, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, informed consent, visit date, FDA, Protocol, Pfizer, demography, efficacy data",19,267,https://drive.google.com/file/d/1MX8HGEWIkUmp-StRVeweDQiemeveCsEE/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:35
125742_S1_M5_CRF_c4591001-1149-11491239.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Collaborative Neuroscience Network, CRF, demographic data, subject enrollment, informed consent, visit date, FDA, Protocol, data management, safety",20,146,https://drive.google.com/file/d/1-oVipxoxx_ebK0QlbaiaJO_3Wv6Xm8Fb/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:40
125742_S1_M5_CRF_c4591001-1147-11471007.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, fda, regulatory-compliance, crf, protocol-amendment, site-information, clinical-trial, subject-demographics, CRF, covid-19-vaccine, informed-consent, Protocol, phase-2-3, ochsner-health-system, subject-enrollment, visit-information, vaccine-administration, subject-identification, safety-data",20,197,https://drive.google.com/file/d/1Mxliim5Q4kjXxZovBbBiFOOqDfceq9Gk/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:44
125742_S1_M5_CRF_c4591001-1168-11681225.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-08,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, data integrity, data management, subject identification, data collection",19,187,https://drive.google.com/file/d/1Ivqgv1l5cGQt3NUduGYRRqxKq4tohuus/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:48
125742_S1_M5_CRF_c4591001-1169-11691055.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,"(1169) Lehigh Valley Hospital, 11691055",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit schedule, FDA, Protocol, c4591001, Pfizer, demography, subject identification, data collection",20,160,https://drive.google.com/file/d/1MzfpeS4fFcizfnpAwsBTyvmY__ZNCwmf/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:52
125742_S1_M5_CRF_c4591001-1147-11471230.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, Ochsner Health System, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, demography, subject identification, data collection",19,421,https://drive.google.com/file/d/1mkelLb0gNaOvaUtwZvuBUVndrZwC5goU/view?usp=drivesdk,pd-production-050123,2025-08-11 22:47:58
125742_S1_M5_CRF_c4591001-1150-11501037.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data, data collection",20,168,https://drive.google.com/file/d/1jgag66HBVVbufbjOeFT-MR4ypsBbBRos/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:01
125742_S1_M5_CRF_c4591001-1150-11501022.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, adverse events, data quality, cohort selection, inclusion/exclusion criteria, subject 11501022, phase 2/3 study, CRF, eCRF audit trail, informed consent, visit date, FDA, Protocol, vaccine, c4591001, Senders Pediatrics, demography, case report form",20,214,https://drive.google.com/file/d/1n9cpYCeTHcqEsBWAn3XKZtWdL64EZ9O7/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:05
125742_S1_M5_CRF_c4591001-1169-11691010.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, quality assurance, efficacy, phase 2/3 study, CRF, informed consent, FDA, Protocol, c4591001, Lehigh Valley Hospital, data management, demography, safety, data collection",20,149,https://drive.google.com/file/d/1vHb7c9aLQS3Uz9SZl0Ei2CWpBAhAmfnI/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:08
125742_S1_M5_CRF_c4591001-1150-11501001.pdf,PDF,c4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,(1150) Senders Pediatrics,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, pediatrics, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, CRF, informed consent, visit date, FDA, Protocol, vaccine, c4591001, eCRF, demography, subject identification, safety, data collection",20,129,https://drive.google.com/file/d/1Gto4dpaRwVRSqJuNaDC5NMN3lJcR4aWK/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:16
125742_S1_M5_CRF_c4591001-1178-11781293.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, cohort selection, inclusion/exclusion criteria, quality assurance, CRF, informed consent, visit date, FDA, Protocol, vaccine, subject details, data integrity, demography, case report form, data collection",20,162,https://drive.google.com/file/d/1HeIPbJWhCM4XvgRdiVd6eV7Z42KVlbdb/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:19
125742_S1_M5_CRF_c4591001-1178-11781167.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, regulatory-compliance, c4591001-study, demographic-data, site-information, adverse-events, clinical-trial, CRF, covid-19-vaccine, visit-schedule, informed-consent, cohort-selection, Protocol, phase-2-3, efficacy-data, united-states, case-report-form, subject-identification, data-quality, fda-submission",20,149,https://drive.google.com/file/d/1zdaKT0ziKNavvJ48qRSHoWf3e30Js5mX/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:23
125742_S1_M5_CRF_c4591001-1167-11671085.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, Holston Medical Group, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, Pfizer, demography, case report form",20,192,https://drive.google.com/file/d/1bpikPCepUXjzVAMsSCAkqi6ifkox5FZ6/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:27
125742_S1_M5_CRF_c4591001-1178-11781107.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, C4591001, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, adverse event monitoring, visit date, FDA, Protocol, data integrity, demography, subject identification, confidential document, data collection",20,185,https://drive.google.com/file/d/1Iclt0GZEnnldZKzlHzr8MEkHjFczOkuN/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:31
125742_S1_M5_CRF_c4591001-1178-11781257.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, adverse events, C4591001, pharmaceutical, cohort selection, inclusion/exclusion criteria, quality assurance, efficacy, CRF, informed consent, visit date, FDA, Protocol, vaccine, demography, safety, data collection",20,227,https://drive.google.com/file/d/14E-pCJBjxfPMjpGnnoEvelx_Z0VZBi3Y/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:36
125742_S1_M5_CRF_c4591001-1178-11781287.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),Clinical Research Associates Inc,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject enrollment, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, demography, efficacy data",20,119,https://drive.google.com/file/d/17mgvly_bNc1qugFfyZ_jj3b1tTO6qeeM/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:44
125742_S1_M5_CRF_c4591001-1178-11781048.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,"Subject No: 11781048, Subject Initials: ---",M5,True,True,False,True,False,"Clinical Trial, Exclusion, Phase 2/3 Study, Inclusion/Exclusion Criteria, United States, Demography, FDA Submission, Safety Data, CRF, Data Verification, Protocol, Regulatory Compliance, eCRF (Electronic Case Report Form), Pfizer-BioNTech, Subject Enrollment, Informed Consent, Site Information, Efficacy Data, Adverse Events, COVID-19 Vaccine",20,169,https://drive.google.com/file/d/1jKqdMn4BtDj3V7vs77F3EuPvbwGiChgg/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:48
125742_S1_M5_CRF_c4591001-1178-11781061.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, cohort selection, inclusion/exclusion criteria, CRF, informed consent, adverse event monitoring, visit date, FDA, vaccine development, Protocol, data management, demography, subject identification, data collection",20,472,https://drive.google.com/file/d/1uOa3Q9sQUepiHIaDmHu1PEA1zuUQV3yG/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:53
125742_S1_M5_CRF_c4591001-1150-11501084.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory, compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, Senders Pediatrics, demography, efficacy data",19,311,https://drive.google.com/file/d/1p9YdCVOhx-kFxSHzeiX80vgn_PXioxMy/view?usp=drivesdk,pd-production-050123,2025-08-11 22:48:57
125742_S1_M5_CRF_c4591001-1150-11501093.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, safety monitoring, visit date, FDA, Protocol, subject identification, efficacy data",19,210,https://drive.google.com/file/d/16Jeb8oeTZ4lEIQ0DSWSt2sJ5Aj52kc1H/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:02
125742_S1_M5_CRF_c4591001-1178-11781012.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,(1178) Clinical Research Associates Inc,M5,True,True,False,True,False,"electronic data capture, site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, phase 2/3 study, protocol amendment, CRF, covid-19 vaccine, demographic data, subject enrollment, informed consent, visit schedule, Protocol, data management, case report form, confidential document, fda regulatory",20,142,https://drive.google.com/file/d/1_eueWJld5BC0zHZPzS_mKozJ6F3FV-yU/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:11
125742_S1_M5_CRF_c4591001-1149-11491313.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, collaborative neuroscience network, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data, data collection",20,334,https://drive.google.com/file/d/1lNPssKn7Fv3vEFLS_FSmyh0RbZIZDxQc/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:16
125742_S1_M5_CRF_c4591001-1167-11671077.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, holston medical group, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data, confidential document, data collection",20,161,https://drive.google.com/file/d/1h-DyQdGegZNBpOYQv8d-UNLXwvHNzcOd/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:20
125742_S1_M5_CRF_c4591001-1218-12181023.pdf,PDF,C4591001 Clinical Trial Case Report Form,2021-03-29,Case Report Form (CRF),Johns Hopkins Center for American Indian Health,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, American Indian, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, data management, demography, case report form, subject identification",20,157,https://drive.google.com/file/d/1FLOF6657-gyl-cLWxsasNpqde4kfQWav/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:24
125742_S1_M5_CRF_c4591001-1221-12211007.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1221) Center for American Indian Health - Gallup,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, gallup, american indian, demography, efficacy data, electronic case report form",20,178,https://drive.google.com/file/d/1tfZ0xmY5ICL3m4lYJ_hzlywBz55x9Clj/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:28
125742_S1_M5_CRF_c4591001-1207-12071055.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1207) Ankara University Medical Faculty,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, CRF, subject data, informed consent, visit date, FDA, Protocol, vaccine, Ankara University, eCRF, data management, demography, data collection",20,166,https://drive.google.com/file/d/1WoDHI-xMrvspeMjgPKjosYC9zNL-ham4/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:31
125742_S1_M5_CRF_c4591001-1194-11941058.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, germany, regulatory compliance, fda, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, Protocol, vaccine, subject details, c4591001, eCRF, demography, data collection",20,416,https://drive.google.com/file/d/10c5OEOlwpUn791h9XAWqO5tALLCr2Py4/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:36
125742_S1_M5_CRF_c4591001-1217-12171031.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-01,form,---,M5,True,True,False,True,False,"Exclusion, Kocaeli University, clinical trial, safety data, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, Turkey, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, Pfizer, demography, efficacy data",19,201,https://drive.google.com/file/d/1TGDmwR6U4zSG3T-PO5IiDzNLjkrIGpgN/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:40
125742_S1_M5_CRF_c4591001-1223-12231252.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-16,form,(1223) Yale New Haven Medical Center,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, confidentiality, medical center, data integrity, data management, demography, subject identification, data collection",20,250,https://drive.google.com/file/d/1AibrOIQb-gZEyyvNZd22AzpMUH_4-nGV/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:44
125742_S1_M5_CRF_c4591001-1178-11781300.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-10-14,clinical trial form,(1178) Clinical Research Associates Inc,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, C4591001, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, data management, demography, subject identification, efficacy data, data collection",20,316,https://drive.google.com/file/d/18KJCSA7vMizFdGKubefPM1murUg7YZ_4/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:48
125742_S1_M5_CRF_c4591001-1218-12181057.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-10-10,Clinical Trial Form,Johns Hopkins Center for American Indian Health,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, Alaska Native, American Indian, COVID-19 vaccine, efficacy, CRF, subject enrollment, informed consent, FDA, Protocol, data management, demography, safety, data collection",20,260,https://drive.google.com/file/d/1G8FOD5H3_BimbQbBq5xDshsImUC6FJIj/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:53
125742_S1_M5_CRF_c4591001-1223-12231159.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1223) Yale New Haven Medical Center,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FDA, Protocol, medical center, demography, safety",19,234,https://drive.google.com/file/d/1GG15RrmZIdr0_S012rQbYg__Z0YlVYQ5/view?usp=drivesdk,pd-production-050123,2025-08-11 22:49:57
125742_S1_M5_CRF_c4591001-1218-12181046.pdf,PDF,C4591001 Clinical Trial CRF,2020-10-10,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, maryland, Protocol, vaccine, c4591001, american indian, demography, subject identification, data collection",20,143,https://drive.google.com/file/d/1mvjHqSOEZYDQJddlTYS4UyXSPkoC449I/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:01
125742_S1_M5_CRF_c4591001-1223-12231181.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1223) Yale New Haven Medical Center,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, clinical research form, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, eCRF, Yale New Haven Medical Center, demography, subject identification, data collection",20,175,https://drive.google.com/file/d/1D1mnAnWzWdW1IoikB5OpQPDXbEgS45JA/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:05
125742_S1_M5_CRF_c4591001-1218-12181012.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-10,form,,M5,True,True,False,True,False,"phase 2/3 trial, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, American Indian, inclusion/exclusion criteria, cohort selection, COVID-19 vaccine, Johns Hopkins, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, demography, efficacy data",19,368,https://drive.google.com/file/d/1uHTR52fgt8oTpBibUacaqPU2Ncrd0io4/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:09
125742_S1_M5_CRF_c4591001-1223-12231014.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,Yale New Haven Medical Center,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, Yale University, informed consent, visit date, FDA, Protocol, medical center, demography, subject identification, confidential document, data collection",19,260,https://drive.google.com/file/d/1EuEjQFKlJZKQzOu7xhlwQQEQfthHNh4Y/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:14
125742_S1_M5_CRF_c4591001-1223-12231075.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1223) Yale New Haven Medical Center,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, informed consent, visit date, FDA, Protocol, eCRF, Yale New Haven Medical Center, demography, efficacy data",20,201,https://drive.google.com/file/d/1leERl2vksnjs-so3h76xrzQ0r8PUdmRM/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:18
125742_S1_M5_CRF_c4591001-1194-11941002.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-10-15,Case Report Form (CRF),,M5,True,True,False,True,False,"electronic data capture, Exclusion, clinical trial, data quality control, IKF Pneumologie GmbH, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, demographic data, subject enrollment, FDA regulatory, informed consent, Germany site, adverse event monitoring, visit schedule, Protocol, case report form, data freezing, confidential document",20,405,https://drive.google.com/file/d/1_veI4DRrscsK_7M2vfuTnesXV44wQyM6/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:22
125742_S1_M5_CRF_c4591001-1185-11851055.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Clinical Trial,2020-10-29,Clinical Research Form (CRF),,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, Germany, regulatory compliance, C4591001 study, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy assessment, phase 2/3 study, CRF, informed consent, adverse event monitoring, vaccine development, Protocol, subject demographics, safety evaluation, Universitaetsklinikum Hamburg-Eppendorf, data collection",20,201,https://drive.google.com/file/d/1Fa1NZgoS6b0uROdJwlwK1n_bJtkvC0rs/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:26
125742_S1_M5_CRF_c4591001-1214-12141018.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,clinical trial form,,M5,True,True,False,True,False,"cardiology institute, Exclusion, clinical trial, safety data, adverse events, regulatory, fda, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, istanbul university, Protocol, vaccine, c4591001, demography, efficacy data",20,222,https://drive.google.com/file/d/1CoUwx1i_7KcT2c2aR2QFjOlWw0cBSS5z/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:30
125742_S1_M5_CRF_c4591001-1223-12231182.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, Yale New Haven Medical Center, demography, subject identification",20,143,https://drive.google.com/file/d/1iXC011NPhWcbWAjfgPLyL3eiddUIuASU/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:34
125742_S1_M5_CRF_c4591001-1218-12181051.pdf,PDF,C4591001 Clinical Trial CRF,2021-03-29,Clinical Trial Form,Johns Hopkins Center for American Indian Health,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, Alaska Native, American Indian, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Protocol, eCRF, data management, demography, data collection",20,251,https://drive.google.com/file/d/17WECLksyeTvj61i-o0x5dlpEPlvntLRs/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:37
125742_S1_M5_CRF_c4591001-1214-12141039.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,---,M5,True,True,False,True,False,"cardiology institute, Exclusion, clinical trial, confidential, regulatory compliance, fda, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, subject data, informed consent, visit date, istanbul university, Protocol, c4591001, medical research, data management, demography, electronic case report form",20,492,https://drive.google.com/file/d/1vBvFsZW-omx_Z91ilK8aLMC0wuJtxoCa/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:43
125742_S1_M5_CRF_c4591001-1220-12201020.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,report,(1220) Shiprock Center for American Indian Health,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, C4591001, data quality, American Indian, inclusion/exclusion criteria, COVID-19 vaccine, clinical research form, phase 2/3 study, CRF, informed consent, visit schedule, FDA, Protocol, Shiprock, eCRF, demography, data freezing",20,392,https://drive.google.com/file/d/1DBIRdG-ABXPegAKpMvz0DKn3NOy8C-yc/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:47
125742_S1_M5_CRF_c4591001-1218-12181015.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-22,form,Johns Hopkins Center for American Indian Health,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, COVID-19 vaccine, quality assurance, protocol amendment, phase 2/3 study, CRF, subject enrollment, informed consent, American Indian/Alaska Native population, FDA, Protocol, eCRF, data management, demography, efficacy data",20,149,https://drive.google.com/file/d/1wmTOEE4W0djDHY4DeC2hUG7TYMGE-LAP/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:51
125742_S1_M5_CRF_c4591001-1213-12131049.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-10,form,---,M5,True,True,False,True,False,"Istanbul University Cerrahpaşa Medical Faculty, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, FOIA document, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,156,https://drive.google.com/file/d/11rbqKzKf9y0ptP1riZyJfjf0T3Q0O_fr/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:55
125742_S1_M5_CRF_c4591001-1220-12201052.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-10-10,Case Report Form (CRF),"Subject No: 12201052, Subject Initials: ---",M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, American Indian health, CRF, demographic data, eCRF audit trail, informed consent, FDA, Protocol, data verification, Pfizer, case report form, Shiprock Center, data freezing",20,149,https://drive.google.com/file/d/1gmvVzXsH13iZef7vZA8xfxsU1NU4g116/view?usp=drivesdk,pd-production-050123,2025-08-11 22:50:58
125742_S1_M5_CRF_c4591001-1217-12171039.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-10,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory, fda, compliance, cohort selection, inclusion/exclusion criteria, crf, efficacy, protocol amendment, CRF, covid-19 vaccine, subject data, informed consent, visit date, Protocol, demography, safety, kocaeli university",20,250,https://drive.google.com/file/d/15RhamVm-KINSL0fhqegc96EQrz7F_Qmx/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:02
125742_S1_M5_CRF_c4591001-1220-12201044.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-10,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, american indian health, informed consent, visit date, Protocol, c4591001, shiprock, demography, efficacy data",20,175,https://drive.google.com/file/d/16kcfRGjuiqIU8SeP9YoPEj-qKphNHGxE/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:07
125742_S1_M5_CRF_c4591001-1221-12211002.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, regulatory, fda, crf, efficacy, adverse-events, clinical-trial, CRF, covid-19-vaccine, informed-consent, cohort-selection, Protocol, phase-2-3, visit-date, american-indian-health, gallup, data-quality, demography, safety",20,618,https://drive.google.com/file/d/1DwcFEhQDR4Yg2IVvBIb-_udZtkqNnGbd/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:13
125742_S1_M5_CRF_c4591001-1218-12181001.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-19,form,Johns Hopkins Center for American Indian Health,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, American Indian, COVID-19 vaccine, protocol amendment, CRF, audit trail, demographic data, subject enrollment, informed consent, FDA, Protocol, data management, data freezing",19,464,https://drive.google.com/file/d/1Ce6iFTZTF7SaC3EbdPWKlCjXLvmXpLRI/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:18
125742_S1_M5_CRF_c4591001-1223-12231166.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, Yale New Haven Medical Center, demography, safety",20,137,https://drive.google.com/file/d/1mx_QCl484ez6lUB89aYqLnScrx13iEwe/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:26
125742_S1_M5_CRF_c4591001-1217-12171044.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-10,form,,M5,True,True,False,True,False,"Exclusion, Kocaeli University, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Turkey, CRF, informed consent, visit date, FDA, Protocol, Phase 2/3 study, Pfizer, demography, efficacy data",19,622,https://drive.google.com/file/d/18chcLqZ3kJa8N30hTyQi8LsRnxYyR8C0/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:32
125742_S1_M5_CRF_c4591001-1223-12231058.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1223) Yale New Haven Medical Center,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, subject details, medical center, eCRF, data management, demography",20,225,https://drive.google.com/file/d/1tP3mIP8BYDuKgYnqWiBI0q9xXC7Zv2CI/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:36
125742_S1_M5_CRF_c4591001-1194-11941033.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-10-16,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, Germany, clinical trial, regulatory compliance, C4591001, pharmaceutical research, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, demography, case report form, subject identification, data collection",20,650,https://drive.google.com/file/d/1ZRBskJMxILZ9QjYTz4bS0NjHTiMhGX3h/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:42
125742_S1_M5_CRF_c4591001-1223-12231024.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),Yale New Haven Medical Center,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, United States, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, medical center, demography, subject identification, case report form, data collection",20,384,https://drive.google.com/file/d/1GBZNgcnaInGTt3csozSucvv72lIAm99n/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:47
125742_S1_M5_CRF_c4591001-1254-12541189.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,clinical trial form,(1254) Bayview Research Group,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, data quality control, regulatory submission, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, subject enrollment, pharmaceutical development, informed consent, visit schedule, Protocol, medical research, data management, subject identification, adverse event reporting",20,173,https://drive.google.com/file/d/1hgK3tqRPv_euZPpRMXUQBeTkxMgjUlzO/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:50
125742_S1_M5_CRF_c4591001-1251-12511029.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1251) Achieve Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, eCRF audit trail, informed consent, visit date, Protocol, data verification, demography data, subject identification, data freezing, confidential document",20,330,https://drive.google.com/file/d/1hRspf3UUUuOF5gMF_cjpDPCtnr8gjWZR/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:54
125742_S1_M5_CRF_c4591001-1254-12541142.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, vaccine administration, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit schedule, Protocol, eCRF, Bayview Research Group, data management, subject identification, confidential document",20,226,https://drive.google.com/file/d/1fbfiBft00kt4BkaUbl52mqoiTOrfm0iO/view?usp=drivesdk,pd-production-050123,2025-08-11 22:51:58
125742_S1_M5_CRF_c4591001-1264-12641133.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, data collection, efficacy data, university of california davis",20,390,https://drive.google.com/file/d/1Ck0dE984RjbU4CIm9w6l6CHPjolZojZH/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:03
125742_S1_M5_CRF_c4591001-1254-12541109.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Research Form (CRF),(1254) Bayview Research Group,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, United States, data quality control, COVID-19 vaccine, phase 2/3 study, Pfizer-BioNTech vaccine, CRF, demographic data, data audit trail, subject enrollment, informed consent, visit schedule, Protocol, c4591001 protocol, electronic case report form, confidential document, data collection",20,183,https://drive.google.com/file/d/13Cg3arYhXGGiKerPTAZTHBXmHLqRZqeB/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:06
125742_S1_M5_CRF_c4591001-1260-12601075.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1260) UMass Memorial Medical Center,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, data privacy, data quality control, regulatory submission, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit schedule, Protocol, c4591001 protocol, medical research, data management, subject identification, adverse event reporting",20,227,https://drive.google.com/file/d/1DbeZ8XcywNWRwUEKMCKL-CxMtxuhCm6u/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:10
125742_S1_M5_CRF_c4591001-1251-12511033.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, inclusion/exclusion criteria, phase 2/3 study, CRF, audit trail, covid-19 vaccine, achieve clinical research, informed consent, visit date, Protocol, data lock, eCRF, frozen data, demography, subject identification",20,383,https://drive.google.com/file/d/1IVX7A177J4cOxtvSAmfcymsFdePGonT5/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:15
125742_S1_M5_CRF_c4591001-1261-12611006.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, benaroya-research-institute, inclusion-exclusion-criteria, regulatory, fda, compliance, crf, efficacy, adverse-events, clinical-trial, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, visit-date, virginia-mason, demography, safety",20,184,https://drive.google.com/file/d/1DbShnnsKiFw3paog0DVERtUjl_vRPR34/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:19
125742_S1_M5_CRF_c4591001-1254-12541014.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1254) Bayview Research Group,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data",19,323,https://drive.google.com/file/d/1sYtEqR91BYDsfhDXLcwCzeVipHrVbANY/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:24
125742_S1_M5_CRF_c4591001-1230-12301025.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory, C4591001, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, Tamboti Medical Centre, subject 12301025, CRF, informed consent, visit date, FDA, Protocol, demography, data collection",19,190,https://drive.google.com/file/d/1vzQUEPIM8LIE_h4d15zOyltjlzykz6NR/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:27
125742_S1_M5_CRF_c4591001-1252-12521011.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,(1252) Waterway Primary Care LLC DBA Tabor City Family Medicine,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, safety data, North Carolina, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy assessment, phase 2/3 study, CRF, demographic data, informed consent, adverse event monitoring, visit date, Protocol, subject identification, electronic case report form",20,401,https://drive.google.com/file/d/1JvMMw2hLKTCACd-Mn7myPtqcqg5VT5ef/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:32
125742_S1_M5_CRF_c4591001-1264-12641195.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-09-15,case report form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, informed consent, visit date, Protocol, demography, case report form, subject identification, efficacy data, university of california davis",20,254,https://drive.google.com/file/d/1U3Vp7Kj2CsCEuDiNv_IDs8GQpgVH0JyT/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:36
125742_S1_M5_CRF_c4591001-1224-12241065.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"lynn institute, Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, denver, informed consent, visit date, Protocol, c4591001, demography, data collection",20,217,https://drive.google.com/file/d/1u4h0kcWLMcOecmLsTa21UWT4GU8lW9_i/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:40
125742_S1_M5_CRF_c4591001-1230-12301045.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, cohort selection, inclusion/exclusion criteria, efficacy, Tamboti Medical Centre, CRF, informed consent, FOIA, visit date, FDA, Protocol, vaccine, demography, safety",20,229,https://drive.google.com/file/d/1iZVmpLmLL9ArGZISlLMQy4Ni6QH225NM/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:45
125742_S1_M5_CRF_c4591001-1254-12541145.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, Bayview Research Group, demography, subject identification, safety",19,161,https://drive.google.com/file/d/1RjAneSr9_jKqJK2sALSmv5FBcufaiNuY/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:49
125742_S1_M5_CRF_c4591001-1254-12541006.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, Pfizer, demography, safety",19,166,https://drive.google.com/file/d/1N76ug928hKt1jr9SjJ29SjnNMzj_9civ/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:52
125742_S1_M5_CRF_c4591001-1248-12481120.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, United States, adverse events, regulatory, data quality, inclusion/exclusion criteria, data compliance, COVID-19 vaccine, clinical trial phase 2/3, CRF, subject data, informed consent, FDA, Protocol, SNBL Clinical Pharmacology Center, demography, efficacy data",19,278,https://drive.google.com/file/d/1CV5tC6_Qya7Qlvp38XI3sadzeuJIVxNg/view?usp=drivesdk,pd-production-050123,2025-08-11 22:52:57
125742_S1_M5_CRF_c4591001-1251-12511250.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, demographic data, eCRF audit trail, informed consent, visit date, Protocol, data verification, Achieve Clinical Research, subject identification, data freezing, confidential document",20,139,https://drive.google.com/file/d/1OB9rrslaeCZcWzm0wjgfyeLDpUoMkLrj/view?usp=drivesdk,pd-production-050123,2025-08-11 22:53:05
125742_S1_M5_CRF_c4591001-1251-12511145.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1251) Achieve Clinical Research,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, safety",20,156,https://drive.google.com/file/d/1gMeg5k3nobbTFvRpVzVjJZOn-2llJyE0/view?usp=drivesdk,pd-production-050123,2025-08-11 22:53:08
125742_S1_M5_CRF_c4591001-1251-12511262.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-22,Clinical Trial Form,,M5,True,True,False,True,False,"Clinical Trial, Exclusion, Demography, Clinical Research Form, FOIA Document, FDA Submission, Phase 2/3, CRF, Data Verification, Confidential Document, Protocol, Regulatory Compliance, c4591001 Trial, Achieve Clinical Research, Subject Enrollment, Informed Consent, Site Information, Efficacy Data, Adverse Events, COVID-19 Vaccine",20,366,https://drive.google.com/file/d/1loG8FP9Tgo0R0lSyUzH9QgWczpb54Iu6/view?usp=drivesdk,pd-production-050123,2025-08-11 22:53:13
125742_S1_M5_CRF_c4591001-1251-12511050.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, informed consent, safety monitoring, visit date, Protocol, c4591001, demography, subject identification, efficacy data, data collection",20,425,https://drive.google.com/file/d/1N9mIgqOswu4gfN3i68OiuKdM-XtAnqh-/view?usp=drivesdk,pd-production-050123,2025-08-11 22:53:18
125742_S1_M5_CRF_c4591001-1260-12601108.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, UMass Memorial Medical Center, subject data, informed consent, visit date, FDA, Protocol, data management, demography, safety",19,227,https://drive.google.com/file/d/1khOOzpC84IwVTVGErxitb4yaN4uFcE3r/view?usp=drivesdk,pd-production-050123,2025-08-11 22:53:23
125742_S1_M5_CRF_c4591001-1251-12511072.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, achieve clinical research, informed consent, visit date, Protocol, eCRF, demography, subject identification, data collection",20,146,https://drive.google.com/file/d/1MwQLn1q1ADUXzp7I8uTVTsjzKJwDB7hN/view?usp=drivesdk,pd-production-050123,2025-08-11 22:53:30
125742_S1_M5_CRF_c4591001-1252-12521010.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Tabor City Family Medicine, Exclusion, clinical trial, c4591001 trial, regulatory compliance, pharmaceutical research, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, FDA submission, informed consent, visit schedule, Protocol, subject identification, Waterway Primary Care LLC, confidential document",20,488,https://drive.google.com/file/d/1cuoH80WqmEBTeZYW_hEND4te5llJtE8b/view?usp=drivesdk,pd-production-050123,2025-08-11 22:53:36
125742_S1_M5_CRF_c4591001-1248-12481218.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, CRF, informed consent, visit date, FDA, Protocol, SNBL Clinical Pharmacology Center, demography, subject identification, data collection",19,130,https://drive.google.com/file/d/1MhDBQ13QWDhGg5SKwIDE8G-W1i5dcvD4/view?usp=drivesdk,pd-production-050123,2025-08-11 22:53:45
125742_S1_M5_CRF_c4591001-1260-12601128.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, data management, demography, umass memorial medical center, subject identification, data collection",20,188,https://drive.google.com/file/d/1H-xJjmwLW4J92onsw_9kSNG_sjR4E4Nj/view?usp=drivesdk,pd-production-050123,2025-08-11 22:53:49
125742_S1_M5_CRF_c4591001-1251-12511239.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-10-01,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, demographic data, subject enrollment, informed consent, FDA, Protocol, Pfizer, Achieve Clinical Research, eCRF, case report form, safety",20,442,https://drive.google.com/file/d/14iuwhLDLoUc4Obj14KpC2tXOz6-xdExq/view?usp=drivesdk,pd-production-050123,2025-08-11 22:53:54
125742_S1_M5_CRF_c4591001-1260-12601035.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, phase 2/3 study, CRF, UMass Memorial Medical Center, demographic data, informed consent, visit date, FDA, Protocol, subject identification, data collection",19,231,https://drive.google.com/file/d/1S2bHAD4LAHIcdYOapcDRput2ndSLemY4/view?usp=drivesdk,pd-production-050123,2025-08-11 22:53:58
125742_S1_M5_CRF_c4591001-1260-12601069.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, UMass Memorial Medical Center, subject information, informed consent, visit date, FDA, Protocol, data management, demography, safety",19,170,https://drive.google.com/file/d/1j6olXzwZP7dEdXpRbprix4GSsenjebvt/view?usp=drivesdk,pd-production-050123,2025-08-11 22:54:02
125742_S1_M5_CRF_c4591001-1260-12601037.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, c4591001 trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, UMass Memorial Medical Center, eCRF audit trail, FDA submission, informed consent, visit date, Protocol, demography, adverse event reporting, efficacy data",20,130,https://drive.google.com/file/d/165mWEHgi-zmtqyjHmlXq46EKw9rQOak1/view?usp=drivesdk,pd-production-050123,2025-08-11 22:54:09
125742_S1_M5_CRF_c4591001-1229-12291083.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"subject-data, phase-2-3-trial, Exclusion, inclusion-exclusion-criteria, vaccine-development, newton-clinical-research, regulatory-compliance, efficacy, adverse-events, clinical-trial, CRF, informed-consent, cohort-selection, Protocol, c4591001, united-states, visit-date, data-quality, demography, fda-submission",20,768,https://drive.google.com/file/d/1JNelMgPt5007BKBZjaf10yCPIiLJPUNx/view?usp=drivesdk,pd-production-050123,2025-08-11 22:54:16
125742_S1_M5_CRF_c4591001-1251-12511060.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, c4591001, Pfizer, demography, subject identification, efficacy data",20,721,https://drive.google.com/file/d/1tmn1ViG82HOj2P6yGeR1qy-6vjcF3nAG/view?usp=drivesdk,pd-production-050123,2025-08-11 22:54:21
125742_S1_M5_CRF_c4591001-1248-12481163.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, confidential, adverse events, regulatory compliance, fda, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, demographic data, subject enrollment, informed consent, visit schedule, Protocol, eCRF, data management, efficacy data, snbl clinical pharmacology center",20,195,https://drive.google.com/file/d/146rt7uTWuSJM0clkkckXot51iqMMyu2l/view?usp=drivesdk,pd-production-050123,2025-08-11 22:54:25
125742_S1_M5_CRF_c4591001-1260-12601018.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, phase 2/3 study, CRF, UMass Memorial Medical Center, demographic data, informed consent, visit date, FDA, Protocol, subject identification, data collection",19,212,https://drive.google.com/file/d/1xEEYaTSEW9w-ticjoz3F3rH3QUlhZHI3/view?usp=drivesdk,pd-production-050123,2025-08-11 22:54:29
125742_S1_M5_CRF_c4591001-1251-12511031.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, United States, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, Achieve Clinical Research, eCRF, demography, subject identification, efficacy data",20,128,https://drive.google.com/file/d/11DqQFz8JZu6NGPU4ek8dNoBx60l9BLlS/view?usp=drivesdk,pd-production-050123,2025-08-11 22:54:37
125742_S1_M5_CRF_c4591001-1270-12701069.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, Kaiser Permanente, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, FOIA document, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,157,https://drive.google.com/file/d/1g4p3CBvcdABODeREMkk6m016SNDpnUlO/view?usp=drivesdk,pd-production-050123,2025-08-11 22:54:40
125742_S1_M5_CRF_c4591001-1264-12641229.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-27,form,University of California Davis Health,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, university of california, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, eCRF, demography, data collection",20,422,https://drive.google.com/file/d/1yi2ZhaefEmK73aE1u_7cvqQfWn4qO-Nr/view?usp=drivesdk,pd-production-050123,2025-08-11 22:54:45
125742_S1_M5_CRF_c4591001-1265-12651149.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, Kaiser Permanente, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, demography, efficacy data",20,155,https://drive.google.com/file/d/12qxWuMDZpEhxGIL59GWD8ZnCo0TnHybL/view?usp=drivesdk,pd-production-050123,2025-08-11 22:54:49
125742_S1_M5_CRF_c4591001-1265-12651101.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, united states, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, kaiser permanente, demography, efficacy data",20,331,https://drive.google.com/file/d/1Yx63MZR6lDMA2yg9XAuXqpjRNHM5NW27/view?usp=drivesdk,pd-production-050123,2025-08-11 22:54:54
125742_S1_M5_CRF_c4591001-1270-12701142.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, eCRF, kaiser permanente, demography, data collection",20,131,https://drive.google.com/file/d/185UNwUK22ffCBIVbPIcTK9DMaR8bteri/view?usp=drivesdk,pd-production-050123,2025-08-11 22:55:02
125742_S1_M5_CRF_c4591001-1270-12701057.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, Kaiser Permanente, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, FOIA document, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,720,https://drive.google.com/file/d/1ZTtresmvmPRDZotagHN_11vcfxfOw6gh/view?usp=drivesdk,pd-production-050123,2025-08-11 22:55:08
FDA-CBER-2021-5683-0123168 to -0126026_125742_S1_M5_c4591001-A-D-adva.xpt,XPT,FDA-CBER-2021-5683-0123168 to -0126026 125742 S1 M5 c4591001-A-D-adva,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1jNrZK5INjATsmSAl9GZlWrAf1er795BM/view?usp=drivesdk,pd-production-050222,2025-08-11 22:55:12
FDA-CBER-2021-5683-0066701 to -0123167_125742_S1_M5_c4591001-A-D-adfacevd.xpt,XPT,FDA-CBER-2021-5683-0066701 to -0123167 125742 S1 M5 c4591001-A-D-adfacevd,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1hzKrvobLZxhwXqBwAynSrugbEYf9zoUT/view?usp=drivesdk,pd-production-050222,2025-08-11 22:56:39
FDA-CBER-2021-5683-0065774 to -0066700_125742_S1_M5_c4591001-A-D-addv.xpt,XPT,FDA-CBER-2021-5683-0065774 to -0066700 125742 S1 M5 c4591001-A-D-addv,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1wqi0jT9y_T4s0aSMoCe7wWWSlocz6ZxO/view?usp=drivesdk,pd-production-050222,2025-08-11 22:56:43
FDA-CBER-2021-5683-0059000 to -0065773_125742_S1_M5_c4591001-A-D-adcevd.xpt,XPT,FDA-CBER-2021-5683-0059000 to -0065773 125742 S1 M5 c4591001-A-D-adcevd,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1BZGRXI-kzJ6ulhb7KjLLIrKtVvQ7smXB/view?usp=drivesdk,pd-production-050222,2025-08-11 22:56:52
FDA-CBER-2021-5683-0058795 to -0058828_125742_S1_M5_bnt162-01-A-define-2-0-0.xsl,XSL,BNT162 Clinical Study Define-XML Document,2021,Data Specification,,M5,False,True,False,False,False,"data-specification, regulatory-compliance, protocol-documentation, pharmaceutical-development, data-quality, safety-data, bnt162, adverse-events, efficacy-data, vaccine, metadata, controlled-terminology, study-design, fda-submission, data-analysis, clinical-trial, Protocol, data-standards",18,4,https://drive.google.com/file/d/1tjwPaev7NtcRQTXvsze5BowdIAjd_RGA/view?usp=drivesdk,pd-production-050222,2025-08-11 22:56:55
FDA-CBER-2021-5683-0058316 to -0058458_125742_S1_M5_c4591001-A-Supp-define.xml,XML,"C4591001 A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS",2021,report,,M5,False,False,False,False,False,"dose-finding, healthy-adults, immunogenicity, fda, tolerability, placebo-controlled, randomized, observer-blind, rna-vaccine, efficacy, safety, clinical-trial, sars-cov-2, data-analysis, covid-19, phase-1-2-3, regulatory",17,29,https://drive.google.com/file/d/1kLB95TA96uuTXE1KhuJR5naPTKTB6OIG/view?usp=drivesdk,pd-production-050222,2025-08-11 22:56:58
FDA-CBER-2021-5683-0058595 to -0058614_125742_S1_M5_c4591001-S-define-2-0-0.xsl,XSL,Clinical Study Define-XML Document,2021,Data,,M5,False,True,False,False,False,"regulatory-compliance, pharmaceutical-development, data-quality, safety-data, data-management, adverse-events, efficacy-data, controlled-terminology, metadata, data-reporting, study-design, fda-submission, data-analysis, clinical-trial, Protocol, data-standards, define-xml, study-protocol",18,4,https://drive.google.com/file/d/1OpnAstoPT7ae2-4MmmMJaKrZ8E-VmnVW/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:01
FDA-CBER-2021-5683-0058829 to -0058954_125742_S1_M5_bnt162-01-S-define.xml,XML,"BNT162-01 A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults",2021,protocol,,M5,False,True,False,True,False,"SARS-CoV-2 vaccine, Exclusion, clinical trial, BNT162, adverse events, regulatory, dose-escalation, immunogenicity, data structure, healthy adults, laboratory tests, FOIA, FDA, Protocol, vital signs, SDTM, COVID-19, safety, phase I/II",19,21,https://drive.google.com/file/d/1tZoKECiNb-4RqZB_5PCQCTq70e3Y72Za/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:04
FDA-CBER-2021-5683-0058653 to -0058675_125742_S1_M5_c4591001-S-Supp-define-2-0-0.xsl,XSL,Define-XML Document for Clinical Trial c4591001,2021,Data,,M5,False,True,False,False,False,"Efficacy, Data Standards, Clinical Trial, Safety, Define-XML, Controlled Terminology, Data Structure, FOIA, Drug Identifier, Regulatory, FDA, Pharmaceutical, Protocol, Adverse Events, Compliance, Datasets, Metadata, Analysis Results",18,4,https://drive.google.com/file/d/10HZ4efYuDXClCv7ouXWsEZcPA4JSQ-i9/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:06
FDA-CBER-2021-5683-0058676 to -0058794_125742_S1_M5_bnt162-01-A-define.xml,XML,"BNT162-01 A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults",2021,report,,M5,False,True,False,True,False,"SARS-CoV-2 vaccine, Exclusion, clinical trial, BNT162, adverse events, data analysis, regulatory submission, dose-escalation, immunogenicity, healthy adults, FOIA document, FDA, Protocol, vital signs, reactogenicity, COVID-19, safety, laboratory analysis, phase I/II",19,26,https://drive.google.com/file/d/1TEuosLVH3ZkXIvrEg48xAxJIrplSlA34/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:10
FDA-CBER-2021-5683-0058955 to -0058999_125742_S1_M5_bnt162-01-S-define-2-0-0.xsl,XSL,Define-XML Document for BNT162 Clinical Trial,2021,Data/Analysis Metadata,,M5,False,True,False,False,False,"regulatory-submission, fda, pharmaceutical, clinical-development, data-quality, bnt162, adverse-events, Protocol, vaccine, metadata, efficacy, safety, clinical-trial, study-design, data-analysis, controlled-terminology, data-standards, define-xml",18,4,https://drive.google.com/file/d/1vBB2VIKQ-3WCf_43UWSzVhjk7ziEdbIV/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:12
FDA-CBER-2021-5683-0058615 to -0058652_125742_S1_M5_c4591001-S-Supp-define.xml,XML,"C4591001 A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults",2021,report,,M5,False,False,False,False,False,"data-structure, healthy-adults, immunogenicity, study-protocol, fda, reactogenicity, rna-vaccine, tolerability, adverse-events, efficacy, safety, clinical-trial, study-design, data-analysis, covid-19, phase-1-2-3, regulatory",17,7,https://drive.google.com/file/d/1cremWWoRBMis7qkht9tLJ4gMlVqBPEN1/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:15
125742_S1_M5_CRF_c4591001-1006-10061176.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, visit date, FDA, Protocol, demography, safety",19,288,https://drive.google.com/file/d/13KG58xrt7qpg7NktYXXhtWyup0jygPoq/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:20
125742_S1_M5_CRF_c4591001-1005-10051411.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2021-03-29,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, fda, data quality, rochester clinical research, phase 2/3 study, CRF, audit trail, covid-19 vaccine, demographic data, subject enrollment, informed consent, visit schedule, Protocol, eCRF, subject identification, confidential document, data collection",20,157,https://drive.google.com/file/d/1RgFy9k1qDL6ub417rJm05ZrkFXN3_PL5/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:23
FDA-CBER-2021-5683-0058459 to -0058478_125742_S1_M5_c4591001-A-Supp-define-2-0-0.xsl,XSL,Define-XML Document for Clinical Trial c4591001-A Supplemental Submission,2021,Data,,M5,False,True,False,False,False,"Data Standards, Clinical Trial, Define-XML, Controlled Terminology, FDA, Pharmaceutical, Data Quality, Regulatory Submission, Efficacy Data, Datasets, Compliance, Adverse Events, Protocol, c4591001-A, Supplemental Submission, Safety Data, Metadata, Analysis Results",18,4,https://drive.google.com/file/d/1y-he_yLrDbFtRaRA3z0zAQd8Qe61hfqV/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:26
125742_S1_M5_CRF_c4591001-1006-10061052.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2021-03-29,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, United States, regulatory compliance, pharmaceutical research, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, subject identification, data collection",20,259,https://drive.google.com/file/d/1oIxIWi9A17MEHCkOGdr8o6hZD3hc15Je/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:30
FDA-CBER-2021-5683-0058479 to -0058594_125742_S1_M5_c4591001-S-define.xml,XML,"C4591001 A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults",2021,protocol,Covance,M5,False,True,False,True,False,"concomitant medications, Exclusion, demographics, clinical trial, virology, adverse events, regulatory, immunogenicity, fda, efficacy, healthy adults, oxygenation parameters, covid-19 vaccine, laboratory tests, phase 1/2/3 study, Protocol, tolerability, safety, data collection",19,25,https://drive.google.com/file/d/1g-6AhRrVbcUFN1nYZcr6X-XWn2x9SSmI/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:33
125742_S1_M5_CRF_c4591001-1006-10061040.pdf,PDF,c4591001 Clinical Trial CRF,2021-03-29,clinical trial form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, data quality, inclusion/exclusion criteria, CRF, FOIA document, informed consent, visit date, FDA, Protocol, vaccine, subject details, c4591001, Pfizer, demography, COVID-19, data collection",20,507,https://drive.google.com/file/d/1csMH48AVMiu57gvZyRP5SOCL46svg7N5/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:39
125742_S1_M5_CRF_c4591001-1006-10061098.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, confidential, data quality, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, demographic data, data audit trail, subject enrollment, informed consent, visit schedule, J. Lewis Research Inc., Protocol, Foothill Family Clinic, Pfizer, data freezing, data collection",20,226,https://drive.google.com/file/d/1bL96pimPHflxJek_Q9_MrIv35zqEGdoI/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:42
125742_S1_M5_CRF_c4591001-1006-10061094.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, data quality control, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, adverse event monitoring, visit schedule, J. Lewis Research Inc., Protocol, Foothill Family Clinic, Pfizer, data management, subject identification",20,249,https://drive.google.com/file/d/1wl7qUEaRpOrF-ABilW-pHlOhOj5K4EE5/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:46
125742_S1_M5_CRF_c4591001-1006-10061020.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Protocol, Pfizer, demography, efficacy data",19,187,https://drive.google.com/file/d/1Ltcpk9-lpOhpxfk74IHG-ac9ko18vyuj/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:50
125742_S1_M5_CRF_c4591001-1003-10031186.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject data, informed consent, safety monitoring, visit date, FDA, Rochester Regional Health, Protocol, demography, efficacy data",19,473,https://drive.google.com/file/d/185iG91TGLMr487XzPf4ClC1p3nY-Bvrx/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:55
125742_S1_M5_CRF_c4591001-1005-10051387.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-10-10,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, safety and efficacy, CRF, Rochester Clinical Research, informed consent, visit date, FDA, Protocol, vaccine, c4591001, demography, data collection",20,202,https://drive.google.com/file/d/1ZR1frX7o0ZaIclEBfW_io8MtTTNKFV-J/view?usp=drivesdk,pd-production-050222,2025-08-11 22:57:59
125742_S1_M5_CRF_c4591001-1005-10051054.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"phase-2-3-trial, Exclusion, inclusion-exclusion-criteria, regulatory-compliance, crf, protocol-amendment, adverse-events, clinical-trial, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, rochester-clinical-research, visit-date, confidential-document, demography, safety-efficacy, fda-submission",20,212,https://drive.google.com/file/d/14OQkTqXAybaalnQzXWugf85UjxSUpflM/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:03
125742_S1_M5_CRF_c4591001-1005-10051069.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, Rochester Clinical Research, informed consent, visit date, FDA, Protocol, c4591001, eCRF, data management, demography, safety, data collection",20,193,https://drive.google.com/file/d/16QJNwchyJidfkdfOcAZeyYLFkSIDvuCb/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:06
125742_S1_M5_CRF_c4591001-1003-10031113.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-06,Clinical Research Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, data quality, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, demographic data, eCRF audit trail, subject enrollment, FDA regulatory, informed consent, visit schedule, Rochester Regional Health, Protocol, data verification, data freezing, confidential document, data collection",20,409,https://drive.google.com/file/d/10izk1lZFLDpNh1PjyYD-1u4LfMKujqYm/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:11
125742_S1_M5_CRF_c4591001-1005-10051214.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,,M5,True,True,False,True,False,"pharmaceutical-research, Exclusion, data-verification, inclusion-exclusion-criteria, regulatory-compliance, data-freezing, protocol-amendment, site-information, clinical-trial, fda-regulated, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, visit-date, subject-identification, data-quality, demography",20,166,https://drive.google.com/file/d/15oNeR4fB-TsJeYhUnXRjF4c11sZinF4V/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:15
125742_S1_M5_CRF_c4591001-1005-10051347.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-22,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, rochester clinical research, CRF, audit trail, covid-19 vaccine, subject data, informed consent, visit date, Protocol, c4591001, eCRF, demography",20,180,https://drive.google.com/file/d/1G9DVzz0o8CV-muDVkcjiZr2v3172s54j/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:19
125742_S1_M5_CRF_c4591001-1005-10051293.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-01,form,,M5,True,True,False,True,False,"Exclusion, data-verification, inclusion-exclusion-criteria, phase-2-3-study, data-freezing, audit-trail, clinical-trial, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, rochester-clinical-research, visit-date, confidential-document, fda-regulatory, subject-identification, demography, quality-control",20,334,https://drive.google.com/file/d/1ix-Mj1oEBGYzL_BTOMDWw5WtawRB8TAM/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:24
125742_S1_M5_CRF_c4591001-1003-10031207.pdf,PDF,c4591001 Clinical Trial CRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, efficacy, CRF, informed consent, visit date, FDA, Rochester Regional Health, Protocol, vaccine, c4591001, demography, safety, data collection",20,174,https://drive.google.com/file/d/1JN6O44LGg78s45tcX4BQI3-d9iNlzXpq/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:27
125742_S1_M5_CRF_c4591001-1005-10051047.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, Rochester Clinical Research, informed consent, visit date, FDA, Protocol, demography, subject identification, safety",19,164,https://drive.google.com/file/d/1_cUE9CsFVG2KumwqBaWfdvA0JSatVtU4/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:31
125742_S1_M5_CRF_c4591001-1003-10031149.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, subject 10031149, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Rochester Regional Health, Protocol, c4591001, demography, data collection",19,213,https://drive.google.com/file/d/1KhWUqnPvnD9ax5rxMa_p1i9euVoF7Vur/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:35
125742_S1_M5_CRF_c4591001-1003-10031197.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),pfe.levissc,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, Rochester General Hospital, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Rochester Regional Health, Protocol, c4591001, eCRF, demography, data collection",20,170,https://drive.google.com/file/d/1bRGQ4g9lLnmh0UQ9bmhyFrCrmwSfZMI9/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:39
125742_S1_M5_CRF_c4591001-1003-10031065.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),pfe.levissc,M5,True,True,False,True,False,"electronic data capture, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, CRF, informed consent, visit date, FDA, Rochester Regional Health, Protocol, c4591001, Pfizer, demography",20,407,https://drive.google.com/file/d/1HTtUirxELFsbCG3GwSQF1Gt8TDOwgutH/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:44
125742_S1_M5_CRF_c4591001-1003-10031038.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),pfe.levissc,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, Rochester General Hospital, cohort selection, inclusion/exclusion criteria, protocol amendment, CRF, informed consent, visit date, FDA, Rochester Regional Health, Protocol, vaccine, c4591001, demography, efficacy data",20,457,https://drive.google.com/file/d/1YEG1TFlrNrJ1Zl3QqJ58Kf_cIYuRTIx9/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:49
125742_S1_M5_CRF_c4591001-1001-10011135.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, NYU Langone Health, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, FDA, Protocol, subject details, c4591001, data integrity, demography, safety, data collection",20,174,https://drive.google.com/file/d/1PQgsP3UxOcpJc6n2X7xHRZcIiWH-nhOy/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:52
125742_S1_M5_CRF_c4591001-1001-10011093.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-06,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, confidential, adverse events, regulatory compliance, data quality, NYU Langone Health, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, demography, subject identification, efficacy data",20,424,https://drive.google.com/file/d/1ZCRzxeOYu2KYaPrvVvZ2OuCzRFxytvD_/view?usp=drivesdk,pd-production-050222,2025-08-11 22:58:57
125742_S1_M5_CRF_c4591001-1001-10011100.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-06,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, adverse events, regulatory compliance, fda, data quality, inclusion/exclusion criteria, efficacy, phase 2/3 study, CRF, covid-19 vaccine, subject data, informed consent, visit date, Protocol, new york university, demography, data collection",20,313,https://drive.google.com/file/d/1N8rl6QcpVkmgwTYcNzX_07jnL5y_ilt_/view?usp=drivesdk,pd-production-050222,2025-08-11 22:59:02
125742_S1_M5_CRF_c4591001-1003-10031111.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),pfe.levissc,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, regulatory compliance, Rochester General Hospital, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Rochester Regional Health, Protocol, c4591001, Pfizer, data management, demography, subject identification, data collection",20,202,https://drive.google.com/file/d/1JOEWP40zjjOnu_9ZpdNte9npRJkwJjAC/view?usp=drivesdk,pd-production-050222,2025-08-11 22:59:05
125742_S1_M5_c4591001-S-Supp-acrf.pdf,PDF,Annotated Study Book for Study Design: C4591001,2021-01-14,protocol,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory, immunogenicity, sample collection, inclusion/exclusion criteria, protocol, efficacy, CRF, informed consent, visit schedule, FDA, Protocol, vaccine, Pfizer, COVID-19, safety, study design, data collection",20,131,https://drive.google.com/file/d/1E4AnM-Gc9FnGq2mIaBtZZzWxqTrLYprZ/view?usp=drivesdk,pd-production-050222,2025-08-11 22:59:10
125742_S1_M5_c4591001-S-acrf.pdf,PDF,Annotated Study Book for Study Design: C4591001,2021-01-14,protocol,,M5,True,True,False,True,False,"Exclusion, clinical trial, central lab, safety data, adverse events, regulatory compliance, randomization, immunogenicity, sample collection, protocol, CRF, informed consent, visit schedule, FDA, Protocol, vaccine, Pfizer, data management, COVID-19, study design",20,131,https://drive.google.com/file/d/1qtdy8Ze3LziVNsLrV5iX2jst0ZOMZxrv/view?usp=drivesdk,pd-production-050222,2025-08-11 22:59:16
125742_S1_M5_bnt162-01-S-acrf.pdf,PDF,BNT162-01 Clinical Study Report,2020-04-22,Case Report Form (CRF),,M5,True,True,False,False,False,"demographic data, data quality, FDA submission, sponsor: BioNTech, informed consent, protocol version, clinical trial, reproductive potential, vaccine development, urine pregnancy test, regulatory compliance, Protocol, BNT162 vaccine, adverse events, phase 1 study, vital signs, study code: 049/20, CRF",18,41,https://drive.google.com/file/d/1nqrtJmxBcPnhaGtAXTuZquaq62pX8UqT/view?usp=drivesdk,pd-production-050222,2025-08-11 22:59:19
125742_S1_M5_c4591001-S-csdrg.pdf,PDF,Clinical Study Data Reviewer's Guide,2021-04-29,report,,M5,False,True,False,True,False,"phase 2/3 trial, Exclusion, clinical trial, safety data, adverse events, data analysis, regulatory compliance, participant demographics, COVID-19 vaccine, data standards, FDA submission, Protocol, data review, Pfizer, BioNTech, data integrity, phase 1 trial, efficacy data, confidential document",19,86,https://drive.google.com/file/d/1TGsQyYiXza2iTQDkSxvfjwPRjhRLQoap/view?usp=drivesdk,pd-production-050222,2025-08-11 22:59:24
125742_S1_M5_bnt162-01-A-adrg.pdf,PDF,Analysis Data Reviewer's Guide,2021-03-09,report,"Pfizer Inc., BioNTech SE",M5,False,True,False,False,False,"data anonymization, BNT162-01, BioNTech, reviewer's guide, data quality, clinical trial, FDA, data processing, safety data, Protocol, vaccine, data standards, study design, analysis data, adverse events, Pfizer, efficacy data, regulatory submission",18,33,https://drive.google.com/file/d/1W815YEPxUr75dG_FwZeMqHTN_wzRplrg/view?usp=drivesdk,pd-production-050222,2025-08-11 22:59:27
125742_S1_M5_bnt162-01-S-csdrg.pdf,PDF,Clinical Study Data Reviewer's Guide,2021-03-08,report,"Pfizer Inc., BioNTech SE",M5,False,True,False,True,False,"data reviewer's guide, Exclusion, clinical trial, confidential information, safety data, data traceability, adverse events, regulatory compliance, pharmaceutical research, data quality, data standards, BNT162 study, FDA submission, vaccine development, Protocol, Pfizer, BioNTech, COVID-19, efficacy data",19,73,https://drive.google.com/file/d/1pDziJmOjYZ4_7r72jqbxVSGvNAlgD3SU/view?usp=drivesdk,pd-production-050222,2025-08-11 22:59:33
125742_S1_M5_5351_c4591001-interim-mth6-sample-crf.pdf,PDF,Annotated Study Book for Study Design: C4591001,2021-02-22,report,,M5,True,True,False,False,False,"medical-terminology, covid-19, quality-assurance, fda, regulatory-compliance, pharmaceutical-development, clinical-trial, adverse-event-reporting, CRF, data-collection, data-management, Protocol, pfizer, c4591001, study-design, united-states, scientific-documentation, safety-data, vaccine-trials",19,225,https://drive.google.com/file/d/1XjBY1nV12Q-92FY3s2SrG4vXT1Pd5mhG/view?usp=drivesdk,pd-production-050222,2025-08-11 22:59:37
125742_S1_M5_5351_c4591001-interim-mth6-sponsor-signature.pdf,PDF,Interim Clinical Study Report for Protocol C4591001,2021-04-29,report,"Dzung Nguyen, Kenneth Koury, John L. Perez",M5,False,True,False,False,False,"SARS-CoV-2 RNA vaccine, immunogenicity, confidential, clinical trial, phase 1/2/3 study, statistical analysis, FDA, 6-month update, tolerability, Protocol, COVID-19, interim report, efficacy, safety, sponsor approval, good clinical practice, vaccine candidate, regulatory approval",18,3,https://drive.google.com/file/d/1QCT46XzJxDOq4y9y9hjspGLs3ZZ9PtT5/view?usp=drivesdk,pd-production-050222,2025-08-11 22:59:42
125742_S1_M5_5351_bnt162-01_20242.pdf,PDF,BioNTech BNT162-01 Clinical Trial Data,2020-11-26,report,,M5,False,True,False,True,False,"CRS Berlin, Exclusion, clinical trial, body measurements, safety data, adverse events, regulatory, BNT162-01, subject identifier, pharmaceutical, data compliance, FOIA, FDA, Protocol, vaccine, time series, medical terminology, BioNTech, lab tests",19,100,https://drive.google.com/file/d/13hXRKkKffSeGYJj9ucAmx7mGgI0bcO_L/view?usp=drivesdk,pd-production-050222,2025-08-11 22:59:46
125742_S1_M5_5351_c4591001-interim-mth6-randomization-sensitive.pdf,PDF,Listing of Randomization Scheme and Actual Vaccine Received – All Subjects ≥16 Years of Age,2021-04-01,report,,M5,False,False,False,False,False,"BNT162b1, phase 1, randomization, data listing, pharmaceutical, clinical trial, FDA, age group, safety data, dose information, vaccine, COVID-19, adverse events, placebo, efficacy data, BNT162b2, regulatory compliance",17,4376,https://drive.google.com/file/d/1Y4KRppiWnpbpFLL7w31izW8ljeKMbq8A/view?usp=drivesdk,pd-production-050222,2025-08-11 23:00:21
125742_S1_M5_5351_bnt162-01_20116.pdf,PDF,BioNTech BNT162-01 Clinical Trial Data,2020-09-25,report,,M5,False,True,False,True,False,"CRS Berlin, Exclusion, clinical trial, alcohol test, body measurements, safety data, Visit 0, adverse events, regulatory compliance, BNT162-01, pharmaceutical, Part A, FOIA, FDA, Protocol, vaccine, ECG, BioNTech, blood samples",19,81,https://drive.google.com/file/d/1SJJy3nB6ss7isIGJQmtvGYUhZ_1cQDP4/view?usp=drivesdk,pd-production-050222,2025-08-11 23:00:25
125742_S1_M5_5351_bnt162-01_10010.pdf,PDF,BioNTech BNT162-01 Clinical Trial Data,2020-09-25,report,,M5,False,True,False,True,False,"visit forms, Exclusion, Germany, clinical trial, safety data, adverse events, regulatory, BNT162-01, pharmaceutical, data compliance, CRS Mannheim, SARS-CoV-2 antibodies, laboratory tests, FDA, Protocol, medical terminology, vital signs, BioNTech, COVID-19",19,75,https://drive.google.com/file/d/1PuxFMBeLqVGgL_dQ8eqc_HPzpZOCj4Vk/view?usp=drivesdk,pd-production-050222,2025-08-11 23:00:29
125742_S1_M5_5351_bnt162-01-interim3-sample-crf.pdf,PDF,BNT162-01 Interim 3 Sample CRF,2020-07-08,form,,"M3, M5",True,False,False,False,False,"pharmaceutical research, sponsor study, eCRF, clinical trial, FDA, vaccine development, safety data, BNT162, regulatory compliance, COVID-19, interim report, body measurements, CRS study, efficacy data, adverse events, data collection, CRF",17,139,https://drive.google.com/file/d/1FjiQgQnWrb9x8G5PiVwt0Be4RRF9xaXW/view?usp=drivesdk,pd-production-050222,2025-08-11 23:00:34
125742_S1_M5_5351_bnt162-01_20215.pdf,PDF,BioNTech BNT162-01 (CRS 049/20) Clinical Trial Data,2021-01-04,report,,M5,False,True,False,True,False,"CRS Berlin, Exclusion, clinical trial, body measurements, safety data, Visit 0, adverse events, regulatory, BNT162-01, pharmaceutical, Part A, FDA, alcohol breath test, Protocol, vaccine, Subject Identifier 276-02-0215, ECG, BioNTech, lab tests",19,97,https://drive.google.com/file/d/1_R4uH1XckU-ehGLUZByO5Q5QKJUFAio4/view?usp=drivesdk,pd-production-050222,2025-08-11 23:00:38
125742_S1_M5_5351_bnt162-01_10075.pdf,PDF,BioNTech BNT162-01 Clinical Trial Data,2020-09-25,report,,M5,False,True,False,True,False,"Exclusion, clinical trial, body measurements, safety data, adverse events, regulatory, visit 0, BNT162-01, subject identifier, pharmaceutical, CRS Mannheim, FOIA document, laboratory tests, FDA, Protocol, vaccine, vital signs, BioNTech, data collection",19,94,https://drive.google.com/file/d/14iYWeAp3vDdJxgqVd7kYkcQOYvopDnHH/view?usp=drivesdk,pd-production-050222,2025-08-11 23:00:42
125742_S1_M5_5351_bnt162-01-interim3-synopsis.pdf,PDF,Interim Clinical Study Report - BNT162-01,2021-03-20,report,Dr. Dr. med. Armin Schultz,"M3, M5",False,True,False,False,False,"ClinicalTrials.gov, dose-escalation, BNT162b1, immunogenicity, EudraCT, SARS-CoV-2 vaccine, Germany, clinical trial, reactogenicity, BNT162, COVID-19, Protocol, interim report, safety, BioNTech SE, phase I/II, healthy adults, BNT162b2",18,20,https://drive.google.com/file/d/1SP1h3IpES8RiBZx6aoJlnyDwo0b9_HRd/view?usp=drivesdk,pd-production-050222,2025-08-11 23:00:47
125742_S1_M5_5351_bnt162-01-interim3-sap.pdf,PDF,Statistical Analysis Plan for BNT162-01 Clinical Trial,2020-11-18,protocol,Susanne Steinhauser,"M3, M5",False,True,False,False,False,"BNT162b1, immunogenicity, EudraCT, SARS-CoV-2 vaccine, WHO UTN, BioNTech, BNT162c2, FOIA, phase 1/2 study, clinical trial, Staburo GmbH, BNT162a1, CRS Clinical Research Services, Protocol, statistical analysis plan, safety, BNT162b2, regulatory compliance",18,35,https://drive.google.com/file/d/1Fh5cBKFEqx9NV5wCdBisp71d0B4Wa-jg/view?usp=drivesdk,pd-production-050222,2025-08-11 23:00:52
125742_S1_M5_5351_bnt162-01-interim3-sponsor-signature.pdf,PDF,BNT162 Interim 3 Clinical Study Report,2021,Report,,"M3, M5",False,False,False,False,False,"Sponsor Signature, Clinical Trial Protocols, Data Analysis, Adverse Event Reporting, CBER Document, BNT162 Clinical Trial, Pharmaceutical Regulations, Vaccine Safety Data, Interim 3 Study Report, Regulatory Compliance, Vaccine Identification, FDA Submission, Vaccine Efficacy Data, Vaccine Approval Process, Clinical Trial Phases, Pharmaceutical Development, Pfizer-BioNTech COVID-19 Vaccine",17,2,https://drive.google.com/file/d/1kVQlAL9hb8Kr34zp59KtF9pGZNLBXtbc/view?usp=drivesdk,pd-production-050222,2025-08-11 23:00:55
125742_S1_M5_5351_bnt162-01-interim3-sponsor-personnel-list.pdf,PDF,Interim Clinical Study Report BNT162-01,2020-11-26,report,"Özlem Türeci, Svetlana Shpyro, Stefan Liebscher, Sean Murphy, Christopher Marshallsay, Frans van Huizen, David Langer, Stefanie Bolte, Martin Bexon, Amélie Caneparo, Claudia Müller, Tania Palanche","M3, M5",False,False,False,False,False,"clinical trial report, trial master file, pharmacovigilance, pharmaceutical development, FDA regulatory, interim analysis, clinical data management, sponsor personnel, ICH guidelines, safety data, quality assurance, BNT162 vaccine, Germany location, biostatistics, efficacy data, adverse events, medical writing",17,1,https://drive.google.com/file/d/1PjKgiT28MCrJiaSr-Ti5DdvW6Y1uX4KF/view?usp=drivesdk,pd-production-050222,2025-08-11 23:00:59
125742_S1_M5_5351_bnt162-01-interim3-protocol.pdf,PDF,"A multi-site, Phase I/II, 2-part, dose escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in healthy and immunocompromised adults",2020-10-05,Clinical Trial Protocol,"Armin Schultz, Özlem Türeci","M3, M5",False,True,False,False,False,"Safety Data, Sponsor Information, Clinical Trial, Phase I/II Study, RNA Vaccine, Germany, COVID-19 Prevention, Healthy Adults, Immunogenicity, Confidentiality, Regulatory Compliance, Protocol, Dosing Regimens, BioNTech RNA Pharmaceuticals, Good Clinical Practice, SARS-CoV-2 Vaccine, Immunocompromised Adults, Dose Escalation Trial",18,338,https://drive.google.com/file/d/128_WdWIjrFv95BycM7RAaNiqKwX1U_Yd/view?usp=drivesdk,pd-production-050222,2025-08-11 23:01:07
125742_S1_M5_5351_bnt162-01-interim3-notes-for-reader.pdf,PDF,Interim Clinical Study Report BNT162-01,2020-11-27,report,,"M3, M5",False,True,False,False,False,"mRNA technology, data harmonization, pharmaceutical development, dose groups, clinical trial, data programming, FDA, safety data, Protocol, COVID-19, interim report, BNT162 vaccine, statistical analysis plan, BioNTech RNA Pharmaceuticals, data cut-off, participant data, adverse events, regulatory submission",18,3,https://drive.google.com/file/d/1emATGkyJGlrDowXWpbGG7hPpO7vpPK7M/view?usp=drivesdk,pd-production-050222,2025-08-11 23:01:10
125742_S1_M5_5351_bnt162-01-interim3-report-body.pdf,PDF,Interim Clinical Study Report - BNT162-01,2021-03-20,report,"Elizabeth Adams, Stefan Liebscher, Armin Schultz","M3, M5",False,True,False,False,False,"BNT162b1, immunogenicity, GCP compliance, dose-escalation, SARS-CoV-2 vaccine, dose-expansion, Germany, clinical trial, reactogenicity, cell-mediated immunity, BNT162, COVID-19, Protocol, interim report, safety, phase I/II, BNT162b2, regulatory identifiers",18,2151,https://drive.google.com/file/d/1_QoGFrPMXamNizOGmXiOX_lkUtq3IW8l/view?usp=drivesdk,pd-production-050222,2025-08-11 23:01:29
125742_S1_M5_5351_bnt162-01-interim3-protocol-deviations.pdf,PDF,Listing of Protocol Deviations - BNT162b1 Safety Set,2020-11-20,report,"BioNTech RNA Pharmaceuticals GmbH, Staburo GmbH","M3, M5",False,True,False,False,False,"visit schedule compliance, data listing, protocol deviations, pharmaceutical company, dose groups, FDA regulation, SDTM data, Germany, BNT162b1 vaccine, clinical trial protocol, safety data, subject numbers, Protocol, data cut-off, phase 1 study, adverse events, data analysis, laboratory data",18,30,https://drive.google.com/file/d/1PYulj-Gc50ptAnQwzpcpXX87aWyWGiRv/view?usp=drivesdk,pd-production-050222,2025-08-11 23:01:33
125742_S1_M5_5351_bnt162-01-interim3-patient-batches.pdf,PDF,Interim Clinical Study Report - BNT162-01 Investigational Product Tracking Table,2020-11-23,report,,"M3, M5",False,False,False,False,False,"BNT162b1, quality control, BNT162-01, pharmaceutical development, batch tracking, expiry date, Germany, clinical trial, data management, RNA vaccine, investigational product, COVID-19, interim report, Mannheim, sequence numbers, medication numbers, regulatory compliance",17,18,https://drive.google.com/file/d/1wX-Zfsrai9WcUI_AUDw1g5MJJPzMaIQE/view?usp=drivesdk,pd-production-050222,2025-08-11 23:01:38
125742_S1_M5_5351_bnt162-01-interim3-lab-measurements.pdf,PDF,Listing of Laboratory Measurements - BNT162b1 Safety Set,2020-11-20,report,,"M3, M5",False,False,False,False,False,"regulatory-submission, fda, staburo, visit-assessments, sdtm-data, laboratory-measurements, safety-data, data-cut-off, adverse-events, chemistry, biontechRNA, data-quality, dose-groups, clinical-trial, urinalysis, data-analysis, bnt162b1",17,7040,https://drive.google.com/file/d/1G3t2wWlsYjHKPECaOXOtNmaUETFVTt44/view?usp=drivesdk,pd-production-050222,2025-08-11 23:02:14
125742_S1_M5_5351_bnt162-01-interim3-investigators.pdf,PDF,Interim Clinical Study Report for BNT162-01,2020-09-02,report,"Dr. Dr. med. Armin Schultz, Dr. med. Friedeborg Seitz, Dr. med. Sybille Baumann, Dr. med. Matthias Berse, Manuela Casjens MD","M3, M5",False,False,False,False,False,"pharmaceutical development, contract research organization, FDA submission, Germany, clinical trial, data integrity, safety data, COVID-19, quality assurance, interim report, BNT162 vaccine, Mannheim, efficacy data, adverse events, investigator list, Berlin, regulatory compliance",17,13,https://drive.google.com/file/d/10baK5kGxwYdRxtycHnolMTB5B80YYrwm/view?usp=drivesdk,pd-production-050222,2025-08-11 23:02:21
125742_S1_M5_5351_bnt162-01-interim3-demographics.pdf,PDF,Listing of Subjects Disposition - BNT162b1 Safety Set,2020-11-20,report,,"M3, M5",False,False,False,False,False,"BNT162b1, vaccine research, subject disposition, BNT162-01, pharmaceutical development, informed consent, dose groups, clinical trial, FDA, protocol versions, safety data, data management, COVID-19, data cut-off, adverse events, data analysis, regulatory compliance",17,59,https://drive.google.com/file/d/1_hQh8M0Fzt20Ih1gLAWD2KmJu3pb4Ygp/view?usp=drivesdk,pd-production-050222,2025-08-11 23:02:25
125742_S1_M5_5351_bnt162-01-interim3-discontinued-patients.pdf,PDF,Listing of Subjects with Premature Discontinuation - BNT162b1 and BNT162b2,2020-11-27,report,,"M3, M5",False,False,False,False,False,"BNT162b1, subject information, pandemic-related, premature discontinuation, pharmaceutical, FOIA, dose groups, clinical trial, FDA, data compliance, safety data, vaccine, adverse events, data cut-off, BNT162b2, data analysis, regulatory",17,2,https://drive.google.com/file/d/18lwST755If8p30ggnF3RWf-JMKPTSCCt/view?usp=drivesdk,pd-production-050222,2025-08-11 23:02:28
125742_S1_M5_5351_bnt162-01-interim3-iec-irb.pdf,PDF,Interim Clinical Study Report for BNT162-01,2020-09-12,report,"Prof. Dr. med. Gerlinde Egerer, Prof. Dr. med. Martin Hildebrandt","M3, M5",False,False,False,False,False,"pharmaceutical research, confidential document, FDA submission, Germany, clinical trial, FOIA request, vaccine development, regulatory compliance, RNA pharmaceuticals, safety data, interim report, BNT162 vaccine, efficacy data, Baden-Württemberg, adverse events, Berlin, independent ethics committee",17,1,https://drive.google.com/file/d/1evd2kp9oElw-ur_dT7HseQ25-UC3xRFa/view?usp=drivesdk,pd-production-050222,2025-08-11 23:02:32
125742_S1_M5_5351_bnt162-01-interim3-excluded-patients.pdf,PDF,Listing of subjects excluded from Safety and Immunogenicity sets - BNT162b1,2020-11-20,report,,"M3, M5",False,False,False,True,False,"BNT162b1, immunogenicity, excluded patients, pharmaceutical, FOIA, dose groups, clinical trial, informed consent, screening, FDA, Staburo GmbH, Exclusion, vaccine, safety, data cut-off, SDTM, data analysis, regulatory",18,4,https://drive.google.com/file/d/1ICxYxVuji-8pwtC_vP9A-QsvvYPfvD7X/view?usp=drivesdk,pd-production-050222,2025-08-11 23:02:35
125742_S1_M5_5351_bnt162-01-interim3-invest-signature.pdf,PDF,Interim 3 Clinical Study Report for BNT162 Vaccine,2021-03-23,report,,"M3, M5",False,False,False,False,False,"clinical trial report, vaccine research, mRNA technology, FDA submission, pharmaceutical development, interim analysis, data compliance, safety data, CBER, COVID-19, quality assurance, United States, BNT162 vaccine, adverse events, efficacy data, regulatory approval, Pfizer",17,1,https://drive.google.com/file/d/1oGjX0Z1PIO3gcDq8kn7gWVm5jh64lkFp/view?usp=drivesdk,pd-production-050222,2025-08-11 23:02:38
125742_S1_M5_5351_bnt162-01-interim3-compliance.pdf,PDF,Listing of Subjects' Inclusion in Analysis Sets - BNT162b1,2020-11-20,report,,"M3, M5",False,False,False,False,False,"regulatory-submission, immunogenicity-data, fda, compliance, pharmaceutical-development, sdtm-data, bio-ntech, safety-data, data-cut-off, subject-listing, staburo-gmbh, bnt162-01, dose-groups, clinical-trial, data-analysis, analysis-sets, bnt162b1",17,484,https://drive.google.com/file/d/1kEvhAV1yZWD2zqN7jcpiR1c_csL2RivA/view?usp=drivesdk,pd-production-050222,2025-08-11 23:02:46
125742_S1_M5_5351_bnt162-01-interim3-adverse-events.pdf,PDF,Listing of Solicited Local Reactions - BNT162b1,2020-11-20,report,,"M3, M5",False,False,False,False,False,"regulatory-submission, fda, data-listing, pharmaceutical-development, bio-ntech, sdtm-data, safety-data, staburo-gmbh, rna-vaccine, data-cut-off, local-reactions, dose-groups, adverse-events, data-analysis, clinical-trial, immunization, bnt162b1",17,338,https://drive.google.com/file/d/1RqswpDGPAiJ_k8LXKNIKrw36BmcCq72L/view?usp=drivesdk,pd-production-050222,2025-08-11 23:02:53
STN 125742-0-0 Section 2.5 Clinical Overview reissue.pdf,PDF,BNT162b2 2.5 Clinical Overview,2021-04-30,report,,,False,False,False,False,False,"efficacy-endpoints, immunogenicity, fda-submission, ethical-considerations, regulatory-approval, therapeutic-context, safety-data, clinical-overview, bioanalytical-methods, adverse-events, biopharmaceutics, bnt162b2-vaccine, vaccine-development, clinical-trial, proposed-indication, covid-19, clinical-pharmacology",17,334,https://drive.google.com/file/d/176VZLKSfHt9NUFanAVQCE76OvyVw4KTi/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:00
FDA-CBER-2021-5683-0205318 to -0208520_125742_S1_M5_c4591001-S-Supp-D-ex.xpt,XPT,FDA-CBER-2021-5683-0205318 to -0208520 125742 S1 M5 c4591001-S-Supp-D-ex,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1IxFvVg4ENyt4gRLViZAwwo8BgxwBTcr0/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:04
FDA-CBER-2021-5683-0208521 to -0216666_125742_S1_M5_c4591001-S-Supp-D-suppvs.xpt,XPT,FDA-CBER-2021-5683-0208521 to -0216666 125742 S1 M5 c4591001-S-Supp-D-suppvs,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1tbn62R9kBuYAkGSiOcGW0aagIwwsqvUA/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:08
FDA-CBER-2021-5683-0196049 to -0205317_125742_S1_M5_c4591001-S-Supp-D-ce.xpt,XPT,FDA-CBER-2021-5683-0196049 to -0205317 125742 S1 M5 c4591001-S-Supp-D-ce,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1rdOww8o4CcBxDGPSXAgV3kjMUnsZ-z6i/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:17
FDA-CBER-2021-5683-0187906 to -0196048_125742_S1_M5_c4591001-S-D-suppvs.xpt,XPT,FDA-CBER-2021-5683-0187906 to -0196048 125742 S1 M5 c4591001-S-D-suppvs,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1sDvhDetH7l9LWNcaEXsuCxL8eBziagA5/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:21
FDA-CBER-2021-5683-0182981 to -0187905_125742_S1_M5_c4591001-S-D-suppmh.xpt,XPT,FDA-CBER-2021-5683-0182981 to -0187905 125742 S1 M5 c4591001-S-D-suppmh,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1l49hlVCXXOmoCYzrHZAllGtQIAwwNob9/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:24
FDA-CBER-2021-5683-0178319 to -0180190_125742_S1_M5_c4591001-S-D-suppho.xpt,XPT,FDA-CBER-2021-5683-0178319 to -0180190 125742 S1 M5 c4591001-S-D-suppho,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1iOd_mWe0fKgjhsTBHAcEZsT8vwrncWHp/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:26
FDA-CBER-2021-5683-0171524 to -0174606_125742_S1_M5_c4591001-S-D-suppds.xpt,XPT,FDA-CBER-2021-5683-0171524 to -0174606 125742 S1 M5 c4591001-S-D-suppds,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1fpqdpVKzMzYtl0VVTelsZqstB5lQjof_/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:29
FDA-CBER-2021-5683-0168683 to -0169081_125742_S1_M5_c4591001-S-D-suppcm.xpt,XPT,FDA-CBER-2021-5683-0168683 to -0169081 125742 S1 M5 c4591001-S-D-suppcm,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/11RiCAWvnY_NwBM_DmhPRO2i9zGFooVcr/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:30
FDA-CBER-2021-5683-0180191 to -0182980_125742_S1_M5_c4591001-S-D-suppis.xpt,XPT,FDA-CBER-2021-5683-0180191 to -0182980 125742 S1 M5 c4591001-S-D-suppis,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1DSeZKjeH23GdQYRVFtbqt5bVp50ijhJw/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:32
FDA-CBER-2021-5683-0174607 to -0178318_125742_S1_M5_c4591001-S-D-suppdv.xpt,XPT,FDA-CBER-2021-5683-0174607 to -0178318 125742 S1 M5 c4591001-S-D-suppdv,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/17R8bjuScY7crPdpZL9WEcNlJONMgfHJg/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:35
FDA-CBER-2021-5683-0165893 to -0168682_125742_S1_M5_c4591001-S-D-is.xpt,XPT,FDA-CBER-2021-5683-0165893 to -0168682 125742 S1 M5 c4591001-S-D-is,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1-OzPHtltp4k4QTNZtBelyQX-eriBiolv/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:39
FDA-CBER-2021-5683-0162690 to -0165892_125742_S1_M5_c4591001-S-D-ex.xpt,XPT,FDA-CBER-2021-5683-0162690 to -0165892 125742 S1 M5 c4591001-S-D-ex,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1W1JsNdetwif-z4qKXOYnPgl4cVY5OzD0/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:43
FDA-CBER-2021-5683-0169082 to -0171523_125742_S1_M5_c4591001-S-D-suppdm.xpt,XPT,FDA-CBER-2021-5683-0169082 to -0171523 125742 S1 M5 c4591001-S-D-suppdm,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1WKGXchUAp6sJFPVaUZxh-n0jXTTCgWPU/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:45
FDA-CBER-2021-5683-0159487 to -0162689_125742_S1_M5_c4591001-S-D-ec.xpt,XPT,FDA-CBER-2021-5683-0159487 to -0162689 125742 S1 M5 c4591001-S-D-ec,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1ad2A81tPQxKWxUz8eDfMh14xm7cUDga9/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:49
FDA-CBER-2021-5683-0158560 to -0159486_125742_S1_M5_c4591001-S-D-dv.xpt,XPT,FDA-CBER-2021-5683-0158560 to -0159486 125742 S1 M5 c4591001-S-D-dv,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1l1h_5hE7i5p3N1UecLwQmAsrykMNxXof/view?usp=drivesdk,pd-production-060122,2025-08-11 23:03:51
FDA-CBER-2021-5683-0149082 to -0158559_125742_S1_M5_c4591001-S-D-ce.xpt,XPT,FDA-CBER-2021-5683-0149082 to -0158559 125742 S1 M5 c4591001-S-D-ce,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1r7rk_s91lxFNmPh3EBNJf9D37SK65bAt/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:00
FDA-CBER-2021-5683-0142307 to -0149081_125742_S1_M5_c4591001-A-Supp-D-adcevd.xpt,XPT,FDA-CBER-2021-5683-0142307 to -0149081 125742 S1 M5 c4591001-A-Supp-D-adcevd,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1NKeLNuuFmA4E3kXceHDRn7o50PsZcn08/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:10
125742_S1_M5_CRF_c4591001-1015-10151071.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Research Form (CRF),pfe.levissc,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, informed consent, safety monitoring, visit schedule, FDA, Protocol, c4591001, demography, subject identification, efficacy data, Boston Medical Center",20,155,https://drive.google.com/file/d/16Fpncif74bDbFciYnOWp8r-kNSFcy4rV/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:14
125742_S1_M5_CRF_c4591001-1015-10151238.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, boston medical center, confidential, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, subject data, informed consent, visit date, Protocol, demography, efficacy data",20,435,https://drive.google.com/file/d/1XvMCkVCtyRHvoInsaFLZxTHfPYePU5Kn/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:19
125742_S1_M5_CRF_c4591001-1015-10151011.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, subject identification, safety, Boston Medical Center",20,205,https://drive.google.com/file/d/1kh2a5jsUeX9Bs-wXO3WaF5g3ATNLvqvG/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:22
125742_S1_M5_CRF_c4591001-1015-10151225.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, FOIA, visit date, FDA, Protocol, subject demographics, Boston Medical Center, eCRF, clinical data, data collection",19,206,https://drive.google.com/file/d/1_KxKtPfot457LNFNODk3OL13nhSdFSIk/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:27
125742_S1_M5_CRF_c4591001-1081-10811194 reissue.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,clinical trial protocol,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit schedule, FDA, Protocol, Sterling Research Group, subject demographics, data management, efficacy data, data collection",19,355,https://drive.google.com/file/d/1ecIjS7pW7yAhQGb76Xd7_w3Bi_3Swyne/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:30
125742_S1_M5_CRF_c4591001-1015-10151101.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, boston medical center, confidential, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, eCRF, demography, subject identification, data collection",20,133,https://drive.google.com/file/d/1XhXAK-7zYbllB_vo6W48RFnrGis_kwgX/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:37
125742_S1_M5_CRF_c4591001-1015-10151035.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, boston medical center, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, subject identification, efficacy data",20,154,https://drive.google.com/file/d/17D5TpORPsK-pedf0amL13iWMU-LMQixy/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:40
125742_S1_M5_CRF_c4591001-1128-11281009 reissue.pdf,PDF,c4591001 Clinical Research Form,2021-03-29,clinical trial form,pfe.levissc,M5,True,True,False,True,False,"Ventavia Research Group, Exclusion, clinical trial, phase 2/3, confidential, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, audit trail, informed consent, visit date, FDA, Protocol, data verification, data lock, eCRF, demography, subject identification",20,364,https://drive.google.com/file/d/1KzoS_Q1z9xIUXYuVz2SvGluuoWcJvlQh/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:44
125742_S1_M5_CRF_c4591001-1013-10131786.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-10-01,form,pfe.levissc,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, regulatory-compliance, phase-2-3-study, site-information, clinical-trial, subject-demographics, CRF, covid-19-vaccine, visit-schedule, informed-consent, data-quality-control, data-management, Protocol, neuroscience-solutions-inc, case-report-form, confidential-document, subject-identification, adverse-event-monitoring, fda-submission",20,629,https://drive.google.com/file/d/1Z72tXhT219zYEWU1AAjVGapMsy1bSkuL/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:50
125742_S1_M5_CRF_c4591001-1015-10151089.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, boston medical center, confidential, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, audit trail, screening disposition, informed consent, visit schedule, Protocol, c4591001, data collection",20,145,https://drive.google.com/file/d/1VQqf5Se0acYptJRya5xqffpxpyp-JCD-/view?usp=drivesdk,pd-production-060122,2025-08-11 23:04:58
125742_S1_M5_CRF_c4591001-1015-10151134.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),pfe.levissc,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, cohort selection, inclusion/exclusion criteria, CRF, subject information, informed consent, visit date, FDA, vaccine development, Protocol, c4591001, Boston Medical Center, eCRF, data management, demography, data collection",20,207,https://drive.google.com/file/d/1_aQIsSMYDsJr6w5RVM6wDEfs1bJRWTEe/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:02
125742_S1_M5_CRF_c4591001-1015-10151047.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, boston medical center, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data, data collection",20,156,https://drive.google.com/file/d/1pB2iQIAAZrIPMm0hiMpK9qk08sVzB2eX/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:06
125742_S1_M5_CRF_c4591001-1013-10131699.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-10-01,form,,M5,True,True,False,True,False,"Exclusion, fda-regulation, inclusion-exclusion-criteria, vaccine-development, crf, adverse-events, clinical-trial, CRF, eCRF-audit-trail, informed-consent, cohort-selection, Protocol, phase-2-3, clinical-neuroscience-solutions, visit-date, case-report-form, confidential-document, subject-identification, data-quality, demography",20,412,https://drive.google.com/file/d/1KK8VxDI6zDkYrmz9e13BwOKwS2s4VIAS/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:11
125742_S1_M5_CRF_c4591001-1013-10131718.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-10-14,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, pharmaceutical, regulatory-compliance, protocol-amendment, adverse-events, clinical-trial, CRF, data-collection, informed-consent, cohort-selection, Protocol, phase-2-3, vaccine, clinical-neuroscience-solutions, visit-date, case-report-form, demography, safety-efficacy, fda-submission",20,428,https://drive.google.com/file/d/1kW-iQqaxlo-KTDpS1Lk34iU_4bOkjqaE/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:15
125742_S1_M5_CRF_c4591001-1013-10131658.pdf,PDF,Clinical Trial Case Report Form,2020-09-15,form,,M5,True,True,False,True,False,"phase-2-3-trial, Exclusion, inclusion-exclusion-criteria, vaccine-development, c4591001-study, adverse-events, clinical-trial, CRF, informed-consent, cohort-selection, Protocol, clinical-neuroscience-solutions, subject-10131658, visit-date, case-report-form, confidential-document, fda-regulatory, data-quality, racial-designation, demography",20,122,https://drive.google.com/file/d/1oMyiOhWtofF2unR_zV9ppuo4EnorFNLy/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:22
125742_S1_M5_CRF_c4591001-1013-10131656.pdf,PDF,Clinical Trial Form - Cohort Selection and Informed Consent,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, united states, regulatory compliance, fda, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, Protocol, vaccine, subject details, c4591001, demography, data collection",20,175,https://drive.google.com/file/d/1Pec5zI0kpCUtsz7usaOkGFJYjd2UiOTz/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:25
125742_S1_M5_CRF_c4591001-1013-10131517.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, confidential, regulatory, fda, pharmaceutical, site-details, subject-information, audit-trail, clinical-trial, CRF, data-collection, informed-consent, cohort-selection, Protocol, phase-2-3, vaccine, visit-date, case-report-form, demography",20,144,https://drive.google.com/file/d/1IUS3PNsaFC4-rq5E9tmn8qqgFeuGiwJl/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:32
125742_S1_M5_CRF_c4591001-1013-10131653.pdf,PDF,Clinical Trial CRF for COVID-19 Vaccine Study c4591001,2021-03-29,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, crf, phase 2/3 study, CRF, covid-19 vaccine, subject data, informed consent, visit date, Protocol, eCRF, demography, efficacy data",20,176,https://drive.google.com/file/d/1zGXX4N7JOkJibmuc7hEr04Ib9Zh6A9oc/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:35
125742_S1_M5_CRF_c4591001-1013-10131255.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, vaccine-development, regulatory-compliance, subject-information, adverse-events, clinical-trial, CRF, eCRF-audit-trail, informed-consent, cohort-selection, Protocol, phase-2-3, clinical-neuroscience-solutions, visit-date, case-report-form, confidential-document, data-quality, demography, fda-submission",20,204,https://drive.google.com/file/d/1d5FTzRgSano6CfkkRYUs1Hy1eFaSo90J/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:39
125742_S1_M5_CRF_c4591001-1013-10131554.pdf,PDF,Clinical Trial Case Report Form,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, confidential, regulatory, fda, pharmaceutical, site-details, subject-information, clinical-trial, CRF, data-collection, informed-consent, cohort-selection, Protocol, phase-2-3, vaccine, visit-date, case-report-form, demography, quality-control",20,463,https://drive.google.com/file/d/1lk1M77FPNYhVKP4UgyLQ__9IaLTLGSqo/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:44
125742_S1_M5_CRF_c4591001-1013-10131386.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, data quality, pharmaceutical, inclusion/exclusion criteria, CRF, informed consent, FOIA, visit date, FDA, Protocol, vaccine, c4591001, demography, COVID-19, subject identification, data collection",20,117,https://drive.google.com/file/d/1QqSwa95VORxyB1H1KOjJDYECc8GHcVt5/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:50
125742_S1_M5_CRF_c4591001-1013-10131229.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, demography, case report form, subject identification, efficacy data",20,157,https://drive.google.com/file/d/1RJ8h_FjiUioEUTnKPelhr74t35dIKoPp/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:54
125742_S1_M5_CRF_c4591001-1013-10131190.pdf,PDF,Clinical Trial Case Report Form (CRF),2021-03-29,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, confidential, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, data management, demography, case report form, subject identification",20,431,https://drive.google.com/file/d/180_LlW14DBTdoC9cIyHnVOC1nLObiT8V/view?usp=drivesdk,pd-production-060122,2025-08-11 23:05:59
125742_S1_M5_CRF_c4591001-1013-10131176.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,,M5,True,True,False,True,False,"pharmaceutical-research, Exclusion, inclusion-exclusion-criteria, vaccine-development, regulatory-compliance, site-information, adverse-events, clinical-trial, CRF, informed-consent, cohort-selection, data-management, Protocol, phase-2-3, visit-date, case-report-form, subject-identification, data-quality, demography, fda-submission",20,507,https://drive.google.com/file/d/1xVOZutb8x69Gd2o9Vlm8BwjqSuQavmRH/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:04
125742_S1_M5_CRF_c4591001-1008-10081628.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-10-16,clinical trial form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, inclusion/exclusion criteria, protocol amendment, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit date, Protocol, clinical research professionals, demography, subject identification, data collection",20,167,https://drive.google.com/file/d/1BzkFPb2nWs7hfvIR2tSGnypjtiHBnJI8/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:08
125742_S1_M5_CRF_c4591001-1008-10081667.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-10-22,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, pharmaceutical development, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data",20,186,https://drive.google.com/file/d/1Fh3mJBubT_9dy94U1xgxMbiprGYviR9W/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:11
125742_S1_M5_CRF_c4591001-1011-10111181.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, clinical research consulting, confidential, regulatory compliance, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, subject data, informed consent, visit date, FDA, vaccine development, Protocol, c4591001, eCRF, demography",20,149,https://drive.google.com/file/d/1o9ATjR8Vjv68aWdMh36Sy0Ah7XKzvwB2/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:15
125742_S1_M5_CRF_c4591001-1009-10091128.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, COVID-19 vaccine, CRF, demographic data, subject enrollment, informed consent, safety monitoring, visit schedule, FDA, Protocol, Pfizer, data management, case report form, efficacy endpoints",20,228,https://drive.google.com/file/d/1vQn0zjemGNeUDvgXUZ6YbHvAox_3_A3X/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:19
125742_S1_M5_CRF_c4591001-1012-10121112.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, informed consent, visit date, FDA, HOPE Research Institute, Protocol, demography, subject identification, data freezing, data collection",19,246,https://drive.google.com/file/d/1gQetW6iZ7ssOzmfM4F6GcWRWZh31KHwy/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:23
125742_S1_M5_CRF_c4591001-1013-10131165.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, confidential, regulatory, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, subject information, informed consent, visit date, FDA, Protocol, vaccine, demography, case report form, data collection",20,191,https://drive.google.com/file/d/1h9meWjyQq_QdHfSjM5ypK49AdZL4kWNA/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:26
125742_S1_M5_CRF_c4591001-1008-10081603.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-10-14,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, eCRF, demography, subject identification, efficacy data, data collection",20,173,https://drive.google.com/file/d/1MbbaU4F83APmUjGn0tZ8TWtqp2LpXppS/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:30
125742_S1_M5_CRF_c4591001-1012-10121163.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, data quality control, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, subject enrollment, FDA submission, informed consent, site-level operations, visit schedule, HOPE Research Institute, Protocol, data management, confidential document",20,225,https://drive.google.com/file/d/1qFBLBNcPEoX38_1Brkt7gtmsPtcp1GOB/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:34
125742_S1_M5_CRF_c4591001-1009-10091135.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, medical research, data management, demography, subject identification, adverse event reporting",20,272,https://drive.google.com/file/d/18GBrSDzGkadi7TDHalGEoQBeF4C_juA0/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:39
125742_S1_M5_CRF_c4591001-1013-10131089.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,,M5,True,True,False,True,False,"quality control, site information, Exclusion, clinical trial, phase 2/3, regulatory, pharmaceutical, cohort selection, inclusion/exclusion criteria, protocol amendment, CRF, subject information, informed consent, visit date, FDA, Protocol, vaccine, demography, case report form, data collection",20,225,https://drive.google.com/file/d/1nwryumTgQXdCXIBOCr8jD5oDZcp8-GAW/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:43
125742_S1_M5_CRF_c4591001-1009-10091149.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, Pfizer, medical research, demography, safety",19,205,https://drive.google.com/file/d/1FV4IVgmU840k2jlZoMQc_vkMGKPVqL4t/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:47
125742_S1_M5_CRF_c4591001-1008-10081337.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2021-03-29,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, inclusion/exclusion criteria, protocol amendment, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit date, Protocol, eCRF, clinical research professionals, demography, subject identification, data collection",20,182,https://drive.google.com/file/d/1PKb3BNEtgkIiFwvwYovORfpX14QWXqWe/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:50
125742_S1_M5_CRF_c4591001-1009-10091123.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, demography, subject identification, efficacy data",20,161,https://drive.google.com/file/d/1jogDCkg0FKeRQFZaE0bCyl6OV5Qtfsp6/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:54
125742_S1_M5_CRF_c4591001-1013-10131084.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, data quality control, regulatory compliance, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, demographic data, subject enrollment, informed consent, visit schedule, Protocol, pfizer-biontech, data management, case report form, fda submission, subject identification, confidential document",20,179,https://drive.google.com/file/d/1c5x76ft4vaqw1UcBKxiYgvjTWJRXuPhr/view?usp=drivesdk,pd-production-060122,2025-08-11 23:06:58
125742_S1_M5_CRF_c4591001-1012-10121097.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, hope research institute, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, eCRF, demography, clinical data, subject 10121097",20,286,https://drive.google.com/file/d/1Vp3dSG37qxVi-04J6_O5WA45HsDVj1vz/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:02
125742_S1_M5_CRF_c4591001-1011-10111029.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"pharmaceutical-research, quality-compliance, phase-2-3-trial, Exclusion, inclusion-exclusion-criteria, electronic-case-report-form, site-information, clinical-trial, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, clinical-research-consulting, visit-date, confidential-document, fda-regulatory, subject-details, demography",20,207,https://drive.google.com/file/d/1chrbdWSHDdu0g-71743O63R5nQHcWLM7/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:06
125742_S1_M5_CRF_c4591001-1008-10081152.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, quality assurance, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, pharmaceutical development, informed consent, visit schedule, Protocol, subject demographics, efficacy data, electronic case report form, data collection",20,124,https://drive.google.com/file/d/1f6ye-8UUbGoRNrQIJua7e2ejFN6IQJ31/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:13
125742_S1_M5_CRF_c4591001-1008-10081056.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"phase-2-3-trial, Exclusion, inclusion-exclusion-criteria, regulatory-compliance, pharmaceutical-development, crf, site-information, clinical-trial, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, visit-date, data-quality, subject-details, demography, fda-submission, clinical-research",20,173,https://drive.google.com/file/d/1gFoL1QoUHyFqXR8h-AE1dPMVOezHrH4E/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:17
125742_S1_M5_CRF_c4591001-1007-10071443.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-10,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, cincinnati children's hospital, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, informed consent, visit date, subject 10071443, Protocol, c4591001, demography, efficacy data",20,157,https://drive.google.com/file/d/10I2ndIsmMom1L2h9XMVYUEzfmzrg6l1E/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:20
125742_S1_M5_CRF_c4591001-1008-10081184.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),pfe.levissc,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, electronic-data-capture, regulatory-compliance, site-information, adverse-events, clinical-trial, CRF, covid-19-vaccine, visit-schedule, informed-consent, cohort-selection, Protocol, phase-2-3, c4591001, subject-identification, data-quality, safety-data, demography, fda-submission",20,146,https://drive.google.com/file/d/1YZyd_8YhK7hX182-7xFJxpYlNOo2ayKq/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:26
125742_S1_M5_CRF_c4591001-1007-10071441.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-29,form,,M5,True,True,False,True,False,"subject-10071441, Exclusion, cincinnati-children's-hospital, inclusion-exclusion-criteria, confidential, verified-data, clinical-trial, fda-regulated, CRF, data-collection, covid-19-vaccine, informed-consent, frozen-data, cohort-selection, Protocol, visit-date, eCRF, c4591001-trial, demography, data-audit-trail",20,169,https://drive.google.com/file/d/19rIztLIFXLQ3Q7jYzwsPc78o1vJgkgWi/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:29
125742_S1_M5_CRF_c4591001-1007-10071306.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-12,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, FDA submission, informed consent, adverse event monitoring, visit date, Protocol, c4591001 protocol, subject identification, Cincinnati Children's Hospital, efficacy endpoints",20,459,https://drive.google.com/file/d/1m42nnLaSyp4QTr93q8BjFHZ-Pljt8cgb/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:35
125742_S1_M5_CRF_c4591001-1007-10071347.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, efficacy data, demography, Cincinnati Children's Hospital",20,181,https://drive.google.com/file/d/1jZfaxmFNDXZhxjFBX4kqExfxbj_brT3A/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:39
125742_S1_M5_CRF_c4591001-1007-10071315.pdf,PDF,c4591001 Clinical Trial eCRF,2021-04-19,Clinical Trial Form,pfe.levissc,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, subject information, informed consent, visit date, FDA, Protocol, vaccine, c4591001, demography, Cincinnati Children's Hospital, data freezing, data collection",20,172,https://drive.google.com/file/d/1WoTAAau30cZT0GfKm_bRVANI7ZE4T4-5/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:42
125742_S1_M5_CRF_c4591001-1007-10071101.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),pfe.levissc,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, efficacy, CRF, subject data, informed consent, visit date, FDA, Protocol, vaccine, c4591001, demography, safety, Cincinnati Children's Hospital",20,201,https://drive.google.com/file/d/1XK_mkY6wbjb5ZNNKDGFeXDFHJNJigl96/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:46
125742_S1_M5_CRF_c4591001-1007-10071117.pdf,PDF,c4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, CRF, subject information, informed consent, visit date, FDA, Protocol, vaccine, c4591001, eCRF, demography, Cincinnati Children's Hospital, data collection",20,341,https://drive.google.com/file/d/1-9agXOfnfE_APKlqDj5FsNeJMKJX_vtX/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:50
125742_S1_M5_CRF_c4591001-1007-10071280.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, CRF, informed consent, visit schedule, FDA, Protocol, vaccine, c4591001, eCRF, data management, demography, subject identification, Cincinnati Children's Hospital, data collection",20,212,https://drive.google.com/file/d/1X1-_EjWxRcMU9FCrUCiPiMCnhDWx6z3M/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:55
125742_S1_M5_CRF_c4591001-1007-10071159.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, CRF, subject enrollment, informed consent, visit data, FDA, Protocol, vaccine, c4591001, demography, COVID-19, safety, Cincinnati Children's Hospital, data collection",20,178,https://drive.google.com/file/d/1it01CKJaiBLrP5esiiRUSn6CnFDPqJUd/view?usp=drivesdk,pd-production-060122,2025-08-11 23:07:59
125742_S1_M5_CRF_c4591001-1007-10071124.pdf,PDF,c4591001 Clinical Trial eCRF,2020-07-30,report,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, CRF, subject data, informed consent, visit date, FDA, Protocol, vaccine, c4591001, eCRF, demography, Cincinnati Children's Hospital, data collection",20,297,https://drive.google.com/file/d/1G_LEwfducEWppxNeRo3MMyT1H3XPg8ep/view?usp=drivesdk,pd-production-060122,2025-08-11 23:08:03
125742_S1_M5_CRF_c4591001-1007-10071192.pdf,PDF,c4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, CRF, subject information, informed consent, visit date, FDA, Protocol, vaccine, c4591001, eCRF, data management, demography, Cincinnati Children's Hospital",20,283,https://drive.google.com/file/d/13605h9wp5ffUOgOsUQwSEtL1VtCFGeTV/view?usp=drivesdk,pd-production-060122,2025-08-11 23:08:07
125742_S1_M5_CRF_c4591001-1007-10071276.pdf,PDF,c4591001 Clinical Trial eCRF,2020-07-30,eCRF (electronic Case Report Form),,M5,True,True,False,True,False,"Exclusion, clinical trial, compliance, pharmaceutical, cohort selection, inclusion/exclusion criteria, efficacy, CRF, subject data, informed consent, FOIA, visit date, FDA, Protocol, vaccine, c4591001, demography, safety, Cincinnati Children's Hospital, data collection",20,187,https://drive.google.com/file/d/1Apm8bywtiT3pv8_qB_a4FVkqEkypn5HA/view?usp=drivesdk,pd-production-060122,2025-08-11 23:08:11
125742_S1_M5_5351_c4591001-interim-mth6-randomization.pdf,PDF,Listing of Subjects Who Transferred to a Different Site – All Subjects ≥16 Years of Age,2021-04-01,report,,M5,False,False,False,False,False,"C4591001, randomization, data listing, compliance, pharmaceutical, clinical trial, subject transfer, FDA, subject request, safety data, CTM request, subject demographics, United States, interim report, phase 4, site transfer, adverse events",17,2,https://drive.google.com/file/d/1qJ_yjkkZvCgfhmyOqcpbx57Se3n9vmNX/view?usp=drivesdk,pd-production-060122,2025-08-11 23:08:14
125742_S1_M5_CRF_c4591001-1007-10071097.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-06,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, efficacy, CRF, subject data, informed consent, FDA, Protocol, vaccine, c4591001, demography, COVID-19, case report form, safety, Cincinnati Children's Hospital",20,249,https://drive.google.com/file/d/1D09T15y32ov6qvLj2_IQfP6XpgQLi1Zu/view?usp=drivesdk,pd-production-060122,2025-08-11 23:08:18
125742_S1_M5_5351_c4591001-interim-mth6-publications.pdf,PDF,"Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults"",","2020-08-12"",",document,,M5,False,False,False,False,False,"FOIA-document, needs-review",2,52,https://drive.google.com/file/d/18O5vcHyxRiD2EMj-tIGT78wTKLotpRAy/view?usp=drivesdk,pd-production-060122,2025-08-11 23:08:27
125742_S1_M5_CRF_c4591001-1007-10071050.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-06-11,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, confidential, regulatory compliance, pharmaceutical research, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, subject enrollment, informed consent, visit date, Protocol, eCRF, data management, Cincinnati Children's Hospital",20,614,https://drive.google.com/file/d/1XXwDZbVwo5owJPDQQElf0OBs-Hhi_idz/view?usp=drivesdk,pd-production-060122,2025-08-11 23:08:33
125742_S1_M5_5351_c4591001-interim-mth6-patient-batches.pdf,PDF,C4591001 Interim Month 6 Patient Batches,2021-03-17,report,,M5,False,False,False,False,False,"strength, vial, phase 3 study, sodium chloride, pharmaceutical, FOIA, clinical trial, FDA, solution, investigational product, vaccine, Argentina, batch information, dosage, BNT162b2, Pfizer, Brazil",17,158,https://drive.google.com/file/d/1y4r2_UH0g-sKbOdyh_7iJiW0KtPhrAo3/view?usp=drivesdk,pd-production-060122,2025-08-11 23:08:39
125742_S1_M5_5351_c4591001-fa-interim-protocol-deviations-sensitive.pdf,PDF,"Listing of Important Protocol Deviations - Phase 2/3 Analysis"",","2020-11-30"",",document,,M5,False,True,False,True,False,"Exclusion, FOIA-document, Protocol, protocol, needs-review",5,46,https://drive.google.com/file/d/17wKBCqljI5Kx3DX5YCTwnTVCC5Onf0hu/view?usp=drivesdk,pd-production-060122,2025-08-11 23:08:44
125742_S1_M5_5351_c4591001-fa-interim-discontinued-patients.pdf,PDF,Listing of Subjects Withdrawn From the Study - COVID-19 Vaccine Candidate Clinical Trials,2020-09-07,report,,M5,False,True,False,True,False,"data-listing, Exclusion, vaccine-development, medical-coding, covid-19, regulatory-compliance, data-snapshot, adverse-events, clinical-trial, data-cutoff, Protocol, pfizer, phase-2, confidential-document, safety-data, subject-withdrawal, fda-submission, phase-1, bnt162b1",19,112,https://drive.google.com/file/d/1OJVFNOSOawpixDr1wLeSADYyhXm-HoQQ/view?usp=drivesdk,pd-production-060122,2025-08-11 23:08:50
125742_S1_M5_5351_c4591001-fa-interim-patient-batches.pdf,PDF,Interim Patient Batches for C4591001 Clinical Trial,2020-11-19,report,,M5,False,False,False,False,False,"vial, fda, brazil, sodium chloride, clinical trial, investigational product, vaccine, interim report, patient batches, c4591001, argentina, safety, confidential, dosage, bnt162b2, solution, regulatory",17,139,https://drive.google.com/file/d/1kxZ4Hfqs9gDyEL5ljEmuWHApdHw0jit7/view?usp=drivesdk,pd-production-060122,2025-08-11 23:08:56
125742_S1_M5_5314_shi-sop-10011.pdf,PDF,Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to SARS-CoV-2 in Test Serum using Cytation 7 Image Reader,2022-01-01,SOP (Standard Operating Procedure),Shi,M5,False,False,False,False,False,"Infectious Disease, UTMB (University of Texas Medical Branch), Clinical Trials, Cytation 7 Image Reader, Shi Lab, Procedure Manual, Antibody Detection, SARS-CoV-2, Regulatory Compliance, Biosafety, Virus Neutralization, Data Acquisition, Quality Assurance, Neutralization Assay, Vaccine Development, Serum Analysis, Pharmaceutical Research",17,16,https://drive.google.com/file/d/1cXuUqUQFfrApbGhYiweuesM0a8me0iTq/view?usp=drivesdk,pd-production-060122,2025-08-11 23:09:01
125742_S1_M5_5351_c4591001-fa-interim-adverse-events.pdf,PDF,Adverse Events Legend,2020-11-24,report,,M5,False,False,False,False,False,"C4591001, SDTM, data quality, interim analysis, data legend, clinical trial, FDA, data management, safety data, data processing, vaccine, data reporting, medical terminology, adverse events, Pfizer, data categorization, regulatory compliance",17,2566,https://drive.google.com/file/d/1ElnMcplpKM1WMJhmlDuqGvJqUP_2Vfdf/view?usp=drivesdk,pd-production-060122,2025-08-11 23:09:22
125742_S1_M2_summary-biopharm.pdf,PDF,Summary of Biopharmaceutic Studies and Associated Analytical Methods,2021-03-17,report,,M2,False,False,False,False,False,"analytical-methods-validation, limit-of-detection, sars-cov-2-assays, covid-19-vaccine, microneutralization-assay, phase-1-and-2-3-studies, antibody-quantitation, fda-regulatory-submission, bioanalytical-methods, biotech-company-pfizer, vaccine-development, lower-limit-of-quantitation, pharmaceutical-clinical-trials, bnt162b2, elispot-assay, confidential-document, biopharmaceutical-characterization",17,3,https://drive.google.com/file/d/16MWSu0sH8AdTeFOeirHDupWFW-Zi6fbt/view?usp=drivesdk,pd-production-060122,2025-08-11 23:09:26
125742_S1_M5_CRF_c4591001-1226-12261300.pdf,PDF,Clinical Trial Report Form,2020-07-30,form,(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, informed consent, visit date, FDA, Protocol, eCRF, demography, subject identification, safety",20,161,https://drive.google.com/file/d/1NsSP2qXzzu42Mlin-aFkC1Xn0jDb_msh/view?usp=drivesdk,pd-production-060123,2025-08-11 23:09:32
125742_S1_M5_CRF_c4591001-1226-12261707.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, C4591001, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, efficacy, Brazil, CRF, informed consent, visit date, FDA, Protocol, vaccine, demography, subject identification, safety",20,215,https://drive.google.com/file/d/19gz611Q8PWFBtE_sPqu5gO3ofMpM7Mbn/view?usp=drivesdk,pd-production-060123,2025-08-11 23:09:36
125742_S1_M5_CRF_c4591001-1226-12261599.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, demographic data, subject enrollment, informed consent, visit date, FDA, Protocol, data management, safety",20,409,https://drive.google.com/file/d/1cafsGNYxmBD1E3b6Dnxlb2HPNXo02j8g/view?usp=drivesdk,pd-production-060123,2025-08-11 23:09:41
125742_S1_M5_CRF_c4591001-1226-12262089.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, efficacy, Brazil, CRF, subject enrollment, informed consent, FDA, Protocol, vaccine, demography, COVID-19, case report form, safety",20,434,https://drive.google.com/file/d/1ZXsjcxuyRrG39NNtS5Ow9jYlLLMDnxY0/view?usp=drivesdk,pd-production-060123,2025-08-11 23:09:45
125742_S1_M5_CRF_c4591001-1226-12261282.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, CEPIC, adverse events, regulatory compliance, C4591001, pharmaceutical, cohort selection, inclusion/exclusion criteria, Brazil, CRF, informed consent, visit date, FDA, Protocol, vaccine, demography, efficacy data",20,140,https://drive.google.com/file/d/1cbGJGnz7cdT0BIssTVywKGS7hRoV5WoX/view?usp=drivesdk,pd-production-060123,2025-08-11 23:09:49
125742_S1_M5_CRF_c4591001-1226-12261745.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, confidential, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Brazil, CRF, subject enrollment, informed consent, visit date, FDA, Protocol, eCRF, data management, demography",20,186,https://drive.google.com/file/d/1ogrA5DGclM__dyb58vEIYNGF4xLUIRfK/view?usp=drivesdk,pd-production-060123,2025-08-11 23:09:53
125742_S1_M5_CRF_c4591001-1226-12262036.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, subject enrollment, informed consent, visit schedule, FDA, Protocol, data management, demography, case report form",20,143,https://drive.google.com/file/d/13eki0ta2Fkqra-tfpjdB-Yu-aEIAs4Oh/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:01
125742_S1_M5_CRF_c4591001-1226-12262240.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-10-16,Case Report Form (CRF),(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, COVID-19 vaccine, efficacy, protocol amendment, Brazil, CRF, subject enrollment, informed consent, FDA, Protocol, demography, case report form, safety, subject identification",20,173,https://drive.google.com/file/d/1OY_HrY5KaRlRhhAIKFkYPpcYY2UA6Bqb/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:06
125742_S1_M5_CRF_c4591001-1226-12261432.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, subject enrollment, informed consent, visit date, FDA, Protocol, eCRF, demography, safety",20,256,https://drive.google.com/file/d/1so1j3vrcWimM375oVNpiENNVVm1ZemQb/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:10
125742_S1_M5_CRF_c4591001-1226-12261477.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Brazil, CRF, demographic data, subject enrollment, informed consent, visit date, FDA, Protocol, Pfizer, data management, case report form",20,185,https://drive.google.com/file/d/1SytgnJIa1jZn5N95s014qXErgOOp2bBz/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:13
125742_S1_M5_CRF_c4591001-1226-12262000.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Clinical Trial Case Report Form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, Brazil clinical site, data quality control, regulatory compliance, COVID-19 vaccine, CEPIC research center, phase 2/3 study, CRF, demographic data, subject enrollment, informed consent, adverse event monitoring, visit schedule, Protocol, data completeness, case report form, C4591001 trial, subject confidentiality",20,329,https://drive.google.com/file/d/1fEP_e5tzyAvaQh0VzDnxvc4xI1ZK2jEt/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:19
125742_S1_M5_CRF_c4591001-1226-12261769.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Brazil, CRF, informed consent, adverse event monitoring, visit schedule, FDA, Protocol, data management, demography, case report form, subject identification",20,222,https://drive.google.com/file/d/1DEOQ8-1WhI3A_zQEXhbT3h6wTfZ2elML/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:24
125742_S1_M5_CRF_c4591001-1226-12261417.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, informed consent, safety monitoring, Protocol, subject demographics, pfizer-biontech, medical research, brazil, data management, case report form, fda submission, data collection",20,206,https://drive.google.com/file/d/18Qir9fBjNvJWqIbU6SQ21V40A_bwXK9b/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:27
125742_S1_M5_CRF_c4591001-1226-12262004.pdf,PDF,C4591001 Clinical Trial eCRF,2020-09-15,Clinical Trial Form,(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, demography, subject identification, safety",20,263,https://drive.google.com/file/d/1mgDmeryGI2sx_b5eZARf1ky38bwT_NZG/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:32
125742_S1_M5_CRF_c4591001-1226-12261571.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, informed consent, visit date, FDA, Protocol, demography, case report form, subject identification, safety",20,185,https://drive.google.com/file/d/1nWbSars0-rp6zccUUz_0z7TNa8Do8yBe/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:36
125742_S1_M5_CRF_c4591001-1226-12261713.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, adverse events, regulatory compliance, data quality, COVID-19 vaccine, efficacy, Brazil, CRF, demographic data, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, case report form, safety",20,182,https://drive.google.com/file/d/1P5DeGbhvt6188OdV_2Y95wSvrYd85tl7/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:40
125742_S1_M5_CRF_c4591001-1226-12261624.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, subject enrollment, informed consent, visit date, FDA, Protocol, eCRF, demography, safety",20,445,https://drive.google.com/file/d/1Qzxtptr456_zAjZ8a2bl73qy6tmAcBQz/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:45
125742_S1_M5_CRF_c4591001-1226-12261072.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"subject-data, Exclusion, latin-america, inclusion-exclusion-criteria, confidential, regulatory-compliance, adverse-events, clinical-trial, CRF, covid-19-vaccine, informed-consent, cohort-selection, Protocol, phase-2-3, c4591001, visit-date, cepic-centro-paulista, data-quality, demography, fda-submission",20,199,https://drive.google.com/file/d/13OorChXH7Jmwb0blQae3kkPwOSvLHEfB/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:49
125742_S1_M5_CRF_c4591001-1226-12261094.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, demographics, clinical trial, phase 2/3, safety data, CEPIC, adverse events, regulatory compliance, data quality, COVID-19 vaccine, Brazil, CRF, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, eCRF, efficacy data",20,486,https://drive.google.com/file/d/1gcIVb8UZirvQh1bUBd7U7bqYeHmF5kbW/view?usp=drivesdk,pd-production-060123,2025-08-11 23:10:55
125742_S1_M5_CRF_c4591001-1226-12261583.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, subject enrollment, informed consent, FDA, Protocol, eCRF, data management, demography, safety",20,202,https://drive.google.com/file/d/1q6HE0rzZmxHJsvyl-xwhcHpIQ5v1MDwD/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:02
125742_S1_M5_CRF_c4591001-1226-12261313.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, demography, subject identification, safety",20,252,https://drive.google.com/file/d/12FrYLGvnKsiTxY1ldsH23YEcKfbuIDUT/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:06
125742_S1_M5_CRF_c4591001-1226-12261241.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, safety data, CEPIC, adverse events, regulatory submission, data quality, COVID-19 vaccine, Brazil, phase 2/3 study, CRF, demographic data, subject enrollment, informed consent, visit schedule, Protocol, data management, efficacy data",19,229,https://drive.google.com/file/d/1Z75S1OwGWDsDnlv6Pw2IaWn0f2wvAEuL/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:11
125742_S1_M5_CRF_c4591001-1226-12261067.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Clinical Trial Case Report Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, CEPIC, regulatory compliance, C4591001, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, Brazil, CRF, subject data, informed consent, FDA, Protocol, eCRF, data management, demography, case report form, efficacy data",20,258,https://drive.google.com/file/d/1-9nN4jSjF1Gsv-fcNYAA0pdBh9DYfx3N/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:15
125742_S1_M5_CRF_c4591001-1226-12261190.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, adverse events, regulatory, C4591001, compliance, inclusion/exclusion criteria, efficacy, Brazil, CRF, subject data, informed consent, FDA, Protocol, vaccine, demography, case report form, safety",20,220,https://drive.google.com/file/d/1B09vpnVGtKb9ejp0hkDaomKOY1jsiHVf/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:19
125742_S1_M5_CRF_c4591001-1226-12261136.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, subject enrollment, informed consent, visit schedule, FDA, Protocol, demography, case report form, safety",20,226,https://drive.google.com/file/d/18ulFamGac5vviHSj0GK-Q2NGvOL1FMK3/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:22
125742_S1_M5_CRF_c4591001-1226-12262238.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-10-16,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, efficacy, Brazil, CRF, subject data, informed consent, FDA, Protocol, vaccine, demography, case report form, safety",20,421,https://drive.google.com/file/d/1e7N5CAzoiRMl_x-ELyPJqnFJqVYVEz8E/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:27
125742_S1_M5_CRF_c4591001-1226-12261836.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),"Subject No: 12261836, Subject Initials: ---",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, data quality, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, Brazil, eCRF audit trail, FDA regulatory, informed consent, safety monitoring, Protocol, subject demographics, Pfizer-BioNTech, case report form, efficacy data, data collection",20,277,https://drive.google.com/file/d/1W2zNHWkg6TyjQltWkrmNmhIl5l6r7Nxi/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:31
125742_S1_M5_CRF_c4591001-1226-12261210.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, CEPIC, adverse events, regulatory compliance, COVID-19 vaccine, CRF, eCRF audit trail, informed consent, FDA, August 2020, Protocol, data verification, subject demographics, subject identification, efficacy data, data freezing, data collection",20,307,https://drive.google.com/file/d/1DrbQLbxb5ABSnz421Pavw5DTxvT2tYW9/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:36
125742_S1_M5_CRF_c4591001-1226-12262052.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, subject enrollment, informed consent, visit date, FDA, Protocol, eCRF, demography, safety",20,433,https://drive.google.com/file/d/1TKAf6vDbKz4HmIBqg4hGSSH2Edt4CSPW/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:40
125742_S1_M5_CRF_c4591001-1226-12261338.pdf,PDF,Clinical Trial Case Report Form (CRF) for C4591001 Study,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, C4591001 study, data quality, COVID-19 vaccine, data lock and freeze, protocol amendment, CRF, demographic data, eCRF audit trail, subject enrollment, FDA regulatory, informed consent, visit schedule, Protocol, CEPIC research site, phase 2/3 clinical trial, Brazil location, case report form, confidential document",20,310,https://drive.google.com/file/d/1AD6_V8Tl7kXcZcR9ctLDmvtdW10uJnmE/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:45
125742_S1_M5_CRF_c4591001-1226-12262272.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, subject enrollment, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, demography, safety",20,205,https://drive.google.com/file/d/1RNPKNEsQUseGCnqtA0TCBHxo3pOk1IBb/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:49
125742_S1_M5_CRF_c4591001-1226-12261864.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, Brazil, CRF, subject information, informed consent, visit date, FDA, Protocol, vaccine, eCRF, demography, data collection",20,198,https://drive.google.com/file/d/1ZvH6FZ0hADpOPEVxC5KPHKbImPWPt_f6/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:53
125742_S1_M5_CRF_c4591001-1226-12261137.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,case report form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, COVID-19 vaccine, CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda, protocol amendment, CRF, informed consent, FDA, August 2020, Protocol, data verification, subject demographics, eCRF, efficacy data, data freezing",20,320,https://drive.google.com/file/d/1rGMnd_2sLviI5TLHInbc4Tylq1B34iVv/view?usp=drivesdk,pd-production-060123,2025-08-11 23:11:58
125742_S1_M5_CRF_c4591001-1226-12262129.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Brazil, CRF, demographic data, subject enrollment, informed consent, adverse event monitoring, visit schedule, FDA, Protocol, Pfizer, eCRF",20,226,https://drive.google.com/file/d/16XSP84ypKbMSFmO0fQUbio4oU6TwGJfz/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:02
125742_S1_M5_CRF_c4591001-1226-12261714.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),"Subject No: 12261714, Subject Initials: ---",M5,True,True,False,True,False,"Exclusion, clinical trial, white, phase 2/3, confidential, male, data quality, Hispanic or Latino, inclusion/exclusion criteria, COVID-19 vaccine, CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda, Brazil, CRF, informed consent, FDA, Protocol, eCRF, demography, 1967, September 2020",20,196,https://drive.google.com/file/d/1lgtge1ynltTi_U99UD4S5-69RJvWKxCu/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:06
125742_S1_M5_CRF_c4591001-1226-12262253.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-10-16,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Brazil, CRF, demographic data, subject enrollment, informed consent, adverse event monitoring, visit date, FDA, Protocol, Pfizer, case report form",20,242,https://drive.google.com/file/d/1BZGyXbb5bAV8tBagS3rBqwcnCaSd0CPO/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:10
125742_S1_M5_CRF_c4591001-1226-12261775.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, data quality, hispanic/latino population, phase 2/3 study, CRF, covid-19 vaccine, demographic data, subject enrollment, eCRF audit trail, informed consent, adverse event monitoring, visit schedule, Protocol, cepic clinical research site, brazil location, data collection, fda regulatory, efficacy endpoints",20,188,https://drive.google.com/file/d/1-1R2--OiMKop4YsfL3vR7kOKFEpn5XnN/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:15
125742_S1_M5_CRF_c4591001-1226-12261545.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"site information, visit dates, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Brazil, CRF, subject information, informed consent, FDA, Protocol, demography, case report form, efficacy data",20,236,https://drive.google.com/file/d/14dey44kO1dUfys31mDaLUDLRD813ouHU/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:19
125742_S1_M5_CRF_c4591001-1226-12261792.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-09-15,form,(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, data quality control, regulatory compliance, latin america, phase 2/3 study, CRF, covid-19 vaccine, demographic data, subject enrollment, eCRF audit trail, informed consent, adverse event monitoring, Protocol, pfizer-biontech, brazil, data management, case report form, fda submission",20,265,https://drive.google.com/file/d/1EWbXYF2PzFBbsUiOQ_r4gu-uOBvrPf2e/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:23
125742_S1_M5_CRF_c4591001-1231-12311147.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, demographic data, informed consent, FDA, Protocol, Pfizer, Latin America, case report form, subject identification, Argentina, efficacy data",20,277,https://drive.google.com/file/d/189x0BxM7fcoszAPItxFeMbPFbAi2cPQR/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:27
125742_S1_M5_CRF_c4591001-1231-12311409.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, safety, Argentina",20,193,https://drive.google.com/file/d/14ur9VRaOssteyb6PBS2mVzSXOVgPOnio/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:31
125742_S1_M5_CRF_c4591001-1231-12311812.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, FDA submission, informed consent, Protocol, data verification, Pfizer-BioNTech, Latin America, data lock, case report form, subject identification, Argentina",20,256,https://drive.google.com/file/d/1B6J6YShvUttA5ZOVviOe6oAl7_-rxOIE/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:36
125742_S1_M5_CRF_c4591001-1231-12311579.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FDA, Protocol, Pfizer, Latin America, demography, case report form, Argentina",20,162,https://drive.google.com/file/d/1TL5YTg8ZZ1pGKUQj93vPOnlSqRCqOheM/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:39
125742_S1_M5_CRF_c4591001-1231-12311711.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, Latin America, demography, case report form, subject identification, safety",20,233,https://drive.google.com/file/d/1a-wts0GOsULc4xBJp3AStLVeLKYvNVnH/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:44
125742_S1_M5_CRF_c4591001-1231-12311901.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject enrollment, informed consent, FDA, Protocol, Pfizer, Latin America, demography, case report form, Argentina, data collection",20,191,https://drive.google.com/file/d/18WeGZ9NIMwrLh3Tiyh-TNQ4vHpDahtkk/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:47
125742_S1_M5_CRF_c4591001-1231-12311294.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, white, phase 2/3, confidential, adverse events, hispanic or latino, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, hospital militar central cirujano mayor dr. cosme argerich, informed consent, visit date, Protocol, vaccine, ecrf, c4591001, demography",20,254,https://drive.google.com/file/d/1rFIed9YGwHQNNnS_bgLNYbeT6JtwIFFF/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:52
125742_S1_M5_CRF_c4591001-1231-12311946.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina",20,279,https://drive.google.com/file/d/1rikAZ5aFN-a3KpX_rMechxkyc2i0bceG/view?usp=drivesdk,pd-production-060123,2025-08-11 23:12:56
125742_S1_M5_CRF_c4591001-1231-12311058.pdf,PDF,c4591001 Clinical Trial eCRF,2021-04-19,clinical trial form,Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FDA, Protocol, c4591001, eCRF, demography, safety, Argentina",20,231,https://drive.google.com/file/d/1gHk18dAz5PFNC3NeN8F7p8XWr3wY7bl-/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:00
125742_S1_M5_CRF_c4591001-1231-12311854.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina, safety",20,248,https://drive.google.com/file/d/1Urr_1o5pKfy3YuE_klcBWfBGm8ej0eMV/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:05
125742_S1_M5_CRF_c4591001-1231-12311844.pdf,PDF,C4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, C4591001, data quality, inclusion/exclusion criteria, data compliance, COVID-19 vaccine, CRF, informed consent, HISPANIC OR LATINO(A) OR OF SPANISH ORIGIN, visit date, FDA, WHITE, Protocol, eCRF, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, Argentina, data collection",20,199,https://drive.google.com/file/d/1iC-aeW0_clVUCVUD09nXQc8Q4ouYJp6i/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:09
125742_S1_M5_CRF_c4591001-1231-12311081.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, Latin America, demography, subject identification, efficacy data",20,226,https://drive.google.com/file/d/1Ax4lCrfOSNhFaTGAperrfyFtBuGScHXb/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:13
125742_S1_M5_CRF_c4591001-1231-12311205.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, efficacy, CRF, hospital, subject data, informed consent, visit date, Protocol, argentina, vaccine, c4591001, demography, safety",20,299,https://drive.google.com/file/d/1XU3QtkmJ3Mjp5n7dwJ-Z_HGdFq7-jgxQ/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:18
125742_S1_M5_CRF_c4591001-1231-12311862.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, FOIA document, eCRF audit trail, subject enrollment, informed consent, FDA, Protocol, Pfizer, demography, case report form, Argentina, efficacy data",20,329,https://drive.google.com/file/d/1U4EpFCP71QXf_Bw9KEi_Gk0HQfglmB81/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:27
125742_S1_M5_CRF_c4591001-1231-12311865.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, FOIA document, informed consent, date of visit, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina",20,192,https://drive.google.com/file/d/1DyoPHAhMj3pEgnBojOHUfBXK8bpopxwP/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:32
125742_S1_M5_CRF_c4591001-1231-12311766.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject enrollment, informed consent, FDA, Protocol, demography, case report form, Argentina, efficacy data",20,284,https://drive.google.com/file/d/1_39fjv283bqORJzT5w26fOJhh4TboJy7/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:36
125742_S1_M5_CRF_c4591001-1231-12311926.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, COVID-19 vaccine, efficacy, CRF, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, Latin America, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina",20,173,https://drive.google.com/file/d/1xGtpvlBaLoq0PsW60B9yRpWi-l-jLh8y/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:41
125742_S1_M5_CRF_c4591001-1231-12311118.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, confidential, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, eCRF audit trail, informed consent, date of visit, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina",20,519,https://drive.google.com/file/d/11DdFK6zFMijDocg1deCeQx2IM7HPVOFU/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:47
125742_S1_M5_CRF_c4591001-1231-12311128.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, safety, Argentina",20,214,https://drive.google.com/file/d/1wgJlx0zSAeWU1R71GfSx7WH1idCPpBWJ/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:51
125742_S1_M5_CRF_c4591001-1231-12311556.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Clinical Trial Case Report Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina, efficacy data",20,248,https://drive.google.com/file/d/1PEfjKxJY-m4VrUN0gQeJSOuq9fjtS5RN/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:55
125742_S1_M5_CRF_c4591001-1231-12311182.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina, data collection",20,231,https://drive.google.com/file/d/1VnPX0Map0BksMpllt5llol9yPZ2xT5eJ/view?usp=drivesdk,pd-production-060123,2025-08-11 23:13:59
125742_S1_M5_CRF_c4591001-1231-12312073.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, data lock and freeze, phase 2/3 study, CRF, demographic data, eCRF audit trail, informed consent, date of visit, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, case report form, subject identification, Argentina",20,193,https://drive.google.com/file/d/17XwpQMW3DEvMCcV2v2pe7OMZZmlrQcSA/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:03
125742_S1_M5_CRF_c4591001-1231-12311538.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data",19,183,https://drive.google.com/file/d/1COCcoBlpOKNh_dQGv5oZ-KO_40EqS7vT/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:07
125742_S1_M5_CRF_c4591001-1231-12311281.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,clinical trial form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, C4591001, data quality, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, FDA, Protocol, subject demographics, eCRF, data integrity, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, visit information, Argentina, electronic case report form",20,229,https://drive.google.com/file/d/1k7CVmjLZfPN1xtyTN3f5VoDxh73D9wSg/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:12
125742_S1_M5_CRF_c4591001-1231-12311295.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina, data collection",20,296,https://drive.google.com/file/d/1okCj7wWyU_y-3ceQTsMQnFIEt9Tdd0g4/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:16
125742_S1_M5_CRF_c4591001-1231-12311635.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, data quality control, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, Argentina site, protocol amendment, phase 2/3 study, CRF, demographic data, FDA submission, informed consent, adverse event monitoring, visit schedule, Protocol, data management, case report form, subject identification, confidential document",20,228,https://drive.google.com/file/d/1Qsl_PhLoSXMk_bwSB-HdHZV72Ov7w75c/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:21
125742_S1_M5_CRF_c4591001-1231-12311387.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, Latin America, demography, subject identification, efficacy data",20,246,https://drive.google.com/file/d/1vg6UgJbRkNGDlxqGGRaWrFfTdKQ-AUSX/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:25
125742_S1_M5_CRF_c4591001-1231-12311352.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Protocol, Pfizer, Latin America, eCRF, demography, data collection",20,588,https://drive.google.com/file/d/1fTk8TsqBj2Y1JaFDzji86M-4buShTKqW/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:31
125742_S1_M5_CRF_c4591001-1231-12311834.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, eCRF, data management, demography, Argentina",20,174,https://drive.google.com/file/d/1uhcbNq0d6I4M8KQXcDzI4HJqHQthoHjd/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:35
125742_S1_M5_CRF_c4591001-1231-12311014.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, demography, case report form, subject identification, safety, Argentina",20,330,https://drive.google.com/file/d/1Pf-QvpfN76k2bljALIq0rcw-3jzOCvfy/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:40
125742_S1_M5_CRF_c4591001-1231-12311815.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, FOIA, FDA, Protocol, medical terminology, Pfizer, Latin America, demography, case report form, subject identification",20,207,https://drive.google.com/file/d/1r9BzyfVWv3hl4vhUWLN2sUlEd8-7OgwN/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:44
125742_S1_M5_CRF_c4591001-1226-12262281.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-10-17,Case Report Form (CRF),(1226) CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, adverse events, regulatory compliance, C4591001, data quality, pharmaceutical, cohort selection, Brazil, CRF, subject enrollment, informed consent, visit schedule, FDA, Protocol, vaccine, demography, case report form",20,175,https://drive.google.com/file/d/1OsnGLhSep33S63mj06gWNCVEMI9pJ2o7/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:48
125742_S1_M5_CRF_c4591001-1231-12311315.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina, data collection",20,202,https://drive.google.com/file/d/1sPucDToCqcePuZujTnkDTL_7gYu4qCAj/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:52
125742_S1_M5_CRF_c4591001-1231-12311448.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, FDA, Protocol, Pfizer, demography, case report form, subject identification, Argentina, efficacy data",20,163,https://drive.google.com/file/d/1EpMT4xlck_tSGQXKEKpCJ18m5dU-hpsd/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:56
125742_S1_M5_CRF_c4591001-1231-12311730.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit schedule, FDA, Protocol, demography, case report form, subject identification, Argentina, data collection",20,183,https://drive.google.com/file/d/1VF_yzKkhlzlaZDo2upLQ8PVk0PykJC04/view?usp=drivesdk,pd-production-060123,2025-08-11 23:14:59
125742_S1_M5_CRF_c4591001-1231-12311510.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, adverse event monitoring, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina",20,145,https://drive.google.com/file/d/1K6qMGAJcAba0x5MQmCcDkcnU_hnUfoEg/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:03
125742_S1_M5_CRF_c4591001-1231-12311379.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, hospital, subject data, informed consent, FDA, Protocol, Pfizer, demography, case report form, Argentina, data collection",20,227,https://drive.google.com/file/d/1_cv3S72YYJfGcMtxpU96LS0e_gsiOCgE/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:07
125742_S1_M5_CRF_c4591001-1231-12312593.pdf,PDF,C4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, CRF, informed consent, FDA, Protocol, subject details, Pfizer, eCRF, demography, Argentina, data collection",20,188,https://drive.google.com/file/d/15TvEmHz8GlIZDqMJ6sSQ_XDjlibA9c3N/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:11
125742_S1_M5_CRF_c4591001-1231-12312205.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina",20,172,https://drive.google.com/file/d/1aQcy0yufwj2e8f4bjIvYLaLG8dS3izU9/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:15
125742_S1_M5_CRF_c4591001-1231-12312080.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, safety monitoring, FDA, Protocol, Pfizer, Latin America, demography, Argentina, efficacy data",20,185,https://drive.google.com/file/d/1daQhYk0IAblaypQI87kzOjmL8FW7pvmi/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:19
125742_S1_M5_CRF_c4591001-1231-12312679.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, demographics, clinical trial, phase 2/3, white race, confidential, data quality, COVID-19 vaccine, CRF, hospital, audit trail, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, case report form, Argentina, Hispanic/Latino",20,254,https://drive.google.com/file/d/1WV8rIULlYXDfcYZxmxPWg0DVh62iqnIK/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:23
125742_S1_M5_CRF_c4591001-1231-12312577.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, female, confidential, C4591001, data quality, Hispanic or Latino, inclusion/exclusion criteria, COVID-19 vaccine, CRF, FOIA document, informed consent, date of visit, FDA, Protocol, demography, case report form, subject identification",20,200,https://drive.google.com/file/d/13XDp5feB2-i7KvNkayVHvHBWfEDIDaoU/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:28
125742_S1_M5_CRF_c4591001-1231-12312660.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, safety, Argentina",20,291,https://drive.google.com/file/d/1tAHhDv-j4dlz0rXDkJctSUxj_Zkm_dzi/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:32
125742_S1_M5_CRF_c4591001-1231-12312420.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, FDA, Protocol, subject details, Latin America, data management, demography, case report form, visit information",20,257,https://drive.google.com/file/d/16bx8wHBVaTiX3hE90CByquKuJ2nN8NF4/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:36
125742_S1_M5_CRF_c4591001-1231-12312390.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, Pfizer, Latin America, demography, subject identification, safety, electronic case report form",20,208,https://drive.google.com/file/d/1JL4f_m41TOWrfdjBLJRyfrE-zbjUkXeI/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:40
125742_S1_M5_CRF_c4591001-1231-12312576.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, data audit trail, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, Argentina",20,227,https://drive.google.com/file/d/1hwi_yKa4iM-YIkUq5JkpD4HnyOCvOI3v/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:45
125742_S1_M5_CRF_c4591001-1231-12312996.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit schedule, FDA, Protocol, Pfizer, Latin America, data management, demography, case report form, subject identification",20,361,https://drive.google.com/file/d/1XKJdWSzCPWMj_h1JjDTBkGHFBUq0m-mK/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:50
125742_S1_M5_CRF_c4591001-1231-12313496.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FOIA, visit date, FDA, Protocol, data management, demography, safety",19,258,https://drive.google.com/file/d/1_JRSFoDdlxCV9XvUnKuBu8wvs8SSoSGl/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:54
125742_S1_M5_CRF_c4591001-1231-12313345.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, FDA, Protocol, Pfizer, eCRF, demography, subject identification, Argentina, efficacy data, data collection",20,202,https://drive.google.com/file/d/15PdmvQQuoxt3MsdLOz09Q8Gf-DeVn3kM/view?usp=drivesdk,pd-production-060123,2025-08-11 23:15:58
125742_S1_M5_CRF_c4591001-1231-12312125.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, demography, case report form, subject identification, Argentina, data collection",20,167,https://drive.google.com/file/d/16RqT-_2PlnYu3PRKISyO3hVkzYUnpD1A/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:02
125742_S1_M5_CRF_c4591001-1231-12312335.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, confidential, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, Pfizer, Latin America, demography, case report form, subject identification",20,176,https://drive.google.com/file/d/1qZk9ED9PQorjNEScbfBZizE1ledY1Zph/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:06
125742_S1_M5_CRF_c4591001-1231-12312476.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, eCRF, demography, safety, Argentina",20,167,https://drive.google.com/file/d/1MDPIJC6QBpErpKJ7tAlpID2dAogU_Kj3/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:10
125742_S1_M5_CRF_c4591001-1231-12312529.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, CRF, subject enrollment, informed consent, FDA, Protocol, Pfizer, Latin America, eCRF, demography, Argentina, data collection",20,215,https://drive.google.com/file/d/10Zd8_Iy_9T7aGvt_BOKg4AK2SluEySaj/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:14
125742_S1_M5_CRF_c4591001-1231-12313610.pdf,PDF,C4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, white, phase 2/3, march 2021, adverse events, male, hispanic or latino, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, hospital militar central cirujano mayor dr. cosme argerich, informed consent, visit date, Protocol, vaccine, c4591001, demography",20,190,https://drive.google.com/file/d/1jSgmUAr_dWmh7Om4sb5dmoIUjwYR2Wzn/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:17
125742_S1_M5_CRF_c4591001-1231-12312982.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory, compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, protocol amendment, CRF, informed consent, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, data management, demography, safety, Argentina",19,349,https://drive.google.com/file/d/1DDpNHy0K8-Pgtruws58LdzkMbtFkknPh/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:22
125742_S1_M5_CRF_c4591001-1231-12313422.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, Latin America, demography, case report form, subject identification, safety",20,601,https://drive.google.com/file/d/1O69acvNT61W3UAti5SwCb-mTxbesHV9c/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:28
125742_S1_M5_CRF_c4591001-1231-12313510.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject enrollment, informed consent, FDA, Protocol, Latin America, demography, case report form, efficacy data",20,342,https://drive.google.com/file/d/1IrvoD3MtECr1DlwLaquHK7XzM5k3NzFH/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:33
125742_S1_M5_CRF_c4591001-1231-12312868.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, female-subject, date-of-visit, demographic-data, clinical-trial, CRF, covid-19-vaccine, visit-schedule, informed-consent, eCRF-audit-trail, data-quality-control, Protocol, phase-2-3, hospital-militar-central-cirujano-mayor-dr-cosme-argerich, confidential-document, subject-identification, hispanic-or-latino-ethnicity, racial-designation, fda-submission",20,441,https://drive.google.com/file/d/1uqPaGC872lSACUOtW2cT4QqNx1znTq3c/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:38
125742_S1_M5_CRF_c4591001-1231-12313437.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"Clinical Trial, Confidential, Exclusion, Demography, Protocol Amendment, Vaccine, Pharmaceutical, FDA Submission, Phase 2/3, CRF, Data Verification, Protocol, Regulatory Compliance, Subject Enrollment, eCRF, Informed Consent, Site Information, Efficacy Data, Adverse Events, Argentina",20,375,https://drive.google.com/file/d/1-hJgFpH6_HjAYJGicVjhRjAI2_yvwUeD/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:42
125742_S1_M5_CRF_c4591001-1231-12313193.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, hospital, eCRF audit trail, subject enrollment, informed consent, visit date, FDA, Protocol, Pfizer, demography, case report form, Argentina",20,290,https://drive.google.com/file/d/1ls18bB2UFIvyahY6D4JC_LUXSZrPb3-R/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:46
125742_S1_M5_CRF_c4591001-1231-12312687.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject enrollment, informed consent, FDA, Protocol, demography, case report form, Argentina, efficacy data",20,221,https://drive.google.com/file/d/1pjTYv5W-8vr4yEqB7TU-t4hHKFgPrEUl/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:50
125742_S1_M5_CRF_c4591001-1231-12312914.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, FOIA document, eCRF audit trail, subject enrollment, informed consent, visit date, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina",20,558,https://drive.google.com/file/d/1oQq73aoP1njG0nRoRqf-LAsQeMC8_LRc/view?usp=drivesdk,pd-production-060123,2025-08-11 23:16:56
125742_S1_M5_CRF_c4591001-1231-12312162.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"subject-data, phase-2-3-trial, Exclusion, latin-america, inclusion-exclusion-criteria, vaccine-development, hospital-militar-central, regulatory-compliance, adverse-events, clinical-trial, CRF, informed-consent, cohort-selection, Protocol, c4591001, visit-date, efficacy-safety, data-quality, demography, fda-submission",20,245,https://drive.google.com/file/d/1SfRLC1IOmk9IJqg0f31z1TrdTay7yMRX/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:00
125742_S1_M5_CRF_c4591001-1231-12312787.pdf,PDF,c4591001 Clinical Trial eCRF,2020-07-30,report,,M5,True,True,False,True,False,"Exclusion, clinical trial, white, phase 2/3, adverse events, regulatory compliance, hispanic or latino, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, hospital militar central cirujano mayor dr. cosme argerich, informed consent, visit date, Protocol, c4591001, demography, electronic case report form",20,195,https://drive.google.com/file/d/14pDOHRB4OuIdA6WBGtLpL1vV_as_RG3X/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:03
125742_S1_M5_CRF_c4591001-1231-12312722.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, Latin America, demography, subject identification, efficacy data",20,177,https://drive.google.com/file/d/1ODB16uKsiw_QP4IF_cKm0RH3-31HGBSV/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:07
125742_S1_M5_CRF_c4591001-1231-12312378.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, data quality, latin america, phase 2/3 study, protocol amendment, CRF, covid-19 vaccine, demographic data, subject enrollment, eCRF audit trail, pharmaceutical development, informed consent, adverse event monitoring, Protocol, data management, case report form, confidential document, fda regulatory",20,208,https://drive.google.com/file/d/1JBftmRS4l1h28qtAbo3t7ismHbPKuVSC/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:12
125742_S1_M5_CRF_c4591001-1231-12313504.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit schedule, FDA, Protocol, Pfizer, data management, demography, case report form, subject identification, Argentina",20,220,https://drive.google.com/file/d/1HqNgrhiZz-klpig8D7T_m5tTJ5NVte3y/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:15
125742_S1_M5_CRF_c4591001-1231-12312749.pdf,PDF,C4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, subject information, informed consent, visit date, hospital militar central, Protocol, argentina, vaccine, c4591001, eCRF, demography",20,217,https://drive.google.com/file/d/16vvFsa3QaJmatFgpHpOJVOKDN8MN1Rpg/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:20
125742_S1_M5_CRF_c4591001-1231-12312885.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, adverse event monitoring, visit schedule, FDA, Protocol, data management, demography, case report form, subject identification, Argentina",20,200,https://drive.google.com/file/d/1Rv3khIvjYf4aJmoAg5VH_phjbsQzSSVy/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:24
125742_S1_M5_CRF_c4591001-1231-12312893.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit schedule, FDA, Protocol, Pfizer, Latin America, demography, subject identification, case report form, Argentina",20,171,https://drive.google.com/file/d/1AQjVwFMXpJ6ILy3l8aXO4boEaZYPebXg/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:27
125742_S1_M5_CRF_c4591001-1231-12313028.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data audit, data quality, COVID-19 vaccine, protocol amendment, CRF, demographic data, subject enrollment, informed consent, FDA, Protocol, Pfizer, eCRF, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, case report form, Argentina",20,180,https://drive.google.com/file/d/14kOxjCf3bOkaMoEyu-tNQRBYzTnBpfFe/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:31
125742_S1_M5_CRF_c4591001-1231-12313184.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit schedule, FDA, Protocol, Pfizer, demography, case report form, subject identification, efficacy data",20,183,https://drive.google.com/file/d/1rNOBelzHosjLDeL_TpehbAXbF3ne1FAI/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:35
125742_S1_M5_CRF_c4591001-1231-12312696.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, eCRF, demography, safety, Argentina",20,157,https://drive.google.com/file/d/1VKHf4sScybAIGtwQxaSB9xWJ1BfQ5uZz/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:38
125742_S1_M5_CRF_c4591001-1231-12313140.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, eCRF, demography, case report form, subject identification, Argentina",20,205,https://drive.google.com/file/d/1grCzPRtkgF0SSmYTlvEx4dy6Y2RTSWZ-/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:42
125742_S1_M5_CRF_c4591001-1231-12312854.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, Latin America, demography, case report form, subject identification, safety",20,213,https://drive.google.com/file/d/1qc6sfgoH-R0Y32ZwBQPyY1jaJQVNdgrI/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:46
125742_S1_M5_CRF_c4591001-1231-12312883.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, female, white race, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, FOIA document, informed consent, date of visit, FDA, Protocol, Pfizer, demography, case report form, subject identification, Hispanic/Latino",20,189,https://drive.google.com/file/d/15Gks1yp7ekCfJaDqJOLMyv8hCW2akT18/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:49
125742_S1_M5_CRF_c4591001-1231-12313753.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, Latin America, demography, case report form, subject identification, safety",20,209,https://drive.google.com/file/d/1j2-0Uu2rG6G3jzxitZwfHIqfumXkD4y5/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:53
125742_S1_M5_CRF_c4591001-1231-12313785.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina, safety",20,247,https://drive.google.com/file/d/1dJm8_Y1gp5vC6x7cwRGcn8Lr8Ky1on7o/view?usp=drivesdk,pd-production-060123,2025-08-11 23:17:57
125742_S1_M5_CRF_c4591001-1231-12313755.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, white race, regulatory compliance, data quality, Hispanic or Latino, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, FDA submission, informed consent, visit date, Protocol, c4591001 protocol, hospital military central, confidential document",20,228,https://drive.google.com/file/d/1ZcBgf9K-mmaMywspSxuKEslkGqzKWmYR/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:01
125742_S1_M5_CRF_c4591001-1231-12313730.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, demographic data, informed consent, FDA, Protocol, Pfizer, Latin America, case report form, subject identification, Argentina",20,329,https://drive.google.com/file/d/1c_r0yI3enhRAVD89BUyUlrwIiVVjvTk2/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:06
125742_S1_M5_CRF_c4591001-1231-12314372.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject enrollment, informed consent, visit date, FDA, Protocol, data verification, Pfizer, data lock, eCRF, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina",20,149,https://drive.google.com/file/d/1Ucq-ZJqSSNnPMKhB1pOLTUXTLUUdM_Kv/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:10
125742_S1_M5_CRF_c4591001-1231-12314041.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Clinical Trial Case Report Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina, safety",20,134,https://drive.google.com/file/d/1nLP_jxST1rEx2eVX4FRQrCAhIxp_wXqr/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:18
125742_S1_M5_CRF_c4591001-1231-12314465.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, C4591001, male, data quality, Hispanic or Latino, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina",20,189,https://drive.google.com/file/d/1nikC-iiMwDjBG4amgz-Q8likZaaj5oSQ/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:22
125742_S1_M5_CRF_c4591001-1231-12314414.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina, adverse event reporting",20,277,https://drive.google.com/file/d/19sPLUulR7tOuZZ2b5Z9eYu8wuj2EXIds/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:27
125742_S1_M5_CRF_c4591001-1231-12313621.pdf,PDF,C4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, fda, data quality, latin america, cohort selection, inclusion/exclusion criteria, CRF, hospital, informed consent, visit date, Protocol, vaccine, c4591001, eCRF, demography, subject identification",20,186,https://drive.google.com/file/d/14OziAk_JDDJ6G0bDrct9EE79PtvZ47_r/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:31
125742_S1_M5_CRF_c4591001-1231-12314216.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory submission, data quality, inclusion/exclusion criteria, data compliance, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,159,https://drive.google.com/file/d/1s1LbbsfI8qHho1_hs-VaizhevodQTloM/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:34
125742_S1_M5_CRF_c4591001-1231-12313689.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit schedule, FDA, Protocol, medical research, data management, demography, case report form, subject identification, Argentina",20,208,https://drive.google.com/file/d/1Tx5bSzK4dn-nywbUZdGutAzlCaYmdGOG/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:38
125742_S1_M5_CRF_c4591001-1231-12314233.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, protocol amendment, CRF, informed consent, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, safety, Argentina",19,181,https://drive.google.com/file/d/14ot5PMT_4hJ9PK_lNdwUSMu-5BBBJDUi/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:42
125742_S1_M5_CRF_c4591001-1231-12313783.pdf,PDF,C4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, subject information, informed consent, visit date, hospital militar central, Protocol, argentina, vaccine, c4591001, eCRF, demography",20,168,https://drive.google.com/file/d/1Bl7febOTso_jwe2knjkyh4rLYYlSfM8r/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:45
125742_S1_M5_CRF_c4591001-1231-12313777.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, hospital, demographic data, subject enrollment, informed consent, visit date, FDA, Protocol, Pfizer, case report form, Argentina",20,192,https://drive.google.com/file/d/1NhV6WnuigDtNDwebhmwwDDgYYGRsuvfp/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:49
125742_S1_M5_CRF_c4591001-1231-12313972.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, eCRF audit trail, informed consent, visit date, FDA, Protocol, Pfizer-BioNTech, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina",20,166,https://drive.google.com/file/d/175p3AUh6z-FDGRo3NE4Aybw4K2rsJUpe/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:52
125742_S1_M5_CRF_c4591001-1231-12314407.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina, data collection",20,178,https://drive.google.com/file/d/1Oq1r_DEGqcQEIWQ21JimHgxu_N4wr8Sr/view?usp=drivesdk,pd-production-060123,2025-08-11 23:18:56
125742_S1_M5_CRF_c4591001-1231-12313674.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina, safety",20,432,https://drive.google.com/file/d/1ZJWyEvw4T6QkdRtWFT2eb36_LTvGXzMF/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:02
125742_S1_M5_CRF_c4591001-1231-12314197.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, compliance, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FOIA, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, data management, demography, safety, Argentina",19,318,https://drive.google.com/file/d/13s6mxrWltDCaD-FzMzJWTwSiDgFN0s05/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:06
125742_S1_M5_CRF_c4591001-1231-12314255.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, data management, demography, case report form, subject identification, Argentina",20,177,https://drive.google.com/file/d/15_sh71jxEgIpzmfBywZS8rOfoL5UOwVN/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:10
125742_S1_M5_CRF_c4591001-1231-12313653.pdf,PDF,C4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, white race, adverse events, regulatory compliance, hispanic or latino, fda, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, hospital militar central cirujano mayor dr. cosme argerich, informed consent, visit date, Protocol, c4591001, demography, electronic case report form",20,485,https://drive.google.com/file/d/1kiTPfqp14fT0QyYE1oOcnbVPjy49l1N9/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:15
125742_S1_M5_CRF_c4591001-1231-12314128.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina, data collection",20,209,https://drive.google.com/file/d/152hceaSxkBs3ShLe_Kama_p0zKpiVqL5/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:19
125742_S1_M5_CRF_c4591001-1231-12313879.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, demographic data, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, eCRF, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, data management, case report form, Argentina",20,263,https://drive.google.com/file/d/1johdgVzLmxP-J9uk8PFvrNmOAbUkWqZw/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:24
125742_S1_M5_CRF_c4591001-1231-12313894.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, MALE, COVID-19 vaccine, efficacy, CRF, informed consent, HISPANIC OR LATINO(A) OR OF SPANISH ORIGIN, visit date, FDA, WHITE, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, safety",19,188,https://drive.google.com/file/d/1-D7nw9kflNdRSwOeIm_g6qoJIxXuRMDe/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:28
125742_S1_M5_CRF_c4591001-1231-12314075.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"visit dates, Exclusion, clinical trial, phase 2/3, confidential, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, data audit trail, informed consent, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, data completeness, demography, case report form, subject identification, Argentina",20,267,https://drive.google.com/file/d/16oSoFDrIdMbO1nOTQLlDl95xld2qLffY/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:32
125742_S1_M5_CRF_c4591001-1231-12314411.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, eCRF audit trail, informed consent, visit schedule, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina",20,123,https://drive.google.com/file/d/1n6ItvwBDbhesdjLTmnStbxH2I2MH9aWS/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:41
125742_S1_M5_CRF_c4591001-1231-12313884.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, visit schedule, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, data management, demography, case report form, Argentina",20,198,https://drive.google.com/file/d/1epXfr0OsogPuP1ibTMNKvl3AuHQvMjT9/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:45
125742_S1_M5_CRF_c4591001-1231-12314335.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, c4591001, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, data management, demography, case report form, subject identification, Argentina",20,116,https://drive.google.com/file/d/165fBEufiAMt4eGS5zxRJNH2QiWcEn2TL/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:53
125742_S1_M5_CRF_c4591001-1231-12313998.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"white-race, phase-2-3-trial, Exclusion, inclusion-exclusion-criteria, vaccine-development, confidential, subject-12313998, audit-trail, clinical-trial, fda-regulated, CRF, data-collection, informed-consent, cohort-selection, Protocol, c4591001, hospital-militar-central-cirujano-mayor-dr-cosme-argerich, visit-date, hispanic-or-latino-ethnicity, demography",20,276,https://drive.google.com/file/d/10hsA4nhLHnkmOgeT4lclfHPDZA8rkh5x/view?usp=drivesdk,pd-production-060123,2025-08-11 23:19:58
125742_S1_M5_CRF_c4591001-1231-12314368.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject enrollment, informed consent, visit schedule, FDA, Protocol, data management, demography, case report form, Argentina",20,170,https://drive.google.com/file/d/1qBsNvVOKc0v9_IUTbPha8_czhXoS9iSN/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:02
125742_S1_M5_CRF_c4591001-1231-12314134.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, confidential, adverse events, regulatory compliance, fda, data quality, latin america, CRF, covid-19 vaccine, subject enrollment, informed consent, Protocol, c4591001, demography, efficacy data, electronic case report form",20,284,https://drive.google.com/file/d/19GKdUC7kSv7NxYZBv3U05zOuR7PVvRq5/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:06
125742_S1_M5_CRF_c4591001-1231-12314395.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, pharmaceutical, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, protocol amendment, CRF, demographic data, subject enrollment, visit schedule, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, safety, Argentina",19,273,https://drive.google.com/file/d/1iU7_Wh-u6yy9c76kCq0ER-teTR4Jaoo9/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:10
125742_S1_M5_CRF_c4591001-1231-12314033.pdf,PDF,C4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, hospital, informed consent, visit date, Protocol, argentina, vaccine, c4591001, eCRF, demography, subject identification",20,185,https://drive.google.com/file/d/16ZbG7uUp-wOzHLZT-_SgYXs0EWgodHKI/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:15
125742_S1_M5_CRF_c4591001-1231-12313715.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina, data collection",20,209,https://drive.google.com/file/d/1zQ-XyTuDijxbjC18-g1uPhgZT8mGWNMi/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:19
125742_S1_M5_CRF_c4591001-1231-12314001.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina, data collection",20,317,https://drive.google.com/file/d/1cOfammGMqwTaLhV-9bJ50ITUHBq5vnRJ/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:25
125742_S1_M5_CRF_c4591001-1231-12314091.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, subject identification, safety, Argentina",20,148,https://drive.google.com/file/d/1uo2N1uBMuqf5MrtLZYl7zozNOL4tzQZW/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:29
125742_S1_M5_CRF_c4591001-1231-12314308.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, female, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, eCRF audit trail, informed consent, date of visit, FDA, Protocol, Pfizer, demography, case report form, subject identification, Argentina, Hispanic/Latino",20,185,https://drive.google.com/file/d/1Swd0hcEPTqh0_6iTaAThSpDVlx90b3xE/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:32
125742_S1_M5_CRF_c4591001-1231-12314494.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, latin-america, inclusion-exclusion-criteria, regulatory-compliance, site-information, adverse-events, clinical-trial, CRF, covid-19-vaccine, visit-schedule, informed-consent, cohort-selection, Protocol, phase-2-3, efficacy-data, pfizer-biontech, subject-identification, data-quality, demography, fda-submission",20,224,https://drive.google.com/file/d/1l4_WJW3AnLSHbI-ksyj0yHA3DQDzH61a/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:37
125742_S1_M5_CRF_c4591001-1231-12314059.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, subject identification, safety, Argentina",20,172,https://drive.google.com/file/d/1VHDV4tra1jl8WZ3lweeP-2U0SAhs-_bS/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:41
125742_S1_M5_CRF_c4591001-1231-12314035.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, FOIA document, informed consent, visit schedule, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina",20,160,https://drive.google.com/file/d/1fJS7PLTWr6mo_l8i_gw0s0qHu-SzHxR1/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:45
125742_S1_M5_CRF_c4591001-1231-12315520.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina, data collection",20,265,https://drive.google.com/file/d/1sUohMjLvc4dn3l9kaEFed0k_Gc-M0vfn/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:49
125742_S1_M5_CRF_c4591001-1231-12315653.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, fda, inclusion/exclusion criteria, quality assurance, phase 2/3 study, CRF, covid-19 vaccine, informed consent, safety monitoring, visit schedule, hospital militar central, Protocol, argentina, subject demographics, eCRF, efficacy data, data collection",20,153,https://drive.google.com/file/d/1ljwT-Mvoow94WYSfCCrN5rcLiVlwCcrH/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:53
125742_S1_M5_CRF_c4591001-1231-12315023.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina, safety",20,158,https://drive.google.com/file/d/1zHP954jE-kEAIoDIQTcttDJv0vqpe9RI/view?usp=drivesdk,pd-production-060123,2025-08-11 23:20:56
125742_S1_M5_CRF_c4591001-1231-12314898.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, demographic data, subject enrollment, informed consent, visit schedule, FDA, Protocol, data verification, Pfizer, data lock, eCRF, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Argentina",20,347,https://drive.google.com/file/d/1xnHPMOfQmBj5WCvFvl1F8EtyPnryYHQt/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:02
125742_S1_M5_CRF_c4591001-1231-12315677.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, visit schedule, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, data management, demography, case report form, Argentina",20,141,https://drive.google.com/file/d/1lmHi3iBet_NtXLwO-QkrKhW0qltJ_vil/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:05
125742_S1_M5_CRF_c4591001-1231-12315186.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,(1231) Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, hospital, informed consent, visit date, Protocol, argentina, vaccine, c4591001, eCRF, demography, subject identification",20,277,https://drive.google.com/file/d/1ZJfiylrXEH5dJN25VLVTxBZWyG2WVtMs/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:09
125742_S1_M5_CRF_c4591001-1231-12314681.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina, safety",20,418,https://drive.google.com/file/d/1tMcDLO4u2rr_chHNUK33TOJzZDoNDl_-/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:14
125742_S1_M5_CRF_c4591001-1231-12315093.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit schedule, FDA, Protocol, Pfizer, demography, case report form, subject identification, Argentina, data collection",20,148,https://drive.google.com/file/d/1GraWYSQB3G9KHPQdUmO7343WhiJ40PGo/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:18
125742_S1_M5_CRF_c4591001-1231-12315542.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, demographic data, informed consent, FDA, Protocol, Pfizer, Latin America, case report form, subject identification, Argentina, data collection",20,165,https://drive.google.com/file/d/15SWELOyCTsLQ2YcB-IYY5lAeuQ8NEu1B/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:21
125742_S1_M5_CRF_c4591001-1231-12315579.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, white race, male gender, C4591001, data quality, Hispanic or Latino, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, date of visit, Protocol, case report form, subject identification, confidential document",20,208,https://drive.google.com/file/d/1mm_V1F_2-SQASFLz4ckHjw3HR7hZebBi/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:25
125742_S1_M5_CRF_c4591001-1231-12315291.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, female, white race, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, demographic data, FOIA document, informed consent, date of visit, FDA, Protocol, case report form, subject identification, Hispanic/Latino",20,208,https://drive.google.com/file/d/10ZSFZae-Q3VGew-uSUxjFl6JECs4_mG1/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:29
125742_S1_M5_CRF_c4591001-1231-12315473.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, medical history, CRF, informed consent, visit date, FDA, Protocol, Pfizer, Latin America, demography, subject identification, Argentina",20,146,https://drive.google.com/file/d/16sbVJS9ZeV-BX2Bem-UX-azgRv4v7Gs1/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:32
125742_S1_M5_CRF_c4591001-1231-12315126.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit schedule, FDA, Protocol, demography, subject identification, safety, Argentina",19,219,https://drive.google.com/file/d/1tKCBNlv7uj51nGE3HJWn6rfRXr6waETe/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:36
125742_S1_M5_CRF_c4591001-1231-12315429.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, FDA submission, informed consent, date of visit, Protocol, Pfizer-BioNTech, Latin America, data management, case report form, subject identification, confidential document",20,164,https://drive.google.com/file/d/1z9S354S5ji-xUqfbYFCNg6B0uzB72SMR/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:40
125742_S1_M5_CRF_c4591001-1231-12314813.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina, data collection",20,160,https://drive.google.com/file/d/1zF2QdAUCGeX130plNcBr7pk9FPOspnIH/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:44
125742_S1_M5_CRF_c4591001-1231-12315632.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit schedule, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, data management, demography, case report form, subject identification, Argentina",20,323,https://drive.google.com/file/d/1BHu2YDYkJTsJML6gdFlJZFroQussNn8X/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:49
125742_S1_M5_CRF_c4591001-1231-12314833.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit schedule, FDA, Protocol, Latin America, data management, demography, case report form, subject identification, Argentina",20,184,https://drive.google.com/file/d/11fxqU93WqBJF7z-h4UwQN1T0NxM4kFCr/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:53
125742_S1_M5_CRF_c4591001-1231-12315404.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, demography, case report form, subject identification, Argentina, data collection",20,178,https://drive.google.com/file/d/1sEpLDuboXWV742W2z6gC9UkrSiIn9i7K/view?usp=drivesdk,pd-production-060123,2025-08-11 23:21:57
125742_S1_M5_CRF_c4591001-1231-12314531.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, adverse events, data audit, regulatory compliance, C4591001, data quality, CRF, hospital, subject enrollment, informed consent, visit schedule, FDA, Protocol, vaccine, demography, Argentina, data collection",20,177,https://drive.google.com/file/d/1vwne04lRg0RdEoEc-bmh2ct71CNGd4rS/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:02
125742_S1_M5_CRF_c4591001-1231-12315559.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FDA, Protocol, Pfizer, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina",20,158,https://drive.google.com/file/d/1HR13w4Zi8SMDlvFqOFELSgi3dSXBKb_t/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:05
125742_S1_M5_CRF_c4591001-1231-12314583.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, demography, subject identification, safety, Argentina",20,275,https://drive.google.com/file/d/1Ar9HkhpbDiDPm4Q0TW6546Hco1QpC8dQ/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:09
125742_S1_M5_CRF_c4591001-1231-12314759.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Clinical Trial Case Report Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, safety, Argentina",20,245,https://drive.google.com/file/d/118I3UgQnNFABY9A_tynB9794oAdcWoth/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:14
125742_S1_M5_CRF_c4591001-1231-12315441.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, eCRF audit trail, informed consent, visit date, Protocol, data verification, subject demographics, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, data completeness, subject identification, data locking and freezing, confidential document",20,204,https://drive.google.com/file/d/1h50OQSMcULfpiOF6GaN79OET5mkQosFe/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:19
125742_S1_M5_CRF_c4591001-1231-12314921.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, data management, demography, case report form, subject identification, Argentina",20,138,https://drive.google.com/file/d/1HGkCk4uPTLrmZWB3Nb5PWaoHsA5G54IY/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:28
125742_S1_M5_CRF_c4591001-1231-12314987.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, protocol amendment, CRF, subject information, informed consent, FDA, Protocol, Latin America, data management, demography, safety",19,133,https://drive.google.com/file/d/1kc2uAXTSxhM2eiBl5dbAQfHV_Y7nfEZM/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:39
125742_S1_M5_CRF_c4591001-1231-12315498.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer-BioNTech, Latin America, data management, demography, case report form, subject identification, Argentina",20,159,https://drive.google.com/file/d/1nbnIH0RplOcxVc7FT-DrDhFzAssApmZM/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:43
125742_S1_M5_CRF_c4591001-1231-12314690.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, subject identification, Argentina, efficacy data",19,159,https://drive.google.com/file/d/1U9LM_aIGKJmVEUCRp8WZseg3WkvyOJxn/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:46
125742_S1_M5_CRF_c4591001-1231-12315301.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, demographic data, subject enrollment, informed consent, visit schedule, FDA, Protocol, data verification, Pfizer, data lock, eCRF, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, case report form, Argentina",20,266,https://drive.google.com/file/d/1H1buNuuRObzXskuEV7XStNQ27VCzn3WC/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:51
125742_S1_M5_CRF_c4591001-1231-12315351.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, C4591001, male, data quality, Hispanic or Latino, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, subject identification, Argentina",20,150,https://drive.google.com/file/d/1Tyq15-gDqRqE7w75q5aGnfED6dWlfDig/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:54
125742_S1_M5_CRF_c4591001-1247-12471092.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Study c4591001,2021-03-29,clinical trial form,,M5,True,True,False,True,False,"Tiervlei Trial Centre, site information, Exclusion, clinical trial, regulatory compliance, data quality, Karl Bremer Hospital, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, c4591001 study, Protocol, subject details, South Africa, demography, data collection",20,471,https://drive.google.com/file/d/1sOWCqb34pALfChVenAtKicJMdnFdyKJP/view?usp=drivesdk,pd-production-060123,2025-08-11 23:22:59
125742_S1_M5_CRF_c4591001-1231-12315622.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, demographic data, informed consent, visit schedule, FDA, Protocol, Pfizer-BioNTech, Latin America, data management, case report form, subject identification, Argentina",20,250,https://drive.google.com/file/d/1y77lFipCr0enhMbk7fJXyF8KbmZwCwmF/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:04
125742_S1_M5_CRF_c4591001-1231-12314562.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, demography, case report form, subject identification, safety, Argentina",20,132,https://drive.google.com/file/d/1kN8igjkL9fu7vdAdvMrpKbbq7IYKy3qf/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:10
125742_S1_M5_CRF_c4591001-1231-12315324.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Latin America location, FDA regulation, clinical trial, Exclusion, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, hospital site, phase 2/3 study, CRF, demographic data, informed consent, adverse event monitoring, visit date, Protocol, medical research, data management, subject identification, C4591001 trial",20,423,https://drive.google.com/file/d/1cT9wVvLzOm3RmubQ32KaK9rJTS0-SIQK/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:16
125742_S1_M5_CRF_c4591001-1231-12315081.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, data audit, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, FDA, Protocol, Pfizer, demography, case report form, subject identification, Argentina, data collection",20,230,https://drive.google.com/file/d/1Qk8E8_OFhhgF1kqANgJDBcdJdVp7r2oR/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:19
125742_S1_M5_CRF_c4591001-1247-12471066.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, regulatory compliance, data quality, Karl Bremer Hospital, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, informed consent, adverse event monitoring, visit schedule, Protocol, South Africa, data management, subject identification",20,514,https://drive.google.com/file/d/1k7gTMkXg9ORKOAtZv9HwmK6wZDPn13vZ/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:24
125742_S1_M5_CRF_c4591001-1231-12315671.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, demography, case report form, subject identification, safety, Argentina",20,173,https://drive.google.com/file/d/15bY8VB_jIJMjJ4WkFAT3UD81xxnizjQ1/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:28
125742_S1_M5_CRF_c4591001-1247-12471121.pdf,PDF,Clinical Trial Case Report Form,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, FDA, Protocol, vaccine, South Africa, eCRF, demography, COVID-19, case report form, subject identification",20,436,https://drive.google.com/file/d/1Nc5TedpaxZnb2QG1-Gq07L7JpxT9dRfe/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:33
125742_S1_M5_CRF_c4591001-1231-12314894.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit schedule, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, subject identification, Argentina, data collection",19,183,https://drive.google.com/file/d/1TibPtCaAGDmUV44iVenjorfc_EcH4YWH/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:37
125742_S1_M5_CRF_c4591001-1231-12315193.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, visit schedule, FDA, Protocol, Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, demography, case report form, Argentina",20,169,https://drive.google.com/file/d/188Jo7rxBhw7urThUoxTtqfjZTrHKwW9R/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:41
125742_S1_M5_CRF_c4591001-1247-12471220.pdf,PDF,Clinical Trial eCRF for COVID-19 Vaccine Candidate c4591001,2021-03-29,Clinical Trial Form,,M5,True,True,False,True,False,"karl bremer hospital, Exclusion, clinical trial, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, subject data, pharmaceutical development, informed consent, visit date, Protocol, c4591001, south africa, tiervlei trial centre, data management, demography, electronic case report form",20,425,https://drive.google.com/file/d/1HEAC7FWJMAh_xqjJ580h1EaeiUjAxD1b/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:45
125742_S1_M5_CRF_c4591001-1247-12471172.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, adverse events, regulatory compliance, data quality, Karl Bremer Hospital, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, FDA submission, informed consent, visit schedule, Protocol, South Africa, efficacy data, confidential document",20,195,https://drive.google.com/file/d/1j5zB6e6q4iij7iTUGrl8_Tz5W8MfO0sf/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:49
125742_S1_M5_CRF_c4591001-1247-12471244.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"karl bremer hospital, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, eCRF, tiervlei trial centre, data management, demography, efficacy data",20,200,https://drive.google.com/file/d/1t-4D_uyQ7tXnxo2MGV9ILWZWy5rLRAHT/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:53
125742_S1_M5_CRF_c4591001-1247-12471135.pdf,PDF,Clinical Trial CRF for COVID-19 Vaccine Candidate c4591001,2021-03-29,Clinical Trial Form,,M5,True,True,False,True,False,"karl bremer hospital, Exclusion, clinical trial, safety data, adverse events, regulatory, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, clinical research, informed consent, visit date, Protocol, c4591001, tiervlei trial centre, demography, efficacy data",20,328,https://drive.google.com/file/d/1g_vTmXiq3H1KV3N2EwZPnGUuBhLBwMQq/view?usp=drivesdk,pd-production-060123,2025-08-11 23:23:58
125742_S1_M5_CRF_c4591001-1247-12471137.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"karl bremer hospital, Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, safety and efficacy, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, tiervlei trial centre, demography, data collection",20,257,https://drive.google.com/file/d/19SW7mxituR7rkZ5_Gmf0RWuWQDel0mDx/view?usp=drivesdk,pd-production-060123,2025-08-11 23:24:02
125742_S1_M5_CRF_c4591001-1247-12471226.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, crf, CRF, covid-19 vaccine, informed consent, visit date, Protocol, south africa, demography, subject identification, efficacy data, data collection",20,223,https://drive.google.com/file/d/18yJOO2pGeCf-0X2Sv9u69l6xf156h8_L/view?usp=drivesdk,pd-production-060123,2025-08-11 23:24:05
125742_S1_M5_CRF_c4591001-1210-12101026.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,form,---,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Turkey, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, demography, subject identification, Medipol University Medical Faculty, efficacy data",20,452,https://drive.google.com/file/d/1ujhTG5t1TUQLaZrv9uDWRQZwk6KwR6re/view?usp=drivesdk,pd-production-060123,2025-08-11 23:24:10
125742_S1_M5_CRF_c4591001-1156-11561001.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical-research-form, inclusion-exclusion-criteria, acevedo-clinical-research-associates, regulatory-compliance, phase-2-3-study, clinical-trial, CRF, data-collection, covid-19-vaccine, eCRF-audit-trail, informed-consent, cohort-selection, Protocol, visit-date, confidential-document, subject-identification, data-quality, demography, fda-submission",20,192,https://drive.google.com/file/d/1FBmsaeE_f6Bus0uc_nYn-ZTbbSiuop2J/view?usp=drivesdk,pd-production-060123,2025-08-11 23:24:15
125742_S1_M5_CRF_c4591001-1226-12261043.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, CEPIC, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, CRF, demographic data, subject enrollment, informed consent, visit date, FDA, Protocol, eCRF, safety",20,259,https://drive.google.com/file/d/1kmjivSasHvaOunnVw63MPrcYFJR0DIIQ/view?usp=drivesdk,pd-production-060123,2025-08-11 23:24:18
125742_S1_M5_CRF_c4591001-1156-11561007.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, fda, cohort selection, quality assurance, protocol amendment, phase 2/3 study, CRF, acevedo clinical research associates, covid-19 vaccine, informed consent, safety monitoring, visit schedule, Protocol, subject demographics, efficacy data, electronic case report form, data collection",20,168,https://drive.google.com/file/d/1WK6sYIGoXBt1JnlkxW-ae4GMsZhE8UF_/view?usp=drivesdk,pd-production-060123,2025-08-11 23:24:22
125742_S1_M5_CRF_c4591001-1156-11561124.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Acevedo Clinical Research Associates, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, subject enrollment, informed consent, visit date, FDA, c4591001 study, Protocol, data management, demography",19,128,https://drive.google.com/file/d/17T5U_nE3UMh8gqwCMBzexy8-gEoVsOYk/view?usp=drivesdk,pd-production-060123,2025-08-11 23:24:32
125742_S1_M5_CRF_c4591001-1166-11661047.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, inclusion/exclusion criteria, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit date, Protocol, subject demographics, rapid medical research, data completeness, data management, subject identification",20,842,https://drive.google.com/file/d/1g3iBJ9n-nMyBjmZGC5TlqFVIeSEPH4xo/view?usp=drivesdk,pd-production-060123,2025-08-11 23:24:38
125742_S1_M5_CRF_c4591001-1162-11621327.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, regulatory-compliance, phase-2-3-study, adverse-events, clinical-trial, CRF, atlanta-research-site, data-collection, covid-19-vaccine, safety-monitoring, informed-consent, cohort-selection, Protocol, efficacy-data, visit-date, fda-regulatory, subject-identification, demography, quality-control",20,125,https://drive.google.com/file/d/1cxV5-F1515bcnV7l1k0llZAKxaZFJHzM/view?usp=drivesdk,pd-production-060123,2025-08-11 23:24:46
125742_S1_M5_CRF_c4591001-1156-11561160.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,Acevedo,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, c4591001 trial, data quality control, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, Pfizer-BioNTech vaccine, CRF, eCRF audit trail, FDA submission, informed consent, visit date, Protocol, demography data, subject identification, adverse event reporting",20,246,https://drive.google.com/file/d/1RaXxTV1daY9xglM0wx9iBsRMJMI4YRWV/view?usp=drivesdk,pd-production-060123,2025-08-11 23:24:51
125742_S1_M5_CRF_c4591001-1209-12091014.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-10-10,Case Report Form (CRF),--- Generated By,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Turkey, CRF, audit trail, informed consent, visit date, FDA, Protocol, Yedikule Chest Diseases and Chest Surgery Training and Application Center, Pfizer, eCRF, demography, subject identification",20,355,https://drive.google.com/file/d/1OnFmEAxXeeLIrhkJWjbVi3VBR0Iuz2Ee/view?usp=drivesdk,pd-production-060123,2025-08-11 23:24:57
125742_S1_M5_CRF_c4591001-1162-11621128.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, regulatory-compliance, phase-2-3-study, subject-information, data-integrity, clinical-trial, fda-regulated, CRF, atlanta-research-site, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, visit-date, c4591001-trial, demography, quality-control, adverse-event-monitoring",20,138,https://drive.google.com/file/d/1AACPEJTBJEu7oX95uISvbNOS1ZctlE31/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:06
125742_S1_M5_CRF_c4591001-1156-11561131.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Acevedo Clinical Research Associates, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, subject identification, efficacy data",20,210,https://drive.google.com/file/d/1SPeP3eIUIc_TGBjs2eoY2mPBR2TBRxm1/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:10
125742_S1_M5_CRF_c4591001-1156-11561015.pdf,PDF,Clinical Research Form (CRF) for c4591001 Study,2020-07-30,form,,M5,True,True,False,True,False,"subject-data, Exclusion, inclusion-exclusion-criteria, confidential, acevedo-clinical-research-associates, regulatory-compliance, c4591001-study, clinical-trial, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, phase-2-3, visit-date, eCRF, data-quality, demography, fda-submission",20,177,https://drive.google.com/file/d/1sX-clJ0wnBZKH7lrSBBdWDSTFdC6Syzi/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:14
125742_S1_M5_CRF_c4591001-1162-11621059.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Atlanta, Exclusion, clinical trial, phase 2/3, confidential, data quality, inclusion/exclusion criteria, CRF, audit trail, informed consent, visit date, FDA, Protocol, vaccine, data verification, c4591001, data lock, eCRF, demography, subject identification",20,214,https://drive.google.com/file/d/1YCkD3C4Hr_4u887cUNXh0rOJ6U6VBSpN/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:19
125742_S1_M5_CRF_c4591001-1157-11571066.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, protocol amendment, CRF, subject information, covid-19 vaccine, paradigm research, informed consent, visit date, Protocol, c4591001, demography, efficacy data, data collection",20,144,https://drive.google.com/file/d/1Lgle7swWhqEPOfZGA77pJVYxU2HAjyFo/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:22
125742_S1_M5_CRF_c4591001-1156-11561044.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, Acevedo Clinical Research Associates, c4591001 trial, regulatory submission, pharmaceutical research, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, eCRF audit trail, informed consent, visit date, Protocol, demography data, confidential document",20,418,https://drive.google.com/file/d/1hBXO-Q7U1Bnd_FLDnVIGmZhwklvt68UQ/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:27
125742_S1_M5_CRF_c4591001-1162-11621276.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, FOIA document, informed consent, visit date, FDA, Protocol, Atlanta Center for Medical Research, demography, subject identification, efficacy data",19,122,https://drive.google.com/file/d/1WI6btcu_e7PXVsCWsjoJR9GMy_kT_xhb/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:34
125742_S1_M5_CRF_c4591001-1161-11611016.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, benchmark research, san angelo, confidential, regulatory compliance, pharmaceutical research, fda, data quality, eligibility criteria, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit schedule, Protocol, subject demographics, clinical data management, data collection",20,256,https://drive.google.com/file/d/1HGj_B91dolxz5idoYgk0PFoyTO74iydN/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:38
125742_S1_M5_CRF_c4591001-1161-11611020.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, Benchmark Research, safety data, confidential, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, San Angelo, informed consent, visit date, Protocol, subject demographics, eCRF, data management, efficacy data",20,734,https://drive.google.com/file/d/1VVLQ3ySmNaW5JyuyVKM14CW0n81tcr_7/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:45
125742_S1_M5_CRF_c4591001-1166-11661078.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, regulatory compliance, data quality, Rapid Medical Research, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, FDA submission, informed consent, adverse event monitoring, visit date, Protocol, demography data, subject identification, electronic case report form, confidential document",20,365,https://drive.google.com/file/d/1mt-ee4Sez0-9HtvQqwMgQnvF9hRHOma_/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:49
125742_S1_M5_CRF_c4591001-1212-12121024.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,"Subject No: 12121024, Subject Initials: ---",M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Turkey, CRF, informed consent, visit date, FDA, Sakarya University Medical Faculty, Protocol, Pfizer, eCRF, demography, safety",20,417,https://drive.google.com/file/d/19hOBWtoN1fUNu92mgvgXuXj2dY_F4OoU/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:54
125742_S1_M5_CRF_c4591001-1210-12101029.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,form,Medipol University Medical Faculty,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, COVID-19 vaccine, efficacy, Turkey, protocol amendment, phase 2/3 study, CRF, informed consent, visit schedule, FDA, Protocol, subject demographics, eCRF, data management, safety, data collection",20,225,https://drive.google.com/file/d/1ekY2QeAEJG3vQC-Co9zHaiAolftvr7qs/view?usp=drivesdk,pd-production-060123,2025-08-11 23:25:58
125742_S1_M5_CRF_c4591001-1156-11561006.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Acevedo Clinical Research Associates, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, safety",20,462,https://drive.google.com/file/d/1ruIhBaEZRYMLyhHW9M0mm7eXbfJBXtqV/view?usp=drivesdk,pd-production-060123,2025-08-11 23:26:03
125742_S1_M5_CRF_c4591001-1163-11631059.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, FOIA document, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,463,https://drive.google.com/file/d/15MPLJXVH0lMWQgnmpFM04KriaxO_UN-2/view?usp=drivesdk,pd-production-060123,2025-08-11 23:26:08
125742_S1_M5_CRF_c4591001-1157-11571134.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1157) Paradigm Research,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, safety",20,131,https://drive.google.com/file/d/1bd09UPTpp-AbCIwZFVV4eT-3nu9BaUkQ/view?usp=drivesdk,pd-production-060123,2025-08-11 23:26:19
125742_S1_M5_5351_c4591001-interim-mth6-interlab-standard.pdf,PDF,List of Laboratories Under Vaccine Research & Development Oversight,2021-03-18,report,"Pfizer Vaccine Research & Development, University of Texas Medical Branch",M5,False,True,False,False,False,"fda-regulatory, university-of-texas-medical-branch, pfizer-vaccine-research, c4591001-protocol, new-york, texas, laboratory-list, new-jersey, phase-1-phase-2-3, Protocol, interim-update, vaccine-development, clinical-trial, neutralization-assay, service-providers, covid-19, sars-cov-2-assays, confidential-document",18,1,https://drive.google.com/file/d/1rbeeW6R6Ef4cQaZIbOIsnJmdHJxIGy99/view?usp=drivesdk,pd-production-070122,2025-08-11 23:26:26
125742_S1_M5_5351_c4591001-interim-mth6-excluded-patients-sensitive.pdf,PDF,Listing of Subjects Excluded From All-Available and Evaluable Efficacy Population - Blinded Placebo-Controlled Follow-up Period,2021-04-01,report,,M5,False,False,False,True,False,"C4591001, FOIA document, dose administration, blinded study, compliance, Exclusion, clinical trial, FDA, 12-15 years old, placebo-controlled, vaccine, efficacy, safety, adverse events, patient eligibility, BNT162b2, data analysis, regulatory",18,198,https://drive.google.com/file/d/15dP8MO5b7Hh6dT4JjTMmwWNc6o0ejFvJ/view?usp=drivesdk,pd-production-070122,2025-08-11 23:26:31
125742_S1_M5_5351_c4591001-interim-mth6-excluded-patients.pdf,PDF,Listing of Subjects Excluded From Immunogenicity and Safety Populations - BNT162b2 (30 μg) COVID-19 Vaccine Clinical Trial,2021-03-25,report,,M5,False,False,False,True,False,"immunogenicity, phase 1, FOIA document, data listing, pharmaceutical research, C4591001 study, data quality, Exclusion, clinical trial, protocol deviation, age groups, COVID-19 vaccine, adverse events, safety, BNT162b2, Pfizer, subject exclusion, regulatory compliance",18,6,https://drive.google.com/file/d/1hM0lRY4XOPwJSom__njp3cEWOAErzrVb/view?usp=drivesdk,pd-production-070122,2025-08-11 23:26:34
125742_S1_M5_5351_c4591001-interim-mth6-errata.pdf,PDF,"Interim Report – 6 Month Update: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals"",","2021-04-29"",",document,,M5,False,True,False,False,False,"Protocol, FOIA-document, needs-review",3,2,https://drive.google.com/file/d/1iTuteIHXL2bnsD5ewF0OCj0mL9CSKsJb/view?usp=drivesdk,pd-production-070122,2025-08-11 23:26:39
125742_S1_M5_5351_c4591001-interim-mth6-sap.pdf,PDF,Protocol C4591001 (PF-07302048) Statistical Analysis Plan,2021-03-17,protocol,,M5,False,True,False,False,False,"dose-finding, laboratory parameters, immunogenicity, phase 1/2/3, clinical trial, FDA, tolerability, placebo-controlled, randomized, observer-blind, SARS-CoV-2, efficacy, safety, RNA vaccine, COVID-19, statistical analysis plan, Protocol, adverse events",18,96,https://drive.google.com/file/d/13d55QGA_82MLsoYdF72hzVbQIxV_OfGM/view?usp=drivesdk,pd-production-070122,2025-08-11 23:26:44
125742_S1_M5_5351_c4591001-interim-mth6-lab-measurements-sensitive.pdf,PDF,Listing of Subjects With First COVID-19 Occurrence After Dose 1 - Blinded Placebo-Controlled Follow-up Period - Dose 1 All-Available Efficacy Population,2021-04-01,report,"C4591001 1003 10031122, C4591001 1003 10031167, C4591001 1003 10031186, C4591001 1003 10031204, C4591001 1005 10051341, C4591001 1005 10051358",M5,False,False,False,False,False,"C4591001, data listing, dose 1, clinical trial, symptoms, blinded, FDA, placebo-controlled, COVID-19, vaccine, United States, efficacy, safety, NAAT, adverse events, follow-up, regulatory",17,430,https://drive.google.com/file/d/135uJvHWdBwMIUmt3vC7ZnylK9EvYnGrH/view?usp=drivesdk,pd-production-070122,2025-08-11 23:26:51
125742_S1_M5_5351_c4591001-fa-interim-narrative-sensitive.pdf,PDF,C4591001 Interim Narrative Safety Report,2020-11-20,report,,M5,False,True,False,False,False,"concomitant medications, data generation, pharmaceutical development, phase 1/2 study, clinical trial, vital signs, Protocol, pfizer, safety narrative, fda submission, unblinded data, demographic information, bnt162b2 vaccine, united states, medical terminology, adverse events, data analysis, regulatory compliance",18,3611,https://drive.google.com/file/d/1LNNW3q165t0BGJy8o7offpsBGZhFNrHz/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:09
125742_S1_M5_5351_c4591001-fa-interim-sap.pdf,PDF,Protocol C4591001 (PF-07302048) Statistical Analysis Plan,2020-11-02,protocol,,M5,False,True,False,False,False,"dose-finding, Protocol, immunogenicity, fda, pharmaceutical, statistical-analysis-plan, tolerability, placebo-controlled, randomized, observer-blind, rna-vaccine, efficacy, safety, clinical-trial, sars-cov-2, confidential, covid-19, phase-1-2-3",18,59,https://drive.google.com/file/d/19OEcLFaicMyVNhKY122pbtylFqD0ayGy/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:14
125742_S1_M5_5351_c4591001-interim-mth6-protocol-deviations.pdf,PDF,Listing of Important Protocol Deviations - All Subjects ≥16 Years of Age,2021-04-01,report,"C4591001 1231, C4591001 1001, C4591001 1003, C4591001 1005, C4591001 1006, C4591001 1007, C4591001 1009, C4591001 1012, C4591001 1013, C4591001 1015, C4591001 1016, C4591001 1018",M5,False,True,False,False,False,"concomitant medication use, FDA regulatory compliance, pharmaceutical quality assurance, data quality and integrity, subject demographics (≥16 years), vaccine dosing and administration, clinical trial enrollment and retention, C4591001 clinical trial, interim data analysis, clinical trial monitoring and oversight, safety data reporting, data listing and tabulation, Protocol, clinical trial protocol deviations, pharmaceutical regulatory submission, vaccine adverse events, COVID-19 vaccine clinical trial, good clinical practice (GCP) compliance",18,68,https://drive.google.com/file/d/1mibwWOl6VkGAIwvtkASTJABUIA-zxIhS/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:20
125742_S1_M5_5351_c4591001-interim-mth6-adverse-events.pdf,PDF,Listing of Severe and Grade 4 Local Reactions (Reactogenicity Subset) – All Subjects ≥16 Years of Age – Safety Population,2021-03-25,report,,M5,False,False,False,False,False,"C4591001, SDTM, 16-55 years old, clinical trial, reactogenicity, local reactions, FDA, listing, vaccine, United States, safety, phase 4, medical terminology, adverse events, Pfizer, data analysis, regulatory compliance",17,3645,https://drive.google.com/file/d/1PTh9EcW5y72kbSLzsXJWFvR6GuTytW2o/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:29
125742_S2_M1_loa-dmf-012683-vials.pdf,PDF,Letter of Authorization for Drug Master File 012683 - Vials,2021-03-26,letter,,M1,False,False,False,False,False,"quality control, stability testing, drug product, compliance, FDA submission, sterile injectable, vials, letter of authorization, vaccine development, drug master file, safety data, United States, pharmaceutical manufacturing, adverse event reporting, clinical trial materials, regulatory approval, efficacy data",17,1,https://drive.google.com/file/d/1OrFJzGR1Y63tV7_rgSeghsIylxUb32pV/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:32
125742_S1_M5_5351_c4591001-interim-mth6-discontinued-patients.pdf,PDF,Listing of Subjects Discontinued From Vaccination and/or From the Study – All Subjects ≥16 Years of Age,2021-04-01,report,,M5,False,True,False,False,False,"C4591001, FOIA document, pharmaceutical research, data listing, subject withdrawal, clinical trial, eligibility criteria, FDA, COVID-19 vaccine, safety data, age group, regulatory compliance, Protocol, vaccination, phase 4, adverse events, follow-up, protocol deviations",18,232,https://drive.google.com/file/d/14DVqgG_r7u8vYUNPUg9I-ix-Apf6Yt-f/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:37
125742_S1_M5_5351_c4591001-interim-mth6-compliance-sensitive.pdf,PDF,Listing of Subjects Who Received Vaccine Not as Randomized – All Subjects ≥16 Years of Age,2021-03-25,report,,M5,False,False,False,False,False,"randomization, data listing, compliance, SDTM, FOIA, clinical trial, unblinded analysis, age groups, FDA, safety data, dose information, adverse events, vaccine administration, efficacy data, BNT162b2, Pfizer, regulatory submission",17,2,https://drive.google.com/file/d/180Gg8TRVk1HMzRRkOBc7LL6IPGzCfTEm/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:41
125742_S2_M1_loa-dmf-031786-vials.pdf,PDF,Letter of Authorization for Drug Master File 031786 - Vials,2021-05-10,letter,,M1,False,False,False,False,False,"supply chain, quality control, stability testing, compliance, FDA submission, vials, drug identification, letter of authorization, vaccine development, drug master file, safety data, United States, pharmaceutical manufacturing, adverse event reporting, clinical trial materials, regulatory approval, efficacy data",17,1,https://drive.google.com/file/d/12esIRzgXz0Ed-TVThjUHcPwzsZL7UIgA/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:44
125742_S2_M1_loa-dmf-011820-vials.pdf,PDF,Letter of Authorization for SCHOTT AG DMF 011820,2020-09-22,letter,Stefanie Stühmer,M1,False,False,False,False,False,"collegeville pa, quality control, pharmaceutical systems, glass vials, mullheim germany, letter of authorization, schott ag, vaccine development, dmf 011820, drug master file, pfizer, confidentiality, biontech rna pharmaceuticals, clinical trials, fda review, pharmaceutical packaging, regulatory compliance",17,1,https://drive.google.com/file/d/1BEgPR9YN-OHVXur0cqwsW2uDoydlGvo2/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:47
125742_S2_M1_loa-dmf-011793-vials.pdf,PDF,Letter of Authorization for Drug Master File 011793 - Vials,2021-03-26,Letter,,M1,False,False,False,False,False,"Pharmaceutical Manufacturing, Clinical Trials, Drug Master File 011793, Letter of Authorization, Efficacy Data, Pharmaceutical Packaging, Adverse Events, Compliance, United States, Quality Assurance, FDA Submission, Regulatory Affairs, Vials, Safety Data, Regulatory Approval, Vaccine Development, Biologics",17,1,https://drive.google.com/file/d/12IX3NqOQioVlDZ7nygQQzSG65ky099X0/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:50
125742_S1_M5_5351_c4591001-interim-mth6-efficacy-response.pdf,PDF,"Listing of Assay Data – Phase 1, 2 Doses, 21 Days Apart – BNT162b2 (30 µg)/Placebo",2021-04-01,report,,M5,False,False,False,False,False,"assay data, immunogenicity, time points, fda, data listing, vaccine groups, pharmaceutical development, clinical trial, age groups, freedom of information act, antibody levels, subject identifiers, efficacy, bnt162b2 vaccine, phase 1 study, placebo, regulatory compliance",17,5,https://drive.google.com/file/d/13L8Yl46HQpZnpQIYgfDInJCM2Woeqlx8/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:54
125742_S2_M1_right-of-reference.pdf,PDF,Statement of Right to Reference for BNT162b2 Vaccine,2021-05-12,report,"Gerresheimer Buende GmbH, Schott Hungary Kft., Schott AG, Schott North America, Inc., Schott Kaisha Private Limited, Stevanato Group S.p.A., Datwyler Pharma Packaging Belgium NV",M1,False,False,False,False,False,"pharmaceutical-manufacturing, quality-compliance, belgium, safety-data, primary-packaging, india, borosilicate-glass-vials, supply-chain, germany, bnt162b2-vaccine, regulatory-affairs, fda-submission, vaccine-development, clinical-trial, united-states, efficacy-data, drug-master-file",17,1,https://drive.google.com/file/d/10NZH8PrEl5ClONbCAIPdVBGOGx06nN-B/view?usp=drivesdk,pd-production-070122,2025-08-11 23:27:58
125742_S2_M1_com25ctpus-carton-puurs.pdf,PDF,Comirnaty 25ct Carton COM25CTPUS - Puurs,2021-04-23,product label,,"M1, M2",False,False,False,False,False,"dosage and administration, covid-19 vaccine, product labeling, pharmaceutical product, puurs manufacturing site, discard after 6 hours, comirnaty, storage requirements, pfizer, biontech, intramuscular injection, suspension for injection, no preservative, multiple dose vial, dilution instructions, manufacturing, fda regulatory",17,1,https://drive.google.com/file/d/1uY429pSZ25IXYuGCMp6lqh2OUfbd9Hbr/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:01
125742_S2_M5_5354_wi235284-protocol.pdf,PDF,Determining RSV Burden and Outcomes in Pregnant Women and Older Adults Requiring Hospitalization,2021-03-23,protocol,,M5,False,True,False,True,False,"study population, Exclusion, clinical trial, respiratory syncytial virus, covid-19, adverse events, data analysis, regulatory, public health, older adults, pregnant women, inclusion/exclusion criteria, vaccine effectiveness, epidemiology, study objectives, Protocol, study methods, medical research, hospitalization",19,60,https://drive.google.com/file/d/1rqds5bf0CZV3Y3-Bq4c5V-2ESim95DIe/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:08
125742_S2_M1_com25ctkz-carton-kzoo.pdf,PDF,"Comirnaty (COVID-19 Vaccine, mRNA) Carton Label",2021-04-23,label,,"M1, M2",False,False,False,False,False,"global-distribution, covid-19-vaccine, regulatory-compliance, comirnaty, dosage-and-administration, intramuscular-injection, fda-approval, sterile-diluent, multiple-dose-vial, discard-after-use, quality-control, patient-safety, carton-label, storage-conditions, mrna-vaccine, lot-number-and-expiration, manufacturing-information",17,1,https://drive.google.com/file/d/1V-T8Ko-Xj5osx0AKg2aIIv3Q5JCTTfMZ/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:11
125742_S2_M1_comvlabkz-vial-kzoo.pdf,PDF,"Comirnaty (COVID-19 Vaccine, mRNA) Vial Label",2021-03-22,label,"BioNTech Manufacturing GmbH, Pfizer Inc.",M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, quality control, storage conditions, drug product, pharmaceutical, manufacturing, date and time, clinical trial, comirnaty, vial label, lot/expiration, dosage information, product identification, geographic location, fda approval, regulatory compliance",17,1,https://drive.google.com/file/d/1JEOUbCuPr-bjJFbuANlAZDLoHuIyb8p6/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:15
125742_S2_M1_fk-diluent-stamp.pdf,PDF,Diluent Stamp for FK Vaccine,2021,report,,M1,False,False,False,False,False,"cber-document, pharmaceutical-research, freedom-of-information, fda-submission, regulatory-compliance, manufacturing-process, vaccine-identifier, safety-data, quality-control, efficacy-data, adverse-events, product-labeling, vaccine-development, clinical-trial, document-release, diluent-information, product-stamp",17,1,https://drive.google.com/file/d/1nT7LsX_GG47zAHWpeZfKBLl9IBSdWyvh/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:18
125742_S2_M1_comvlabp-vial-puurs.pdf,PDF,"Comirnaty (COVID-19 Vaccine, mRNA) Vial Label",2021-03-22,label,"BioNTech Manufacturing GmbH, Pfizer Inc.",M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, foia document, puurs manufacturing site, manufacturing, clinical trial, drug identification, intramuscular administration, lot number, comirnaty, vial label, storage requirements, dosage information, expiration date, fda approval, gmp compliance, regulatory compliance",17,1,https://drive.google.com/file/d/1xOcqITOfJ5fPAN6D6xw9KsPkRc2ajNXP/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:20
125742_S2_M1_fk-diluent-carton.pdf,PDF,Diluent Carton Labeling for FK Vaccine,2021,report,,M1,False,False,False,False,False,"diluent carton labeling, quality control, storage conditions, FDA submission, pharmaceutical development, vaccine formulation, phase 1/2 study, adverse event monitoring, manufacturing process, CBER, regulatory compliance, safety profile, United States, clinical trial materials, drug product information, efficacy data, FK vaccine",17,1,https://drive.google.com/file/d/1K8eyhqiSnwpKDs-1mT6j8G9_tK0UbwQh/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:23
125742_S2_M1_loa-dmf-011321-vials.pdf,PDF,Letter of Authorization for DMF Type III #011321,2020-08-25,letter,Andrea Salmaso,M1,False,False,False,False,False,"piombino dese, italy, silver spring, maryland, quality compliance, sars-cov-2 mrna vaccine, dmf type iii, letter of authorization, clinical trial materials, stevanato group, fda submission, collegeville, pennsylvania, pharmaceutical manufacturing, document control, drug product information, vial specifications, regulatory affairs, pfizer inc., biontech rna pharmaceuticals",17,1,https://drive.google.com/file/d/1UCLyrSulRS0Vf0BpQQnerFLVVtCamO7Q/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:27
125742_S2_M1_loa-dmf-10953-stopper.pdf,PDF,Letter of Authorization for DMF 10953,2020-09-17,letter,"Renaud Janssen, Tabassam Sharif",M1,False,False,False,False,False,"bla application, collegeville pa, fda, datwyler pharma packaging belgium, compliance, sars-cov-2 mrna vaccine, letter of authorization, quality, vaccine development, drug master file, rubber compounds, pfizer, biontech, dmf 10953, regulatory affairs, pharmaceutical packaging, clinical trials",17,2,https://drive.google.com/file/d/12iSb7kIBvFNB3LAMYQmmio1n1oYyg0oV/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:32
125742_S2_M1_hospira-diluent-label.pdf,PDF,Comirnaty Diluent Label,2021-05-10,label,,M1,False,False,False,False,False,"covid-19 vaccine, diluent, mrna vaccine, fda, drug product, pharmaceutical, quality control, compliance, clinical trial, label, comirnaty, nucleoside modified, efficacy, safety, adverse events, regulatory approval, manufacturing",17,1,https://drive.google.com/file/d/1PCm3vK9VKGIp49AWvSaxFbHMLNZs_zWg/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:35
125742_S2_M1_hospira-diluent-carton.pdf,PDF,Hospira Diluent Carton Labeling,2021,regulatory submission,,M1,False,False,False,False,False,"quality control, diluent, carton labeling, drug product, pharmaceutical product, FDA submission, compliance, product labeling, clinical trial, CBER, safety data, United States, adverse events, Hospira, medical device, regulatory approval, efficacy data",17,1,https://drive.google.com/file/d/1nByX1EpqTxVUwHmgeTQOsQ3-6UDRbs03/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:38
125742_S2_M1_com195lkz-carton-kzoo.pdf,PDF,Comirnaty Carton Label - Kzoo,2021-04-23,label,,M1,False,False,False,False,False,"expiration, BioNTech, pharmaceutical, clinical trial, carton label, Pfizer, FDA, lot number, intramuscular injection, COVID-19, vaccine, Comirnaty, storage, dosage, administration, manufacturing, regulatory",17,1,https://drive.google.com/file/d/1PCLQIobvw2Z80FXjyPZd9H39U1gv-5kY/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:41
125742_S2_M1_com195lpus-carton-puurs.pdf,PDF,Comirnaty Carton Label COM195LPUS - Puurs,2021-04-23,label,,M1,False,False,False,False,False,"clinical-trial-materials, covid-19-vaccine, regulatory-compliance, dosage-administration, lot-number-expiration, puurs-belgium, no-preservative, pharmaceutical-label, comirnaty, quality-control, intramuscular-injection, suspension-formulation, multiple-dose-vial, pfizer-biontech, storage-conditions, fda-approval, manufacturing",17,1,https://drive.google.com/file/d/1tXD24TWQABg7IvXkIbOYYQFC8dTKvdjv/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:45
FDA-CBER-2021-5683-0285652 to -0286071_125742_S1_M5_c4591001-S-D-pe.xpt,XPT,FDA-CBER-2021-5683-0285652 to -0286071 125742 S1 M5 c4591001-S-D-pe,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1JgppA70nRA6j49rRMmuBlWRhpUTNN344/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:47
FDA-CBER-2021-5683-0282366 to -0285643_125742_S1_M5_c4591001-S-D-mb.xpt,XPT,FDA-CBER-2021-5683-0282366 to -0285643 125742 S1 M5 c4591001-S-D-mb,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1Hp2XgGwgcIU-haQkEB9ztgZJYgqbcAAV/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:50
FDA-CBER-2021-5683-0285644 to -0285651_125742_S1_M5_c4591001-S-D-mo.xpt,XPT,FDA-CBER-2021-5683-0285644 to -0285651 125742 S1 M5 c4591001-S-D-mo,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1WvFwBUjqKQXAVr4oFcIfiC-izlhueVuU/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:52
FDA-CBER-2021-5683-0286072 to -0286266_125742_S1_M5_c4591001-S-Supp-D-relrec.xpt,XPT,FDA-CBER-2021-5683-0286072 to -0286266 125742 S1 M5 c4591001-S-Supp-D-relrec,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1bNdudfP98nvF4ZL2z8uFKZ6-xuHssm7k/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:53
FDA-CBER-2021-5683-0296904 to -0307543_125742_S1_M5_c4591001-S-D-suppce.xpt,XPT,FDA-CBER-2021-5683-0296904 to -0307543 125742 S1 M5 c4591001-S-D-suppce,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1e-lrtUf1U9RrpjucWi5t8Pn_FQq_eck9/view?usp=drivesdk,pd-production-070122,2025-08-11 23:28:58
FDA-CBER-2021-5683-0286267 to -0296903_125742_S1_M5_c4591001-S-Supp-D-suppce.xpt,XPT,FDA-CBER-2021-5683-0286267 to -0296903 125742 S1 M5 c4591001-S-Supp-D-suppce,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1dI8YktL16S7RZB8mS6HDVA_WPBwGVzX8/view?usp=drivesdk,pd-production-070122,2025-08-11 23:29:04
FDA-CBER-2021-5683-0225100 to -0225597_125742_S1_M5_c4591001-A-D-adcm.xpt,XPT,FDA-CBER-2021-5683-0225100 to -0225597 125742 S1 M5 c4591001-A-D-adcm,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/15pTnduhpC6j9KZHDX3oLLhXA3in-6xw3/view?usp=drivesdk,pd-production-070122,2025-08-11 23:29:09
FDA-CBER-2021-5683-0225598 to -0282129_125742_S1_M5_c4591001-A-Supp-D-adfacevd.xpt,XPT,FDA-CBER-2021-5683-0225598 to -0282129 125742 S1 M5 c4591001-A-Supp-D-adfacevd,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1NDlw1lWqIVTWOt_S-1ZKfEeooRLWuIKN/view?usp=drivesdk,pd-production-070122,2025-08-11 23:30:57
FDA-CBER-2021-5683-0282130 to -0282328_125742_S1_M5_c4591001-S-D-cm.xpt,XPT,FDA-CBER-2021-5683-0282130 to -0282328 125742 S1 M5 c4591001-S-D-cm,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1OpprTHmWB76slT9JN2LYor5VFzwNt-st/view?usp=drivesdk,pd-production-070122,2025-08-11 23:30:59
FDA-CBER-2021-5683-0282329 to -0282365_125742_S1_M5_c4591001-S-D-ie.xpt,XPT,FDA-CBER-2021-5683-0282329 to -0282365 125742 S1 M5 c4591001-S-D-ie,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1U6VSegO2MRQAVlxgX9lT-qS-gkHsf83Q/view?usp=drivesdk,pd-production-070122,2025-08-11 23:31:00
125742_S1_M5_CRF_c4591001-1027-10271191.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"quality control, Exclusion, clinical trial, safety data, United States, adverse events, regulatory, pharmaceutical, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, medical research, demography, efficacy data",19,637,https://drive.google.com/file/d/14orQzCgVl3CAYtvvyg-jacHpVLYgBE1_/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:06
125742_S1_M5_CRF_C4591001-1019-10191037.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data",19,363,https://drive.google.com/file/d/1nLYthiZfzSx-rXaURvCDq9pzvKQlOnPy/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:10
125742_S1_M5_CRF_c4591001-1019-10191071.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, diagnostics research group, CRF, subject information, informed consent, visit date, Protocol, vaccine, c4591001, eCRF, data management, demography",20,165,https://drive.google.com/file/d/1spfdb84-dnR27NsCz3SdpN2x6VP3Tn0A/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:14
125742_S1_M5_CRF_c4591001-1019-10191010.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1019) Diagnostics Research Group,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, demography, safety",19,707,https://drive.google.com/file/d/1EClwV8hb8C7rRmBdPvPw_Y0-4eBIqNYd/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:20
125742_S1_M5_CRF_c4591001-1019-10191021.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1019) Diagnostics Research Group,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory, fda, compliance, cohort selection, inclusion/exclusion criteria, crf, diagnostics research group, 2020, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data",20,174,https://drive.google.com/file/d/1tmiyPqQPeLkNYJnPvthQNd-kc94zvjRa/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:23
125742_S1_M5_CRF_c4591001-1019 -10191002.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, informed consent, visit date, FDA, Protocol, data management, subject identification, efficacy data",19,194,https://drive.google.com/file/d/1dXNScEl3KxuJW8wmFsQPws4kDp63gsoQ/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:27
125742_S1_M5_CRF_c4591001-1019-10191146.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, united states, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, diagnostics research group, phase 2/3 study, CRF, covid-19 vaccine, informed consent, safety monitoring, visit date, Protocol, c4591001, demography, efficacy data",20,151,https://drive.google.com/file/d/1DZhJyPxbo6n3Hoo9OoFI0a-5Gx7rFH-o/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:30
125742_S1_M5_CRF_c4591001-1019-10191229.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, Pfizer, demography, safety",19,316,https://drive.google.com/file/d/1NK9i-33Wc247hTFIuQFMByGrpey3-jD9/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:35
125742_S1_M5_CRF_c4591001-1019-10191145.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, inclusion/exclusion criteria, diagnostics research group, phase 2/3 study, vaccine identifier c4591001, CRF, audit trail, covid-19 vaccine, informed consent, date of visit, visit schedule, Protocol, subject demographics, data collection",20,372,https://drive.google.com/file/d/1ez9WxDtnvF0VZLeQV88QFOMb1CeTXHWJ/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:40
125742_S1_M5_CRF_c4591001-1019-10191226.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, diagnostics research group, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, subject identification, efficacy data",20,382,https://drive.google.com/file/d/1OBGlRBwM0GjUjkD5SF9lCNC7iT8h_zon/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:44
125742_S1_M5_CRF_c4591001-1019-10191254.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1019) Diagnostics Research Group,M5,True,True,False,True,False,"Exclusion, clinical trial, united states, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, clinical research form, efficacy, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography",20,160,https://drive.google.com/file/d/1gjXguxQr-epDs7UBkDZ1_Kk-qGdqeV9w/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:48
125742_S1_M5_CRF_c4591001-1021-10211044.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, informed consent, visit details, FDA, Protocol, Pfizer, data management, demography, data collection",19,201,https://drive.google.com/file/d/1B1ent5jlnoBc8AvPV7v4VL8DFOMcnzpd/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:52
125742_S1_M5_CRF_c4591001-1019-10191215.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Diagnostics Research Group, Protocol, subject details, c4591001, demography, data collection",20,213,https://drive.google.com/file/d/1D8xZGZA13-SnGmx0YqnXI3zKsZsfinON/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:56
125742_S1_M5_CRF_c4591001-1021-10211081.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, clinical research, informed consent, visit date, FDA, Protocol, medical research, demography, subject identification, data collection",19,176,https://drive.google.com/file/d/1zfXD1E69VlWKZaFSaRRIOFxsC0dWRJme/view?usp=drivesdk,pd-production-070323,2025-08-11 23:31:59
125742_S1_M5_CRF_c4591001-1022-10221024.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, wenatchee valley hospital, confidential document, data collection",20,418,https://drive.google.com/file/d/1UMF_nAszTtSTvxKkU5xRGmmoniOiPPXz/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:04
125742_S1_M5_CRF_c4591001-1021-10211190.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory, PMG Research of Raleigh, compliance, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, FDA, Protocol, vaccine, c4591001, demography, case report form, efficacy data",20,163,https://drive.google.com/file/d/10xG8nGTIvjeTgpqAI4I1d78Lhx3j_HQU/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:08
125742_S1_M5_CRF_c4591001-1021-10211127.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory, data quality, inclusion/exclusion criteria, data compliance, COVID-19 vaccine, safety and efficacy, phase 2/3 study, CRF, subject data, informed consent, visit date, FDA, Protocol, Pfizer, demography",19,180,https://drive.google.com/file/d/17bgTie2Sf8E8VCvBluAkOQQeaThibNtR/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:12
125742_S1_M5_CRF_c4591001-1021-10211181.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, PMG Research of Raleigh, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Protocol, Pfizer, data management, demography",19,235,https://drive.google.com/file/d/14ZS8WNWh2s3YvSnYCZvYrfy6eiWphfAG/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:16
125742_S1_M5_CRF_c4591001-1021-10211084.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit schedule, FDA, Protocol, subject details, Pfizer, data management, demography, data collection",19,186,https://drive.google.com/file/d/1KDlkpBJ_h3_21ea8RMygot6MzrHOjyU9/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:19
125742_S1_M5_CRF_c4591001-1039-10391010.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Wilson Parke, safety and efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, ARC Clinical Research, demography, subject identification, data collection",19,466,https://drive.google.com/file/d/11RT1vWt7Rlrat4HkpyFJXvhoU9Ehd8K3/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:24
125742_S1_M5_CRF_c4591001-1028-10281060.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"subject 10281060, Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, demography, Lillestol Research LLC",19,280,https://drive.google.com/file/d/1-BdX4bC8QpMFQcPXJ6nuKMfxqDQfeFA9/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:28
125742_S1_M5_CRF_c4591001-1039-10391075.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, United States, regulatory, data quality, pharmaceutical, inclusion/exclusion criteria, data compliance, COVID-19 vaccine, phase 2/3 study, CRF, subject data, clinical research, informed consent, visit date, FDA, Protocol, demography",19,334,https://drive.google.com/file/d/1_vIedn4xC-vCS8sPTwImko038LVbbUcm/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:33
125742_S1_M5_CRF_c4591001-1030-10301110.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,Clinical Trial Form,(1030) University Hospital of Cleveland,M5,True,True,False,True,False,"Exclusion, Inclusion/Exclusion Criteria, Clinical Trial Phase 2/3, Clinical Trial Form, Demography, Adverse Event Monitoring, Subject Identification, FDA Submission, Safety Data, CRF, Data Verification, Confidential Document, Protocol, Regulatory Compliance, University Hospital of Cleveland, Visit Date, Informed Consent, Cohort Selection, COVID-19 Vaccine Trial, Efficacy Data",20,366,https://drive.google.com/file/d/1wQjY6Pjp73hrcVQNqtrDteO6XmAkm2Fq/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:37
125742_S1_M5_CRF_c4591001-1028-10281283.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-27,form,Lillestol Research LLC,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, c4591001 trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, Pfizer-BioNTech vaccine, CRF, subject enrollment, FDA submission, informed consent, adverse event monitoring, visit date, Protocol, data management, demography data",20,191,https://drive.google.com/file/d/1JE9Anr1bLtqsfbahhM12erj9Uca-zTjc/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:42
125742_S1_M5_CRF_c4591001-1039-10391039.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, FOIA document, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,171,https://drive.google.com/file/d/1JJkQLFh4tlpi7GBw9tSE-Zb18Ps0XwnM/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:46
125742_S1_M5_CRF_c4591001-1038-10381051.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, Holston Medical Group, adverse events, regulatory compliance, subject 10381051, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, data management, demography, efficacy data, data collection",19,305,https://drive.google.com/file/d/1LqeWd4jG1TzGBxtEYVNfMnb9DmHjJKoS/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:51
125742_S1_M5_CRF_c4591001-1030-10301059.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1030) University Hospital of Cleveland,M5,True,True,False,True,False,"university hospital, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data",20,172,https://drive.google.com/file/d/1MKrt0LzMg8RCtCoDc5vsppk2GoVD4Rqn/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:55
125742_S1_M5_CRF_c4591001-1028-10281033.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,Lillestol Research LLC,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, c4591001 trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, demographic data, FDA submission, informed consent, visit schedule, Protocol, data management, subject identification, adverse event reporting, electronic case report form",20,155,https://drive.google.com/file/d/1aekbREMOKETCoeHqfSHSUJYZHj_Z_uVB/view?usp=drivesdk,pd-production-070323,2025-08-11 23:32:58
125742_S1_M5_CRF_c4591001-1038-10381050.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Holston Medical Group, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, Pfizer, eCRF, demography, subject identification",20,237,https://drive.google.com/file/d/1XRftcfY5tsPVyqiBKiCrKpAL67gc_bjW/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:02
125742_S1_M5_CRF_c4591001-1038-10381101.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1038) Holston Medical Group,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Protocol, c4591001, eCRF, medical site, demography",19,146,https://drive.google.com/file/d/1DnNHUsSx1jR7RlPjdmHxCoXOlE_oiCRC/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:06
125742_S1_M5_CRF_c4591001-1028-10281083.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, visit date, FDA, Protocol, Pfizer, demography, safety",19,146,https://drive.google.com/file/d/1VKhCyJwxyHgYcWVK3e7DcxONMJMTY2v1/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:15
125742_S1_M5_CRF_c4591001-1027-10271105.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, c4591001, PharmQuest, data management, demography, efficacy data, data collection",20,277,https://drive.google.com/file/d/1QUMtcKtOuK8QeeSSrRmcOu_zIHn3Ulzj/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:19
125742_S1_M5_CRF_c4591001-1037-10371214.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1037) CNS Healthcare Memphis,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Memphis, CRF, informed consent, visit date, FDA, Protocol, data verification, data lock, eCRF, demography, subject identification",19,153,https://drive.google.com/file/d/1S3vgKuB_N246vbcRGkIVfka_Os5iOCpc/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:22
125742_S1_M5_CRF_c4591001-1039-10391012.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Wilson Parke, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, data integrity, ARC Clinical Research, data management, subject identification",19,142,https://drive.google.com/file/d/1MdjQdwi50sIgFokb1D9whqvWag2-vTk_/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:26
125742_S1_M5_CRF_c4591001-1022-10221108.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, Wenatchee Valley Hospital, CRF, subject enrollment, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, data management, demography",19,172,https://drive.google.com/file/d/1orO4-i2Z0VRxGnTAPzOfMq_iBqoGu1Vo/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:30
125742_S1_M5_CRF_c4591001-1028-10281205.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit schedule, Protocol, c4591001, lillestol research, demography, subject identification",20,296,https://drive.google.com/file/d/17cfj6TvYzGBGIFJM98vARGyYGuYnewLv/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:34
125742_S1_M5_CRF_c4591001-1028-10281028.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, lillestol research, demography, efficacy data",20,179,https://drive.google.com/file/d/16ufYOeN-lHSRQfdwSkbOknNyTDKPEgu_/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:38
125742_S1_M5_CRF_c4591001-1037-10371052.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, Memphis, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, eCRF, demography, subject identification, data collection",19,259,https://drive.google.com/file/d/1kZj2Mr7JlMcdNJ6bq6-MTb--bb9U2y6n/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:42
125742_S1_M5_CRF_c4591001-1028-10281059.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, visit date, FDA, Protocol, Pfizer, demography, safety",19,200,https://drive.google.com/file/d/1-7MUmljQQa9uyDRUa4dQZk9B2xsLDvwU/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:45
125742_S1_M5_CRF_c4591001-1037-10371141.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, CNS Healthcare Memphis, c4591001 trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, subject 10371141, phase 2/3 study, CRF, eCRF audit trail, FDA submission, informed consent, visit date, Protocol, clinical data management, demography data, confidential document",20,162,https://drive.google.com/file/d/1dUMNvYClDqG-zeay7xjVLutRU3KDiRtB/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:49
125742_S1_M5_CRF_c4591001-1027-10271054.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, PharmQuest site, phase 2/3 study, CRF, demographic data, eCRF audit trail, informed consent, visit date, Protocol, c4591001 protocol, subject identification, confidential document, data collection",20,203,https://drive.google.com/file/d/1_fnUouvQVdirM-wIcF0OsYccVANJA065/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:52
125742_S1_M5_CRF_c4591001-1022-10221164.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, data quality control, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, racial/ethnic diversity, phase 2/3 study, CRF, informed consent, visit date, Protocol, c4591001 protocol, Wenatchee Valley Hospital Clinics, FOIA release, demography data, subject identification, electronic case report form (eCRF), confidential document",20,197,https://drive.google.com/file/d/1mED2SLwRkN_8cyDVgo8ShprpsRvqAxBy/view?usp=drivesdk,pd-production-070323,2025-08-11 23:33:56
125742_S1_M5_CRF_c4591001-1028-10281003.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, united states, adverse events, data audit, regulatory compliance, pharmaceutical research, fda, data quality, cohort selection, phase 2/3 study, CRF, covid-19 vaccine, clinical research, informed consent, Protocol, subject demographics, medical terminology, data collection",20,174,https://drive.google.com/file/d/1Umhv6TJfEzemnsxYZc1Nltqyo6oPSiyl/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:00
125742_S1_M5_CRF_c4591001-1022-10221142.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Wenatchee Valley Hospital, CRF, subject information, informed consent, visit date, FDA, Protocol, Pfizer, demography, efficacy data",19,203,https://drive.google.com/file/d/1xsUuWo5T_5ZKHHXXbcoZ3YxAU9KrXHdD/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:03
125742_S1_M5_CRF_c4591001-1022-10221053.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, Wenatchee Valley Hospital, CRF, subject data, informed consent, visit date, FDA, Protocol, Pfizer, demography, data collection",19,397,https://drive.google.com/file/d/1mfdnvuvOmkG1oY520kpDtKPYncWje70i/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:08
125742_S1_M5_CRF_c4591001-1037-10371318.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, Memphis, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, demography, clinical data, subject identification, data collection",19,129,https://drive.google.com/file/d/15cbsuTpc5SzmSwJ2imGxn5n1unFEAC_t/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:16
125742_S1_M5_CRF_c4591001-1039-10391038.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, FDA submission, informed consent, adverse event monitoring, visit date, Protocol, Wilson Parke site, ARC Clinical Research, demography data, subject identification",20,383,https://drive.google.com/file/d/1YUJlhvCzN9Np9NW0GpZEU9cWmpZN5r5X/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:21
125742_S1_M5_CRF_c4591001-1044-10441139.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,Clinical Research Form (CRF),,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, regulatory compliance, pharmaceutical research, Virginia Research Center, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, informed consent, visit date, Protocol, subject identification, confidential document",20,184,https://drive.google.com/file/d/1CZ0UCH8CKUk9fFmmCQ-08JolGIJ2zN1x/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:25
125742_S1_M5_CRF_c4591001-1046-10461175.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, demographic data, subject enrollment, informed consent, visit schedule, Protocol, data verification, north alabama research center, data lock, subject identification, electronic case report form",20,386,https://drive.google.com/file/d/16MKY0DTrOac4rKHWgqBdgbV_COVk3iL1/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:30
125742_S1_M5_CRF_c4591001-1048-10481088.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,(1048) The Pain Center of Arizona,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, data quality control, regulatory compliance, pharmaceutical research, Arizona, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, FDA submission, informed consent, visit schedule, Protocol, medical terminology, data management, subject identification, adverse event reporting",20,159,https://drive.google.com/file/d/1-QbmYs5L0-Y0sRCSdNlFtZiKEoab6sWw/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:34
125742_S1_M5_CRF_c4591001-1047-10471254.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, medical research center, c4591001, demography, subject identification, efficacy data",20,195,https://drive.google.com/file/d/1IrpIgJt71phqF5uG_wk0ZbTRx7jX7fbY/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:38
125742_S1_M5_CRF_c4591001-1047-10471252.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,form,"Subject No: 10471252, Subject Initials: ---",M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, informed consent, visit date, FDA, Protocol, medical research center, c4591001, data management, demography, data collection",20,546,https://drive.google.com/file/d/1QoQ_foHsPpTLk6ryqmMy8iYzObA4fqVx/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:44
125742_S1_M5_CRF_c4591001-1042-10421034.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, HealthFirst Medical Group, FDA, visit date, Protocol, c4591001, demography, efficacy data",20,404,https://drive.google.com/file/d/1wd3-RvjjpQXJj0cgHN5jpO-Nc9IgdBB0/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:48
125742_S1_M5_CRF_c4591001-1042-10421259.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, HealthFirst Medical Group, FDA, visit date, Protocol, c4591001, eCRF, demography, safety",20,144,https://drive.google.com/file/d/1jZ5gmosw3ak7d0Qlr_z-iALW2xDWaRY0/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:52
125742_S1_M5_CRF_c4591001-1048-10481104.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, the pain center of arizona, confidential, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, safety and efficacy, subject 10481104, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography",20,287,https://drive.google.com/file/d/1t-cPgGTUPdF9csPvB6DgA0Ei7-RqaeCk/view?usp=drivesdk,pd-production-070323,2025-08-11 23:34:56
125742_S1_M5_CRF_c4591001-1044-10441111.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(b) (6),M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, Virginia Research Center, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, demography, subject identification, efficacy data",19,159,https://drive.google.com/file/d/1yDHFbqQWJjv7c3SmjjO10PT_PWtVu_PG/view?usp=drivesdk,pd-production-070323,2025-08-11 23:35:05
125742_S1_M5_CRF_c4591001-1042-10421217.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, HealthFirst Medical Group, Protocol, demography, subject identification, safety, data collection",19,672,https://drive.google.com/file/d/1jZHGoodQZvx9ji1k07LoqG41opg7X4He/view?usp=drivesdk,pd-production-070323,2025-08-11 23:35:10
125742_S1_M5_CRF_c4591001-1047-10471194.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, visit documentation, cohort selection, efficacy, CRF, informed consent, FDA, Protocol, vaccine, medical research center, c4591001, demography, subject identification, safety, data collection",20,366,https://drive.google.com/file/d/1E4n39vFgEOovGi9X915fXzEPeSogP-eR/view?usp=drivesdk,pd-production-070323,2025-08-11 23:35:15
125742_S1_M5_CRF_c4591001-1054-10541067.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, Collaborative Neuroscience Network, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, Pfizer, demography, subject identification",19,192,https://drive.google.com/file/d/1_81WvP8fslIBe4qPl_ZOkypDSubYTnOP/view?usp=drivesdk,pd-production-070323,2025-08-11 23:35:19
125742_S1_M5_CRF_c4591001-1044-10441093.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, subject 10441093, demography, clinical data, data collection, virginia research center",20,152,https://drive.google.com/file/d/1r_p5a1HTT7_yUMSm0ETGvlIDzGIf-Hx5/view?usp=drivesdk,pd-production-070323,2025-08-11 23:35:29
125742_S1_M5_CRF_c4591001-1042-10421129.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, CRF, subject data, informed consent, visit date, FDA, Protocol, medical terminology, demography",19,152,https://drive.google.com/file/d/10CW6ooqw_Gw9dZ0rt-vj6M1xHI_Rpijp/view?usp=drivesdk,pd-production-070323,2025-08-11 23:35:33
125742_S1_M5_CRF_c4591001-1048-10481032.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, The Pain Center of Arizona, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, Arizona location, phase 2/3 study, CRF, eCRF audit trail, FDA submission, informed consent, visit date, Protocol, demography data, subject identification, confidential document",20,302,https://drive.google.com/file/d/1bUWuKcG-E0RErYri_tkMnt_1kPtYKexr/view?usp=drivesdk,pd-production-070323,2025-08-11 23:35:37
125742_S1_M5_CRF_c4591001-1046-10461046.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"North Alabama Research Center, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, demographic data, informed consent, visit date, FDA, Protocol, data integrity, data management, subject identification",19,151,https://drive.google.com/file/d/1fC3gCac-AU_FEa4o_VIy5nD0Aqs0D86H/view?usp=drivesdk,pd-production-070323,2025-08-11 23:35:41
125742_S1_M5_CRF_c4591001-1044-10441163.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory, Virginia Research Center, compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, safety, data collection",19,174,https://drive.google.com/file/d/1PHUk3JEkvumcQy7lbRPGo0PbVh3bsU_n/view?usp=drivesdk,pd-production-070323,2025-08-11 23:35:45
125742_S1_M5_CRF_c4591001-1047-10471189.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject enrollment, informed consent, FDA, Protocol, medical research center, data management, demography, safety, data collection",19,184,https://drive.google.com/file/d/1mxhYxzuJU4e0JzYNP5yyhY-D9VQJI1Sd/view?usp=drivesdk,pd-production-070323,2025-08-11 23:35:48
125742_S1_M5_CRF_c4591001-1047-10471012.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, electronic case report form (ecrf), cohort selection, protocol amendment, phase 2/3 study, CRF, audit trail, covid-19 vaccine, demographic data, subject enrollment, informed consent, visit schedule, Protocol, medical affiliated research center, data lock",20,192,https://drive.google.com/file/d/18NbeBX6aJ5FSepncTx62NmCpYh_jq2gM/view?usp=drivesdk,pd-production-070323,2025-08-11 23:35:53
125742_S1_M5_CRF_c4591001-1052-10521172.pdf,PDF,Clinical Trial Case Report Form,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, regulatory-compliance, adverse-events, clinical-trial, subject-demographics, CRF, covid-19-vaccine, visit-schedule, informed-consent, cohort-selection, data-management, Protocol, phase-2-3, efficacy-data, united-states, case-report-form, eCRF, data-quality, fda-submission, long-beach-clinical-trials",20,1141,https://drive.google.com/file/d/1xalsKayWyCDYnN95hV6aK72Px5zP4Lbt/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:00
125742_S1_M5_CRF_c4591001-1047-10471114.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, medical research center, c4591001, demography, efficacy data, data collection",20,185,https://drive.google.com/file/d/13mfWVOTW3TDGe-1ozXagm9sJNYQSHn0B/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:04
125742_S1_M5_CRF_c4591001-1047-10471318.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-14,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, FDA submission, informed consent, visit date, Protocol, data verification, medical research center, subject demographics, c4591001 protocol, eCRF, adverse event reporting, data freezing",20,147,https://drive.google.com/file/d/1ywoIgBJxAB_sferjiC6VSEYiaLRsSj8R/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:07
125742_S1_M5_CRF_c4591001-1046-10461118.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"North Alabama Research Center, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, pharmaceutical, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, FOIA, FDA, Protocol, demography, safety",19,153,https://drive.google.com/file/d/18sxGDq3uyPgtuJhNYQTv6gZQUdo6g8OU/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:11
125742_S1_M5_CRF_c4591001-1044-10441152.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, regulatory, fda, compliance, crf, efficacy, adverse-events, clinical-trial, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, phase-2-3, visit-date, virginia-research-center, demography, safety",20,230,https://drive.google.com/file/d/1jQwsl1KsEO3Ej4O3Q3PjvigyuBMP9Hhu/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:15
125742_S1_M5_CRF_c4591001-1042-10421166.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, inclusion/exclusion criteria, phase 2/3 study, CRF, audit trail, covid-19 vaccine, subject data, informed consent, visit date, Protocol, healthcare provider, medical group, data management, demography",20,202,https://drive.google.com/file/d/1J-iOS1E39yc6f5xNVgd5qned9T_qkxSK/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:19
125742_S1_M5_CRF_c4591001-1039-10391120.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory submission, data quality, cohort selection, inclusion/exclusion criteria, data compliance, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, clinical data management, ARC Clinical Research, subject identification, confidential document",19,220,https://drive.google.com/file/d/1gtteY0HImE2tY31B7juaP5oZELAMB5CK/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:23
125742_S1_M5_CRF_c4591001-1046-10461009.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, clinical research form, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, north alabama research center, demography, data collection",20,203,https://drive.google.com/file/d/1TKdKMbw800pwnqBWUD_R3y5uPgu1I7Jj/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:27
125742_S1_M5_CRF_c4591001-1047-10471290.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, phase 2/3 study, CRF, subject information, informed consent, visit date, FDA, Protocol, medical research center, c4591001, demography, data collection",20,221,https://drive.google.com/file/d/1cxz6x3BU9bdLSNubEE82z-6IOLUNNn7r/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:32
125742_S1_M5_CRF_c4591001-1044-10441194.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,clinical trial protocol,(1044) Virginia Research Center,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, United States, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, medical research, demography, subject identification, data collection",20,679,https://drive.google.com/file/d/1j-w76mdGKjIBZVKHqxP9dl3mLvvLWowN/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:37
125742_S1_M5_CRF_c4591001-1042-10421023.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, HealthFirst Medical Group, FDA, visit date, Protocol, c4591001, data management, demography, subject identification, data collection",20,469,https://drive.google.com/file/d/1X76c-GZ4Ufy8bS7vdxRC1g4FXUA1PH-J/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:42
125742_S1_M5_CRF_c4591001-1090-10901354.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,clinical trial form,"Wake Research Associates, LLC",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, data quality control, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, FDA submission, pharmaceutical development, informed consent, Protocol, c4591001 protocol, medical research, clinical data collection, data management, demography data, subject identification, adverse event reporting",20,154,https://drive.google.com/file/d/1GLXgAu0I98T1pACqE9gPHhmAI7_AYdG_/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:46
125742_S1_M5_CRF_c4591001-1090-10901492.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-09,form,"Wake Research Associates, LLC",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, subject information, covid-19 vaccine, clinical research, pharmaceutical development, informed consent, visit date, Protocol, c4591001, vaccine research, demography, data collection",20,220,https://drive.google.com/file/d/14qEqyjMBBNTvO8Tn2VmRvdH0RhLYZUaq/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:50
125742_S1_M5_CRF_c4591001-1057-10571137.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1057) CNS Healthcare Jacksonville,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, demography, subject identification, efficacy data, Jacksonville, FL",19,216,https://drive.google.com/file/d/1n8QgRDi3k2M-r2C_Ou3bqVCY--2MycZ2/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:54
125742_S1_M5_CRF_c4591001-1071-10711023.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Trial Form,(1071) Quality Clinical Research,M5,True,True,False,True,False,"quality control, Exclusion, clinical trial, safety data, United States, adverse events, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, efficacy data, data collection",20,141,https://drive.google.com/file/d/1iZwel5sLTicIWtwKFudVjXtBpkW9Zshe/view?usp=drivesdk,pd-production-070323,2025-08-11 23:36:58
125742_S1_M5_CRF_c4591001-1056-10561022.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, Indago Research Health Center, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, demographic data, eCRF audit trail, informed consent, visit date, FDA, Protocol, subject identification, confidential document, data collection",19,141,https://drive.google.com/file/d/1BuoBxsmeHFYymi6KfCHmspbuRd175-e3/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:01
125742_S1_M5_CRF_c4591001-1090-10901384.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, Wake Research Associates, informed consent, visit date, FDA, Protocol, c4591001, demography, safety",20,146,https://drive.google.com/file/d/1H7-NxZ6YCysZNh8gLhWLikwdS1tae5Ot/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:05
125742_S1_M5_CRF_c4591001-1090-10901175.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, eCRF, data management, subject identification, data collection",19,280,https://drive.google.com/file/d/1KbV-EUfdGE5JulA-qhPdd0SEOuSxGpnS/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:09
125742_S1_M5_CRF_c4591001-1054-10541173.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, united states, adverse events, collaborative neuroscience network, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, efficacy, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, safety",20,427,https://drive.google.com/file/d/1sry0UFJDQF7e76lYgJsVljxmF8LU3gTB/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:14
125742_S1_M5_CRF_c4591001-1090-10901507.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-16,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, Wake Research Associates, informed consent, visit date, FDA, Protocol, c4591001, demography, safety",19,164,https://drive.google.com/file/d/1nmNo1vZjO1B2Qt0RhR696IWi2KYnlFZZ/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:18
125742_S1_M5_CRF_c4591001-1057-10571065.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, subject identification, jacksonville, fl",20,165,https://drive.google.com/file/d/1sGH6odd-_p8h1yIy2SOlfvfMk9MeLp-3/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:21
125742_S1_M5_CRF_c4591001-1090-10901187.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, safety monitoring, visit date, Protocol, c4591001, demography, data collection, efficacy data, wake research associates",20,252,https://drive.google.com/file/d/1ML9yC0U3zgiseLvOcfYVo-iXJQGavjAD/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:25
125742_S1_M5_CRF_c4591001-1068-10681091.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, Bozeman Health, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Protocol, Pfizer, data management, demography",19,217,https://drive.google.com/file/d/1Y26U6LPCWdzN5WOtql01DuR-XF_t3DMI/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:29
125742_S1_M5_CRF_c4591001-1090-10901536.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,clinical trial protocol,"(1090) Wake Research Associates, LLC",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, United States, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, medical research, demography, subject identification, data collection",20,161,https://drive.google.com/file/d/1Zu4H840Cq4G9vtRfoNj1zdJtIqngUCQf/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:33
125742_S1_M5_CRF_c4591001-1057-10571188.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, clinical research, informed consent, FOIA, visit date, FDA, Protocol, demography, subject identification, data collection",19,145,https://drive.google.com/file/d/1PGGQekoT8f0p_RBIv7__S0i-1PHzr_6Q/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:37
125742_S1_M5_CRF_c4591001-1054-10541168.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, united states, adverse events, collaborative neuroscience network, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, efficacy, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, safety",20,164,https://drive.google.com/file/d/1wF43zOofb9SQmWRq2L79WWkS7r7cxACa/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:41
125742_S1_M5_CRF_c4591001-1090-10901300.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, Wake Research Associates, informed consent, visit date, FDA, Protocol, demography, subject identification, safety",19,243,https://drive.google.com/file/d/1HaKceyyU6uTFEaBWuM9WgOWH81UZA7sR/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:45
125742_S1_M5_CRF_c4591001-1090-10901099.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,"Wake Research Associates, LLC",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, clinical research form, CRF, covid-19 vaccine, pharmaceutical development, informed consent, visit date, Protocol, c4591001, demography, subject identification, data collection",20,255,https://drive.google.com/file/d/1mR2bNfq-sw7eynqjBzV2FDATwDbhwjMm/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:49
125742_S1_M5_CRF_c4591001-1071-10711171.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"quality control, site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, clinical research, informed consent, Protocol, subject demographics, eCRF, data management, efficacy data, data collection",20,169,https://drive.google.com/file/d/1G9jrRhxyq-QIcKlyx_7XewfdrV3Rsb6F/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:53
125742_S1_M5_CRF_c4591001-1068-10681079.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, c4591001 trial, United States, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Bozeman Health Clinical Research, phase 2/3 study, CRF, eCRF audit trail, FDA submission, informed consent, adverse event monitoring, Protocol, subject demographics, medical terminology, efficacy data",20,282,https://drive.google.com/file/d/1AYr6webbY5s_xH5gL3cuMqbq2wntSbOK/view?usp=drivesdk,pd-production-070323,2025-08-11 23:37:57
125742_S1_M5_CRF_c4591001-1090-10901486.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, subject details, data integrity, data management, demography, data collection",19,149,https://drive.google.com/file/d/146mbjd2p4BizQ4-vNeWPGbc6l5fGc4qG/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:01
125742_S1_M5_CRF_c4591001-1068-10681066.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, Bozeman Health, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data",19,162,https://drive.google.com/file/d/1pXnUr-oe8GLTGFwSWsm8uOzgOdC7ny7m/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:05
125742_S1_M5_CRF_c4591001-1057-10571327.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-16,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data, Jacksonville, FL",19,426,https://drive.google.com/file/d/1NfxJBNDo9fkou5NItD-iEBLaE-teFKXI/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:10
125742_S1_M5_CRF_c4591001-1054-10541186.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Collaborative Neuroscience Network, protocol amendment, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, data verification, data management, subject identification, data freezing",19,179,https://drive.google.com/file/d/1chnD7yn-9XGda_b0IRYttAfEHv2AukN8/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:13
125742_S1_M5_CRF_c4591001-1090-10901140.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, safety",19,224,https://drive.google.com/file/d/12l0nh4AXtOVkPCMDx2-4KD9YNxE-kc2a/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:18
125742_S1_M5_CRF_c4591001-1068-10681111.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, Bozeman Health, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, data management, demography, efficacy data",19,175,https://drive.google.com/file/d/19jmlV85oBeyfuEH1HxWyQV7bReFOM-bG/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:22
125742_S1_M5_CRF_c4591001-1090-10901394.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,"Wake Research Associates, LLC",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, geographic location, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, data verification, demography, subject identification, data freezing, data collection",19,179,https://drive.google.com/file/d/1PR7UdcxrKvxHib8B0xUFx1VHvpKAnkAt/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:26
125742_S1_M5_CRF_c4591001-1057-10571052.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, cns-healthcare, confidential, fda, regulatory-compliance, crf, protocol-amendment, clinical-trial, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, visit-date, subject-10571052, data-quality, demography, jacksonville-florida",20,796,https://drive.google.com/file/d/1IzdT8llx6OjDPeCiavNIofyF9yaiMNU_/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:31
125742_S1_M5_CRF_c4591001-1071-10711169.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1071) Quality Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, adverse event monitoring, visit date, FDA, Protocol, c4591001, eCRF, demography, subject identification, efficacy data",20,171,https://drive.google.com/file/d/1h75mrJSVGlQyyHLoEdK1GO3GIWeXqx00/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:35
125742_S1_M5_CRF_c4591001-1071-10711172.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data",20,195,https://drive.google.com/file/d/1uZudQyEOUyyXqvw5RDRNWQS_EiwjGhyl/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:38
125742_S1_M5_CRF_c4591001-1090-10901415.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, data quality, cohort selection, inclusion/exclusion criteria, protocol amendment, CRF, Wake Research Associates, informed consent, visit date, FDA, Protocol, vaccine, c4591001, data lock, eCRF, demography, subject identification",20,304,https://drive.google.com/file/d/1YvsLjzMXj8LVjTK_FZrJbP8e7pj31txX/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:42
125742_S1_M5_CRF_c4591001-1092-10921010.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, data quality, inclusion/exclusion criteria, data compliance, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, FOIA document, informed consent, visit date, FDA, Protocol, Sterling Research Group, data verification, data locking, subject identification, data freezing",19,222,https://drive.google.com/file/d/1wNSvyVm-4VdB_slNAHfe1jt0lTpfbHXU/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:47
125742_S1_M5_CRF_c4591001-1092-10921208.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, Sterling Research Group, subject identification, efficacy data",19,191,https://drive.google.com/file/d/1uNj4cA7O5kQfyLLfoJnFhlz8sJEBI9eN/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:51
125742_S1_M5_CRF_c4591001-1110-11101321.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,(1110) Clinical Research of South Florida,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, clinical research, informed consent, visit date, Protocol, eCRF, data management, South Florida, subject identification",20,162,https://drive.google.com/file/d/1wBx1LQVxSwIU8vOLzFQux6WO_fpugRbX/view?usp=drivesdk,pd-production-070323,2025-08-11 23:38:54
125742_S1_M5_CRF_c4591001-1110-11101236.pdf,PDF,Clinical Study Report Form,2021,report,,M5,True,False,False,False,False,"pharmaceutical research, data quality, FDA submission, geographic location, phase 4 study, clinical trial, vaccine development, safety data, CBER, data management, clinical study protocol, case report form, CRF, efficacy data, medical terminology, adverse events, c4591001-1110-11101236, regulatory compliance",18,464,https://drive.google.com/file/d/1PEswVi9bwvpsbcl-Jco7OM24dtG6bZRS/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:04
125742_S1_M5_CRF_c4591001-1110-11101367.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-10-01,Clinical Trial Form,,M5,True,True,False,True,False,"Data Integrity, Clinical Trial, Exclusion, Phase 2/3 Study, Inclusion/Exclusion Criteria, Visit Documentation, Subject Identification, FDA Submission, Safety Data, CRF, Protocol, Regulatory Compliance, Demographic Data, Informed Consent, Site Information, Cohort Selection, Efficacy Data, South Florida, Adverse Events, COVID-19 Vaccine",20,179,https://drive.google.com/file/d/1KA4chYgxkhfqqscjkc65nBz9TlXmR-OO/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:07
125742_S1_M5_CRF_c4591001-1110-11101031.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, South Florida, subject identification, data collection",20,199,https://drive.google.com/file/d/1S78twdCMKjnXpzGjtHlGqpoC3DztUl5u/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:12
125742_S1_M5_CRF_c4591001-1110-11101176.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, subject details, c4591001, eCRF, demography, South Florida, data collection",20,181,https://drive.google.com/file/d/152qwgY6eOP06CYW29V_WpQSQFsimbb94/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:15
125742_S1_M5_CRF_c4591001-1092-10921120.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,"(1092) Sterling Research Group, Ltd.",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, confidential, data audit, regulatory, data quality, inclusion/exclusion criteria, CRF, subject information, informed consent, visit date, FDA, Protocol, vaccine, c4591001, eCRF, demography, data collection",20,284,https://drive.google.com/file/d/1jknMu2nIP5dCGiNzq75xIFhmiQgErUdY/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:19
125742_S1_M5_CRF_c4591001-1111-11111011.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, efficacy, Fleming Island Center for Clinical Research, CRF, informed consent, visit date, FDA, Protocol, vaccine, c4591001, demography, safety",20,510,https://drive.google.com/file/d/1BxjbGn7MsWWXgjT1nddQRgYIn7e9eYuf/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:25
125742_S1_M5_CRF_c4591001-1111-11111010.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Fleming Island Center for Clinical Research, CRF, audit trail, demographic data, subject enrollment, informed consent, visit date, FDA, Protocol, eCRF, data management",19,711,https://drive.google.com/file/d/1mM9vyd_E0MbR42UfD5-BWWiC8Th3HEz1/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:31
125742_S1_M5_CRF_c4591001-1110-11101187.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Trial Form,(1110) Clinical Research of South Florida,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, data integrity, demography, South Florida, efficacy data, data collection",20,170,https://drive.google.com/file/d/1vPEirtPzWP9YlSWHKpjd6sc0UJSKtohe/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:35
125742_S1_M5_CRF_c4591001-1110-11101271.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,"(1110) Clinical Research of South Florida, 11101271",M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, clinical research, informed consent, visit date, Protocol, c4591001, demography, south florida, subject identification, confidential document, data collection",20,203,https://drive.google.com/file/d/1JWqztTb16HRF7mOky3NIqDP6o4HbJWrP/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:38
125742_S1_M5_CRF_c4591001-1110-11101220.pdf,PDF,Clinical Trial CRF for COVID-19 Vaccine Candidate c4591001,2021-03-29,Clinical Trial Form,(1110) Clinical Research of South Florida,M5,True,True,False,True,False,"phase 2/3 trial, eCRF (electronic CRF), Exclusion, clinical trial, safety data, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, CRF (case report form), informed consent, visit date, FDA, Protocol, c4591001, demography, South Florida, data collection",20,128,https://drive.google.com/file/d/12NpQwBViWElOp44t8AMiXS6YZ6NuLrl_/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:47
125742_S1_M5_CRF_c4591001-1110-11101302.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, phase 2/3 study, CRF, subject information, informed consent, visit date, FDA, Protocol, c4591001, demography, South Florida, data collection",20,144,https://drive.google.com/file/d/1Lj9RaVCun-CmQ6qbMC-F2Il-sS1nTQIN/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:51
125742_S1_M5_CRF_c4591001-1092-10921123.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, Sterling Research Group, demography, subject identification, data collection",19,233,https://drive.google.com/file/d/1BNeg0X4z5QGqVC-tJRmwD5hyFafw6u9G/view?usp=drivesdk,pd-production-070323,2025-08-11 23:39:54
125742_S1_M5_CRF_c4591001-1110-11101160.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, demography, South Florida, subject identification, safety, data collection",19,126,https://drive.google.com/file/d/1qyVeJT7CnJtGiQ0WUiaIIc7pAId4HeKJ/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:02
125742_S1_M5_CRF_c4591001-1092-10921048.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, fda, regulatory-compliance, crf, subject-information, adverse-events, clinical-trial, CRF, covid-19-vaccine, informed-consent, cohort-selection, Protocol, phase-2-3, efficacy-data, visit-date, sterling-research-group, data-quality, safety-data, demography",20,244,https://drive.google.com/file/d/1oFy1Si8qo1qGF2PSmsA9S4Ossdxg1bm_/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:07
125742_S1_M5_CRF_c4591001-1092-10921015.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, Sterling Research Group, c4591001, eCRF, demography, safety",20,186,https://drive.google.com/file/d/1H_ZsFNUDp25RZehSD9H2nlwy4TsrZRe9/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:11
125742_S1_M5_CRF_c4591001-1110-11101165.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, medical research, demography, South Florida, subject identification, data collection",20,153,https://drive.google.com/file/d/1kpq9OsTJNxQMecYQaDDj0KA2TtzpnkB6/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:14
125742_S1_M5_CRF_c4591001-1110-11101164.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, demography, South Florida, subject identification, efficacy data",19,150,https://drive.google.com/file/d/18PSdGR7DFfRAteoEtQICtuEYxHP_FWPS/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:18
125742_S1_M5_CRF_c4591001-1092-10921187.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,"Sterling Research Group, Ltd.",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, regulatory compliance, pharmaceutical research, fda, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, subject enrollment, informed consent, visit date, Protocol, c4591001, data management, demography, efficacy data, data collection",20,191,https://drive.google.com/file/d/1MkjPcXwHet4B9II3D1tVU-O2vlcoseTk/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:21
125742_S1_M5_CRF_c4591001-1092-10921021.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,"(1092) Sterling Research Group, Ltd.",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, united states, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, informed consent, visit date, Protocol, subject details, c4591001, medical research, demography, data collection",20,245,https://drive.google.com/file/d/1dgfKww1i7Mh5g0UzH0agFSm5Tvtfrx4Z/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:25
125742_S1_M5_CRF_c4591001-1124-11241223.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1124) Omega Medical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, c4591001 trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, FDA submission, informed consent, visit date, Protocol, medical research, data management, demography data, subject identification, adverse event reporting",20,127,https://drive.google.com/file/d/1fQmAe0gMaR2JXbjBa83ooFWqu5yVZiO1/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:34
125742_S1_M5_CRF_c4591001-1111-11111092.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,Fleming Island Center for Clinical Research,M5,True,True,False,True,False,"Exclusion, clinical trial, fleming island, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, safety monitoring, visit date, Protocol, c4591001, demography, efficacy data, data collection",20,315,https://drive.google.com/file/d/1ZnPLfAiQOy6fcL8y__JtGxl2nbFbOHRN/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:39
125742_S1_M5_CRF_c4591001-1111-11111103.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,Fleming Island Center for Clinical Research,M5,True,True,False,True,False,"Exclusion, florida, clinical trial, adverse events, regulatory compliance, fda, data quality, clinical research site, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, safety monitoring, visit date, Protocol, c4591001, demography, efficacy data",20,906,https://drive.google.com/file/d/11EYpHyFa7nKiRyCd4COlSgEhcqn-c1Sy/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:45
125742_S1_M5_CRF_c4591001-1111-11111095.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"visit dates, Exclusion, clinical trial, united states, confidential, regulatory compliance, fda, electronic case report form (ecrf), data quality, inclusion/exclusion criteria, phase 2/3 study, CRF, audit trail, covid-19 vaccine, subject enrollment, informed consent, Protocol, medical terminology, fleming island center for clinical research, demography data",20,205,https://drive.google.com/file/d/1ok_l25M3-E_llZIpaJo01J3dR2-DjXh7/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:50
125742_S1_M5_CRF_c4591001-1130-11301031.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, United States, adverse events, regulatory compliance, Kaiser Permanente, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,230,https://drive.google.com/file/d/1G5vtqRJAZi5hRHIK_ejm-FBz7zSR9Stq/view?usp=drivesdk,pd-production-070323,2025-08-11 23:40:54
125742_S1_M5_CRF_c4591001-1122-11221051.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-09,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, VA medical center, informed consent, visit date, FDA, Protocol, demography, subject identification, safety, data collection",19,118,https://drive.google.com/file/d/1usg5Jmxevlwz1YuOni64bEVCjqcNugQF/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:03
125742_S1_M5_CRF_c4591001-1111-11111109.pdf,PDF,Clinical Trial CRF for c4591001 Study,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, united states, adverse events, regulatory compliance, pharmaceutical research, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, Protocol, vaccine, c4591001, fleming island center for clinical research, demography, data collection",20,229,https://drive.google.com/file/d/1jyUH3BwKRk8Hjdwo1UHlh0Q6rcXSf0rr/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:07
125742_S1_M5_CRF_c4591001-1123-11231204.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, adverse events, regulatory compliance, fda, meridian clinical research, data quality, inclusion/exclusion criteria, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit schedule, Protocol, subject demographics, eCRF, data management",20,155,https://drive.google.com/file/d/1aw3v1t2iYgANOrwSPhJJFn6Gp9RbxVXa/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:10
125742_S1_M5_CRF_c4591001-1125-11251014.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1125) Meridian Clinical Research,M5,True,True,False,True,False,"quality control, Exclusion, clinical trial, phase 2/3, safety data, united states, adverse events, regulatory submission, fda, meridian clinical research, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data",20,382,https://drive.google.com/file/d/1bI6K3OIuyIYZz9RQhnvb8nPD-Gb-dJS2/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:15
125742_S1_M5_CRF_c4591001-1124-11241128.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1124) Omega Medical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, c4591001 trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, safety assessment, FDA submission, informed consent, adverse event monitoring, visit date, Protocol, demography data, subject identification, efficacy endpoints",20,352,https://drive.google.com/file/d/1dQq_gOdwYsVV2zsYKU9OeuYgF4Vr3o09/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:20
125742_S1_M5_CRF_c4591001-1126-11261017.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, adverse events, regulatory compliance, Kaiser Permanente, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, scientific terminology, subject identification, data collection",19,429,https://drive.google.com/file/d/1QLy2OdKHd45jmELnYGtphPin2oZFyUzS/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:25
125742_S1_M5_CRF_c4591001-1111-11111193.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-15,form,Fleming Island Center for Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, frozen data, demography, subject identification, data collection",20,160,https://drive.google.com/file/d/1G9iONaVo5AAqUsHmETmIyj-ZTo2RGlXd/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:29
125742_S1_M5_CRF_c4591001-1124-11241106.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, regulatory-compliance, phase-2-3-study, subject-information, adverse-events, clinical-trial, omega-medical-research, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, efficacy-data, visit-date, eCRF, safety-data, demography, fda-submission",20,135,https://drive.google.com/file/d/10bT5Yi6TLUdt2jq1dsqzhsEXMtgNjEQ7/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:39
125742_S1_M5_CRF_c4591001-1111-11111099.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Research Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, data quality control, regulatory submission, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, pharmaceutical development, informed consent, visit schedule, Protocol, medical research, data management, demography data, subject identification, adverse event reporting",20,187,https://drive.google.com/file/d/1TldYIrPlkVh9JheHtR2skZXLFsaz2u__/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:43
125742_S1_M5_CRF_c4591001-1124-11241207.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, inclusion/exclusion criteria, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit schedule, Protocol, subject demographics, omega medical research, eCRF, frozen data, data collection",20,149,https://drive.google.com/file/d/1MA-3-jqXoq-I9C6_JXlv0jvo0sw2z7cx/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:46
125742_S1_M5_CRF_c4591001-1122-11221026.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, Cleveland VA Medical Center, demography, subject identification, data collection",19,152,https://drive.google.com/file/d/1IFqY_5peQdgMPI8YTxbtZqQf3DRINz-_/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:50
125742_S1_M5_CRF_c4591001-1125-11251020.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,(1125) Meridian Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, safety monitoring, visit date, Protocol, subject details, c4591001, demography, efficacy data, data collection",20,250,https://drive.google.com/file/d/13mIzSQrWaTz892ubCnlwtJFtecPHA6gT/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:54
125742_S1_M5_CRF_c4591001-1122-11221053.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-13,form,Louis Stokes Cleveland VA Medical Center,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, subject demographics, medical center, eCRF, data management, subject identification, veterans affairs",20,241,https://drive.google.com/file/d/1ChEyc4ZXeKjA-9sKJau_nVDUXcI1kPJB/view?usp=drivesdk,pd-production-070323,2025-08-11 23:41:58
125742_S1_M5_CRF_c4591001-1111-11111130.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, fleming-island-center-for-clinical-research, fda-regulation, inclusion-exclusion-criteria, vaccine-development, adverse-events, clinical-trial, CRF, eCRF-audit-trail, informed-consent, cohort-selection, Protocol, phase-2-3, visit-date, case-report-form, confidential-document, subject-identification, data-quality, racial-designation, demography",20,138,https://drive.google.com/file/d/1DJ2epJH6cIuDJmUUvQ7Qsg6vUwuKIbws/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:03
125742_S1_M5_CRF_c4591001-1125-11251154.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, fda, meridian clinical research, data quality, inclusion/exclusion criteria, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, date of visit, visit schedule, Protocol, subject demographics, subject identification, data collection",20,395,https://drive.google.com/file/d/1TxlwUdyAYJLmPP1EhmT81wk0u0VUW9SA/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:07
125742_S1_M5_CRF_c4591001-1131-11311021.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, PriMED Clinical Research, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, pharmaceutical development, informed consent, safety monitoring, visit date, Protocol, data management",20,170,https://drive.google.com/file/d/1egaIzgDi3YO49p471cPMElLxpfLUbV80/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:11
125742_S1_M5_CRF_c4591001-1125-11251243.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-10,form,Meridian Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, safety monitoring, visit date, Protocol, c4591001, demography, subject identification, efficacy data",20,202,https://drive.google.com/file/d/10sNnlz6uqdkr0ZcvlG_a5GHltpWbknqn/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:15
125742_S1_M5_CRF_c4591001-1126-11261244.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-10,form,(1126) Kaiser Permanente Santa Clara,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, Kaiser Permanente, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject enrollment, informed consent, FDA, Protocol, c4591001, data management, demography, safety",19,150,https://drive.google.com/file/d/1x7v5DEeLDicAO31P0JHkP_FlAnGwgyDf/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:19
125742_S1_M5_CRF_c4591001-1123-11231381.pdf,PDF,Clinical Study Report Form,2021,report,,M5,True,False,False,False,False,"c4591001-1123-11231381, vaccine research, medical research, FDA submission, pharmaceutical development, phase 4 study, clinical trial, data management, safety data, CBER, quality assurance, United States, case report form, clinical study report, CRF, efficacy data, adverse events, regulatory compliance",18,131,https://drive.google.com/file/d/1DM5LkIc3pkv_U6XR7UeelWUb9tySqiGv/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:29
125742_S1_M5_CRF_c4591001-1111-11111016.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, audit trail, informed consent, date of visit, Protocol, vaccine, c4591001, fleming island center for clinical research, demography, case report form, subject identification",20,224,https://drive.google.com/file/d/1vG7SJvfiUZedhyTYgEWbzrUa0Ah01sk0/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:33
125742_S1_M5_CRF_c4591001-1111-11111139.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Fleming Island Center for Clinical Research, phase 2/3 study, CRF, eCRF audit trail, informed consent, visit date, Protocol, data verification, data completeness, demography data, subject identification, data locking and freezing, confidential document",20,159,https://drive.google.com/file/d/1GWfVlRHorYRBzeYE_20hj25hLG8es0X5/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:37
125742_S1_M5_CRF_c4591001-1130-11301081.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-16,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, Kaiser Permanente, inclusion/exclusion criteria, COVID-19 vaccine, geographic location, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, medical terminology, demography, efficacy data, data collection",20,228,https://drive.google.com/file/d/1pZ_BRamEkWz02tnATlqItzudVggZEKIu/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:40
125742_S1_M5_CRF_c4591001-1131-11311204.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, PriMED Clinical Research, United States, adverse events, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, FDA, Protocol, c4591001, medical terminology, data management, demography, safety, data collection",20,369,https://drive.google.com/file/d/1cz4CrMiO5VEL1WeO3iOM27ZitEhryUkl/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:45
125742_S1_M5_CRF_c4591001-1135-11351368.pdf,PDF,Clinical Trial Case Report Form,2020-09-15,form,---,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, geographic location, CRF, informed consent, visit date, FDA, Protocol, demography, case report form, Anaheim Clinical Trials, subject identification, efficacy data",20,271,https://drive.google.com/file/d/1fBpOWVfOdWQDhcVe-CL82t-3t0i1mVTO/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:49
125742_S1_M5_CRF_c4591001-1131-11311095.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, PriMED Clinical Research, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, medical terminology, safety",19,416,https://drive.google.com/file/d/1Q0xEm25eGKO4A7XXt9g5z5w3HjGoYDaz/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:53
125742_S1_M5_CRF_c4591001-1141-11411270.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-27,form,,M5,True,True,False,True,False,"subject-data, Exclusion, inclusion-exclusion-criteria, fda, regulatory-compliance, crf, university-of-iowa, site-information, adverse-events, clinical-trial, CRF, covid-19-vaccine, informed-consent, Protocol, phase-2-3, efficacy-data, visit-date, data-quality, safety-data, demography",20,205,https://drive.google.com/file/d/1sZVtkuYQZBWrSLGtXqs9J8VEcNbDYNvm/view?usp=drivesdk,pd-production-070323,2025-08-11 23:42:58
125742_S1_M5_CRF_c4591001-1131-11311140.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, PriMED Clinical Research, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, safety",20,193,https://drive.google.com/file/d/1vmqWmcXbyJscFXK80Hfgv9NkQW4q1H25/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:02
125742_S1_M5_CRF_c4591001-1135-11351033.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Protocol, Pfizer, demography, Anaheim Clinical Trials, efficacy data",19,193,https://drive.google.com/file/d/1tKVsrJDkVrNgVS3Z2c8uUDQkVStTMbVt/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:06
125742_S1_M5_CRF_c4591001-1141-11411113.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, university of iowa, quality assurance, phase 2/3 study, CRF, covid-19 vaccine, subject enrollment, informed consent, visit schedule, Protocol, eCRF, data management, demography, efficacy data, confidential document",20,147,https://drive.google.com/file/d/1eI4Jd-qfVaFiOO6GU6zk6rbng5miurKM/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:10
125742_S1_M5_CRF_c4591001-1141-11411143.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, University of Iowa Hospital and Clinics, demography, efficacy data",19,165,https://drive.google.com/file/d/1tP3xROOOq-aF5PocQL2H30oyZLzaUqWJ/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:14
125742_S1_M5_CRF_c4591001-1135-11351563.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-10-27,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, United States, adverse events, regulatory compliance, pharmaceutical, inclusion/exclusion criteria, CRF, informed consent, visit date, FDA, Protocol, vaccine, c4591001, demography, Anaheim Clinical Trials, case report form, efficacy data",20,169,https://drive.google.com/file/d/1V5rzSSUWPhhBGe7kjjfz4N0C7kIYHpaW/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:18
125742_S1_M5_CRF_c4591001-1135-11351434.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, vaccine-development, confidential, regulatory-compliance, anaheim-clinical-trials, adverse-events, clinical-trial, fda-regulated, CRF, data-collection, subject-identifier, informed-consent, cohort-selection, Protocol, phase-2-3, visit-date, case-report-form, data-quality, demography",20,138,https://drive.google.com/file/d/1wL9RyvOT4q5tlM0CqcNKAhxIcljhXDAy/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:26
125742_S1_M5_CRF_c4591001-1135-11351265.pdf,PDF,Clinical Trial CRF for c4591001 Study,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"phase 2/3 trial, Exclusion, FDA regulation, clinical trial, data quality, cohort selection, inclusion/exclusion criteria, CRF, eCRF audit trail, informed consent, adverse event monitoring, visit date, vaccine development, c4591001 study, Protocol, data management, demography, Anaheim Clinical Trials, subject identification, confidential document",20,356,https://drive.google.com/file/d/1YdwGAm1bZfoIdpi7aBrL8wpy4ElcoLpK/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:31
125742_S1_M5_CRF_c4591001-1131-11311100.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, PriMED Clinical Research, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, protocol amendment, CRF, subject information, informed consent, visit date, FDA, Protocol, demography, safety",19,412,https://drive.google.com/file/d/1CGcXDyNWONmGZYx8QJcsJ9JN4ZueG0pH/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:36
125742_S1_M5_CRF_c4591001-1131-11311222.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, PriMED Clinical Research, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, safety",20,144,https://drive.google.com/file/d/1OWXyQD39mEU_aKcl2VJz4u0mE-ljHQ4P/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:40
125742_S1_M5_CRF_c4591001-1131-11311145.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, PriMED Clinical Research, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, safety",20,259,https://drive.google.com/file/d/1kvyXd5mwvEPJpFaQUeylk8Ya-W81RC4y/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:44
125742_S1_M5_CRF_c4591001-1131-11311161.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, PriMED Clinical Research, United States, regulatory compliance, pharmaceutical research, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, adverse event monitoring, visit schedule, Protocol, subject demographics, c4591001 protocol, data management, data collection",20,653,https://drive.google.com/file/d/1qVAjVNO4dRsOO-Xkp9Gjr7TwVzF8WUO4/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:50
125742_S1_M5_CRF_c4591001-1141-11411140.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Research Form (CRF),,M5,True,True,False,True,False,"visit dates, Exclusion, FDA regulation, clinical trial, safety data, c4591001 trial, vaccine administration, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, informed consent, Protocol, subject demographics, University of Iowa Hospital and Clinics, efficacy data, confidential document",20,209,https://drive.google.com/file/d/1bpPZv26SAb3HgeGK0AZad1UD1i1lMVsn/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:54
125742_S1_M5_CRF_c4591001-1131-11311067.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, PriMED Clinical Research, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, demography, efficacy data",20,396,https://drive.google.com/file/d/1_skKa1jtNSc5lPg8X3RVQXrY7-eqYraP/view?usp=drivesdk,pd-production-070323,2025-08-11 23:43:59
125742_S1_M5_CRF_c4591001-1141-11411153.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, audit trail, informed consent, visit date, FDA, Protocol, subject demographics, University of Iowa Hospital and Clinics, eCRF, data collection",19,280,https://drive.google.com/file/d/1or8vSUGlx2gFywCKcyb3SayodiG-6qF9/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:04
125742_S1_M5_CRF_c4591001-1135-11351143.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, subject 11351143, Anaheim Clinical Trials, safety",19,249,https://drive.google.com/file/d/196jdABzYYlYZLf-1FV4pVK1GjhG_v_M2/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:09
125742_S1_M5_CRF_c4591001-1141-11411230.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, University of Iowa Hospital and Clinics, c4591001, eCRF, demography, efficacy data",20,175,https://drive.google.com/file/d/1WgyB-ISQ0TZxrYt2RRe0fSzZRgeDBvH6/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:13
125742_S1_M5_CRF_c4591001-1141-11411221.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"phase 2/3 trial, Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, demographic data, subject enrollment, clinical research, informed consent, University of Iowa, visit date, FDA, Protocol, eCRF, data management",19,233,https://drive.google.com/file/d/1-uI26weJQ1ZPxmoOAkZ4tT69MYQ0Us3x/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:17
125742_S1_M5_CRF_c4591001-1131-11311151.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, PriMED Clinical Research, United States, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy assessment, phase 2/3 study, CRF, demographic data, subject enrollment, informed consent, adverse event monitoring, visit date, Protocol, data integrity",20,723,https://drive.google.com/file/d/132j0hf6CoJpHXJCds5jZwa66dUtW0d7f/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:22
125742_S1_M5_CRF_c4591001-1131-11311094.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, PriMED Clinical Research, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, safety",20,222,https://drive.google.com/file/d/1DnBCBKOQd0rf-5CP_SiUgPc3tkOtBYE3/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:26
125742_S1_M5_CRF_c4591001-1131-11311216.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, PriMED Clinical Research, United States, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, subject enrollment, informed consent, adverse event monitoring, visit date, FDA, Protocol, medical terminology, data management",19,235,https://drive.google.com/file/d/13YI_ktKHDXgqUBufPPDE8URFF6p-_eEo/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:30
125742_S1_M5_CRF_c4591001-1135-11351257.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2021,Clinical Trial Form,,M5,True,False,False,False,False,"pharmaceutical research, FDA submission, clinical trial, phase 4 study, COVID-19 vaccine, safety data, data management, quality assurance, clinical trial protocol, United States, case report form, vaccine development, CRF, efficacy data, medical terminology, adverse events, data collection, regulatory compliance",18,123,https://drive.google.com/file/d/1F9_qbmhJt8qwpSAq9t6DCZcwS7dlRwqe/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:39
125742_S1_M5_CRF_c4591001-1195-11951023.pdf,PDF,Clinical Trial Case Report Form (CRF),2021-03-29,form,,M5,True,True,False,True,False,"Exclusion, Germany, clinical trial, confidential, data quality, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, audit trail, demographic data, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, eCRF, case report form, Medizentrum Essen Borbeck",20,641,https://drive.google.com/file/d/1azAIen56fDXW5zfESgHGBBlmlJemgM-n/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:45
125742_S1_M5_CRF_c4591001-1152-11521222.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, California Research Foundation, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data",20,182,https://drive.google.com/file/d/1-A_ZvGcs5dO0BEl22_GDOlZLfTPlRLFX/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:48
125742_S1_M5_CRF_c4591001-1152-11521260.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, regulatory submission, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, data lock and freeze, phase 2/3 study, CRF, California Research Foundation, pharmaceutical development, informed consent, visit date, Protocol, demography data, subject identification, electronic case report form (eCRF)",20,161,https://drive.google.com/file/d/1pDafyuDwUWMWZuGjQwUWoLIun-_4UYjt/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:52
125742_S1_M5_CRF_c4591001-1170-11701121.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, audit trail, informed consent, visit date, FDA, Protocol, Pfizer, data lock, eCRF, demography, subject identification, North Texas Infectious Diseases Consultants",20,191,https://drive.google.com/file/d/1cLFW-hEpzFUO4AbX2yZkgRsg8sSInk2F/view?usp=drivesdk,pd-production-070323,2025-08-11 23:44:56
125742_S1_M5_CRF_c4591001-1171-11711045.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, fda, inclusion/exclusion criteria, quality assurance, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit schedule, Protocol, subject demographics, martin diagnostic clinic, subject identification, data freezing, data collection",20,213,https://drive.google.com/file/d/14Hj5gntl3HMwEnLvRDb0WMhXRaJ9EnQQ/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:00
125742_S1_M5_CRF_c4591001-1195-11951132.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-10-19,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, germany, adverse events, regulatory compliance, essen, fda, data quality, medizentrum essen borbeck, phase 2/3 study, CRF, covid-19 vaccine, informed consent, Protocol, demography, case report form, subject identification, efficacy data",20,652,https://drive.google.com/file/d/1Dyk69gFhKfZ2tl4JQy3oYBnPivx5BPPC/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:06
125742_S1_M5_CRF_c4591001-1171-11711212.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, Martin Diagnostic Clinic, demography, subject identification, efficacy data",20,294,https://drive.google.com/file/d/14hzSaGK8CF0NCRS3gf9HWTsAE5Aq5Kl3/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:10
125742_S1_M5_CRF_c4591001-1152-11521095.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Research Form (CRF),,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, regulatory submission, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, California Research Foundation, informed consent, adverse event monitoring, visit date, Protocol, medical research, data management, demography data, subject identification",20,582,https://drive.google.com/file/d/132KlsOu-hdiMP3j1e6rO5b6iw9Jkw_Z4/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:16
125742_S1_M5_CRF_c4591001-1195-11951017.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, germany, confidential, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, medizentrum essen borbeck, CRF, informed consent, visit date, Protocol, vaccine, c4591001, subject 11951017, demography, data collection",20,714,https://drive.google.com/file/d/1O2_zwsUbX_-slNIAJtfP8zb3MPO1lKwZ/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:22
125742_S1_M5_CRF_c4591001-1177-11771317.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, C4591001, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, Japan, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, eCRF, East-West Medical Research Institute, demography, efficacy data",20,241,https://drive.google.com/file/d/1StfLKcjspZ7pCMm71d6GCwqF6pbsa2Wy/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:26
125742_S1_M5_CRF_c4591001-1195-11951014.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-10-15,Clinical Research Form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, subject enrollment, informed consent, visit schedule, Protocol, confidentiality, data management, Medizentrum Essen Borbeck, subject identification",20,202,https://drive.google.com/file/d/1U81WQFm4kKX89KBUVOf9dhzU8e1LPtDH/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:30
125742_S1_M5_CRF_c4591001-1170-11701217.pdf,PDF,c4591001 Clinical Trial CRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, informed consent, subject 11701217, visit date, FDA, Protocol, vaccine, c4591001, eCRF, demography, North Texas Infectious Diseases Consultants",20,507,https://drive.google.com/file/d/1HmWefn7XEgRBIGt3ft2Qje-SSBGwb9mI/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:35
125742_S1_M5_CRF_c4591001-1170-11701013.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, confidential information, c4591001 trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, subject enrollment, informed consent, visit date, Protocol, data management, adverse event reporting, North Texas Infectious Diseases Consultants",20,146,https://drive.google.com/file/d/139lhbh_W642fOp3zejOO3md_LZ4tALrd/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:39
125742_S1_M5_CRF_c4591001-1171-11711023.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, data lock and freeze, phase 2/3 study, protocol amendment, CRF, demographic data, eCRF audit trail, informed consent, visit date, Protocol, subject 11711023, Martin Diagnostic Clinic, confidential document",20,211,https://drive.google.com/file/d/1eVr_jJnVAVybYGF3FbnWpC-O-stHyZ-R/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:43
125742_S1_M5_CRF_c4591001-1152-11521450.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, California Research Foundation, informed consent, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data",20,143,https://drive.google.com/file/d/1K7t0jYkmHE4QxahcfX5skG2pXeiGz7pc/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:47
125742_S1_M5_CRF_c4591001-1152-11521411.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, california research foundation, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, safety monitoring, visit date, Protocol, c4591001, demography, subject identification, efficacy data",20,143,https://drive.google.com/file/d/1pk_UZPcP3uYEUGxVl5rfp97fFldUKDXm/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:55
125742_S1_M5_CRF_c4591001-1152-11521497.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, regulatory-compliance, adverse-events, clinical-trial, CRF, covid-19-vaccine, california-research-foundation, informed-consent, cohort-selection, Protocol, phase-2-3, efficacy-data, visit-date, subject-identification, eCRF, data-quality, safety-data, demography, fda-submission",20,150,https://drive.google.com/file/d/1Qrhl27BotdkV4eOJDrCtlSWAwP_bO9B_/view?usp=drivesdk,pd-production-070323,2025-08-11 23:45:59
125742_S1_M5_CRF_c4591001-1177-11771222.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory, fda, data quality, east-west medical research institute, cohort selection, inclusion/exclusion criteria, crf, efficacy, protocol amendment, CRF, covid-19 vaccine, subject data, informed consent, visit date, Protocol, demography, safety",20,201,https://drive.google.com/file/d/1lonxNBzV-2cY5R9hQptDk4VO_xNNL64N/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:02
125742_S1_M5_CRF_c4591001-1170-11701090.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, trial visit, vaccine administration, regulatory compliance, fda, inclusion/exclusion criteria, crf, protocol amendment, CRF, covid-19 vaccine, subject enrollment, informed consent, visit date, Protocol, subject demographics, north texas infectious diseases consultants",20,207,https://drive.google.com/file/d/1dJ-fwDnyKhrxpqplORhj-HWmtx-7OllQ/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:06
125742_S1_M5_CRF_c4591001-1195-11951059.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,,M5,True,True,False,True,False,"site information, Exclusion, Germany, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, subject data, informed consent, FDA, Protocol, demography, Medizentrum Essen Borbeck, safety",19,190,https://drive.google.com/file/d/1Mgjaxu4cOSUEyfVE0SEfC-cXGc2VQ7vo/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:10
125742_S1_M5_CRF_c4591001-1195-11951006.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, Pfizer, subject identification, Medizentrum Essen Borbeck, data collection",19,528,https://drive.google.com/file/d/1sSOn73XynsCHp3ebnYpw_wqjr9GR7wjR/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:15
125742_S1_M5_CRF_c4591001-1152-11521551.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, California Research Foundation, informed consent, visit date, FDA, Protocol, c4591001, demography, efficacy data, data collection",20,203,https://drive.google.com/file/d/1Frlo0uqgjqk9yA7zSoi1XB2YAT4WEvbE/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:20
125742_S1_M5_CRF_c4591001-1152-11521316.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,case report form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, california research foundation, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, demography, subject identification, efficacy data, data collection",20,224,https://drive.google.com/file/d/1HTXmqW4W-E10G0Du8E9Oyw8tPSoTTp40/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:25
125742_S1_M5_CRF_c4591001-1195-11951131.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-10-19,form,,M5,True,True,False,True,False,"Exclusion, Germany, clinical trial, phase 2/3, adverse events, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, Pfizer, demography, case report form, Medizentrum Essen Borbeck, subject identification, safety",20,264,https://drive.google.com/file/d/18UH5sdk9NB580W2MOAKrDe2E0KFztmUq/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:29
125742_S1_M5_CRF_c4591001-1195-11951003.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-10-15,clinical trial form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, Germany, data quality control, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, adverse event monitoring, visit date, Protocol, medical center, eCRF, data management, demography, subject identification",20,257,https://drive.google.com/file/d/1nZRyFITxw6Lo2CP7f90RXyJOKi0aQfPH/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:32
125742_S1_M5_CRF_c4591001-1195-11951008.pdf,PDF,Clinical Trial CRF for C4591001 Study,2020-10-15,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, Germany, clinical trial, adverse events, regulatory compliance, C4591001 study, data quality, cohort selection, inclusion/exclusion criteria, efficacy, CRF, informed consent, visit date, FDA, Protocol, vaccine, eCRF, demography, Medizentrum Essen Borbeck, safety",20,500,https://drive.google.com/file/d/1et9_yARXF41sbdSYb8HpXk34dUEtM8Gz/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:38
125742_S1_M5_CRF_c4591001-1152-11521053.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, California Research Foundation, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, data collection",20,178,https://drive.google.com/file/d/15NSF-iJ3dyZuXxE5NkQoehWubLvWHcWS/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:42
125742_S1_M5_CRF_c4591001-1152-11521476.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, california research foundation, fda, data quality, cohort selection, inclusion/exclusion criteria, safety and efficacy, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, data collection",20,208,https://drive.google.com/file/d/1QclCpYv3rvIXoRw9zLNSG6PLwBbxHTx-/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:46
125742_S1_M5_CRF_c4591001-1177-11771204.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,Subject No: 11771204,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, confidential, regulatory compliance, C4591001, inclusion/exclusion criteria, Japan, CRF, informed consent, visit date, FDA, Protocol, vaccine, eCRF, East-West Medical Research Institute, demography, efficacy data, data collection",20,157,https://drive.google.com/file/d/1BQeyazwJ8X31QNBfUolo5A8Gd7xnBrQZ/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:49
125742_S1_M5_CRF_c4591001-1152-11521085.pdf,PDF,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, case report form (CRF), regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, subject data, California, informed consent, visit date, FDA, Protocol, medical research, demography",20,124,https://drive.google.com/file/d/1i-GLGoZKiMkVzVWQ-o-72PuP31GtRFlZ/view?usp=drivesdk,pd-production-070323,2025-08-11 23:46:58
125742_S1_M5_CRF_c4591001-1197-11971097.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,"Dr. Lars Pohlmeier, Torsten Drescher",M5,True,True,False,True,False,"Exclusion, Germany, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, demography, subject identification, safety",20,195,https://drive.google.com/file/d/10i8dtcWWEEN_d-dFBXsfOJ_I7S9HSIEs/view?usp=drivesdk,pd-production-070323,2025-08-11 23:47:03
125742_S2_M5_54_ezeanolue-e-2019.pdf,PDF,Clinical Study Report for Investigational Drug,2020-04-09,report,"Ezeanolue, E.",M5,False,False,False,False,False,"medical research, data quality, FDA submission, pharmaceutical development, clinical trial, drug identification, data analysis, safety data, CBER, document management, United States, clinical study report, investigational drug, phase 1 study, adverse events, efficacy data, regulatory compliance",17,195,https://drive.google.com/file/d/1RjMYMVo9xvdsMOVMCjoOtmadcWRyqBig/view?usp=drivesdk,pd-production-080122,2025-08-11 23:47:14
FDA-CBER-2021-5683-0308157 to -0396186_125742_S1_M5_c4591001-S-D-suppface.xpt,XPT,FDA-CBER-2021-5683-0308157 to -0396186 125742 S1 M5 c4591001-S-D-suppface,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1RrxJcHP1JU0l-vubdqN4cVU1sXfFQ89m/view?usp=drivesdk,pd-production-080122,2025-08-11 23:47:27
FDA-CBER-2021-5683-0396188 to -0396192_125742_S1_M5_c4591001-S-D-suppmo.xpt,XPT,FDA-CBER-2021-5683-0396188 to -0396192 125742 S1 M5 c4591001-S-D-suppmo,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1aAYqNiqeig2nZOwqP_vkv_anAkoBVjaJ/view?usp=drivesdk,pd-production-080122,2025-08-11 23:47:28
FDA-CBER-2021-5683-0396193 to -0396194_125742_S1_M5_c4591001-S-D-supppe.xpt,XPT,FDA-CBER-2021-5683-0396193 to -0396194 125742 S1 M5 c4591001-S-D-supppe,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1vAWnT37ScOzfFW3n6HkNBEvOT_l7Q0uV/view?usp=drivesdk,pd-production-080122,2025-08-11 23:47:29
FDA-CBER-2021-5683-0396195_125742_S1_M5_bnt162-01-S-D-relrec.xpt,XPT,FDA-CBER-2021-5683-0396195 125742 S1 M5 bnt162-01-S-D-relrec,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1w8fN-zGM7T7tYIUKrvo10koRjoqiwkMG/view?usp=drivesdk,pd-production-080122,2025-08-11 23:47:30
FDA-CBER-2021-5683-0396196_125742_S1_M5_bnt162-01-S-D-supppe.xpt,XPT,FDA-CBER-2021-5683-0396196 125742 S1 M5 bnt162-01-S-D-supppe,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1hY21sH_DJhkuvPKhw1V02QbjJ6Vy27zb/view?usp=drivesdk,pd-production-080122,2025-08-11 23:47:32
FDA-CBER-2021-5683-0396199_125742_S1_M5_bnt162-01-S-D-tv.xpt,XPT,FDA-CBER-2021-5683-0396199 125742 S1 M5 bnt162-01-S-D-tv,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/14gaSXGMOhgFmxm30t4VdF-KU1uUTxM-W/view?usp=drivesdk,pd-production-080122,2025-08-11 23:47:33
FDA-CBER-2021-5683-0396197_125742_S1_M5_bnt162-01-S-D-supprp.xpt,XPT,FDA-CBER-2021-5683-0396197 125742 S1 M5 bnt162-01-S-D-supprp,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1WG7WT2I-bCPy72LDVPwi6RVEUzVKyvSv/view?usp=drivesdk,pd-production-080122,2025-08-11 23:47:34
FDA-CBER-2021-5683-0396187_125742_S1_M5_c4591001-S-D-pr.xpt,XPT,FDA-CBER-2021-5683-0396187 125742 S1 M5 c4591001-S-D-pr,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1gjE6c-0CXsHA7nP1lQGGSAe-fhhKUNyX/view?usp=drivesdk,pd-production-080122,2025-08-11 23:47:35
FDA-CBER-2021-5683-0396198_125742_S1_M5_bnt162-01-S-D-te.xpt,XPT,FDA-CBER-2021-5683-0396198 125742 S1 M5 bnt162-01-S-D-te,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/156Squfb8XtkdJ9Rvmn6GR_ThXA_lwjvO/view?usp=drivesdk,pd-production-080122,2025-08-11 23:47:37
125742_S10_M1_appendix-1.pdf,PDF,BNT162b2 Clinical Trial Tables,2021-06-30,report,,M1,False,False,False,False,False,"SDTM, older adults, FOIA, clinical trial, Staburo GmbH, local reactions, FDA, data cut-off, vaccine, adverse events, safety, BioNTech SE, younger adults, BNT162b2, systemic reactions, data analysis, regulatory",17,17,https://drive.google.com/file/d/1QzSONW7lw-0_PJ-GH1rkEoyx_OPlxOem/view?usp=drivesdk,pd-production-080123,2025-08-11 23:47:42
125742_S116_M1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Clinical Trial Submission,2021-09-21,report,Donna Boyce,M1,False,False,False,False,False,"data-compliance, mrna-technology, cber, immunogenicity, pharmaceutical-industry, phase-3-study, regulatory-approval, safety-data, adverse-events, efficacy-data, pfizer-covid-19-vaccine, fda-submission, vaccine-development, clinical-trial, united-states, quality-assurance, pandemic-response",17,2,https://drive.google.com/file/d/1pt6rgRqPi3XXh857oekxrEZtHQzeZ3AC/view?usp=drivesdk,pd-production-080123,2025-08-11 23:47:46
125742_S105_M1_cover.pdf,PDF,Request for Comments and Advice - Biologic Product Deviation Reports (BPDRs),2021-09-15,letter,"Marion Gruber, Ph.D., Amit Patel, Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D., Captain Michael Smith, Ph.D.",M1,False,False,False,False,False,"biologics-license-application, clinical-trials, pfizer-inc, quality-compliance, fda-submission, biotech-partnerships, new-york-city, biologic-product-deviation-reports, comirnaty, global-product-development, product-registration, silver-spring-maryland, regulatory-affairs, vaccine-development, covid-19, safety-reporting, emergency-use-authorization",17,2,https://drive.google.com/file/d/1J9EwthcljcGeT4O_6j_UnuVLLuxDqh6v/view?usp=drivesdk,pd-production-080123,2025-08-11 23:47:50
125742_S113_M1_cover.pdf,PDF,Notification of Submission of Final C4591007 Substudy Protocols to IND 19736,2021-09-21,letter,"Marion Gruber, Ph.D.",M1,False,True,False,False,False,"BLA 125742, PF-07302048, FDA regulatory submission, immunogenicity, post-marketing requirement, COMIRNATY, COVID-19 vaccine, tolerability, BNT162, Protocol, post-marketing commitment, clinical trial protocols, IND 19736, safety, phase 1 study, healthy children and young adults, phase 2/3 study, Pfizer Global Regulatory Affairs",18,2,https://drive.google.com/file/d/1fpkInlpGrbtF7PPrPm440JrU1yk9Pgl2/view?usp=drivesdk,pd-production-080123,2025-08-11 23:47:54
125742_S10_M1_cover.pdf,PDF,Response to CBER's 25 June 2021 Information Request for BLA 125742 COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-07-02,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Vaccine licensing and registration, Biologics License Application (BLA), Safety and efficacy data, Interim report response, Collegeville, PA location, Silver Spring, MD location, Regulatory compliance, Investigational New Drug (IND), FDA-CBER regulatory submission, Vaccine research and review, Information request response, Biologics Evaluation and Research, BNT162/PF-07302048 clinical trial, Vaccine research and development, Pfizer Global Regulatory Affairs, BLA 125742 application",17,2,https://drive.google.com/file/d/1XZk_S_Xb61YfWgErJrWW3IAAbt4cGrLf/view?usp=drivesdk,pd-production-080123,2025-08-11 23:47:58
125742_S102_M1_request-waiver-ldr.pdf,PDF,Request for a Waiver - Lot Distribution Reports,2021-09-14,request,,M1,False,False,False,False,False,"regulatory-submission, clinical-trials, fda, quarterly-reporting, data-format, compliance, pharmaceutical-industry, comirnaty, pfizer, biontech, lot-distribution-report, document-waiver, vaccine-development, bnt162b2, quality-systems, emergency-use-authorization, manufacturing-information",17,1,https://drive.google.com/file/d/1N-XTya-aBeKNe73_uYuE4iH4MnsQk_RT/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:01
125742_S10_M1_response-25jun2021.pdf,PDF,Response to FDA Request for Information,2021-06-25,response,,M1,False,False,False,False,False,"BNT162b2 vaccine, FOIA document, younger and older subjects, Pfizer/BioNTech, response document, compliance, July 2021, Module 1.11.3, data analysis, solicited adverse reactions, STN 125742, safety data, dose level, summary tables, FDA information request, pharmaceutical clinical trial, regulatory submission",17,4,https://drive.google.com/file/d/11SjHRExg58mVpBc_DIfbkzyhLYTp3yuH/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:04
125742_S105_M1_req-comments-advice-bpdr.pdf,PDF,Request for Comments and Advice – BPDR Reporting,2021-09-15,memo,"Donna Boyce, Ramachandra Naik",M1,False,False,False,False,False,"eua authorization, transparency reporting, clinical trial data, us regulatory affairs, safety reporting, pharmaceutical development, pharmaceutical industry, biopharmaceutical products, bla approval, quality assurance, covid-19 pandemic response, lot release certification, biologic product deviation reporting, fda regulations, vaccine manufacturing, pfizer-biontech covid-19 vaccine, regulatory compliance",17,1,https://drive.google.com/file/d/1Gp0Qo09GXkpBdGjU43UIAH3OsghvbeXL/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:07
125742_S116_M1_lab-1451-10-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-09-22,fact sheet,,M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, immunocompromised individuals, booster dose, vaccine distribution, pharmaceutical, emergency use authorization, comirnaty, regulatory compliance, vaccine administration, safety and efficacy, pfizer-biontech, vaccine information, united states, adverse events, fda approval, clinical trials",17,8,https://drive.google.com/file/d/1mQXM52A89TclQdNDV_HTZY9iLt2SGeuR/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:10
125742_S102_M1_cover.pdf,PDF,Request for Waiver - Lot Distribution Reports for COMIRNATY (COVID-19 mRNA Vaccine),2021-09-15,letter,"Marion Gruber, Ph.D., Amit Patel, Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D., Captain Michael Smith, Ph.D.",M1,False,False,False,False,False,"biologics-license-application, covid-19-vaccine, regulatory-reporting, pfizer-inc, biotech-partnerships, waiver-request, global-product-development, comirnaty, vaccine-quality-control, silver-spring, lot-distribution-report, clinical-trial-compliance, regulatory-affairs, fda-submission, vaccine-development, vaccine-safety-data, new-hampshire",17,2,https://drive.google.com/file/d/12Wg8mo9jd1kPPBeYaT51TWBxMQXQlr0Q/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:14
125742_S116_M1_pp-cvv-usa-0389.pdf,PDF,LOW DEAD-VOLUME (LDV) SYRINGES AND/OR NEEDLES GUIDE,2021,guide,,M1,False,False,False,False,False,"vial, eua, low-dead-volume, fda, clinical-considerations, compliance, technical, syringe, comirnaty, needle, dose-extraction, vaccine, efficacy, pfizer-biontech, safety, covid-19, regulatory",17,3,https://drive.google.com/file/d/1bCmWi_FAKbLQdZFFngEGZzMfNnlJDitL/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:18
125742_S117_M1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Clinical Trial Submission,2021-09-21,Regulatory Submission,Donna Boyce,M1,False,False,False,False,False,"Vaccine Trials Locations, Vaccine Trials Protocols, Adverse Event Reporting, Regulatory Operations, Vaccine Trials Data Management, Vaccine Trials Quality Assurance, Pharmaceutical Compliance, COVID-19 Vaccine, Vaccine Safety Data, Vaccine Trials Monitoring, Pfizer Clinical Trial, Vaccine Identification, FDA Submission, Vaccine Efficacy Data, Regulatory Approval, Vaccine Development, Vaccine Trials Phase",17,2,https://drive.google.com/file/d/1EH_9UdNvMMfUUCFMfeH7YZUgwgnSRA70/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:23
125742_S117_M1_lab-1448-1-0.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Intramuscular Injection, Vaccine Indications, Vaccine Efficacy, Vaccine Warnings and Precautions, Clinical Trials, Vaccine Administration, COMIRNATY, FDA Approval, Vaccine Dosage and Administration, Immunogenicity, Adverse Reactions, Regulatory Compliance, Vaccine Postmarketing Experience, Pharmaceutical Prescribing Information, COVID-19 Vaccine, Vaccine Safety, Vaccine Contraindications",17,20,https://drive.google.com/file/d/103ufdN5nWJqIcHwio6eCo8tT6us3D1xP/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:27
125742_S116_M1_pp-cvv-usa-0387.pdf,PDF,"Pfizer-BioNTech COVID-19 Vaccine (COMIRNATY®) Storage, Handling, and Preparation Checklist",2021,protocol,,M1,False,True,False,False,False,"eua-authorization, thermal-shipping-container, vaccine-indications, covid-19-vaccine, regulatory-compliance, dry-ice, safety-information, comirnaty, adverse-events, storage-handling-preparation, Protocol, fact-sheets, pfizer-biontech, clinical-trial, united-states, prescribing-information, fda-approval, vaccine-administration",18,4,https://drive.google.com/file/d/1zqoSyoaHTj68BNiyujuEBkefoLly3UDd/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:31
125742_S117_M1_lab-1451-10-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-09-22,fact sheet,,M1,False,False,False,False,False,"pharmaceutical manufacturing, mrna vaccine, covid-19 vaccine, immunocompromised individuals, booster dose, vaccine efficacy, vaccine distribution, adverse event reporting, emergency use authorization, regulatory compliance, vaccine information, vaccine safety, vaccine administration, united states, medical terminology, fda approval, clinical trials",17,8,https://drive.google.com/file/d/1TZJfslOV2ojpoXxjKdwxvDpurD05z1Oe/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:34
125742_S116_M1_lab-1457-14-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021-09-22,fact sheet,,M1,False,False,False,False,False,"reporting-requirements, clinical-trials, regulatory-compliance, booster-dose, healthcare-providers, immunocompromised, safety-data, comirnaty, vaccine, dosing-regimen, vaccine-administration, pfizer-biontech, adverse-events, covid-19, fda-approval, immunization, emergency-use-authorization",17,48,https://drive.google.com/file/d/1p3aZyWj9-1APx8DgUV1kV8rJkI4TSDlt/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:40
125742_S117_M1_lab-1457-14-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021-09-22,fact sheet,,M1,False,False,False,False,False,"clinical-trials, regulatory-compliance, booster-dose, healthcare-providers, immunocompromised, safety-data, vaccination-program, comirnaty, vaccine, sars-cov-2, pfizer-biontech, adverse-events, primary-series, covid-19, fda-approval, immunization, emergency-use-authorization",17,48,https://drive.google.com/file/d/1P-UGEM758rirvdyKthV9ulMMhZw-o8jp/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:45
125742_S118_M1_pp-cvv-usa-0426.pdf,PDF,"COMIRNATY® (COVID-19 Vaccine, mRNA) IVR & Live Operator Script",2022-04-26,script,,M1,False,False,False,False,False,"high-risk-populations, covid-19 vaccine, fda-approved, regulatory-compliance, booster-dose, safety-information, vaccination-series, comirnaty, clinical-trial-data, dosing-regimen, indication-and-use, adverse-event-monitoring, pfizer-biontech, geographic-distribution, customer-service-script, immunocompromised, emergency-use-authorization",17,8,https://drive.google.com/file/d/1m3fLV2_F-FmBpaB-fN0dqunTDSYMEeKv/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:49
125742_S123_M1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Clinical Trial Submission,2021-09-28,Regulatory Submission,Donna Boyce,M1,False,False,False,False,False,"CBER Submission, Pharmaceutical Operations, FDA Regulatory Submission, Adverse Event Reporting, Vaccine Trials Phase, Vaccine Safety Data, Pharmaceutical Departments, Regulatory Compliance, Pfizer Clinical Trial, Vaccine Identification, Vaccine Geographic Distribution, Vaccine Efficacy Data, Vaccine Data Types, COVID-19 Vaccine, Vaccine Development, Regulatory Approval Process, Vaccine Submission Timeline",17,2,https://drive.google.com/file/d/1PmSzeIAj_cFbfh4ACatnxvfX6--frors/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:53
125742_S117_M1_pp-cvv-usa-0422.pdf,PDF,Pfizer COVID-19 Vaccine Labeling,2022-04,report,,M1,False,False,False,False,False,"approval, covid-19 vaccine, fda, compliance, pharmaceutical, submission, labeling, quality, pfizer, efficacy, safety, adverse events, united states, data, responsive design, clinical trials, regulatory",17,16,https://drive.google.com/file/d/1ea2-mrJYG6jl4uoguMMlwL6ZAnlDfl2e/view?usp=drivesdk,pd-production-080123,2025-08-11 23:48:57
125742_S118_M1_lab-1451-10-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-09-22,fact sheet,,M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, immunocompromised individuals, booster dose, safety information, public health, vaccine distribution, patient education, emergency use authorization, regulatory compliance, pharmaceutical manufacturing, adverse event reporting, united states, efficacy data, medical terminology, fda approval, clinical trials",17,8,https://drive.google.com/file/d/1jn3yoLs3IpzRyOsnJ0WTMLwLBrsLXsmi/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:00
125742_S118_M1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Clinical Trial Submission,2021-09-26,report,Donna Boyce,M1,False,False,False,False,False,"data-compliance, mrna-technology, cber, immunogenicity, us-locations, pharmaceutical-industry, phase-3-study, regulatory-approval, safety-data, adverse-events, efficacy-data, pfizer-covid-19-vaccine, fda-submission, vaccine-development, clinical-trial, digital-signature, pandemic-response",17,2,https://drive.google.com/file/d/1fsp-wsmp4VbQKsdO4yH8KNcsxsKzvDb2/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:04
125742_S118_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION for COMIRNATY (COVID-19 Vaccine, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, regulatory approval, fda, patient counseling, pharmaceutical product, adverse reactions, warnings and precautions, comirnaty, intramuscular injection, safety data, adverse events, immunization, efficacy data, prescribing information, clinical trials",17,20,https://drive.google.com/file/d/16Y-mkb1YO18hlXLotpGKqmUS9tgvli4F/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:08
125742_S118_M1_lab-1457-14-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021-09-22,fact sheet,,M1,False,False,False,False,False,"occupational-exposure, clinical-trials, regulatory-compliance, healthcare-providers, age-groups, safety-data, comirnaty, vaccine, dosage-information, booster-doses, pfizer-biontech, adverse-events, immunocompromised-individuals, covid-19, fda-approval, immunization, emergency-use-authorization",17,48,https://drive.google.com/file/d/1Ly9SrFRygH4MXFDiU5qXKJq6vcPC5YA1/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:14
125742_S123_M1_lab-1451-10-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-09-22,fact sheet,,M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, immunocompromised individuals, booster dose, vaccine efficacy, pharmaceutical development, vaccine distribution, vaccine formulation, emergency use authorization, regulatory compliance, vaccine administration, vaccine information, vaccine safety, united states, adverse events, fda approval, clinical trials",17,8,https://drive.google.com/file/d/183E0mkmQCRpRiEGlotSaFZim_xIueMEZ/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:17
125742_S125_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, regulatory approval, fda, vaccine schedule, adverse reactions, contraindications, warnings and precautions, comirnaty, safety data, intramuscular injection, immunization, postmarketing experience, efficacy data, prescribing information, clinical trials",17,20,https://drive.google.com/file/d/1wVJ3GlpCJ_Y7wT1ZameCLmG-qfmAhyFU/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:21
125742_S123_M1_pp-cvv-usa-0430.pdf,PDF,Pfizer Labeling for COVID-19 Vaccine,2021,report,,M1,False,False,False,False,False,"Vaccine Development, Vaccine Approval, Clinical Trials, FDA-CBER-2021-5683, Pharmaceutical Industry, Medical Informatics, Regulatory Submission, Efficacy Data, Adverse Events, Pfizer COVID-19 Vaccine, Responsive Design, Compliance, Quality Assurance, United States, Regulatory Affairs, Safety Data, Vaccine Labeling",17,18,https://drive.google.com/file/d/1TO-LwvoyKrUB95ReXsld03_usn9z9vEN/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:26
125742_S125_M1_2253.pdf,PDF,Pfizer Clinical Trial Submission to FDA,2021-10-01,Regulatory Submission,Donna Boyce,M1,False,False,False,False,False,"Data Integrity, College ville Facility, Adverse Event Reporting, Vaccine Identifier, Efficacy Data, Submissions and Operations Support, CBER Regulatory Filing, Regulatory Compliance, Pfizer Clinical Trial, Pharmaceutical Submissions, Biologics License Application, FDA Submission, Regulatory Affairs, Clinical Trial Phase, Safety Data, Geographic Location, Vaccine Development",17,2,https://drive.google.com/file/d/1BhxQ15M5vv36wMEiuMr5DEXoVwt-ZAq7/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:29
125742_S125_M1_lab-1451-10-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-09-22,fact sheet,,M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, immunocompromised individuals, booster dose, vaccine distribution, pharmaceutical development, vaccine formulation, vaccine reporting, public health, vaccine effectiveness, emergency use authorization, regulatory compliance, vaccine information, vaccine safety, vaccine administration, fda approval, clinical trials",17,8,https://drive.google.com/file/d/1u6vgzFnKmTRLvNFPA65VlcIOBuk7sczB/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:32
125742_S123_M1_lab-1457-14-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021-09-22,fact sheet,,M1,False,False,False,False,False,"occupational-exposure, clinical-trials, regulatory-compliance, healthcare-providers, age-groups, safety-data, vaccine, dosage-information, booster-doses, pfizer-biontech, adverse-events, fact-sheet, immunocompromised-individuals, covid-19, fda-approval, immunization, emergency-use-authorization",17,48,https://drive.google.com/file/d/1bR2XlgCGB2CDEZOFvjyo93GK3VZ0Bf_T/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:38
125742_S123_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,report,,M1,False,False,False,False,False,"dosage and administration, pharmaceutical, prescribing information, adverse reactions, COMIRNATY, clinical trial, SARS-CoV-2, intramuscular injection, COVID-19, vaccine, myocarditis, FDA approval, safety, efficacy, pericarditis, immunization, regulatory",17,20,https://drive.google.com/file/d/1X5gNb35Ycx-TNQeAylUwpCfeXTzOkTxb/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:41
125742_S125_M1_lab-1457-14-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021-09-22,fact sheet,,M1,False,False,False,False,False,"medical-product-information, clinical-trials, pharmaceutical-industry, regulatory-compliance, healthcare-providers, safety-data, vaccine, booster-doses, pfizer-biontech, adverse-events, dosing-schedule, immunocompromised-patients, covid-19, fda-approval, immunization, united-states, emergency-use-authorization",17,48,https://drive.google.com/file/d/1agyVXZNKPBW15zvlN_IibvBpfCGVw-i9/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:47
125742_S125_M1_pp-cvv-usa-0424.pdf,PDF,Comirnaty BLA Paid Search (SEM) Recommendation - Consumer Facing,2021-09-30,recommendation,,M1,False,False,False,False,False,"consumer-facing, covid-19 vaccine, side effects, fda, compliance, technical, comirnaty, pfizer, biontech, paid search, safety, clinical trials, united states, data, search engine marketing, adverse events, regulatory",17,4,https://drive.google.com/file/d/1ofbqLbILP0spCnOxlfQ3eN7d3QYcGW0p/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:50
125742_S126_M1_lab-1448-1-0.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08,Prescribing Information,,M1,False,False,False,False,False,"Immunization, Syncope, mRNA Vaccine, Clinical Trials, Immunocompetence, Warnings and Precautions, COMIRNATY, Dosage and Administration, FDA Approval, Pharmaceutical, Adverse Reactions, Myocarditis, Regulatory Compliance, Pericarditis, Prescribing Information, COVID-19 Vaccine, Intramuscular Injection",17,20,https://drive.google.com/file/d/1t3Mk7KRGcYgJyPCtBjhenCS72Co5Mpo-/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:55
125742_S126_M1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Submission to FDA,2021-10-01,Regulatory Submission,Donna Boyce,M1,False,False,False,False,False,"Clinical Trials, Regulatory Operations, Vaccine Trials, Vaccine Monitoring, Pharmaceutical Compliance, COVID-19 Vaccine, Efficacy Data, Vaccine Logistics, Adverse Events, Vaccine Identification, Vaccine Deployment, Vaccine Distribution, FDA Submission, Safety Data, Regulatory Approval, Vaccine Development, Pfizer",17,2,https://drive.google.com/file/d/16W9_eQ9tThwp4WPAPB4rjjZ1c-YtBCI3/view?usp=drivesdk,pd-production-080123,2025-08-11 23:49:59
125742_S126_M1_lab-1457-14-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021-09-22,fact sheet,,M1,False,False,False,False,False,"reporting-requirements, eua, clinical-trials, fda, dosage, booster-dose, healthcare-providers, age-groups, immunocompromised, vaccine, efficacy, pfizer-biontech, adverse-events, safety, covid-19, immunization, regulatory",17,48,https://drive.google.com/file/d/1_yACvZ8CQSAdQIsZ0FDEddBOv8k2ay6m/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:04
125742_S126_M1_lab-1451-10-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-09-22,fact sheet,,M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, immunocompromised individuals, booster dose, vaccine distribution, public health, emergency use authorization, comirnaty, regulatory compliance, safety and efficacy, pfizer-biontech, vaccine information, united states, pharmaceutical industry, adverse events, fda approval, clinical trials",17,8,https://drive.google.com/file/d/1rRz2D4s43pg_6ySkWwuv1ak8HCZubCno/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:08
125742_S129_M1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Clinical Trial Submission,2021-12-06,Regulatory Submission,Donna Boyce,M1,False,False,False,False,False,"Operations Support, Regulatory Timeline, Data Integrity, Clinical Trial Protocols, Geographic Distribution, Pharmaceutical Compliance, COVID-19 Vaccine, Efficacy Data, CBER, Adverse Events, Pfizer Clinical Trial, Vaccine Identification, FDA Submission, PPLS Submissions, Safety Data, Regulatory Approval, Phase 3 Study",17,2,https://drive.google.com/file/d/1BfU7JqlkT-d4SGIuRj6f-xbzTjeLemNp/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:12
125742_S129_M1_lab-1457-14-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021-09-22,fact sheet,,M1,False,False,False,False,False,"reporting, eua, clinical-trials, fda, booster-dose, healthcare-providers, age-groups, immunocompromised, comirnaty, adverse-events, vaccine, efficacy, pfizer-biontech, safety, covid-19, immunization, regulatory",17,48,https://drive.google.com/file/d/1JB2d8-S-KsA5v2hMSdp-gSCaz7fJDcoF/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:18
125742_S129_M1_lab-1451-10-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-09-22,fact sheet,,M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, vaccine efficacy, immunocompromised individuals, booster dose, vaccine distribution, vaccine formulation, public health, patient education, emergency use authorization, regulatory compliance, vaccine safety, pharmaceutical manufacturing, vaccine administration, vaccine information, fda approval, clinical trials",17,8,https://drive.google.com/file/d/1A5WjLC1ptCnYXAw3LoQYalF3fQPU8y4h/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:21
125742_S12_M1_cover.pdf,PDF,Response to FDA 13July2021 Information Request Regarding Preservative Exception or Alternative Submittal,2021-07-15,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Captain Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"BLA 125742, COVID-19 mRNA vaccine, FOIA document, Center for Biologics Evaluation and Research, vaccine efficacy, BioNTech, preservative exception, multiple-dose vial, vaccine development, 21 CFR 610.15(a), Pfizer Inc., global product development, vaccine safety, FDA information request, regulatory affairs, BNT162/PF-07302048, pharmaceutical/clinical trial",17,2,https://drive.google.com/file/d/1iarMV7IpQHTISXaNFMliKRUitqnMllEB/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:26
125742_S129_M1_pp-cvv-usa-0442.pdf,PDF,Pfizer COVID-19 Vaccine Labeling Documents,2021,report,,M1,False,False,False,False,False,"Adverse events, Vaccine efficacy, Vaccine distribution, FOIA, Labeling, Vaccine safety, FDA, COVID-19 vaccine, CBER, Compliance, Quality assurance, United States, Pharmaceutical industry, Clinical trials, Regulatory approval, Vaccine development, Pfizer",17,4,https://drive.google.com/file/d/1QhD9TGEkxPOWtf0gRTJEUTppJVa8ShxR/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:29
125742_S129_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, regulatory approval, fda, vaccine schedule, adverse reactions, contraindications, warnings and precautions, comirnaty, safety data, intramuscular injection, immunization, postmarketing experience, efficacy data, prescribing information, clinical trials",17,20,https://drive.google.com/file/d/1FXI4H-uNy18kHmmKMYCB1W1GL5QTchsV/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:33
125742_S126_M1_pp-cvv-usa-0429.pdf,PDF,Summary of Comments on pp-cvv-usa-0429,2021-09-28,report,oliviamassey,M1,False,False,False,False,False,"pp-cvv-usa-0429, cber, summary-report, usa, regulatory-compliance, fda-submission, fda-cber-2021-5683-0952058, fda-cber-2021-5683-0952059, safety-data, pp-cvv-usa-0389, fda-cber-2021-5683-0952057, adverse-events, efficacy-data, vaccine-development, clinical-trial, fda-cber-2021-5683-0952060, pp-cvv-usa-0387",17,4,https://drive.google.com/file/d/1yhGhdBo0-nmSOyID1VtmvNfjAyGWHjn2/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:36
125742_S131_M1_lab-1457-14-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021-09-22,fact sheet,,M1,False,False,False,False,False,"eua, clinical-trials, fda, dosage, booster-dose, healthcare-providers, age-groups, immunocompromised, comirnaty, vaccine, efficacy, pfizer-biontech, adverse-events, safety, covid-19, immunization, regulatory",17,48,https://drive.google.com/file/d/1bmwdbILSiNwGi248XPaxwI3yGXTmF6RR/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:43
125742_S131_M1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Clinical Trial Submission,2021-10-09,report,Donna Boyce,M1,False,False,False,False,False,"covid-19 vaccine, cber, quality control, medical research, public health, pharmaceutical development, phase 1/2/3 studies, approval process, clinical trial, safety data, pfizer, fda submission, digital signature, united states, efficacy data, regulatory affairs, adverse events",17,2,https://drive.google.com/file/d/10Dx8WeQmblzxiqAIEEJVEphuICAR4WLR/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:47
125742_S131_M1_lab-1451-10-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-09-22,fact sheet,,M1,False,False,False,False,False,"pharmaceutical manufacturing, mrna vaccine, covid-19 vaccine, vaccine efficacy, immunocompromised individuals, public health, vaccine distribution, booster doses, emergency use authorization, pandemic response, regulatory compliance, vaccine hesitancy, vaccine safety, vaccine information, vaccine administration, fda approval, clinical trials",17,8,https://drive.google.com/file/d/18Y5ZWRAEead1rs-45QoFRhf_1dKMj5R4/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:50
125742_S131_M1_pp-cvv-usa-0431.pdf,PDF,Pfizer Labeling Documents,2021,report,,M1,False,False,False,False,False,"cber, global-distribution, clinical-trials, quality-assurance, regulatory-compliance, product-information, pharmaceutical-labeling, safety-data, adverse-events, pfizer, efficacy-data, foia-request, data-transparency, vaccine-development, fda-submission, product-identification, document-repository",17,4,https://drive.google.com/file/d/11B8Hy5c1Q7YoUyy5-gtv0WnPmNFL9_7W/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:54
125742_S138_M1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Submission to FDA,2021-10-22,Regulatory Submission,Donna Boyce,M1,False,False,False,False,False,"Clinical Trials, Regulatory Filing, Pharmaceutical Regulations, COVID-19 Vaccine, Efficacy Data, CBER, Submissions and Operations Support, Adverse Events, Regulatory Compliance, United States, Pfizer Inc., FDA Submission, Quality Assurance, Safety Data, Regulatory Approval, Vaccine Development, PPLS - Shanghai",17,2,https://drive.google.com/file/d/1WmNUA3ChjqHAXulOu8C7Qxz_UecwWHt1/view?usp=drivesdk,pd-production-080123,2025-08-11 23:50:58
125742_S131_M1_pp-cvv-usa-0391.pdf,PDF,Thermal Shipping Container Dry Ice Replenishment Instructions for Pfizer-BioNTech COVID-19 Vaccine (COMIRNATY®),2021-10-05,instructions,,M1,False,False,False,False,False,"covid-19 vaccine, fda emergency use authorization, vaccine distribution, fact sheets, comirnaty, regulatory compliance, occupational health, temperature monitoring, dry ice replenishment, vaccine handling, pfizer-biontech, clinical trials, vaccine administration, storage instructions, thermal shipping container, prescribing information, safety information",17,6,https://drive.google.com/file/d/1MXi3hEA4snFXmMnuIeU-IyBGlo7kEjEH/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:04
125742_S136_M1_cover.pdf,PDF,Summary Monthly Safety Report for COMIRNATY (COVID-19 mRNA Vaccine),2021-10-15,report,"Marion Gruber, Ph.D., Amit Patel",M1,False,False,False,False,False,"virus-free, vaccines, clinical-trials, new-hampshire, fda-submission, periodic-reporting, global-product-development, comirnaty, pfizer, safety-report, silver-spring, regulatory-affairs, adverse-events, covid-19, confidential-information, electronic-submission, mrna-vaccine",17,2,https://drive.google.com/file/d/15LSDxZv3FzDD16uFGo-zQoCBcUVT76-M/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:07
125742_S131_M1_pp-cvv-usa-0432.pdf,PDF,Pfizer-BioNTech COVID-19 Vaccine (COMIRNATY) Handling and Storage Checklist,2021,protocol,,M1,False,True,False,False,False,"covid-19-vaccine, vaccine-recipients, clinical-considerations, regulatory-compliance, fda-eua, vaccine-handling, vaccine-storage, safety-information, comirnaty, adverse-events, quality-control, vaccine-providers, Protocol, pfizer-biontech, vaccine-preparation, united-states, pharmaceutical-protocol, vaccine-administration",18,5,https://drive.google.com/file/d/1XUWuUQHYr-z--cPyE_6tzbvXR7ktFksH/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:10
125742_S131_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION for COMIRNATY (COVID-19 Vaccine, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, vaccine efficacy, patient counseling, pharmaceutical product, contraindications, regulatory submission, warnings and precautions, comirnaty, safety data, intramuscular injection, adverse events, immunization, prescribing information, fda approval, clinical trials",17,20,https://drive.google.com/file/d/1hoM05nVrCgJg-CBfgeAGl_xj_Bv0PsJE/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:14
125742_S13_M1_cover.pdf,PDF,Response to CBER's 6 July 2021 Information Request regarding BLA 125742 for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-07-16,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"BLA 125742, Vaccine Approval, Vaccine Efficacy, Clinical Trials, Pfizer Global Regulatory Affairs, COVID-19 mRNA Vaccine, Stable HIV Cohort, Vaccine Safety, Regulatory Submission, Collegeville, PA, Adverse Events, Silver Spring, MD, Biologics License Application, Regulatory Affairs, Vaccine Development, FDA CBER Information Request, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1_tEMFrJQe883EnM57F8yis4ZaQzEkdDy/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:18
125742_S13_M1_response-06july2021.pdf,PDF,BNT162b2 BLA STN 125742/0 Response to FDA Request for Information,2021-07-06,response,"Pfizer, BioNTech, FDA",M1,False,False,False,False,False,"withdrawal-from-study, appendices, pharmaceutical-industry, regulatory-compliance, biontec h, serious-adverse-events, medical-research, response-to-information-request, safety-data, stable-hiv-cohort, adverse-events, pfizer, vaccine-development, fda-submission, united-states, clinical-trial, bnt162b2",17,4,https://drive.google.com/file/d/1U3nhZwW11h0gofqg4Ymp-eSO5hhax5hJ/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:21
125742_S141_M1_lab-1457-15-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19),2021-10-20,fact sheet,,M1,False,False,False,False,False,"pfizer-biontech vaccine, healthcare provider information, immunocompromised individuals, booster dose, vaccine distribution, comirnaty, primary vaccination series, safety data, fda approval, clinical trials, vaccine administration, united states, covid-19, immunization, emergency use authorization, efficacy data, regulatory compliance",17,47,https://drive.google.com/file/d/17inrnOHKApefeWeQ-kFMP2Px71rVfZj0/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:26
125742_S141_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, vaccine efficacy, contraindications, regulatory submission, warnings and precautions, comirnaty, safety data, intramuscular injection, vaccine indications, adverse events, immunocompetence, prescribing information, fda approval, post-marketing experience, clinical trials",17,20,https://drive.google.com/file/d/1p4MYWd1_2xR6XOxTZ-nQbU3J4uaRZB7s/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:30
125742_S138_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, immunogenicity, vaccine efficacy, contraindications, regulatory submission, warnings and precautions, comirnaty, safety data, intramuscular injection, vaccine indications, adverse events, patient counseling information, prescribing information, fda approval, clinical trials",17,20,https://drive.google.com/file/d/191EFC0nfLcKb08l80Pawx4k92chGlohN/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:34
125742_S138_M1_pp-cvv-usa-0416.pdf,PDF,"BioNTech and Pfizer Comirnaty® (COVID-19 Vaccine, mRNA) Promotional Audio",2021-10,Promotional material,"BioNTech, Pfizer",M1,False,False,False,False,False,"Vaccine distribution, Vaccine efficacy, In-store audio advertisement, Vaccine administration, Vaccine safety, COVID-19 vaccine, mRNA vaccine, Pharmacist outreach, Clinical trial data, FDA approval, Comirnaty, Adverse event reporting, Vaccine identification, Vaccine marketing, Pharmaceutical-healthcare partnership, Regulatory compliance, Pharmaceutical promotion",17,1,https://drive.google.com/file/d/13mb2YNMhxVtg1rXuK3UDZYAzlo8sO1VU/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:37
125742_S141_M1_lab-1451-11-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-10-20,fact sheet,,M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, immunocompromised individuals, booster dose, pharmaceutical product, vaccine distribution, emergency use authorization, comirnaty, regulatory compliance, disease prevention, safety and efficacy, pfizer-biontech, vaccine information, primary vaccination series, fda approval, recipient and caregiver guidance, clinical trials",17,9,https://drive.google.com/file/d/1mFe_FctctjpNkr7n_jLDU81n4glauSei/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:41
125742_S138_M1_lab-1457-15-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19),2021-10-20,fact sheet,,M1,False,False,False,False,False,"covid-19 vaccine, healthcare provider information, immunocompromised individuals, booster dose, primary vaccination series, comirnaty, regulatory compliance, safety data, pfizer-biontech, efficacy data, united states, fda approval, pharmaceutical industry, adverse events, emergency use authorization, vaccination guidance, clinical trials",17,47,https://drive.google.com/file/d/1eQZIPbrYk2800YMZXLPC1Cjs2lTa-fcd/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:45
125742_S141_M1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Submission to FDA,2021-10-25,Regulatory Submission,Donna Boyce,M1,False,False,False,False,False,"PPLS (Pfizer Pharmaceutical Logistics and Submissions), Clinical Trials, Pharmaceutical Industry, COVID-19 Vaccine, Efficacy Data, CBER (Center for Biologics Evaluation and Research), Adverse Events, Compliance, Vaccine Identification, Quality Assurance, FDA Submission, Regulatory Affairs, Vaccine Distribution, Safety Data, Regulatory Approval, Vaccine Development, Pfizer",17,2,https://drive.google.com/file/d/1jqf2EIvO7s9HGULsFkGrS_c8w_eE6bc_/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:49
125742_S138_M1_lab-1451-11-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-10-20,fact sheet,,M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, immunocompromised individuals, booster dose, clinical trial phases, vaccine formulation, vaccine interchangeability, emergency use authorization, regulatory compliance, comirnaty, primary vaccination, pfizer-biontech, vaccine information, vaccine administration, efficacy data, fda approval, safety information",17,9,https://drive.google.com/file/d/1vac-WkM3FucDyiHT5AbEc9i_47cDELqM/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:53
125742_S144_m1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, patient information, pharmaceutical, adverse reactions, vaccine development, comirnaty, safety data, intramuscular injection, regulatory compliance, immunization, united states, efficacy data, prescribing information, fda approval, clinical trials",17,20,https://drive.google.com/file/d/1k_vVneEkw3mYv986XgbZdnW3O_OdxGH3/view?usp=drivesdk,pd-production-080123,2025-08-11 23:51:57
125742_S144_M1_lab-1451-11-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-10-20,fact sheet,,M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, eua authorization, booster dose, immunocompromised individuals, clinical trial data, vaccine distribution, comirnaty, primary vaccination, safety and efficacy, pfizer-biontech, pharmaceutical manufacturing, united states, public health information, adverse events, fda approval, regulatory compliance",17,9,https://drive.google.com/file/d/12ndY96UJC2eSRz1GhQS7ZU1IGlMvGWCx/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:00
125742_S144_M1_2253.pdf,PDF,Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use,2021-10-27,form,Donna Boyce,M1,False,False,False,False,False,"covid-19-vaccine, biologics, bla-application, regulatory-compliance, package-insert, product-code, clinical-data, promotional-labeling, material-id-code, drug-advertising, comirnaty, manufacturer, professional-consumer-materials, pfizer, mainz-germany, fda-submission, dissemination-date",17,2,https://drive.google.com/file/d/1WswrY5NcBYlzYLBYdytFHfPzDa5sH10b/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:03
125742_S141_M1_pp-cvv-usa-0473.pdf,PDF,Pfizer COVID-19 Vaccine Labeling,2021,report,,M1,False,False,False,False,False,"mobile, covid-19 vaccine, fda, compliance, desktop, labeling, responsive design, submission, quality, safety data, pfizer, adverse events, united states, annotations, efficacy data, clinical trials, regulatory",17,14,https://drive.google.com/file/d/1l9R902wqfQupLiwriPdy1Ie_T1jWg-TZ/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:07
125742_S144_M1_lab-1457-15-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19),2021-10-20,fact sheet,,M1,False,False,False,False,False,"pfizer-biontech vaccine, healthcare provider information, immunocompromised individuals, booster doses, primary vaccination series, regulatory compliance, safety data, comirnaty vaccine, fda approval, efficacy data, united states, covid-19, pharmaceutical industry, adverse events, emergency use authorization, vaccination guidance, clinical trials",17,47,https://drive.google.com/file/d/1Mzatb4SDX9KvyYphMfET76wnlzdk8c5U/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:11
125742_S144_M1_pp-cvv-usa-0478.pdf,PDF,Clinical Study Report for Investigational Drug [Redacted],2021,Report,,M1,False,False,False,False,False,"medical research, FDA submission, pharmaceutical development, clinical trial, drug identification, data analysis, FOIA request, safety data, CBER, quality assurance, United States, clinical study report, investigational drug, adverse events, data redaction, efficacy data, regulatory compliance",17,38,https://drive.google.com/file/d/1LITk--07L507Zy4eRnmbywyIaDi3MbUs/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:17
125742_S16_M1_cover.pdf,PDF,Response to FDA Information Request Regarding PREA Post-Marketing Commitment Goal Dates for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-07-23,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D.",M1,False,False,False,False,False,"dose-finding, pediatric-studies, clinical-trials, regulatory-compliance, prea-commitment, collegeville-pa, silver-spring-md, data-submission, fda-communication, global-product-development, safety-efficacy, regulatory-affairs, vaccine-development, bla-submission, covid-19, confidential-information, mrna-vaccine",17,2,https://drive.google.com/file/d/1crsqVk-n2_urVVRpFdzbHFd_SxXBSRfb/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:20
125742_S1_M5_CRF_c4591001-1072-10721007.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"optimal research, Exclusion, clinical trial, safety data, united states, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, medical terminology, demography, efficacy data",20,179,https://drive.google.com/file/d/19FwVFV_ajCMDKTakEEQ9886-GkBNvRNu/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:23
125742_S16_M1_psp-agreed-clean.pdf,PDF,"Agreed Pediatric Study Plan for COVID-19 Vaccine (BNT162, PF-07302048)",2021-07-22,Protocol,,M1,False,False,False,False,False,"Deferral of pediatric studies, PF-07302048, Investigational new drug (IND), Immunization, Safety and efficacy data, Regulatory submission, Pediatric clinical trial, Dosage form, Intramuscular injection, Disease epidemiology, Diagnosis methods, COVID-19 vaccine, SARS-CoV-2, BNT162, Pediatric population, Treatment and prevention strategies, Pfizer",17,23,https://drive.google.com/file/d/1me6lX1bZIqupnlDG-1aVzeZkjiio8YQZ/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:27
125742_S16_M1_response-15jul2021.pdf,PDF,Response to FDA Request for Information,2021-07-15,response,"Ramachandra Naik, Elisa Harkins",M1,False,True,False,False,False,"regulatory-submission, july-2021-timeline, fda-request, pediatric-study-plan, module-1-response, cber-review, dose-finding-study, bb-ind-019736, safety-data, epidemiology-considerations, prea-requirement, clinical-trial-c4591007, efficacy-data, Protocol, bnt162b2-vaccine, pfizer-biontech, infant-population, confidential-document",18,4,https://drive.google.com/file/d/1Vb7p1n6-FXHlm4GmviJxmXlOaTanapFE/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:31
125742_S16_M1_ped-studies-deferral-req.pdf,PDF,"Agreed Pediatric Study Plan for COVID-19 Vaccine (BNT162, PF-07302048)",2021-07-22,report,,M1,False,False,False,False,False,"BB-IND 019736, C4591001, PF-07302048, immunogenicity, clinical trial, children, pediatric studies, COVID-19 vaccine, FDA, BNT162, safety data, infants, adolescents, PFIZER CONFIDENTIAL, deferral request, efficacy data, regulatory submission",17,3,https://drive.google.com/file/d/1t6_JdigFmYmy0wBoE30BArndQk9R8jX1/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:36
125742_S18_M1_cover.pdf,PDF,Response to 22 July 2021 Information Request Regarding Clinical Shell Tables for Study C4591001,2021-07-26,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"BLA 125742, Vaccine Approval, BioNTech, Global Regulatory Affairs - Vaccines, COVID-19 mRNA Vaccine, Clinical Trial Study C4591001, SARS-CoV-2, Collegeville, PA, Regulatory Compliance, Clinical Safety and Efficacy Data, Silver Spring, MD, Pfizer Inc., Biologics License Application, Information Request Response, FDA Regulatory Submission, Vaccine Development, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1MHeIzIPlKgKpkGGS_ZAZ3-kvoVHLw8s-/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:40
125742_S18_M1_response-22jul2021.pdf,PDF,Response to FDA Information Request Regarding Clinical Shell Tables for Study C4591001,2021-07-22,response,Laura Gottschalk,M1,False,False,False,False,False,"regulatory-submission, blinding, covid-19-vaccine, fda-interaction, compliance, safety-data, case-definition, comirnaty, adverse-events, efficacy-data, pfizer, data-reporting, study-c4591001, clinical-trial, data-analysis, bnt162b2, pcr-testing",17,10,https://drive.google.com/file/d/1QAUkcXvxtTNOO9e8CG4_0Ju5c6wFY-gX/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:43
125742_S1_M5_CRF_c4591001-1072-10721064.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, subject 10721064, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, Optimal Research LLC, demography, efficacy data",19,363,https://drive.google.com/file/d/1VyzKMjrzoScUg01vs5PZRk8uh70Lpf9F/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:48
125742_S1_M5_CRF_c4591001-1077-10771049.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Regional Clinical Research, Inc., Protocol, demography, subject identification, safety",19,153,https://drive.google.com/file/d/1hFrFcmbof6llrMn1LSOBkeui7W9qNKYT/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:52
125742_S1_M5_CRF_c4591001-1072-10721037.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, Pfizer, demography, safety",19,478,https://drive.google.com/file/d/1Yq7VY6lFVtW2DwFZ85rHgeO_m1ssgJXc/view?usp=drivesdk,pd-production-080123,2025-08-11 23:52:58
125742_S1_M5_CRF_c4591001-1077-10771226.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory, data quality, pharmaceutical, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, safety",19,319,https://drive.google.com/file/d/1jGN2gDFtTJynYD9bfUTTMpXhxCLENWmR/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:02
125742_S1_M5_CRF_c4591001-1079-10791004.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-06,form,,M5,True,True,False,True,False,"pharmaceutical-research, Exclusion, inclusion-exclusion-criteria, fda, regulatory-compliance, crf, clinical-trial, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, phase-2-3, visit-date, subject-identification, eCRF, data-quality, demography, charlotte-nc",20,217,https://drive.google.com/file/d/1auXTjqj-4waMNCGvpNBD3rcPnU1BTbAq/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:06
125742_S1_M5_CRF_c4591001-1077-10771194.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Regional Clinical Research, Inc., Protocol, demography, subject identification, safety",19,158,https://drive.google.com/file/d/14pQW1QrNyC8w8wWtSlEsUmNNb7MaHx9C/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:09
125742_S1_M5_CRF_c4591001-1077-10771137.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regional clinical research, confidential, regulatory compliance, fda, data quality, inclusion/exclusion criteria, protocol amendment, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit date, Protocol, subject demographics, electronic case report form, data collection",20,178,https://drive.google.com/file/d/1MKToqgdHjyLepqIgfcp6ZqKFwVm-eiD5/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:14
125742_S1_M5_CRF_c4591001-1077-10771188.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, informed consent, visit date, Regional Clinical Research, Inc., Protocol, data verification, data completeness, subject identification, data locking and freezing, confidential document",20,371,https://drive.google.com/file/d/1I4EuJbSLvI0zlzSYcvGLG-FFXe7e3UF0/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:19
125742_S1_M5_CRF_c4591001-1080-10801013.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, PMG Research, demographic data, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, data collection, efficacy data, Raleigh",19,380,https://drive.google.com/file/d/1ba8bF7NPBHv7BahfX0pCrbxoKXFRM-kv/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:24
125742_S1_M5_CRF_c4591001-1079-10791199.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"PMG Research of Charlotte LLC, Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, subject enrollment, informed consent, visit date, FDA, c4591001 study, Protocol, data lock",19,121,https://drive.google.com/file/d/1ntlz3zN1lmXJL_HYVI4WLAW_7iUyK1pK/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:34
125742_S1_M5_CRF_c4591001-1079-10791183.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"PMG Research of Charlotte LLC, Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, safety",19,128,https://drive.google.com/file/d/1KMdTuFIFj2WrPHIQvFHR7NxOlhvFZ5tT/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:42
125742_S1_M5_CRF_c4591001-1079-10791228.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, adverse events, regulatory compliance, fda, data quality, pmg research, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, demographic data, subject enrollment, informed consent, visit schedule, Protocol, charlotte, nc, eCRF, data management",20,170,https://drive.google.com/file/d/1JuAQfp7bx4E83x_gWPwKAEHbGfk1Z9Tn/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:45
125742_S1_M5_CRF_c4591001-1080-10801035.pdf,PDF,c4591001 Clinical Trial CRF,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, Raleigh, NC, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, PMG Research, subject data, FOIA document, informed consent, visit date, FDA, Protocol, c4591001, demography",19,171,https://drive.google.com/file/d/1haHvk3C8GwjFltdFu99VzP1Oo3tztPlJ/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:49
125742_S1_M5_CRF_c4591001-1079-10791044.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"PMG Research of Charlotte LLC, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject enrollment, informed consent, visit date, FDA, c4591001 study, Protocol, demography, efficacy data",19,178,https://drive.google.com/file/d/1ruj8XrC8AzlLZNn8NswAA97cg3Y3NcaP/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:53
125742_S1_M5_CRF_c4591001-1079-10791076.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"PMG Research of Charlotte LLC, Exclusion, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, FDA submission, informed consent, visit date, Protocol, c4591001 protocol, medical research, data management, subject identification, adverse event reporting",20,209,https://drive.google.com/file/d/1657YJ8eALtVHiD8FsD0niDgpo5EGnw7V/view?usp=drivesdk,pd-production-080123,2025-08-11 23:53:57
125742_S1_M5_CRF_c4591001-1079-10791246.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"PMG Research of Charlotte LLC, Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, CRF, subject information, informed consent, visit date, FDA, Protocol, eCRF, demography",19,154,https://drive.google.com/file/d/1c_h4L01tv01Z6ynzS-f5ow-2Ez1Wrx3g/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:00
125742_S1_M5_CRF_c4591001-1080-10801059.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, PMG Research, informed consent, FDA, Protocol, data integrity, Cary, demography, data collection, safety, Raleigh",19,154,https://drive.google.com/file/d/144o_39ebEx1I2azBrly40ooTSqdIY62x/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:04
125742_S1_M5_CRF_c4591001-1080-10801006.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, PMG Research, informed consent, visit date, FDA, Protocol, c4591001, Cary, demography, efficacy data, Raleigh",20,307,https://drive.google.com/file/d/1zkB_e80n-LOHdI2gRG5L8qrWsvhUitGj/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:10
125742_S1_M5_CRF_c4591001-1083-10831050.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Research Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, Benchmark Research site, data quality control, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, demographic data, eCRF audit trail, subject enrollment, FDA regulatory, informed consent, data generation and management, visit schedule, Protocol, data freezing and locking, confidential document",20,451,https://drive.google.com/file/d/1UYAwcCFSvzao_I2bbmfkX9W6n5RbIQEf/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:15
125742_S1_M5_CRF_c4591001-1083-10831023.pdf,PDF,c4591001 Clinical Trial CRF,2021-04-19,clinical trial form,Benchmark Research,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, adverse event monitoring, visit date, Protocol, demography, fda submission, subject identification, efficacy data, electronic case report form, benchmark research",20,191,https://drive.google.com/file/d/1ts9ZPnwEj-wXhVerHzfoBuSBsZoFj42Q/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:20
125742_S1_M5_CRF_c4591001-1082-10821149.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, subject 10821149, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, Knoxville, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, New Orleans Center for Clinical Research, c4591001, eCRF, demography",20,154,https://drive.google.com/file/d/1pkNbP_K8F3h8YiMu48KD2C2vV4GIqtTa/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:24
125742_S1_M5_CRF_c4591001-1083-10831029.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Benchmark Research, safety data, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data",20,543,https://drive.google.com/file/d/1QweFdRNrZYX877EcOff-aGEqXfS8S1hV/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:29
125742_S1_M5_CRF_c4591001-1082-10821083.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, Knoxville, CRF, informed consent, visit date, FDA, vaccine development, Protocol, New Orleans Center for Clinical Research, c4591001, demography, subject identification, data collection",20,206,https://drive.google.com/file/d/1Hum7d9DtQ-ZOgseGmFGEVfiQkItS4QIN/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:33
125742_S1_M5_CRF_c4591001-1082-10821094.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, phase 2/3 study, Knoxville, CRF, demographic data, informed consent, visit date, FDA, Protocol, New Orleans, data management, subject identification",19,183,https://drive.google.com/file/d/1hivpLM-SvnyfUx26nftAKEfyDv5pyzvR/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:37
125742_S1_M5_CRF_c4591001-1082-10821076.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"crf-data-collection, Exclusion, inclusion-exclusion-criteria, phase-2-3-study, new-orleans-clinical-research-center, protocol-amendment, clinical-trial, CRF, covid-19-vaccine, visit-schedule, informed-consent, eCRF-audit-trail, data-quality-control, Protocol, efficacy-data, confidential-document, fda-regulatory, subject-identification, safety-data, demography",20,194,https://drive.google.com/file/d/1IYsrOQqRmQsisMpcLr_68xrou6iy-zW_/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:41
125742_S1_M5_CRF_c4591001-1080-10801152.pdf,PDF,c4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, PMG Research, subject information, informed consent, visit date, FDA, Protocol, c4591001, eCRF, Cary, demography, data collection, Raleigh",20,179,https://drive.google.com/file/d/1Ij30wQAKbIyomHBC6KtXeKJ5RwwZWePn/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:45
125742_S1_M5_CRF_c4591001-1084-10841266.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"clinical trials organization, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject data, informed consent, visit date, FDA, Protocol, Texas, demography, efficacy data",19,247,https://drive.google.com/file/d/1LysqZ0cbvyzOozLWSqHiRVeCSL8hDnwe/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:50
125742_S1_M5_CRF_c4591001-1083-10831194.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Benchmark Research, safety data, adverse events, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, data management, demography, subject identification, efficacy data, data collection",19,162,https://drive.google.com/file/d/1tZpl0Fcyc1qJnQnEM9gE-Ui1UF032T1e/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:54
125742_S1_M5_CRF_c4591001-1083-10831162.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, data audit trail, informed consent, visit date, FDA, Protocol, demography, subject identification, data collection",19,255,https://drive.google.com/file/d/1iZZYzAtq0qBlxUUTFK59wxxeqz1ZDsnv/view?usp=drivesdk,pd-production-080123,2025-08-11 23:54:58
125742_S1_M5_CRF_c4591001-1084-10841219.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, vaccine-development, regulatory-compliance, phase-2-3-study, site-information, clinical-trial, subject-demographics, CRF, covid-19-vaccine, texas-clinical-trials, eCRF-audit-trail, informed-consent, data-quality-control, Protocol, case-report-form, confidential-document, subject-identification, adverse-event-monitoring, fda-submission",20,213,https://drive.google.com/file/d/1i-6to_IgqIvqkl125A2C98E55YHWoY42/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:02
125742_S1_M5_CRF_c4591001-1083-10831124.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, Benchmark Research, confidential, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data",20,470,https://drive.google.com/file/d/1oBWywm3ERE6-cCEkHAKlp1OmecEz4QHR/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:07
125742_S1_M5_CRF_c4591001-1083-10831173.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Benchmark Research, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Protocol, c4591001, demography, efficacy data",19,451,https://drive.google.com/file/d/1duf3v8ib5Ls2m8jJRdJjgdp7ruydLQkl/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:15
125742_S1_M5_CRF_c4591001-1084-10841141.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, data quality control, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, eCRF audit trail, informed consent, adverse event monitoring, visit date, vaccine development, Protocol, c4591001 protocol, demography, Texas clinical site, case report form, subject identification, confidential document",20,185,https://drive.google.com/file/d/1K_Wi4y3puuuTupHHNK7q7PPAmD5nnKWk/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:19
125742_S1_M5_CRF_c4591001-1083-10831060.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, pharmaceutical research, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, clinical data management, demography, subject identification, data collection",19,912,https://drive.google.com/file/d/1wbd343VBGv0S2-y-yUWwWSIIoTGi8-Q_/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:25
125742_S1_M5_CRF_c4591001-1084-10841480.pdf,PDF,Clinical Trial CRF for c4591001 Study,2021-03-29,Clinical Trial Form,"Subject No: 10841480, Subject Initials: ---",M5,True,True,False,True,False,"Clinical Trial, Exclusion, Inclusion/Exclusion Criteria, Demography, Frozen Data, Vaccine, Pharmaceutical, FDA Submission, Safety Data, Data Capture, CRF, c4591001 Study, Protocol, Regulatory Compliance, Texas, Informed Consent, Site Information, Cohort Selection, Efficacy Data, Visit Schedule",20,174,https://drive.google.com/file/d/14TaZB7zGJWxAPPSy-uMwb8TiOKKiF8Pn/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:29
125742_S1_M5_CRF_c4591001-1087-10871121.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, clinical research, informed consent, visit date, FDA, vaccine development, Protocol, Pfizer, subject identification, data collection",19,169,https://drive.google.com/file/d/124etMQf6rNZkMpJAZ-sR1GcT4hXIUE4a/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:32
125742_S1_M5_CRF_c4591001-1084-10841538.pdf,PDF,Clinical Trial CRF for c4591001 Study,2020-10-10,Clinical Trial Form,,M5,True,True,False,True,False,"phase 2/3 trial, Exclusion, FDA regulation, clinical trial, cohort selection, inclusion/exclusion criteria, CRF, eCRF audit trail, informed consent, adverse event monitoring, visit date, vaccine development, c4591001 study, Protocol, data verification, data management, demography, Texas clinical site, subject identification, confidential document",20,428,https://drive.google.com/file/d/1th7oIjr_ILSiQqYvkUb5rsCh1esAi-Fj/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:37
125742_S1_M5_CRF_c4591001-1087-10871070.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, subject ID, clinical trial, phase 2/3, Wilmington, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, Pfizer, data management, demography",19,308,https://drive.google.com/file/d/1yCduevwikMOAV55M21Qq0jMJSpRsZUjt/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:42
125742_S1_M5_CRF_c4591001-1084-10841317.pdf,PDF,Clinical Trial eCRF for COVID-19 Vaccine Candidate c4591001,2021-03-29,eCRF (electronic Case Report Form),,M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, c4591001, Texas, eCRF, data management, demography, subject identification, safety, data collection",20,156,https://drive.google.com/file/d/1UWLxq6qzmNTDaPA3Dt-qXGZ2PGwD9fPd/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:45
125742_S1_M5_CRF_c4591001-1084-10841470.pdf,PDF,Clinical Trial CRF for COVID-19 Vaccine Candidate c4591001,2021-03-29,Clinical Trial Form,(1084) Clinical Trials of Texas,M5,True,True,False,True,False,"phase 2/3 trial, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, texas, protocol amendment, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, eCRF, demography, efficacy data",20,361,https://drive.google.com/file/d/1OrHy9V4TW9YgjaSvc9HD2U44ycQX_jxB/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:50
125742_S1_M5_CRF_c4591001-1087-10871029.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"phase 2/3 trial, Exclusion, clinical trial, data quality, inclusion/exclusion criteria, data compliance, COVID-19 vaccine, CRF, demographic data, subject enrollment, informed consent, visit date, FDA, c4591001 study, Protocol, Pfizer, data management, PMG Research of Wilmington, confidential document",19,337,https://drive.google.com/file/d/1c11V7pLHnZmP2_3h1TwysZzKoNFYuB16/view?usp=drivesdk,pd-production-080123,2025-08-11 23:55:56
125742_S1_M5_CRF_c4591001-1087-10871150.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, safety monitoring, visit date, Protocol, c4591001, wilmington, demography, efficacy data",20,365,https://drive.google.com/file/d/1JK9jpXL_5yn92vtgxLqpERsxG_Ut8wZP/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:00
125742_S1_M5_CRF_c4591001-1087-10871286.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, informed consent, Protocol, subject demographics, wilmington, eCRF, data integrity, efficacy data, data collection",20,734,https://drive.google.com/file/d/1Tg3CaUtWCb-zuNFDgWksv1hUvZ1HmC7f/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:06
125742_S1_M5_CRF_c4591001-1087-10871266.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,"(1087) PMG Research of Wilmington, LLC",M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, Wilmington, adverse events, regulatory, data quality, compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, demography, safety",19,152,https://drive.google.com/file/d/1huO0OHNz9nARewU5M5VdkdmA8wjzvnky/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:10
125742_S1_M5_CRF_c4591001-1087-10871289.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, Pfizer, data management, subject identification, PMG Research of Wilmington",19,203,https://drive.google.com/file/d/11nfSCe-cCwG28hx-cOSfM7fWoETa2fAp/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:14
125742_S1_M5_CRF_c4591001-1087-10871355.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, pharmaceutical research, fda, inclusion/exclusion criteria, quality assurance, phase 2/3 study, CRF, covid-19 vaccine, demographic data, subject enrollment, informed consent, safety monitoring, visit schedule, Protocol, wilmington, data management, efficacy data",20,158,https://drive.google.com/file/d/1RtFdRZ1ypjok09wrGYXifTaVEt_BrHLK/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:18
125742_S1_M5_CRF_c4591001-1087-10871354.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, Wilmington, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, PMG Research, demographic data, subject enrollment, informed consent, visit date, FDA, Protocol, Pfizer, eCRF",19,118,https://drive.google.com/file/d/16j4gjbPshKLq_Bh9agHCGbF68pmwMZlY/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:28
125742_S1_M5_CRF_c4591001-1087-10871228.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, FDA, Protocol, Pfizer, demography, subject identification, visit information, efficacy data",19,334,https://drive.google.com/file/d/10bBm2O-fqP51Godw96ybp2cOelWjVoZh/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:32
125742_S1_M5_CRF_c4591001-1087-10871152.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, subject enrollment, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, data management, PMG Research of Wilmington",19,162,https://drive.google.com/file/d/1pf_JDUnbMfnT6p5rBaS9ojrUw0NgUBXU/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:36
125742_S1_M5_CRF_c4591001-1087-10871191.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, c4591001 trial, United States, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, FDA submission, informed consent, adverse event monitoring, visit date, Protocol, demography data, PMG Research of Wilmington, efficacy endpoints",20,163,https://drive.google.com/file/d/1hnwJiyNPbkUvVhONPdz0IBTT3iE1Dc_c/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:40
125742_S1_M5_CRF_c4591001-1089-10891073.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, PMG Research of Salisbury, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, informed consent, visit date, FDA, Protocol, c4591001, Pfizer, demography, data collection",20,211,https://drive.google.com/file/d/1dPf9ccQRqxa0ImQmUtci3cLojZ3IyRpk/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:44
125742_S1_M5_CRF_c4591001-1088-10881139.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, PMG Research of Hickory LLC, CRF, demographic data, eCRF audit trail, informed consent, visit date, FDA, Protocol, data management, subject identification",19,352,https://drive.google.com/file/d/10sIXZXFF1tPKNvn8XOHTfAe5elZPu6J-/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:49
125742_S1_M5_CRF_c4591001-1089-10891088.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory, Salisbury, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, PMG Research, subject information, audit trail, informed consent, visit date, FDA, Protocol, eCRF, demography",19,198,https://drive.google.com/file/d/1cAgH6JpQH8Ug99FF6RyISnNUhYvsUfcd/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:53
125742_S1_M5_CRF_c4591001-1089-10891065.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"quality control, Exclusion, clinical trial, confidential, regulatory compliance, fda, inclusion/exclusion criteria, pmg research, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit schedule, Protocol, subject demographics, salisbury site, eCRF, data management, data collection",20,190,https://drive.google.com/file/d/1dO4-yP9zuy69IcM848SdmArQVUdl7N85/view?usp=drivesdk,pd-production-080123,2025-08-11 23:56:57
125742_S1_M5_CRF_c4591001-1089-10891150.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Salisbury site, confidential, adverse events, regulatory compliance, data quality, COVID-19 vaccine, phase 2/3 study, CRF, PMG Research, demographic data, subject enrollment, informed consent, visit schedule, FDA, Protocol, Pfizer, data management",19,205,https://drive.google.com/file/d/1nIS0_5vPHhIj6M-piL_llY71-bcnc9Wx/view?usp=drivesdk,pd-production-080123,2025-08-11 23:57:01
125742_S1_M5_CRF_c4591001-1088-10881126.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"phase 2/3 trial, Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, site details, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, c4591001 study, Protocol, Pfizer, data management, demography, confidential document",19,384,https://drive.google.com/file/d/1N1USJeyK7Tekx4qXIKMTnwl6pkTOPEJm/view?usp=drivesdk,pd-production-080123,2025-08-11 23:57:06
125742_S1_M5_CRF_c4591001-1089-10891042.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, Salisbury, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, PMG Research, informed consent, visit date, FDA, Protocol, Pfizer, demography, subject identification, data collection",19,252,https://drive.google.com/file/d/1egoiNRm2FLepk7lxwKS8NdVUSP1V9syQ/view?usp=drivesdk,pd-production-080123,2025-08-11 23:57:10
125742_S1_M5_CRF_c4591001-1088-10881220.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, PMG Research, demographic data, informed consent, safety monitoring, visit date, FDA, Protocol, subject identification, efficacy data",19,144,https://drive.google.com/file/d/1ldfpo2ATqTfEcYhM4vD3hONU3eXupCRm/view?usp=drivesdk,pd-production-080123,2025-08-11 23:57:19
125742_S1_M5_CRF_c4591001-1089-10891181.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, inclusion/exclusion criteria, salisbury, pmg research, efficacy, phase 2/3 study, CRF, covid-19 vaccine, subject data, informed consent, visit date, Protocol, demography, safety",20,139,https://drive.google.com/file/d/1n89GOd0a2_-c81kznJ2Z8okigDoDnYVn/view?usp=drivesdk,pd-production-080123,2025-08-11 23:57:27
125742_S1_M5_CRF_c4591001-1087-10871557.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-01,form,"(1087) PMG Research of Wilmington, LLC",M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, safety monitoring, visit date, FDA, Protocol, Wilmington, LLC, subject identification, efficacy data",19,158,https://drive.google.com/file/d/1oGBRxmD8FJzr8DVST4mSrbXRaYpgYAKq/view?usp=drivesdk,pd-production-080123,2025-08-11 23:57:30
125742_S1_M5_CRF_c4591001-1089-10891289.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, Salisbury, NC, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject data, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, demography",19,139,https://drive.google.com/file/d/1Wqm7hv0VPUkvrznyBzv2LiOf_Mm9BTuE/view?usp=drivesdk,pd-production-080123,2025-08-11 23:57:37
125742_S1_M5_CRF_c4591001-1089-10891182.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,"(1089) PMG Research of Salisbury, Subject No: 10891182",M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, demographic data, eCRF audit trail, informed consent, visit date, Protocol, data verification, Pfizer-BioNTech, subject identification, data freezing, confidential document",20,524,https://drive.google.com/file/d/1EYjnahA1xXmypyxLCEWEqGlGHG08MtXj/view?usp=drivesdk,pd-production-080123,2025-08-11 23:57:43
125742_S1_M5_CRF_c4591001-1089-10891273.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, subject ID, clinical trial, safety data, PMG Research of Salisbury, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, efficacy data",19,146,https://drive.google.com/file/d/1vB1BW1eZi9R7qgPvVAG1pySx5Wzh4nwY/view?usp=drivesdk,pd-production-080123,2025-08-11 23:57:47
125742_S1_M5_CRF_c4591001-1094-10941112.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,"(1094) LinQ Research, LLC",M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data, data collection",20,931,https://drive.google.com/file/d/1Vpm7v_dD1uwyWA8YN43ehfOY72CnDk7O/view?usp=drivesdk,pd-production-080123,2025-08-11 23:57:53
125742_S1_M5_CRF_c4591001-1094-10941155.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, adverse events, LinQ Research, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, safety",20,164,https://drive.google.com/file/d/1IRg39VUiactNQoU9MMTN5IGCNHU_K_ph/view?usp=drivesdk,pd-production-080123,2025-08-11 23:57:57
125742_S1_M5_CRF_c4591001-1097-10971026.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, adverse events, regulatory compliance, fda, data quality, waterway, inclusion/exclusion criteria, phase 2/3 study, CRF, audit trail, covid-19 vaccine, demographic data, subject enrollment, informed consent, visit schedule, Protocol, eCRF, main street physician's care",20,236,https://drive.google.com/file/d/1_bhSo3csIfVfOs3Mi1S-5wbyOD0B-0NP/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:01
125742_S1_M5_CRF_c4591001-1097-10971011.pdf,PDF,Clinical Study Report Form,2021,report,,M5,True,False,False,False,False,"pharmaceutical research, FDA submission, clinical trial, phase 4 study, FOIA request, vaccine development, safety data, CBER, COVID-19, quality assurance, United States, case report form, clinical study report, CRF, efficacy data, adverse events, data collection, regulatory compliance",18,372,https://drive.google.com/file/d/1DiuRmZznmkPz-NwgYT8OOjJG_Ws3-dsj/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:08
125742_S1_M5_CRF_c4591001-1097-10971017.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit schedule, FDA, Protocol, data management, demography, subject identification, safety",19,436,https://drive.google.com/file/d/1hjMtHZy6YPlZurzuBkPj0dh3Yg3CiJz1/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:12
125742_S1_M5_CRF_c4591001-1097-10971025.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, main-street-physician-care, phase-2-3-study, site-information, adverse-events, clinical-trial, CRF, covid-19-vaccine, informed-consent, cohort-selection, Protocol, efficacy-data, visit-date, fda-regulatory, subject-identification, waterway-location, data-quality, safety-data, demography",20,147,https://drive.google.com/file/d/1wXSsLOLPg2RJXIPJTjAUC36Wh1wZNsMq/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:15
125742_S1_M5_CRF_c4591001-1097-10971023.pdf,PDF,Clinical Study Report Form,2021,report,,M5,True,False,False,False,False,"c4591001-1097-10971023, pharmaceutical research, FDA submission, medical product, phase 4 study, clinical trial, vaccine development, safety data, CBER, data management, quality assurance, United States, case report form, CRF, efficacy data, adverse events, data analysis, regulatory compliance",18,184,https://drive.google.com/file/d/1m9CgzhWMHPfoia6ML3U-fpZluKYHQGOH/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:21
125742_S1_M5_CRF_c4591001-1097-10971061.pdf,PDF,c4591001 Clinical Trial CRF,2021-03-29,Clinical Trial Form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, subject data, informed consent, visit date, FDA, Protocol, vaccine, c4591001, demography, data collection",20,406,https://drive.google.com/file/d/1mKa_0T4T-z5DNAH_ccYwqAnqL3v-30DD/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:26
125742_S1_M5_CRF_c4591001-1097-10971031.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, FOIA document, clinical research, pharmaceutical development, informed consent, visit date, FDA, Protocol, demography, subject identification, data collection",19,320,https://drive.google.com/file/d/117wpjTxvbcvGbZyy6ma2AVXyf9Kxjvpg/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:30
125742_S1_M5_CRF_c4591001-1097-10971087.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, pharmaceutical development, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,204,https://drive.google.com/file/d/15uGAIaTDRjzdkoqP0C2NdItJpbmRh7bL/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:34
125742_S1_M5_CRF_c4591001-1097-10971084.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, demographics, clinical trial, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, data management, subject identification, safety",19,252,https://drive.google.com/file/d/11YBgmGdyg1233Vk5vOCdoBanHEeIQkZH/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:39
125742_S1_M5_CRF_c4591001-1107-11071031.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, data quality control, Coastal Clinical Research, regulatory compliance, visit documentation, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, FDA submission, informed consent, adverse event monitoring, Protocol, data management, demography data, subject identification",20,583,https://drive.google.com/file/d/1UU5wbOIR7S6yIt0nbT2VHi24acL_ccD8/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:45
125742_S1_M5_CRF_c4591001-1097-10971064.pdf,PDF,Clinical Study Report Form,2021,report,,M5,True,False,False,False,False,"drug identifier, medical research, public health, pharmaceutical, FDA submission, clinical trial, phase 4 study, safety data, CBER, quality assurance, vaccine, case report form, CRF, efficacy data, adverse events, data collection, data analysis, regulatory compliance",18,264,https://drive.google.com/file/d/1Lm76ikWOoD8-3YsDxD09OkI5WTVlVNXQ/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:52
125742_S1_M5_CRF_c4591001-1101-11011115.pdf,PDF,c4591001 Clinical Trial eCRF,2020-10-01,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, Prairie Fields Family Medicine, CRF, subject information, informed consent, visit date, FDA, Protocol, vaccine, c4591001, eCRF, demography, data collection",20,181,https://drive.google.com/file/d/1Aq8yAAOV1Q-rw2QMvwJST5_sPHSETVIO/view?usp=drivesdk,pd-production-080123,2025-08-11 23:58:56
125742_S1_M5_CRF_c4591001-1107-11071044.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, United States, Coastal Clinical Research, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, FDA submission, informed consent, safety monitoring, visit schedule, Protocol, demography data, efficacy data",20,372,https://drive.google.com/file/d/1dE2MKnjTVbfNUw-hEeqbA5WYOG4fqErV/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:00
125742_S1_M5_CRF_c4591001-1098-10981024.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,"Salma Mazhar, MD, PA",M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, primary care clinic, regulatory compliance, fda, inclusion/exclusion criteria, quality assurance, geographic location, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, medical terminology, data integrity, demography, subject identification, data collection",20,885,https://drive.google.com/file/d/1yPb6Ol8n_v5nHn6qJt1QzsJTf4KsoPh2/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:07
125742_S1_M5_CRF_c4591001-1109-11091204.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, date-of-visit, quality-assurance, accel-research-sites, phase-2-3-study, protocol-amendment, site-information, clinical-trial, subject-demographics, CRF, data-collection, covid-19-vaccine, visit-schedule, informed-consent, eCRF-audit-trail, Protocol, confidential-document, fda-regulatory, subject-identification",20,224,https://drive.google.com/file/d/1rg6fFlHDDhYnBNLPsYUhpGKygzwMa5a0/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:11
125742_S1_M5_CRF_c4591001-1107-11071191.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, fda, coastal clinical research, inclusion/exclusion criteria, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit schedule, Protocol, data verification, subject demographics, eCRF, data integrity, data freezing, data collection",20,243,https://drive.google.com/file/d/1OTMvdtOThfVwCP0vfdzJp-U1Jz_t60Uf/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:14
125742_S1_M5_CRF_c4591001-1107-11071065.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, coastal clinical research, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, subject enrollment, data auditing, informed consent, Protocol, data verification, eCRF, demography, efficacy data, data collection",20,206,https://drive.google.com/file/d/1RSnOFOUruYKBf4f9xQ6zS930fWp2qFnC/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:18
125742_S1_M5_CRF_c4591001-1109-11091111.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, subject enrollment, informed consent, visit date, FDA, Protocol, clinical research unit, data management, demography, Accel Research Sites",19,399,https://drive.google.com/file/d/1Z3GXgUg12Jgfi_A_uPngA7KIDTuFltxs/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:23
125742_S1_M5_CRF_c4591001-1109-11091036.pdf,PDF,c4591001 Clinical Trial CRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, demography, safety",20,176,https://drive.google.com/file/d/1w3KHPhMAHPd0OnP2VHHh1SU06VKvp13V/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:27
125742_S1_M5_CRF_c4591001-1107-11071196.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Coastal Clinical Research, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, eCRF audit trail, informed consent, adverse event monitoring, visit date, FDA, Protocol, c4591001, data integrity, demography, data collection",20,112,https://drive.google.com/file/d/1MGvvhkiiOxJmy_tbPMIXAa19vczAvgB7/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:34
125742_S1_M5_CRF_c4591001-1109-11091164.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, vaccine-development, regulatory-compliance, crf, phase-2-3-study, protocol-amendment, adverse-events, clinical-trial, CRF, covid-19-vaccine, informed-consent, cohort-selection, Protocol, subject-enrollment, visit-date, data-quality, demography, fda-submission, clinical-research-unit",20,195,https://drive.google.com/file/d/12f7vyAIQBLtkIB8GPHyuTxrwRUx0toib/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:38
125742_S1_M5_CRF_c4591001-1109-11091269.pdf,PDF,c4591001 Clinical Trial eCRF,2020-07-30,report,,M5,True,True,False,True,False,"Exclusion, confidential, covid-19, fda, regulatory-compliance, accel-research-sites, protocol-amendment, adverse-events, clinical-trial, CRF, phase-3, data-collection, visit-schedule, informed-consent, Protocol, vaccine, subject-enrollment, eCRF, data-quality, demography",20,223,https://drive.google.com/file/d/1oNybXMck41-dXwK3IWb5XQXPligeP6b0/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:42
125742_S1_M5_CRF_c4591001-1109-11091084.pdf,PDF,COVID-19 Vaccine Clinical Trial CRF,2020-07-30,form,,M5,True,True,False,True,False,"accel research sites, Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, subject enrollment, informed consent, safety monitoring, visit schedule, Protocol, data management, demography data, electronic case report form, confidential document",20,242,https://drive.google.com/file/d/12gr7pFtMhaAtH-8osjjVic-Sm36dSZQt/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:47
125742_S1_M5_CRF_c4591001-1109-11091074.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, data-verification, inclusion-exclusion-criteria, regulatory-compliance, accel-research-sites, data-freezing, protocol-amendment, clinical-trial, fda-regulated, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, Protocol, visit-date, subject-identification, demography, quality-control, clinical-research-unit",20,303,https://drive.google.com/file/d/1SLeFTy1hB25WH3iENWlufOJE_LaHUmRN/view?usp=drivesdk,pd-production-080123,2025-08-11 23:59:51
125742_S1_M5_CRF_c4591001-1107-11071116.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, Coastal Clinical Research, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, demographic data, eCRF audit trail, informed consent, visit date, Protocol, data verification, subject identification, data freezing, confidential document",20,142,https://drive.google.com/file/d/1_4HsNPxkU01zHJmCae9ucmAl8jLpoZcK/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:00
125742_S1_M5_CRF_c4591001-1109-11091558.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, covid-19 vaccine, informed consent, safety monitoring, visit date, Protocol, c4591001, demography, subject identification, efficacy data, data collection",20,197,https://drive.google.com/file/d/1Bnku42p9jq3Hw4Um_c2Qq8T67OE03Iov/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:04
125742_S1_M5_CRF_c4591001-1109-11091448.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, regulatory-compliance, accel-research-sites, phase-2-3-study, adverse-events, clinical-trial, CRF, covid-19-vaccine, informed-consent, cohort-selection, Protocol, efficacy-data, united-states, visit-date, eCRF, data-quality, safety-data, demography, fda-submission",20,343,https://drive.google.com/file/d/1DKX_PuTxxRUBJ9XunZwklaCjANMomk9S/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:10
125742_S1_M5_CRF_c4591001-1109-11091387.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"pharmaceutical-research, Exclusion, inclusion-exclusion-criteria, regulatory-compliance, data-integrity, site-information, clinical-trial, CRF, data-collection, covid-19-vaccine, eCRF-audit-trail, informed-consent, cohort-selection, Protocol, visit-date, confidential-document, phase-2-3-clinical-trial, subject-details, demography, fda-submission",20,131,https://drive.google.com/file/d/1Q2G4PY9xMCbbF8mPscZYB5hpELse2sD_/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:17
125742_S1_M5_CRF_c4591001-1116-11161045.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, MedPharmics, protocol amendment, CRF, demographic data, subject enrollment, informed consent, visit schedule, FDA, Protocol, efficacy data",19,329,https://drive.google.com/file/d/1R3Nd0GOEHLyYo62nLj4xzHoYakdYAta-/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:22
125742_S1_M5_CRF_c4591001-1109-11091503.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, date-of-visit, accel-research-sites, phase-2-3-study, demographic-data, site-information, clinical-trial, CRF, data-collection, covid-19-vaccine, visit-schedule, informed-consent, Protocol, subject-enrollment, confidential-document, fda-regulatory, subject-identification, quality-control, data-audit-trail",20,157,https://drive.google.com/file/d/1nrMt95KMiGe5GDbGnqkjf-MOl3iJZVxE/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:26
125742_S1_M5_CRF_c4591001-1109-11091415.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, demography-data, clinical-research-form, inclusion-exclusion-criteria, date-of-visit, electronic-case-report-form, accel-research-sites, phase-2-3-study, protocol-amendment, clinical-trial, CRF, covid-19-vaccine, visit-schedule, informed-consent, data-quality-control, Protocol, vaccine-administration, confidential-document, fda-regulatory, subject-identification",20,265,https://drive.google.com/file/d/189k-tJpnV2pqyKCFkZAlaXpmvcPRVxAZ/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:31
125742_S1_M5_CRF_c4591001-1109-11091284.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"accel research sites, Exclusion, clinical trial, united states, confidential, adverse events, regulatory compliance, fda, data quality, protocol amendment, phase 2/3 study, CRF, audit trail, covid-19 vaccine, informed consent, visit schedule, Protocol, subject demographics, medical terminology, data collection",20,195,https://drive.google.com/file/d/1-NDAbq_6BRdv1_0LAlsO8PZQscM2tKQw/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:35
125742_S1_M5_CRF_c4591001-1109-11091276.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, fda, regulatory-compliance, accel-research-sites, crf, subject-information, protocol-amendment, adverse-events, clinical-trial, CRF, data-collection, covid-19-vaccine, informed-consent, cohort-selection, data-management, Protocol, visit-date, demography, safety-efficacy",20,165,https://drive.google.com/file/d/13yRaK7wqXGs6VYQnXiyJ9H5iTaWs5dah/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:38
125742_S1_M5_CRF_c4591001-1116-11161198.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, MedPharmics, LLC, phase 2/3 study, CRF, eCRF audit trail, subject enrollment, informed consent, adverse event monitoring, Protocol, c4591001 protocol, data completeness, demography data, confidential document",20,178,https://drive.google.com/file/d/1wUXJ9VSrG5wp3ryUDHTQavVvmWLfUU3Q/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:42
125742_S1_M5_CRF_c4591001-1116-11161160.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, safety data, c4591001 trial, United States, data quality control, inclusion/exclusion criteria, COVID-19 vaccine, MedPharmics, LLC, efficacy assessment, phase 2/3 study, CRF, demographic data, eCRF audit trail, subject enrollment, informed consent, adverse event monitoring, visit schedule, Protocol",20,343,https://drive.google.com/file/d/1AeBZra1kHPeBT6IOpxmN-ldRIPwiVLOP/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:47
125742_S1_M5_CRF_c4591001-1127-11271112.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Heartland Research Associates, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, safety",20,129,https://drive.google.com/file/d/1DIZIa7Sou6hRSlT3USjZFj7w_K_GAr6t/view?usp=drivesdk,pd-production-080123,2025-08-12 00:00:57
125742_S1_M5_CRF_c4591001-1116-11161059.pdf,PDF,c4591001 Clinical Trial eCRF,2020-07-30,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, United States, adverse events, regulatory compliance, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, MedPharmics, CRF, informed consent, visit date, FDA, Protocol, vaccine, c4591001, eCRF, demography",20,182,https://drive.google.com/file/d/1JAqTbZp3ldPcF-MXSBD5pp5bqCQwVCeK/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:00
125742_S1_M5_CRF_c4591001-1116-11161224.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, pharmaceutical research, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, phase 2/3 study, CRF, subject data, informed consent, visit date, FDA, Protocol, data management, demography",19,840,https://drive.google.com/file/d/1ABnaMXn3z02mqlIAUqJjP9n1DQjqk-Kk/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:06
125742_S1_M5_CRF_c4591001-1127-11271023.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"site information, heartland research associates, Exclusion, clinical trial, phase 2/3, safety data, covid-19, adverse events, regulatory, fda, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, Protocol, vaccine, subject details, demography, efficacy data",20,279,https://drive.google.com/file/d/1ukn-k7oOuipZhyemf_0ssPOhYJwEu3zH/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:11
125742_S1_M5_CRF_c4591001-1116-11161253.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, clinical research form, MedPharmics, LLC, phase 2/3 study, CRF, informed consent, adverse event monitoring, visit date, Protocol, c4591001 protocol, demography, subject identification, data collection",20,565,https://drive.google.com/file/d/15-3Upa-eAkKQovSVJpAAj82tBj2kJSuy/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:16
125742_S1_M5_CRF_c4591001-1116-11161131.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, safety data, United States, adverse events, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, informed consent, MedPharmics LLC, visit date, Protocol, c4591001 protocol, efficacy data",20,184,https://drive.google.com/file/d/1a-Ls5sTufpaLpE1Q4cGST5jvkYhsCdCA/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:21
125742_S1_M5_CRF_c4591001-1139-11391024.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, Duke University Medical Center, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, efficacy data",20,190,https://drive.google.com/file/d/1rPfPDklE8wJzshDzcereI9AhOLQd_msQ/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:25
125742_S1_M5_CRF_c4591001-1136-11361082.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-27,form,(1136) Clinical Research Center of Nevada,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, nevada, covid-19 vaccine, informed consent, visit date, Protocol, subject details, c4591001, medical research, demography, data collection",20,224,https://drive.google.com/file/d/1-0_47qmDzDtKJdzMb9EpfpLSiAujEnxr/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:29
125742_S1_M5_CRF_c4591001-1139-11391068.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, Duke University Medical Center, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data",19,148,https://drive.google.com/file/d/1FERvGkS7SfERhR776vTazKUgqvS4S_uS/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:32
125742_S1_M5_CRF_c4591001-1140-11401009.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"suny upstate medical university, Exclusion, clinical trial, confidential, adverse events, regulatory compliance, fda, data quality, inclusion/exclusion criteria, clinical research form, phase 2/3 study, CRF, audit trail, covid-19 vaccine, subject enrollment, informed consent, visit schedule, Protocol, demography, data collection",20,506,https://drive.google.com/file/d/1ZdB5imuD4fTWri8I2NlhPesapEio7we0/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:39
125742_S1_M5_CRF_c4591001-1140-11401002.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-06,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, SUNY Upstate Medical University, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, demography, subject identification, efficacy data",19,265,https://drive.google.com/file/d/1RiI8cK7vyEhVO_bTnimh0hLYOKNW3dHM/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:44
125742_S1_M5_CRF_c4591001-1140-11401020.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"suny upstate medical university, Exclusion, clinical trial, united states, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, efficacy, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, safety",20,271,https://drive.google.com/file/d/1mHn6uomzKFgknldWUQdC4IIoWuxIYII4/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:49
125742_S1_M5_CRF_c4591001-1136-11361102.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-10-29,clinical trial form,(1136) Clinical Research Center of Nevada,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, Nevada, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, efficacy data",20,150,https://drive.google.com/file/d/1bsoqsfx5qvoK0s69KGk02PODWmvJJ15Z/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:52
125742_S1_M5_CRF_c4591001-1136-11361029.pdf,PDF,Clinical Trial Case Report Form,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, audit trail, demographic data, Nevada, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, case report form, subject identification",20,432,https://drive.google.com/file/d/1YTdo78ZlFvmYqxvrqeSp_Z_6YAwEb968/view?usp=drivesdk,pd-production-080123,2025-08-12 00:01:57
125742_S1_M5_CRF_c4591001-1140-11401035.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"suny upstate medical university, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data, data collection",20,250,https://drive.google.com/file/d/1c1QXT8iAOjNo-9CVAeC58bnH9LOThKWG/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:00
125742_S1_M5_CRF_c4591001-1140-11401066.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"suny upstate medical university, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, protocol amendment, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data, data collection",20,212,https://drive.google.com/file/d/1b-AxHxC7TRqgTZqjnEZ1Da_bhPYlDZwy/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:05
125742_S1_M5_CRF_c4591001-1140-11401244.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, SUNY Upstate Medical University, safety data, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, eCRF audit trail, informed consent, visit date, FDA, Protocol, demography, efficacy data",19,216,https://drive.google.com/file/d/1w1LZmUhd9KXTPVh7ynbvde8Gr_S5FQ0B/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:09
125742_S1_M5_CRF_c4591001-1140-11401181.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, inclusion-exclusion-criteria, fda, regulatory-compliance, crf, demographic-data, adverse-events, clinical-trial, CRF, suny-upstate-medical-university, covid-19-vaccine, informed-consent, cohort-selection, Protocol, phase-2-3, efficacy-data, visit-date, data-quality, safety-data, clinical-research",20,216,https://drive.google.com/file/d/17Bv-ZkMXNdvL740BcLcMzVttvZnyQm6I/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:13
125742_S1_M5_CRF_c4591001-1140-11401306.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-22,clinical trial form,(1140) SUNY Upstate Medical University,M5,True,True,False,True,False,"Exclusion, clinical trial, SUNY Upstate Medical University, safety data, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, clinical research form, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, subject identification",20,225,https://drive.google.com/file/d/1dgw5LXQZcwC8w_I3XFKfVQucDVEfMix8/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:17
125742_S1_M5_CRF_c4591001-1140-11401156.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1140) SUNY Upstate Medical University,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory submission, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, audit trail, covid-19 vaccine, subject information, informed consent, visit date, Protocol, c4591001, frozen data, demography, upstate medical university",20,147,https://drive.google.com/file/d/1PvZHkMCdWPwpK1lnaVIkPGZOmM-_hXY5/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:21
125742_S1_M5_CRF_c4591001-1140-11401180.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1140) SUNY Upstate Medical University,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory submission, fda, cohort selection, inclusion/exclusion criteria, efficacy, protocol amendment, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, safety, upstate medical university, data collection",20,164,https://drive.google.com/file/d/1NMb4nikvMsofD780R8rsxtxun70eeJnJ/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:25
125742_S1_M5_CRF_c4591001-1140-11401078.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Research Form (CRF),,M5,True,True,False,True,False,"Exclusion, SUNY Upstate Medical University, data quality control, inclusion/exclusion criteria, clinical research form, COVID-19 vaccine trial, CRF, demographic data, eCRF audit trail, subject enrollment, FDA regulatory, informed consent, visit date, vaccine development, c4591001 study, clinical trial protocol, Protocol, phase 2/3 clinical trial, data management, confidential document",20,230,https://drive.google.com/file/d/1_NBpK3PbNN-MD1ARr-rxQ3VkcsLyHllw/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:29
125742_S1_M5_CRF_c4591001-1140-11401117.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, SUNY Upstate Medical University, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, data management, demography, safety",19,219,https://drive.google.com/file/d/1IxVXnU8ysPFM_ZC3CxuO0DUBdcPHC_VP/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:34
125742_S1_M5_CRF_c4591001-1140-11401282.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-13,form,(1140) SUNY Upstate Medical University,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, New York, demography, subject identification, efficacy data",20,152,https://drive.google.com/file/d/1YsnDAI7F295fn9khgMzsuD8sHSQHA4D5/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:37
125742_S1_M5_CRF_c4591001-1140-11401285.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-14,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, SUNY Upstate Medical University, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, eCRF audit trail, informed consent, visit date, FDA, Protocol, subject demographics, efficacy data",19,192,https://drive.google.com/file/d/1Ec-lXKe864ULuCwKIPJIIiKyi3XrWwMM/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:41
125742_S1_M5_CRF_c4591001-1142-11421032.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, university of texas, phase 2/3 study, CRF, safety assessment, covid-19 vaccine, subject data, informed consent, adverse event monitoring, visit date, Protocol, demography data, fda submission, efficacy endpoints",20,258,https://drive.google.com/file/d/1RDFLlaE7VEANJEvym5gveVWXXICj_z-Y/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:45
125742_S1_M5_CRF_c4591001-1142-11421256.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, University of Texas - Galveston, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, subject demographics, safety, data collection",19,175,https://drive.google.com/file/d/1a3JRNMHTDWE_EONllqIt15TDPoURwJHc/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:48
125742_S1_M5_CRF_c4591001-1142-11421044.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, University of Texas - Galveston, CRF, subject information, informed consent, visit date, FDA, Protocol, demography, safety",19,526,https://drive.google.com/file/d/1r1j1HG70dx5Pkz2f6pJFTAlf5HaA6Pgk/view?usp=drivesdk,pd-production-080123,2025-08-12 00:02:54
125742_S1_M5_CRF_c4591001-1142-11421202.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"phase 2/3 trial, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, University of Texas - Galveston, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, safety",19,129,https://drive.google.com/file/d/1idXnG8P2Rm_Y_DtuaS-RMOey1uS8iSxr/view?usp=drivesdk,pd-production-080123,2025-08-12 00:03:03
125742_S1_M5_CRF_c4591001-1142-11421215.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, University of Texas - Galveston, CRF, subject information, informed consent, visit date, FDA, Protocol, demography, efficacy data",19,133,https://drive.google.com/file/d/1-9nhaYibXbqslQc_YpvB2ZLbKbv9OoWY/view?usp=drivesdk,pd-production-080123,2025-08-12 00:03:10
125742_S1_M5_CRF_c4591001-1203-12031026.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, CRF, berlin, subject data, informed consent, visit date, Protocol, vaccine, c4591001, crs clinical research services, demography, electronic case report form",20,231,https://drive.google.com/file/d/1omG6tZuc7bFFmutJsvP-y3u-cMBHZWJV/view?usp=drivesdk,pd-production-080123,2025-08-12 00:03:14
125742_S1_M5_CRF_c4591001-1142-11421084.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, University of Texas - Galveston, protocol amendment, CRF, subject enrollment, informed consent, visit schedule, FDA, Protocol, subject demographics, Pfizer, data collection",19,153,https://drive.google.com/file/d/1prGVg3akABdvsBqFsQpHGd3XKWtXYpD7/view?usp=drivesdk,pd-production-080123,2025-08-12 00:03:17
125742_S1_M5_CRF_c4591001-1142-11421247.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, university of texas - galveston, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, eCRF, demography, efficacy data, data collection",20,141,https://drive.google.com/file/d/1F7zw-4A6i9aUZnil20PK9xBPhC3QZieJ/view?usp=drivesdk,pd-production-080123,2025-08-12 00:03:21
125742_S1_M5_CRF_c4591001-1204-12041023.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),(1204) Icahn School of Medicine at Mount Sinai,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, Mount Sinai, confidential, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, audit trail, subject enrollment, informed consent, date of visit, FDA, Protocol, eCRF, demography, data collection",20,144,https://drive.google.com/file/d/1_FagNvMKBa_d6QEjV85m84PF0x4DN8Zs/view?usp=drivesdk,pd-production-080123,2025-08-12 00:03:25
125742_S1_M5_CRF_c4591001-1142-11421073.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Research Form (CRF),,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, safety data, c4591001 trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, University of Texas - Galveston, phase 2/3 study, CRF, eCRF audit trail, informed consent, visit date, vaccine development, Protocol, subject demographics, efficacy data, confidential document",20,181,https://drive.google.com/file/d/1J8xtRgd0quO4nWBQgE1gb0d2DexuOwx4/view?usp=drivesdk,pd-production-080123,2025-08-12 00:03:28
125742_S1_M5_CRF_c4591001-1232-12321213.pdf,PDF,C4591001 Clinical Trial eCRF,2021-03-29,eCRF (electronic Case Report Form),"Subject No: 12321213, Subject Initials: ---",M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Protocol, Pfizer, eCRF, data management, demography, Columbus Regional Research Institute",20,201,https://drive.google.com/file/d/1xMULFcPIZPiEFZrzKLykCJCYVnFmuz1q/view?usp=drivesdk,pd-production-080123,2025-08-12 00:03:32
125742_S1_M5_CRF_c4591001-1204-12041280.pdf,PDF,C4591001 Clinical Trial eCRF,2020-10-01,Clinical Trial Form,(1204) Icahn School of Medicine at Mount Sinai,M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, mount sinai, visit date, Protocol, c4591001, eCRF, data management, demography, clinical data",20,143,https://drive.google.com/file/d/1mZQ6zm63nsZL6GxDElu2N6zrgRNeemjg/view?usp=drivesdk,pd-production-080123,2025-08-12 00:03:36
125742_S1_M5_CRF_c4591001-1204-12041078.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1204) Icahn School of Medicine at Mount Sinai,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, informed consent, visit date, Protocol, data verification, data completeness, data locking, demography data, subject identification, data freezing, confidential document",20,162,https://drive.google.com/file/d/1Eg6LU3ykTUdWV4b5fFeTxK1uQ8Edc74f/view?usp=drivesdk,pd-production-080123,2025-08-12 00:03:40
125742_S1_M5_CRF_c4591001-1205-12051028.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-10-30,clinical trial form,(1205) Hacettepe University Medical Faculty,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, safety data, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, Turkey, phase 2/3 study, CRF, eCRF audit trail, Hacettepe University, informed consent, adverse event monitoring, visit date, Protocol, demography data, C4591001 trial, efficacy data",20,127,https://drive.google.com/file/d/1ZUXpZMcUVDh8rM2Wc6vsLeqT83F0gpAi/view?usp=drivesdk,pd-production-080123,2025-08-12 00:03:50
125742_S1_M5_CRF_c4591001-1232-12321299.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, C4591001, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, subject 12321299, CRF, informed consent, visit date, FDA, Protocol, demography, case report form, Columbus Regional Research Institute, data collection",20,141,https://drive.google.com/file/d/14iScNtKuflI_Lh8JrDAESz3lN8-iiEX1/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:00
125742_S1_M5_CRF_c4591001-1232-12321175.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,"Subject No: 12321175, Subject Initials: ---",M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, clinical research form, phase 2/3 study, CRF, FDA submission, informed consent, adverse event monitoring, visit date, Protocol, C4591001 protocol, data management, demography data, subject identification, Columbus Regional Research Institute, data collection",20,161,https://drive.google.com/file/d/1G3KpZTCTKSwEP085Hbv-WxEIzsJSj_7B/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:04
125742_S1_M5_CRF_c4591001-1204-12041138.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1204) Icahn School of Medicine at Mount Sinai,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, Mount Sinai, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, FOIA document, informed consent, visit schedule, Protocol, data verification, Pfizer-BioNTech, eCRF, data completeness, subject identification, data freezing",20,195,https://drive.google.com/file/d/17n_1EE73UdK8kbpbrfidWR5ZF8DWyct4/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:08
125742_S1_M5_CRF_c4591001-1205-12051075.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2021-03-29,Clinical Research Form (CRF),Subject No: 12051075,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Turkey, phase 2/3 study, CRF, demographic data, Hacettepe University, informed consent, visit schedule, FDA, Protocol, Pfizer-BioNTech, eCRF, efficacy data",20,125,https://drive.google.com/file/d/1s6KKLomW5eqa2oPsZwcUip6aG7wE6lR6/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:17
125742_S1_M5_CRF_c4591001-1205-12051077.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-10-10,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, demographic data, Hacettepe University, informed consent, visit date, FDA, Protocol, data verification, subject identification, efficacy data, data freezing",19,183,https://drive.google.com/file/d/1anzuXfiUVVvP5ACpmC59fbTkqdQGVt6f/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:21
125742_S1_M5_CRF_c4591001-1204-12041234.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,(1204) Icahn School of Medicine at Mount Sinai,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, data lock and freeze, phase 2/3 study, CRF, eCRF audit trail, pharmaceutical development, informed consent, visit date, Protocol, data verification, C4591001 protocol, demography data, subject identification, confidential document",20,210,https://drive.google.com/file/d/16DejoAFBOjpfEA52QgMgObxkSCoxvZ7P/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:25
125742_S1_M5_CRF_c4591001-1232-12321293.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data, Columbus Regional Research Institute",19,172,https://drive.google.com/file/d/1-M6OVredvgcFWy0yOTgvrZ-OhcJBep1J/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:29
125742_S1_M5_CRF_c4591001-1232-12321159.pdf,PDF,C4591001 Clinical Trial Case Report Form,2020-07-30,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, C4591001, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject information, informed consent, visit date, FDA, Protocol, eCRF, data management, demography, case report form, Columbus Regional Research Institute",20,128,https://drive.google.com/file/d/1WrX9HDwMJVdJqBpsJsQGaXGm08x7rgWI/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:36
125742_S1_M5_CRF_c4591001-1235-12351205.pdf,PDF,c4591001 Clinical Trial eCRF,2020-10-20,Clinical Trial Form,"Subject No: 12351205, Subject Initials: ---",M5,True,True,False,True,False,"Clinical Trial, Safety, Exclusion, Inclusion/Exclusion Criteria, United States, Demography, Efficacy, Vaccine, Pharmaceutical, FDA Submission, Phase 2/3, CRF, Data Verification, LSU Health Shreveport, Protocol, Regulatory Compliance, c4591001, eCRF, Informed Consent, Adverse Events",20,175,https://drive.google.com/file/d/1dCBAO9syXhXKQTQgEsqdYz5zuYF10aZv/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:40
125742_S1_M5_CRF_c4591001-1241-12411053.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, audit trail, demographic data, subject enrollment, informed consent, adverse event monitoring, Protocol, c4591001 protocol, Latin America, confidential document, data collection",20,236,https://drive.google.com/file/d/1crWhuyGL7Kfh-Y5h3C9N5-DDG5xs39kP/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:43
125742_S1_M5_CRF_c4591001-1235-12351071.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1235) LSU Health Shreveport,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject data, informed consent, visit date, FDA, Protocol, c4591001, Pfizer, Louisiana, demography, data collection",20,623,https://drive.google.com/file/d/1Z9LzWcpTodSP3hGdUyfl3sEgqM0ZPlDM/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:51
125742_S1_M5_CRF_c4591001-1241-12411067.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, confidential, regulatory compliance, fda, data quality, latin america, inclusion/exclusion criteria, crf, phase 2/3 study, CRF, audit trail, covid-19 vaccine, subject data, informed consent, visit date, Protocol, medical research, demography",20,263,https://drive.google.com/file/d/1Cg7444naAlkKF6xm-Pw_qWU7LYRJAyS6/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:55
125742_S1_M5_CRF_c4591001-1235-12351130.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, LSU Health Shreveport, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data, data collection",20,160,https://drive.google.com/file/d/1ZerQecG0O6srsKpbbkMeijz-BHlRioPe/view?usp=drivesdk,pd-production-080123,2025-08-12 00:04:59
125742_S1_M5_CRF_c4591001-1241-12411051.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, quality assurance, protocol amendment, phase 2/3 study, CRF, demographic data, informed consent, FDA, Protocol, eCRF, data management, subject identification, efficacy data",20,301,https://drive.google.com/file/d/1hELGiB3iBwmxphEvc4aAV6wHDOYoOABL/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:03
125742_S1_M5_CRF_c4591001-1241-12411208.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, hospital, demographic data, informed consent, visit date, FDA, Protocol, data management, subject identification, efficacy data",19,270,https://drive.google.com/file/d/1QiaRyZXQd6WMWDZBDvytIupyQJpg2p2H/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:07
125742_S1_M5_CRF_c4591001-1241-12411206.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, latin america location, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, medical terminology, c4591001 protocol, data management, demography data, subject identification, adverse event reporting, fda regulatory",20,187,https://drive.google.com/file/d/1rfLw6xLviyh7A1S37iRMuLRLB7Av1edM/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:11
125742_S1_M5_CRF_c4591001-1241-12411117.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,Irma Dulce,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, data quality, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, hospital, subject information, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, demography, efficacy data",20,331,https://drive.google.com/file/d/1PpkQ8oCwOB_Z6VrUb2Fiz9g1eDqh7Fdc/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:15
125742_S1_M5_CRF_c4591001-1241-12411197.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, subject identification",19,326,https://drive.google.com/file/d/1i817yjfY_of77j14wuQNluWt2vBW9Rsk/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:20
125742_S1_M5_CRF_c4591001-1241-12411279.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, clinical research form, phase 2/3 study, CRF, demographic data, eCRF audit trail, FDA regulatory, informed consent, visit schedule, vaccine development, Protocol, c4591001 protocol, Brazil location, subject identification, confidential document",20,294,https://drive.google.com/file/d/1RpVBPnXcbeD-35OW9TMqKOP1aTJPGGrU/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:24
125742_S1_M5_CRF_c4591001-1241-12411343.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,,M5,True,True,False,True,False,"Hospital Irma Dulce, Exclusion, FDA regulation, clinical trial, Good Clinical Practice, data quality control, regulatory submission, eligibility criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, adverse event monitoring, visit schedule, Protocol, c4591001 protocol, medical research, data management, subject identification",20,209,https://drive.google.com/file/d/1lYckVUg2y5Om7h0gZEjVxqvS_1svM-VT/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:28
125742_S1_M5_CRF_c4591001-1241-12411269.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, data quality control, regulatory submission, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, Protocol, c4591001 protocol, data management, subject identification, adverse event reporting, electronic case report form, confidential document",20,303,https://drive.google.com/file/d/1U7tKJuHg4hHUri3Co0NT1sNTsPjzNaQq/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:33
125742_S1_M5_CRF_c4591001-1241-12411347.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2021,Form,,M5,True,False,False,False,False,"medical research, data quality, FDA submission, pharmaceutical development, phase 4 study, clinical trial, COVID-19 vaccine, safety data, clinical research form, CBER, clinical trial protocol, data management, case report form, CRF, vaccine identification, efficacy data, adverse events, regulatory compliance",18,248,https://drive.google.com/file/d/1tx0E2NvLfzBcPJE723KAt9inI4wOlqFF/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:41
125742_S1_M5_CRF_c4591001-1241-12411410.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, safety",19,300,https://drive.google.com/file/d/1WQCbCPe0VCxESAgIN8copGTPEyZbktyW/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:46
125742_S1_M5_CRF_c4591001-1241-12411385.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-07-30,case report form,Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, fda, data quality, latin america, inclusion/exclusion criteria, CRF, covid-19 vaccine, informed consent, visit schedule, Protocol, c4591001, data management, demography, case report form, subject identification",20,297,https://drive.google.com/file/d/1fAWREYRRIV6LobrjKHWhw31HB50NPEok/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:50
125742_S1_M5_CRF_c4591001-1241-12411561.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, Brazil, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data",19,299,https://drive.google.com/file/d/11fGUYWwNliSR5C7K9ruKTfzyaKzLv_8L/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:54
125742_S1_M5_CRF_c4591001-1241-12411514.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, subject details, demography, safety, data collection",19,252,https://drive.google.com/file/d/1ewk5fb_cwyFHtG7iVWWPPv9-imP0lXBh/view?usp=drivesdk,pd-production-080123,2025-08-12 00:05:58
125742_S1_M5_CRF_c4591001-1241-12411493.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Hospital Irma Dulce, Exclusion, clinical trial, regulatory compliance, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, data audit trail, subject enrollment, informed consent, visit date, FDA, Protocol, demography, data collection",19,261,https://drive.google.com/file/d/1bKVou1thMEPlyqeD0VnGyj1t-GiMTbGO/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:02
125742_S1_M5_CRF_c4591001-1241-12411766.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, safety monitoring, visit date, FDA, Protocol, subject identification, efficacy data",19,213,https://drive.google.com/file/d/1EcbUj8FYMe4Y_CSkKv_mGRhVxtByhFNv/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:06
125742_S1_M5_CRF_c4591001-1241-12411471.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,Clinical Research Form (CRF),(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, c4591001 trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, adverse event monitoring, visit date, Protocol, Latin America, medical research, data management, subject identification",20,217,https://drive.google.com/file/d/10mtjfNuuNYlx94Bz3n5JQKeeGpSWaBKj/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:10
125742_S1_M5_CRF_c4591001-1241-12411825.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,clinical trial form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, demographic data, eCRF audit trail, subject enrollment, informed consent, visit schedule, Protocol, data verification, data management, subject identification, data freezing, confidential document",20,159,https://drive.google.com/file/d/18mr2ArUgEzqQ_hhXrppTIkJToohuY6M-/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:14
125742_S1_M5_CRF_c4591001-1241-12411468.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, crf, efficacy, protocol amendment, CRF, covid-19 vaccine, informed consent, visit date, Protocol, hospital irma dulce, site 1241, demography, safety, data collection",20,219,https://drive.google.com/file/d/18hsJ51NscmIkohSbA5gxbI8jNrCwCOn1/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:18
125742_S1_M5_CRF_c4591001-1241-12411679.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2021-03-29,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, c4591001 trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, hospital site, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, visit date, Protocol, demography data, efficacy data, fda regulatory",20,159,https://drive.google.com/file/d/11KZjn5LRsH6OnkDzkfsXcUR15fUduZz_/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:21
125742_S1_M5_CRF_c4591001-1241-12411568.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, eCRF audit trail, informed consent, visit date, FDA, Protocol, data verification, demography, subject identification, confidential document, data collection",19,267,https://drive.google.com/file/d/11oC5cCpyS6NRQujvnJR1Z5OFt9g2g9bu/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:25
125742_S1_M5_CRF_c4591001-1241-12411643.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory submission, data quality, inclusion/exclusion criteria, data compliance, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,179,https://drive.google.com/file/d/1a3vRKlZMLsotdG_qT4AuRRXfzcl0AQP1/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:29
125742_S1_M5_CRF_c4591001-1241-12411829.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, latin america, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, demographic data, eCRF audit trail, informed consent, adverse event monitoring, visit date, Protocol, medical terminology, data management, fda submission, subject identification",20,208,https://drive.google.com/file/d/1XlBLSZktRJpjaJ52Ywqy9l8PTjOfQ3lT/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:32
125742_S1_M5_CRF_c4591001-1241-12412055.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, c4591001 trial, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, informed consent, visit date, Protocol, data verification, data locking, subject identification, data freezing, confidential document",20,139,https://drive.google.com/file/d/1gGCMn8nocJEV2VHnk9--gCq20WgVBIhB/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:42
125742_S1_M5_CRF_c4591001-1241-12412111.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Latin America location, FDA regulation, clinical trial, Exclusion, data quality control, inclusion/exclusion criteria, COVID-19 vaccine, data lock and freeze, phase 2/3 study, CRF, demographic data, eCRF audit trail, informed consent, date of visit, visit schedule, Protocol, c4591001 protocol, subject identification, confidential document",20,261,https://drive.google.com/file/d/1QF-lTK1-dKh77efNmOv3-Mb2mP78mVa9/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:46
125742_S1_M5_CRF_c4591001-1241-12412053.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-09-15,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, Brazil, CRF, informed consent, visit date, FDA, Protocol, vaccine, c4591001, eCRF, demography, case report form, subject identification",20,205,https://drive.google.com/file/d/1VjjuJARzHEl49bL9tAQDdyvK-C64W10H/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:50
125742_S1_M5_CRF_c4591001-1241-12411930.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, eCRF audit trail, informed consent, visit date, Protocol, clinical data management, demography, subject identification, confidential document, data collection",20,203,https://drive.google.com/file/d/1J4vAf0CI_QSVmntJ2c1AkjnalLRcduBr/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:54
125742_S1_M5_CRF_c4591001-1241-12411915.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy assessment, phase 2/3 study, CRF, demographic data, informed consent, adverse event monitoring, visit schedule, Protocol, safety evaluation, data management, Brazil location, subject identification",20,184,https://drive.google.com/file/d/1Jsm_Q5xGeBX1Dd0PRPrzwAR1uATb4ACo/view?usp=drivesdk,pd-production-080123,2025-08-12 00:06:58
125742_S1_M5_CRF_c4591001-1241-12412035.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,Hospital Irma Dulce,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, Brazil, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001 protocol, eCRF, demography, safety",20,184,https://drive.google.com/file/d/1qChnTMoz5pjDZmepuq17rmQuqjDlRJnJ/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:02
125742_S1_M5_CRF_c4591001-1241-12412109.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, subject details, c4591001, demography, efficacy data",20,112,https://drive.google.com/file/d/1tD1B9p8Sx4q_oL6G9s8QS_ZbU_NNVysu/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:08
125742_S1_M5_CRF_c4591001-1241-12411978.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,Subject No: 12411978,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, clinical study phases, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, CRF, demographic data, informed consent, visit date, FDA, Protocol, data management, subject identification, data freezing",19,216,https://drive.google.com/file/d/11bauZz0pv_P7N37uNeVcso6oWy3s-r3D/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:12
125742_S1_M5_CRF_c4591001-1241-12411887.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, demographic data, informed consent, adverse event monitoring, visit date, FDA, Protocol, hospital setting, data management, subject identification",19,291,https://drive.google.com/file/d/1JoId4ubVhVSPbdT3TvVaTJLFII6Mpyr2/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:16
125742_S1_M5_CRF_c4591001-1241-12411862.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, immunogenicity, data quality, inclusion/exclusion criteria, COVID-19 vaccine, SARS-CoV-2, Brazil, phase 2/3 study, CRF, subject data, informed consent, visit date, FDA, Protocol, eCRF, demography, safety",20,188,https://drive.google.com/file/d/10L_jyjv7bZW2MONRVMue4eQqSwKNCqp4/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:20
125742_S1_M5_CRF_c4591001-1241-12411967.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, protocol amendment, CRF, demographic data, eCRF audit trail, clinical research, informed consent, visit date, Protocol, subject identification, confidential document, data collection",20,187,https://drive.google.com/file/d/1AOXu_5jGWfGkTCDRcSoqn4jwwXWyn3dM/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:24
125742_S1_M5_CRF_c4591001-1241-12412191.pdf,PDF,Clinical Trial CRF for c4591001 Study,2021-03-29,Clinical Trial Form,Irma Dulce,M5,True,True,False,True,False,"quality control, site information, Exclusion, clinical trial, regulatory compliance, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, FDA, c4591001 study, Protocol, vaccine, subject details, eCRF, data management, demography, data collection",20,200,https://drive.google.com/file/d/1LQkvxxJFE6xLEJmNtPsvoREjwy3DmStY/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:27
125742_S1_M5_CRF_c4591001-1241-12412218.pdf,PDF,Clinical Trial CRF for c4591001 Study,2020-10-15,Clinical Trial Form,,M5,True,True,False,True,False,"quality control, Exclusion, clinical trial, subject 12412218, safety data, adverse events, regulatory, pharmaceutical, cohort selection, inclusion/exclusion criteria, CRF, informed consent, visit date, FDA, c4591001 study, Protocol, vaccine, hospital irma dulce, demography, efficacy data",20,208,https://drive.google.com/file/d/1HPkY8in56n2YW4OagIkAxxYLeWtZk28v/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:31
125742_S1_M5_CRF_c4591001-1241-12412411.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-10-20,Case Report Form (CRF),,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, confidential, data quality, inclusion/exclusion criteria, CRF, hospital, audit trail, subject enrollment, informed consent, date of visit, FDA, Protocol, vaccine, data verification, c4591001, demography, data freezing",20,281,https://drive.google.com/file/d/1gwYn7Ta5Wciix-uyv_yXSPUcGN9A49Ib/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:35
125742_S1_M5_CRF_c4591001-1246-12461025.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, Jongaie Research site, FDA submission, informed consent, subject 12461025, visit date, Protocol, c4591001 protocol, clinical data management, demography, confidential document",20,360,https://drive.google.com/file/d/11hN6eum17IhlrKb5iwVQRfQGMNQ-VALu/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:41
125742_S1_M5_CRF_c4591001-1241-12412546.pdf,PDF,Clinical Trial Case Report Form (CRF),2020-10-01,form,Irma Dulce,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, c4591001, demography, case report form, subject identification, efficacy data",20,165,https://drive.google.com/file/d/141y_We9SZz_lJc1f2nsj5OcNI4Hfai30/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:44
125742_S1_M5_CRF_c4591001-1241-12412369.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-10-01,form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, Latin America, demography, subject identification, efficacy data",20,172,https://drive.google.com/file/d/1r9YTZBSperenN5QwdYuvNPgYJrzwSpNr/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:48
125742_S1_M5_CRF_c4591001-1241-12412263.pdf,PDF,Clinical Trial CRF for c4591001 Study,2020-10-16,Clinical Trial Form,(1241) Hospital Irma Dulce,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, CRF, hospital, subject information, clinical research, informed consent, visit date, FDA, c4591001 study, Protocol, vaccine, demography, data collection",20,199,https://drive.google.com/file/d/1HwsaQIprN-E7aUJ92LgYfDPKrtpqM7rq/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:52
125742_S1_M5_CRF_c4591001-1241-12412190.pdf,PDF,Clinical Trial CRF for c4591001 Study,2021-03-29,Clinical Trial Form,Irma Dulce,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, Brazil, CRF, hospital, subject information, informed consent, visit date, FDA, c4591001 study, Protocol, vaccine, demography, safety, data collection",20,212,https://drive.google.com/file/d/1xc8dxRR6DNw05vJbNC5JxXJJcAtW7J6f/view?usp=drivesdk,pd-production-080123,2025-08-12 00:07:56
125742_S1_M5_CRF_c4591001-1246-12461070.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, informed consent, visit details, FDA, Protocol, data management, demography, subject identification, data collection",19,331,https://drive.google.com/file/d/1VpwxCqK20C3OHdHMnBbyYlNdEyzE5yHf/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:01
125742_S1_M5_CRF_c4591001-1246-12461131.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, Jongaie Research, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, safety",19,194,https://drive.google.com/file/d/1sYtTRvddwEP7RCJaxgqjlOfz1O2a6VY2/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:05
125742_S1_M5_CRF_c4591001-1246-12461035.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, Jongaie Research site, FDA submission, informed consent, visit date, Protocol, data verification, c4591001 protocol, subject 12461035, clinical data management, demography data, confidential document",20,165,https://drive.google.com/file/d/1mVB5Xq-hOd5-xodpGYcvmT6rtjSGYH4b/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:09
125742_S1_M5_CRF_c4591001-4444-44441145.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, white race, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, hospital site, phase 2/3 study, CRF, eCRF audit trail, FDA submission, informed consent, visit date, Protocol, c4591001 protocol, demography data, Hispanic/Latino population, confidential document",20,234,https://drive.google.com/file/d/1BdvDRY3DKlv-9j8wch8pNH9vrTKuEi1H/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:14
125742_S1_M5_CRF_c4591001-4444-44441007.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,Clinical Research Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, data privacy, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, data quality control, regulatory compliance, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, subject enrollment, FOIA document, FDA submission, informed consent, adverse event monitoring, visit schedule, Protocol, c4591001 protocol, data management",20,179,https://drive.google.com/file/d/1PnEkKyVoJiUkzHUAyEl0IedbQmp_Z7HR/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:18
125742_S1_M5_CRF_c4591001-4444-44441161.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, white race, data quality, inclusion/exclusion criteria, COVID-19 vaccine, hospital site, phase 2/3 study, CRF, eCRF audit trail, FDA regulatory, informed consent, visit date, Protocol, demography data, subject identification, Hispanic/Latino population, data locking and freezing, confidential document",20,155,https://drive.google.com/file/d/1iNvFbqzt1KXOCLYw_DBcZKIDP4yynJIW/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:22
125742_S1_M5_CRF_c4591001-4444-44441249.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2021-03-29,clinical trial form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, adverse event monitoring, visit date, FDA, Protocol, c4591001, demography, subject identification, Argentina",20,131,https://drive.google.com/file/d/1gZ2e5IIf--57NB2pDmyc8o1VUzc2Li9J/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:30
125742_S1_M5_CRF_c4591001-4444-44441297.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, subject identification, Argentina, data collection",20,203,https://drive.google.com/file/d/1U9VHO6CkWDs0981Bh8f6s7zPVThmsw8H/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:33
125742_S1_M5_CRF_c4591001-1246-12461110.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, eCRF audit trail, Jongaie Research site, FDA submission, informed consent, visit date, Protocol, c4591001 protocol, clinical data management, subject 12461110, confidential document",20,178,https://drive.google.com/file/d/1X4ganME32nH8RtvpqBmjusrpeprErOF9/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:37
125742_S1_M5_CRF_c4591001-4444-44441371.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,clinical trial form,(4444) Hospital Militar Central Cirujano Mayor Dr Cosme Argerich,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, subject enrollment, informed consent, safety monitoring, FDA, Protocol, c4591001, Pfizer-BioNTech, demography, Argentina, efficacy data, electronic case report form",20,250,https://drive.google.com/file/d/1YJ8uK1P0yWIb6di4uJfLFeO5FqRHYURg/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:43
125742_S1_M5_CRF_c4591001-4444-44441035.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, white race, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, hospital site, phase 2/3 study, CRF, eCRF audit trail, informed consent, visit date, c4591001 study, Protocol, demography data, male subject, Hispanic/Latino population, confidential document",20,127,https://drive.google.com/file/d/10afEhzxnszVtv-L2QEmgbrqjTOJj7d1V/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:50
125742_S1_M5_CRF_c4591001-4444-44441422.pdf,PDF,c4591001 Clinical Trial eCRF,2020-09-15,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, confidential, regulatory compliance, cohort selection, inclusion/exclusion criteria, CRF, subject information, audit trail, informed consent, visit date, FDA, Protocol, vaccine, c4591001, eCRF, demography, data collection",20,184,https://drive.google.com/file/d/1o0e5rds-bdOo0b9gp9Q5RcwyEsFWjHN9/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:54
125742_S1_M5_CRF_c4591001-4444-44441473.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,clinical trial form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, c4591001 trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, informed consent, adverse event monitoring, visit date, Protocol, subject demographics, medical terminology, Latin America, data management, subject identification",20,223,https://drive.google.com/file/d/1pOTJgwpMC99DFclzhsa0C_d_NXPGwwjX/view?usp=drivesdk,pd-production-080123,2025-08-12 00:08:59
125742_S1_M5_CRF_c4591001-4444-44441470.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-09-15,case report form,,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, date of visit, FDA, Protocol, c4591001, demography, case report form, subject identification, Argentina",20,280,https://drive.google.com/file/d/18A6QGndnVWbzAtkkX3brjcpFg90PAKXv/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:03
125742_S1_M5_CRF_c4591001-4444-44441385.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, eCRF audit trail, informed consent, visit date, FDA, Protocol, demography, subject identification, Argentina",19,166,https://drive.google.com/file/d/15RaCD2mbsK6c7ozhpX-2RbhfPJbCOZmS/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:07
125742_S1_M5_CRF_c4591001-4444-44441595.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, c4591001 trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, hospital site, phase 2/3 study, CRF, demographic data, data audit trail, informed consent, adverse event monitoring, visit date, Protocol, data management, subject identification, confidential document",20,192,https://drive.google.com/file/d/1a3AI247FWQ2dDvBl6HILJgwMhRxEfOLz/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:10
125742_S1_M5_CRF_c4591001-4444-44441550.pdf,PDF,c4591001 Clinical Trial CRF,2020-09-15,Clinical Trial Form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, adverse events, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, hospital, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, subject identification, Argentina, efficacy data",20,239,https://drive.google.com/file/d/1T744JhRbb_gjSeC-iVw-Gstd_xgJw9AR/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:14
125742_S1_M5_CRF_c4591001-4444-44441634.pdf,PDF,Clinical Study Report Form,2021,report,,M5,True,False,False,False,False,"data anonymization, pharmaceutical research, data quality, FDA submission, clinical trial, phase 4 study, FOIA request, vaccine development, safety data, CBER, COVID-19, data management, case report form, CRF, efficacy data, adverse events, clinical study protocol, regulatory compliance",18,245,https://drive.google.com/file/d/1KxF39sficWSa5l4cm3UOnJIvIzzR29or/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:22
125742_S1_M5_CRF_c4591001-4444-44441665.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"quality control, vaccine efficacy, Exclusion, clinical trial, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, regulatory compliance, COVID-19 vaccine, vaccine safety, phase 2/3 study, CRF, FOIA document, data auditing, FDA submission, informed consent, adverse event monitoring, Protocol, subject demographics, c4591001 protocol, data management, data collection",20,266,https://drive.google.com/file/d/1G9yWOs4Ea2sD5X-OENTJwSLSb-pXRIHA/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:26
125742_S1_M5_CRF_c4591001-4444-44441748.pdf,PDF,c4591001 Clinical Trial Case Report Form,2020-09-15,Case Report Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit schedule, FDA, Protocol, data verification, c4591001, data completeness, demography, case report form, subject identification, Argentina",20,253,https://drive.google.com/file/d/19Tq6efxmM9gFhEw_tcrqts6tHLSJamiu/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:29
125742_S1_M5_CRF_c4591001-4444-44441761.pdf,PDF,c4591001 Clinical Trial eCRF,2020-09-15,clinical trial form,(4444) Hospital Militar Central Cirujano Mayor Dr Cosme Argerich,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, FDA, Protocol, Pfizer, eCRF, demography, subject identification, Argentina, data collection",20,171,https://drive.google.com/file/d/1qDPwIrzzJqtM_iRIUH_QHyOrO_GcV2Wz/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:33
125742_S1_M5_CRF_c4591001-4444-44442304.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, safety data, c4591001 trial, regulatory submission, data quality, inclusion/exclusion criteria, COVID-19 vaccine, hospital site, phase 2/3 study, CRF, informed consent, adverse event monitoring, visit date, Protocol, Latin America, demography data, subject identification, efficacy endpoints",20,214,https://drive.google.com/file/d/1y-0WYSEKVvNgzzfXnQTwFLwE7A0VjLdC/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:38
125742_S1_M5_CRF_c4591001-4444-44442021.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2021-03-29,form,Cosme Argerich,M5,True,True,False,True,False,"Exclusion, clinical trial, c4591001 trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, safety assessment, subject enrollment, FDA submission, informed consent, adverse event monitoring, visit date, Protocol, data management, demography data, Hospital Militar Central, efficacy endpoints",20,161,https://drive.google.com/file/d/169oud8z9uHORAWIbrhTyxPYXQ51fQ0T5/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:41
125742_S1_M5_CRF_c4591001-4444-44441771.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, adverse events, regulatory compliance, data quality, COVID-19 vaccine, protocol amendment, CRF, informed consent, FDA, Protocol, subject demographics, eCRF, data management, Argentina, efficacy data",19,142,https://drive.google.com/file/d/102dc2bmCCRe2cHpOqEwQJ7jiMa-qU2c-/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:50
125742_S1_M5_CRF_c4591001-4444-44442009.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, safety data, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy assessment, phase 2/3 study, CRF, demographic data, informed consent, adverse event monitoring, visit date, Protocol, c4591001 protocol, subject identification",20,205,https://drive.google.com/file/d/1nwps2nvy7-ACbmx0oaZKjgpHXwbqOpga/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:55
125742_S1_M5_CRF_c4591001-4444-44441873.pdf,PDF,c4591001 Clinical Trial eCRF,2021-03-29,clinical trial form,(4444) Hospital Militar Central Cirujano Mayor Dr Cosme Argerich,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, safety and efficacy, CRF, informed consent, FDA, Protocol, Pfizer, eCRF, demography, subject identification, Argentina, data collection",20,160,https://drive.google.com/file/d/1xWvxPYJQl0ljNRuP5EtgFf1rCoVGcZH3/view?usp=drivesdk,pd-production-080123,2025-08-12 00:09:58
125742_S1_M5_CRF_c4591001-4444-44442041.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, adverse events, regulatory compliance, data quality, COVID-19 vaccine, protocol amendment, CRF, informed consent, FDA, Protocol, subject demographics, eCRF, data management, Argentina, efficacy data",19,182,https://drive.google.com/file/d/1rnLwqcs_a54RfkRPaqIg7G3ZoZvz0CK1/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:02
125742_S1_M5_CRF_c4591001-4444-44442278.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-09-15,form,,M5,True,True,False,True,False,"white-race, Exclusion, inclusion-exclusion-criteria, electronic-case-report-form, hispanic-latino-ethnicity, regulatory-compliance, phase-2-3-study, demographic-data, clinical-trial, CRF, hospital-military-central, covid-19-vaccine, informed-consent, cohort-selection, data-quality-control, Protocol, visit-date, confidential-document, subject-identification, fda-submission",20,153,https://drive.google.com/file/d/1fi0eeHFLDoprCoqrOSLG_cs0FiTnqI4B/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:06
125742_S1_M5_CRF_c4591001-4444-44442012.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,clinical trial form,,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, c4591001 trial, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, informed consent, adverse event monitoring, visit schedule, Protocol, Latin America, hospital setting, data management, subject identification",20,119,https://drive.google.com/file/d/1hB4A73O2ZIXMIcqz9JKqFfGjt2oQ1xzs/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:16
125742_S1_M5_CRF_c4591001-4444-44441979.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,Clinical Research Form (CRF),Cosme Argerich,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, data quality control, regulatory compliance, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, subject enrollment, FDA submission, informed consent, Protocol, data verification, data lock, eCRF, Argentina, adverse event reporting, data freezing, Hospital Militar Central",20,176,https://drive.google.com/file/d/1gHPb6mxFmFlUGev-GNE6Nbx5S8ccXNqS/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:20
125742_S1_M5_CRF_c4591001-4444-44442319.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-09-15,clinical trial form,,M5,True,True,False,True,False,"phase 2/3 trial, Exclusion, clinical trial, Hospital Militar Central Cirujano Mayor Dr Cosme Argerich, adverse events, regulatory compliance, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, Argentina, efficacy data",20,139,https://drive.google.com/file/d/1q-AEw2JfoIompM6VDgxZUW8-nt9e9iWP/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:23
125742_S29_M1_cover.pdf,PDF,Preliminary requested changes and comments on the draft Package Insert for COMIRNATY,2021-08-02,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"BLA 125742, Vaccine Approval, Vaccine Submission, Vaccine Efficacy, Package Insert, Clinical Trials, Pfizer Global Regulatory Affairs, COMIRNATY, Vaccine Compliance, COVID-19 mRNA Vaccine, FDA Regulatory Affairs, Silver Spring, MD, Collegeville, PA, Adverse Events, Vaccine Development, Vaccine Safety, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1k7MF-siM0O3KGPjld8_td77ho2g-mNSE/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:28
125742_S2_M1_lab-1448-0-1-annotated.pdf,PDF,Prescribing Information for TRADENAME COVID-19 mRNA Vaccine,2020-12,report,,M1,False,False,False,False,False,"dosage and administration, pharmaceutical, adverse reactions, clinical trial, contraindications, mechanism of action, warnings and precautions, COVID-19 vaccine, mRNA vaccine, safety data, specific populations, intramuscular injection, VAERS reporting, FDA approval, efficacy data, nonclinical toxicology, regulatory submission",17,29,https://drive.google.com/file/d/1DgX8KtmQd8nVutiK1KtilS0Gnzw80dyI/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:32
125742_S20_M1_response-22jul2021.pdf,PDF,Response to FDA Information Request for BNT162b2 (COMIRNATY) BLA STN 125742/0,2021-07-27,response,Laura Gottshalk,M1,False,True,False,False,False,"biologics-license-application, covid-19-vaccine, evaluable-efficacy-population, regulatory-compliance, pharmaceutical-development, blinded-placebo-controlled-study, sponsor-response, safety-data, information-request, comirnaty, adverse-events, efficacy-data, Protocol, united-states, fda-submission, clinical-trial, bnt162b2, pcr-testing",18,7,https://drive.google.com/file/d/1DlgH1ZqDse4deHTzb2JN1YhhzeRfSizP/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:35
125742_S2_M1_lab-1448-0-1-pkg-insert-clean.pdf,PDF,HIGHLIGHTS OF PRESCRIBING INFORMATION for TRADENAME (COVID-19 mRNA vaccine [nucleoside-modified]),2021-05,Prescribing Information,,M1,False,False,False,False,False,"Intramuscular Injection, Vaccine Efficacy, Clinical Trials, Warnings and Precautions, Dosage Forms and Strengths, Use in Specific Populations, Dosage and Administration, Pharmaceutical Compliance, COVID-19 vaccine, mRNA vaccine, Adverse Reactions, Indications and Usage, Prescribing Information, FOIA Document, Contraindications, Regulatory Approval, Vaccine Safety",17,29,https://drive.google.com/file/d/1efh_-ONnL3GsG5T5knbMUjofvRUT7y4C/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:40
125742_S24_M1_cover.pdf,PDF,Response to FDA 27 July 2021 Information Request for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-07-30,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Captain Michael Smith, Ph.D. (CBER)",M1,False,False,False,False,False,"FOIA document, Biologics License Application (BLA), Regulatory affairs, BioNTech, Vaccine development, Pfizer Global Regulatory Affairs, Safety and efficacy, Center for Biologics Evaluation and Research (CBER), COVID-19 vaccine, Collegeville, PA, Pharmaceutical industry, Clinical trial data, Vaccine effectiveness assessment, FDA information request, Regulatory compliance, Office of Vaccines Research and Review, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1GFIL7urMn4VQDUjiUjWx335qR_Q9FPN7/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:43
125742_S28_M1_cover.pdf,PDF,BLA 125742 COVID-19 mRNA Vaccine (BNT162/PF-07302048) Follow up Response to 22 July 2021 Information Request,2021-08-02,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"covid-19 vaccine, bnt162/pf-07302048, bla 125742, silver spring, md, biontec h, clinical trial, information request, safety data, study c4591001, collegeville, pa, pfizer inc., fda submission, global product development, efficacy data, regulatory affairs, adverse events, data analysis",17,2,https://drive.google.com/file/d/1ehxwFRVdnowtCAPPU80FVHbGIxIMiZaq/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:47
125742_S24_M1_response-27jul2021.pdf,PDF,Response to FDA Information Request Regarding Assessment of Vaccine Effectiveness,2021-07-30,report,"Michael Smith, Elisa Harkins Tull",M1,False,False,False,False,False,"confidence interval, Center for Biologics Evaluation and Research, vaccine efficacy, dose timing, clinical trial, vaccine effectiveness, regulatory submission, SARS-CoV-2, safety data, COVID-19, biologics license application, United States, vaccine administration, FDA information request, Pfizer, data analysis, BNT162b2 (COMIRNATY)",17,11,https://drive.google.com/file/d/1VoFn0JhvwMkTMhc5H74GZ0tOHgGvlpu3/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:51
125742_S21_M1_cover.pdf,PDF,Response to 13 July 2021 Information Request for BLA 125742 COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-07-29,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, PhD",M1,False,False,False,False,False,"BLA 125742, COVID-19 mRNA vaccine, FOIA document, Adverse events, FDA Center for Biologics Evaluation and Research, Regulatory submission, Pharmaceutical/clinical trial, Pfizer Global Regulatory Affairs, Efficacy data, Silver Spring, MD, Collegeville, PA, Pharmacovigilance Plan, Safety data, Regulatory compliance, Vaccine development, BNT162/PF-07302048, Myocarditis and pericarditis",17,2,https://drive.google.com/file/d/1Nv4sqFG64ugA3Egu6s7c8FjET1oNao1D/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:55
125742_S23_M1_cover.pdf,PDF,Response to 26 July 2021 Information Request Regarding Disposition of Participants in Safety Populations who Experienced Pregnancy,2021-07-30,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"BLA 125742, Pfizer Global Regulatory Affairs, Vaccine Clinical Trials, CBER Information Request, COVID-19 mRNA Vaccine, Pharmacovigilance, Silver Spring, MD, Safety Population, Collegeville, PA, Adverse Event Monitoring, Regulatory Compliance, Biologics License Application, Vaccine Approval Process, FDA Regulatory Submission, Vaccine Development, BNT162/PF-07302048, Pregnancy Outcomes",17,2,https://drive.google.com/file/d/1yFnvcEVNwb2rCYtSKVBCOv3oGoDQRGxT/view?usp=drivesdk,pd-production-080123,2025-08-12 00:10:59
125742_S27_M1_cover.pdf,PDF,Response to FDA Information Request for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-08-02,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, BLA 125742, Vaccine approval and submission, Regulatory affairs, Vaccine efficacy and safety data, Vaccine clinical trials, Vaccine regulatory requirements, Vaccine compliance and quality, Vaccine age groups, Vaccine adverse events, Study C4591001, Vaccine geographic distribution, Biologics License Application, FDA information request, Clinical safety summary, Vaccine development, Pfizer Global Regulatory Affairs",17,2,https://drive.google.com/file/d/1YXC7AB-5bERNlyxzz3ZDgg1BBX2bnGUQ/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:03
125742_S23_M1_response-26jul2021.pdf,PDF,Response to FDA Information Request Regarding Disposition of Participants in Safety Populations Who Experienced Pregnancy,2021-07-30,response,Laura Gottschalk,M1,False,False,False,False,False,"regulatory-submission, office-of-vaccines-research-and-review, biologics-license-application, pregnancy-exposure, pregnancy-outcomes, comirnaty-vaccine, center-for-biologics-evaluation-and-research, clinical-trial-safety, adverse-events, fda-information-request, bnt162b2-vaccine, vaccine-development, sars-cov-2, pfizer-biontech, data-analysis, covid-19, dose-timing",17,6,https://drive.google.com/file/d/1UVHchQ-3np54muZd-s76kM9mn_BAT9os/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:07
125742_S20_M1_cover.pdf,PDF,Follow-up Response to 22 July 2021 Information Request for BLA 125742 COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-07-28,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"clinical-trials, covid-19-vaccine, pfizer-inc, regulatory-compliance, silver-spring-md, safety-data, fda-communication, global-product-development, adverse-events, efficacy-data, vaccine-registration, biotech-partnership, data-submission, regulatory-affairs, vaccine-development, information-request, bla-submission",17,2,https://drive.google.com/file/d/175qj1tcjbWsocSrF8rVZY1H7E1eDAlXk/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:10
125742_S31_M1_cover.pdf,PDF,Response to FDA 28 July 2021 Information Request for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-08-03,letter,"Marion Gruber, Ph.D., Ramachandra S. Naik, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"FOIA document, Biologics License Application (BLA), Regulatory submission, Vaccine development, Pfizer Global Regulatory Affairs, Myocarditis/pericarditis, Center for Biologics Evaluation and Research (CBER), Vaccine safety, COVID-19 vaccine, mRNA vaccine, Clinical trial data, Food and Drug Administration (FDA), Subclinical cases, FDA information request, Pharmacovigilance plan, Post-marketing safety study, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1eeS3Va-j0_E6uZV9GPgFEJv9_luYYOzf/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:14
125742_S32_M1_cover.pdf,PDF,Biologics License Application (BLA) for COVID-19 Vaccine,2021-08-05,Memo,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D.",M1,False,False,False,False,False,"Adverse Event Reporting, Safety and Efficacy, FDA Submission, Pharmaceutical Industry, Compliance and Quality, Regulatory Agencies, Pharmaceutical Departments, Global Regulatory Lead, Confidential Information, Vaccine Identification, Regulatory Affairs, Biologics License Application, Vaccine Approval Process, COVID-19 Vaccine, Vaccine Development, Time-Sensitive Document, Clinical Trial Data",17,2,https://drive.google.com/file/d/1NICH0W3-XXlIt3l2C9u533ykpKWTR_Xo/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:18
125742_S2_M1_pharmacovigilance-plan.pdf,PDF,Pharmacovigilance Plan for Biologic License Application #125742 of COVID-19 mRNA Vaccine (BNT162b2),2021-05-17,Risk Management Plan,,M1,False,False,False,False,False,"covid-19 vaccine, pharmacovigilance, post-approval monitoring, safety specification, epidemiology, vaccine development, risk management plan, regulatory compliance, drug interactions, quality assurance, biologic license application, fda submission, pharmaceutical industry, bnt162b2, adverse events, data analysis, clinical trials",17,93,https://drive.google.com/file/d/1vSk8G0ZIzc3rLThrWTd0vhf1wnkNKBPN/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:24
125742_S32_M1_response-02aug2021.pdf,PDF,Response to FDA Information Request Regarding Validation Report VR-MVR-10077,2021-08-05,report,,M1,False,True,False,False,False,"Pharmaceutical quality, Biologics License Application (BLA), Validation report, Pharmaceutical manufacturing, Regulatory submission, Linearity, Center for Biologics Evaluation and Research (CBER), COVID-19 vaccine, Pfizer confidential, BNT162b2 (COMIRNATY) BLA, Compliance, Analytical method validation, Clinical trial data, Adverse event reporting, Protocol, FDA information request, SARS-CoV-2 detection, Vaccine development",18,10,https://drive.google.com/file/d/1aH3FHJz0hR2moollm9NN-h_cCy4Tjm47/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:29
125742_S2_M1_loa-dmf-15209-vials.pdf,PDF,Letter of Authorization for Drug Master File 15209 - Vials,2021-03-26,letter,,M1,False,False,False,False,False,"quality control, medical products, compliance, drug development, vials, letter of authorization, regulatory submission, vaccine development, drug master file, safety data, United States, FDA approval, product identification, pharmaceutical manufacturing, efficacy data, adverse events, clinical trials",17,1,https://drive.google.com/file/d/15YKCDAR90lp82G8xdl1W6uBJC0mat3JU/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:32
125742_S31_M1_response-28jul2021.pdf,PDF,Response to FDA Information Request Regarding Post-marketing Safety Study(ies),2021-08,report,,M1,False,True,False,False,False,"Department of Defense, pediatric population, NHLBI, COMIRNATY, adverse event monitoring, age and sex stratification, long-term follow-up, Vaccine Safety Datalink, post-marketing safety study, pericarditis, clinical trial protocol, myocarditis, data collection and analysis, Protocol, vaccine safety, FDA information request, BNT162b2, regulatory submission",18,17,https://drive.google.com/file/d/1gYmGvNWewX5XYAanR1yQrxLsmz_xZ4U4/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:35
125742_S33_M5_c4591001_adc19ef-ve-sev-7pd2-cdc-eval-sas.pdf,PDF,adc19ef -ve-sev-7pd2-cdc-eval SAS Program,2021-08-04,SAS program,,M5,False,False,False,False,False,"CDISC standards, safety evaluation, FOIA document, data quality, FDA submission, SAS programming, adc19ef, clinical trial, unblinded analysis, Phase 2 study, data management, data processing, data visualization, statistical reporting, adverse events, data analysis, regulatory compliance",17,6,https://drive.google.com/file/d/1n-4Q1odk1NRFwPNiA6KuzyXZcC2IbXAY/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:38
125742_S41_M1_response-10aug2021.pdf,PDF,Response to FDA Information Request,2021-08-11,response,,M1,False,True,False,False,False,"regulatory-submission, data-monitoring, covid-19-vaccine, clinical-trials, regulatory-compliance, pharmaceutical-development, medical-terminology, statistical-analysis, comirnaty, post-marketing-surveillance, fda-information-request, public-health, Protocol, adverse-events, safety-studies, confidential, vaccine-approval, bnt162b2",18,17,https://drive.google.com/file/d/1ZKFUEs6HOnySIcuAq8ahpraxDHaDqonu/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:42
125742_S39_M1_cover.pdf,PDF,Response to second round of requested changes and comments on the draft Package Insert for COMIRNATY,2021-08-09,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"BLA 125742, BNT162/PF-07302048, Package Insert, Clinical Trials, FDA Office of Vaccines Research and Review, COMIRNATY, COVID-19 mRNA Vaccine, Regulatory Submission, Efficacy Data, Silver Spring, MD, Collegeville, PA, Adverse Events, Regulatory Compliance, Biologics License Application, Safety Data, Vaccine Development, Pfizer Global Regulatory Affairs",17,2,https://drive.google.com/file/d/1URjaA7JRq-mrmRr6GMoFiaRBoRvNG2YN/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:46
125742_S33_M1_cover.pdf,PDF,Response to FDA Information Requests for COVID-19 mRNA Vaccine BLA,2021-08-05,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"BLA 125742, Vaccine Approval, Clinical Trials, Vaccine Registration, FDA Information Request, COVID-19 mRNA Vaccine, Efficacy Data, SARS-CoV-2, Collegeville, PA, Confidential Information, Silver Spring, MD, Regulatory Affairs, Biologics License Application, Safety Data, Vaccine Research and Review, Vaccine Development, Pfizer",17,2,https://drive.google.com/file/d/1aJug1k5JMHW1TDlIWUbbY-eFD-EpHzS2/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:50
125742_S33_M1_response-22jul-03aug.pdf,PDF,Response to FDA Information Request for BNT162b2 (COMIRNATY) BLA STN 125742/0,2021-08-05,response,"Laura Gottshalk, Michael Smith",M1,False,True,False,False,False,"Adverse events, BNT162b2 vaccine, Immunization, Data analysis, Regulatory submission, SAS programs, Efficacy data, Clinical trial C4591001, SARS-CoV-2, Pfizer confidential, CDC definition, COVID-19, COMIRNATY BLA, CBER, Compliance, Protocol, Safety data, FDA information request",18,5,https://drive.google.com/file/d/17GABPc1P1Gxet6YLMURGiuRNhoBTRLno/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:54
125742_S33_M5_c4591001_adc19ef-ve-sev-7pd2-cdc-wo-eval-sas.pdf,PDF,adc19ef -ve-sev-7pd2-cdc-wo-eval SAS Program,2021-08-04,SAS Program,,M5,False,False,False,False,False,"cdisc-standards, pharmaceutical, regulatory-compliance, adc19ef, phase-2-3-trials, clinical-trial, data-quality, safety-data, sas-programming, unblinded-analysis, adverse-events, efficacy-data, data-management, data-reporting, data-processing, fda-submission, data-analysis",17,6,https://drive.google.com/file/d/1kgyjnn1IzSqeY9zMV5o8DLBMvEX0g5oq/view?usp=drivesdk,pd-production-080123,2025-08-12 00:11:58
125742_S41_M1_cover.pdf,PDF,Response to FDA 10August 2021 Information Request,2021-08-11,letter,"Marion Gruber, Ph.D., Ramachandra S. Naik, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"bnt162-pf-07302048, biologics-license-application, covid-19-vaccine, trade-secret-information, pfizer-inc, collegeville-pa, center-for-biologics-evaluation-and-research, information-request-response, safety-data, silver-spring-md, global-product-development, regulatory-affairs, fda-submission, vaccine-development, confidential-information, vaccine-research-and-review, post-marketing-studies",17,2,https://drive.google.com/file/d/1GvC2qKZgV2Ev36ZJnHcafCOlLB4navpx/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:01
125742_S41_M5_5354_c4591021-protocol.pdf,PDF,Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech COVID-19 Vaccine,2021-05-20,protocol,,M5,False,True,False,False,False,"Pfizer-BioNTech, immunocompromised individuals, Europe, non-interventional study, pregnant people, secondary data collection, vaccine effectiveness, COVID-19 vaccine, mRNA vaccine, Protocol, post-authorization safety study, adverse events of special interest, vaccine safety, cohort study, self-controlled risk interval, BNT162b2, neonates, regulatory compliance",18,74,https://drive.google.com/file/d/1dG1Ey4LJvzC1aEH9ILNF5X2RnUEeu_Cj/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:08
125742_S46_M1_cover.pdf,PDF,Response to FDA Information Request Regarding Draft COMIRNATY Vial and Carton Labels,2021-08-13,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"bnt162-pf-07302048, regulatory-submission, biologics-license-application, covid-19-vaccine, global-regulatory-affairs, serialization, vaccine-distribution, collegeville-pa, vial-labels, silver-spring-md, comirnaty, fda-review, carton-labels, vaccine-development, confidential-information, pandemic-response, product-quality",17,2,https://drive.google.com/file/d/1bFOs8ai0WrP0AXEJJChCiE_xLjjAUYOo/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:12
125742_S49_M1_cover.pdf,PDF,Response to FDA 13 August 2021 Information Requests for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-08-16,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D.",M1,False,False,False,False,False,"vaccine-manufacturing, clinical-trials, covid-19-vaccine, collegeville-pennsylvania, regulatory-compliance, follow-up-duration, safety-data, global-product-development, vaccine-registration, fda-information-request, efficacy-data, silver-spring-maryland, regulatory-affairs, vaccine-development, bla-submission, vaccine-approval, pfizer-biontech-collaboration",17,2,https://drive.google.com/file/d/1g5p8sys4DJHsI2DV9PbdNw4IBXcM8oCn/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:15
125742_S45_M1_cover.pdf,PDF,Response to FDA 09 August 2021 Information Request,2021-08-12,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, BLA 125742, Regulatory affairs, Vaccine research and review, Virus sequencing data, Pharmaceutical regulatory compliance, Vaccine safety and efficacy, Clinical trial C4591001, Silver Spring, MD, Collegeville, PA, Confidential information, Global product development, Biologics License Application, BioNTech/Pfizer vaccine, FDA-CBER submission, Vaccine development, Information request response",17,2,https://drive.google.com/file/d/1JoStdcYfHzWoA9NYIaB2BKmcl-j_BgGJ/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:19
125742_S45_M1_response-09aug2021.pdf,PDF,Response to FDA Information Request Regarding Sequencing Data,2021-08,response,"Michael Smith, Elisa Harkins Tull",M1,False,True,False,False,False,"covid-19-vaccine, hiv-positive-subjects, regulatory-compliance, vaccine-efficacy, safety-data, study-c4591001, comirnaty, adverse-events, pfizer, information-request, covid-19-pneumonia, data-reporting, Protocol, fda-submission, data-analysis, clinical-trial, genomic-sequencing, bnt162b2",18,7,https://drive.google.com/file/d/1viv53NHmfPnU0m9D57Q3Zz6DmB9FZGWF/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:23
125742_S54_M1_response-16aug2021.pdf,PDF,Response to FDA Information Request Regarding Diluent Packaging Labels,2021-08,response,"Michael Smith, Elisa Harkins",M1,False,False,False,False,False,"diluent packaging labels, Pfizer-BioNTech, vaccine distribution, quality control, clinical trial data, product labeling, pharmaceutical development, vaccine approval, regulatory submission, carton and container labels, COVID-19 vaccine, SARS-CoV-2, BLA STN 125742/0, safety and efficacy, vaccine administration, FDA information request, BNT162b2 (COMIRNATY)",17,6,https://drive.google.com/file/d/1ZEzU8-kBxdK1c9vPlRId37jyiJ7e1Ne3/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:27
125742_S62_M1_cover.pdf,PDF,Response to FDA 17August2021 Information Request,2021-08-18,letter,"Marion Gruber, Ph.D., Ramachandra Naik, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, BLA 125742, Vaccine efficacy, Regulatory affairs, Adverse events, FDA submission, Clinical trial phases, Postmarketing commitment, SARS-CoV-2, Silver Spring, MD, Collegeville, PA, Compliance, Biologics License Application, Safety data, Vaccine development, Postmarketing requirement, Pfizer Global Regulatory Affairs",17,2,https://drive.google.com/file/d/1Q0KhAwQfT2c8ftpP31_as5tiAU9JFl92/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:30
125742_S54_M1_cover.pdf,PDF,Response to FDA Information Request Regarding Carton and Container Labels for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-08-17,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Captain Michael Smith, Ph.D., Laura Gottshalk, Ph.D.",M1,False,False,False,False,False,"vaccine-identification, bnt162-pf-07302048, regulatory-submission, biologics-license-application, covid-19-vaccine, global-regulatory-affairs, pfizer-inc, safety-and-efficacy, regulatory-compliance, manufacturing-sites, document-confidentiality, carton-and-container-labels, fda-information-request, biotech-partnership, clinical-trial-data, vaccine-development, product-packaging",17,2,https://drive.google.com/file/d/1FbSTgNipzaaq9DjlFG0sgJuxTjFkW_Au/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:34
125742_S64_M1_cover.pdf,PDF,Response to FDA 18 August 2021 Information Request Regarding Inclusion of Draft Carton and Container Labels in a Single Amendment,2021-08-19,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Captain Michael Smith, Ph.D., Laura Gottshalk, Ph.D.",M1,False,False,False,False,False,"BLA 125742, BNT162/PF-07302048, Vaccine Approval, Manufacturing Locations, Carton and Container Labels, Clinical Trials, Diluent Information, Vaccine Providers, Regulatory Interactions, COVID-19 mRNA Vaccine, Vaccine Packaging, Regulatory Compliance, Biologics License Application, FDA Submission, Vaccine Safety and Efficacy, Vaccine Development, Pfizer Global Regulatory Affairs",17,2,https://drive.google.com/file/d/1V-VtB35D2awKeTOfaCJ-APMq0EhaNFPO/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:38
125742_S52_M1_response-13aug2021.pdf,PDF,Response to FDA Information Request Regarding Safety-Related Postmarketing Requirement/Postmarketing Commitment Studies,2021-08-16,response,,M1,False,True,False,False,False,"Pfizer-BioNTech, FOIA document, pharmaceutical clinical trials, Sentinel system, vaccine approval, COMIRNATY, safety data, pericarditis, Protocol, BLA STN 125742/0, postmarketing requirements, myocarditis, postmarketing commitments, adverse events, EU active surveillance, FDA information request, BNT162b2, regulatory compliance",18,12,https://drive.google.com/file/d/19VQ1Q3S8SsFoyy1EH0-iffwbKGTVCsYf/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:41
125742_S58_M1_cover.pdf,PDF,Response to FDA 17August2021 Fourth Round of Comments on the Draft Package Insert for COMIRNATY,2021-08-18,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"BLA 125742, Package Insert, Clinical Trials, COMIRNATY, COVID-19 mRNA Vaccine, Efficacy Data, Silver Spring, MD, Pfizer Global Regulatory, Adverse Events, Compliance, Collegeville, PA, Regulatory Affairs, FDA Submission, Biologics License Application, Safety Data, Vaccine Research and Review, Vaccine Development",17,2,https://drive.google.com/file/d/1qjG1lDXjHm7AMZoulifP2o3lmn14v0Cp/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:45
125742_S51_M1_cover.pdf,PDF,Response to FDA 13August2021 Third Round of Comments on the Draft Package Insert for COMIRNATY,2021-08-16,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"BLA 125742, Package Insert, Clinical Trials, BioNTech, COMIRNATY, COVID-19 mRNA Vaccine, Efficacy Data, Silver Spring, MD, Collegeville, PA, Adverse Events, Compliance, Regulatory Affairs, FDA Submission, Safety Data, Vaccine Development, Pfizer, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1XC1QAkuO9IhtwVjpfaWXYiNRy55L_0Hf/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:48
125742_S49_M1_response-13aug2021.pdf,PDF,Response to FDA Information Request Regarding Duration of Follow-up in Study C4591001 (16+ Years of Age),2021-08,report,,M1,False,False,False,False,False,"regulatory-submission, clinical-trial-c4591001, evaluable-efficacy-population, bnt162b2-comirnaty, safety-population, infection-status, dose-2, data-tables, safety-data, blinded-data, fda-information-request, efficacy-data, august-2021, vaccine-clinical-trial, follow-up-duration, pfizer-confidential, age-group-16-plus",17,17,https://drive.google.com/file/d/1FknX2Q_vl7NBB7JFw_fbr7WdVMNwUXjo/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:52
125742_S52_M1_cover.pdf,PDF,Response to FDA 13 August 2021 Information Request for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-08-16,letter,"Marion Gruber, Ph.D., Ramachandra Naik, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"BLA 125742, FOIA document, Regulatory affairs, Vaccine research and review, BioNTech, Postmarketing requirements, FDA submission, Postmarketing commitments, COVID-19 vaccine, Pharmaceutical industry, Biologics License Application, Clinical trials, Vaccine manufacturing, Safety data, Vaccine development, Regulatory compliance, Pfizer",17,2,https://drive.google.com/file/d/1skOaVss7VHEKeUPbuATHkKbz4HqZZgwp/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:56
125742_S62_M1_response-17aug2021.pdf,PDF,Response to FDA Information Request,2021-08-18,response,,M1,False,True,False,False,False,"safety evaluation, FOIA document, Pfizer-BioNTech, adolescent dose evaluation, COMIRNATY, study C4591031, vaccine development, COVID-19 vaccine, SARS-CoV-2, troponin I assessment, postmarketing requirement/commitment, pharmacovigilance plan, Protocol, study C4591007, FDA information request, BNT162b2, pharmaceutical clinical trial, regulatory submission",18,6,https://drive.google.com/file/d/1yz1aekAp0Xyi3iLfQcvD4_ISCHYs7jwJ/view?usp=drivesdk,pd-production-080123,2025-08-12 00:12:59
125742_S64_M1_carton-ca-7114-hospira.pdf,PDF,10 mL Plastic Vial Reference Drawing,2018-07-31,drawing template,J. Cotton,M1,False,False,False,False,False,"quality control, drawing template, Rocky Mount, vial packaging, sterile diluent, storage conditions, dimensional specifications, labeling requirements, clinical trial supplies, sodium chloride injection, Lake Forest, IL, product identification, pharmaceutical manufacturing, aseptic technique, Hospira, Pfizer, FDA compliance",17,1,https://drive.google.com/file/d/1OIa7Drhf2immOtdLDVqqeEZMd3_Bk42r/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:02
125742_S64_M1_diluent-carton-fresenius-kabi.pdf,PDF,"Sodium Chloride Injection, USP 0.9% Diluent Carton Label",2020-11-17,form,"Alicia Dodson, Cherita Holt",M1,False,False,False,False,False,"quality control, diluent, foia document, storage conditions, carton label, sodium chloride injection, clinical trial supplies, product identifier, fresenius kabi, sterile solution, preservative-free, dosage information, digital signatures, usp 0.9%, fda regulated, pharmaceutical packaging, regulatory compliance",17,1,https://drive.google.com/file/d/1FCDJLQQ87CFhkZOgvwPbnTV550NzBXtd/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:06
125742_S64_M1_vial-diluent-rl-7302-hospira.pdf,PDF,Vial Diluent Label for RL-7302,2018-07-31,label,J. Cotton,M1,False,False,False,False,False,"expiration-date, single-dose-vial, regulatory-compliance, technical-specifications, fda-regulations, manufacturing-process, united-states-market, sodium-chloride-injection, pharmaceutical-label, quality-control, pfizer, rl-7302, drug-diluent, hospira, lot-number, sterile-product, ndc-number",17,1,https://drive.google.com/file/d/1UlPFKZdLwv2qFwuunES9SKO0oVsDh_Cp/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:09
125742_S65_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, public health, patient information, pharmaceutical, adverse reactions, vaccine development, comirnaty, safety data, regulatory compliance, immunization, united states, efficacy data, prescribing information, fda approval, clinical trials",17,20,https://drive.google.com/file/d/1FtlaKik95hN4FBvgd5_RLam16Smmqr_o/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:13
125742_S65_M1_eua-lab-1451-8-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-08-23,fact sheet,,M1,False,False,False,False,False,"safety-and-efficacy, covid-19-vaccine, clinical-trials, pharmaceutical-manufacturing, regulatory-compliance, vaccine-distribution, vaccine-supply-chain, vaccine-storage-and-handling, vaccine-hesitancy, vaccine-information, vaccine-monitoring-and-surveillance, vaccine-administration, public-health-education, immunocompromised-individuals, fda-approval, mrna-vaccine, emergency-use-authorization",17,8,https://drive.google.com/file/d/1gFz47RDJ_WfYZ8k_01S-ZUAKfvznvxNL/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:16
125742_S65_M1_eua-lab-1450-12-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19),2021-08-23,fact sheet,,M1,False,False,False,False,False,"covid-19 vaccine, immunocompromised individuals, adverse event reporting, clinical trial data, public health, vaccine distribution, emergency use authorization, healthcare provider guidance, safety and efficacy, pfizer-biontech, medical product information, vaccine administration, united states, vaccination providers, pharmaceutical industry, fda approval, regulatory compliance",17,41,https://drive.google.com/file/d/1rBm20ehze4MKyLdGiagpwc-Qm5H-X_-w/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:21
125742_S64_M1_diluent-vial-fresenius-kabi.pdf,PDF,"Sodium Chloride Injection, USP 0.9% 2 mL Single Dose Vial for Drug Diluent Use",2020-11-17,product label,"Alicia Dodson, Cherita Holt",M1,False,False,False,False,False,"drug diluent, quality control, product labeling, Fresenius Kabi, Lake Zurich, Illinois, pharmaceutical product, FDA submission, product manufacturing, product release, sodium chloride injection, clinical trial support, lot number, digitally signed, preservative-free, single-dose vial, expiration date, regulatory compliance",17,1,https://drive.google.com/file/d/19zqnb8B_w92qsqycVO3DCF9usKFrkKxY/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:24
125742_S65_M1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Clinical Trial Submission,2021-08-27,report,Donna Boyce,M1,False,False,False,False,False,"BNT162b2, phase 3 study, quality control, FDA submission, pharmaceutical development, clinical trial, FOIA request, data compliance, COVID-19 vaccine, safety data, CBER, United States, digital signature, efficacy data, regulatory affairs, adverse events, Pfizer",17,2,https://drive.google.com/file/d/1shOu3r3hogdZ8JZTNJ6-jvhKL664Shkd/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:28
125742_S66_M1_2253.pdf,PDF,Pfizer Inc. Submission to FDA for COVID-19 Vaccine Approval,2021-08-26,Regulatory Submission,Donna Boyce,M1,False,False,False,False,False,"Vaccine Development, Pharmaceutical Manufacturing, Clinical Trials, COVID-19 Vaccine, Efficacy Data, CBER, Biopharmaceuticals, Adverse Events, Compliance, United States, Pfizer Inc., FDA Submission, Quality Assurance, Regulatory Affairs, Safety Data, Regulatory Approval, Pharmaceutical Regulatory",17,2,https://drive.google.com/file/d/1i7NLToZ0ixgwYsC7GJZK9YNicBjymJ53/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:32
125742_S66_M1_eua-lab-1450-12-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19),2021-08-23,fact sheet,,M1,False,False,False,False,False,"covid-19 vaccine, immunocompromised individuals, adverse event reporting, clinical trial data, public health, vaccine distribution, vaccination administration, vaccine safety and efficacy, disease prevention, medical product information, pfizer-biontech, healthcare provider guidance, united states, fda approval, pharmaceutical industry, emergency use authorization, regulatory compliance",17,41,https://drive.google.com/file/d/1QpcUqXq2QvdCil5JksqK-iqlEpC03Xce/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:37
125742_S65_M1_pp-cvv-usa-0349-01.pdf,PDF,Clinical Study Report for Investigational Drug/Vaccine,2021,Report,,M1,False,False,False,False,False,"data package, FDA submission, investigational vaccine, pharmaceutical development, phase 1 trial, clinical trial, phase 3 trial, CBER, safety data, United States, clinical study report, investigational drug, phase 2 trial, adverse events, product approval, efficacy data, regulatory compliance",17,95,https://drive.google.com/file/d/1yIWeXZ86ghO264RqlvRPXxlMg5tpDa-j/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:44
125742_S66_M1_eua-lab-1451-8-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-08-23,fact sheet,,M1,False,False,False,False,False,"vaccine-fact-sheet, covid-19-vaccine, clinical-trials, vaccine-recipients, regulatory-compliance, vaccine-efficacy, comirnaty, vaccine-caregivers, vaccine-information, vaccine-safety, vaccine-administration, pfizer-biontech, united-states, immunocompromised-individuals, fda-approval, mrna-vaccine, emergency-use-authorization",17,8,https://drive.google.com/file/d/1iloYR4YCvHYOK8bIu2F998d5OOV4Vjc3/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:48
125742_S66_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, vaccine efficacy, adverse reactions, vaccine dosage forms, comirnaty, safety data, regulatory compliance, intramuscular injection, vaccine administration, immunization, vaccine contraindications, vaccine warnings and precautions, prescribing information, fda approval, clinical trials",17,20,https://drive.google.com/file/d/11C9HVbsXxEEyyk3ElhO6UmgbXaYIgwzT/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:52
125742_S66_M1_pp-cvv-usa-0357.pdf,PDF,Pfizer COVID-19 Vaccine USPI and FAQ,2021,report,,M1,False,False,False,False,False,"covid-19 vaccine, pfizer-biontech vaccine, global distribution, labeling, emergency use authorization, comirnaty, regulatory compliance, safety data, foia (freedom of information act), document management, medical information, uspi (united states prescribing information), efficacy data, pharmaceutical industry, adverse events, fda approval, clinical trials",17,149,https://drive.google.com/file/d/1qgDJSxVsqORVXXAUY6jlvsKTNYVTWxtZ/view?usp=drivesdk,pd-production-080123,2025-08-12 00:13:57
125742_S71_M1_cover.pdf,PDF,BLA 125742 COVID-19 mRNA Vaccine (BNT162/PF-07302048) Follow-Up Response to FDA 19 August 2021 Information Request,2021-08-20,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Captain Michael Smith, Ph.D., Laura Gottshalk, Ph.D.",M1,False,False,False,False,False,"Biologics License Application (BLA), BioNTech, FDA submission, PMC Study C4591014, clinical trial, information request, data compliance, COVID-19 vaccine, vaccine development, safety data, CBER, Collegeville, PA, efficacy data, regulatory affairs, adverse events, Pfizer, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1Objzql661IbvpYbWoyWTY4D-biRfUjvT/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:01
125742_S67_M1_attachment-infographic-lots.pdf,PDF,Infographic on Lot Information,2021,infographic,,M1,False,False,False,False,False,"cber, pharmaceutical-manufacturing, compliance, product-traceability, infographic, lot-information, regulatory-approval, safety-data, adverse-events, clinical-trial-data, efficacy-data, quality-control, product-identification, vaccine-development, fda-submission, data-visualization, foia-document",17,1,https://drive.google.com/file/d/1Hk8JtTsfE0sTjjqfdFvBbQ61TQTMNpKA/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:04
125742_S69_M1_cover.pdf,PDF,Response to FDA 19 August 2021 Information Request,2021-08-19,letter,"Marion Gruber, Ph.D., Michael Smith, Ph.D., Laura Gottshalk, Ph.D., Ramachandra S. Naik, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"Pfizer-Global-Regulatory, biologics-license-application, clinical-trials, vaccine-efficacy, postmarketing-studies, BNT162-vaccine, information-request-response, safety-data, SARS-CoV-2, COVID-19-vaccine, vaccine-safety, regulatory-affairs, vaccine-development, FDA-submission, data-clarification, PF-07302048-vaccine, BLA-125742",17,2,https://drive.google.com/file/d/1i1VzkE8VYSFuJPbCnfbCf6TwcnAsnuUS/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:08
125742_S68_M1_cover.pdf,PDF,Response to FDA 18August 2021 Fifth Round of Comments on the Draft Package Insert for COMIRNATY,2021-08-19,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Captain Michael Smith, Ph.D., Laura Gottshalk, Ph.D.",M1,False,False,False,False,False,"BLA 125742, Vaccine Development, BNT162/PF-07302048, Vaccine Approval, Package Insert, COMIRNATY, COVID-19 mRNA Vaccine, Silver Spring, MD, Collegeville, PA, Regulatory Compliance, Adverse Events, Biologics License Application, FDA Submission, Vaccine Licensing, Safety and Efficacy, Pfizer Global Regulatory Affairs, Clinical Trial Data",17,2,https://drive.google.com/file/d/1sZR9zjgPatkYSzv5dfbCSBYSunKcJpAS/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:12
125742_S67_M1_attachment-hcp-letter.pdf,PDF,Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Approval and Lot Information,2021-08,letter,,M1,False,False,False,False,False,"biologics-license-application, covid-19-vaccine, vaccine-lots, healthcare-professionals, quality-compliance, product-information, clinical-trials, safety-data, comirnaty, efficacy-data, geographic-locations, pfizer-biontech, distribution, regulatory-affairs, fda-approval, manufacturing, emergency-use-authorization",17,1,https://drive.google.com/file/d/1LudazhJCUuc77MlokVZ5IF_1Iyyx8SAb/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:15
125742_S69_M1_response-19aug2021.pdf,PDF,Response to FDA Information Request Regarding Postmarketing Requirement/Postmarketing Commitment Studies,2021-08-19,response,,M1,False,True,False,False,False,"BNT162b2 vaccine, FOIA document, FDA information request, Clinical trial studies, C4591014 study, Myocarditis assessment, Long-term sequelae, COMIRNATY vaccine, Postmarketing commitment, C4591021 study, Protocol, BLA STN 125742/0, C4591012 study, C4591022 study, Pharmacovigilance plan, Pfizer-BioNTech response, Postmarketing requirement, Regulatory compliance",18,6,https://drive.google.com/file/d/12K0gdH1qjpUmwm0SOcoR5ts29XKTRvbW/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:19
125742_S71_M1_response-19aug2021.pdf,PDF,Response to FDA Information Request Regarding Postmarketing Commitment Study C4591014,2021-08-20,response,,M1,False,False,False,False,False,"postmarketing commitment, Pfizer-BioNTech, pharmaceutical development, C4591014, clinical trial, COMIRNATY, data compliance, COVID-19 vaccine, safety data, study completion date, pharmacovigilance plan, adverse events, final report submission, FDA information request, BNT162b2, efficacy data, regulatory submission",17,3,https://drive.google.com/file/d/184PjZIeOaorUqA8lxp1-cv_4nuiZTkIF/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:23
125742_S6_M1_cover.pdf,PDF,COVID-19 mRNA Vaccine (BNT162/PF-07302048) COVID-19 Case Strain Sequencing Report,2021-06-07,report,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"BLA 125742, Biologics License Application (BLA), Vaccine efficacy, Vaccine approval, FDA submission, Pfizer Global Regulatory Affairs, Vaccine safety, COVID-19 vaccine, mRNA vaccine, SARS-CoV-2, Collegeville, PA, Silver Spring, MD, Clinical trial data, COVID-19 case strain sequencing, Regulatory compliance, Vaccine development, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1VSUm88UqEezZxUJ2WXBMK8zSkVT8Dc34/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:27
125742_S67_M1_cover.pdf,PDF,Response to CBER 18 August 2021 Information Request Regarding Identification of BLA Compliant Lots and Dear HCP Letter,2021-08-19,letter,"Marion Gruber, Ph.D., Ramachandra S. Naik, Ph.D., Captain Michael Smith, Ph.D., Laura Gottshalk, Ph.D., Donna Boyce, Mary Malarky, Elisa Harkins",M1,False,False,False,False,False,"vaccine-identification, bnt162-pf-07302048, regulatory-submission, compliance-quality, covid-19-vaccine, biologics-license-application, pfizer-global-regulatory-affairs, cber-ocbq, collegeville-pa, bb-ind-19736, dear-hcp-letter, silver-spring-md, clinical-trial-data, safety-efficacy, adverse-events, fda-approval, information-request-response",17,2,https://drive.google.com/file/d/1T-MGxnlYLjr6V6M2ZrvkhVeoY1DhefAf/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:32
125742_S67_M1_response-18aug2021.pdf,PDF,Response to FDA Information Request Regarding Identification of BLA Compliant Lots and Dear HCP Letter,2021-08-19,response,"Donna Boyce, Mary Malarkey",M1,False,False,False,False,False,"lot-identification, covid-19-vaccine, clinical-trials, quality-compliance, vaccine-distribution, comirnaty-vaccine, pharmaceutical-development, safety-data, hcp-letter, adverse-events, fda-information-request, efficacy-data, regulatory-affairs, pfizer-biontech, united-states, bla-submission, vaccine-approval",17,3,https://drive.google.com/file/d/1nMgN829g5xRWHbICuLzHEbmVGRP9lHNP/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:35
125742_S70_M1_cover.pdf,PDF,Response to FDA 19August 2021 Sixth Round of Comments on the Draft Package Insert for COMIRNATY,2021-08-20,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Captain Michael Smith, Ph.D., Laura Gottshalk, Ph.D.",M1,False,False,False,False,False,"BLA 125742, Vaccine Approval, Package Insert, Clinical Trials, COMIRNATY, COVID-19 mRNA Vaccine, Efficacy Data, Silver Spring, MD, Collegeville, PA, Adverse Events, Compliance, Regulatory Affairs, FDA Submission, Biologics License Application, Safety Data, Vaccine Development, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1uZbIkzmEz5txYLo5yF34eyLjBoac-tfF/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:40
125742_S6_M5_c4591001_adxb-sas.pdf,PDF,ADXB SAS Program,2021-06-01,SAS program,,M5,False,False,False,False,False,"data-compliance, pharmaceutical, fda-submission, adc19ef-dataset, data-quality, data-variables, sas-programming, unblinded-analysis, adsl-dataset, data-transformation, data-flags, data-processing, clinical-trial, sdtm-dataset, data-analysis, data-formats, adxb-dataset",17,8,https://drive.google.com/file/d/1syelVIsiZ6ftKGVth_XrmB2wuGdnw1uN/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:43
125742_S75_M1_attachment-hcp-letter.pdf,PDF,Pfizer-BioNTech COVID-19 Vaccine COMIRNATY Approval Letter,2021-08-23,letter,Donna Boyce,M1,False,False,False,False,False,"biologics-license-application, covid-19-vaccine, healthcare-professional, vaccine-distribution, clinical-trials, product-information, safety-information, lot-numbers, comirnaty, quality-control, vaccine-administration, pfizer-biontech, regulatory-affairs, immunocompromised-individuals, fda-approval, manufacturing, emergency-use-authorization",17,3,https://drive.google.com/file/d/1hR_4_2g8xHUuAvATNjmfmviwS1wVgrz9/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:47
125742_S75_M1_cover.pdf,PDF,Response to FDA 20 August 2021 Information Request Regarding Identification of BLA Compliant Lots and Dear HCP Letter,2021-08-20,letter,"Marion Gruber, Ph.D., Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottshalk, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"bla-application, quality-compliance, collegeville-pa, silver-spring-md, safety-data, biontec h-partnership, pfizer-global, adverse-events, efficacy-data, product-identification, healthcare-provider-communication, vaccine-development, fda-submission, regulatory-affairs, clinical-trial, covid-19, information-request-response",17,2,https://drive.google.com/file/d/1zUZPDpyb4NS4il9lsBllQQzgtTqcA1Cm/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:51
125742_S74_M1_response-20aug2021.pdf,PDF,Response to FDA Information Request - BNT162b2 (COMIRNATY) BLA STN 125742/0,2021-08-20,report,,M1,False,False,False,False,False,"Pfizer-BioNTech, unsolicited adverse events, COMIRNATY, clinical trial, blinded follow-up, age groups, COVID-19 vaccine, safety data, SARS-CoV-2, BLA STN 125742/0, serious adverse events, adverse events, Phase 2/3, FDA information request, BNT162b2, data analysis, regulatory submission",17,4,https://drive.google.com/file/d/18L4RXzm4OPGc7Ir-ajYVzB2rh5FO93CQ/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:55
125742_S72_M1_cover.pdf,PDF,Change in Sponsor Authorized Representative for BLA 125742 (COVID-19 mRNA Vaccine),2021-08-20,letter,"Marion Gruber, Ph.D., Neda Aghajani Memar, Amit Patel, Elisa Harkins",M1,False,False,False,False,False,"biologics-license-application, covid-19-vaccine, global-regulatory-affairs, pf-07302048, vaccine-efficacy, vaccine-adverse-events, collegeville-pa, fda-cber, silver-spring-md, bnt162, vaccine-safety, sponsor-authorized-representative, regulatory-affairs, vaccine-development, vaccine-approval, vaccine-submission, mrna-vaccine",17,2,https://drive.google.com/file/d/1vqsqu3lgSoPEx93wiO06Uq2oqYZNI8Y2/view?usp=drivesdk,pd-production-080123,2025-08-12 00:14:58
125742_S74_M1_cover.pdf,PDF,Response to FDA 20 August 2021 Information Request,2021-08-20,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottshalk, Ph.D.",M1,False,False,False,False,False,"Pfizer-Global-Regulatory, vaccine-licensing, biologics-evaluation, CBER-information-request, clinical-trial-C4591001, safety-data, SARS-CoV-2, vaccine-registration, Silver-Spring-MD, COVID-19-vaccine, adverse-event-data, regulatory-affairs, vaccine-development, Collegeville-PA, FDA-submission, BNT162/PF-07302048, BLA-125742",17,2,https://drive.google.com/file/d/1HVKEd0q2j57E77Ig3bHcV-ZtisR8VJZa/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:03
125742_S73_M1_cover.pdf,PDF,Response to FDA 20 August 2021 Seventh Round of Comments on the Draft Package Insert for COMIRNATY,2021-08-20,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandr a S. Naik, Ph.D., Captain Michael Smith, Ph.D., Laura Gottshalk, Ph.D.",M1,False,False,False,False,False,"data-compliance, bnt162-pf-07302048, regulatory-submission, biologics-license-application, covid-19-vaccine, clinical-trials, pfizer-global-regulatory-affairs, package-insert, collegeville-pa, safety-data, comirnaty, efficacy-data, product-registration, fda-review, vaccine-development, adverse-events, vaccine-approval",17,2,https://drive.google.com/file/d/1IfAiCJK99OcmfKbNL5sQMu67rggiZC2d/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:06
125742_S75_M1_attachment-infographic-lots.pdf,PDF,Recommendation - Identification of BLA Lots Identifier Options,2021,report,,M1,False,False,False,False,False,"vaccine-identification, lot-traceability, document-approval, compliance, fda-submission, shipping-container, pharmaceutical-manufacturing, infographic, regulatory-approval, qr-code, healthcare-provider-communication, data-management, quality-control, product-labeling, clinical-trial, biologic-license-application, document-management",17,2,https://drive.google.com/file/d/1rJ2F3gqHiFMtCE3iDi5BrQD2VBrmPXgF/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:10
125742_S72_M1_letter-of-authorization.pdf,PDF,Letter of Authorization to Appoint US Agent,2021-08-03,letter,"Dr. Sierk Poetting, Dr. Oliver Hennig, Martin Lang, Jan Kürschner, Dr. Gruber, Amit Patel, Neda Aghajani Memar, Paul Rohlfing, Elisa Harkins",M1,False,False,False,False,False,"global-regulatory-affairs, pfizer-inc, vaccines, compliance, authorization-letter, clinical-trial-communication, regulatory-approval, biontech-manufacturing, germany, regulatory-affairs, fda-submission, united-states, vaccine-development, covid-19, us-agent-appointment, quality-assurance, contact-information",17,2,https://drive.google.com/file/d/1JlnPiPZVUwlHsaRmJPGjdTIxmKzRJURO/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:14
125742_S76_M1_cover.pdf,PDF,Response to FDA 21 August 2021 Eighth Round of Comments on the Draft Package Insert for COMIRNATY,2021-08-21,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottshalk, Ph.D.",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Package insert, FOIA document, Biologics License Application (BLA), Regulatory affairs, COMIRNATY, Vaccine safety and efficacy, Silver Spring, MD, Collegeville, PA, Confidential information, Clinical development, Vaccine approval process, Vaccine manufacturing, FDA review and comments, Vaccine research and development, Pfizer, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1wx1-9MOKN0oG69rgNO4Qufiq7g9g_UGl/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:17
125742_S82_M1_cover.pdf,PDF,Structured Product Labeling (SPL) for COMIRNATY (COVID-19 mRNA Vaccine) BLA Package Insert,2021-08-26,Submission,"Marion Gruber, Ph.D., Amit Patel, Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D., Captain Michael Smith, Ph.D.",M1,False,False,False,False,False,"Biologics License Application (BLA), Vaccine Efficacy, Vaccine Approval, Structured Product Labeling (SPL), Package Insert, BioNTech, Global Regulatory Affairs, COMIRNATY, Regulatory Submission, Vaccine Labeling, Silver Spring, MD, Collegeville, PA, Pfizer Inc., FDA Correspondence, COVID-19 Vaccine, Vaccine Development, Vaccine Safety",17,2,https://drive.google.com/file/d/11Bax8Idu0jfNX3Jp9iTNdJiG4K_9czCr/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:21
125742_S78_M1_cover.pdf,PDF,Response to FDA 21 August 2021 Information Request Regarding Dear HCP Letter,2021-08-21,letter,"Marion Gruber, Ph.D., Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottshalk, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"Vaccine-distribution, Vaccine-development, Regulatory-compliance, Clinical-trial-data, BNT162-PF-07302048, Dear-HCP-letter, Biologics-License-Application, Vaccine-manufacturing, Pharmaceutical-regulatory-affairs, COVID-19-vaccine, Vaccine-post-marketing-surveillance, Pfizer-Global-Regulatory-Affairs, Safety-and-efficacy, FDA-submission, Vaccine-approval-process, Information-request-response, BLA-125742",17,2,https://drive.google.com/file/d/1Y5syD6rXBj2AyHhG3bKQ5mHr0PBkNC2F/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:25
125742_S7_M1_cover.pdf,PDF,Response to CBER's 8 June 2021 Information Request for BLA 125742 COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-06-16,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"bnt162-pf-07302048, regulatory-submission, bla-125742, covid-19-vaccine, global-regulatory-affairs, pfizer-inc, biologics-license-application, biotech-development, product-development, collegeville-pa, fda-cber, clinical-data, vaccine-research-review, information-request, silver-spring-md, vaccine-compliance, safety-efficacy",17,2,https://drive.google.com/file/d/1KKSxHyiMY5TnPJ4rR9euevunT75MKhg5/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:29
125742_S87_M1_2253-multiple-product.pdf,PDF,Multiple Product Submission,2021,report,,M1,False,False,False,False,False,"clinical-trials, covid-19-vaccine, usa-market, pharmaceutical-industry, medical-research, product-application, safety-data, adverse-events, efficacy-data, meningococcal-vaccine, quality-control, public-health, vaccine-development, fda-submission, regulatory-affairs, vaccine-manufacturing, pneumococcal-vaccine",17,1,https://drive.google.com/file/d/1YV4zuBRqdL_54lCYJJQ-_NYHuhKYtW7w/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:32
125742_S77_M1_response-21aug2021-pmc.pdf,PDF,Response to FDA Information Request Regarding Postmarketing Requirement/Postmarketing Commitment Studies,2021-08-21,report,,M1,False,True,False,False,False,"clinical-trials, pharmaceutical-research, regulatory-compliance, phase-2-trials, postmarketing-commitments, safety-data, phase-1-trials, comirnaty, adverse-events, efficacy-data, pfizer, Protocol, vaccine-development, fda-submission, covid-19, bnt162b2, postmarketing-requirements, phase-3-trials",18,10,https://drive.google.com/file/d/1GIMIEOK7JF8aLIbZ8wl95eZW3zMDqQK2/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:36
125742_S85_M1_cover.pdf,PDF,Pfizer COVID-19 Vaccine BLA Submission and Post-Authorization Safety Studies,2021-08-30,letter,"Marion Gruber, Ph.D., Amit Patel, Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D., Captain Michael Smith, Ph.D.",M1,False,True,False,False,False,"Post-Authorization Safety Study, Vaccine Data and Documentation, Clinical Trials, Vaccine Approval Process, FDA Regulatory Affairs, SARS-CoV-2, Protocol, Vaccine Departments and Organizations, Vaccine Efficacy and Safety, Pfizer COVID-19 Vaccine, Adverse Event Monitoring, Biologics License Application, Regulatory Compliance, Investigational New Drug, United States, Vaccine Identification, Vaccine Development, BLA Submission",18,2,https://drive.google.com/file/d/1cqsiyIeBeEpq5x6hTau9cO86CWV6-M_Q/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:40
125742_S75_M1_response-20aug2021.pdf,PDF,Response to FDA Information Request Regarding Label for Identification of BLA Lots and Dear HCP Letter,2021-08-20,response,"Ramachandra Naik, Elisa Harkins Tull",M1,False,False,False,False,False,"Pfizer-BioNTech, Vaccine distribution, Regulatory compliance, Vaccine lot identification, Dear Healthcare Provider letter, COVID-19 vaccine, Vaccine safety and efficacy, Vaccine labeling, Public health, Pharmaceutical industry, Clinical trial data, Adverse event reporting, Vaccine approval process, Vaccine development, FDA-CBER information request, BLA submission, COMIRNATY (BNT162b2)",17,4,https://drive.google.com/file/d/13OyI_WPcr3AQO6LkBeASJNZdZHfzOMdy/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:45
125742_S77_M1_response-21aug2021-attachment-pmc.pdf,PDF,Response to FDA Information Request Regarding Postmarketing Requirement/Postmarketing Commitment Studies,2021-08-21,report,,M1,False,True,False,False,False,"BNT162b2 vaccine, FOIA document, pharmaceutical clinical trials, safety and effectiveness, final report submissions, Pfizer-BioNTech, active surveillance study, COMIRNATY vaccine, study completion dates, myocarditis and pericarditis, pediatric studies, long-term sequelae, protocol submissions, Protocol, postmarketing requirements, postmarketing commitments, FDA information request, regulatory compliance",18,5,https://drive.google.com/file/d/1RfAtbrzJ04quXuAoHpll6yG8UKwuKnD8/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:48
125742_S77_M1_cover.pdf,PDF,Response to FDA 21August 2021 Information Request,2021-08-21,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Captain Michael Smith, Ph.D., Laura Gottshalk, Ph.D.",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Biologics License Application (BLA), Regulatory affairs, Safety and efficacy, Pfizer Global Regulatory Affairs, Pharmaceutical regulatory compliance, Vaccine documentation, Silver Spring, MD, Collegeville, PA, Confidential information, Clinical trial data, Vaccine approval process, Vaccine identification, Postmarketing requirements and commitments, FDA-CBER submission, Vaccine development, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1289uOK1ex0Ev1OSgOdlcbqX1_TWZo-sY/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:52
125742_S78_M1_attachment-hcp-letter.pdf,PDF,Important Product Information - Pfizer-BioNTech COVID-19 Vaccine,2021-08-23,letter,Donna Boyce,M1,False,False,False,False,False,"biologics-license-application, covid-19-vaccine, vaccine-distribution, vaccine-expiration, regulatory-compliance, product-information, vaccine-lot-information, vaccine-labeling, comirnaty, germany, pfizer-biontech, healthcare-professional-communication, united-states, immunocompromised-individuals, fda-approval, quality-assurance, emergency-use-authorization",17,2,https://drive.google.com/file/d/1qfTA-0-HldJSz-8iUttRurdLj7Ap9vab/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:55
125742_S87_m1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Clinical Trial Submission,2021-09-01,report,Donna Boyce,M1,False,False,False,False,False,"phase 3 study, public health, FDA submission, pharmaceutical development, clinical trial, data compliance, COVID-19 vaccine, safety data, CBER, quality assurance, United States, adverse events, digital signature, medical product regulation, efficacy data, regulatory approval, Pfizer",17,2,https://drive.google.com/file/d/17d8NsBgEhO--FU7seh4309RWGm7k_Cks/view?usp=drivesdk,pd-production-080123,2025-08-12 00:15:59
125742_S87_M1_lab-0722-9-0.pdf,PDF,Highlights of Prescribing Information for Trumenba (Meningococcal Group B Vaccine),2019-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, infectious disease, pharmaceutical product, trumenba, adverse reactions, drug labeling, vaccine development, regulatory compliance, meningococcal vaccine, efficacy, safety, immunization, pediatric use, medical product information, prescribing information, fda approval, clinical trials",17,15,https://drive.google.com/file/d/1hSl6b6gFdFyRNQRsqE9ZoRhq8IhtZ_wO/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:02
125742_S88_M1_pp-cvv-usa-0378.pdf,PDF,Pfizer-BioNTech COVID-19 Vaccine (COMIRNATY) IVR & Live Operator Script,2021,script,,M1,False,False,False,False,False,"covid-19 vaccine, immunocompromised individuals, vaccine distribution, vaccine formulation, vaccine effectiveness, emergency use authorization, vaccine documentation, comirnaty, regulatory compliance, customer service, pfizer-biontech, vaccine administration, united states, pharmaceutical industry, clinical trials, fda approval, safety information",17,8,https://drive.google.com/file/d/1QExMSpn_4YrRXVnAK3FInbQpDtjGwphU/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:06
125742_S89_M1_cover.pdf,PDF,Request for Comments and Advice - Pfizer/BioNTech's Plan for Reporting Adverse Events,2021-09-07,letter,"Marion Gruber, Amit Patel, Ramachandra S. Naik, Laura Gottschalk, Michael Smith",M1,False,False,False,False,False,"bla-125742, regulatory-submission, global-regulatory-affairs, covid-19-vaccine, product-development, fda-cber, safety-data, comirnaty, vaccine-registration, pfizer, virus-free-submission, sars-cov-2, vaccine-development, request-for-comments, wo71-g112, mrna-vaccine, adverse-event-reporting",17,2,https://drive.google.com/file/d/1DnZ_ElYNVSXGSBSVCkVdIvFDzdgwHmpa/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:09
125742_S89_M1_comments-advice-req.pdf,PDF,"Request for Comments and Advice on COVID-19 Vaccine (BNT162, PF-07302048) Postmarketing Adverse Event Reporting",2021-09,memo,Pfizer,M1,False,False,False,False,False,"reporting-requirements, vaccine-indications, biologics-license-application, covid-19-vaccine, clinical-trials, pharmaceutical-industry, pf-07302048, regulatory-compliance, fda-cber, safety-data, bnt162, adverse-event-reporting, data-management, medical-product-development, postmarketing-surveillance, immunocompromised-patients, emergency-use-authorization",17,3,https://drive.google.com/file/d/19Y56Sy7lsuld4Y2IjHJM3dat8oDPplV2/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:13
125742_S87_M1_eua-lab-1451-8-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-08-23,fact sheet,,M1,False,False,False,False,False,"covid-19-vaccine, clinical-trials, vaccine-distribution, regulatory-compliance, vaccine-efficacy, comirnaty, vaccine-information, fda-approval, vaccine-safety, vaccine-administration, pfizer-biontech, adverse-events, vaccine-interchangeability, immunocompromised-patients, patient-education, mrna-vaccine, emergency-use-authorization",17,8,https://drive.google.com/file/d/1hkzRfnpM5Di-q_eZlcYeTZ1HL8pL58mv/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:16
125742_S88_M1_2253.pdf,PDF,Pfizer COVID-19 Vaccine Clinical Trial Submission,2021-09-01,report,Donna Boyce,M1,False,False,False,False,False,"data-compliance, product-approval, medical-research, phase-3-study, medical-product-quality, pharmaceutical-development, safety-data, adverse-events, pfizer, vaccine, efficacy-data, regulatory-affairs, fda-submission, digital-signature, clinical-trial, covid-19, united-states",17,2,https://drive.google.com/file/d/13xlC84GiJpN7ymq-hEuAD5pjQBV3pj_9/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:21
125742_S87_M1_pp-pna-usa-4653.pdf,PDF,Pfizer Prevnar 20 and Prevnar 13 Virtual Exhibit,2021,presentation,,M1,False,False,False,False,False,"clinical-trial-materials, medical-information, vaccine-lifecycle, hcp-resources, prevnar-20, regulatory-compliance, product-promotion, pharmaceutical-marketing, prevnar-13, virtual-exhibit, product-landing-pages, vaccine-information, product-labeling, covid-19-virus, digital-content, united-states, fda-submission",17,8,https://drive.google.com/file/d/1X4ARnfZm4BLDu3tX_RIPdITSELls35zS/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:24
125742_S87_M1_lab-0469-18-0.pdf,PDF,Highlights of Prescribing Information for PREVNAR 13,2010,report,,M1,False,False,False,False,False,"dosage and administration, PREVNAR 13, pharmaceutical, pediatric, adverse reactions, clinical trial, contraindications, warnings and precautions, Streptococcus pneumoniae, intramuscular injection, invasive disease, vaccine, FDA approval, safety and efficacy, otitis media, adult, suspension",17,43,https://drive.google.com/file/d/1UGuhmGRy7mdw4R6iWemUgPfhwG4kS5vi/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:28
125742_S87_M1_lab-1436-1-0.pdf,PDF,Highlights of Prescribing Information for PREVNAR 20,2021-06,prescribing information,,M1,False,False,False,False,False,"dosage and administration, patient counseling, pregnancy and lactation, contraindications, streptococcus pneumoniae, mechanism of action, regulatory submission, drug interactions, intramuscular injection, pneumonia prevention, vaccine, FDA approval, toxicology, immunocompetence, post-marketing surveillance, adverse events, clinical trials",17,18,https://drive.google.com/file/d/1P2g4FPly9G7BK53uzK7hw-0VLZ8kNbsq/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:31
125742_S87_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION for COMIRNATY (COVID-19 Vaccine, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, immunogenicity, regulatory approval, adverse reactions, COMIRNATY, contraindications, vaccine effectiveness, warnings and precautions, COVID-19 vaccine, mRNA vaccine, safety data, intramuscular injection, postmarketing surveillance, SARS-CoV-2, vaccine schedule, prescribing information, clinical trials",17,20,https://drive.google.com/file/d/1L_BlqCH151dTjZ1UdrY-hZzlOIhbxfJ3/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:35
125742_S87_M1_eua-lab-1450-12-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19),2021-08-23,fact sheet,,M1,False,False,False,False,False,"reporting-requirements, multisystem-inflammatory-syndrome, covid-19-vaccine, clinical-trials, regulatory-compliance, vaccine-efficacy, healthcare-providers, vaccination-administration, intramuscular-injection, vaccine-formulation, vaccine-safety, pfizer-biontech, adverse-events, united-states, immunocompromised-individuals, fda-approval, emergency-use-authorization",17,41,https://drive.google.com/file/d/1JSUXkmsp_gmDOm-3TheuX1jnqo4MMl6s/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:40
125742_S94_M1_2253.pdf,PDF,Pfizer Inc. Submission to FDA for COVID-19 Vaccine Approval,2021-09-08,Regulatory Submission,Donna Boyce,M1,False,False,False,False,False,"Vaccine Development, Vaccine Distribution, Vaccine Pharmacovigilance, Clinical Trials, Vaccine Monitoring, COVID-19 Vaccine, Efficacy Data, Adverse Events, Compliance, Vaccine Identification, Pfizer Inc., FDA Submission, Quality Assurance, Vaccine Deployment, Safety Data, Regulatory Approval, Pharmaceutical Regulatory",17,2,https://drive.google.com/file/d/13SOYmfOplxlte_Ij_Mcj_Ro_KS6ApRI5/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:44
FDA-CBER-2021-5683-1007276_125742_S2_M1_comirnaty-04.jpg,JPG,Comirnaty Clinical Study Report,2021-04,report,,M1,False,False,False,False,False,"immunogenicity, pharmaceutical-research, image, phase-3-study, product-information, manufacturing-process, regulatory-compliance, regulatory-approval, safety-data, comirnaty, adverse-events, efficacy-data, quality-control, vaccine-development, fda-submission, data-analysis, clinical-trial, covid-19",18,1,https://drive.google.com/file/d/1Eu-e3YO9qP_xNpnx2sU2fd4V1NN9Hh0L/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:47
125742_S94_M1_eua-lab-1451-9-0.pdf,PDF,"Vaccine Information Fact Sheet for Recipients and Caregivers about COMIRNATY (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine",2021-09-01,fact sheet,,M1,False,False,False,False,False,"eua-authorization, covid-19-vaccine, clinical-trials, pharmaceutical-industry, regulatory-compliance, vaccine-distribution, safety-data, comirnaty, immunocompromise, vaccine-information, efficacy-data, pfizer-biontech, adverse-events, united-states, fda-approval, mrna-vaccine, vaccine-administration",17,8,https://drive.google.com/file/d/19JukU8p4cTkoXwsmyTkY8c7U2nVZaRrl/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:50
FDA-CBER-2021-5683-1007279_125742_S2_M1_comirnaty-07.jpg,JPG,Comirnaty Clinical Study Report,2021-07,report,,M1,False,False,False,False,False,"immunogenicity-data, covid-19-vaccine, pharmaceutical-research, image, phase-3-study, regulatory-compliance, comirnaty-vaccine, regulatory-approval, safety-data, adverse-events, efficacy-data, quality-control, vaccine-development, fda-submission, pfizer-biontech, data-analysis, clinical-trial-report, manufacturing-information",18,1,https://drive.google.com/file/d/1xhov4Oe1KPHmnpHY-k-YEjZeACjHMS3o/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:53
FDA-CBER-2021-5683-1007275_125742_S2_M1_comirnaty-03.jpg,JPG,"Comirnaty (COVID-19 Vaccine, mRNA) Clinical Study Report",2021-11-25,report,,M1,False,False,False,False,False,"mrna vaccine, covid-19 vaccine, vaccine distribution, public health, image, pharmaceutical development, comirnaty, safety data, fda submission, clinical study report, adverse events, product quality, united states, efficacy data, vaccine manufacturing, regulatory approval, phase 3 clinical trial, regulatory compliance",18,1,https://drive.google.com/file/d/1MqqB8ewrO77zQH2Wm67gk5Kd4drZLcba/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:56
125742_S9_M1_response-29jun2021.pdf,PDF,Response to FDA Request for Information on BNT162b2 BLA STN 125742/0,2021-06-29,response,,M1,False,False,False,False,False,"regulatory-submission, clinical-trial-c4591001, biologics-license-application, fda-request, randomization-date, quality-compliance, pediatric-population, pharmaceutical-development, vaccine-authorization, reactogenicity-subset, safety-data, data-sets, vaccination-date, bnt162b2-vaccine, pfizer-biontech, clinical-information, data-analysis",17,3,https://drive.google.com/file/d/1yKXrgQR2QugPjodij5wJBj7Qi-Vttr7L/view?usp=drivesdk,pd-production-080123,2025-08-12 00:16:59
FDA-CBER-2021-5683-1007273_125742_S2_M1_comirnaty-01.jpg,JPG,Comirnaty Clinical Study Report,2021,report,,M1,False,False,False,False,False,"immunogenicity-data, covid-19-vaccine, pharmaceutical-research, image, phase-3-study, regulatory-compliance, comirnaty-vaccine, regulatory-approval, safety-data, adverse-events, efficacy-data, trial-participants, dose-administration, vaccine-development, fda-submission, pfizer-biontech, data-analysis, clinical-trial-report",18,1,https://drive.google.com/file/d/1luhbqpEfmDVQx_B_adnlJNyWjaIqX4t6/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:02
125742_S94_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, pharmaceutical, adverse reactions, intramuscular administration, comirnaty, safety data, regulatory compliance, suspension for injection, vaccine indications, immunization, united states, efficacy data, prescribing information, fda approval, clinical trials",17,20,https://drive.google.com/file/d/1Qls7hat8lvPqnri5Ob7CSc2Y61dYj-XF/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:06
FDA-CBER-2021-5683-1007238-1007272_125742_S2_M1_comirnaty.xml,XML,Highlights of Prescribing Information for COMIRNATY (COVID-19 mRNA Vaccine),2021,Prescribing Information,"Pfizer Laboratories Div Pfizer Inc, Pfizer Manufacturing Belgium NV, Pharmacia & Upjohn Company LLC, Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC, Pfizer Inc, Pfizer Ireland Pharmaceuticals, Hospira Zagreb d.o.o., SGS Lab, Simon",M1,False,False,False,False,False,"Intramuscular Injection, Pharmaceutical Manufacturing, Geographic Locations, mRNA Vaccine, TOZINAMERAN, Clinical Trials, Pharmaceutical Quality, COMIRNATY, Dosage and Administration, FDA Approval, Regulatory Compliance, Adverse Events, Indications and Usage, Prescribing Information, Preparation and Dilution, COVID-19 Vaccine, Pfizer",17,24,https://drive.google.com/file/d/1epbnzw-ZpG12DjNTUKzewwj-nvRWuVBl/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:10
125742_S94_M1_pp-cvv-usa-0408.pdf,PDF,Pfizer COVID-19 Vaccine USPI and FAQs,2021,report,,M1,False,False,False,False,False,"covid-19 vaccine, cber, fda, public health, pharmaceutical, labeling, medical product, product information, regulatory compliance, safety data, pfizer, faq, adverse events, united states, efficacy data, clinical trials, uspi",17,21,https://drive.google.com/file/d/1ybtaQdXCsJ6hxIlYTV0_3fnvSM_ZMYn1/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:14
FDA-CBER-2021-5683-1007280_125742_S2_M1_comirnaty-08.jpg,JPG,Comirnaty Clinical Study Report,2021-08,report,,M1,False,False,False,False,False,"medical-product-review, covid-19-vaccine, pharmaceutical-research, phase-3-study, regulatory-compliance, comirnaty-vaccine, regulatory-approval, safety-data, biopharmaceutical-company, adverse-events, efficacy-data, public-health, vaccine-development, fda-submission, image, data-analysis, quality-assurance, clinical-trial-report",18,1,https://drive.google.com/file/d/1-7VjxxMbZZYD9V-XuGqoLBJTyt_oJR9n/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:16
125742_S8_M1_cover.pdf,PDF,Response to 9 June 2021 Information Request,2021-06-17,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,True,False,False,False,"compliance-quality, bnt162-pf-07302048, study-c4591007, clinical-trials, prea-milestones, covid-19-vaccine, safety-efficacy-data, biologics-license-application, collegeville-pa, fda-cber, bb-ind-19736, silver-spring-md, study-c4591001, Protocol, pfizer-global-regulatory, regulatory-affairs, vaccine-development, bla-submission",18,2,https://drive.google.com/file/d/1oKhfm5CRO2AMXKuz1gYtN3eOV6QDDTgG/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:23
FDA-CBER-2021-5683-1007281_125742_S2_M1_comirnaty-09.jpg,JPG,Comirnaty Clinical Study Report,2021,report,,M1,False,False,False,False,False,"Pfizer-BioNTech, phase 3 study, quality control, public health, pharmaceutical, clinical trial, FOIA request, FDA, safety data, SARS-CoV-2, COVID-19, vaccine, data submission, adverse events, Comirnaty, image, efficacy data, regulatory approval",18,1,https://drive.google.com/file/d/1zGH7JltnVAJ64PSVtdUJef8olKSb81Dv/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:25
FDA-CBER-2021-5683-1007274_125742_S2_M1_comirnaty-02.jpg,JPG,"Comirnaty (COVID-19 Vaccine, mRNA) Biologics License Application",2021,Image file,,M1,False,False,False,False,False,"Clinical Trials, image, Regulatory Approval, FDA, Efficacy Data, Vaccine Manufacturing, Adverse Events, Vaccine Identification, Regulatory Compliance, Biologics License Application, Comirnaty, Pharmaceutical Submission, Vaccine Distribution, Safety Data, COVID-19 Vaccine, Vaccine Development, Pharmaceutical Organization, Vaccine Deployment",18,1,https://drive.google.com/file/d/1O2NyYBqheEy9X7mAWCiCZiOErjoA2ieW/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:28
FDA-CBER-2021-5683-1007278_125742_S2_M1_comirnaty-06.jpg,JPG,Comirnaty Clinical Study Report,2021-06,report,,M1,False,False,False,False,False,"pharmaceutical-research, image, phase-3-study, fda-submission, regulatory-compliance, regulatory-approval, safety-data, comirnaty, adverse-events, efficacy-data, quality-control, medical-product, vaccine-development, clinical-trial, pfizer-biontech, data-analysis, covid-19, united-states",18,1,https://drive.google.com/file/d/1clooxpiScIGpb1B522q6fqgQGHKW7J2K/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:31
FDA-CBER-2021-5683-1007277_125742_S2_M1_comirnaty-05.jpg,JPG,Comirnaty Clinical Study Report,2021-05,report,,M1,False,False,False,False,False,"mrna-technology, immunogenicity-data, pharmaceutical-research, image, phase-3-study, regulatory-compliance, comirnaty-vaccine, regulatory-approval, safety-data, adverse-events, efficacy-data, covid-19-pandemic, quality-control, vaccine-development, fda-submission, pfizer-biontech, data-analysis, clinical-trial-report",18,1,https://drive.google.com/file/d/1zFqCrc6oKM5vWXMwnWfPpUTP7A66QceR/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:34
125742_S94_M1_eua-lab-1457-13-0.pdf,PDF,Fact Sheet for Healthcare Providers Administering Pfizer-BioNTech COVID-19 Vaccine,2021-09-01,fact sheet,,M1,False,False,False,False,False,"reporting-requirements, clinical-trials, regulatory-compliance, pharmaceutical, dosage-administration, immunocompromised, safety-data, public-health, vaccine, medical-product, pfizer-biontech, adverse-events, united-states, covid-19, fda-approval, immunization, emergency-use-authorization",17,41,https://drive.google.com/file/d/1UVmqOLr8_v7Dk8EKJAEYkyG0ksMy5vrb/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:38
125742_S9_M1_cover.pdf,PDF,Response to CBER's 29 June 2021 Information Request regarding COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-07-02,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"Biologics License Application (BLA), BNT162/PF-07302048, Vaccine Approval, Clinical Trials, FDA Center for Biologics Evaluation and Research (CBER), BioNTech, Data Submission, Vaccine Efficacy, Pharmaceutical Compliance, COVID-19 mRNA Vaccine, Collegeville, PA, Adverse Events, Regulatory Affairs, Pfizer Inc., Vaccine Development, Vaccine Safety, Information Request",17,2,https://drive.google.com/file/d/1krd2WCZhVluLYlResycUXa6ODjIC4CGH/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:43
FDA-CBER-2021-5683-1007348_125742_S82_M1_comirnaty-11.jpg,JPG,Comirnaty Clinical Study Report,2021,report,,M1,False,False,False,False,False,"mrna-technology, immunogenicity-assessment, pharmaceutical-manufacturing, phase-3-study, regulatory-compliance, comirnaty-vaccine, regulatory-approval, safety-data, adverse-events, efficacy-data, covid-19-pandemic, quality-control, vaccine-development, fda-submission, image, data-analysis, clinical-trial-report, biontech-pfizer-collaboration",18,1,https://drive.google.com/file/d/1J6qHV57O02BqsynnrH0i6DAt9sblEmEC/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:45
FDA-CBER-2021-5683-1007338_125742_S82_M1_comirnaty-01.jpg,JPG,"Comirnaty (COVID-19 Vaccine, mRNA) Biologics License Application",2021,Image file,,M1,False,False,False,False,False,"Pharmaceutical Manufacturing, Immunization, Clinical Trials, image, Regulatory Approval, Biological Products, FDA, Efficacy Data, Pharmacovigilance, Adverse Events, Pandemic Response, Compliance, Biologics License Application, Comirnaty, Pharmaceutical Submission, Safety Data, COVID-19 Vaccine, Vaccine Development",18,1,https://drive.google.com/file/d/1ckZAsQ8BvUAHkJ0SrQeQ5gKojtY-YbZb/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:48
FDA-CBER-2021-5683-1007341_125742_S82_M1_comirnaty-04.jpg,JPG,Comirnaty Clinical Study Report,2021,report,,M1,False,False,False,False,False,"mrna-technology, pharmaceutical-manufacturing, phase-3-study, regulatory-compliance, comirnaty-vaccine, regulatory-approval, safety-data, adverse-events, efficacy-data, covid-19-pandemic, immunogenicity-analysis, quality-control, vaccine-development, fda-submission, image, clinical-trial-report, data-compilation, biontech-pfizer-collaboration",18,1,https://drive.google.com/file/d/18Wy7WAb1HB9LryqCsX77uwJRHfwcGwgj/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:51
FDA-CBER-2021-5683-1007284_125742_S2_M1_comirnaty-12.jpg,JPG,Comirnaty Clinical Study Report,2021-12,report,,M1,False,False,False,False,False,"covid-19 vaccine, quality control, medical research, public health, image, pharmaceutical development, comirnaty, safety data, fda submission, clinical study report, adverse events, united states, pharmaceutical industry, efficacy data, vaccine manufacturing, regulatory approval, phase 3 clinical trial, regulatory compliance",18,1,https://drive.google.com/file/d/1LTAa5N4vvUCYPdPJs1oxVZXvwTZDa1PE/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:53
FDA-CBER-2021-5683-1007340_125742_S82_M1_comirnaty-03.jpg,JPG,Comirnaty Clinical Study Report,2021,report,,M1,False,False,False,False,False,"immunogenicity-data, covid-19-vaccine, pharmaceutical-research, image, phase-3-study, regulatory-compliance, comirnaty-vaccine, regulatory-approval, safety-data, patient-demographics, adverse-events, efficacy-data, dose-administration, vaccine-development, fda-submission, pfizer-biontech, data-analysis, clinical-trial-report",18,1,https://drive.google.com/file/d/1QOc5Td0ddTi1tP5UIXdSKbGee-kfo_kN/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:56
FDA-CBER-2021-5683-1007339_125742_S82_M1_comirnaty-02.jpg,JPG,"Comirnaty (COVID-19 Vaccine, mRNA) Biologics License Application Supplement",2021,Regulatory Submission,,M1,False,False,False,False,False,"Immunization, mRNA Vaccine, Clinical Trials, image, Regulatory Approval, Public Health, Regulatory Submission, FDA, Efficacy Data, Pharmaceutical, Adverse Events, Compliance, Biologics License Application, Comirnaty, Quality Assurance, Safety Data, COVID-19 Vaccine, Vaccine Development",18,1,https://drive.google.com/file/d/10wPIojJKot6bqbhJzNgkK1kYXRLQTCAT/view?usp=drivesdk,pd-production-080123,2025-08-12 00:17:59
FDA-CBER-2021-5683-1007347_125742_S82_M1_comirnaty-10.jpg,JPG,Comirnaty Clinical Study Report,2021-11-25,report,,M1,False,False,False,False,False,"immunogenicity, pharmaceutical-research, image, phase-3-study, regulatory-compliance, biopharmaceutical, regulatory-approval, safety-data, comirnaty, adverse-events, efficacy-data, quality-control, vaccine-development, fda-submission, data-analysis, clinical-trial, covid-19, manufacturing",18,1,https://drive.google.com/file/d/1oOVDKpSy07VURai6h5pN3VfOg7cd9F1w/view?usp=drivesdk,pd-production-080123,2025-08-12 00:18:02
FDA-CBER-2021-5683-1007342_125742_S82_M1_comirnaty-05.jpg,JPG,Comirnaty Clinical Study Report,2021-05,report,,M1,False,False,False,False,False,"phase 3 study, quality control, immunogenicity, fda, covid-19, pharmaceutical, submission, image, clinical trial, comirnaty, safety data, pfizer, vaccine, adverse events, united states, efficacy data, regulatory approval, manufacturing",18,1,https://drive.google.com/file/d/1_2tUJ7TSG-h87jt_Nvxxmz-QE_E_ukgF/view?usp=drivesdk,pd-production-080123,2025-08-12 00:18:04
FDA-CBER-2021-5683-1007314-1007337_125742_S82_M1_comirnaty.xml,XML,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021,prescribing information,"Pfizer Laboratories Div Pfizer Inc, Pfizer Manufacturing Belgium NV, Pharmacia & Upjohn Company LLC, Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC, Pfizer Inc, Pfizer Ireland Pharmaceuticals, Hospira Zagreb d.o.o., SGS Lab, Simon",M1,False,False,False,False,False,"dosage and administration, vaccine composition, TOZINAMERAN, clinical trial data, COMIRNATY, COVID-19 vaccine, mRNA vaccine, intramuscular injection, SARS-CoV-2, diluent preparation, storage and handling, FDA approval, safety and efficacy, active immunization, pharmaceutical regulations, prescribing information, Pfizer manufacturing",17,18,https://drive.google.com/file/d/1tOyGojRgCMG5EJjioeGM20UhdRnekrne/view?usp=drivesdk,pd-production-080123,2025-08-12 00:18:08
FDA-CBER-2021-5683-1007345_125742_S82_M1_comirnaty-08.jpg,JPG,Comirnaty Clinical Study Report,2021-08,report,,M1,False,False,False,False,False,"clinical-trial-protocol, immunogenicity-data, covid-19-vaccine, pharmaceutical-research, image, phase-3-study, regulatory-compliance, comirnaty-vaccine, regulatory-approval, safety-data, adverse-events, efficacy-data, quality-control, vaccine-development, fda-submission, pfizer-biontech, data-analysis, clinical-trial-report",18,1,https://drive.google.com/file/d/1rZyciiI6z_iBgQ76BiK61rISSn64XhSq/view?usp=drivesdk,pd-production-080123,2025-08-12 00:18:11
FDA-CBER-2021-5683-1007343_125742_S82_M1_comirnaty-06.jpg,JPG,Comirnaty Clinical Study Report,2021-06,report,,M1,False,False,False,False,False,"covid-19 vaccine, quality control, medical research, public health, image, pharmaceutical development, comirnaty, safety data, fda submission, clinical study report, adverse events, united states, pharmaceutical industry, efficacy data, vaccine manufacturing, regulatory approval, phase 3 clinical trial, regulatory compliance",18,1,https://drive.google.com/file/d/1oU5LOhu9_Smc90Nb4JCP1n4vGzB32rl5/view?usp=drivesdk,pd-production-080123,2025-08-12 00:18:13
FDA-CBER-2021-5683-1007346_125742_S82_M1_comirnaty-09.jpg,JPG,Comirnaty Clinical Study Report,2021-09,report,,M1,False,False,False,False,False,"mrna-technology, immunogenicity, clinical-study-report, pharmaceutical-research, image, comirnaty-vaccine, manufacturing-quality, regulatory-approval, dose-regimen, safety-data, adverse-events, efficacy-data, public-health, vaccine-development, fda-submission, pfizer-biontech, phase-3-trial, covid-19",18,1,https://drive.google.com/file/d/17-2RR54KZdiBAAjtGddPuc28XdTWYAb0/view?usp=drivesdk,pd-production-080123,2025-08-12 00:18:16
FDA-CBER-2021-5683-1007282_125742_S2_M1_comirnaty-10.jpg,JPG,Comirnaty Clinical Study Report,2021-11,report,,M1,False,False,False,False,False,"clinical-trial-protocol, immunogenicity-data, covid-19-vaccine, pharmaceutical-research, image, phase-3-study, regulatory-compliance, comirnaty-vaccine, regulatory-approval, safety-data, adverse-events, efficacy-data, quality-control, vaccine-development, fda-submission, pfizer-biontech, data-analysis, clinical-trial-report",18,1,https://drive.google.com/file/d/1-VMydkVY4rcQhCLS8hxDb6gck2u2nI63/view?usp=drivesdk,pd-production-080123,2025-08-12 00:18:19
FDA-CBER-2021-5683-1007285-1007313_125742_S2_M1_lab-1448-0-1-pkg-insert-clean.doc,DOC,TRADENAME (COVID-19 mRNA vaccine [nucleoside-modified]) Prescribing Information,2021-05,Prescribing Information,,M1,False,False,False,False,False,"Intramuscular Injection, Vaccine Efficacy, Clinical Trials, Geriatric Use, Pediatric Use, Immunocompetence, Allergic Reactions, Dosage and Administration, Regulatory Submission, COVID-19 vaccine, mRNA vaccine, SARS-CoV-2, Adverse Reactions, Indications and Usage, FDA approval, Prescribing Information, Vaccine Safety",17,10,https://docs.google.com/document/d/1uGOI5ouVc-2zISsWmPQTz4RBEupd890c/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-080123,2025-08-12 00:18:23
FDA-CBER-2021-5683-1007283_125742_S2_M1_comirnaty-11.jpg,JPG,Comirnaty Clinical Study Report,2021,report,,M1,False,False,False,False,False,"phase 3 study, BioNTech, clinical research, pharmaceutical, submission, clinical trial, FOIA request, FDA, safety data, vaccine, adverse events, Comirnaty, image, efficacy data, regulatory approval, Pfizer, data analysis, regulatory compliance",18,1,https://drive.google.com/file/d/19xUXM2oh8J1N5Gv5AwCwkbCliCrAXzag/view?usp=drivesdk,pd-production-080123,2025-08-12 00:18:25
FDA-CBER-2021-5683-1007344_125742_S82_M1_comirnaty-07.jpg,JPG,Comirnaty Clinical Study Report,2021,report,,M1,False,False,False,False,False,"pharmaceutical-research, image, phase-3-study, regulatory-compliance, regulatory-approval, safety-data, comirnaty, adverse-events, efficacy-data, biontech, pfizer, quality-control, vaccine-development, fda-submission, data-analysis, clinical-trial, covid-19, mrna-vaccine",18,1,https://drive.google.com/file/d/1muktVw-_VPOB2MjKY2JdtFGP3BCvfS7D/view?usp=drivesdk,pd-production-080123,2025-08-12 00:18:28
FDA-CBER-2021-5683-0396239-0396241_125742_S1_M5_bnt162-01-S-D-suppeg.xpt,XPT,FDA-CBER-2021-5683-0396239-0396241 125742 S1 M5 bnt162-01-S-D-suppeg,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1-rbZ8yym5o-W-NDVmd_djOAPBT4dPm70/view?usp=drivesdk,pd-production-090122,2025-08-12 00:18:30
FDA-CBER-2021-5683-0396234-0396238_125742_S1_M5_bnt162-01-S-D-suppdv.xpt,XPT,FDA-CBER-2021-5683-0396234-0396238 125742 S1 M5 bnt162-01-S-D-suppdv,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1vYfAAgdGpfxI38hjCIAvmz8tC51Om_qd/view?usp=drivesdk,pd-production-090122,2025-08-12 00:18:31
FDA-CBER-2021-5683-0396228-0396233_125742_S1_M5_bnt162-01-S-D-rp.xpt,XPT,FDA-CBER-2021-5683-0396228-0396233 125742 S1 M5 bnt162-01-S-D-rp,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1XXIWxJ1ujjh4VsVk6sE_VkXz3TPXrWI6/view?usp=drivesdk,pd-production-090122,2025-08-12 00:18:32
FDA-CBER-2021-5683-0396242-0396246_125742_S1_M5_bnt162-01-S-D-suppxa.xpt,XPT,FDA-CBER-2021-5683-0396242-0396246 125742 S1 M5 bnt162-01-S-D-suppxa,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1QwZsuDUKPFAinVyZmKJxcq_T4N-43UFL/view?usp=drivesdk,pd-production-090122,2025-08-12 00:18:33
FDA-CBER-2021-5683-0396214-0396222_125742_S1_M5_bnt162-01-S-D-cm.xpt,XPT,FDA-CBER-2021-5683-0396214-0396222 125742 S1 M5 bnt162-01-S-D-cm,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1TV_8lSqYXkIOcYxB8v6bEt-E-T_p0ATy/view?usp=drivesdk,pd-production-090122,2025-08-12 00:18:34
FDA-CBER-2021-5683-0396249-0396254_125742_S1_M5_bnt162-01-S-D-xb.xpt,XPT,FDA-CBER-2021-5683-0396249-0396254 125742 S1 M5 bnt162-01-S-D-xb,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1jSA2aChRyZF1QXhZMacS5fMgmijCeaD0/view?usp=drivesdk,pd-production-090122,2025-08-12 00:18:35
FDA-CBER-2021-5683-0396247-0396248_125742_S1_M5_bnt162-01-S-D-ta.xpt,XPT,FDA-CBER-2021-5683-0396247-0396248 125742 S1 M5 bnt162-01-S-D-ta,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1YxVXIvAn2kzpeUY7bt2yLOGcHEMvu5yT/view?usp=drivesdk,pd-production-090122,2025-08-12 00:18:36
FDA-CBER-2021-5683-0396223-0396227_125742_S1_M5_bnt162-01-S-D-dv.xpt,XPT,FDA-CBER-2021-5683-0396223-0396227 125742 S1 M5 bnt162-01-S-D-dv,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1L8HzaQEKYhOU5J8owEbS1Lg6oGHlsNZ1/view?usp=drivesdk,pd-production-090122,2025-08-12 00:18:38
FDA-CBER-2021-5683-0396200-0396213_125742_S1_M5_bnt162-01-A-D-adae.xpt,XPT,FDA-CBER-2021-5683-0396200-0396213 125742 S1 M5 bnt162-01-A-D-adae,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1ZMOc9gj2Y4saIsUXFJNozqKFHjQkQ2HF/view?usp=drivesdk,pd-production-090122,2025-08-12 00:18:39
FDA-CBER-2021-5683-0396255-0484341_125742_S1_M5_c4591001-S-Supp-D-suppface.xpt,XPT,FDA-CBER-2021-5683-0396255-0484341 125742 S1 M5 c4591001-S-Supp-D-suppface,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1mKG3LZ-_ELswvjYWag2ovD41Be_DdyIK/view?usp=drivesdk,pd-production-090122,2025-08-12 00:18:52
104B_BLA 125742-0_08-20-2021_Telecon_Information Reques.pdf,PDF,Teleconference Information Request for BLA 125742-0,2021-08-20,Memo,,,False,False,False,False,False,"FOIA document, Pharmaceutical clinical trial, Information request, Drug/vaccine development, Regulatory submission, Regulatory approval, BLA 125742-0, Data management, Efficacy data, Teleconference, FDA communication, Adverse event reporting, Compliance, Quality assurance, Safety data, Clinical trial phases, Pharmaceutical industry",17,1,https://drive.google.com/file/d/10rOY2Yz3DOgbgRWj0ncRV1RLlnveaEVV/view?usp=drivesdk,pd-production-090123,2025-08-12 00:18:56
106_2_BLA 125742-0_08-20-2021_Telecon_Labeling via FAX_e.pdf,PDF,7th set of PI labeling comments and request for table with subjects who reported unsolicited AEs during blinded follow-up in study C4591001,2021-08-20,email,"Gottschalk, Laura, Harkins Tull, Elisa, Devlin, Carmel M, Aghajani Memar, Neda, Smith, Michael (CBER), Naik, Ramachandra",,False,False,False,False,False,"regulatory-submission, clinical-trial-c4591001, biologics-license-application, office-of-vaccines-research-and-review, data-tabulation, withdrawal-due-to-adverse-events, serious-adverse-events, package-insert-labeling, safety-data-request, center-for-biologics-evaluation-and-research, blinded-follow-up, fda-communication, age-group-analysis, bnt162b2-vaccine, unsolicited-adverse-events, data-reporting-requirements, adverse-event-reporting",17,2,https://drive.google.com/file/d/171_aV4ld5nVN3e0ilFH4EtC-yeRaI-Te/view?usp=drivesdk,pd-production-090123,2025-08-12 00:19:00
104_BLA 125742-0_08-20-2021_Telecon_Information Reques.pdf,PDF,COMIRNATY (COVID-19 mRNA Vaccine) BLA 125742/0 - CBER Comments on Label and Dear HCP Letter,2021-08-20,Email,"Naik, Ramachandra, Harkins Tull, Elisa, Rohlfing, Paul, Aghajani Memar, Neda, Boyce, Donna, Smith, Michael (CBER), Gottschalk, Laura",,False,False,False,False,False,"COMIRNATY Vaccine, Pfizer-BioNTech, Dear HCP Letter, Vaccine Efficacy, Regulatory Communication, Adverse Event Reporting, Pharmaceutical Industry, Label and Labeling, FDA CBER Review, Vaccine Lot Identification, Regulatory Compliance, Vaccine Distribution, Vaccine Approval Process, COVID-19 Vaccine, Clinical Trial Data, Vaccine Safety, BLA Submission",17,1,https://drive.google.com/file/d/1bP6YZHR6Cqlni-2tLlk2Rbwu1B6w5yji/view?usp=drivesdk,pd-production-090123,2025-08-12 00:19:04
104A_BLA 125742-0_08-20-2021_Telecon_Information Reques.pdf,PDF,Teleconference Information Request,2021-08-20,memo,,,False,False,False,False,False,"fda-cber-2021-5683-1024836, regulatory-submission, compliance, pharmaceutical, bla-125742-0, information-request, safety-data, adverse-events, efficacy-data, vaccine, communication, united-states, clinical-trial, regulatory-affairs, teleconference, data-request, quality-assurance",17,1,https://drive.google.com/file/d/1PyJjaC0DyPZLRpzybCqEwzyl7d7iPCMp/view?usp=drivesdk,pd-production-090123,2025-08-12 00:19:07
112A_1_BLA 125742-0_08-21-2021_Telecon_Information Reques.pdf,PDF,Biologics License Application (BLA) 125742-0 Teleconference Information Request,2021-08-21,Teleconference Memo,,,False,False,False,False,False,"Vaccine Candidate, Data Reporting, BLA 125742-0, August 2021, Teleconference, CBER (Center for Biologics Evaluation and Research), Adverse Events, Regulatory Compliance, Product Approval Process, Biologics License Application, Quality Assurance, Investigational New Drug, FDA Regulatory Submission, Safety and Efficacy, Pharmaceutical Development, Information Request, Clinical Trial Data",17,1,https://drive.google.com/file/d/1HAcx1idx-M1Om8W6xEXQy6j0AItAyxQ1/view?usp=drivesdk,pd-production-090123,2025-08-12 00:19:10
114_2_BLA 125742-0_08-21-2021_Telecon_Labeling via FAX_e.pdf,PDF,STN 125742.0: 8th set of PI labeling comments,2021-08-21,email,"Gottschalk, Laura, Harkins Tull, Elisa, Naik, Ramachandra, Smith, Michael (CBER), Devlin, Carmel M, Aghajani Memar, Neda",,False,False,False,False,False,"Biologics License Application (BLA), Vaccine research and review, Pfizer-FDA collaboration, Pharmaceutical industry-regulator interaction, Biologics Center for Evaluation and Research (CBER), FDA regulatory communication, Pharmaceutical product development, Deadline and response coordination, Confidential information exchange, Clinical trial data review, Regulatory document review process, Package Insert (PI) labeling, Vaccine safety and efficacy data, Submission and response timeline, Regulatory compliance and quality, Regulatory project management, Product identification (STN 125742.0)",17,1,https://drive.google.com/file/d/1pBAhMVcaY9QOOfcqS8U9oao4-QPLPimB/view?usp=drivesdk,pd-production-090123,2025-08-12 00:19:14
113_2_BLA 125742-0_08-21-2021_Telecon_Information Reques.pdf,PDF,STN 125742.0: IR RE PMR's and PMC's,2021-08-21,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Naik, Ramachandra, Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M",,False,True,False,False,False,"Information requests (IRs), FOIA document, Safety and efficacy data, Protocol submissions, Pharmaceutical clinical trials, FDA regulatory affairs, Study completion and reporting, BLA 125742-0, COMIRNATY vaccine, Post-marketing requirements (PMRs), Post-marketing commitments (PMCs), Center for Biologics Evaluation and Research (CBER), Protocol, Study C4591001, Study C4591007, Pfizer Inc., Pediatric studies, Study C4591023",18,6,https://drive.google.com/file/d/1tkA-07-wS14xxtn4YZIpIa-ylkLt5rts/view?usp=drivesdk,pd-production-090123,2025-08-12 00:19:18
11_BLA 125742-0_06-29-2021_Telecon_Information Reques.pdf,PDF,Clinical Information Request Regarding Study C4591001,2021-06-29,Email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"Reactogenicity subset, FOIA document, Data analysis, Information request, OVRR, STN 125742.0, Vaccination date, Pfizer-BioNTech COVID-19 vaccine, CBER, Randomization date, Study C4591001, Clinical trial, DVRPA, Data quality, FDA regulatory review, Regulatory compliance, Vaccine development",17,2,https://drive.google.com/file/d/12GCJjJR28U2GS4sAUBZMkMLqFFk1K7HV/view?usp=drivesdk,pd-production-090123,2025-08-12 00:19:22
112_1_BLA 125742-0_08-21-2021_Telecon_Information Reques.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) BLA 125742/0 - CBER Comments on Draft Dear HCP Letter",2021-08-21,Email,"Naik, Ramachandra, Harkins Tull, Elisa, Smith, Michael (CBER), Gottschalk, Laura, Devlin, Carmel M, Boyce, Donna",,False,False,False,False,False,"BLA 125742, FDA CBER, Dear HCP Letter, Immunization, Vaccine Approval, Clinical Trials, Vaccine Lot Information, COMIRNATY, Regulatory Submission, Efficacy Data, SARS-CoV-2, Pharmaceutical Regulations, Label Identification, Adverse Events, Compliance, Vaccine Distribution, COVID-19 Vaccine",17,1,https://drive.google.com/file/d/1nGG8jCQXmCAQbyori23u_-h0QIgZRSPX/view?usp=drivesdk,pd-production-090123,2025-08-12 00:19:26
125742_S1_M5_5351_c4591001-interim-mth6-compliance.pdf,PDF,Listing of Medication Errors - All Subjects ≥ 16 Years of Age,2021-04-01,report,,M5,False,False,False,False,False,"C4591001, data listing, compliance, pharmaceutical, product administration, dose changes, concomitant medication, medication errors, clinical trial, FDA, non-drug treatment, safety data, subject discontinuation, age group, product storage, adverse events, regulatory submission",17,8500,https://drive.google.com/file/d/1s4whXkYE1ZgM-9Twh2M81fxZTLM2TDxd/view?usp=drivesdk,pd-production-090123,2025-08-12 00:20:03
125742_S1_M5_CRF_c4591001-1093-10931058.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, safety data, United States, adverse events, regulatory compliance, data quality, COVID-19 vaccine, protocol amendment, CRF, subject enrollment, informed consent, FDA, Protocol, c4591001, Meridian Clinical Research, demography, efficacy data",19,154,https://drive.google.com/file/d/19iSh5et2x1mxxlgTTFoOKCudYIS1G5Rh/view?usp=drivesdk,pd-production-090123,2025-08-12 00:20:06
125742_S1_M5_5351_c4591001-interim-mth6-narrative-sensitive.pdf,PDF,C4591001 Interim Month 6 Narrative Safety Report,2021-04-28,report,,M5,False,True,False,False,False,"PF-07302048, demographic data, data generation, SDTM, FOIA, clinical trial, Pfizer, FDA, COVID-19 vaccine, safety data, vital signs, Protocol, United States, adverse events, narrative report, BNT162b2, phase 3, regulatory submission",18,3697,https://drive.google.com/file/d/1AtQjDCfM_MsYLXJucrrNTl0H7ECDibru/view?usp=drivesdk,pd-production-090123,2025-08-12 00:20:23
125742_S1_M5_CRF_c4591001-1093-10931141.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, informed consent, visit date, FDA, Protocol, c4591001, Meridian Clinical Research, eCRF, demography, efficacy data, data collection",20,420,https://drive.google.com/file/d/1PkjDNk6wjFckl_rJ4H0MIvBrZvxJT_nc/view?usp=drivesdk,pd-production-090123,2025-08-12 00:20:28
125742_S1_M5_CRF_c4591001-1093-10931128.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1093) Meridian Clinical Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, protocol amendment, phase 2/3 study, CRF, demographic data, informed consent, visit date, FDA, Protocol, subject identification, efficacy data",19,112,https://drive.google.com/file/d/1MkYDEIjA1gEe3fmCK3gm1AehW-opYBx8/view?usp=drivesdk,pd-production-090123,2025-08-12 00:20:38
125742_S1_M5_CRF_c4591001-1093-10931067.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Trial,2020-07-30,form,"Subject No: 10931067, Subject Initials: ---",M5,True,True,False,True,False,"Exclusion, clinical trial, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, subject information, audit trail, informed consent, visit date, FDA, Protocol, data verification, Meridian Clinical Research, data lock, eCRF, demography",20,133,https://drive.google.com/file/d/1_P6qEez8H-9ojULupja_xrPnfIemoD_M/view?usp=drivesdk,pd-production-090123,2025-08-12 00:20:46
125742_S1_M5_CRF_c4591001-1095-10951101.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1095) Tekton Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory, data quality, inclusion/exclusion criteria, COVID-19 vaccine, STAGE 3 cohort, CRF, informed consent, safety monitoring, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data",19,389,https://drive.google.com/file/d/1jZdRQ496GhG2SaApyggn5LoJ76ldwFjm/view?usp=drivesdk,pd-production-090123,2025-08-12 00:20:51
125742_S1_M5_CRF_c4591001-1095-10951134.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1095) Tekton Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, safety data, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, subject identification, efficacy data",19,177,https://drive.google.com/file/d/1iRbbuDay8Yrl3rRtmb_0YXgaipU6I5hI/view?usp=drivesdk,pd-production-090123,2025-08-12 00:20:55
125742_S1_M5_CRF_c4591001-1095-10951141.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1095) Tekton Research,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, United States, adverse events, regulatory, pharmaceutical, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, quality compliance, informed consent, visit date, FDA, Protocol, c4591001, demography, efficacy data",19,164,https://drive.google.com/file/d/1PdtjPrET14zUWXz8hwk7dTc1TbLPulGB/view?usp=drivesdk,pd-production-090123,2025-08-12 00:20:59
125742_S1_M5_CRF_c4591001-1095-10951107.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1095) Tekton Research,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, United States, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, Pfizer/BioNTech, informed consent, visit date, FDA, Protocol, demography, subject identification, efficacy data",19,214,https://drive.google.com/file/d/1WRYq5SPbiARzrIndGLOgSGwVVKpZQ9P5/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:03
125742_S1_M5_CRF_c4591001-1095-10951080.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1095) Tekton Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, informed consent, visit date, FDA, Protocol, c4591001, demography, subject identification, safety",19,219,https://drive.google.com/file/d/17QW2zWD4TdwsxPcsftinieweYpNCLSjG/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:07
125742_S1_M5_CRF_c4591001-1095-10951125.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject information, covid-19 vaccine, informed consent, safety monitoring, visit date, Protocol, c4591001, tekton research, demography, efficacy data, data collection",20,195,https://drive.google.com/file/d/1n5d1rreoTLglq-CkanwoAiqKvuH2-h-c/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:11
125742_S1_M5_CRF_c4591001-1095-10951009.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, united states, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, clinical research form, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, tekton research, demography, efficacy data",20,460,https://drive.google.com/file/d/1YVsY1_73XKL3LLyiiSHLGGIKfUnG-01u/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:16
125742_S1_M5_CRF_c4591001-1095-10951173.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1095) Tekton Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, phase 2/3, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, CRF, subject data, informed consent, visit date, FDA, Protocol, Pfizer, demography, safety",19,220,https://drive.google.com/file/d/1J6YtpMd7tu1bNH-CFmRSUiENRjsJvsuH/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:21
125742_S1_M5_CRF_c4591001-1095-10951256.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-09-15,form,,M5,True,True,False,True,False,"Exclusion, FDA regulation, clinical trial, confidential information, Tekton Research site, pharmaceutical research, data quality, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, audit trail, FOIA document, informed consent, date of visit, Protocol, subject demographics, c4591001 protocol, eCRF, data collection",20,125,https://drive.google.com/file/d/1I1KwmrpVwp14Hu_y9LERo_gSHiWt2jWm/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:29
125742_S1_M5_CRF_c4591001-1095-10951206.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial,2020-07-30,clinical trial form,,M5,True,True,False,True,False,"Exclusion, clinical trial, United States, Tekton Research, adverse events, regulatory compliance, data quality, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, phase 2/3 study, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, demography, safety",20,182,https://drive.google.com/file/d/1yk5AreU8K5rJLrsWS41RsZyM18-aCjvI/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:32
125742_S1_M5_CRF_c4591001-1095-10951204.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,Tekton Research,M5,True,True,False,True,False,"site information, Exclusion, clinical trial, adverse events, regulatory, data quality, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, efficacy, protocol amendment, CRF, informed consent, visit date, FDA, Protocol, demography, subject identification, safety",19,147,https://drive.google.com/file/d/1t2UQODemB_W3_DzNboBzoxfMFxkIpvu6/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:36
125742_S1_M5_CRF_c4591001-1095-10951197.pdf,PDF,Clinical Research Form for COVID-19 Vaccine Trial c4591001,2020-07-30,Clinical Research Form (CRF),,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, Tekton Research, regulatory compliance, cohort selection, inclusion/exclusion criteria, COVID-19 vaccine, CRF, informed consent, visit date, FDA, Protocol, c4591001, eCRF, data management, demography, subject identification, efficacy data, data collection",20,917,https://drive.google.com/file/d/1MPQFhStIDGV1UHIjWfwpoVX8eMW6Bgz8/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:43
125742_S38_M1_response-22jul2021.pdf,PDF,Response to FDA Information Request Regarding Clinical Shell Tables for Study C4591001 Follow-Up #4 (Safety 508 Tables),2021-08,response,Laura Gottshalk,M1,False,False,False,False,False,"16 years and older, clinical trial, COMIRNATY, phase 2/3, COVID-19 vaccine, safety data, PFIZER CONFIDENTIAL, SARS-CoV-2, CBER, data tables, adverse events, active immunization, BLA 125742/0, FDA information request, BNT162b2, efficacy data, regulatory submission",17,5,https://drive.google.com/file/d/11U06nRwsCVUliE7vRjmik23plAe-eFp0/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:46
125742_S1_M5_CRF_c4591001-1095-10951228.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,(1095) Tekton Research,M5,True,True,False,True,False,"site information, Exclusion, FDA regulation, clinical trial, data quality control, regulatory submission, inclusion/exclusion criteria, COVID-19 vaccine, phase 2/3 study, CRF, demographic data, clinical research, pharmaceutical development, informed consent, adverse event monitoring, visit schedule, Protocol, c4591001 protocol, data management, subject identification",20,603,https://drive.google.com/file/d/1X3Pyutqp6r_u6jP6wG4N2dwuGR3dqgLa/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:52
125742_S38_M1_cover.pdf,PDF,Response to FDA Information Request for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-08-09,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Biologics License Application (BLA), Regulatory affairs, Information request response, BioNTech, Vaccine approval, Silver Spring, MD, Collegeville, PA, Clinical trial data, Adverse event reporting, Pfizer Inc., Vaccine compliance, Global Product Development, Safety data, FDA-CBER submission, Vaccine development, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1nXaQBvL9qeKfxgc1hsdMagjSR_1t5gqv/view?usp=drivesdk,pd-production-090123,2025-08-12 00:21:56
125742_S1_M5_CRF_c4591001-1095-10951180.pdf,PDF,Clinical Research Form (CRF) for COVID-19 Vaccine Clinical Trial,2020-07-30,form,,M5,True,True,False,True,False,"Exclusion, clinical trial, safety data, adverse events, regulatory compliance, fda, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, covid-19 vaccine, informed consent, visit date, Protocol, c4591001, tekton research, data management, demography, efficacy data, electronic case report form",20,136,https://drive.google.com/file/d/1dySCOzZe63KEpnOb_4O7IPU0hbDUhnpE/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:00
125742_S54_M1_vial-rl-7302-rocky-mount-hospira.pdf,PDF,Vial Label Specifications for RL-7302 Sodium Chloride Injection,2018-07-31,specification,J. Cotton,M1,False,False,False,False,False,"pharmaceutical manufacturing, NDC, Lake Forest, quality control, GS1 DataBar, RL-7302, sodium chloride injection, FDA, lot number, vial label, sterile diluent, human readable information, expiration date, Hospira, barcode, Pfizer, regulatory compliance",17,1,https://drive.google.com/file/d/15a72VCJk1xtMewBMLDSqVwer9xsy5WYh/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:03
125742_S6_M5_acrf.pdf,PDF,Annotated Study Book for Study Design: C4591001,2021-01-14,protocol,,M5,True,True,False,True,False,"Exclusion, clinical trial, CBER, adverse events, randomization, immunogenicity, sample collection, COVID-19 vaccine, protocol, pregnancy test, CRF, microbiology, FDA, Protocol, vaccination, vital signs, Pfizer, physical examination, safety, study design",20,131,https://drive.google.com/file/d/1olBlQuwDdw5d_jG-MhWsZlBnV6NmqJy8/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:08
125742_S6_M5_csdrg.pdf,PDF,Clinical Study Data Reviewer's Guide,2021-06-04,report,,M5,False,True,False,False,False,"pharmaceutical research, BioNTech, data quality, FDA submission, clinical trial, COVID-19 vaccine, safety data, Protocol, United States, adverse events, BLA analysis, data standards, sequencing data, participant data, data review, Pfizer, efficacy data, regulatory compliance",18,8,https://drive.google.com/file/d/1WZt1sUD6ZSksPy0QrAjqIrHpzW3HmW9H/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:11
125742_S54_M1_diluent-vial-fresenius-kabi.pdf,PDF,"Sodium Chloride Injection, USP 0.9% 2 mL Single Dose Vial for Drug Diluent Use",2020-11-17,product label,"Alicia Dodson, Cherita Holt",M1,False,False,False,False,False,"drug diluent, quality control, product labeling, product stability, pharmaceutical product, FDA submission, product release, product distribution, sodium chloride injection, clinical trial support, product traceability, product safety, single-dose vial, product identification, product storage, manufacturing, regulatory compliance",17,1,https://drive.google.com/file/d/1HvMXnm8qDY9MXGZE7Kp9KhLkRlt3oJzq/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:15
12_BLA 125742-0_07-01-2021_Memo_Filing Checklist_RPM.pdf,PDF,RPM Filing Checklist for BLA 125742/0 (COMIRNATY COVID-19 mRNA Vaccine),2021-07-01,Memo,BioNTech Manufacturing GmbH,,False,False,False,False,False,"FOIA document, Proposed indication, Regulatory submission, Filing checklist, COMIRNATY vaccine, Regulatory designations, Application timeline, COVID-19 vaccine, CBER review process, Applicant information, Quality and compliance, Combination product assessment, BLA 125742/0, Pharmaceutical regulatory filing, Data types (safety, efficacy), Vaccine dosage and formulation, Application type",17,18,https://drive.google.com/file/d/1GyRsBFiUM0pb4xI8Gzg3rv9Ff32_8a8L/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:18
14_BLA 125742-0_07-02-2021_Telecon_Advice.pdf,PDF,Teleconference Advice on Clinical Information Request,2021-07-02,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"safety_data, fda_interaction, vaccines_research, cber_division, clinical_trial, document_request, efficacy_data, pharmaceutical_development, teleconference, interim_report, regulatory_submission, data_compliance, regulatory_review, data_clarification, bnt162_vaccine, adverse_events, pfizer_biontecht",17,3,https://drive.google.com/file/d/1pGK6dMi2rfh0tiCTYEoCqFRTcrP5wxaL/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:22
125742_S6_M5_adrg.pdf,PDF,Analysis Data Reviewer Guide for BLA Sequencing Data Analysis,2021-06-04,guide,"BioNTech SE, PFIZER INC.",M5,False,True,False,False,False,"regulatory-submission, analysis-data, document-compliance, covid-19-vaccine, data-reviewer-guide, data-quality, safety-data, study-c4591001, statistical-analysis, adverse-events, pfizer, biontech, efficacy-data, fda-review, data-processing, clinical-trial, Protocol, data-standards",18,12,https://drive.google.com/file/d/1qwS5jIMb0Ky_tCt-YWaG-q-hviG0A6Gi/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:26
16_BLA 125742-0_07-06-2021_Telecon_Information Reques.pdf,PDF,Information Request for Clinical Data on Severe AEs and Withdrawals in Stable HIV Cohort,2021-07-06,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"vaccine_approval_process, fda_regulatory_review, severe_adverse_events, withdrawal_from_study, regulatory_compliance, vaccine_development, stable_hiv_cohort, pfizer_clinical_operations, safety_data_analysis, cber_division_of_vaccines, interim_study_report, clinical_trial_data_request, sae_and_ae_descriptions, clinical_trial_phases, bnt162b2, blinded_placebo-controlled_follow-up, data_submission_and_communication",17,2,https://drive.google.com/file/d/1JT3g6hrhsRx3iAvg9Q82ubvRaRzanNk8/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:29
125742_S79_M1_cover.pdf,PDF,Final Labeling Change - BLA Package Insert for COMIRNATY,2021-08-23,letter,"Marion Gruber, Ph.D., Amit Patel, Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D., Captain Michael Smith, Ph.D.",M1,False,False,False,False,False,"regulatory-submission, virus-free, biologics-license-application, covid-19-vaccine, global-regulatory-affairs, compliance, structured-product-labeling, package-insert, collegeville-pa, silver-spring-md, comirnaty, labeling-change, clinical-trial-data, safety-efficacy, pfizer-biontech, vaccine-development, fda-approval",17,2,https://drive.google.com/file/d/1KvzvuaKyw0cCMR6kafJgMgrYm9MqMf8n/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:33
125742_S54_M1_diluent-carton-fresenius-kabi.pdf,PDF,"Sodium Chloride Injection, USP 0.9% Diluent Carton",2020-11-17,product label,"Alicia Dodson, Cherita Holt",M1,False,False,False,False,False,"quality control, diluent, product labeling, Fresenius Kabi, pharmaceutical product, product packaging, storage conditions, product composition, FDA regulation, clinical trial, sodium chloride injection, sterile solution, product safety, dosage information, product identification, product review, product approval",17,1,https://drive.google.com/file/d/1bpVELXKKfT6P8iccUp92wlK6NVRnwzda/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:36
125742_S54_M1_carton-ca-7114-rocky-mount-hospira.pdf,PDF,Carton Label for 10 mL Sodium Chloride Injection,2018-07-31,form,J. Cotton,M1,False,False,False,False,False,"quality control, 10 mL vial, sterile diluent, technical specifications, NDC number, carton label, sodium chloride injection, FDA, lot number, regulatory compliance, document template, pharmaceutical manufacturing, expiration date, Hospira, geographic location, Pfizer, Rocky Mount facility",17,1,https://drive.google.com/file/d/1mOjki2fPsSWqqz27zAy8gFgv1_qL3ULU/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:40
28C_BLA 125742-0_07-20-2021_Memo_Review.pdf,PDF,Data Fitness Findings Report for IND27034 BioNTech SE and Pfizer,2021-04,report,"BioNTech SE, Pfizer",,False,False,False,False,False,"C4591001, immunogenicity, data quality, FOIA, clinical trial, phase 1/2/3 study, FDA, COVID-19 vaccine, tolerability, RNA vaccine, 12-15 years of age, efficacy, safety, IND27034, adverse events, SDTM, regulatory submission",17,3,https://drive.google.com/file/d/1poLyZ8LHOeuQousb_TGzeVtZAylHAwg-/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:43
24_2_BLA 125742-0_07-15-2021_Telecon_Information Reques.pdf,PDF,Information Request for Study C4591007,2021-07-15,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,True,False,False,False,"BLA 125742, compliance, pediatric population, OVRR, clinical trial, information request, FDA, CBER, Protocol, vaccine, protocol, study completion, data submission, safety, efficacy, adverse events, Pfizer, regulatory submission",18,2,https://drive.google.com/file/d/19du1ZUkMJb2kmAayLMMWx2g9ySqGe2ic/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:46
28D_BLA 125742-0_07-20-2021_Memo_Review.pdf,PDF,Data Fitness Findings Report for BNT162 Clinical Trial,2020-11,report,"BioNTech SE, Pfizer",,False,False,False,False,False,"healthy-adults, data-cutoff, covid-19-vaccine, fda-submission, regulatory-compliance, data-quality, bnt162, adverse-events, interim-analysis, efficacy, sdtm, clinical-trial, medical-dictionary, phase-1-2, safety, inda-27034, final-analysis",17,10,https://drive.google.com/file/d/1SKSerU5VK25FuJgw6Qu995djJd5SxDLO/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:50
22_BLA 125742-0_07-15-2021_Meeting Summary_Committee .pdf,PDF,"July Monthly Meeting Summary"",","2021-07-15"",",document,,,False,False,False,False,False,"2021, FOIA-document, needs-review",3,9,https://drive.google.com/file/d/1jkXTJwo1cdK7jgY-xNLe54bH_lytCh2U/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:54
23_1_BLA 125742-0_07-15-2021_Telecon_Information Reques.pdf,PDF,Telecon Information Request for Pfizer-BioNTech COVID-19 Vaccine Pharmacovigilance Plan,2021-07-15,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"bla-125742, fda-regulatory, covid-19-vaccine, bb-ind-19736, cber-review, vaccine-risk-assessment, eua-27034, data-submission, information-request, clinical-safety, myocarditis-pericarditis, data-evaluation, pharmacovigilance-plan, pfizer-biontech, adverse-events, july-2021, teleconference",17,3,https://drive.google.com/file/d/18AXv1XHZ6n7LgXefhC9CUs1bZC1sFqC4/view?usp=drivesdk,pd-production-090123,2025-08-12 00:22:58
28L_BLA 125742-0_07-20-2021_Memo_Review.pdf,PDF,Data Fitness Findings Report,2021-04,report,"BioNTech SE, Pfizer",,False,False,False,False,False,"rna vaccine, covid-19 vaccine, immunogenicity, fda, data quality, phase 1/2/3, inda 27034, clinical trial, medical dictionary, eua amendment, tolerability, 12-15 years of age, efficacy, safety, sdtm, data fitness, adverse events",17,2,https://drive.google.com/file/d/1k9gmfFSqjlRUirbgVgxuCpfLUx_chMRp/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:01
28_BLA 125742-0_07-20-2021_Memo_Review.pdf,PDF,BLA 125742/EU A 27034 Data Validation Report Summary and Subsequent Follow-up with Pfizer,2021-07-20,Memo,"Pfizer, Pfizer-BioNTech SE",,False,False,False,False,False,"BLA 125742, Dose Escalation, Data Discrepancies, COVID-19 Vaccine (BNT162b2), Efficacy Analysis, Adverse Event Reporting, Clinical Trial Data Validation, Safety Analysis, Immunogenicity, Emergency Use Authorization (EUA), Data Quality Issues, Phase 3 Clinical Trials, Phase 1/2 Clinical Trials, FDA Regulatory Submission, Teleconference with Sponsor, Healthy Adult Population, Data Cleaning",17,5,https://drive.google.com/file/d/1b4PwEEb9nB-xG2sR0r_QG4TtOqcqcMjG/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:05
20_1_BLA 125742-0_07-13-2021_Telecon_Information Reques.pdf,PDF,Information Request Regarding the Pharmacovigilance Plan for BLA 125742,2021-07-13,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"bla-125742, regulatory-compliance, vaccine-risk-management, eua-fact-sheet, cber-division-of-vaccines, pericarditis, fda-information-request, myocarditis, pharmacovigilance-plan, vaccine-safety, clinical-trial-data, adverse-event-monitoring, july-2021, vaccine-post-marketing-surveillance, foia-document, vaccine-approval-process, pfizer-vaccine",17,2,https://drive.google.com/file/d/1Lh9z2bRB3so2C6GgeXiGulIthTJWQ2i6/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:10
30A_BLA 125742-0_07-22-2021_Telecon_Information Reques.pdf,PDF,Information Request Regarding Clinical Shell Tables for Study C4591001,2021-07-22,Information Request,"Elisa Harkins, Laura Gottschalk",,False,False,False,True,False,"Vaccine Efficacy, Efficacy Analysis, Exclusion, COMIRNATY, COVID-19 mRNA Vaccine, FDA Information Request, BioNTech RNA Pharmaceuticals, Vaccine Safety, Immunogenicity Data, BLA STN 125742/0, Study C4591001, Adverse Events, Regulatory Compliance, FOIA Document, CBER Division of Vaccines, Pfizer Inc., Clinical Trial Reporting, Pharmaceutical Clinical Trial",18,17,https://drive.google.com/file/d/14iYQm3zZAo6ePiZSoYns-1lwWgICB92f/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:14
19_2_BLA 125742-0_07-13-2021_Telecon_Information Reques.pdf,PDF,COMIRNATY (COVID-19 mRNA Vaccine) - Request for Exception or Alternative to Preservative Requirement,2021-07-13,Email,"Naik, Ramachandra, Harkins Tull, Elisa, Gottschalk, Laura, Smith, Michael (CBER), Aghajani Memar, Neda, Devlin, Carmel M",,False,False,False,False,False,"BLA 125742, Clinical trial information, Vaccine research and review, Safety and efficacy data, Biologics evaluation and review, Regulatory submission, Information request, FDA regulatory, 21 CFR 610.15, Multiple-dose vial, COMIRNATY, Exception or alternative request, COVID-19 vaccine, Teleconference, Compliance and quality, Preservative requirement, Pfizer",17,1,https://drive.google.com/file/d/1A7CytYZ9O2xHFu78VVfR50ojnl4qaT1c/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:17
17_BLA 125742-0_07-06-2021_Telecon_Advice_PNR Accepta.pdf,PDF,Teleconference Advice on Proposed Proprietary Name COMIRNATY,2021-07-06,Email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"Division of Vaccines and Related Products Applications, Biologics License Application (BLA), Proprietary Name Review, Clinical Trials, Pharmaceutical Industry, COMIRNATY, Regulatory Consultation, Center for Biologics Evaluation and Research (CBER), Drug Naming, FDA Approval, Teleconference, Regulatory Submission, Communication, Regulatory Compliance, Advertising and Promotional Labeling, Vaccine Development, Pfizer",17,1,https://drive.google.com/file/d/11t8QhKHNjkSB_5ywyyM1U8KM9rSCp6k-/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:21
34_2_BLA 125742-0_07-27-2021_Telecon_Information Reques.pdf,PDF,Information Request for Assessment of Vaccine Effectiveness,2021-07-27,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"Blinded follow-up and placebo crossover, FOIA document, Pharmaceutical clinical trial, Confidence intervals, Cumulative incidence rates, STN 125742.0, Vaccine effectiveness metrics, Unblinding and data analysis, Dose 2 follow-up, CBER (Center for Biologics Evaluation and Research), Prolonged post-vaccination period, Risk difference and risk ratio, Pfizer and BioNTech Manufacturing GmbH, Vaccine safety and efficacy data, Vaccine effectiveness assessment, FDA information request, Regulatory compliance",17,3,https://drive.google.com/file/d/1jvbfCCfVirBkpGe_5MfYPFP-PGHLrKk0/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:25
43_2_BLA 125742-0_08-04-2021_Telecon_Information Reques.pdf,PDF,Comments on LRP template submitted to STN 125742/0.14 on 7/20,2021-08-04,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Rohlfing, Paul, Naik, Ramachandra, Gottschalk, Laura",,False,True,False,False,False,"BLA 125742, FDA CBER, FOIA document, Pharmaceutical clinical trial, Clarification request, RNA encapsulation, Lipid analysis, Regulatory submission, Attachment templates, Electronic protocol, Lot release protocol (LRP), Protocol, Compliance documentation, Technical review, Quality control, Vaccine development, Response deadline, Pfizer",18,4,https://drive.google.com/file/d/1EKLGPkSV3fUGvd_8KMEICu5WEx0eFeE8/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:30
41_1_BLA 125742-0_08-03-2021_Telecon_Information Reques.pdf,PDF,STN 125742.0: Clinical/stats IR,2021-08-03,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,True,False,False,False,"safety_data, case_definition, cber, data_quality, fda_review, clinical_trial, covid-19_vaccine, efficacy_analysis, protocol_deviation, data_request, data_integrity, Protocol, pfizer, regulatory_submission, hospitalization, sas_program, statistical_analysis, adverse_events",18,2,https://drive.google.com/file/d/1pwRpj5d3jaw4Ay-Y7skRkcITBTkc4bJt/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:33
38_1_BLA 125742-0_08-02-2021_Telecon_Information Reques.pdf,PDF,Questions regarding the Validation Report VR-MVR-10077,2021-08-02,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,True,False,False,False,"Binding antibody, FOIA document, Pharmaceutical clinical trial, Validation report, Quality control sample, Precision, Regulatory submission, BLA 125742-0, FDA review, Assay robustness, Linearity, Exploratory endpoint, Protocol, Reference standard, Accuracy, Immunogenicity assay, Assay specificity, Pfizer",18,4,https://drive.google.com/file/d/1Ztf-3ti4x6PpWxRBIif1ZwRlIZ5Cmrqj/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:37
29_BLA 125742-0_07-20-2021_Telecon_Information Reques.pdf,PDF,COMIRNATY BLA - Pediatric PMR Studies,2021-07-20,Email,"Naik, Ramachandra, Harkins Tull, Elisa, Gottschalk, Laura, Smith, Michael (CBER), Aghajani Memar, Neda, Devlin, Carmel M",,False,True,False,False,False,"Biologics License Application (BLA), Partial Waiver Request, Vaccine Epidemiology, FDA Center for Biologics Evaluation and Research (CBER), Infant and Child Immunization, COMIRNATY, Vaccine Safety and Efficacy, Regulatory Timelines and Milestones, Pfizer Pharmaceutical, Protocol, Vaccine Clinical Development, Regulatory Compliance, Pediatric Clinical Trials, Vaccine Approval Process, FDA Regulatory Submission, Deferred Pediatric Studies, Pediatric Dose Evaluation, Pediatric Research Equity Act (PREA)",18,1,https://drive.google.com/file/d/1Ts46gJOZ3enGoXg8Jywc_sAEz0IcBswO/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:41
37_BLA 125742-0_07-29-2021_Telecon_Information Reques.pdf,PDF,Comment regarding analyses for safety for the two age groups,2021-07-29,email,"Gottschalk, Laura, Harkins Tull, Elisa, Naik, Ramachandra, Smith, Michael (CBER), Devlin, Carmel M, Aghajani Memar, Neda",,False,False,False,False,False,"data-compliance, regulatory-submission, biologics-license-application, covid-19-vaccine, vaccine-efficacy, pharmaceutical-development, center-for-biologics-evaluation-and-research, vaccine-research-and-review, clinical-trial-safety, comirnaty, age-group-analysis, pfizer, information-request, fda-review, regulatory-affairs, adverse-events, data-request",17,1,https://drive.google.com/file/d/1PyHuZUK4iYK5PJKs54ww8V9IU_PZhzP9/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:45
30_BLA 125742-0_07-22-2021_Telecon_Information Reques.pdf,PDF,Information Request Regarding Clinical Shell Tables for Study C4591001,2021-07-22,email,"Gottschalk, Laura, Harkins Tull, Elisa, Naik, Ramachandra, Smith, Michael (CBER), Devlin, Carmel M, Aghajani Memar, Neda",,False,False,False,False,False,"regulatory timeline, data quality, FDA regulatory, clinical trial, information request, data compliance, vaccine development, shell tables, study C4591001, CBER, safety data, clinical data, BLA 125742/0, efficacy data, adverse events, Pfizer, regulatory submission",17,1,https://drive.google.com/file/d/18GS7cbnlRqXxsLXt3mzDmdy0JfZ-nCzm/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:49
31_2_BLA 125742-0_07-26-2021_Telecon_Information Reques.pdf,PDF,Disposition of Participants in Safety Populations who Experienced Pregnancy,2021-07-26,email,"Gottschalk, Laura, Harkins Tull, Elisa, Naik, Ramachandra, Smith, Michael (CBER), Devlin, Carmel M, Aghajani Memar, Neda",,False,False,False,False,False,"office-of-vaccines-research-and-review, biologics-license-application, pregnancy-outcomes, data-tabulation, vaccine-efficacy, safety-population-data, regulatory-project-management, pfizer-pharmaceutical, center-for-biologics-evaluation-and-research, information-request, clinical-trial-safety, fda-regulatory-review, vaccine-safety, bnt162b2-vaccine, july-2021, vaccine-dose-information, adverse-event-reporting",17,2,https://drive.google.com/file/d/10PZb1oeTyJLsqN0ML4zlJaTkVTgqRmX8/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:53
48A_BLA 125742-0_08-05-2021_Telecon_Labeling via FAX_e.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Prescribing Information",2021-08-05,Prescribing Information,,,False,False,False,False,False,"Immunization, Vaccine Efficacy, mRNA Vaccine, Postmarketing Surveillance, Clinical Studies, Warnings and Precautions, COMIRNATY, Dosage and Administration, COVID-19 Vaccine, SARS-CoV-2, Vaccine Safety, Adverse Reactions, Pharmaceutical Prescribing Information, Coronavirus Disease 2019 (COVID-19), Contraindications, Regulatory Approval, Intramuscular Injection",17,41,https://drive.google.com/file/d/10-tBMC9GIkTwkB4Zf3Cyy_qXrvf7vds4/view?usp=drivesdk,pd-production-090123,2025-08-12 00:23:58
36_BLA 125742-0_07-28-2021_Telecon_Labeling Target Cl.pdf,PDF,"Preliminary Comments on Package Insert for COMIRNATY (COVID-19 Vaccine, mRNA)",2021-07-28,email,"Naik, Ramachandra, Harkins Tull, Elisa, Gottschalk, Laura, Smith, Michael (CBER), Aghajani Memar, Neda, Devlin, Carmel M",,False,False,False,False,False,"data-compliance, regulatory-submission, biologics-evaluation, email-communication, covid-19-vaccine, package-insert, clinical-data, safety-data, vaccines-research-review, comirnaty, efficacy-data, pfizer, us-based, fda-review, adverse-events, july-2021, quality-assurance",17,1,https://drive.google.com/file/d/18d48_CqR0vlun1GxutzFXKA_At3fR1DY/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:02
35_BLA 125742-0_07-28-2021_Telecon_Information Reques.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) - CBER comments regarding postmarketing safety study(ies)",2021-07-28,email,"Naik, Ramachandra, Harkins Tull, Elisa, Gottschalk, Laura, Smith, Michael (CBER), Aghajani Memar, Neda, Devlin, Carmel M",,False,True,False,False,False,"fda_regulatory_review, vaccine_safety_data_collection, vaccine_clinical_trial_phases, covid-19_vaccine, vaccine_safety_profile_characterization, vaccine_safety_data_analysis, vaccine_efficacy_and_safety, comirnaty_vaccine, pharmacovigilance_plan, myocarditis_adverse_event, postmarketing_surveillance, center_for_biologics_evaluation_and_research, vaccine_clinical_trial_design, regulatory_submission_amendment, vaccine_adverse_event_monitoring, vaccine_regulatory_approval_process, Protocol, clinical_trial_safety_study",18,2,https://drive.google.com/file/d/1XLvSnW0jebPs3gAHQ77-uoeMREa9By5-/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:06
57_BLA 125742-0_08-09-2021_Telecon_Labeling via FAX_e.pdf,PDF,"Comments on the Carton and Container labels for COMIRNATY (COVID-19 Vaccine, mRNA)",2021-08-09,email,"Smith, Michael (CBER), Aghajani Memar, Neda, Harkins Tull, Elisa, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"FOIA document, Active immunization, Diluent labeling, Regulatory submission, Pharmaceutical/clinical trial, FDA review, Center for Biologics Evaluation & Research (CBER), Office of Vaccines Research & Review, Pfizer, SARS-CoV-2, Quality assurance, Carton and container labeling, Product identifier, Dosage and administration, Regulatory compliance, COMIRNATY (COVID-19 Vaccine, mRNA), Storage conditions",17,3,https://drive.google.com/file/d/1mU8bdPnF56eeTpfWe93_5ERzLT6Te4bc/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:09
56_BLA 125742-0_08-09-2021_Telecon_Information Reques.pdf,PDF,Clinical Information Request Regarding Sequencing Data for COVID-19 Case,2021-08-09,Email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"BNT162b2 vaccine, FOIA document, Pharmaceutical clinical trial, Genomic sequencing data, Regulatory submission (STN 125742.0), CBER division, COVID-19 case report, Vaccine research and review, Elderly patient population, Regulatory information request, HIV-positive patient subgroup, COVID-19 pneumonia, Adverse event investigation, Vaccine breakthrough infection, FDA regulatory review, Vaccine safety monitoring, Pfizer-BioNTech collaboration",17,2,https://drive.google.com/file/d/1G3jvtL5zXR3ednes5-6EpPbrpuo6MLmA/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:13
59_1_BLA 125742-0_08-10-2021_Telecon_Information Reques.pdf,PDF,"BLA 125742/0 – COMIRNATY (COVID-19 Vaccine, mRNA) - Comments regarding safety-related postmarketing studies",2021-08-10,email,"Naik, Ramachandra, Harkins Tull, Elisa, Smith, Michael (CBER), Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M",,False,True,False,False,False,"FOIA document, Pharmaceutical clinical trial, Risk window, Postmarketing safety studies, Regulatory submission, Biostatistical analysis, FDA review, COMIRNATY vaccine, Vaccine safety, COVID-19 vaccine, Sample size calculation, Protocol, Myocarditis, Adverse event monitoring, Self-controlled risk interval (SCRI), Pharmacovigilance plan, Exposure misclassification, Regulatory compliance",18,3,https://drive.google.com/file/d/19XF2h4RpMdEg7H0WubeQT-7V2pNti90a/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:17
50_BLA 125742-0_08-06-2021_Memo_Committee Memo_APLB.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Suspension for Intramuscular Injection BLA 125742/0 Sponsor: Pfizer Inc.",2021-08-06,Memo,"Ramachandran Naik, Laura Montague, Michael Smith, Susan Wollersheim, Oluchi Elekwachi, Lisa Stockbridge, Pfizer Inc.",,False,False,False,False,False,"Biologics License Application (BLA), Regulatory Terminology, Regulatory Reviewer, FDA Regulatory Review, Clinical Studies, Compliance and Quality, Dosage and Administration, Vaccine Safety and Efficacy, COVID-19 Vaccine, CBER (Center for Biologics Evaluation and Research), Adverse Reactions, Vaccine Labeling and Packaging, Pharmaceutical Submission, Vaccine Approval Process, OCBQ/DCM/APLB (Office of Compliance and Biologics Quality, Division of Compliance, Advertising, Promotions, and Labeling Branch), Prescribing Information (PI), Intramuscular Injection",17,6,https://drive.google.com/file/d/1Pr2yw0-aLvFkTQ-612l-nNEZpjNdAQqJ/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:21
5_BLA 125742-0_06-08-2021_Telecon_Information Reques.pdf,PDF,STN 125742.0: Clinical Information Request,2021-06-08,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"prescribing_information, regulatory_compliance, data_quality, immunogenicity_data, vaccine_research_and_development, confidential_communication, cber_division_of_vaccines_and_related_products_applications, reactogenicity_subset, usphs_officer, safety_population, fda_submission, foia_document, bnt162b2_vaccine, fact_sheet_for_healthcare_providers, clinical_information_request, biologics_license_application, c4591001_study",17,2,https://drive.google.com/file/d/1oBVjZv6c_SxVYd_xCTvMuNhwi--QUA4i/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:25
48_BLA 125742-0_08-05-2021_Telecon_Labeling via FAX_e.pdf,PDF,Second round of PI comments for STN 125742.0,2021-08-05,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"regulatory-submission, email-communication, biologics-license-application, safety-efficacy-data, quality-compliance, package-insert, pfizer-pharmaceutical, privileged-confidential, cber-division-of-vaccines, clinical-trial-data, stn-125742, august-2021, fda-review, vaccine-development, labeling-comments, teleconference, foia-document",17,1,https://drive.google.com/file/d/141H-Y8HzCI5D_ohRXxx0WkTwus445nvA/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:28
67_3_BLA 125742-0_08-13-2021_Telecon_Information Reques.pdf,PDF,Telecon Information Request,2021-08-13,email,"Smith, Michael (CBER), Aghajani Memar, Neda, Naik, Ramachandra, Gottschalk, Laura, Harkins Tull, Elisa, Devlin, Carmel M",,False,False,False,False,False,"Data analysis, FOIA document, Safety and efficacy data, Pharmaceutical clinical trial, Biologics License Application (BLA), Information request, FDA submission, Pfizer vaccine, Age cohort analysis, Teleconference, CBER (Center for Biologics Evaluation and Research), Dose 2 follow-up, Adverse event monitoring, Young adults, Older adults, Regulatory compliance, Vaccine development",17,3,https://drive.google.com/file/d/1ymZzVvOzbOloLABhYv_ucY3txWZxt_k4/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:32
69_1_BLA 125742-0_08-13-2021_Telecon_Information Reques.pdf,PDF,"STN 125742/0 – COMIRNATY (COVID-19 Vaccine, mRNA) - Safety-related Postmarketing Requirement/Postmarketing Commitment studies",2021-08-13,email,"Naik, Ramachandra, Harkins Tull, Elisa, Smith, Michael (CBER), Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M",,False,True,False,False,False,"FOIA document, Postmarketing requirements, Sentinel system, Pharmaceutical/clinical trial, FDA regulation, COMIRNATY, Postmarketing commitments, COVID-19 vaccine, Pharmacovigilance, Epidemiologic studies, Pregnancy registry, Myocarditis, Protocol, Pericarditis, Subclinical myocarditis, Adverse event monitoring, Safety data, BLA submission",18,4,https://drive.google.com/file/d/1RlLYHTqdAr4_f5A11LzyRC02LXz94pr_/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:36
63_BLA 125742-0_08-12-2021_Telecon_Other.pdf,PDF,"Teleconference Summary for BLA 125742/0 (COVID-19 Vaccine, mRNA (COMIRNATY))",2021-08-12,teleconference summary,"Marion Gruber, Ph.D., Mary Malarkey, Ramachandra Naik, Ph.D., Neda Aghajani Memar, Donna Boyce, Carmel Devlin, Jennifer Huff, Kevin Nepveux, Amit Patel, Paul Rohlfing, Nicholas Warne",,False,True,False,False,False,"vaccine distribution, vaccine efficacy, COMIRNATY, vaccine packaging, vaccine labeling, FDA, COVID-19 vaccine, EUA material, licensed material, Protocol, vaccine turnover, vaccine lot identification, vaccine safety, BLA 125742/0, teleconference, regulatory approval, vaccine storage, clinical trials",18,2,https://drive.google.com/file/d/1Tqv-2h4q4zzNEjD145ShjZjpYN_Ph4up/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:40
71_6_BLA 125742-0_08-13-2021_Telecon_Information Reques.pdf,PDF,Telecon Information Request,2021-08-13,email,"Smith, Michael (CBER), Aghajani Memar, Neda, Naik, Ramachandra, Gottschalk, Laura, Harkins Tull, Elisa, Devlin, Carmel M",,False,False,False,False,False,"regulatory-submission, age-cohorts, biologics-license-application, hiv-positive-participants, evaluable-efficacy-population, pfizer-correspondence, safety-population, vaccine-efficacy, dose-2-timeline, vaccines-research-review, fda-communication, clinical-trial-data, cber-division, bnt162b2-vaccine, follow-up-time, unblinding-process, data-request",17,2,https://drive.google.com/file/d/1JndSqsIIpgrAA84vXKEb4cjVFvNhvETl/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:44
6_BLA 125742-0_06-09-2021_Telecon_Information Reques.pdf,PDF,Request for Dates Associated with PREA Deferred Studies,2021-06-09,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,True,False,False,False,"Data request, FOIA document, PREA deferred studies, Study completion, Pharmaceutical clinical trials, Biologics License Application (BLA), Final protocol submission, Final report submission, Center for Biologics Evaluation and Research (CBER), Vaccine Research and Review Division, Pfizer BLA 125742-0, Pediatric age groups, Protocol, Study C4591001, Study C4591007, FDA regulatory review, Regulatory compliance, Vaccine development",18,1,https://drive.google.com/file/d/1VeVemoVub0C12U7x4n5EQHC1VXSpLxZO/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:48
98_BLA 125742-0_08-19-2021_Telecon_Labeling via FAX_e.pdf,PDF,Teleconference on Labeling for BLA 125742-0,2021-08-19,email,"Gottschalk, Laura, Harkins Tull, Elisa, Devlin, Carmel M, Aghajani Memar, Neda, Smith, Michael (CBER), Naik, Ramachandra",,False,False,False,False,False,"Pfizer Clinical Trials, CBER Office of Vaccines, Compliance and Quality Assurance, Data Review and Feedback, BLA 125742-0, FDA Regulatory Review, Biologics Evaluation and Review, Deadline and Turnaround Time, Tracked Changes and Annotations, Package Insert (PI), Geographic Location: United States, Confidential Communication, Teleconference Communication, Pharmaceutical Labeling, Regulatory Project Management, Vaccine Research and Review, Submission Tracking Number (STN)",17,1,https://drive.google.com/file/d/1OSjgIhsdg0mtDZVLLkSm60KtsD32GOv6/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:52
91_2_BLA 125742-0_08-18-2021_Telecon_Labeling via FAX_e.pdf,PDF,5th Set of PI Labeling Comments for STN 125742.0,2021-08-18,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Naik, Ramachandra, Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M",,False,False,False,False,False,"Biologics License Application (BLA), Vaccine Division and Applications, Vaccine Safety and Efficacy Data, Pharmaceutical Regulatory Affairs, FDA Center for Biologics Evaluation and Research (CBER), Deadline and Timelines, Pfizer Vaccine Product, Package Insert (PI) Labeling, Teleconference and Email Communication, Privileged and Confidential Information, FDA-CBER Regulatory Review, Regulatory Compliance and Quality, Pharmaceutical Clinical Trials, Pharmaceutical Regulatory Review Process, Vaccine Development, Regulatory Submission and Approval, Pharmaceutical Labeling and Packaging",17,2,https://drive.google.com/file/d/13PQCiwrj8VeU9j7y14tH1T0LxnrwZzUo/view?usp=drivesdk,pd-production-090123,2025-08-12 00:24:58
80_2_BLA 125742-0_08-17-2021_Telecon_Information Reques.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) - Follow-up comments regarding safety-related Postmarketing Requirement/Postmarketing Commitment studies",2021-08-17,email,"Naik, Ramachandra, Harkins Tull, Elisa, Gottschalk, Laura, Smith, Michael (CBER), Aghajani Memar, Neda, Devlin, Carmel M, Rohlfing, Paul",,False,True,False,False,False,"Myocarditis safety evaluation, FOIA document, Pharmaceutical clinical trial, Postmarketing requirements, Regulatory submission, Crossover study design, FDA review, COMIRNATY vaccine, Pediatric study, Efficacy data, Postmarketing commitments, Compliance with regulations, Protocol, Adverse event monitoring, Safety data, Troponin testing, Pharmacovigilance plan, Vaccine development",18,2,https://drive.google.com/file/d/1uvWR6coDjm040joq6HIeNaBM93bQV09_/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:02
90_1_BLA 125742-0_08-18-2021_Telecon_Labeling via FAX_e.pdf,PDF,Comments regarding inclusion of draft carton and container labels in a single amendment,2021-08-18,email,"Gottschalk, Laura, Harkins Tull, Elisa, Smith, Michael (CBER), Naik, Ramachandra, Devlin, Carmel M, Aghajani Memar, Neda",,False,False,False,False,False,"regulatory-submission, clinical-trial-materials, manufacturing-sites, covid-19-vaccine, approval-process, biologics-license-application, regulatory-compliance, pharmaceutical-industry, vaccine-distribution, comirnaty-vaccine, labeling-and-packaging, data-management, quality-control, product-identification, vaccine-diluent, vaccine-development, fda-correspondence",17,2,https://drive.google.com/file/d/1DSehPjKNNfX8JaGJMYa7uunUghMZ55e0/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:05
72_BLA 125742-0_08-13-2021_Telecon_Labeling via FAX_e.pdf,PDF,3rd set of PI labeling comments,2021-08-13,email,"Smith, Michael (CBER), Aghajani Memar, Neda, Naik, Ramachandra, Gottschalk, Laura, Harkins Tull, Elisa, Devlin, Carmel M",,False,False,False,False,False,"product-approval, regulatory-submission, biologics-license-application, compliance-requirements, package-insert, us-based-operations, data-exchange, clinical-trial-data, cber-division, adverse-events, fda-review, vaccine-development, safety-efficacy, labeling-comments, teleconference, quality-assurance, pfizer-vaccine",17,2,https://drive.google.com/file/d/1JLzkbRM0hd4_DM2iPw5CrDg_HQydvN4w/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:09
96_2_BLA 125742-0_08-19-2021_Telecon_Information Reques.pdf,PDF,Information Request Regarding PMRs and PMCs for BLA 125742-0,2021-08-19,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Naik, Ramachandra, Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M",,False,True,False,False,False,"post-marketing-commitments, regulatory-submission, response-deadline, myocarditis-assessment, bla-125742-0, clinical-trial-c4591021, comirnaty-vaccine, pediatric-heart-network, center-for-biologics-evaluation-and-research, date-corrections, safety-data, fda-communication, pfizer-communication, clinical-trial-c4591007, Protocol, post-marketing-requirements, data-clarification, vaccine-research-and-review",18,2,https://drive.google.com/file/d/1qiCA6eBeQ745XCznOWhCiglMUHhRPnoN/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:13
88_2_BLA 125742-0_08-18-2021_Telecon_Information Reques.pdf,PDF,"BLA 125742/0 – COMIRNATY (COVID-19 Vaccine, mRNA) – Identification of BLA-compliant lots and Letter to HCP",2021-08-18,email,"Naik, Ramachandra, Boyce, Donna, Smith, Michael (CBER), Gottschalk, Laura, Harkins Tull, Elisa, Devlin, Carmel M, Aghajani Memar, Neda, Rohlfing, Paul, Malarkey, Mary",,False,False,False,False,False,"Pfizer-BioNTech, Lot identification, Vaccine efficacy, Vaccine distribution, FDA regulatory, COMIRNATY, Vaccine safety, COVID-19 vaccine, Vaccine labeling, Pharmacovigilance, Clinical trial data, Adverse event reporting, CBER (FDA), HCP communication, Vaccine manufacturing, Regulatory compliance, BLA submission",17,1,https://drive.google.com/file/d/1rlTiP9kNb9HabZ6ZqpMVtgXBCU6vxTPE/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:17
76_BLA 125742-0_08-16-2021_Telecon_Labeling via FAX_e.pdf,PDF,"Second set of comments and questions on the carton and container labels for COMIRNATY (COVID-19 Vaccine, mRNA)",2021-08-16,memo,"Smith, Michael (CBER), Harkins Tull, Elisa, Naik, Ramachandra, Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M",,False,False,False,False,False,"BLA 125742, FOIA document, Fresenius Kabi, safety considerations, QR code placement, Kalamazoo, FDA review, carton and container labels, lot number, COVID-19 vaccine, medication error minimization, diluent labeling, regulatory guidance, expiration date, Hospira, COMIRNATY (COVID-19 Vaccine, mRNA), pharmaceutical/clinical trial",17,3,https://drive.google.com/file/d/1iU3PG439zLNDMNlfTEKjYNSGsE3kWLFa/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:21
FDA-CBER-2021-5683-1024870-1040913_Slipsheet.pdf,PDF,FDA FOIA Request #2021-5683 Redacted Records,2021,FOIA document,,,False,False,True,False,False,"Bates numbering, FOIA exemptions, medical research, pharmaceutical development, data privacy, Center for Biologics Evaluation and Research (CBER), record management, safety data, FDA FOIA request, regulatory submissions, Exemption, adverse events, pharmaceutical industry, efficacy data, drug/vaccine identifiers, clinical trials, data redaction, regulatory compliance",18,1,https://drive.google.com/file/d/1mCPf7qFbi8L414gP1vbxZcVKilIwnf-h/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:24
82_BLA 125742-0_08-17-2021_Telecon_Labeling via FAX_e.pdf,PDF,4th set of PI labeling comments,2021-08-17,email,"Smith, Michael, Harkins Tull, Elisa, Naik, Ramachandra, Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M",,False,False,False,False,False,"product-approval, regulatory-submission, cber, biologics-license-application, compliance, package-insert, safety-data, data-exchange, pfizer, quality-control, efficacy-data, fda-review, vaccine-development, clinical-trial, labeling-comments, adverse-events, regulatory-timeline",17,1,https://drive.google.com/file/d/1GkzQldrm16N5AoHmHhhc623EBwMQtLbQ/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:28
70_2_BLA 125742-0_08-13-2021_Telecon_Information Reques.pdf,PDF,STN 125742.0: One clinical question,2021-08-13,email,"Smith, Michael (CBER), Aghajani Memar, Neda, Naik, Ramachandra, Gottschalk, Laura, Harkins Tull, Elisa, Devlin, Carmel M",,False,False,False,False,False,"safety_data, cber, surveillance_time, dose_1, table_o, clinical_trial, usphs, efficacy_data, data_request, regulatory_affairs, fda_submission, vaccine_efficacy, august_2021, dose_2, pfizer, covid-19, bnt162b2",17,3,https://drive.google.com/file/d/1YERpDiq1fmW4pcyjunakSBq_m7Kayqs1/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:32
97_1_BLA 125742-0_08-19-2021_Telecon_Information Reques.pdf,PDF,Telecon Information Request,2021-08-19,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Naik, Ramachandra, Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M",,False,True,False,False,False,"FOIA document, Pharmaceutical clinical trial, Information request, Safety and efficacy data, CBER division, Pfizer vaccine, BLA 125742-0, Regulatory submission, Regulatory timeline, Data quality assurance, FDA regulatory communication, Teleconference, Protocol, Study completion and report submission, PMR and PMC studies, Adverse event monitoring, Data compliance, Vaccine development",18,3,https://drive.google.com/file/d/1puQqHf-EczEufw5LMfAS8c7J1i6lWRJG/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:36
9_2_BLA 125742-0_06-25-2021_Telecon_Information Reques.pdf,PDF,Information Request Regarding BNT162 Interim 3 Report,2021-06-25,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"FOIA document, Pharmaceutical clinical trial, Information request, Privileged and confidential, CBER division, Dose 1 and Dose 2 data, Vaccine research and review, Biologics license application, Vaccine safety and efficacy, Regulatory review officer, BNT162 vaccine, Older and younger subject cohorts, Numerical inconsistencies, Data tables and formats, FDA regulatory review, Response deadline, Solicited adverse events",17,5,https://drive.google.com/file/d/1xJ6Pj7Q8q8V2AewbUc_1neaCNZfoPLrM/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:39
FDA-CBER-2021-5683-1040914_125742_S1_M5_bnt162-01-S-D-mh.xpt,XPT,FDA-CBER-2021-5683-1040914 125742 S1 M5 bnt162-01-S-D-mh,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1fE78n44QF8JXhCLz9QxUGjhCTsoL6_Ky/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:40
FDA-CBER-2021-5683-1040915-1045839_125742_S1_M5_C4591001-A-D-admh.xpt,XPT,FDA-CBER-2021-5683-1040915-1045839 125742 S1 M5 C4591001-A-D-admh,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1nGSr10d5xg1NSBwBXI8RBtINiQy_pN5j/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:50
FDA-CBER-2021-5683-1045840-1049564_125742_S1_M5_C4591001-S-D-co.xpt,XPT,FDA-CBER-2021-5683-1045840-1049564 125742 S1 M5 C4591001-S-D-co,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1nmNNYAKb98fkGdnspc6JLTCId574ePtH/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:54
FDA-CBER-2021-5683-1049565-1049659_125742_S1_M5_C4591001-S-D-faho.xpt,XPT,FDA-CBER-2021-5683-1049565-1049659 125742 S1 M5 C4591001-S-D-faho,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1609MqWrxgDHtF-MyqMGh0DNSFZPQsneT/view?usp=drivesdk,pd-production-090123,2025-08-12 00:25:56
FDA-CBER-2021-5683-1049660-1051265_125742_S1_M5_C4591001-S-D-ho.xpt,XPT,FDA-CBER-2021-5683-1049660-1051265 125742 S1 M5 C4591001-S-D-ho,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/17Gl4Bf9MUyhvChDpmcAUGLmjG75rrQ8N/view?usp=drivesdk,pd-production-090123,2025-08-12 00:26:01
FDA-CBER-2021-5683-1051266-1053273_125742_S1_M5_C4591001-S-D-lb.xpt,XPT,FDA-CBER-2021-5683-1051266-1053273 125742 S1 M5 C4591001-S-D-lb,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/19jSTVdVHEo8VK3t6QIjbEClkpp60gWl-/view?usp=drivesdk,pd-production-090123,2025-08-12 00:26:04
FDA-CBER-2021-5683-1053274-1058198_125742_S1_M5_C4591001-S-D-mh.xpt,XPT,FDA-CBER-2021-5683-1053274-1058198 125742 S1 M5 C4591001-S-D-mh,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1hOwZjl5HuZoPRXll3Yp51tRSpCEWp5oA/view?usp=drivesdk,pd-production-090123,2025-08-12 00:26:09
FDA-CBER-2021-5683-1060086-1060087_28F_IND27034 - BNT162-01 - Multiple baseline records in LB.xlsx,XLSX,Multiple Baseline Records for BNT162-01 Clinical Trial,2020-06-09,data,,,False,False,False,False,False,"visit 0, BNT162-01, baseline data, FOIA, clinical trial, screening, visit 1, FDA, flow cytometry, safety data, vaccine development, blood analysis, CBER, adverse events, hematology, pharmaceutical data, regulatory compliance",17,2,https://docs.google.com/spreadsheets/d/1GUHjNWgLKYZF57Keu25kzEJu_YQq1oaG/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-090123,2025-08-12 00:26:11
FDA-CBER-2021-5683-1060089_28H_IND27034 - c4591001-safety-fa-eff - AEACN is DRUG WITHDRAWN but no ADVERSE EVENT record in DS.xlsx,XLSX,Safety and Efficacy Analysis for Clinical Trial C4591001,2020,Data,,,False,False,False,False,False,"C4591001, compliance, safety analysis, medication error, pregnancy, pharmaceutical, clinical trial, death, FOIA, FDA, drug withdrawal, vaccine, efficacy analysis, data, adverse events, disposition event, regulatory",17,1,https://docs.google.com/spreadsheets/d/1I-rxahqB1_MwprgWkPqVMN2g76WO3lMa/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-090123,2025-08-12 00:26:14
FDA-CBER-2021-5683-1058209-1060003_28A_2-c4591001-safety-fa-eff.xlsx,XLSX,c4591001-safety-fa-eff Study Data,2020-11-21,data,,,False,True,False,False,False,"regulatory-submission, immunogenicity, cdisc-standards, fda, data-quality, laboratory-data, tolerability, ind27034, adverse-events, vaccine, vital-signs, efficacy, safety, clinical-trial, Protocol, data-analysis, covid-19, phase-1-2-3",18,2,https://docs.google.com/spreadsheets/d/1b-Io88Hn6EOuqeNHFVQRpH41qDmWQMa2/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-090123,2025-08-12 00:26:25
FDA-CBER-2021-5683-1060088_28G_IND27034 - BNT162-01 - Multiple baseline records in VS.xlsx,XLSX,Multiple Baseline Records in Vital Signs for BNT162-01 Clinical Trial,2020-06,data,,,False,False,False,False,False,"pharmaceutical research, prime vaccination, BNT162-01, medical research, data quality, baseline data, clinical trial, screening, FOIA request, FDA, data management, safety data, vaccine, adverse events, vital signs, data analysis, regulatory compliance",17,1,https://docs.google.com/spreadsheets/d/1d9BZLHBXy4FbdV9IluuQrMzp0bvLHJu5/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-090123,2025-08-12 00:26:27
FDA-CBER-2021-5683-1060004-1060071_28B_3-bnt162-01.xlsx,XLSX,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults",2020-11-21,report,,,False,False,False,False,False,"dose-escalation, immunogenicity, healthy-adults, regulatory-submission, fda, data-quality, rna-vaccine, ind27034, bnt162-01, adverse-events, sars-cov-2, safety, clinical-trial, sdtm, phase-1-2, covid-19, adam",17,3,https://docs.google.com/spreadsheets/d/1_lepwNWXA1Cl8iSAmSZ94ErYnByBsLsL/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-090123,2025-08-12 00:26:31
FDA-CBER-2021-5683-1058199-1058203_125742_S1_M5_C4591001-S-D-suppie.xpt,XPT,FDA-CBER-2021-5683-1058199-1058203 125742 S1 M5 C4591001-S-D-suppie,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1p5ZOTFbNV2Kz5BmshjOX5PFOuUPWYIbS/view?usp=drivesdk,pd-production-090123,2025-08-12 00:26:32
FDA-CBER-2021-5683-1060085_28E_IND27034 - BNT162-01 - AEACN is DRUG WITHDRAWN but no ADVERSE EVENT record in DS.xlsx,XLSX,BNT162-01 Clinical Trial Safety Data,2020-07-10,Data,,,False,False,False,False,False,"fda, compliance, pharmaceutical, adverse event, clinical trial, pyrexia, bnt162, ind27034, drug withdrawal, safety data, treatment, vaccine, time series, medical terminology, disposition event, data analysis, regulatory",17,1,https://docs.google.com/spreadsheets/d/1LsxVE4Fiw0b22UfFbwf77iVDad0t7U-W/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-090123,2025-08-12 00:26:35
FDA-CBER-2021-5683-1064475-1066330_28K_Part III - CoreDF-IND27034-c4591001-subset-2021-04-19T10-50.xlsx,XLSX,CoreDF - FDA Validator Report for IND 27034 (C4591001 Subset),2021-04-19,data,CBER eData Team,,False,True,False,False,False,"SDTM Data, Data Integrity, Data Compliance, Data Reporting, Data Visualization, FDA Validator, Clinical Data Management, Data Review, Data Quality, Regulatory Submission, CBER, Data Standardization, Protocol, Pharmaceutical Trials, Data Validation, C4591001 Clinical Trial, Data Training, IND 27034",18,1,https://docs.google.com/spreadsheets/d/1vN6wER7VSR7T5K6ZUevd1rfy3IWttGsm/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-090123,2025-08-12 00:26:45
FDA-CBER-2021-5683-1064474_28J_Part II - IND27034 - 12-15years - AEACN of DRUG WITHDRAWN but no DS ADVERSE EVENT record (1).xlsx,XLSX,IND27034 - 12-15 years - AEACN of DRUG WITHDRAWN but no DS ADVERSE EVENT record,2020-2021,Data,,,False,False,False,True,False,"quality control, compliance, pharmaceutical, Exclusion, clinical trial, medication errors, death, FDA, disposition events, safety data, data management, vaccine, United States, IND27034, pregnancy, adverse events, phase 3, data analysis",18,1,https://docs.google.com/spreadsheets/d/135YJNFkmDLR2JKg2wTOeMQJvl26FQO9M/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-090123,2025-08-12 00:26:48
FDA-CBER-2021-5683-1060090-1064473_28I_Part II - CoreDF- IND27034 - 12-15years.xlsx,XLSX,FDA CBER CoreDF Report for IND 27034 (12-15 years),2021,report,CBER eData Team,,False,True,False,True,False,"Exclusion, clinical trial, CBER, adverse events, regulatory submission, data quality, data compliance, CoreDF, efficacy, data standards, data reporting, FDA, Protocol, IND 27034, data review, SDTM, 12-15 years, safety, data validation",19,1,https://docs.google.com/spreadsheets/d/1yFO8Cm2vAQDUD6xI3QdhO0cKoHUJ9SnQ/edit?usp=drivesdk&ouid=106698971417007077985&rtpof=true&sd=true,pd-production-090123,2025-08-12 00:27:02
FDA-CBER-2021-5683-1066333-1067534_125742_S6_M5_c4591001-A-D-adsl.xpt,XPT,FDA-CBER-2021-5683-1066333-1067534 125742 S6 M5 c4591001-A-D-adsl,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1MdqSQsPUUCti7vJTRIKxJrzdL6LBJz8i/view?usp=drivesdk,pd-production-090123,2025-08-12 00:27:06
FDA-CBER-2021-5683-1067535-1067562_125742_S6_M5_c4591001-A-D-adxb.xpt,XPT,FDA-CBER-2021-5683-1067535-1067562 125742 S6 M5 c4591001-A-D-adxb,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1i2ccsAC3OwdlQVpSAsSBfyJON3c2IdS2/view?usp=drivesdk,pd-production-090123,2025-08-12 00:27:07
FDA-CBER-2021-5683-1067563-1070765_125742_S6_M5_c4591001-S-D-ex.xpt,XPT,FDA-CBER-2021-5683-1067563-1070765 125742 S6 M5 c4591001-S-D-ex,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1yaTvktO5fDhS8pCbDNrlbqXa4cxa66x1/view?usp=drivesdk,pd-production-090123,2025-08-12 00:27:11
FDA-CBER-2021-5683-1072126-1072170_125742_S6_M5_define2-0-0-2.xsl,XSL,Define-XML Document for FDA Submission,2021,Data Dictionary,,M5,False,True,False,False,False,"Data Standards, Study Metadata, Clinical Trials, Data Analysis, Define-XML, Controlled Terminology, FDA Submission, Data Documentation, Data Quality, Pharmaceutical, Efficacy Data, Protocol, Regulatory Compliance, Adverse Events, Data Dictionary, Data Formatting, Safety Data, Data Referencing",18,4,https://drive.google.com/file/d/1I1K-2kleZBukCtfpPFfxUZhlm1hmB7i6/view?usp=drivesdk,pd-production-090123,2025-08-12 00:27:13
FDA-CBER-2021-5683-1071996-1072061_125742_S6_M5_define.xml,XML,C4591001 Study Subject-Level Analysis Dataset,2021,dataset,"DM.INVID, DM.INVNAM",M5,False,False,False,False,False,"dose-finding, immunogenicity, fda, subject-level-data, dataset, tolerability, placebo-controlled, randomized, observer-blind, efficacy, safety, clinical-trial, sars-cov-2, covid-19, mrna-vaccine, phase-1-2-3, regulatory",17,16,https://drive.google.com/file/d/1hs0km61R1PRxP7VV4VP7_-0PAupNS6VL/view?usp=drivesdk,pd-production-090123,2025-08-12 00:27:16
FDA-CBER-2021-5683-1072081-1072125_125742_S6_M5_define2-0-0.xsl,XSL,FDA CBER Define-XML Document,2021,Data Dictionary,,M5,False,True,False,False,False,"Clinical Trials, Standards, Define-XML, Controlled Terminology, FOIA, FDA, Pharmaceutical, CBER, Data Quality, Efficacy Data, Datasets, Regulatory Compliance, Adverse Events, Protocol, Data Dictionary, Safety Data, Metadata, Analysis Results",18,4,https://drive.google.com/file/d/1Iol5XlBdtXrOd2G_VGpASf29PAEVFRyZ/view?usp=drivesdk,pd-production-090123,2025-08-12 00:27:18
FDA-CBER-2021-5683-1072062-1072080_125742_S6_M5_define-1.xml,XML,"C4591001 A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults",2021,report,,M5,False,False,False,False,False,"rna vaccine, covid-19 vaccine, immunogenicity, fda, exposure, microbiology, demographics, clinical trial, phase 1/2/3 study, tolerability, efficacy, safety, xml, healthy adults, adverse events, data analysis, regulatory",17,1,https://drive.google.com/file/d/1H9IM5wsmZhUX1As4wlWEP8OTFFmrbO50/view?usp=drivesdk,pd-production-090123,2025-08-12 00:27:22
FDA-CBER-2021-5683-1070766-1071967_125742_S6_M5_c45941001-S-D-dm.xpt,XPT,FDA-CBER-2021-5683-1070766-1071967 125742 S6 M5 c45941001-S-D-dm,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1sWs6evp4f5C2cJjGEXoqTRqbvXkOg2K6/view?usp=drivesdk,pd-production-090123,2025-08-12 00:27:24
FDA-CBER-2021-5683-1071968-1071995_125742_S6_M5_c45941001-S-D-xb.xpt,XPT,FDA-CBER-2021-5683-1071968-1071995 125742 S6 M5 c45941001-S-D-xb,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1lvQm6v8phDZZlU173eZlNRzT2UegaztR/view?usp=drivesdk,pd-production-090123,2025-08-12 00:27:25
9_PM_S105_BLA 125742-9_09-20-2021_Telecon_Advice.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Biologic Product Deviation Report Correspondence",2021-09-20,email,"Gottschalk, Laura, Patel, Amit, Devlin, Carmel M, Harkins Tull, Elisa, Stafford, Adrienne, Smith, Michael (CBER), Naik, Ramachandra",,False,False,False,False,False,"Biologic Product Deviation Report, Regulatory submission, Vaccine development, COMIRNATY, BLA 125742/9, EUA reporting, COVID-19 vaccine, CBER, Pharmacovigilance, Compliance, Pharmaceutical industry, Clinical trials, Quality assurance, Safety monitoring, Regulatory project management, FDA correspondence, Pfizer",17,1,https://drive.google.com/file/d/1ZpELgyC13y1SFgWSh4FEkAzPGwvsgjYG/view?usp=drivesdk,pd-production-100123,2025-08-12 00:27:30
6_PM_S102_2_BLA 125742-8_09-21-2021_Memo_600.81 Lot Distributi.pdf,PDF,"Memo: Lot Distribution Waiver Request for COMIRNATY (COVID-19 Vaccine, mRNA)",2021-09-21,Memo,D. Thompson,,False,False,False,False,False,"BLA 125742, Safety Reporting, Postmarketing Surveillance, Vaccine Approval, Clinical Trials, Periodic Benefit-Risk Evaluation, Adverse Event Reporting, Data Compliance, COMIRNATY, Electronic Submission, Pharmaceutical Regulations, Lot Distribution Waiver, CBER, Regulatory Compliance, FDA Submission, Emergency Use Authorization, COVID-19 Vaccine",17,3,https://drive.google.com/file/d/1NzpCgtFXCmNZ2f-rWIolIX4Vy6uGjBxe/view?usp=drivesdk,pd-production-100123,2025-08-12 00:27:33
4_PM_S89_BLA 125742-5_09-22-2021_Telecon_Advice.pdf,PDF,Teleconference Advice on Reporting Adverse Events for COVID-19 Vaccine (COMIRNATY),2021-09-22,email,"Gottschalk, Laura, Patel, Amit, Harkins Tull, Elisa, Devlin, Carmel M, Naik, Ramachandra, Smith, Michael (CBER), Stafford, Adrienne Kaye, Pelt, Rich R",,False,False,False,False,False,"Pfizer-BioNTech, FOIA document, Data submission requirements, FDA regulatory compliance, Post-authorization safety monitoring, Multisystem inflammatory syndrome in children, COMIRNATY, Periodic safety reports, COVID-19 vaccine, Teleconference, Pharmaceutical/clinical trials, Adverse event reporting, VAERS reporting, Regulatory advice, CBER responses, EUA and BLA submissions, Spontaneous adverse event reports",17,2,https://drive.google.com/file/d/1IuJum_0poWrks3KzO3Nnsn5PKOhJqUFG/view?usp=drivesdk,pd-production-100123,2025-08-12 00:27:37
7_PM_S102_BLA 125742-8_09-29-2021_Letter_Waiver Request.pdf,PDF,Request for Waiver under Title 21 Code of Federal Regulations 600.90(a),2021-09-29,letter,"Christopher Okoye, Craig Zinderman, Lori Austin-Hansberry, Amit Patel",,False,False,False,False,False,"reporting-requirements, data-compliance, biologics-license-application, covid-19-vaccine, safety-monitoring, quarterly-reporting, new-york-city, fda-regulatory-submission, waiver-request, regulatory-guidance, comirnaty, biontech-manufacturing, clinical-trial-data, silver-spring-maryland, lot-distribution-reporting, electronic-submission, emergency-use-authorization",17,3,https://drive.google.com/file/d/1tsY9OzY9vLUHBz1c-i2L1OAaCJM3THD-/view?usp=drivesdk,pd-production-100123,2025-08-12 00:27:41
19736_S0491_M1_smsr-01aug2021-31aug2021.pdf,PDF,Summary Monthly Safety Report (SMSR) for COVID-19 mRNA Vaccine (BNT162b2),2021-09-14,report,,M1,False,False,False,False,False,"vaccine safety monitoring, Pfizer-BioNTech, monthly safety report, regulatory approval, clinical trial data, vaccine composition, confidential document, pharmaceutical development, international regulatory aspects, COVID-19 vaccine, mRNA vaccine, reporting period, vaccine storage and handling, adverse events, centralized authorization, vaccine administration, BNT162b2",17,11782,https://drive.google.com/file/d/1SlIYsKNTuVmKMrbPucV2glFXB6mRFV0a/view?usp=drivesdk,pd-production-100123,2025-08-12 00:28:21
8_PM_S102_BLA 125742-8_09-29-2021_Telecon_Other.pdf,PDF,FDA Waiver Response Letter for COMIRNATY,2021-09-29,letter,"Patel, Amit, Okoye, Christopher, Austin-Hansberry, Lori",,False,False,False,False,False,"Public-Health, COMIRNATY, Adverse-Events, Vaccine, Epidemiology, Regulatory-Compliance, Teleconference, Safety-Data, Correspondence, Regulatory-Approval, Pharmaceutical-Development, Biostatistics, FDA-Waiver, Biologics-License-Application, Clinical-Trials, Efficacy-Data, Pfizer",17,2,https://drive.google.com/file/d/1LpmM23_R6dm7UnxbJqEOZLag59J0X4c7/view?usp=drivesdk,pd-production-100123,2025-08-12 00:28:25
5_PM_S102_1_BLA 125742-8_09-21-2021_Memo_600.81 Lot Distributi.pdf,PDF,Lot Distribution Waiver Request Memo,2021-09-21,memo,D. Thompson,,False,False,False,False,False,"BLA 125742, FDA CBER, safety reporting, periodic safety update, COMIRNATY, medical review, electronic submission, vaccine development, data management, quality assurance, United States, adverse events, lot distribution, waiver request, pharmaceutical industry, clinical trials, regulatory compliance",17,3,https://drive.google.com/file/d/1PN5X2YJABpkFaD1Mkt-mSOGs_yKKFRkh/view?usp=drivesdk,pd-production-100123,2025-08-12 00:28:27
2_PM_S89_BLA 12572-5_09-10-2021_Telecon_Advice.pdf,PDF,CBER Responses to Pfizer/BioNTech's Plan for Reporting Adverse Events,2021-09-10,memo,"Amit Patel, Laura Gottschalk",,False,False,False,False,False,"Division of Vaccines and Related Products Applications, FOIA document, immunocompromised patients, 15-day reporting, Pfizer/BioNTech, OVRR, FDA regulatory, COMIRNATY, EUA, COVID-19 vaccine, CBER, Silver Spring, MD, VAERS, ICSR, adverse event reporting, BLA submission, pharmaceutical clinical trial",17,4,https://drive.google.com/file/d/1h7Y-rdTXjcHPmEoTO5AhtDDy51Tqc6xm/view?usp=drivesdk,pd-production-100123,2025-08-12 00:28:31
3_PM_S89_BLA 125742-5_09-21-2021_Telecon_Other.pdf,PDF,Teleconference Summary for BLA 125742-5 Submission,2021-09-21,Teleconference Summary,,,False,False,False,False,False,"September 2021, Pharmaceutical Industry, FDA Interaction, Pharmaceutical Compliance, Regulatory Submission, Efficacy Data, Drug Identifier: BLA 125742-5, CBER (Center for Biologics Evaluation and Research), Adverse Events, BLA Submission, United States, Biologics License Application, Quality Assurance, Safety Data, Regulatory Approval, Teleconference Summary, Clinical Trial Data",17,1,https://drive.google.com/file/d/1etbKArbBmiwbp52GuSvtuTXwtUNWlab5/view?usp=drivesdk,pd-production-100123,2025-08-12 00:28:34
19736_S0453_M1_smsr-01jul2021-31jul2021.pdf,PDF,Summary Monthly Safety Report (SMSR) for COVID-19 mRNA Vaccine (BNT162b2),2021-08-13,report,,M1,False,False,False,False,False,"Monthly safety report, Adverse events, Pfizer-BioNTech, FOIA release, Confidential document, Reporting period, Worldwide Medical & Safety, COVID-19 vaccine, mRNA vaccine, Pharmacovigilance, Comirnaty, Lipid nanoparticles, Regulatory approval, Centralized authorization, Excipients, BNT162b2, Dose preparation",17,10366,https://drive.google.com/file/d/1Rmv5yeKZaCGZMSz5auxLmx5i668Yn30s/view?usp=drivesdk,pd-production-100123,2025-08-12 00:28:44
19736_S0453_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) 019736 Prophylactic Immunization Against COVID-19 in Adults ≥ 16 Years of Age",2021-08-14,report,"Özlem Türeci, Neda Aghajani Memar",M1,False,False,False,False,False,"PF-07302048, adult population, BioNTech, medical officer, FDA submission, Mainz, Germany, clinical trial, New York, USA, director, COVID-19 vaccine, prophylactic immunization, BNT162, safety data, efficacy data, regulatory affairs, adverse events, Pfizer",17,3,https://drive.google.com/file/d/1qzehLB3vD6chn44MTkA5TOW10oVINALl/view?usp=drivesdk,pd-production-100123,2025-08-12 00:28:50
19736_S0408_M1_smsr-01jun2021-30jun2021.pdf,PDF,PF-07302048 (BNT162b2) Reporting Period Summary Monthly Safety Report (SMSR) 7,2021-07-14,report,,M1,False,False,False,False,False,"eu centralized procedure, european union reference date, covid-19 vaccine, monthly safety report, worldwide medical and safety, confidential document, fda, pf-07302048, clinical trial, lipid nanoparticles, reporting period, safety data, adverse events, pfizer-biontech, international birth date, bnt162b2, regulatory approval",17,8768,https://drive.google.com/file/d/11uOaG9yoo1M0EvrBL_ZndDBZRn_P800U/view?usp=drivesdk,pd-production-100123,2025-08-12 00:29:27
19736_S0453_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 eCTD Sequence 0453 Monthly Safety Report,2021-08-14,report,"Marion Gruber, Ph.D., Neda Aghajani Memar, Pharm.D.",M1,False,False,False,False,False,"benefit-risk-evaluation, regulatory-submission, data-compliance, covid-19-vaccine, pfizer-global-regulatory-affairs, new-york-location, silver-spring-location, pharmaceutical-manufacturing, ectd-sequence, adverse-events, safety-report, ind-summary, fda-review, monthly-report, clinical-trial, vaccine-development, confidential-information",17,2,https://drive.google.com/file/d/1AQ7rjeDZWYN7cIM41_Ywwfr7kjvRXziC/view?usp=drivesdk,pd-production-100123,2025-08-12 00:29:31
19736_S0491_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 eCTD Sequence 0491 IND Summary Monthly Safety Report,2021-09-15,report,"Marion Gruber, Ph.D., Amit Patel",M1,False,False,False,False,False,"data-compliance, covid-19-vaccine, ind-submission, monthly-safety-report, new-york, fda-cber, ectd-sequence, silver-spring-md, hin-e2c-r2-pbrer, global-product-development, regulatory-approval, adverse-events, pfizer, virus-free-submission, regulatory-affairs, clinical-trial, vaccine-development",17,2,https://drive.google.com/file/d/1x9HUAVrxczbrLd1jT0WOx7NqA0GA3t-I/view?usp=drivesdk,pd-production-100123,2025-08-12 00:29:34
19736_S0491_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) Clinical Trial and Regulatory Submission",2021-09-15,Regulatory Submission,"Özlem Türeci, Amit Patel",M1,False,False,False,False,False,"PF-07302048, Clinical Trial, BioNTech, Mainz, Germany, New York, USA, Active Immunization, Efficacy Data, BNT162, Adverse Events, Compliance, Regulatory Affairs, FDA Submission, Quality Assurance, Safety Data, COVID-19 Vaccine, Vaccine Development, Pfizer",17,3,https://drive.google.com/file/d/10nV9IPZwOU3n9P9hexGCk1JIfvVNxXqp/view?usp=drivesdk,pd-production-100123,2025-08-12 00:29:40
19736_S0369_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) 019736 Prophylactic Immunization Against COVID-19 in Adults ≥ 16 Years of Age",2021-06-16,report,"Özlem Türeci, Neda Aghajani Memar",M1,False,False,False,False,False,"pharmaceutical research, FDA submission, Mainz, Germany, clinical trial, New York, USA, COVID-19 vaccine, prophylactic immunization, vaccine development, safety data, adults 16+, BioNTech SE, vaccine identification, efficacy data, regulatory affairs, adverse events, Pfizer Global Regulatory Affairs, regulatory compliance",17,3,https://drive.google.com/file/d/1zetVS6-KHtKSPaUZQ0loVSgfQp4y6EiF/view?usp=drivesdk,pd-production-100123,2025-08-12 00:29:46
19736_S0366_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 eCTD Sequence 0366 Serial No. 0365 IND Summary Monthly Safety Report,2021-06-15,report,"Marion Gruber, Ph.D., Neda Aghajani Memar, Pharm.D.",M1,False,False,False,False,False,"covid-19-vaccine, monthly-safety-report, new-york-city, ectd-sequence, ind-report, safety-data, global-product-development, adverse-events, pfizer, efficacy-data, virus-free-submission, silver-spring-maryland, regulatory-affairs, fda-submission, vaccine-development, clinical-trial, confidential-information",17,2,https://drive.google.com/file/d/14T0lIb72kCAVvdHhWrVbeybU-8mSWM0M/view?usp=drivesdk,pd-production-100123,2025-08-12 00:29:50
19736_S0369_M1_cover.pdf,PDF,"IND Annual Report for COVID-19 Vaccine (BNT162, PF-07302048)",2021-06-16,report,Neda Aghajani Memar,M1,False,False,False,False,False,"PF-07302048, pharmaceutical regulatory, IND annual report, vaccine research and review, DSUR format, FDA, COVID-19 vaccine, CBER, BNT162, safety data, vaccine development, global product development, efficacy data, regulatory affairs, adverse events, Pfizer, clinical trials",17,1,https://drive.google.com/file/d/13I7EgWXK2_VhPeES6GHl_xutRt_ib-J0/view?usp=drivesdk,pd-production-100123,2025-08-12 00:29:53
19736_S0369-dsur-22apr2020-21apr2021.pdf,PDF,"Development Safety Update Report (DSUR) for COVID-19 Vaccine (BNT162, PF-07302048)",2021-06-10,report,"Barbara De Bernardi, EU Qualified Person Deputy",,False,False,False,False,False,"vaccine composition, Europe, development safety update report, BioNTech, clinical trial, confidential information, FDA, COVID-19 vaccine, mRNA vaccine, safety data, dosing schedule, qualified person for pharmacovigilance, efficacy data, adverse events, Pfizer, Italy, regulatory submission",17,578,https://drive.google.com/file/d/1ew8qyZS0DVxKP1eu9nmQeHiHa8w-YJyK/view?usp=drivesdk,pd-production-100123,2025-08-12 00:30:01
19736_S0408_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 eCTD Sequence 0408 IND Summary Monthly Safety Report,2021-07-15,report,"Marion Gruber, Ph.D., Neda Aghajani Memar, Pharm.D.",M1,False,False,False,False,False,"covid-19-vaccine, ind-submission, monthly-safety-report, pf-07302048, regulatory-compliance, new-york-city, fda-cber, virus-scanning, safety-data, pfizer-global, bnt162, adverse-events, silver-spring-maryland, regulatory-affairs, clinical-trial, vaccine-development, confidential-information",17,2,https://drive.google.com/file/d/1YUOzWRK3maXgxAtz-02kqQxJgnLs9HpQ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:30:05
19736_S0366_M1_smsr-30apr2021-31may2021.pdf,PDF,PF-07302048 (BNT162b2) Reporting Period Summary Monthly Safety Report (SMSR) 6,2021-06-13,report,,M1,False,False,False,False,False,"vaccine composition, monthly safety report, covid-19 vaccine, vaccine efficacy, confidential document, fda, clinical trial, reporting period, medical and safety, vaccine storage and handling, adverse events, pfizer-biontech, vaccine safety, vaccine administration, european union, regulatory approval, data analysis",17,7450,https://drive.google.com/file/d/1t3Kgmd2xetVR6U_67lSj0JcqPfk2G8s2/view?usp=drivesdk,pd-production-100123,2025-08-12 00:30:41
19736_S0366_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) 019736 Prophylactic Immunization Against COVID-19 in Adults ≥ 16 Years of Age",2021-06-15,report,"Özlem Türeci, MD, Neda Aghajani Memar",M1,False,False,False,False,False,"phase 3 study, PF-07302048, adult population, medical officer, FDA submission, Mainz, Germany, clinical trial, New York, USA, COVID-19 vaccine, prophylactic immunization, BNT162, safety data, BioNTech SE, efficacy data, adverse events, Pfizer Global Regulatory Affairs, regulatory compliance",17,3,https://drive.google.com/file/d/136JdXqSbIAhJX_7gBpoW8LcNIpRxpcBz/view?usp=drivesdk,pd-production-100123,2025-08-12 00:30:47
19736_S0335-M1_smsr-01apr2021-29apr2021.pdf,PDF,PF-07302048 (BNT162b2) Reporting Period Summary Monthly Safety Report (SMSR) 5,2021-05-13,report,,M1,False,False,False,False,False,"european union reference date, vaccine composition, monthly safety report, covid-19 vaccine, quality control, confidential document, clinical trial, reporting period, vaccine development, centralized authorization, pfizer-biontech, medical safety, vaccine administration, international birth date, regulatory affairs, adverse events, data analysis",17,5983,https://drive.google.com/file/d/1eaOmwXRkPSaX6XSnmuMD8mS6lqJlxrkQ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:31:15
19736_S0408_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) 019736 Prophylactic Immunization Against COVID-19 in Adults ≥ 16 Years of Age",2021-07-15,report,"Özlem Türeci, Neda Aghajani Memar",M1,False,False,False,False,False,"phase 1, FDA submission, Mainz, Germany, clinical trial, phase 0, phase 2, New York, USA, COVID-19 vaccine, vaccine development, prophylactic immunization, safety data, BioNTech SE, efficacy data, regulatory affairs, adverse events, phase 3, Pfizer Global Regulatory Affairs",17,3,https://drive.google.com/file/d/1NoyE2r2cl9RwgJVBkXQt4RKLaw7-5l4p/view?usp=drivesdk,pd-production-100123,2025-08-12 00:31:22
19736_S0289_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) 019736 Prophylactic immunization against COVID-19 in adults ≥ 16 years of age - Summary Monthly Safety Report (SMSR)",2021-04-15,report,"Özlem Türeci, Neda Aghajani Memar",M1,False,False,False,False,False,"medical officer, regulatory affairs, FDA submission, adults 16+ years, Mainz, Germany, clinical trial, phase 0, New York, USA, COVID-19 vaccine, prophylactic immunization, BioNTech SE, monthly report, vaccine identification, safety report, adverse events, Pfizer Global Regulatory Affairs, regulatory compliance",17,3,https://drive.google.com/file/d/1aTOwhJKXOWcrZc9PdOPY33qPV5gNWSye/view?usp=drivesdk,pd-production-100123,2025-08-12 00:31:28
19736_S0335_M1_cover.pdf,PDF,IND Summary Monthly Safety Report,2021-05-14,report,"Marion Gruber, Ph.D., Neda Aghajani Memar, Pharm.D.",M1,False,False,False,False,False,"benefit-risk-evaluation, office-of-vaccines-research-and-review, data-compliance, covid-19-vaccine, new-hampshire-avenue, pfizer-global-regulatory-affairs, pf-07302048, bb-ind-19736, center-for-biologics-evaluation-and-research, bnt162, adverse-events, safety-report, silver-spring, regulatory-affairs, fda-submission, monthly-report, clinical-trial",17,2,https://drive.google.com/file/d/13dte2j7C85qjhQpvUTPrF4MSxksB_aVs/view?usp=drivesdk,pd-production-100123,2025-08-12 00:31:31
19736_S0335_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) 019736 Prophylactic Immunization Against COVID-19 in Adults ≥ 16 Years of Age",2021-05-14,report,"Özlem Türeci, Neda Aghajani Memar",M1,False,False,False,False,False,"PF-07302048, medical officer, adult population, FDA submission, Mainz, Germany, clinical trial, New York, USA, COVID-19 vaccine, prophylactic immunization, BNT162, safety data, BioNTech SE, efficacy data, regulatory affairs, adverse events, Pfizer Global Regulatory Affairs, regulatory compliance",17,3,https://drive.google.com/file/d/1CbQh8dBcbGNx37L6da848q15Sioin8jw/view?usp=drivesdk,pd-production-100123,2025-08-12 00:31:37
19736_S0243_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 eCTD Sequence 0243 IND Summary Monthly Safety Report,2021-03-15,report,"Marion Gruber, Ph.D., Neda Aghajani Memar, Pharm.D.",M1,False,False,False,False,False,"global-regulatory-affairs, covid-19-vaccine, monthly-safety-report, virus-scanning, ectd-sequence, maryland, ind-report, safety-data, global-product-development, pfizer, silver-spring, regulatory-affairs, fda-submission, vaccine-development, clinical-trial, confidential-information, new-hampshire",17,2,https://drive.google.com/file/d/1oTA-062JeZyUKIzZqNsSpHBXew0ez73V/view?usp=drivesdk,pd-production-100123,2025-08-12 00:31:40
19736_S0243-smsr-01feb2021-28feb2021.pdf,PDF,PF-07302048 (BNT162b2) Reporting Period Summary Monthly Safety Report (SMSR) 3,2021-03-12,report,,,False,False,False,False,False,"covid-19-vaccine, monthly-safety-report, pf-07302048, fda-submission, regulatory-approval, vaccine-storage, safety-data, adverse-events, eu-reference-date, worldwide-medical-safety, pfizer-biontech, clinical-trial, vaccine-composition, reporting-period, bnt162b2, vaccine-administration, confidential-document",17,3409,https://drive.google.com/file/d/1rmOUtm33hgilk_GqJBVH6RaLU1bNQ_uu/view?usp=drivesdk,pd-production-100123,2025-08-12 00:32:03
19736_S0289_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 eCTD Sequence 0289 Serial No. 0288 IND Summary Monthly Safety Report,2021-04-15,report,"Marion Gruber, Ph.D.",M1,False,False,False,False,False,"PF-07302048, BioNTech, compliance, eCTD, clinical trial, FDA, COVID-19 vaccine, emergency use authorization, BNT162, VAERS, IND 19736, global product development, data reporting, safety report, adverse events, Pfizer, regulatory submission",17,2,https://drive.google.com/file/d/1gGKAmHdCPvlPi7lJxE9PowQg2o_MJ3o_/view?usp=drivesdk,pd-production-100123,2025-08-12 00:32:06
19736_S0289_M1_smsr-01mar2021-31mar2021.pdf,PDF,PF-07302048 (BNT162b2) Reporting Period Summary Monthly Safety Report (SMSR) 4,2021-04-14,report,,M1,False,False,False,False,False,"european union reference date, covid-19 vaccine, monthly safety report, mrna vaccine, fda, worldwide medical and safety, pf-07302048, pharmaceutical, clinical trial, lipid nanoparticles, safety data, international birth date, centralized authorization, adverse events, confidential, bnt162b2, regulatory approval",17,4823,https://drive.google.com/file/d/10fjn-hmIgPlo1XhNgC4Jn20CkJCD4pj6/view?usp=drivesdk,pd-production-100123,2025-08-12 00:32:31
19736_S0243_M1_1571.pdf,PDF,"Monthly Safety Report for COVID-19 Vaccine (BNT162, PF-07302048)",2021-03-15,report,"Özlem Türeci, Neda Aghajani Memar",M1,False,False,False,False,False,"PF-07302048, monthly safety report, BioNTech, Mainz, Germany, pharmaceutical, clinical trial, FDA, COVID-19 vaccine, prophylactic immunization, BNT162, CBER, vaccine development, United States, data compliance, regulatory affairs, adverse events, Pfizer",17,3,https://drive.google.com/file/d/1E6StTryEynHVExBrajwpUY0agYJ_YvqU/view?usp=drivesdk,pd-production-100123,2025-08-12 00:32:37
125742_S7_M1_356h.pdf,PDF,Response to 8 June 2021 Clinical Information Request,2021-06-16,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"safety_data, regulatory_compliance, ireland, united_states, croatia, covid-19_vaccine, belgium, efficacy_data, bnt162, clinical_trial_response, pfizer_regulatory_affairs, comirnaty, fda_submission, germany, quality_control, manufacturing_information, global_distribution",17,6,https://drive.google.com/file/d/1PT03d5aSfCtxYdGwY5PKLnIy0tNcUbv8/view?usp=drivesdk,pd-production-100123,2025-08-12 00:32:45
19736_S0214_M1_1571.pdf,PDF,"Monthly Safety Report for COVID-19 Vaccine (BNT162, PF-07302048)",2021-02-15,report,"Özlem Türeci, Elisa Harkins",M1,False,False,False,False,False,"PF-07302048, monthly safety report, FOIA document, BioNTech, Mainz, Germany, clinical trial, FDA, COVID-19 vaccine, prophylactic immunization, BNT162, safety data, Collegeville, PA, vaccine development, pharmaceutical regulatory compliance, regulatory affairs, adverse events, Pfizer",17,3,https://drive.google.com/file/d/1I9rKnuJRqgzafE92EIEni-qpAC3Ty6Dd/view?usp=drivesdk,pd-production-100123,2025-08-12 00:32:51
125742_S76_M1_356h.pdf,PDF,Response to FDA 21 August 2021 Eighth Round of Comments on the Draft Package Insert for COMIRNATY,2021-08-21,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"pharmaceutical regulatory response, PF-07302048, clinical trial data, BioNTech, vaccine efficacy, FDA submission, COMIRNATY, vaccine release, vaccine quality, COVID-19 vaccine, BNT162, vaccine package insert, vaccine compliance, vaccine safety, vaccine testing, vaccine manufacturing, Pfizer",17,7,https://drive.google.com/file/d/16N7qRm0Btmi27CnOJp2JPbCwoBP4PYTH/view?usp=drivesdk,pd-production-100123,2025-08-12 00:32:59
19736_S0214_M1_smsr-01jan2021-31jan2021.pdf,PDF,PF-07302048 (BNT162b2) Reporting Period Summary Monthly Safety Report (SMSR),2021-02-12,report,,M1,False,False,False,False,False,"PF-07302048, regulatory approval, BioNTech, FOIA, European Union, clinical trial, lipid nanoparticles, FDA, SARS-CoV-2, mRNA, COVID-19, vaccine, adverse events, safety report, BNT162b2, Pfizer, monthly report",17,1917,https://drive.google.com/file/d/1RUOwHpxB-TF8wl7gBXbfa-Xuj7MT1IVO/view?usp=drivesdk,pd-production-100123,2025-08-12 00:33:12
125742_S72_M1_356h.pdf,PDF,"Letter of Authorization to Appoint US Agent for COVID-19 mRNA Vaccine (BNT162, PF-07302048)",2021-08-20,Letter,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"Pharmaceutical Manufacturing, PF-07302048, Vaccine Approval, US Agent Appointment, Immunization, Clinical Trials, BioNTech Manufacturing, COMIRNATY, Vaccine Production, COVID-19 mRNA Vaccine, Pharmacovigilance, SARS-CoV-2, BNT162, Regulatory Affairs, FDA Submission, Drug Product Testing, Pfizer Global Regulatory Affairs",17,7,https://drive.google.com/file/d/1pNyjOUALjZFxWiOHhjn0LB1-NZnrh3Mx/view?usp=drivesdk,pd-production-100123,2025-08-12 00:33:21
125742_S85_M1_356h.pdf,PDF,Provision of Structured Product Labeling (SPL) for the Final Package Insert for COMIRNATY,2021-08-26,Regulatory Submission,"Amit Patel, Ruben Rizzi",M1,False,False,False,False,False,"Vaccine Efficacy, Chesterfield, MO, BioNTech, Package Insert, Clinical Trials, COMIRNATY, Regulatory Submission, Vaccine Safety, Vaccine Manufacturing, Adverse Events, Regulatory Compliance, Kalamazoo, MI, FDA Submission, Structured Product Labeling, COVID-19 Vaccine, Puurs, Belgium, Pfizer",17,7,https://drive.google.com/file/d/1aBanIgSCqyNzKHuYiRuj-uDwsJCfUPhy/view?usp=drivesdk,pd-production-100123,2025-08-12 00:33:30
19736_S0185_M1_smsr-01dec2020-31dec2020.pdf,PDF,Summary Monthly Safety Report (SMSR) for BNT162b2 COVID-19 mRNA Vaccine,2021-01,report,,M1,False,False,False,False,False,"EU authorization, Pfizer-BioNTech, immunogenicity, regulatory approval, vaccine distribution, pharmacovigilance, confidential document, vaccine formulation, clinical trial, COVID-19 vaccine, mRNA vaccine, adverse events, vaccine administration, safety report, BNT162b2, vaccine storage, SARS-CoV-2 spike protein",17,378,https://drive.google.com/file/d/1x1bjxdwX_c6kJJiV76WD65W5kZF_XAxU/view?usp=drivesdk,pd-production-100123,2025-08-12 00:33:36
125742_S9_M1_356h.pdf,PDF,Response to 29 June 2021 Information Request regarding datasets,2021-07-02,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, PF-07302048, Pharmaceutical manufacturing, DMF 011793, COMIRNATY, DMF 10953, Data submission, BNT162, DMF 011321, IND 19736, DMF 012683, DMF 011820, DMF 15209, Regulatory compliance, DMF 9543",17,6,https://drive.google.com/file/d/1iCvd0kerciiUns4JPo40Urf8EspSG3qQ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:33:44
125742_S79_M1_356h.pdf,PDF,Provision of the Final Package Insert for COMIRNATY,2021-08-23,memo,"Ruben.Rizzi@biontech.de, Amit Patel, Amitkumar.Patel@pfizer",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, Andover, Massachusetts, Regulatory submission, Mainz, Germany, Pharmaceutical/clinical trial, COMIRNATY, New York, USA, Vaccine safety and efficacy, Kalamazoo, Michigan, Chesterfield, Missouri, FDA approval, IND 19736, Adverse event monitoring, Puurs, Belgium, Drug product manufacturing and testing",17,7,https://drive.google.com/file/d/1lE98fHzzFagT53LWEkaQJX_rWCf6clVE/view?usp=drivesdk,pd-production-100123,2025-08-12 00:33:53
125742_S82_M1_356h.pdf,PDF,Provision of Structured Product Labeling (SPL) for the Final Package Insert for COMIRNATY,2021-08-26,Regulatory submission,"Ruben.Rizzi@biontech.de, Amit Patel, Director, Pfizer Global Regulatory Affairs - Vaccines, Amitkumar.Patel@pfizer",M1,False,False,False,False,False,"Package insert, PF-07302048, Drug product testing, Vaccine efficacy, BioNTech, Regulatory submission, Structured Product Labeling (SPL), Vaccine approval, COMIRNATY, Vaccine safety, FDA, COVID-19 vaccine, BNT162, Vaccine compliance, Vaccine manufacturing, Clinical trials, Pfizer",17,7,https://drive.google.com/file/d/1qEmIOvxc61X_xxD6EiK9YbQpcz8uXWwt/view?usp=drivesdk,pd-production-100123,2025-08-12 00:34:02
125742_S71_M1_356h.pdf,PDF,Response to FDA 19 August 2021 IR for Study Completion Date and Final Report Submission Date for Study C4591014,2021-08-20,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Vaccine efficacy, FDA submission, Adverse events, Pharmaceutical/clinical trial, Study C4591014, COMIRNATY, Pfizer, Vaccine safety, BNT162, Compliance, Vaccine manufacturing",17,7,https://drive.google.com/file/d/1xJFZRhWysqzwZkBeCzTLyKtdzGCWC0k8/view?usp=drivesdk,pd-production-100123,2025-08-12 00:34:10
125742_S89_M1_356h.pdf,PDF,Request for Comments and Advice for Pfizer/BioNTech's Plan for Reporting Adverse Events,2021-09-07,memo,"Ruben.Rizzi@biontech.de, Amit Patel, Director, Pfizer Global Regulatory Affairs - Vaccines, Amitkumar.Patel@pfizer.com",M1,False,False,False,False,False,"vaccine manufacturing, Europe, vaccine efficacy, BioNTech, FDA submission, drug substance testing, clinical trial, COMIRNATY, COVID-19 vaccine, drug product testing, packaging, United States, vaccine safety, fill and finish, adverse event reporting, regulatory affairs, Pfizer",17,7,https://drive.google.com/file/d/153ZTx2vERKdbraApEwdwbbNGhWYrU-AY/view?usp=drivesdk,pd-production-100123,2025-08-12 00:34:19
19736_S0185_M1_1571.pdf,PDF,Investigational New Drug Application (IND),2022-03-01,form,,M1,False,True,False,True,False,"safety reporting, Exclusion, clinical trial, phase 3 trial, phase 2 trial, regulatory submission, sponsor information, pharmaceutical research, adverse event, investigational new drug application, quality assurance, medical device, drug development, protocol amendment, drug identification, fda regulation, Protocol, phase 1 trial, data management",19,3,https://drive.google.com/file/d/1oXuWrl1l5oVavEZoxOcqsbCf7mFRYT4z/view?usp=drivesdk,pd-production-100123,2025-08-12 00:34:22
125742_S80_M1_356h.pdf,PDF,Provision of the final Package Insert for COMIRNATY with addition of license number,2021-08-24,memo,"Ruben.Rizzi@biontech.de, Amit Patel, Amitkumar.Patel@pfizer",M1,False,False,False,False,False,"regulatory-submission, drug-product, covid-19-vaccine, compliance, package-insert, drug-substance, safety-data, comirnaty, quality-control, pfizer, biontech, efficacy-data, adverse-events, geographic-locations, clinical-trial, fda-approval, manufacturing",17,7,https://drive.google.com/file/d/1CEQW93yupJ7CxahfRv_rk5h9v5n4jTa-/view?usp=drivesdk,pd-production-100123,2025-08-12 00:34:30
125742_S75_M1_356h.pdf,PDF,Clinical Study Report for Investigational Drug [Redacted],2021,Report,"(b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (b) (6)",M1,False,False,False,False,False,"drug-identification, clinical-study-report, medical-research, regulatory-compliance, phase-3-study, pharmaceutical-development, clinical-trial, cber-review, safety-data, redacted-information, adverse-events, efficacy-data, united-states, fda-submission, data-analysis, investigational-drug, quality-assurance",17,7,https://drive.google.com/file/d/1rS_UGANeMgznAzQXLaVilT5d5-S-UcqS/view?usp=drivesdk,pd-production-100123,2025-08-12 00:34:35
125742_S74_M1_356h.pdf,PDF,Response to FDA 20 August 2021 Information Request Regarding Completion of Unsolicited Adverse Event Table,2021-08-20,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Unsolicited adverse events, Vaccine efficacy, Vaccine approval, Pharmaceutical/clinical trial, COMIRNATY, Pfizer, Vaccine safety, BNT162, Adverse event reporting, FDA information request, Vaccine manufacturing",17,7,https://drive.google.com/file/d/1twyALjCsARShqBhkXRh2VSgYGQiKi4Pb/view?usp=drivesdk,pd-production-100123,2025-08-12 00:34:44
125742_S77_M1_356h.pdf,PDF,Response to FDA 21 August IR regarding review and confirmation of the list of studies and dates for PMRs and PMCs,2021-08-21,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, COVID-19 vaccination, FOIA document, PF-07302048, Regulatory affairs, Immunization, Drug substance and product testing, FDA submission, Pharmaceutical/clinical trial, COMIRNATY, Post-marketing requirements (PMRs), Post-marketing commitments (PMCs), Manufacturing sites, SARS-CoV-2, BNT162, Compliance and quality, Vaccine development",17,7,https://drive.google.com/file/d/1JWfD97wY2SR9R2b_DZnVT2fmXVXIVtqw/view?usp=drivesdk,pd-production-100123,2025-08-12 00:34:52
125742_S73_M1_356h.pdf,PDF,Response to FDA 20 August 2021 Seventh Round of Comments on the Draft Package Insert for COMIRNATY,2021-08-20,memo,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, FOIA document, PF-07302048, quality control, BioNTech, FDA submission, Germany, COMIRNATY, Pfizer, vaccine development, Belgium, BNT162, drug product testing, United States, regulatory affairs, manufacturing, pharmaceutical/clinical trial",17,7,https://drive.google.com/file/d/1J_oYZ0_TCjPnvR5NNOa7cExu5hFv8wBF/view?usp=drivesdk,pd-production-100123,2025-08-12 00:35:01
19736_S0185_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) IND Summary Monthly Safety Report,2021-01-15,report,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"cber, covid-19-vaccine, vaccines, monthly-safety-report, pf-07302048, fda, clinical-trials, compliance, collegeville-pa, silver-spring-md, safety-data, global-product-development, bnt162, pfizer, ind-summary, regulatory-affairs, adverse-events",17,2,https://drive.google.com/file/d/1Vn2HnH6s2Y5yUNciJA-7gA1d3aKpLZiB/view?usp=drivesdk,pd-production-100123,2025-08-12 00:35:04
125742_S8_M1_356h.pdf,PDF,Response to 9 June 2021 Information Request - PREA,2021-06-17,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"regulatory-submission, covid-19-vaccine, quality-compliance, europe, response-to-information-request, safety-data, adverse-events, efficacy-data, drug-product-testing, prea-requirement, fda-review, pfizer-biontech, clinical-trial, united-states, vaccine-development, regulatory-affairs, manufacturing-information",17,6,https://drive.google.com/file/d/1ZnlLmdhVRJL3nJa6qjZNVHXvLznlykGX/view?usp=drivesdk,pd-production-100123,2025-08-12 00:35:13
125742_S70_M1_356h.pdf,PDF,Response to FDA 19 August 2021 Sixth Round of BLA PI Comments for COMIRNATY,2021-08-19,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, Vaccine composition and formulation, Vaccine distribution, FDA regulatory affairs, Pharmaceutical/clinical trial, BioNTech Manufacturing, COMIRNATY, Vaccine quality control, Vaccine administration, Vaccine safety and efficacy, Vaccine manufacturing, Vaccine development, Regulatory compliance, BLA submission, Pfizer Global Regulatory Affairs",17,7,https://drive.google.com/file/d/1B6LoSl6ngpyeh331Jt5ZQ5pd9u0zy2x2/view?usp=drivesdk,pd-production-100123,2025-08-12 00:35:21
19736_S0214_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 eCTD Sequence 0214 Serial No. 0213 IND Summary Monthly Safety Report,2021-02-15,report,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"benefit-risk-evaluation, covid-19-vaccine, ind-submission, collegeville-pa, fda-cber, ectd-sequence, silver-spring-md, global-product-development, adverse-events, pfizer, safety-report, virus-free-submission, regulatory-affairs, clinical-trial, monthly-report, biologics-evaluation-and-research, vaccine-research-and-review",17,2,https://drive.google.com/file/d/1M-kilybkbHjRYtTtFii_WxKTwq1kwYc2/view?usp=drivesdk,pd-production-100123,2025-08-12 00:35:25
125742_S78_M1_356h.pdf,PDF,Response to FDA 21 August 2021 Information Request Regarding Dear HCP Letter,2021-08-21,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"PF-07302048, SGS Lab, Fresenius Kabi, Clinical Trials, Pharmaceutical Regulatory Affairs, BioNTech, COMIRNATY, Pfizer, SARS-CoV-2, BNT162, Hospira, FDA Submission, Drug Product Testing, Manufacturing, COVID-19 Vaccine, Sterility Testing, Information Request",17,7,https://drive.google.com/file/d/1T85iXkIWxyEZkOuqW1uQow8n__dQ7HHv/view?usp=drivesdk,pd-production-100123,2025-08-12 00:35:34
125742_S57_M1_356h.pdf,PDF,Response to FDA 16 August 2021 Information Request Regarding Diluent Suppliers,2021-08-17,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, PF-07302048, Drug product testing, Regulatory submission, Pharmaceutical/clinical trial, Germany, COMIRNATY, Diluent suppliers, Drug product manufacturing, Belgium, BNT162, Compliance, United States, Quality control, FDA information request",17,7,https://drive.google.com/file/d/1t-BjC0SiDqYCtSZOERHRmmq_AISGBCYM/view?usp=drivesdk,pd-production-100123,2025-08-12 00:35:43
125742_S59_M1_356h.pdf,PDF,"COMIRNATY COVID-19 Vaccine (BNT162, PF-07302048) Regulatory Submission",2021-08-18,Regulatory Submission,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"Vaccine Approval, SARS-CoV-2 Vaccination, FDA Interaction, COMIRNATY, BioNTech Manufacturing, Andover PAI Response, Regulatory Submission, COVID-19 mRNA Vaccine, Vaccine Compliance, Vaccine Manufacturing, Vaccine Packaging, DMF References, Vaccine Efficacy and Safety, Vaccine Formulation, IND 19736, Drug Product Testing, Pfizer Global Regulatory Affairs",17,7,https://drive.google.com/file/d/1xZG7OZUUTmkMdlN8M96-KbrDG_rBDlGF/view?usp=drivesdk,pd-production-100123,2025-08-12 00:35:52
125742_S52_M1_356h.pdf,PDF,Response to FDA 13 August 2021 Information Request Regarding Safety-related Postmarketing Requirement/Postmarketing Commitment Studies,2021-08-14,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"FOIA document, Pharmaceutical clinical trial, PF-07302048, Regulatory affairs, BioNTech, FDA submission, SGS Lab, COMIRNATY, Postmarketing commitment, Pfizer, COVID-19 vaccine, BNT162, Vaccine manufacturing, Safety data, Hospira, Regulatory compliance, Postmarketing requirement",17,8,https://drive.google.com/file/d/121zOdrDeCHYc1JHjFGiw8YRxdbeJ6pp_/view?usp=drivesdk,pd-production-100123,2025-08-12 00:36:01
125742_S54_M1_356h.pdf,PDF,Response to FDA 16 August 2021 Information Request Regarding Carton and Container Labels,2021-08-17,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, COVID-19 vaccination, FOIA document, PF-07302048, Manufacturing and testing sites, Drug substance and product, Regulatory submission, Active immunization, Pharmaceutical/clinical trial, Carton and container labels, COMIRNATY, Quality compliance, Intramuscular administration, SARS-CoV-2, BNT162, FDA information request, Pfizer Global Regulatory Affairs",17,7,https://drive.google.com/file/d/1ZAoIh9ntkOQD4xqGcRUlFbq8vnxP208k/view?usp=drivesdk,pd-production-100123,2025-08-12 00:36:10
125742_S55_M1_356h.pdf,PDF,CMC Amendment Regarding 9-Month Shelf Life Extension for the Undiluted Drug Product at -90 to -60 C,2021-08-17,Regulatory submission,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, PF-07302048, COVID-19 vaccination, Regulatory affairs, BioNTech, Regulatory submission, COMIRNATY, Shelf life extension, FDA, SARS-CoV-2, BNT162, CMC amendment, IND 19736, Vaccine manufacturing, Pfizer, Pharmaceutical development",17,7,https://drive.google.com/file/d/1jomM-5iXLGZfhuBhbN9nN2MvjfG1cuGw/view?usp=drivesdk,pd-production-100123,2025-08-12 00:36:19
125742_S53_M1_356h.pdf,PDF,Response to FDA 13 August 2021 Information Request from the DMPQ Team Regarding Facilities,2021-08-17,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Chesterfield, MO, BioNTech, Regulatory submission, Pharmaceutical/clinical trial, Clondalkin, Ireland, COMIRNATY, Facilities and manufacturing, Sterility testing, BNT162, Kalamazoo, MI, FDA information request, Puurs, Belgium, Pfizer",17,7,https://drive.google.com/file/d/1mhCEDXPtoIOzT7fqLALFFZlBzmj3M4sQ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:36:27
125742_S60_M1_356h.pdf,PDF,Response to FDA 17 August 2021 Information Request Regarding Drug Substance and Drug Product,2021-08-18,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, FOIA document, Pharmaceutical clinical trial, PF-07302048, Regulatory affairs, Immunization, COMIRNATY, Manufacturing sites, SARS-CoV-2, BNT162, Vaccine testing, Quality control, Compliance, Drug substance, Drug product, FDA information request, Vaccine development",17,7,https://drive.google.com/file/d/1NlAiO98p4BbAUlJ9Hmmz1bM_7jiVWmAq/view?usp=drivesdk,pd-production-100123,2025-08-12 00:36:36
125742_S58_M1_356h.pdf,PDF,Response to FDA 17 August 2021 Fourth Round of BLA Prescribing Information Comments,2021-08-18,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, stability testing, COVID-19 vaccination, COMIRNATY, vaccine development, regulatory compliance, packaging, SARS-CoV-2, quality assurance, drug product formulation, fill and finish, manufacturing and testing sites, FDA review and comments, BLA submission, pharmaceutical/clinical trial",17,7,https://drive.google.com/file/d/1VoKzCXaqfahoJ4Ho4n8q4OvKvgqcTHNv/view?usp=drivesdk,pd-production-100123,2025-08-12 00:36:45
125742_S56_M1_356h.pdf,PDF,Information Request Regarding Implementing New Method for Endotoxin,2021-08-17,memo,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, DMF references, FOIA document, PF-07302048, Chesterfield, MO, drug substance and product testing, FDA submission, endotoxin testing, Clondalkin, Ireland, COMIRNATY, manufacturing sites, BNT162, Kalamazoo, MI, IND 19736, Puurs, Belgium, Pfizer Global Regulatory Affairs, pharmaceutical/clinical trial",17,7,https://drive.google.com/file/d/1vFUNZg6xDhJ15DQne6IsfSk62Ph8R1l0/view?usp=drivesdk,pd-production-100123,2025-08-12 00:36:54
125742_S63_M1_356h.pdf,PDF,Response to FDA 18 August 2021 Information Request Regarding DBSQC Comments,2021-08-19,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, SGS Lab, FDA submission, Fresenius Kabi, Pharmaceutical/clinical trial, COMIRNATY, Pfizer, Vaccine safety and efficacy, Sterility testing, BNT162, Hospira, Vaccine manufacturing",17,7,https://drive.google.com/file/d/1QcIEmbMzPQ8-479Gv2OCAnyP8fMTIVng/view?usp=drivesdk,pd-production-100123,2025-08-12 00:37:02
125742_S68_M1_356h.pdf,PDF,Fifth Round of BLA PI Comments for COMIRNATY,2021-08-19,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"Vaccine Approval, BioNTech, Clinical Trials, Packaging, IND and DMF References, COMIRNATY, Formulation, Compliance and Quality, Efficacy Data, Fill and Finish, Adverse Events, Regulatory Affairs, Drug Product Testing, Manufacturing, COVID-19 Vaccine, Pfizer, BLA Submission",17,7,https://drive.google.com/file/d/1dJpriQgvHEL_gjIF4FHRhazKSgraGkdV/view?usp=drivesdk,pd-production-100123,2025-08-12 00:37:11
125742_S50_M1_356h.pdf,PDF,"Response to FDA 13 August 2021 Information Request Regarding Test Methods, Lot Release Process, and Lot Release Protocol",2021-08-16,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,True,False,False,False,"Vaccine Approval, Vaccine Testing, Test Methods, Clinical Trials, BioNTech Manufacturing, COMIRNATY, FDA Interaction, Pharmaceutical Compliance, Regulatory Submission, Vaccine Packaging, Protocol, Vaccine Identification, Pfizer Manufacturing, Lot Release Process, Vaccine Formulation, Quality Control, COVID-19 Vaccine, Vaccine Development",18,8,https://drive.google.com/file/d/1eNvqgKBKTkxA7Q5rasOASeVimazmNFG3/view?usp=drivesdk,pd-production-100123,2025-08-12 00:37:20
125742_S6_M5_5314_vr-vtn-10436.pdf,PDF,SARS-CoV-2 Whole Genome Sequencing Data Collection and Analysis Guidelines,2021-06-04,protocol,,M5,False,False,False,False,False,"whole genome sequencing, workflow, PF-07302048, Illumina, quality control, bioinformatics, regulatory, FDA, lineage classification, SARS-CoV-2, Ion Torrent, COVID-19, guidelines, data repository, data collection, data analysis, clinical trials",17,11,https://drive.google.com/file/d/1dXjOc5jsC__8FYnWMyc7Ge3SH9ROQitc/view?usp=drivesdk,pd-production-100123,2025-08-12 00:37:24
125742_S67_M1_356h.pdf,PDF,Response to FDA 18 August 2021 Information Request for Graphic of BLA-Compliant Lots and Dear HCP Letter,2021-08-19,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, Regulatory affairs, SGS Lab, BioNTech, Pharmaceutical/clinical trial, COMIRNATY, Pfizer, Lot release, Sterility testing, Dear HCP letter, Compliance, Hospira, Vaccine manufacturing, FDA information request, BLA submission",17,7,https://drive.google.com/file/d/1xamqVkirVGKVon3AytgqdwSQsrvT4dYD/view?usp=drivesdk,pd-production-100123,2025-08-12 00:37:33
125742_S51_M1_356h.pdf,PDF,Response to FDA 13 August 2021 Third Round of BLA Prescribing Information Comments,2021-08-14,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, Active immunization, SARS-CoV-2 vaccination, Puurs, Belgium, Andover, Massachusetts, Pharmaceutical/clinical trial, COMIRNATY, Drug product manufacturing, Kalamazoo, Michigan, Intramuscular administration, Chesterfield, Missouri, Vaccine safety and efficacy data, FDA review and comments, Regulatory compliance, BLA submission",17,8,https://drive.google.com/file/d/1n_moY3tfM0AS_1E34ppj4GygKH_MBarg/view?usp=drivesdk,pd-production-100123,2025-08-12 00:37:44
125742_S62_M1_356h.pdf,PDF,Response to FDA 17 August 2021 Regarding Follow-up Comments Related to Safety-related Postmarketing Requirement/Postmarketing Commitment Studies,2021-08-18,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, Regulatory affairs, Drug product testing, Pharmaceutical/clinical trial, Germany, COMIRNATY, Ireland, Belgium, Croatia, Postmarketing requirement/commitment, Compliance, BioNTech Manufacturing GmbH, United States, Safety data, Vaccine manufacturing",17,7,https://drive.google.com/file/d/166YWVKiTiXYLYHUUYM1sUnAhAJgPEX5S/view?usp=drivesdk,pd-production-100123,2025-08-12 00:37:53
125742_S5_M3_requirements-travel-belgium.pdf,PDF,Travel Requirements for Pfizer Puurs Plant Visit,2021-04-19,memo,,M3,False,False,False,False,False,"quarantine-rules, pcr-test, international-business-travel, covid-19-travel-restrictions, regulatory-compliance, essential-sector-exemption, puurs-plant, belgium, site-visit-coordination, pfizer, passenger-locator-form, travel-requirements, document-instructions, employee-communication, bta-code, clinical-trial-logistics, pharmaceutical-operations",17,2,https://drive.google.com/file/d/1RxPMNybbITwUm-_orHYdGj9rv5CUvswr/view?usp=drivesdk,pd-production-100123,2025-08-12 00:37:56
125742_S6_M5_5351_c4591001-sequencing-report.pdf,PDF,BNT162b2 COVID-19 Case Strain Sequencing Report,2021-06-04,report,,M5,False,False,False,False,False,"scientific-terms, fda, compliance, confidential, sequencing, adverse-events, phase-2-3, vaccine, variants, efficacy, safety, clinical-trial, geographic-locations, data-analysis, covid-19, bnt162b2, regulatory",17,41,https://drive.google.com/file/d/1cxx1qQpUvxKaHE01ipWxTevNnf9qVSHx/view?usp=drivesdk,pd-production-100123,2025-08-12 00:38:01
125742_S61_M1_356h.pdf,PDF,Response to FDA 17 August 2021 Information Request Regarding Shelf Life and Date of Manufacture,2021-08-18,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Vaccine efficacy, Date of manufacture, Regulatory submission, Pharmaceutical/clinical trial, COMIRNATY, Vaccine safety, BNT162, Shelf life, Compliance, Global locations, FDA information request, Pfizer manufacturing, Vaccine development",17,7,https://drive.google.com/file/d/1A6fO1pGfHfMqEWEMSsOsu18ecG--uhmy/view?usp=drivesdk,pd-production-100123,2025-08-12 00:38:09
125742_S6_M1_356h.pdf,PDF,"COVID-19 mRNA Vaccine (nucleoside modified) COMIRNATY COVID-19 Vaccine (BNT162, PF-07302048) Liquid 30 mcg Intramuscular",2021-06-03,report,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Vaccine efficacy, Regulatory affairs, Vaccine packaging, BioNTech, COMIRNATY vaccine, Pfizer, Vaccine safety, Vaccine testing, Vaccine adverse events, Vaccine compliance, BNT162 vaccine, Clinical trial, Vaccine quality, Vaccine release, PF-07302048 vaccine, Vaccine manufacturing",17,6,https://drive.google.com/file/d/1pnHPogZGd0LOGTE5-g1VOe55lrz5E1uQ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:38:17
125742_S69_M1_356h.pdf,PDF,Response to FDA 19 August 2021 Information Request Regarding Safety-related Postmarketing Requirement/Postmarketing Commitment Studies,2021-08-19,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Immunization, FDA submission, Vaccine development, Pharmaceutical/clinical trial, COMIRNATY, SARS-CoV-2, BNT162, Postmarketing requirement/commitment, Safety data, Manufacturing, Pfizer",17,7,https://drive.google.com/file/d/1M6Ejv7dUZMUthcaEl7wzLLFUbi2qLIDd/view?usp=drivesdk,pd-production-100123,2025-08-12 00:38:26
125742_S64_M1_356h.pdf,PDF,Response to FDA 18 August 2021 Information Request Regarding Inclusion of Draft Carton and Container Labels in a Single Amendment,2021-08-19,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"drug-product, covid-19-vaccine, europe, labeling, safety-data, comirnaty, quality-control, pfizer, biontech, packaging, efficacy-data, regulatory-affairs, fda-submission, adverse-events, clinical-trial, united-states, manufacturing",17,7,https://drive.google.com/file/d/1icXP-9CNJ4vRUFaCGRIaSwDOLKVgoKA_/view?usp=drivesdk,pd-production-100123,2025-08-12 00:38:34
125742_S43_M1_356h.pdf,PDF,Response to FDA 05 August 2021 CMC Information Request (Related to 11 facilities questions),2021-08-07,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, FOIA document, PF-07302048, Vaccine formulation and packaging, Regulatory submission, Pharmaceutical/clinical trial, CMC (Chemistry, Manufacturing, and Controls), COMIRNATY, Kalamazoo, Michigan, Sterility testing, BNT162, Vaccine manufacturing facilities, Chesterfield, Missouri, FDA information request, Vaccine testing and release, Puurs, Belgium, Pfizer Global Regulatory Affairs",17,6,https://drive.google.com/file/d/1fzu7-vGS0GR8WWBWY_xpOaD2-jgc8nJz/view?usp=drivesdk,pd-production-100123,2025-08-12 00:38:43
125742_S31_M1_356h.pdf,PDF,Response to 28 July 2021 Information Request Regarding the Pharmacovigilance Plan,2021-08-03,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"Pfizer Global Regulatory Affairs - Vaccines, Vaccine Approval, Clinical Trials, FDA Interaction, COMIRNATY, COVID-19 mRNA Vaccine, Regulatory Submission, Manufacturing Sites, Adverse Events, Compliance, Pharmacovigilance Plan, IND 19736, Vaccine Identification, Drug Product Testing, Safety Data, Vaccine Development, Information Request",17,6,https://drive.google.com/file/d/1zDgd7WIMrVfdoRECOK7mcmqQ67TwU1eb/view?usp=drivesdk,pd-production-100123,2025-08-12 00:38:51
125742_S46_M1_356h.pdf,PDF,Response to FDA 09 August 2021 Draft COMIRNATY Vial and Carton Labels,2021-08-12,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, Drug product testing, DMF references, Pfizer Manufacturing Belgium NV, Regulatory submission, Hospira Zagrab Ltd., SGS Lab Simon SA, Pharmaceutical/clinical trial, COMIRNATY, Sterility testing, Collegeville, PA, BioNTech Manufacturing GmbH, Vial and carton labels, IND 19736, Kalamazoo, MI",17,6,https://drive.google.com/file/d/1Q05KWiehY6k-oyteJuIK1YKfIc5iA4TK/view?usp=drivesdk,pd-production-100123,2025-08-12 00:38:59
125742_S33_M1_356h.pdf,PDF,Response to 22 July 2021 and 03 August 2021 Information Request (efficacy 508 tables and SAS programs),2021-08-05,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, FOIA document, PF-07302048, Regulatory affairs, Vaccine distribution, Drug substance and product testing, Vaccine approval, Pharmaceutical/clinical trial, SAS programs, COMIRNATY, Efficacy data, Vaccine safety and efficacy, Manufacturing sites, BNT162, Compliance and quality, Vaccine development, Pfizer Global Regulatory Affairs",17,6,https://drive.google.com/file/d/1KDEFWcZmlOphpCDu5BHIoq2BH6vHm21D/view?usp=drivesdk,pd-production-100123,2025-08-12 00:39:07
125742_S4_M1_356h.pdf,PDF,Response to 18 May 2021 Information Request regarding datasets,2021-05-19,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Vaccine efficacy, FDA submission, Adverse events, Pharmaceutical/clinical trial, COMIRNATY, Pfizer, Vaccine safety, BNT162, Quality control, Global distribution, Vaccine manufacturing",17,6,https://drive.google.com/file/d/1nmUQCxyRmhHDqQylUmOMD8fDbdagIlWl/view?usp=drivesdk,pd-production-100123,2025-08-12 00:39:15
125742_S35_M1_356h.pdf,PDF,Response to FDA 04 August 2021 IR (CMC related questions regarding the potency assay for determination of IVE by flow cytometry),2021-08-06,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, IVE determination, FOIA document, PF-07302048, Potency assay, Regulatory submission, Pharmaceutical/clinical trial, CMC-related questions, COMIRNATY, BioNTech Manufacturing, BNT162, Compliance and quality, FDA inquiry response, Flow cytometry, Vaccine testing and release, Vaccine manufacturing, Pfizer Global Regulatory Affairs",17,6,https://drive.google.com/file/d/1wYTYYxA3bn80BVNVQVfR8SASr1aHkiKW/view?usp=drivesdk,pd-production-100123,2025-08-12 00:39:24
125742_S5_M3_guidelines-travel-red-zone-belgium.pdf,PDF,Guidelines for Business Travel from a Red Zone to Belgium,2021-05-23,guidelines,,M3,False,False,True,False,False,"bla-125742, pcr-test, covid-19-vaccine, fda, compliance, pf-07302048, quarantine, business-travel, belgium, cross-border-worker, bnt162, pfizer, safety, clinical-trial, travel-guidelines, red-zone, Exemption, regulatory",18,2,https://drive.google.com/file/d/1syfn_LKl-La2mUnpAhVcW2gawmeeDC43/view?usp=drivesdk,pd-production-100123,2025-08-12 00:39:27
125742_S37_M1_356h.pdf,PDF,Response to FDA 05 August Information Request (CMC related diluent queries),2021-08-07,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Diluent, BioNTech, Regulatory submission, Vaccine approval, CMC (Chemistry, Manufacturing, and Controls), COMIRNATY, Pfizer, Vaccine safety and efficacy, BNT162, Compliance and quality, Pharmaceutical/clinical trials, FDA information request, Vaccine manufacturing",17,6,https://drive.google.com/file/d/1zZ5EpEwGTV78av23Of0VvzbdhjZDGuyn/view?usp=drivesdk,pd-production-100123,2025-08-12 00:39:35
125742_S49_M1_356h.pdf,PDF,Response to FDA 13 August 2021 Information Request Regarding Duration of Follow-up in Study C4591001 (16+ Years of Age),2021-08-14,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, Pharmaceutical clinical trial, PF-07302048, Regulatory affairs, BioNTech, COMIRNATY, Pfizer, Vaccine safety and efficacy, Sterility testing, BNT162, SGS Lab Simon, Study C4591001, Hospira Zagreb, FDA information request, Vaccine manufacturing",17,8,https://drive.google.com/file/d/1813XuRZu1MuvsXa2v_P-uFCbCpTJy0H5/view?usp=drivesdk,pd-production-100123,2025-08-12 00:39:44
125742_S42_M1_356h.pdf,PDF,Response to FDA 04 August 2021 Information Request (CMC related comments on the lot release protocol template),2021-08-07,memo,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,True,False,False,False,"COVID-19 mRNA vaccine, Lot release protocol, FOIA document, PF-07302048, Regulatory affairs, BioNTech, FDA submission, Pharmaceutical/clinical trial, CMC (Chemistry, Manufacturing, and Controls), COMIRNATY, Pfizer, Vaccine testing, Sterility testing, BNT162, Protocol, Compliance, Quality assurance, Vaccine manufacturing",18,6,https://drive.google.com/file/d/1SO4LOEkSjCgKdIJcFXj_TiKvpfonx2s6/view?usp=drivesdk,pd-production-100123,2025-08-12 00:39:52
125742_S38_M1_356h.pdf,PDF,Response to FDA 22 July 2021 IR related to item 6 regarding provision of safety 508 compliant tables,2021-08-07,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"508 Compliance, Intramuscular Administration, Clinical Trials, BioNTech Manufacturing, COMIRNATY, COVID-19 Vaccination, SARS-CoV-2, Vaccine Packaging, Pfizer Manufacturing, Regulatory Affairs, FDA Submission, Drug Product Testing, Vaccine Formulation, Safety Data, COVID-19 Vaccine, Vaccine Development, Pharmaceutical Regulatory",17,6,https://drive.google.com/file/d/1aglFZmqs_9fgHn_C-Le0Rb6LXBz7wpWq/view?usp=drivesdk,pd-production-100123,2025-08-12 00:40:01
125742_S39_M1_356h.pdf,PDF,Response to FDA 05 August 2021 second round of BLA PI comments,2021-08-07,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, Manufacturing and testing sites, Immunization against SARS-CoV-2, Regulatory affairs, Vaccine clinical trials, FDA submission, COMIRNATY, Prescribing Information (PI) comments, Sterility testing, Pandemic response, Pharmacovigilance, BLA (Biologics License Application), Quality assurance, Drug substance and drug product, Regulatory compliance, Pharmaceutical development",17,6,https://drive.google.com/file/d/1jL8v4Ho5OiohCcRdwlBJ2wAu5hezur2N/view?usp=drivesdk,pd-production-100123,2025-08-12 00:40:10
125742_S32_M1_356h.pdf,PDF,Response to 02 August 2021 Information Request Regarding the Validation Report VR-MVR-10077,2021-08-05,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, Validation report, BioNTech, FDA submission, Pharmaceutical/clinical trial, Packaging, COMIRNATY, Formulation, Sterility testing, BNT162, Fill and finish, Manufacturing, Pfizer",17,6,https://drive.google.com/file/d/1EbvfT5MdqznOFTbvC7ng-2SUkoUX4_lH/view?usp=drivesdk,pd-production-100123,2025-08-12 00:40:18
125742_S45_M1_356h.pdf,PDF,Response to 09 August 2021 Information Request Regarding Sequencing Data,2021-08-11,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, Sequencing data, Drug product testing, Immunization, COVID-19 vaccination, Regulatory affairs, Pharmaceutical/clinical trial, COMIRNATY, Manufacturing sites, SARS-CoV-2, Compliance, Regulatory submissions, Quality assurance, Vaccine development, Information request response",17,6,https://drive.google.com/file/d/1sNRPosQkArawVEWrEchXXWOnDwHFSZCQ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:40:26
125742_S44_M1_356h.pdf,PDF,Response to FDA 10 August 2021 Information Request (CMC Testing Related),2021-08-11,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product formulation, FOIA document, PF-07302048, BioNTech, Regulatory submission, Pharmaceutical/clinical trial, CMC testing, COMIRNATY, Pfizer, Quality compliance, Sterility testing, BNT162, SGS Lab Simon, Hospira Zagreb, FDA information request, Vaccine manufacturing",17,6,https://drive.google.com/file/d/17KulInBKGiksd1eQu6pGkh2h24z1cT2N/view?usp=drivesdk,pd-production-100123,2025-08-12 00:40:35
125742_S36_M1_356h.pdf,PDF,Response to FDA 02 August 2021 CMC IR regarding validation of assay methods and lot release,2021-08-07,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, FDA response, FOIA document, PF-07302048, BioNTech, Regulatory submission, Pharmaceutical/clinical trial, Assay validation, COMIRNATY, Lot release, Germany, Belgium, BNT162, United States, Quality control, Manufacturing, Pfizer",17,6,https://drive.google.com/file/d/1axgz4YCNumTUAoNWN2MbC45wbL-A2gP8/view?usp=drivesdk,pd-production-100123,2025-08-12 00:40:44
125742_S34_M1_356h.pdf,PDF,Response to FDA 03 August 2021 Information Request (CMC related comments and requests for additional information),2021-08-06,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"PF-07302048, Vaccine Approval, Chemistry, Manufacturing, and Controls (CMC), COMIRNATY, BioNTech Manufacturing, Vaccine Compliance, FDA Information Request, Pharmaceutical Regulatory Submission, Vaccine Clinical Trials, BNT162, Vaccine Manufacturing, Vaccine Packaging, Vaccine Formulation, Vaccine Quality, COVID-19 Vaccine, Vaccine Testing, Pfizer Global Regulatory Affairs",17,6,https://drive.google.com/file/d/11IO-juQF5wiEjCLQ38ji5mofbgV-vW6O/view?usp=drivesdk,pd-production-100123,2025-08-12 00:40:51
125742_S3_M1_356h.pdf,PDF,Request for Proprietary Name Review,2021-05-19,form,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"regulatory-submission, manufacturing-sites, covid-19-vaccine, europe, vaccine-efficacy, vaccine-authorization, vaccine-compliance, pfizer, biontech, drug-product-testing, fda-review, vaccine-development, clinical-trial, vaccine-safety, vaccine-quality, united-states, proprietary-name-review",17,6,https://drive.google.com/file/d/1ZzkAjuACbMA49xrMWKEQWmailwkAsYoU/view?usp=drivesdk,pd-production-100123,2025-08-12 00:41:00
125742_S48_M1_356h.pdf,PDF,Response to FDA 06 August 2021 Information Request Regarding Measurement of Endotoxins,2021-08-13,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Regulatory submission, Manufacturing, Vaccine development, Pharmaceutical/clinical trial, Endotoxin measurement, COMIRNATY, Quality compliance, Geographic locations, BNT162, FDA information request, Pfizer",17,8,https://drive.google.com/file/d/1fQvjfwgqQlue1EL1udiuOycdtDYay9MZ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:41:09
125742_S30_M1_356h.pdf,PDF,Follow-Up Response to FDA 26 July CMC IR regarding manufacturing and equipment,2021-08-03,report,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, sterility testing, FOIA document, PF-07302048, quality control, BioNTech, drug product, FDA submission, COMIRNATY, Pfizer, global locations, BNT162, equipment, drug substance, regulatory affairs, manufacturing, pharmaceutical/clinical trial",17,6,https://drive.google.com/file/d/1HLVKqvH7labZfd3WBu6P8W2buE2VhsLM/view?usp=drivesdk,pd-production-100123,2025-08-12 00:41:18
125742_S40_M1_356h.pdf,PDF,Response to FDA 06 August 2021 CMC IR regarding drug product,2021-08-07,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, FDA response, FOIA document, PF-07302048, Drug product testing, BioNTech, Regulatory submission, Vaccine development, Pharmaceutical/clinical trial, Packaging, COMIRNATY, Drug product manufacturing, BNT162, Fill and finish, CMC information request, Formulation, Pfizer",17,6,https://drive.google.com/file/d/1cI_Oblq83okLavs21xiZmB-mAj5_slJq/view?usp=drivesdk,pd-production-100123,2025-08-12 00:41:26
125742_S47_M1_356h.pdf,PDF,Response to FDA 11 August 2021 Information Request Regarding the Saline Diluent,2021-08-13,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, COVID-19 vaccination, FOIA document, PF-07302048, Immunization, BioNTech, Regulatory submission, Vaccine development, Pharmaceutical/clinical trial, COMIRNATY, Pfizer, SARS-CoV-2, BNT162, Saline diluent, Quality control, FDA information request, Manufacturing",17,8,https://drive.google.com/file/d/1zku8reCrh5wARIbznmkDcQDpG9x-Ke9_/view?usp=drivesdk,pd-production-100123,2025-08-12 00:41:35
125742_S41_M1_356h.pdf,PDF,Response to 10 August 2021 Information Request Regarding Comments Received for the Postmarketing Safety Study(ies),2021-08-11,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, Regulatory affairs, Drug substance testing, Postmarketing safety study, COMIRNATY, Drug product manufacturing, Drug product release testing, Sterility testing, Compliance and quality, Pharmaceutical/clinical trials, BioNTech Manufacturing GmbH, Regulatory submissions, Adverse event monitoring, Vaccine development, Pharmaceutical manufacturing sites",17,6,https://drive.google.com/file/d/1CjjSjlJ1V_-xeOK_pbW-IhzUBu2RfDhi/view?usp=drivesdk,pd-production-100123,2025-08-12 00:41:43
125742_S5_M1_356h.pdf,PDF,Response to 20 May 2021 Information Request regarding facilities,2021-05-24,memo,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, DMF references, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Drug substance and product testing, Pharmaceutical/clinical trial, COMIRNATY, Pfizer, Facility information, Vaccine safety and efficacy, BNT162, Compliance and quality, Regulatory submissions, IND 19736, Vaccine manufacturing",17,6,https://drive.google.com/file/d/1vuSRcvliQnrul5myyYr3ix081y2aBnsd/view?usp=drivesdk,pd-production-100123,2025-08-12 00:41:51
125742_S19_M1_356h.pdf,PDF,"Response to 2 July 2021 Information Request - Chemistry, Manufacturing & Controls",2021-07-27,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, Pharmaceutical clinical trial, PF-07302048, BioNTech, Chemistry, Manufacturing & Controls, Regulatory submission, Vaccine approval, Vaccine efficacy, COMIRNATY, Pfizer, Vaccine safety, FDA, Sterility testing, BNT162, Vaccine manufacturing",17,6,https://drive.google.com/file/d/1gED04ad7zD2GCxZkGljwNHeGwuVU16fV/view?usp=drivesdk,pd-production-100123,2025-08-12 00:41:59
125742_S2_M1_356h.pdf,PDF,Application to Market a New or Abbreviated New Drug or Biologic for Human Use,2021-05-18,form,"Ruben.Rizzi@biontech.de, Elisa Harkins, Global Regulatory Lead, Pfizer Global Regulatory Affairs - Vaccines, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"clinical trial phases, abbreviated new drug application, drug/vaccine identification, pharmaceutical company, FDA regulation, rare disease designation, application form, product description, data types, new drug application, biologics license application, orphan drug designation, technical/scientific terminology, adverse event reporting, geographic location, compliance and quality, regulatory submission",17,6,https://drive.google.com/file/d/1jKX0NaugthQhOI9o1zdI9ljSGFdXuAC9/view?usp=drivesdk,pd-production-100123,2025-08-12 00:42:03
125742_S17_M1_356h.pdf,PDF,Response to FDA's 09 July 2021 Information Request Regarding the validation of RNA integrity by the capillary gel electrophoresis (CGE) method,2021-07-22,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Manufacturing, Vaccine development, Pharmaceutical/clinical trial, COMIRNATY, Capillary gel electrophoresis, RNA integrity validation, BNT162, Compliance, Quality assurance, FDA information request, Pfizer",17,6,https://drive.google.com/file/d/1lpkD0DOc0DugGmCLYTtQtDtpLJKXSc0o/view?usp=drivesdk,pd-production-100123,2025-08-12 00:42:11
125742_S2_M1_environmental-analysis.pdf,PDF,Environmental Analysis for Investigational New Drug Submission,2021-03-15,report,"(b) (6), (b) (6), (b) (6), (b) (6)",M1,False,False,False,False,False,"gmp, cber, ectd, regulatory-compliance, stability-testing, pharmaceutical-development, clinical-trial, environmental-analysis, safety-data, adverse-events, efficacy-data, united-states, fda-submission, investigational-new-drug, 2021, vaccine-research, quality-assurance",17,1,https://drive.google.com/file/d/1P1eOLGAYmpAcD9XJD_jKWgwFWwMpq5UJ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:42:16
125742_S18_M1_356h.pdf,PDF,Response to 22 July 2021 Information Request regarding clinical study shell tables for study C4591001,2021-07-26,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"quality control, BioNTech, manufacturing, Germany, clinical trial, COMIRNATY, Ireland, FDA, COVID-19 vaccine, safety data, Belgium, Croatia, United States, efficacy data, adverse events, Pfizer, regulatory submission",17,6,https://drive.google.com/file/d/13yrz9Jg2ilkaR7wdg1IjPz0DQCipLXWr/view?usp=drivesdk,pd-production-100123,2025-08-12 00:42:24
125742_S29_M1_356h.pdf,PDF,Preliminary requested changes and comments on the draft Package Insert for COMIRNATY,2021-08-02,memo,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Package insert, FOIA document, Regulatory affairs, Drug product testing, BioNTech, Active immunization, FDA submission, COVID-19 vaccination, Pharmaceutical/clinical trial, COMIRNATY, Intramuscular administration, SARS-CoV-2, Collegeville, PA, Kalamazoo, MI, Vaccine manufacturing, Pfizer",17,6,https://drive.google.com/file/d/1E8Omn5n9gSpLT_3mtaBDYkMlsxmaUCuw/view?usp=drivesdk,pd-production-100123,2025-08-12 00:42:32
125742_S2_M5_5.4_who-2019.pdf,PDF,WHO Guidelines on Nonclinical Evaluation of Vaccines,2005,guideline,,M5,False,True,False,False,False,"nonclinical evaluation, delivery devices, regulatory expectations, toxicity assessment, quality assessment, WHO guidelines, preclinical testing, product characterization, vaccine development, Protocol, regulatory guidance, excipients, clinical trials, immunogenicity studies, infectious disease prevention, adjuvants, novel vaccines, biotechnology",18,33,https://drive.google.com/file/d/15YYW3dKdQAQVpLlLfj10BvxLLKuvTxZs/view?usp=drivesdk,pd-production-100123,2025-08-12 00:42:35
125742_S26_M1_356h.pdf,PDF,"Response to U.S. Food and Drug Administration (FDA) FORM FDA 483, Issued on 23 July 2021 for Pfizer Andover facility",2021-08-02,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, FOIA document, PF-07302048, Pfizer manufacturing facilities, Pharmaceutical quality control, Drug substance and product testing, COMIRNATY, Vaccine safety and efficacy, BNT162, Vaccine production and testing, Pharmaceutical/clinical trials, Adverse event reporting, Regulatory submissions, Vaccine distribution and supply chain, Global regulatory affairs, Regulatory compliance, FDA regulatory response",17,6,https://drive.google.com/file/d/1-rrSXB5tY-PEkTmSNl11Skjtpw5MsanM/view?usp=drivesdk,pd-production-100123,2025-08-12 00:42:43
125742_S2_M5_5.4_singh-dk-2020.pdf,PDF,"SARS-CoV-2 infection leads to acute infection with dynamic cellular and inflammatory flux in the lung that varies across nonhuman primate species"",","2020-06-05"",",document,,M5,False,False,False,False,False,"FOIA-document, 2020, needs-review",3,88,https://drive.google.com/file/d/1D5dDahATxxtYV5vxHc8Yc4ZfLIn69lcH/view?usp=drivesdk,pd-production-100123,2025-08-12 00:42:51
125742_S24_M1_356h.pdf,PDF,Response to 27 July 2021 Information Request Regarding Assessment of Vaccine Effectiveness,2021-07-29,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Pharmaceutical/clinical trial, Packaging, COMIRNATY, Formulation, COVID-19 vaccine, Sterility testing, BNT162, Fill and finish, Compliance, Manufacturing, Pfizer, Vaccine effectiveness",17,6,https://drive.google.com/file/d/1V-gWSb-DrJf7B561F7YIHwR3kbNIidoj/view?usp=drivesdk,pd-production-100123,2025-08-12 00:42:59
125742_S2_M5_5.4_who-2005.pdf,PDF,WHO Guidelines on Nonclinical Evaluation of Vaccines,2005,guideline,,M5,False,True,False,False,False,"safety evaluation, nonclinical evaluation, delivery devices, novel vaccine technologies, toxicity assessment, quality assessment, biotechnology advancements, WHO guidelines, preclinical testing, product characterization, vaccine development, Protocol, regulatory guidance, excipients, immunogenicity studies, infectious disease prevention, adjuvants, regulatory expectations",18,33,https://drive.google.com/file/d/1SL_wI2DQkWFmt9j-RyCg0LAT1dl4qpVM/view?usp=drivesdk,pd-production-100123,2025-08-12 00:43:02
125742_S15_M1_356h.pdf,PDF,Response to 16 July 2021 Information Request regarding lot release,2021-07-20,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Vaccine development, Pharmaceutical/clinical trial, Packaging, COMIRNATY, Lot release, Formulation, BNT162, Fill and finish, Compliance, Manufacturing, Pfizer",17,6,https://drive.google.com/file/d/1beKtl7LCTTj-YBs-FJ7y5uEyWCGm0EnE/view?usp=drivesdk,pd-production-100123,2025-08-12 00:43:10
125742_S21_M1_356h.pdf,PDF,"Response to 13 July 2021 Information Request Regarding CBER Request to Add Myocarditis and Pericarditis to the PVP"",","2021-07-28"",",document,,M1,False,False,False,False,False,"FOIA-document, needs-review",2,6,https://drive.google.com/file/d/1vOEXhtEQ7G8Asiw25uhIxFa8VgSPzf51/view?usp=drivesdk,pd-production-100123,2025-08-12 00:43:19
125742_S28_M1_356h.pdf,PDF,Follow up Response to 22 July 2021 Information Request,2021-08-02,report,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Elisa Harkins Tull",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, SGS Lab, FDA submission, Pharmaceutical/clinical trial, COMIRNATY, Pfizer, Vaccine safety and efficacy, Sterility testing, BNT162, Compliance and quality, Hospira, Vaccine manufacturing",17,6,https://drive.google.com/file/d/1oQMDiENMkYM61angAy9gFyexGbFO9IHh/view?usp=drivesdk,pd-production-100123,2025-08-12 00:43:27
125742_S25_M1_356h.pdf,PDF,Response to 26 July 2021 Information Request Regarding Manufacturing and Equipment,2021-07-29,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"regulatory-submission, fill-and-finish, covid-19-vaccine, fda-response, europe, compliance, comirnaty, equipment, pfizer, biontech, quality-control, drug-product-testing, packaging, united-states, inda, manufacturing, dmf",17,6,https://drive.google.com/file/d/1UVZ-lIqZ_FLkpm84tBMo3f9X1SvcIy5W/view?usp=drivesdk,pd-production-100123,2025-08-12 00:43:36
125742_S16_M1_356h.pdf,PDF,Response to 15 July 2021 Information Request regarding PREA post-marketing commitment goal dates,2021-07-22,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, PF-07302048, Regulatory affairs, Drug substance testing, Drug product testing, PREA post-marketing commitment, FDA submission, Pharmaceutical/clinical trial, COMIRNATY, Drug product manufacturing, Sterility testing, BNT162, Compliance, Pharmaceutical organizations, Vaccine development",17,6,https://drive.google.com/file/d/1oYUql6Gbbm2HVXijyHcPXecPMjbEFfai/view?usp=drivesdk,pd-production-100123,2025-08-12 00:43:44
125742_S22_M1_356h.pdf,PDF,Response to 16 July 2021 Information Request Regarding Sterility Methods and Endotoxin Test,2021-07-30,report,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Endotoxin test, COVID-19 vaccination, Vaccine development, Pharmaceutical/clinical trial, COMIRNATY, Sterility methods, Intramuscular administration, SARS-CoV-2, BNT162, Manufacturing, Pfizer",17,6,https://drive.google.com/file/d/16gvVrwF9kiQ-RzHWb2fl5qubXL23DGQY/view?usp=drivesdk,pd-production-100123,2025-08-12 00:43:52
125742_S20_M1_356h.pdf,PDF,Follow-up Response to 22 July 2021 Information Request regarding clinical study shell tables for study C4591001,2021-07-27,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, Pharmaceutical clinical trial, FDA regulatory submission, Manufacturing and testing sites, Active immunization, SARS-CoV-2 vaccination, COMIRNATY vaccine, Intramuscular administration, DMF 012683, DMF 9543, DMF 15209, DMF 011793, DMF 011820, DMF 011321, DMF 10953, Follow-up response, Liquid formulation, BNT162 vaccine, IND 19736, PF-07302048 vaccine, COVID-19 disease",17,6,https://drive.google.com/file/d/1Mo-KLBIFE5XYRDbu6gu5g0yYyudDmPhh/view?usp=drivesdk,pd-production-100123,2025-08-12 00:44:01
125742_S27_M1_356h.pdf,PDF,"Response to 29 July 2021 Information Request for COMIRNATY COVID-19 Vaccine (BNT162, PF-07302048)",2021-08-02,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"Adverse events, Drug product testing, FOIA document, Pharmaceutical clinical trial, PF-07302048, Regulatory affairs, BioNTech, FDA submission, Vaccine development, Immunization, COMIRNATY, COVID-19 vaccine, SARS-CoV-2, BNT162, Safety data, Manufacturing, Pfizer",17,6,https://drive.google.com/file/d/1zglJzTnhXiFzFRKZSZDxqX2I5a88bJ43/view?usp=drivesdk,pd-production-100123,2025-08-12 00:44:09
125742_S14_M1_356h.pdf,PDF,"COMIRNATY COVID-19 Vaccine (BNT162, PF-07302048) Regulatory Submission",2021-07-19,Regulatory Submission,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"PF-07302048, Vaccine Efficacy, BioNTech, Drug Substance Testing, Manufacturing, COMIRNATY, Regulatory Submission, FDA Approval, Vaccine Safety, BNT162, Adverse Events, Vaccine Formulation, Sterility Testing, Drug Product Testing, Intramuscular Administration, COVID-19 Vaccine, Pfizer",17,6,https://drive.google.com/file/d/11Kk4_RXxpMtppX9omtCBJvMnZ2eMqhhF/view?usp=drivesdk,pd-production-100123,2025-08-12 00:44:17
125742_S2_M5_5.4_sedic-m-2020.pdf,PDF,Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey,2020-01-01,report,"Maja Sedic, Joseph J. Senn, Andy Lynn, Michael Laska, Mike Smith, Stefan J. Platz, Joseph Bolen, Stephen Hoge, Alex Bulychev, Eric Jacquinet, Victoria Bartlett, Peter F. Smith",M5,False,False,False,False,False,"safety-evaluation, lipid-nanoparticle, protein-expression, pharmaceutical-pathobiology, regulatory-compliance, exaggerated-pharmacology, drug-discovery, sprague-dawley-rat, foia-document, toxicology, intravenous-infusion, preclinical-studies, hematology, pharmacokinetics, modified-mrna, pharmacology, cynomolgus-monkey",17,14,https://drive.google.com/file/d/1b9mRP555e6rgzA-LEKoiV0pz2WuaZs7M/view?usp=drivesdk,pd-production-100123,2025-08-12 00:44:22
125742_S23_M1_356h.pdf,PDF,Response to 26 July 2021 Information Request Regarding Disposition of Participants in Safety Populations who Experienced Pregnancy,2021-07-29,memo,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com, Neda Aghajani Memar, neda.aghajanimemar@pfizer.com",M1,False,False,False,False,False,"Drug product testing, FOIA document, Pharmaceutical clinical trial, PF-07302048, Puurs, Belgium, Andover, Massachusetts, Participant safety, COMIRNATY, Kalamazoo, Michigan, COVID-19 vaccine, BNT162, IND 19736, FDA information request, Regulatory compliance, Vaccine manufacturing, Pfizer Global Regulatory Affairs, Pregnancy outcomes",17,6,https://drive.google.com/file/d/16B_tpDU0HvEVo1nuaeZ1bQdjvYNGufdt/view?usp=drivesdk,pd-production-100123,2025-08-12 00:44:31
125742_S1_M5_5351_c4591001-fa-interim-investigators.pdf,PDF,"C4591001 Interim Investigators List"",","2020-11-19"",",document,,M5,False,False,False,False,False,"FOIA-document, needs-review",2,81,https://drive.google.com/file/d/1_clSc4zVHgQQnBtaQ2INBeb57F6yzI6t/view?usp=drivesdk,pd-production-100123,2025-08-12 00:44:36
125742_S1_M5_5351_bnt162-01-interim3-reports.pdf,PDF,Neutralizing Antibody Titer and SARS-CoV-2 RBD-Specific Antibody Concentration in Serum from Participants in the BNT162 Trial,2020-11-29,report,"Anders Goldgrube, Alexander Muik","M3, M5",False,False,False,False,False,"safety assessment, binding antibody, neutralizing antibody, pharmaceutical research, BNT162b, Germany, clinical trial, virus neutralization, FDA, vaccine development, SARS-CoV-2, antibody concentration, interim report, BNT162 vaccine, confidentiality, data analysis, regulatory submission",17,524,https://drive.google.com/file/d/1cGm3Cv_viqpjPjAHeL_nrHEEePU_Q92v/view?usp=drivesdk,pd-production-100123,2025-08-12 00:44:47
125742_S1_M5_5351_c4591001-interim-mth6-investigators.pdf,PDF,"C4591001 Interim Month 6 Investigators List"",","2021-03-19"",",document,,M5,False,False,False,False,False,"FOIA-document, needs-review",2,91,https://drive.google.com/file/d/153ISycK1NyXRwMeh8uizLEUeyhJViFoH/view?usp=drivesdk,pd-production-100123,2025-08-12 00:44:53
125742_S136_M1_356h.pdf,PDF,Monthly Safety Report - 01SEP2021-30SEP2021,2021-10-15,report,"Ruben.Rizzi@biontech.de, Amit Patel, Amitkumar.Patel@pfizer.com",M1,False,False,False,False,False,"covid-19 vaccine, monthly safety report, clinical trial data, sars-cov-2 vaccination, europe, biontech manufacturing, pfizer global regulatory affairs, adverse event monitoring, manufacturing sites, vaccine development, quality assurance, comirnaty vaccine, fda submission, united states, pharmaceutical industry, drug product testing, regulatory compliance",17,7,https://drive.google.com/file/d/1S0ADbf_n8I_z09kSSxWBaYDPqWy-t1qv/view?usp=drivesdk,pd-production-100123,2025-08-12 00:45:01
125742_S102_M1_356h.pdf,PDF,Request for a Waiver - Lot Distribution Reports (LDR),2021-09-14,Request,"Ruben.Rizzi@biontech.de, Amit Patel, Amitkumar.Patel@pfizer.com, Amit Patel, Paul Lucas, Anthony Giessert",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Lot distribution reports, Regulatory affairs, BioNTech, Fresenius Kabi, FDA submission, COMIRNATY, Diluent production, Pfizer, BNT162, Pharmaceutical/clinical trials, Compliance, Hospira, Vaccine manufacturing",17,7,https://drive.google.com/file/d/1q7_6FiZvhJH5xT0h4Nj331MDIIurHL24/view?usp=drivesdk,pd-production-100123,2025-08-12 00:45:10
125742_S12_M1_356h.pdf,PDF,Response to 13 July 2021 Information Request regarding preservative-free multi-dose vial,2021-07-15,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Preservative-free multi-dose vial, FDA submission, Pharmaceutical/clinical trial, COMIRNATY, Pfizer, Vaccine safety and efficacy, Sterility testing, BNT162, SGS Lab Simon, Hospira Zagreb, Vaccine manufacturing",17,6,https://drive.google.com/file/d/1AaakEBdcBG7pgZ2A7RhugHowJcE3cfhl/view?usp=drivesdk,pd-production-100123,2025-08-12 00:45:19
125742_S112_M1_356h.pdf,PDF,"Correction to Drug Substance Documents for COVID-19 mRNA Vaccine (BNT162, PF-07302048)",2021-09-16,Regulatory Submission,"Ruben Rizzi, Amit Patel, Amitkumar Patel, Paul Lucas, Anthony Giessert",M1,False,False,False,False,False,"PF-07302048, Fresenius Kabi, Diluent, BioNTech, Drug Substance, COMIRNATY, Regulatory Submission, COVID-19 mRNA Vaccine, FDA, BNT162, Compliance, Testing, Hospira, Sterility, Manufacturing, Pfizer, Drug Product",17,7,https://drive.google.com/file/d/1zb8SRNtFcFvBcQlikr--B73VRHxl-IoB/view?usp=drivesdk,pd-production-100123,2025-08-12 00:45:27
125742_S105_M1_356h.pdf,PDF,Request for Comments and Advice – Biologic Product Deviation Reports (BPDRs),2021-09-14,memo,"Ruben.Rizzi@biontech.de, Amit Patel, Director, Pfizer Global Regulatory Affairs - Vaccines, Amitkumar.Patel@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, Regulatory affairs, BioNTech, Pharmaceutical/clinical trial, COMIRNATY, Pfizer, FDA, Biologic Product Deviation Reports (BPDRs), BNT162, IND 19736, DMF 012683, DMF 15209, Vaccine manufacturing, DMF 9543",17,7,https://drive.google.com/file/d/1XL-eXaMpAat3btGJyuB6f_zOHAY83-02/view?usp=drivesdk,pd-production-100123,2025-08-12 00:45:37
125742_S113_M1_356h.pdf,PDF,Submission Notification of Final C4591007 Substudy Protocols to IND 19736,2021-09-21,Submission,"Ruben.Rizzi@biontech.de, Amit Patel, Director, Pfizer Global Regulatory Affairs - Vaccines, Amitkumar.Patel@pfizer.com",M1,False,True,False,False,False,"COVID-19 mRNA vaccine, Drug product testing, FOIA document, PF-07302048, BioNTech, Regulatory submission, SGS Lab Simon SA, Vaccine clinical trial, Pharmaceutical/clinical trial, COMIRNATY, Pfizer, Sterility testing, BNT162, Protocol, Hospira Zagreb, FDA approval, IND 19736, Vaccine manufacturing",18,7,https://drive.google.com/file/d/1bI5wbJws7UR-40Hw_50zoSZVbTNtPtI9/view?usp=drivesdk,pd-production-100123,2025-08-12 00:45:45
125742_S11_M1_356h.pdf,PDF,"Response to Information Requests regarding COVID-19 mRNA Vaccine (BNT162, PF-07302048) Lot Release Protocols, Samples and Reagents",2021-07-09,Response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,True,False,False,False,"PF-07302048, Vaccine Efficacy, BioNTech, Clinical Trials, Lot Release Protocols, COMIRNATY, Samples and Reagents, COVID-19 mRNA Vaccine, Vaccine Safety, BNT162, Protocol, Compliance, Regulatory Affairs, FDA Submission, Quality Assurance, Manufacturing, Vaccine Development, Pfizer",18,6,https://drive.google.com/file/d/1afUpmsnPBBDCHvIQofn0iXXwKmpHN9tf/view?usp=drivesdk,pd-production-100123,2025-08-12 00:45:53
125742_S1_M5_5351_c4591001-fa-interim-interlab-standard.pdf,PDF,Interim Inter-laboratory Standard for C4591001 Vaccine Clinical Trial,2020-09-29,report,,M5,False,False,False,False,False,"FOIA document, pharmaceutical research, clinical trial phases, FDA submission, clinical trial, project management, inter-laboratory standard, vaccine development, safety data, quality assurance, interim report, C4591001 vaccine, biostatistics, efficacy data, adverse events, data analysis, regulatory compliance",17,22,https://drive.google.com/file/d/11-tbC3jOo3LHpqubrng65LhLOTyrmSyI/view?usp=drivesdk,pd-production-100123,2025-08-12 00:45:57
125742_S10_M1_356h.pdf,PDF,Response to 29 June 2021 Information Request regarding BNT162-01 Interim Report 3,2021-07-02,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, Pfizer Global Regulatory Affairs - Vaccines, FOIA document, FDA regulatory submission, Pfizer Manufacturing Belgium NV, Hospira Zagrab Ltd., SGS Lab Simon SA, drug product formulation and testing, Germany, COMIRNATY, Belgium, Croatia, BioNTech Manufacturing GmbH, United States, safety and efficacy data, BNT162-01 clinical trial, pharmaceutical/clinical trial",17,6,https://drive.google.com/file/d/1OtXWsZGGxI0LKbluHqIUJg0WBPAphdVR/view?usp=drivesdk,pd-production-100123,2025-08-12 00:46:06
125742_S13_M1_356h.pdf,PDF,Response to 6 July 2021 Information Request regarding HIV Cohort,2021-07-16,response,"Ruben.Rizzi@biontech.de, Elisa Harkins, Elisa.HarkinsTull@pfizer.com",M1,False,False,False,False,False,"COVID-19 mRNA vaccine, vaccine manufacturing, FOIA document, PF-07302048, quality control, FDA submission, COMIRNATY, global locations, vaccine development, safety data, BNT162, immunization, efficacy data, regulatory affairs, adverse events, drug product testing, pharmaceutical/clinical trial",17,6,https://drive.google.com/file/d/1SIIpulLNG8uDJdjXdQbM-jTRdzfuWQpK/view?usp=drivesdk,pd-production-100123,2025-08-12 00:46:14
125742_S1_M1_meeting-correspondence.pdf,PDF,BNT162b2 Module 1.6.3 Correspondence Regarding Meetings,2020,Correspondence,"Pfizer, FDA",M1,False,False,False,False,False,"CMC and Facilities Information, Vaccine Development, Nonclinical Study Data, Proprietary Name Review, Phase 1/2/3 Clinical Study, Licensure Submissions, BNT162b2 Vaccine, FDA Regulatory Interactions, Pharmaceutical Correspondence, Confidential Document, CRMTS Meeting Tracking, COVID-19 Pandemic Response, Clinical Trial Meetings, Emergency Use Authorization, Toxicology Packages, Absorption Disposition Metabolism Excretion, Regulatory Submissions",17,636,https://drive.google.com/file/d/1l1bY3SE-5pwbf-P3fWlKL91BLOQE1Fmw/view?usp=drivesdk,pd-production-100123,2025-08-12 00:46:23
125742_S0136_M5_smsr-01sep2021-30sep2021.pdf,PDF,Summary Monthly Safety Report (SMSR) for COVID-19 mRNA Vaccine (BNT162b2),2021-10-14,report,,M5,False,False,False,False,False,"Monthly safety report, Dosing information, Pfizer-BioNTech, Regulatory submission, Reporting period, Vaccine safety, COVID-19 vaccine, mRNA vaccine, Regulatory agencies, Clinical trial data, Adverse event monitoring, Comirnaty, Vaccine composition, Centralized authorization, Confidential document, BNT162b2, Pharmaceutical development",17,13261,https://drive.google.com/file/d/1r9kXbXD2a8y71QRsgPNob0_8j4Sozx4J/view?usp=drivesdk,pd-production-100123,2025-08-12 00:46:36
019736_S70_M1_cover.pdf,PDF,Response to FDA 29 July 2020 Information Request - Clinical Assay Qualification,2020-08-25,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"Center for Biologics Evaluation and Research, PF-07302048, antibody quantitation, BioNTech, FDA submission, Global Regulatory Affairs, assay qualification, clinical trial, information request, virus neutralization, data compliance, vaccine development, BNT162, COVID-19, Collegeville, PA, regulatory affairs, Pfizer",17,2,https://drive.google.com/file/d/1Jj43V807xv1-Nsk2bufoKQe32NhYE8lq/view?usp=drivesdk,pd-production-100123,2025-08-12 00:46:39
019736_S488_M5_c4591007-p2-3-parent-icd-pbo-controlled-selected-dose-track.pdf,PDF,Phase 2/3 Placebo-Controlled Selected Dose Study Informed Consent Document,2021-09-13,Informed Consent Document,Study Doctor,M5,False,True,False,False,False,"protocol C4591007, informed consent, clinical trial, Pfizer, FDA, data management, safety data, placebo-controlled, Protocol, pediatric study, patient enrollment, global study, selected dose, efficacy data, medical terminology, adverse events, phase 2/3 study, regulatory compliance",18,31,https://drive.google.com/file/d/1w90Uh8CYyYLMQNHiP-A7vbF40OHx69MZ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:46:43
019736_S70_M5_vr-tm-10294.pdf,PDF,Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-2 RBD Protein in Human Serum,2020,protocol,,M5,False,False,False,False,False,"diagnostic testing, antibody quantitation, vaccine research, RBD protein, serum analysis, Luminex assay, quality control, Pearl River, NY, pharmaceutical development, clinical trial, data analysis, SARS-CoV-2, COVID-19, method validation, Pfizer, IgG antibodies, regulatory compliance",17,19,https://drive.google.com/file/d/1wbEvfmdD7-sfmHwWh5ZUiS14KESLHwL0/view?usp=drivesdk,pd-production-100123,2025-08-12 00:46:47
019736_S70_M5_vr-mqr-10211-10212-pq.pdf,PDF,SARS-CoV-2 dLIA Precision Qualification Data for Documentation re VR-MQR-10211 and VR-MQR-10212,2020-08-18,report,,M5,False,False,False,False,False,"Clinical Trials, Data Analysis, Precision Qualification, Diagnostic Testing, Confidential, VR-MQR-10212, Immunoassay, Pharmaceutical, SARS-CoV-2, FOIA Document, VR-MQR-10211, dLIA, Regulatory Compliance, Quality Assurance, FDA Submission, Vaccine Development, Pfizer",17,27,https://drive.google.com/file/d/1fN8K1zS8JaNZgl-w0BCpujOwAp4ZzzKb/view?usp=drivesdk,pd-production-100123,2025-08-12 00:46:51
019736_S70_M5_vr-mqr-10214-att02.pdf,PDF,QCS Data Listing,2020-07-28,data,,M5,False,False,False,False,False,"pearl-river, data-listing, pharmaceutical-research, quality-control-sample, pf-07302048, fda-submission, regulatory-compliance, new-york, vaccine-identifier, pfizer, titer-data, vaccine-development, clinical-trial, data-analysis, vaccine-research, quality-assurance, confidential-document",17,6,https://drive.google.com/file/d/1qn9MfeIhmLNjiIOYs1l4mfXUa6IBVq-V/view?usp=drivesdk,pd-production-100123,2025-08-12 00:46:55
019736_S488_M5_c4591007-p2-3-younger-children-assent-troponin-icd.pdf,PDF,Assent Template for Younger Children (Phase 2/3 Clinical Study),2021-09-13,Assent Form,NAME OF THE PI,M5,False,True,False,False,False,"quality management, safety assessment, pediatric population, protocol C4591007, laboratory tests, informed consent, pediatric research, clinical trial, Pfizer, coronavirus, assent form, COVID-19 vaccine, data management, Protocol, United States, adverse events, phase 2/3 study, regulatory compliance",18,9,https://drive.google.com/file/d/18n0YJiifN1wokYG5ft910n7eJXzXZovd/view?usp=drivesdk,pd-production-100123,2025-08-12 00:46:58
11_PM_S136_BLA 125742-31_10-30-2021_Memo_Final Review Memo.pdf,PDF,Final Review Memo for BLA 125742-31,2021-10-30,Memo,,,False,False,False,False,False,"Data analysis, Biologics License Application (BLA), Pharmaceutical product, Compliance review, Safety and efficacy evaluation, Regulatory submission, October 2021, FDA review, BLA 125742-31, Final memo, CBER (Center for Biologics Evaluation and Research), Clinical trial data, Adverse event reporting, Medical product lifecycle, Quality assurance, Regulatory approval process, Vaccine development",17,2,https://drive.google.com/file/d/1nLqH26L4jqfkA8kW9uL72FJdOgHi-T76/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:01
019736_S70_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) Clinical Trial Protocol",2020-08-25,protocol,"Özlem Türeci, MD, Elisa Harkins",M1,False,False,False,False,False,"PF-07302048, adult population, BioNTech, FDA submission, Mainz, Germany, clinical trial, COVID-19 vaccine, prophylactic immunization, BNT162, vaccine development, safety data, Collegeville, PA, protocol, efficacy data, regulatory affairs, adverse events, Pfizer",17,3,https://drive.google.com/file/d/1XV0LGvrJyOqEEkxGA6Y_F64Q9OOeakuo/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:07
019736_S488_M5_c4591007-p2-3-parent-troponin-icd.pdf,PDF,Informed Consent for Pediatric Study: Obtaining Serum Samples for Potential Troponin I Testing,2021-09-13,Informed Consent Form,Study Doctor,M5,False,True,False,False,False,"protocol C4591007, informed consent, troponin I testing, clinical trial, adverse event monitoring, site and country information, parental decision-making, safety data, Pfizer confidential, study template, pediatric study, Protocol, voluntary participation, medical terminology, assent process, serum sample collection, phase 2/3 study, FDA compliance",18,28,https://drive.google.com/file/d/1ykXxH9ko7ob_gKIjP6wl4DwvGuHTrjWh/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:11
019736_S70_M5_vr-mqr-10214.pdf,PDF,Qualification of the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay,2020-08-18,report,"Ingrid L. Scully, Mark W. Cutler, Pei-Yong Shi, Camila R. Fontes-Garfias, Antonio E. Muruato, Tyler Garretson, Michael W. Pride, David Cooper, Charles Tan",M5,False,False,False,False,False,"PF-07302048, vaccine research, microneutralization assay, quality control, Pearl River, NY, assay qualification, clinical trial, mNeonGreen virus, diagnostic assay, FDA, human genetics, SARS-CoV-2, bioassay development, immunoassay, assay performance, biostatistics, Pfizer",17,21,https://drive.google.com/file/d/1oMmpIN1w71vTgpvLAa1mkXz9qeK6z1py/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:17
019736_S70_M5_vr-mqr-10211-att01.pdf,PDF,Supportive Data for VR-MQR-10211,2020-08-07,report,,M5,False,False,False,False,False,"PF-07302048, clinical trial data, data listing, Pearl River, NY, FDA submission, pharmaceutical compliance, non-clinical data, VR-MQR-10211 study, sample precision, supportive documentation, Pfizer confidential, quality assurance, linearity evaluation, experimental data, vaccine research and development, regulatory affairs, analytical method validation",17,45,https://drive.google.com/file/d/1TSqJFacrE5QL_LqLTyzYCVbVLM_eu2do/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:22
019736_S70_M5_vr-mqr-10214-att01-shi-sop-10011.pdf,PDF,Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to SARS-CoV-2 in Test Serum using Cytation 7 Image Reader,2022-01-01,protocol,Shi,M5,False,False,False,False,False,"cell-based assay, quality control, viral infection, 96-well plate, clinical trial, data analysis, antibody detection, UTMB Shi Lab, vaccine development, SARS-CoV-2, COVID-19, neutralization assay, laboratory protocol, SOP, Texas, Cytation 7 image reader, regulatory compliance",17,16,https://drive.google.com/file/d/1Sv4Da2ILqjMq9j8-nHjIRjuVsW-CFBp3/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:26
019736_S70_M5_vr-mqr-10214-att03.pdf,PDF,QCS Infection Ratio Data Listing,2020-07-28,data,,M5,False,False,False,False,False,"PF-07302048, vaccine research, clinical trial data, data listing, Pearl River, NY, FDA submission, infection ratio, pharmaceutical development, FOIA document, safety data, quality assurance, attachment, quality control sample, version 1.0, efficacy data, Pfizer, regulatory compliance",17,6,https://drive.google.com/file/d/1KkwRhC5I8JWC_K3co0XpWMe64tROvfg9/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:30
019736_S70_M5_vr-mqr-10211-10212-dlq.pdf,PDF,SARS-CoV-2 dLIA Linearity Qualification Data re VR-MQR-10211 and VR-MQR-10212 Experimental Data Listing - Linearity,2020-08-18,report,,M5,False,False,False,False,False,"Clinical Trial, Data Analysis, Confidential, VR-MQR-10212, Assay Validation, Experimental Data Listing, FDA, Regulatory Submission, SARS-CoV-2, Linearity Qualification, VR-MQR-10211, dLIA, CBER, Compliance, Vaccine Development, Pfizer, Pharmaceutical Research",17,32,https://drive.google.com/file/d/1Ur1ERbF14l9QqFonT_oPAn6FAvcTNsBY/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:33
019736_S70_M5_vr-mqr-10211.pdf,PDF,Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for Quantitation of IgG Antibodies to SARS-CoV-2 S1 Protein in Human Sera,2020-08-18,report,,M5,False,False,False,False,False,"immunogenicity, linearity, regulatory-compliance, new-york, antibody-quantitation, luminex-assay, precision, quality-control, pfizer, lower-limit-of-quantitation, sars-cov-2, assay-qualification, fda-submission, data-analysis, clinical-trial, covid-19, vaccine-research",17,29,https://drive.google.com/file/d/1sp7Yp2OXK5N5UR4x8Uw0212lPCji5McY/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:39
019736_S70_M5_vr-mqr-10212-att01.pdf,PDF,Supportive Data for VR-MQR-10212,2020-08-07,report,,M5,False,False,False,False,False,"non-clinical-data, data-listing, linearity-evaluation, pf-07302048, analytical-methods, regulatory-compliance, confidential, quality-control, pfizer, clinical-trial-data, pearl-river-ny, vaccine-development, fda-submission, vr-mqr-10212, vaccine-research, supportive-data, precision-evaluation",17,43,https://drive.google.com/file/d/1OGsMUFiosTumLebhwRlCUiMdputVo9mM/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:44
019736_S70_M5_vr-mqr-10214-att01.pdf,PDF,Precision Experiment Data Listing,2020-07-28,data,,M5,False,False,False,False,False,"PF-07302048, FOIA document, clinical trial data, data listing, Pearl River, NY, FDA submission, pharmaceutical development, precision experiment, data quality, safety data, experimental data, vaccine research and development, vaccine candidate, efficacy data, adverse events, Pfizer, regulatory compliance",17,9,https://drive.google.com/file/d/123M7ZXe4PYLTfmKjyzSjv3svWEts4cwf/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:48
125742_2_BLA 125742-0_05-18-2021_Telecon_Information Reques.pdf,PDF,Teleconference Information Request for BLA 125742/0,2021-05-18,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"usphs-officer, sdtm-adam-datasets, teleconference-request, vaccine-research-review, dataset-clarification, cber-division-vaccines, reactogenicity-data, eua-amendment, clinical-trial-data, fda-regulatory-review, biologics-evaluation-center, vaccines-related-products, bla-submission, data-quality-compliance, regulatory-review-officer, pfizer-vaccine, information-request-response",17,1,https://drive.google.com/file/d/1DXSHvWpbM74trgmomMb4mwEm3OVz_89e/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:52
1_PM_S85_BLA 125742-4_09-30-2021_Telecon_Advice.pdf,PDF,COMIRNATY STN 125742 - PMR/PMC Communications,2021-09-30,email,"Gemignani, Helen S, Amitkumar.Patel@pfizer.com",,False,True,False,False,False,"BLA 125742, Veteran's Affairs Health System, Clinical Trials, Active Safety Surveillance, Study C4591012, OVRR PMR/PMC Coordinator, Interim Reports, COMIRNATY, Protocol, Myocarditis, Regulatory Compliance, Pericarditis, Final Reports, PMR/PMC, FDA Correspondence, Vaccine Safety, Study C4591009, Pfizer-BioNTech COVID-19 Vaccine",18,2,https://drive.google.com/file/d/1lLENqSVq5POF7LcGE-0uJ58aKvBqOkPa/view?usp=drivesdk,pd-production-100123,2025-08-12 00:47:55
019736_S70_M5_vr-sop-lc-11120.pdf,PDF,Data Review Procedures for Direct Luminex Immunoassays in LIMS v6,2019-09-04,SOP (Standard Operating Procedure),,M5,False,False,False,False,False,"LabWare, Clinical Trials, Data Analysis, Vaccine Research, LIMS, SAS, Luminex Immunoassay, Assay Validation, Pharmaceutical, Metadata, Immunogenicity, Regulatory Compliance, Quality Assurance, Data Review, Pearl River, SOP, Pfizer",17,14,https://drive.google.com/file/d/1WI4Pwk5WbmFi8f1gPaN6kv1x8bgYjkWF/view?usp=drivesdk,pd-production-100123,2025-08-12 00:48:00
019736_S70_M5_vr-mqr-10212.pdf,PDF,Qualification Report for a Single-plex Direct Luminex Assay (dLIA) for Quantitation of IgG Antibodies to SARS-CoV-2 RBD Protein in Human Sera,2020-08-18,report,"Guy Singh, Darryl Charles, Estee Dilli, Nathaniel Garcia, Danka Pavliakova, Warren Kalina, Charles Tan, David Cooper, Michael Pride",M5,False,False,False,False,False,"fda-regulatory, human-serum-samples, pfizer-vaccine-research, assay-precision, new-york-location, receptor-binding-domain, spike-protein-antibodies, clinical-trial-qualification, luminex-assay, vaccine-research-and-development, covid-19-diagnostics, immunoassay-diagnostics, drug-identifier-pf-07302048, clinical-assay-development, lower-limit-of-quantitation, assay-performance-parameters, sars-cov-2-antibody-quantitation",17,29,https://drive.google.com/file/d/13E36ZJgITIWY5mVlDfYyZ9sHJ7r1utpB/view?usp=drivesdk,pd-production-100123,2025-08-12 00:48:07
019736_S70_M5_vr-tm-10293.pdf,PDF,Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-2 S1 Protein in Human Serum,2020-01-01,protocol,,M5,False,False,False,False,False,"antibody quantitation, vaccine research, quality control, serum analysis, Luminex assay, Pearl River, NY, laboratory procedure, clinical trial, data analysis, vaccine development, SARS-CoV-2, COVID-19, S1 protein, protocol, Pfizer, IgG antibodies, regulatory compliance",17,19,https://drive.google.com/file/d/1fjK6rOj4kVIhKIMukXIWAA88fwm8URw7/view?usp=drivesdk,pd-production-100123,2025-08-12 00:48:12
019736_S70_M1_response-ir-29jul2020-clin-assay-qual.pdf,PDF,"Response to FDA Information Request Regarding Clinical Assay Qualification for SARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048)",2020-08-20,report,Pfizer,M1,False,False,False,False,False,"PF-07302048, clinical trial data, clinical assay qualification, response to FDA, CBER requests, clinical assay validation, vaccine development, SARS-CoV-2 mRNA vaccine, BNT162, Pfizer confidential, August 2020, COVID-19 vaccine, safety and efficacy, BB-IND 19736, FDA information request, pharmaceutical R&D, regulatory submission",17,20,https://drive.google.com/file/d/1F_kXL_sX3Vlpfr1ITncV9lHv_CE_lFR6/view?usp=drivesdk,pd-production-100123,2025-08-12 00:48:17
019736_S488_M5_c4591007-protocol-amend3-track.pdf,PDF,PF-07302048 (BNT162 b2 RNA-Based COVID-19 Vaccine) Protocol C4591007,2021-09-10,Protocol,"BioNTech, Pfizer",M5,False,True,False,False,False,"Pfizer Confidential, Phase 1/2/3 Study, Efficacy Endpoints, Vaccine Eligibility, COVID-19 Vaccine, Dose-Finding Study, Severe COVID-19 Cases, Safety and Immunogenicity, Regulatory Compliance, Adverse Events Monitoring, Concomitant Medication Reporting, SARS-CoV-2 RNA Vaccine, FDA Submission, Protocol, Clinical Trial Protocol, Unblinding Procedures, Troponin I Testing, Pediatric Population",18,212,https://drive.google.com/file/d/1qI3YIN99nxd5iBvAjWf2VamXKp0E7gx0/view?usp=drivesdk,pd-production-100123,2025-08-12 00:48:26
019736_S488_M5_c4591007-protocol-amend3.pdf,PDF,PF-07302048 (BNT162 b2 RNA-Based COVID-19 Vaccine) Protocol C4591007,2021-09-10,Protocol,Pfizer,M5,False,True,False,False,False,"Phase 1/2/3 Study, Healthy Children and Young Adults, Serum Biomarkers, RNA-Based Vaccine, Vaccine Candidate Identification, COVID-19 Vaccine, EudraCT Registration, Severe COVID-19 Cases, Safety and Immunogenicity, Regulatory Compliance, Adverse Events Monitoring, Concomitant Medication Reporting, Protocol, FDA Submission, Clinical Trial Protocol, Pfizer-BioNTech Collaboration, Unblinding Procedures, Pediatric Population",18,212,https://drive.google.com/file/d/1qoVGl8dUX2EXqTn2zMesWAK2BfIDPbiZ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:48:34
019736_S444_M5_c4591007-p2-3-children-assent-pbo-cont-select-dose-icd-track.pdf,PDF,Assent Form for Younger Children in Phase 2/3 Placebo-Controlled Selected Dose Clinical Study,2021-08-06,Assent Form,[NAME OF THE PI],M5,False,True,False,False,False,"Clinical Trial, Informed Consent, Phase 2/3 Study, Efficacy Evaluation, Protocol, COVID-19, Regulatory Compliance, Adverse Event Monitoring, Placebo-Controlled, Assent Form, FDA Submission, Site-Level Documentation, Global Clinical Operations, Safety Data, Vaccine Development, Pfizer, Quality Management System, Pediatric Population",18,9,https://drive.google.com/file/d/1MVATqUPJ26SCHvnz2Wm2WYkoelX0TzO6/view?usp=drivesdk,pd-production-100123,2025-08-12 00:48:38
019736_S444_M5_c4591007-p2-3-younger-child-assent-lower-dose-eval.pdf,PDF,Assent Template for Younger Children - Phase 1/2/3/4 Clinical Study,2021-08-09,Assent Form,NAME OF THE PI,M5,False,True,False,False,False,"phase 1, pediatric, informed consent, clinical trial, Pfizer, phase 2, FDA, COVID-19 vaccine, assent form, data management, Protocol, protocol, efficacy, safety, phase 4, adverse events, phase 3, regulatory compliance",18,9,https://drive.google.com/file/d/1XF3Yc0V-kIIbhzgh0Ms-Jj8SeLCTydHU/view?usp=drivesdk,pd-production-100123,2025-08-12 00:48:43
019736_S488_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 IND Amendment - Clinical: Study C4591007 Protocol Amendment,2021-09-14,letter,"Marion Gruber, Ph.D., Pfizer Inc.",M1,False,True,False,False,False,"New York, NY, PF-07302048, immunogenicity, FDA submission, informed consent, clinical trial, vaccine development, safety data, BNT162, COVID-19, pediatric study, Silver Spring, MD, SARS-CoV-2, Protocol, global product development, regulatory affairs, adverse events, protocol amendment",18,3,https://drive.google.com/file/d/1447-ONXdEqDrLzkczjuWQblt12ffYtQS/view?usp=drivesdk,pd-production-100123,2025-08-12 00:48:47
019736_S444_M5_c4591007-p2-3-older-child-assent-lower-dose-eval.pdf,PDF,"Phase 2/3 Lower Dose Evaluation, Older Assent",2021-08-09,Assent Form,,M5,False,False,False,False,False,"covid-19 vaccine, fda, pediatric population, pandemic, clinical trial, phase 2/3, world health organization, assent form, safety data, pfizer, adverse events, quality management system, efficacy data, bnt162b2, lower dose evaluation, electronic document management, regulatory compliance",17,8,https://drive.google.com/file/d/1pvnVYsow-f_LrWoRpNy9S6p6R0gPsCH0/view?usp=drivesdk,pd-production-100123,2025-08-12 00:48:51
019736_S444_M5_c4591007-protocol-amend2.pdf,PDF,PF-07302048 (BNT162 b2 RNA-Based COVID-19 Vaccine) Protocol C4591007 Final Protocol Amendment 2,2021-08-06,Protocol,Pfizer,M5,False,True,False,True,False,"Exclusion, regulatory-compliance, safety-tolerability-immunogenicity, protocol-amendment, clinical-trial, healthy-children-young-adults, covid-19-vaccine, Protocol, adverse-events-of-special-interest, pfizer-biontech, risk-assessment, confidential-document, study-procedures, phase-1-2-3-study, pediatric-safety-database, unplanned-visit, dose-evaluation, fda-submission, global-clinical-trial",19,186,https://drive.google.com/file/d/1SsQsMfUXhKLUTZ4tfQlenaR_r7Dod8_k/view?usp=drivesdk,pd-production-100123,2025-08-12 00:48:58
019736_S444_M5_c4591007-p2-3-parent-icd-pbo-controlled-selected-dose-track.pdf,PDF,Phase 2/3 Placebo-Controlled Selected Dose Study Informed Consent Document,2021-08-02,Informed Consent Document,,M5,False,True,False,False,False,"global, pharmaceutical, informed consent, clinical trial, phase 2, placebo-controlled, Protocol, pediatric study, protocol, data collection, safety, efficacy, selected dose, template, C4591007, adverse events, phase 3, regulatory compliance",18,33,https://drive.google.com/file/d/1r9BXBfWVQl4ZO7Ku7eJgcVIu-BKz7-VH/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:02
019736_S444_M5_c4591007-p2-3-parent-icd-lower-dose-eval.pdf,PDF,"Phase 2/3 Lower Dose Evaluation, Parental Consent",2021-08-09,Informed Consent,,M5,False,True,False,False,False,"compliance, informed consent, clinical trial, Pfizer, parental consent, phase 2, FDA, Protocol, pediatric study, protocol, efficacy, safety, adverse events, data, C4591007, lower dose evaluation, phase 3, regulatory",18,24,https://drive.google.com/file/d/1FGKCTV31RMw17lqjy-jGxWlgU4JjqLP3/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:05
019736_S444_M5_c4591007-p2-3-parent-icd-pbo-controlled-selected-dose.pdf,PDF,Informed Consent Document for Pediatric Clinical Trial,2021-08-06,Informed Consent Form,Study Doctor,M5,False,True,False,False,False,"Participant Enrollment, Clinical Trial, Selected Dose, Informed Consent, Pediatric Study, FDA, Efficacy Data, Protocol, Protocol C4591007, Adverse Events, Regulatory Compliance, United States, Voluntary Participation, Phase 2/3, Safety Data, Medical Terminology, Placebo-Controlled, Pfizer",18,30,https://drive.google.com/file/d/1kG8lxstfauU0WbL7aC5GUG-azR-Ov3hG/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:09
019736_S488_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) Informed Consent Documents for Study C4591007",2021-09-14,Informed Consent Document,"Özlem Türeci, Amit Patel",M1,False,False,False,False,False,"PF-07302048, Clinical Trial, Mainz, Germany, Informed Consent, New York, USA, Efficacy Data, BNT162, Regulatory Compliance, Study C4591007, Adverse Events, BioNTech SE, FDA Submission, Medical Officer, Regulatory Affairs, Safety Data, COVID-19 Vaccine, Pfizer",17,3,https://drive.google.com/file/d/1m4w_FzFMmuJ2s_hXJV5NGFCXn3cEF5UR/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:15
019736_S444_M5_c4591007-p2-3-adult-participant-icd-lower-dose-eval.pdf,PDF,Informed Consent Template for Phase 2/3 Lower Dose Evaluation (Adult) Clinical Study,2021-08-09,Informed Consent Form,,M5,False,True,False,False,False,"Voluntary Participation, Clinical Trial, Pfizer Confidential, Informed Consent, Lower Dose Evaluation, Phase 2/3 Study, Adult Participants, Efficacy Data, Protocol, Protocol C4591007, Adverse Events, Regulatory Compliance, United States, FDA Regulations, Safety Data, Medical Terminology, Pharmaceutical Research, Participant Recruitment",18,22,https://drive.google.com/file/d/1EnXz4QK3_CqqG-iNS_zztig0IhDHcraJ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:18
019736_S488_M5_c4591007-p2-3-parent-icd-pbo-controlled-selected-dose.pdf,PDF,Informed Consent Document for Phase 2/3 Placebo-Controlled Selected Dose Study,2021-09-13,Informed Consent Form,Study Doctor,M5,False,True,False,False,False,"informed consent, clinical trial, Pfizer, FDA, vaccine development, safety data, placebo-controlled, Protocol, pediatric study, protocol, global study, TMF documentation, selected dose, C4591007, adverse events, phase 2/3 study, efficacy data, regulatory compliance",18,31,https://drive.google.com/file/d/1JCz6DcMosyh2CiXVuK6Ripl-SE339wAs/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:22
019736_S488_M5_c4591007-p2-3-older-children-assent-troponin-icd.pdf,PDF,Phase 2/3 Obtaining Serum Samples for Potential Troponin I Testing (all age groups),2021-09-13,Informed Consent Form,,M5,False,True,False,False,False,"covid-19 vaccine, fda, pandemic, informed consent, clinical trial, phase 2, safety data, troponin i, pfizer, pediatric study, Protocol, global health, serum samples, efficacy data, bnt162b2, adverse events, phase 3, regulatory compliance",18,10,https://drive.google.com/file/d/1MRr4Pro93kOdjsVNOFQd_-0Us7t_i64P/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:25
019736_S444_M5_c4591007-p1-parent-icd-lower-dose-eval.pdf,PDF,"Phase 1 Lower Dose Evaluation, Parental Consent Study",2021-08-09,Informed Consent,,M5,False,True,False,False,False,"pharmaceutical research, data quality, protocol C4591007, informed consent, clinical trial, regulatory submission, parental consent, safety data, Pfizer confidential, Protocol, pediatric study, patient enrollment, adverse events, global study, efficacy data, phase 1 study, drug development, FDA compliance",18,24,https://drive.google.com/file/d/1A5Bkex4s8zii6a8_X_-Oz2hnfk19_9mT/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:28
019736_S444_M5_c4591007-protocol-amend2-track.pdf,PDF,PF-07302048 (BNT162 b2 RNA-Based COVID-19 Vaccine) Protocol C4591007 Final Protocol Amendment 2,2021-08-06,Protocol,,M5,False,True,False,True,False,"Clinical Protocol Amendment, Exclusion, Dose Evaluation, SARS-CoV-2, FDA Submission, Clinical Trial Protocol, BNT162b2, Adverse Events of Special Interest, Pediatric Population, PF-07302048, Phase 1/2/3 Study, Protocol, Regulatory Compliance, Pericarditis, Pfizer, BioNTech, Safety and Immunogenicity, Myocarditis, COVID-19 Vaccine",19,207,https://drive.google.com/file/d/11ATad82VjR72ijVVeD-EShIQ40nrEA-F/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:37
019736_S470_M5_c4591012-protocol.pdf,PDF,Post-Emergency Use Authorization Active Safety Surveillance Study among Individuals in the Veteran's Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine,2021-08-31,protocol,"Yinong Young-Xu, Cynthia de Luise, Mei Sheng Duh",M5,False,True,False,False,False,"comorbidities, immunocompromised patients, Veterans Affairs Health System, demographic data, single-dose recipients, elderly patients, dose completion rate, adverse event surveillance, epidemiological research, COVID-19 vaccine, clinical trial protocol, Protocol, vaccine utilization patterns, post-authorization safety study, prior SARS-CoV-2 infection, medical history, Pfizer-BioNTech vaccine, regulatory compliance",18,195,https://drive.google.com/file/d/1Um9yHUYcB_3gu3vs6y8ChFFWoR9U2eM-/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:42
019736_S470_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) Clinical Trial",2021-08-30,Report,"Özlem Türeci, Amit Patel",M1,False,False,False,False,False,"Phase 4, Immunization, Clinical Trial, Germany, Efficacy Data, SARS-CoV-2, Adverse Events, Vaccine Identification, Compliance, Regulatory Affairs, FDA Submission, BioNTech SE, Quality Assurance, Safety Data, COVID-19 Vaccine, United States, Pfizer",17,3,https://drive.google.com/file/d/1QTzOx-tSeni7tXhLtPLY-qz9ZQHIxn4u/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:48
019736_S444_M5_c4591007-p2-3-children-assent--cont-select-dose-icd.pdf,PDF,Assent Template for Younger Children (Phase 2/3 Placebo Controlled Selected Dose),2021-08-06,Informed Consent Form,NAME OF THE PI,M5,False,True,False,False,False,"quality management, pediatric population, laboratory tests, informed consent, clinical trial, Pfizer, FDA, COVID-19 vaccine, assent form, placebo-controlled, document management, Protocol, efficacy, safety, medical examination, adverse events, phase 2/3 study, regulatory compliance",18,9,https://drive.google.com/file/d/1CFt185HDxiyK95WNKfjQfjCAhS3x-SOn/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:53
019736_S470_M5_c4591012-protocol-track.pdf,PDF,Post-Emergency Use Authorization Active Safety Surveillance Study among Individuals in the Veteran's Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine,2021-01-27,study protocol,"Yinong Young-Xu, Cynthia de Luise, Mei Sheng Duh",M5,False,True,False,False,False,"covid-19 vaccine, comorbidities, single-dose, fda, utilization patterns, non-interventional study, immunocompromised, clinical epidemiology, elderly, prior infection, risk management, Protocol, post-authorization study, veterans affairs health system, pfizer-biontech, safety surveillance, adverse events, regulatory",18,237,https://drive.google.com/file/d/1yy77AZysmMe_u_1nK5eF3ZPq3ly2CFoM/view?usp=drivesdk,pd-production-100123,2025-08-12 00:49:58
019736_S470_M5_c4591009-protocol.pdf,PDF,Pfizer-BioNTech COVID-19 Vaccine C4591009 Non-Interventional Study Protocol,2021-08-19,protocol,,M5,False,True,False,False,False,"covid-19 vaccine, immunocompromised individuals, relative risk, post-approval safety study, non-interventional study, pregnant women, fda, secondary data collection, baseline characteristics, history of covid-19, birth outcomes, Protocol, clinical data, pfizer-biontech, safety events, united states, dose series, regulatory",18,71,https://drive.google.com/file/d/1ry2XBB_Mrt1Hgzp7gMfBWyTS8sgYgNWJ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:03
019736_S488_M5_c4591007-p2-3-parent-addendum-icd-pbo-cont-selected-dose.pdf,PDF,Informed Consent Addendum for COVID-19 Vaccine Clinical Trial,2021-09-13,Informed Consent Addendum,,M5,False,True,False,False,False,"Tolerability, Clinical Trial, Pfizer Confidential, Safety, Informed Consent, Phase 1 Study, Phase 2/3 Study, FDA Approval, Immunogenicity, Dose Adjustment, Protocol C4591007, Regulatory Compliance, Dose-Finding, Protocol, Emergency Use Authorization, COVID-19 Vaccine, Placebo-Controlled, Pediatric Population",18,3,https://drive.google.com/file/d/10ZbzoIfWGzjpkQSjxMXIpcphRhZRw-q9/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:07
019736_S470_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 IND Amendment - Protocol Amendment for Study C4591012,2021-08-30,letter,"Marion Gruber, Ph.D., Pfizer Inc.",M1,False,True,False,False,False,"post-authorization, PF-07302048, comorbidities, Veteran's Affairs Health System, clinical trial, IND amendment, FDA, vaccine development, safety study, BNT162, COVID-19, CBER, Protocol, adverse events, immunocompromised, protocol amendment, Pfizer Global Regulatory Affairs, regulatory submission",18,3,https://drive.google.com/file/d/1-d3yEjbJzSizmmGY90ua8fwmnkBw56ux/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:10
019736_S444_M5_c4591007-p1-younger-children-assent-lower-dose-eval-icd.pdf,PDF,Assent Template for Younger Children - Phase 1/2/3/4 Clinical Study,2021-08-09,Informed Consent Form,NAME OF THE PI,M5,False,True,False,False,False,"phase 1, assent, pediatric, informed consent, clinical trial, Pfizer, phase 2, FDA, COVID-19 vaccine, Protocol, protocol, efficacy, safety, phase 4, site, adverse events, phase 3, regulatory",18,9,https://drive.google.com/file/d/1_J8_tHYK4WgjIC1xxgUMyYjVfwMU9gQV/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:15
019736_S444_M5_c4591007-p1-older-children-assent-lower-dose-eval-icd.pdf,PDF,"Phase 1 Lower Dose Evaluation, Older Assent",2021-08-09,Informed Consent Form,,M5,False,False,False,False,False,"Global Locations, Clinical Trial, Phase 1 Study, Informed Consent, Sponsor Confidential, Efficacy Evaluation, Urgent Public Health Need, Regulatory Compliance, Adverse Event Monitoring, Assent Form, Pandemic Response, Electronic Document Management, Safety Data, COVID-19 Vaccine, BNT162b2, Quality Management System, Pediatric Population",17,8,https://drive.google.com/file/d/1021iK2qdferlXVPQsuFk5zB482csVDdM/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:18
019736_S414_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 IND Amendment - Protocol Amendment for Study C4591001,2021-07-20,letter,"Marion Gruber, Ph.D., Neda Aghajani Memar, Pharm.D., Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D., Captain Michael Smith, Ph.D.",M1,False,True,False,False,False,"PF-07302048, immunogenicity, FDA submission, clinical trial, phase 1/2/3 study, IND amendment, Pfizer, COVID-19 vaccine, SARS-CoV-2, BNT162, study C4591001, vaccine development, Protocol, efficacy, safety, regulatory affairs, protocol amendment, data analysis",18,2,https://drive.google.com/file/d/1CZpjQBRG07be4dDg-SPi7rKNfn2xKFjf/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:22
019736_S444_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 IND Amendment – Clinical: Study C4591007 Protocol Amendment,2021-08-10,letter,"Marion Gruber, Ph.D.",M1,False,True,False,False,False,"regulatory-submission, immunogenicity, pfizer-global-regulatory-affairs, pf-07302048, pediatric-population, dose-evaluation, safety-data, bnt162, adverse-events, Protocol, silver-spring-maryland, protocol-amendment, fda-review, vaccine-development, clinical-trial, biologic-license-application, covid-19, confidential-information",18,3,https://drive.google.com/file/d/1cEci5Ld_f5tjs4WeiPkEuS22wdeqKSjb/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:27
019736_S387_M5_c4591008-interim-unplanned-hospitalization.pdf,PDF,"Participant Reported Unplanned Hospitalization for BNT162b2 Clinical Trial C4591008"",","2021-05-11"",",document,,M5,False,True,False,False,False,"Protocol, FOIA-document, needs-review",3,4,https://drive.google.com/file/d/1dZjCDhXYzMFhQmDZZF1PacoRvG7YEcB-/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:31
019736_S414_M5_c4591001-amendment-17-clean.pdf,PDF,PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001 Final Protocol Amendment 17,2021-07-20,Protocol,,M5,False,True,False,False,False,"Randomized controlled trial, Safety and tolerability, Variant of concern, Regulatory submission, Clinical trial protocol, Efficacy evaluation, Immunogenicity assessment, Healthy individuals, Phase 1/2/3 study, COVID-19 vaccine, Unblinded study, Convalescent visit, Protocol, Coronavirus vaccines, Adverse event monitoring, Dose-finding, Confidential document, Pfizer-BioNTech vaccine",18,233,https://drive.google.com/file/d/1grgvuXK3X3-0G5IGpLXULtr6nE2Fb5V1/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:38
019736_S387_M5_c4591008-interim-sap.pdf,PDF,Non-Interventional Statistical Analysis Plan For Primary Data Collection Study,2020-06-01,Statistical Analysis Plan,"Merrill, Peter, Shostak, Jack, Wen, Jun",M5,False,True,False,False,False,"Pfizer-BioNTech, safety evaluation, post-authorization, FOIA document, non-interventional study, epidemiology, interim analysis, observational cohort, clinical trial, FDA, COVID-19 vaccine, Protocol, United States, statistical analysis plan, healthcare workers, adverse events, data collection, regulatory compliance",18,69,https://drive.google.com/file/d/1twtcQu1mgmHoBQITrLN1UFQYOa7Y6C_6/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:44
019736_S387_M5_c4591008-interim-sample-icd.pdf,PDF,HERO Together: A post-Emergency Use Authorization observational cohort study to evaluate the safety of the Pfizer-BioNTech COVID-19 vaccine in US healthcare workers,2021-06-21,consent_form,Emily O'Brien,M5,False,True,False,False,False,"pfizer-biontech_covid-19_vaccine, north_carolina, united_states, duke_clinical_research_institute, sponsor_information, clinical_trial, observational_cohort_study, informed_consent, healthcare_workers, contact_information, Protocol, vaccine_safety, data_collection, protocol, post-authorization_study, irb_review, fda_regulatory, adverse_events",18,14,https://drive.google.com/file/d/10uuSwqAsEI_jczPdyKSi7rk1hBaFokKw/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:47
019736_S387_M5_c4591012-interim-sponsor-signature.pdf,PDF,Post-Emergency Use Authorization Active Safety Surveillance Study among Individuals in the Veteran's Affairs Health System Receiving Pfizer-BioNTech COVID-19 Vaccine,2021-06-22,report,"Cynthia de Luise, Mei Sheng Duh",M5,False,True,False,False,False,"veterans-affairs-health-system, statistical-reporting, non-interventional-study, vaccine-effectiveness, covid-19-vaccine, regulatory-submission, epidemiology, post-authorization-safety-study, real-world-evidence, data-quality-control, Protocol, clinical-trial-data, adverse-event-monitoring, safety-surveillance, data-analysis, fda-regulatory-compliance, pfizer-biontech-vaccine, public-health-research",18,1,https://drive.google.com/file/d/15c3Ve1QGxUZyrBuPqhparNYWFCIw3v8s/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:51
019736_S414_M5_c4591001-amendment-17-track.pdf,PDF,PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001 Final Protocol Amendment 17,2021-07-20,Protocol,,M5,False,True,False,False,False,"Safety and Efficacy Assessment, BNT162 Vaccine, Phase 1/2/3 Study, PF-07302048 Vaccine, Convalescent Visit Requirement, Systemic Event Overlap Clarification, Statistical Analysis Methods, Regulatory Submission (IND, EudraCT), COVID-19 Vaccine, Dose-Finding Study, Non-Pfizer COVID-19 Vaccine Prohibition, Protocol, Randomized Controlled Trial, Adverse Event Monitoring, FOIA Document, Clinical Trial Protocol, Pfizer-BioNTech Collaboration, Immunogenicity Evaluation",18,234,https://drive.google.com/file/d/153dpm_voMt27A0dVpGlHQhw0toFm19IT/view?usp=drivesdk,pd-production-100123,2025-08-12 00:50:57
019736_S398_M1_cover.pdf,PDF,Response to FDA 30 June 2021 Information Request for COVID-19 Vaccine (BNT162/PF-07302048),2021-07-06,letter,"Marion Gruber, Ph.D., Neda Aghajani Memar, Pharm.D., Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D., Captain Michael Smith, Ph.D.",M1,False,False,False,False,False,"clinical-trials, covid-19-vaccine, new-hampshire-avenue, investigator-brochure, informed-consent, bb-ind-19736, virus-scanning, silver-spring-md, safety-data, biontec h-partnership, pfizer-global, adverse-events, product-registration, regulatory-affairs, fda-submission, vaccine-development, confidential-information",17,2,https://drive.google.com/file/d/1hNhhA6xXWThTI-p9tHghDViUI6pm-GaH/view?usp=drivesdk,pd-production-100123,2025-08-12 00:51:01
019736_S398_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) 019736 Active immunization to prevent COVID-19 caused by SARS-CoV-2",2021-07-06,report,"Özlem Türeci, Neda Aghajani Memar",M1,False,False,False,False,False,"PF-07302048, medical officer, FDA submission, Mainz, Germany, clinical trial, New York, USA, COVID-19 vaccine, SARS-CoV-2, BNT162, safety data, active immunization, BioNTech SE, efficacy data, regulatory affairs, adverse events, Pfizer Global Regulatory Affairs, regulatory compliance",17,3,https://drive.google.com/file/d/1W62TyGB6h5NDubieXr_KZTrDCp_mIFxd/view?usp=drivesdk,pd-production-100123,2025-08-12 00:51:07
019736_S387_M5_c4591008-interim-withdrawn-subjects.pdf,PDF,List of Withdrawn Subjects from BNT162b2 Protocol C4591008,2021-06-22,report,,M5,False,True,False,False,False,"protocol C4591008, data listing, SDTM, clinical trial, withdrawn subjects, FDA, data management, safety data, CBER, data cutoff, vaccine, Protocol, adverse events, demographic information, hospitalization, participant data, BNT162b2, Pfizer",18,6,https://drive.google.com/file/d/1xYHTAjCev_9nT6qs5ZyW0DbavPwO4t1b/view?usp=drivesdk,pd-production-100123,2025-08-12 00:51:10
019736_S444_M5_c4591007-p1-adult-participant-icd-lower-dose-eval.pdf,PDF,Informed Consent Template for Phase 1 Lower Dose Evaluation (Adult) Clinical Study,2021-08-09,Informed Consent Form,Study Doctor,M5,False,True,False,False,False,"Pfizer Confidential, Participant Rights, Informed Consent, Lower Dose Evaluation, Participant Eligibility, FDA Regulatory Compliance, Adult Participants, Efficacy Data, Investigational Product, Protocol, Adverse Events, Sponsor-Investigator Communication, Pharmaceutical Clinical Study, Voluntary Participation, Safety Data, Clinical Trial Protocol, Phase 1 Clinical Trial, Study Procedures",18,22,https://drive.google.com/file/d/1-pCDAytt-lc3A2SEy2MlKqfEYEiK643F/view?usp=drivesdk,pd-production-100123,2025-08-12 00:51:14
019736_S427_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) 019736 Active immunization to prevent COVID-19 caused by SARS-CoV-2",2021-07-27,report,"Özlem Türeci, Neda Aghajani Memar",M1,False,False,False,False,False,"PF-07302048, FDA submission, Mainz, Germany, Chief Medical Officer, Director, clinical trial, New York, USA, COVID-19 vaccine, SARS-CoV-2, BNT162, safety data, active immunization, BioNTech SE, efficacy data, adverse events, Pfizer Global Regulatory Affairs, regulatory compliance",17,3,https://drive.google.com/file/d/151ZmozhcG1hDJrsvsGTo6JO9w0vsontr/view?usp=drivesdk,pd-production-100123,2025-08-12 00:51:20
019736_S387_M5_c4591012-interim-protocol.pdf,PDF,Post-Emergency Use Authorization Active Safety Surveillance Study among Individuals in the Veteran's Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine,2021-01-27,protocol,"Yinong Young-Xu, Cynthia de Luise, Mei Sheng Duh",M5,False,True,False,False,False,"covid-19 vaccine, comorbidities, single-dose, real-world data, prior sars-cov-2 infection, safety surveillance research, non-interventional study, clinical epidemiology, elderly, Protocol, post-authorization study, veterans affairs health system, pfizer-biontech, adverse events of special interest, safety surveillance, immunocompromised, vaccine utilization patterns, regulatory compliance",18,145,https://drive.google.com/file/d/1YbH_2H42Op_BXW04GF38t4hgDbXtr7yT/view?usp=drivesdk,pd-production-100123,2025-08-12 00:51:29
019736_S387_M5_c4591012-interim-report-body.pdf,PDF,Post-Emergency Use Authorization Active Safety Surveillance Study among Individuals in the Veteran's Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine,2021-06-22,Interim Report,"Yinong Young-Xu, Cynthia de Luise, Mei Sheng Duh",M5,False,True,False,False,False,"Pfizer-BioNTech, Clinical Epidemiology, Veterans Affairs Health System, Non-Interventional Study, Safety Surveillance, Comorbidities, Risk Management and Safety Surveillance, Elderly Population, Prior SARS-CoV-2 Infection, Post-Authorization Study, Demographic and Health Characteristics, Vaccine Utilization Patterns, Protocol, Single-Dose Vaccination, Dose Completion Rate, COVID-19 Vaccine, Adverse Events of Special Interest, Immunocompromised Individuals",18,160,https://drive.google.com/file/d/1GIAjbBM3TECCXeAYDg7AAxRvtVdSlqdU/view?usp=drivesdk,pd-production-100123,2025-08-12 00:51:37
019736_S387_M5_c4591012-interim-abstract.pdf,PDF,Post-Emergency Use Authorization Active Safety Surveillance Study among Individuals in the Veteran's Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine,2021-06-22,Interim Report Abstract,"Yinong Young Xu, Cynthia de Luise, Mei Sheng Duh",M5,False,True,False,False,False,"FDA Emergency Use Authorization, Vaccine Pharmacovigilance, Veterans Affairs Health System, Non-Interventional Study, Epidemiological Data Analysis, Adverse Event Reporting, Interim Report, Safety Signal Monitoring, Rapid Cycle Analysis, Pharmaceutical Research and Development, Post-EUA Safety Surveillance, Public Health Surveillance, Regulatory Compliance, Electronic Medical Records, Protocol, Vaccine Safety and Efficacy, Clinical Trial Phase 4, Pfizer-BioNTech COVID-19 Vaccine",18,10,https://drive.google.com/file/d/1xLZQjpvyktZy3WjqMfOCPjGvMqg_kODj/view?usp=drivesdk,pd-production-100123,2025-08-12 00:51:42
019736_S444_M1_1571.pdf,PDF,Informed Consent Document for C4591007,2021-08-10,Informed Consent Document,"Özlem Türeci, Neda Aghajani Memar",M1,False,False,False,False,False,"PF-07302048, Biologics License Application (BLA), Investigational New Drug (IND), Clinical Trial Phase 3, Informed Consent, Active Immunization, Efficacy Data, BNT162, Adverse Events, United States, Compliance, Regulatory Affairs, FDA Submission, BioNTech SE, Safety Data, COVID-19 Vaccine, Pfizer Global Regulatory Affairs",17,3,https://drive.google.com/file/d/1A4YizMqQerTb2Tt6OgY1ljlC7alQBP_h/view?usp=drivesdk,pd-production-100123,2025-08-12 00:51:48
019736_S387_M5_c4591008-interim-report-body.pdf,PDF,Pfizer-BioNTech COVID-19 Vaccine C4591008 Non-Interventional Interim Report,2021-06-22,report,Emily O'Brien,M5,False,True,False,True,False,"Exclusion, observational-study, post-authorization-study, pregnancy, covid-19, immunocompromised, interim-report, fda, real-world-data, healthcare-workers, vaccine-safety, adverse-events, clinical-trial, incidence-rates, Protocol, pfizer-biontech, united-states, emergency-use-authorization, duke-clinical-research-institute",19,329,https://drive.google.com/file/d/1Tj-WyKgqmXKjzwZImgdBKvDP2mX-SrPj/view?usp=drivesdk,pd-production-100123,2025-08-12 00:51:53
019736_S398_M1_response-30june2021-icd-myo-peri.pdf,PDF,Response to FDA Information Request Regarding Updating Informed Consent Documents and Investigator's Brochure with Information Related to Myocarditis and Pericarditis,2021-07,response,,M1,False,False,False,False,False,"medical-information, covid-19-vaccine, investigator-brochure, pf-07302048, informed-consent, bb-ind-19736, confidential, safety-data, bnt162, pericarditis, pfizer, myocarditis, adverse-events, fda-submission, clinical-trial, data-update, pharmaceutical-regulatory",17,12,https://drive.google.com/file/d/1ByMOYYiXVja5h9-xp0szKIdPTUPFvpBq/view?usp=drivesdk,pd-production-100123,2025-08-12 00:51:58
019736_S387_M5_c4591008-interim-sponsor-signature.pdf,PDF,"HERO-Together: A post-Emergency Use Authorization observational cohort study to evaluate the safety of the Pfizer-BioNTech COVID-19 vaccine in US healthcare workers, their families, and their communities",2018-08-15,Non-Interventional Study Report/Manuscript,"Heather Rubino, Emily O'Brien",M5,False,True,False,False,False,"Pfizer-BioNTech, Non-Interventional Study, Data Analysis, FDA Regulatory Aspects, Observational Cohort Study, Compliance and Quality, Epidemiology, Pharmacovigilance, Families, Safety Evaluation, Protocol, Healthcare Workers, United States, Adverse Events, Clinical Trial Reporting, Post-Emergency Use Authorization, Communities, COVID-19 Vaccine",18,1,https://drive.google.com/file/d/1PUHCMymfghhvU4u7EE2I6c3iWrx37KBD/view?usp=drivesdk,pd-production-100123,2025-08-12 00:52:01
019736_S414_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) 019736 Active immunization to prevent COVID-19 caused by SARS-CoV-2",2021-07-20,report,"Özlem Türeci, MD, Chief Medical Officer, BioNTech SE, Neda Aghajani Memar, Pharm.D., Director, Pfizer Global Regulatory Affairs - Vaccines",M1,False,False,False,False,False,"PF-07302048, compliance, FDA submission, pharmaceutical development, Germany, clinical trial, COVID-19 vaccine, SARS-CoV-2, BNT162, safety data, United States, active immunization, BioNTech SE, efficacy data, regulatory affairs, adverse events, Pfizer",17,3,https://drive.google.com/file/d/1frEHnswrDQyUPkU6a_cxjNEMZL4x25ev/view?usp=drivesdk,pd-production-100123,2025-08-12 00:52:08
019736_S387_M1_cover.pdf,PDF,Interim Report for COVID-19 Vaccine (BNT162/PF-07302048) Post-Authorization Safety Studies,2021-06-30,report,"Marion Gruber, Ph.D., Neda Aghajani Memar, Pharm.D., Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D., Captain Michael Smith, Ph.D.",M1,False,True,False,False,False,"interim-report, covid-19-vaccine, veterans-affairs, pf-07302048, c4591012, post-authorization-safety-study, bb-ind-19736, eua-27034, safety-data, global-product-development, bnt162, healthcare-workers, adverse-events, pfizer, Protocol, c4591008, fda-submission, regulatory-affairs",18,2,https://drive.google.com/file/d/17r9PZ8UI19X5Fs5ergqDMfBL5Luu-cFR/view?usp=drivesdk,pd-production-100123,2025-08-12 00:52:14
019736_S325_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 IND Amendment - Statistical Analysis Plan for Study C4591020,2021-05-07,letter,"Marion Gruber, Ph.D., Neda Aghajani Memar, Pharm.D., Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D.",M1,False,True,False,False,False,"phase 3 study, PF-07302048, immunogenicity, BioNTech, FDA submission, vaccine formulation, clinical trial, IND amendment, data compliance, COVID-19 vaccine, vaccine development, BNT162, Protocol, United States, statistical analysis plan, safety, regulatory affairs, Pfizer",18,2,https://drive.google.com/file/d/1YxA3PYfHrsy-t4whFBX83pC3qoJxbmp8/view?usp=drivesdk,pd-production-100123,2025-08-12 00:52:18
019736_S387_M5_c4591008-interim-compliance.pdf,PDF,BNT162b2 Protocol C4591008 Medication/Treatment Data,2021-05-11,report,,M5,False,True,False,False,False,"Moderna, injection site, FOIA document, data generation, SDTM, clinical trial, medication data, FDA, safety data, Protocol, data cutoff, vaccine, dose information, adverse events, subject demographics, BNT162b2, Pfizer, regulatory compliance",18,1325,https://drive.google.com/file/d/1H_9PDaeTZ9F61honVCJRjC56aKc_rn-6/view?usp=drivesdk,pd-production-100123,2025-08-12 00:52:28
019736_S31_M1_1571.pdf,PDF,"BioNTech RNA Pharmaceuticals GmbH COVID-19 Vaccine (BNT162, PF-07302048) Clinical Trial Protocol",2020-07-09,Protocol,"Özlem Türeci, MD, Chief Medical Officer, BioNTech SE, Elisa Harkins, Global Regulatory Lead, Pfizer Global Regulatory Affairs - Vaccines",M1,False,False,False,False,False,"PF-07302048, Mainz, Germany, Efficacy Data, BNT162, Clinical Trial Protocol, Collegeville, PA, Adverse Events, Compliance, Regulatory Affairs, FDA Submission, Quality Assurance, Prophylactic Immunization, Safety Data, COVID-19 Vaccine, Vaccine Development, Vaccine Identification, Pharmaceutical Research",17,3,https://drive.google.com/file/d/1ZrR-dD1dZwa1oMXoUWO4ro6sajKD8e9X/view?usp=drivesdk,pd-production-100123,2025-08-12 00:52:34
019736_S325_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) 019736 Prophylactic Immunization Against COVID-19 in Adults ≥ 16 Years of Age",2021-05-07,report,"Özlem Türeci, MD, Neda Aghajani Memar, Pharm.D.",M1,False,False,False,False,False,"PF-07302048, FDA submission, Mainz, Germany, pharmaceutical development, clinical trial, New York, USA, COVID-19 vaccine, prophylactic immunization, BNT162, safety data, medical leadership, BioNTech SE, vaccine identification, efficacy data, adverse events, Pfizer Global Regulatory Affairs, regulatory compliance",17,3,https://drive.google.com/file/d/1pJTDISf2zRLC4NkJNQgzUPpLpb5_nxKT/view?usp=drivesdk,pd-production-100123,2025-08-12 00:52:41
019736_S268_M5_wi255886-sap.pdf,PDF,Avon Community Acquired Pneumonia Study (Avon CAP): A Pan-pandemic Acute Lower Respiratory Tract Disease Surveillance Study,2021-03-24,Statistical analysis plan,,M5,False,False,False,True,False,"pseudonymization, pandemic, University of Bristol, Exclusion, surveillance study, clinical trial, vaccine effectiveness, NHS databases, FDA, data management, inclusion/exclusion criteria, IRAS, ISRCTN, COVID-19, statistical analysis plan, respiratory disease, Pfizer, REC",18,40,https://drive.google.com/file/d/1j-5IR00594ddTOM2RnLBmeACVQU78O_y/view?usp=drivesdk,pd-production-100123,2025-08-12 00:52:44
019736_S31_M5_vr-tm-10294.pdf,PDF,Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-2 RBD Protein in Human Serum,2020-01-01,protocol,,M5,False,False,False,False,False,"antibody quantitation, vaccine research, quality control, serum analysis, Luminex assay, RBD protein, clinical trial, SARS-CoV-2, IgG antibodies, safety, procedure, method validation, Pearl River, materials and equipment, Pfizer, data analysis, regulatory compliance",17,19,https://drive.google.com/file/d/1vKN9ircc2u66eV4377A4Vw0NaG_XuJyW/view?usp=drivesdk,pd-production-100123,2025-08-12 00:52:50
019736_S325_M5_c4591020-sap-track.pdf,PDF,Statistical Analysis Plan for Protocol C4591020 (PF-07302048),2021-05-06,protocol,,M5,False,True,False,False,False,"phase 3 study, immunogenicity, FOIA document, clinical trial, FDA, tolerability, Protocol, COVID-19, lyophilized formulation, vaccine candidate, safety, statistical analysis plan, adverse events, healthy adults, BNT162b2, Pfizer, data analysis, regulatory",18,32,https://drive.google.com/file/d/1Wf-gB5FiGBcRyegnmXUDF7HD_buGFiNd/view?usp=drivesdk,pd-production-100123,2025-08-12 00:52:54
019736_S31_M5_vr-mqr-10212.pdf,PDF,Clinical Study Report for Vaccine Candidate,2021-10-21,report,,M5,False,False,False,False,False,"phase 3 study, pharmaceutical research, drug development, FDA submission, medical product, clinical trial, safety data, CBER, quality assurance, United States, vaccine candidate, clinical study report, product identification, efficacy data, adverse events, data analysis, regulatory compliance",17,28,https://drive.google.com/file/d/15NmIEsHPCtkAOEckuwtgRS3wqqoL63dE/view?usp=drivesdk,pd-production-100123,2025-08-12 00:52:59
019736_S31_M5_vr-mqr-10214.pdf,PDF,Clinical Study Report for Vaccine Candidate vr-mqr-10214,2021,Report,,M5,False,False,False,False,False,"phase 3 study, vr-mqr-10214, clinical research, FDA submission, pharmaceutical development, drug/vaccine identifier, clinical trial, data analysis, CBER, safety data, quality assurance, vaccine candidate, efficacy data, phase 1 study, adverse events, phase 2 study, regulatory compliance",17,19,https://drive.google.com/file/d/1AVz1bVcXVjebZDStQ2vbZ_ysGukVSb_B/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:03
019736_S325_M5_c4591020-sap.pdf,PDF,Statistical Analysis Plan for Protocol C4591020 (PF-07302048),2021-05-05,Protocol,,M5,False,True,False,False,False,"phase-3, immunogenicity, fda, statistical-analysis-plan, demographics, confidential, tolerability, adverse-events, pfizer, systemic-events, local-reactions, Protocol, safety, vaccine-candidate, clinical-trial, covid-19, bnt162b2, regulatory",18,30,https://drive.google.com/file/d/1KWPSvTjdCGI5NsuIeLuHegotMjASEldv/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:07
019736_S31_M5_vr-mqr-10211.pdf,PDF,Clinical Study Report for Vaccine Candidate vr-mqr-10211,2021,report,,M5,False,False,False,False,False,"phase 3 study, FDA submission, pharmaceutical development, drug/vaccine identifier, clinical trial, data analysis, CBER, safety data, quality assurance, vr-mqr-10211, vaccine candidate, clinical study report, efficacy data, phase 1 study, adverse events, phase 2 study, regulatory compliance",17,28,https://drive.google.com/file/d/1TqzRJVrmVLlAUL0qdYdDm7QoKbxrSh2h/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:11
019736_S387_M5_c4591008-interim-protocol.pdf,PDF,"HERO-Together: A post-Emergency Use Authorization observational cohort study to evaluate the safety of the Pfizer-BioNTech COVID-19 vaccine in US healthcare workers, their families, and their communities",2021-04-20,Protocol,"Emily O'Brien, PhD",M5,False,True,False,True,False,"Exclusion, post-authorization study, adverse events, regulatory compliance, FDA emergency use authorization, immunocompromised individuals, real-world data, COVID-19 vaccine, vaccine safety, pregnant individuals, FOIA document, clinical trial protocol, Protocol, Duke Clinical Research Institute, observational cohort study, Pfizer-BioNTech, safety evaluation, healthcare workers, incidence rates",19,43,https://drive.google.com/file/d/1JbvB9MylmHGEmuulYJL_lf2jz6C1VqSZ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:16
019736_S31_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162; PF-07302048) BB-IND 19736 IND Amendment – Clinical: Response to FDA Information Request,2020-07-10,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D.",M1,False,False,False,False,False,"PF-07302048, BioNTech, FDA submission, antibody assays, phase 1/2 study, clinical trial, COVID-19 vaccine, safety data, BNT162, CBER, SARS-CoV-2, vaccine development, BB-IND 19736, phase 2b/3 study, efficacy data, regulatory affairs, Pfizer",17,2,https://drive.google.com/file/d/1QFWKRH5hBr2koWmPghKWRM1N5KF5PfCj/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:20
019736_S387_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) - Phase 4 Clinical Trial",2021-06-30,report,"Özlem Türeci, MD, Neda Aghajani Memar, Pharm.D.",M1,False,False,False,False,False,"Adverse events, PF-07302048, Immunization, Phase 4 clinical trial, FDA submission, Mainz, Germany, New York, USA, Efficacy data, COVID-19 vaccine, SARS-CoV-2, BNT162, BLA 125549, BioNTech SE, Safety data, Regulatory compliance, Vaccine development, Pfizer Global Regulatory Affairs",17,3,https://drive.google.com/file/d/1tPJy0rAH1Ha81ZM5ffhyFWgdyeOoY-F-/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:27
019736_S387_M5_c4591008-interim-abstract.pdf,PDF,"A Post-Emergency Use Authorization Observational Cohort Study to Evaluate the Safety of the Pfizer-BioNTech COVID-19 Vaccine in US Healthcare Workers, Their Families, and Their Communities",2021-06-22,Non-Interventional Study Report Abstract,"Emily O'Brien, PhD",M5,False,True,False,False,False,"communities, safety evaluation, real-world data, pharmacovigilance, age stratification, clinical trial, immunocompromised, Pfizer-BioNTech COVID-19 vaccine, FDA, Protocol, post-EUA observational study, families, healthcare workers, Duke Clinical Research Institute, pregnancy, incidence rates, adverse events, emergency use authorization",18,4,https://drive.google.com/file/d/1nfD8BQXFke4KIuxLtWoSLEP1jC0r5Rve/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:31
019736_S387_M5_c4591008-interim-non-hospitalization.pdf,PDF,BNT162b2 Protocol C4591008 Participant Reported Non-Hospitalization Safety Events of Interest,2021-04-29,report,,M5,False,True,False,False,False,"demographic data, participant safety, data generation, C4591008, clinical trial, FDA, Protocol, data cutoff, vaccine, PFIZER, adverse events, COVID-19, non-hospitalization, medical conditions, BNT162b2, SDTM, data analysis, regulatory compliance",18,72,https://drive.google.com/file/d/1mLcfROMKUnVyVJH57_Y_zbpCsNzMVGjQ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:35
019736_S387_M5_c4591008-interim-demographics.pdf,PDF,BNT162b2 Protocol C4591008 Demographic Data,2021-05-11,report,,M5,False,True,False,False,False,"demographic data, SDTM, FOIA, phase 4 study, clinical trial, source data, FDA, Protocol, data cutoff, vaccine, COVID-19, adverse events, safety, efficacy, BNT162b2, Pfizer, data analysis, regulatory compliance",18,270,https://drive.google.com/file/d/1goUo5akm5pXAnO8Sgzf7PtexFhzpmfHk/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:40
019736_S31_M1_response-ir-06jul2020-c4591001.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BB-IND 19736 M 1.11.3 - Clinical Information Amendment",2020-07-09,report,Pei-Yong Shi,M1,False,True,False,False,False,"PF-07302048, University of Texas Medical Branch, neutralizing antibody assay, BioNTech, Luminex assay, FDA submission, IgG binding assay, assay qualification, clinical trial, COVID-19 vaccine, SARS-CoV-2, BNT162, regulatory compliance, Protocol, BB-IND 19736, Phase 2b/3, Pfizer, Phase 1/2",18,4,https://drive.google.com/file/d/1BERnvUbN5zpfI8BaCVAyDfEVYVC0albP/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:44
019736_S268_M5_wi235284-protocol.pdf,PDF,Determining RSV Burden and Outcomes in Pregnant Women and Older Adults Requiring Hospitalization,2021-03-23,protocol,,M5,False,True,False,True,False,"study population, Exclusion, clinical trial, respiratory syncytial virus, covid-19, data analysis, regulatory, older adults, pregnant women, inclusion/exclusion criteria, vaccine effectiveness, test-negative controls, efficacy, study objectives, Protocol, study methods, healthcare, safety, hospitalization",19,60,https://drive.google.com/file/d/18xSA5Q_9FXQsnNjQwJwuafdoT91OaGfg/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:52
019736_S268_M5_wi255886-protocol.pdf,PDF,Avon Community Acquired Pneumonia Study (Avon CAP) Protocol,2021-01-30,Protocol,"Professor Adam Finn, David Baum, Dr Catherine Hyams, Dr Izak Heys, Dr Rajeka Lazarus, Dr Jennifer Oliver, Leon Danon, Jo Southern, Beth Begier, Robin Hubler, Bradford Gessner, Sharon Gray, Harish Madhava, Fred Angulo, John M. McLaughlin",M5,False,True,False,False,False,"Acute Lower Respiratory Tract Disease Surveillance, RSV, Global Epidemiology, IRAS 283899, University of Bristol Sponsor, UOB Confidential, NIHR Academic Clinical Fellow, Version 2.2, Respiratory Medicine, FOIA Document, Collaborators, Pfizer Funded Study, Pneumococcal Vaccines, Protocol, Infectious Diseases and Microbiology, Research Programme Manager, Clinical Trial Protocol, Pediatric Infectious Diseases",18,65,https://drive.google.com/file/d/12c02R24XnCxT7oNGBy144ETvFB5UANIQ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:53:58
019736_S31_M5_vr-tm-10293.pdf,PDF,Single-plex Luminex Assay for Quantitation of IgG Antibodies to SARS-CoV-2 S 1 Protein in Human Serum,2020-01-01,protocol,,M5,False,False,False,False,False,"biomarker testing, antibody quantitation, vaccine research, quality control, Luminex assay, FDA submission, clinical trial, technical protocol, SARS-CoV-2, vaccine development, efficacy, safety, human serum, Pearl River, Pfizer, data analysis, regulatory compliance",17,19,https://drive.google.com/file/d/1M0kSNa2gxvMM7M4Qchhpv3g5BOhGkQvi/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:02
019736_S31_M5_vr-mqr-10214-att01-shi-sop-10011.pdf,PDF,Manual 96-well Neutralization Assay for the Detection of Functional Antibodies to SARS-CoV-2 in Test Serum using Cytation 7 Image Reader,2022-01-01,SOP (Standard Operating Procedure),Shi Lab,M5,False,False,False,False,False,"Cell Culture, Clinical Trial, UTMB (University of Texas Medical Branch), Viral Infection, Cytation 7 Image Reader, Imaging Techniques, Antibody Detection, SARS-CoV-2, Regulatory Compliance, Biosafety, Procedure Documentation, Confidential Information, Quality Control, Neutralization Assay, Vaccine Development, Serum Analysis, Pharmaceutical Research",17,16,https://drive.google.com/file/d/1ypTjfwNlE98KhQBNk_4W0n56iMxofVK5/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:06
019736_S296_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) 019736 Prophylactic Immunization Against COVID-19 in Adults ≥ 16 Years of Age",2021-04-15,report,"Özlem Türeci, MD, Neda Aghajani Memar, Pharm.D.",M1,False,False,False,False,False,"PF-07302048, adult population, FDA submission, Mainz, Germany, pharmaceutical development, clinical trial, New York, USA, COVID-19 vaccine, prophylactic immunization, BNT162, safety data, BioNTech SE, vaccine identification, efficacy data, adverse events, Pfizer Global Regulatory Affairs, regulatory compliance",17,3,https://drive.google.com/file/d/1nJh_I_YCBDQ53vSb2rSbJedL99_1RsWS/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:12
019736_S387_M5_c4591008-interim-excluded-subjects.pdf,PDF,BNT162b2 Protocol C4591008 Subjects Excluded from the Analyses,2021-04-29,report,,M5,False,True,False,True,False,"Exclusion, clinical trial, safety data, enrollment, sdtm, vaccine administration, adverse events, data analysis, regulatory, fda, data cutoff, protocol, excluded subjects, demographic data, Protocol, pfizer, vaccine, bnt162b2, c4591008",19,13,https://drive.google.com/file/d/1u24vrss8goqzDP38ISq5RM36-1DIxNW5/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:15
019736_S387_M5_c4591008-interim-protocol-deviations.pdf,PDF,BNT162b2 Protocol C4591008 Participant Reported Death,2021-05-24,report,PFIZER,M5,False,True,False,False,False,"BNT162b2 vaccine, demographic data, FOIA document, pharmaceutical research, C4591008 study, clinical trial, FDA regulation, participant death, data management, Protocol, data cutoff, COVID-19 related, source data generation, vaccine safety, SDTM data format, adverse event reporting, protocol deviation, regulatory submission",18,1,https://drive.google.com/file/d/11egsaZAp1g9th8eExMVuVn9v50Jznowx/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:18
019736_S157_M5_vr-mvp-10074.pdf,PDF,Validation Protocol for the SARS-CoV-2 mNeonGreen Virus Microneutralization Assay,2020-12-02,protocol,,M5,False,True,False,False,False,"antibody-testing, fda, vaccine-research, regulatory-compliance, assay-development, virus-detection, epidemiological-studies, quality-control, pfizer, pearl-river-ny, Protocol, sars-cov-2, preclinical-studies, clinical-trial, data-analysis, validation-protocol, microneutralization-assay, quantitative-analysis",18,20,https://drive.google.com/file/d/11ILfcfeJqicwAb-Ba6izTfYq13DpEY-x/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:23
019736_S222_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 CMC Amendment – Briefing Package Type C Written Response Only,2021-02-18,Briefing document,"Marion Gruber, Ph.D., Neda Aghajani Memar, Pharm.D., Ramachandra S. Naik, Ph.D.",M1,False,True,False,False,False,"Briefing package, Type C meeting, PF-07302048, Clinical study C4591020, Regulatory affairs, FDA CBER, Safety and immunogenicity, Healthy adults 18-55 years, Written response only, IND amendment, Informed consent document, COVID-19 vaccine, Lyophilized formulation, BNT162, CMC amendment, Protocol, BB-IND 19736, Ready-to-use formulation",18,2,https://drive.google.com/file/d/1BvNtaMiDCoIM95IsTMFiJ-LGvyDVs3LK/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:27
019736_S268_M5_c4591014-protocol.pdf,PDF,Pfizer-BioNTech COVID-19 BNT162b2 Vaccine Effectiveness Study - Kaiser Permanente Southern California,2021-03-22,protocol,"Sara Y. Tartof, Heidi Fischer, Jeff Slezak, John M. McLaughlin, Fred Angulo",M5,False,True,False,False,False,"Pfizer-BioNTech, Kaiser Permanente Southern California, retrospective cohort design, non-interventional study, medical development and scientific/clinical affairs, secondary data collection, vaccine effectiveness, clinical trial protocol, SARS-CoV-2 infection, COVID-19, test-negative case-control design, vaccine effectiveness by patient characteristics, acute respiratory illness, Protocol, vaccine effectiveness by strain type, BNT162b2, retrospective database study, regulatory compliance",18,42,https://drive.google.com/file/d/1BzmOH5UdSMb4PEUPphxraNOxga1pIhIY/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:33
019736_S222_M1_1571.pdf,PDF,Briefing Document for Type C Written Response Only,2021-02-18,report,"Özlem Türeci, Neda Aghajani Memar",M1,False,False,False,False,False,"prophylactic-immunization, covid-19-vaccine, pf-07302048, fda-submission, new-york, safety-data, bnt162, adverse-events, efficacy-data, mainz, biontech, pfizer, regulatory-affairs, clinical-trial, vaccine-development, type-c-meeting, written-response",17,3,https://drive.google.com/file/d/1qxVa6ruxd1tbKRDPB6YsbUrzH4WLYCe9/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:38
019736_S196_M5_c4591011-protocol.pdf,PDF,Active Safety Surveillance of the Pfizer-BioNTech COVID-19 Vaccine in the United States Department of Defense Population Following Emergency Use Authorization,2021-01-29,protocol,"Renu Garg, Mei Sheng Duh",M5,False,True,False,False,False,"covid-19 vaccine, vaccine distribution, vaccine efficacy, non-interventional study, utilization patterns, sub-cohorts, real-world evidence, united states department of defense, clinical trial protocol, Protocol, adverse events of special interest, pfizer-biontech, post-authorization study, vaccine safety, safety surveillance, emergency use authorization, epidemiological data, regulatory compliance",18,171,https://drive.google.com/file/d/1hdKInZRYJxmqHfcOEsQwIrhTniAdrR0G/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:45
019736_S222_M5_c4591020-informed-consent-form.pdf,PDF,Phase 3 Clinical Study Informed Consent Template,2021-02-02,Informed Consent Form,,M5,False,True,False,False,False,"phase 3 study, clinical research, informed consent, clinical trial, FDA, safety data, Protocol, C4591020, protocol, United States, study participant, voluntary participation, template, study team, efficacy data, adverse events, Pfizer, regulatory compliance",18,25,https://drive.google.com/file/d/1BBl8os8Y7xlvLrYxR0SLhZfTngAZNE5_/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:49
019736_S222_M5_c4591020-protocol.pdf,PDF,"A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of the Vaccine Candidate BNT162b2 Against COVID-19 in Healthy Adults 18 Through 55 Years of Age",2021-01-18,Protocol,,M5,False,True,False,True,False,"phase 3 study, Exclusion, confidential, adverse events, regulatory submission, immunogenicity, EudraCT, COVID-19 vaccine, healthy adults, BNT162b2, PF-07302048, FDA, clinical trial protocol, Protocol, Pfizer, BioNTech, tolerability, safety, lyophilized formulation",19,87,https://drive.google.com/file/d/19TbLKepshM8JOFFVbrlDzi2zhbKzaLSa/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:53
019736_S157_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) Prophylactic Immunization in Adults",2020-12-04,report,"Özlem Türeci, Elisa Harkins",M1,False,False,False,False,False,"PF-07302048, BioNTech, Mainz, Germany, clinical trial, BB-IND 013812, FDA, COVID-19 vaccine, prophylactic immunization, BNT162, Collegeville, PA, efficacy, BLA 125549, safety, BB-IND 013278, regulatory affairs, adverse events, Pfizer",17,3,https://drive.google.com/file/d/1JY6-MKR5HH4E8-OHQ2tsZHDh2GsQdGF9/view?usp=drivesdk,pd-production-100123,2025-08-12 00:54:59
019736_S196_M5_c4591012-protocol.pdf,PDF,Post-Emergency Use Authorization Active Safety Surveillance Study among Individuals in the Veteran's Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine,2021-01-27,protocol,"Yinong Young-Xu, Cynthia de Luise, Mei Sheng Duh",M5,False,True,False,False,False,"Pfizer-BioNTech, comorbidities, Veterans Affairs Health System, confidential document, single-dose recipients, epidemiology, data analysis, adverse event surveillance, COVID-19 vaccine, clinical trial protocol, elderly, Protocol, post-authorization safety study, United States, prior SARS-CoV-2 infection, immunocompromised, vaccine utilization patterns, regulatory compliance",18,145,https://drive.google.com/file/d/1H2I2txcPEOucTBLgOw6oBHzj7KeLpHJv/view?usp=drivesdk,pd-production-100123,2025-08-12 00:55:09
019736_S196_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 IND Amendment - Post-authorization Safety Studies,2021-01-29,letter,"Marion Gruber, Ph.D., Neda Aghajani Memar, Pharm.D., Ramachandra S. Naik, Ph.D.",M1,False,True,False,False,False,"Department of Defense, regulatory affairs, pharmacovigilance, BioNTech, FDA submission, clinical trial, New York, COVID-19 vaccine, Protocol, Silver Spring, post-authorization study, healthcare workers, global product development, data reporting, safety surveillance, Veterans Affairs, adverse events, Pfizer",18,2,https://drive.google.com/file/d/1hNd_EVNsQv71RyiNn-UsaZhLcDRUPL68/view?usp=drivesdk,pd-production-100123,2025-08-12 00:55:13
019736_S268_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) Phase 4 Clinical Trial",2021-03-30,report,"Özlem Türeci, MD, Neda Aghajani Memar",M1,False,False,False,False,False,"Pfizer Global Regulatory Affairs - Vaccines, Adverse events, PF-07302048, Regulatory affairs, Clinical trial documentation, Phase 4 clinical trial, FDA submission, Mainz, Germany, New York, USA, Efficacy data, COVID-19 vaccine, BNT162, Compliance, BioNTech SE, Quality assurance, Safety data, Prophylactic immunization",17,3,https://drive.google.com/file/d/1cXZmLQxN1bqSVKi2l3msHIoBDYQA80xJ/view?usp=drivesdk,pd-production-100123,2025-08-12 00:55:19
019736_S196_M1_1571.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) Prophylactic Immunization Phase 4 Study",2021-01-29,report,"Özlem Türeci, Neda Aghajani Memar",M1,False,False,False,False,False,"Adverse events, PF-07302048, FOIA document, Phase 4 clinical trial, Regulatory submission, Mainz, Germany, FDA regulatory, New York, USA, Efficacy data, COVID-19 vaccine, BNT162, Compliance, BioNTech SE, Quality assurance, Safety data, Pfizer Global Regulatory Affairs, Prophylactic immunization",17,3,https://drive.google.com/file/d/1bWeU4WWZXTV0ohq5C25zr6h6V_lAh4BO/view?usp=drivesdk,pd-production-100123,2025-08-12 00:55:25
019736_S196_M5_c4591008-protocol.pdf,PDF,HERO Together: A post-Emergency Use Authorization observational cohort study to evaluate the safety of the Pfizer-BioNTech COVID-19 vaccine in US healthcare workers,2021-01-27,protocol,"Emily O'Brien, PhD",M5,False,True,False,False,False,"Pfizer-BioNTech, safety evaluation, clinical significance, non-interventional study, age stratification, pregnancy, observational cohort, immunocompromised, COVID-19 vaccine, Protocol, protocol, healthcare workers, post-authorization study, FDA approval, Duke Clinical Research Institute, incidence rates, adverse events, emergency use authorization",18,43,https://drive.google.com/file/d/15GLjUWMQYsRilpTH1oIDkWtE_U-p90s9/view?usp=drivesdk,pd-production-100123,2025-08-12 00:55:29
019736_S268_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 IND Amendment – Post-authorization Vaccine Effectiveness Studies,2021-03-31,letter,"Marion Gruber, Ph.D., Pfizer Inc.",M1,False,True,False,False,False,"post-authorization, PF-07302048, product development, regulatory affairs, older adults, pregnant women, clinical trial, vaccine effectiveness, IND amendment, FDA, BNT162, COVID-19, Protocol, efficacy, safety, respiratory syncytial virus, test negative design, Emory University",18,3,https://drive.google.com/file/d/13wzMsteWqw4Dy2IjM-V_xwYdgaaNyFh8/view?usp=drivesdk,pd-production-100123,2025-08-12 00:55:33
019736_S157_M1_cover.pdf,PDF,COVID-19 Vaccine (BNT162/PF-07302048) BB-IND 19736 IND Amendment - New Protocol,2020-12-04,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D.",M1,False,True,False,False,False,"COVID-19 prevention, PF-07302048, microneutralization assay, quality control, BioNTech, FDA submission, vaccine approval, serology assay, clinical trial, vaccine development, BNT162, Collegeville, PA, Protocol, BB-IND 19736, regulatory affairs, SARS-CoV-2 detection, Pfizer, data validation",18,2,https://drive.google.com/file/d/19UpxUQBkRlDowpzVdcxVStdgAt9A2NWk/view?usp=drivesdk,pd-production-100123,2025-08-12 00:55:36
FDA-CBER-2021-5683-0484442-0484451-125742_S1_M5_bnt162-01-S-D-ex.xpt,XPT,FDA-CBER-2021-5683-0484442-0484451-125742 S1 M5 bnt162-01-S-D-ex,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1OJsGSU-sUVolkYjKMcAQvBCLFhE9nHjw/view?usp=drivesdk,pd-production-100322,2025-08-12 00:55:38
FDA-CBER-2021-5683-0484461-0537913-125742_S1_M5_c4591001-S-D-face.xpt,XPT,FDA-CBER-2021-5683-0484461-0537913-125742 S1 M5 c4591001-S-D-face,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1YA1NPC2jU5UqDppF7nUcvzbrTCbxI7DW/view?usp=drivesdk,pd-production-100322,2025-08-12 00:56:15
FDA-CBER-2021-5683-0484452-0484460-125742_S1_M5_bnt162-01-S-D-ti.xpt,XPT,FDA-CBER-2021-5683-0484452-0484460-125742 S1 M5 bnt162-01-S-D-ti,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1-UxG8VonPghz5tWUUf2lW_9yV_B5_0E9/view?usp=drivesdk,pd-production-100322,2025-08-12 00:56:17
FDA-CBER-2021-5683-0484379-0484383-125742_S1_M5_bnt162-01-S-D-dm.xpt,XPT,FDA-CBER-2021-5683-0484379-0484383-125742 S1 M5 bnt162-01-S-D-dm,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1uPoBhDu84N-v85aKNZBYCC5bEMqr2Hbb/view?usp=drivesdk,pd-production-100322,2025-08-12 00:56:18
FDA-CBER-2021-5683-0484419-0484441-125742_S1_M5_bnt162-01-S-D-eg.xpt,XPT,FDA-CBER-2021-5683-0484419-0484441-125742 S1 M5 bnt162-01-S-D-eg,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1Fw82DPYumkPHbW5X77i58kFJ1lEqpymg/view?usp=drivesdk,pd-production-100322,2025-08-12 00:56:19
FDA-CBER-2021-5683-0484384-0484408-125742_S1_M5_bnt162-01-S-D-ds.xpt,XPT,FDA-CBER-2021-5683-0484384-0484408-125742 S1 M5 bnt162-01-S-D-ds,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/16z9kUNZRV5LGpjejWpuNo_p9e-k7T7kJ/view?usp=drivesdk,pd-production-100322,2025-08-12 00:56:21
FDA-CBER-2021-5683-0537914-0539336-125742_S1_M5_bnt162-01-A-D-adfacevd.xpt,XPT,FDA-CBER-2021-5683-0537914-0539336-125742 S1 M5 bnt162-01-A-D-adfacevd,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1Aj_zAj4bWmdjRtSWdX8H0edku3-3d5EY/view?usp=drivesdk,pd-production-100322,2025-08-12 00:56:26
FDA-CBER-2021-5683-0484342-0484355-125742_S1_M5_bnt162-01-S-D-ae.xpt,XPT,FDA-CBER-2021-5683-0484342-0484355-125742 S1 M5 bnt162-01-S-D-ae,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1iRp3yBlOoWZct2DD5dwJ7zuK3vZBYc8V/view?usp=drivesdk,pd-production-100322,2025-08-12 00:56:27
FDA-CBER-2021-5683-0539337-0539815-125742_S1_M5_bnt162-01-A-D-advs.xpt,XPT,FDA-CBER-2021-5683-0539337-0539815-125742 S1 M5 bnt162-01-A-D-advs,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1lruQHjmSLZUVu1O9BxtoKaLpbfdUSfRs/view?usp=drivesdk,pd-production-100322,2025-08-12 00:56:29
FDA-CBER-2021-5683-0484356-0484378-125742_S1_M5_bnt162-01-S-D-xa.xpt,XPT,FDA-CBER-2021-5683-0484356-0484378-125742 S1 M5 bnt162-01-S-D-xa,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1Zf_Lr9G0b1YT2xHvsE2vIzZxxrJxnvLC/view?usp=drivesdk,pd-production-100322,2025-08-12 00:56:30
FDA-CBER-2021-5683-0484409-0484418-125742_S1_M5_bnt162-01-S-D-ec.xpt,XPT,FDA-CBER-2021-5683-0484409-0484418-125742 S1 M5 bnt162-01-S-D-ec,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1gzOvRdUFeQtM2BrLZgNEjx4cwEgIiXb0/view?usp=drivesdk,pd-production-100322,2025-08-12 00:56:32
FDA-CBER-2021-5683-0539816-0593326-125742_S1_M5_c4591001-01-S-Supp-D-face.xpt,XPT,FDA-CBER-2021-5683-0539816-0593326-125742 S1 M5 c4591001-01-S-Supp-D-face,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/11XjVaY9a-eDvjxe6N8QO83zUQCwRg1SZ/view?usp=drivesdk,pd-production-110122,2025-08-12 00:57:05
125742_S1_M4_20256434.pdf,PDF,"A Combined Fertility and Developmental Study (Including Teratogenicity and Postnatal Investigations) of BNT162b1, BNT162b2 and BNT162b3 by Intramuscular Administration in the Wistar Rat",2020-12-22,report,"BioNtech SE, Charles River Laboratories France Safety Assessment SAS",M4,False,False,False,False,False,"BNT162b1, preclinical study, safety assessment, Saint-Germain-Nuelles, France, FDA submission, Mainz, Germany, pharmaceutical development, clinical trial, intramuscular administration, fertility, developmental toxicity, BNT162b3, Wistar rat, GLP compliance, regulatory affairs, BNT162b2, teratogenicity",17,1145,https://drive.google.com/file/d/18CJ_QmA8bUYjfQIBodGv34dQqFbAifnV/view?usp=drivesdk,pd-production-110122,2025-08-12 00:57:17
FDA-CBER-2021-5683-0593621-0593664-125742_S1_M5_bnt162-01-S-Supp-D-suppae.xpt,XPT,FDA-CBER-2021-5683-0593621-0593664-125742 S1 M5 bnt162-01-S-Supp-D-suppae,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1tvfQLIMR3hSUIu_zC8giVk_k8yy1-nx2/view?usp=drivesdk,pd-production-110122,2025-08-12 00:57:18
FDA-CBER-2021-5683-0593744-0593769-125742_S1_M5_bnt162-01-S-Supp-D-suppds.xpt,XPT,FDA-CBER-2021-5683-0593744-0593769-125742 S1 M5 bnt162-01-S-Supp-D-suppds,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1AovzAZfmCIFhAu_Jh5jLQfaSCXnGuHai/view?usp=drivesdk,pd-production-110122,2025-08-12 00:57:20
FDA-CBER-2021-5683-0593482-0593595-125742_S1_M5_bnt162-01-S-D-pe.xpt,XPT,FDA-CBER-2021-5683-0593482-0593595-125742 S1 M5 bnt162-01-S-D-pe,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1_DvAHd7omXsADcmfVmGkqc0Y998vtu42/view?usp=drivesdk,pd-production-110122,2025-08-12 00:57:21
FDA-CBER-2021-5683-0593770-0593800-125742_S1_M5_bnt162-01-S-Supp-D-suppec.xpt,XPT,FDA-CBER-2021-5683-0593770-0593800-125742 S1 M5 bnt162-01-S-Supp-D-suppec,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1S1aWMfj1JONy8wqAWz7xvfCFW-DS5sNF/view?usp=drivesdk,pd-production-110122,2025-08-12 00:57:22
FDA-CBER-2021-5683-0593665-0593743-125742_S1_M5_bnt162-01-S-Supp-D-suppcm.xpt,XPT,FDA-CBER-2021-5683-0593665-0593743-125742 S1 M5 bnt162-01-S-Supp-D-suppcm,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1w_GNf9tVG3js4bDK2fX74RgU26jkiaRS/view?usp=drivesdk,pd-production-110122,2025-08-12 00:57:24
FDA-CBER-2021-5683-0593327-0593481-125742_S1_M5_bnt162-01-S-D-ce.xpt,XPT,FDA-CBER-2021-5683-0593327-0593481-125742 S1 M5 bnt162-01-S-D-ce,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1UOsf3YJullroB47moBr9iXEEzhWLgJrR/view?usp=drivesdk,pd-production-110122,2025-08-12 00:57:26
FDA-CBER-2021-5683-0593596-0593620-125742_S1_M5_bnt162-01-S-D-se.xpt,XPT,FDA-CBER-2021-5683-0593596-0593620-125742 S1 M5 bnt162-01-S-D-se,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/19VloLVAkMtji6xZDRu4qzy_eJsXF5ieq/view?usp=drivesdk,pd-production-110122,2025-08-12 00:57:27
FDA-CBER-2021-5683-0593801-0593831-125742_S1_M5_bnt162-01-S-Supp-D-suppex.xpt,XPT,FDA-CBER-2021-5683-0593801-0593831-125742 S1 M5 bnt162-01-S-Supp-D-suppex,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1ON3gqFmPG_BvZ0_W1E0v27jhUlgi9vfc/view?usp=drivesdk,pd-production-110122,2025-08-12 00:57:28
105_BLA 125742-0_08-20-2021_Telecon_Advice_Information.pdf,PDF,Teleconference Advice on COVID-19 Vaccine Lot Numbers,2021-08-20,email,"Naik, Ramachandra, Boyce, Donna, Malarkey, Mary, Gruber, Marion, Harkins Tull, Elisa, Rohlfing, Paul, Aghajani Memar, Neda, Smith, Michael (CBER), Gottschalk, Laura",,False,False,False,False,False,"Center for Biologics Evaluation and Research, FDA Regulatory Advice, Vaccine Compliance Requirements, Lot Release Compliance, Vaccine Safety and Efficacy, Vaccine Labeling and Promotion, Vaccine Regulatory Guidance, Vaccine Labeling and Packaging, COMIRNATY BLA, Pfizer-BioNTech Correspondence, Adverse Event Monitoring, Vaccine Inventory and Distribution, Vaccine Lot Traceability, COVID-19 Vaccine, Office of Vaccines Research and Review, Regulatory Submission and Approval, Clinical Trial Data",17,3,https://drive.google.com/file/d/1p2i8jSulPoBhbcf39kdok_dG-wh0xaM5/view?usp=drivesdk,pd-production-110123,2025-08-12 00:57:33
100_BLA 125742-0_08-20-2021_Memo_Other.pdf,PDF,COMIRNATY (BioNTech Manufacturing GmbH) COVID-19 mRNA Vaccine Product Testing Plan,2021-08-20,memo,"Marion Gruber, PhD, Jerry P. Weir, PhD, Maryna Eichelberger, PhD, John A. Eltermann, Jr., MS, RPh, Suzanne Carter",,False,True,True,False,False,"COVID-19 mRNA Vaccine, Vaccine Development, CBER Review, Clinical Trials, Exempt, FOIA Document, COMIRNATY, Product Testing Plan, Biological Product, Protocol, Regulatory Compliance, Quality Assurance, Surveillance, Pharmaceutical Manufacturing, FDA Approval, Lot Release, Efficacy and Safety Data, BioNTech Manufacturing GmbH, Exemption",19,5,https://drive.google.com/file/d/1VpExKmVm6KqSNw1i29bsa51_6_nVReop/view?usp=drivesdk,pd-production-110123,2025-08-12 00:57:37
103_2_BLA 125742-0_08-20-2021_Memo_Test Results.pdf,PDF,Test Results Memo for COMIRNATY (COVID-19 mRNA Vaccine),2021-08-20,memo,"Hsiaoling Wang, Tao Pan, Kori Francis, Maryna Eichelberger, Mary A. Malarkey",,False,False,False,False,False,"FOIA document, quality control, test results, drug product, acceptance criteria, FDA submission, OCBQ, COMIRNATY, lipid nanoparticle size, COVID-19 vaccine, CBER, DBSQC, regulatory compliance, LACBRP, Silver Spring, MD, polydispersity index, pharmaceutical/clinical trial",17,2,https://drive.google.com/file/d/1Mb2MOXdcrqfpOy3MgRoqJMmGFz9VZ1Ui/view?usp=drivesdk,pd-production-110123,2025-08-12 00:57:41
100A_BLA 125742-0_08-20-2021_Memo_Other.pdf,PDF,COMIRNATY (BioNTech Manufacturing GmbH) COVID-19 mRNA Vaccine Product Testing Plan,2021-08-20,Memo,"Marion Gruber, PhD, Jerry P. Weir, PhD, Maryna Eichelberger, PhD, John A. Eltermann, Jr., MS, RPh, Suzanne Carter",,False,True,True,False,False,"Safety, FDA Regulatory Approval, COVID-19 mRNA Vaccine, Potency, Purity, Efficacy, CBER Review, Availability, Exempt, COMIRNATY, Product Testing Plan, Laboratory Quality System, Protocol, Surveillance, 21 CFR 610.2(a), Lot Release, Compliance, BioNTech Manufacturing GmbH, Exemption",19,5,https://drive.google.com/file/d/1YJQOMXaDeXe3l3UKTImahPXyDIDmmpvx/view?usp=drivesdk,pd-production-110123,2025-08-12 00:57:45
101_Courtesy Copy_BLA 125742-0_Pharmacovigilance Plan Review-Addendum Memo - COMIRNATY.pdf,PDF,Pharmacovigilance Plan Review: Addendum Memo,2021-08-06,memo,"Meghna Alimchandani, MD, Kerry Welsh, MD, Ramachandra Naik, PhD, Manette Niu, MD, Narayan Nair, MD, Deborah Thompson, MD",,False,False,False,False,False,"post-authorization, clinical-trials, pharmacovigilance, epidemiology, regulatory-review, COMIRNATY, Pfizer, FDA, CBER, COVID-19, VAERS, vaccine-safety, adverse-events, data-analysis, BNT162b2, OBE, DE",17,9,https://drive.google.com/file/d/1VT12lDdQCtfNedyO9r5raRBVZDGf5HMZ/view?usp=drivesdk,pd-production-110123,2025-08-12 00:57:49
102_1_BLA 125742-0_08-20-2021_Memo_Test Results.pdf,PDF,"CBER In-support Sterility and Bacterial Endotoxin Test (BET) Results for COVID-19 mRNA Vaccine, COMIRNATY",2021-08-20,memo,"Hyesuk Kong, Karla Garcia, Seth Schulte, Mary A. Malarkey, Maryna Eichelberger, James L. Kenney, Michael Smith, Laura Gottschalk, Ramachandra Naik",,False,False,False,False,False,"COVID-19 mRNA vaccine, Vaccine lot release, Microbiology laboratory, COMIRNATY, Bacterial endotoxin testing, Pfizer partnership, Membrane filtration, Sterility testing, Quality control, Compliance, Compendial test methods, Spike recovery, BLA 125742/0, Regulatory approval, FDA-CBER document, Acceptance criteria, In-support testing",17,2,https://drive.google.com/file/d/1Yvh8-wi2SUHqv2Ooblk8gmDC4Cfsl-hY/view?usp=drivesdk,pd-production-110123,2025-08-12 00:57:53
118_1_BLA 125742-0_08-22-2021_Inspection Related_Inspect.pdf,PDF,FDA Inspection Report for Pfizer Andover Facility,2021-07,report,Pfizer,,False,False,False,False,False,"Standard operating procedures, Deviation investigations, BLA 125742-0, FDA inspection, Pfizer Andover facility, COVID-19 vaccine, Pre-License Inspection (PLI), Cleaning validation, CDER, Compliance, BNT162b2 drug substance, Quality control, Regulatory approval, Environmental monitoring, Facility maintenance, Raw material storage, New England District Office",17,3,https://drive.google.com/file/d/1RXa7WL9DGwtK95h6bLX2gIE-HFPq1U-1/view?usp=drivesdk,pd-production-110123,2025-08-12 00:57:56
10_BLA 125742-11_12-22-2021_Memo_Committee Memo_CMC.pdf,PDF,CMC Review Memorandum,2021-12-22,memo,"Xiao Wang, Anissa Cheung",,False,False,False,False,False,"regulatory-submission, cmc-review, biologics-license-application, covid-19-vaccine, lipid-nanoparticles, product-description, manufacturing-process, sars-cov-2-spike-protein, process-validation, process-parameter, product-correspondence, quality-control, biontech, fda-review, pfizer, ovrr-dvp, mrna-vaccine",17,2,https://drive.google.com/file/d/1yogm5nxQGLZsrMM10UWA9RoR8SsDmkyH/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:00
116_BLA 125742-0_08-21-2021_Inspection Related_Establi.pdf,PDF,Establishment Inspection Report,2021-07-19,report,KRJ,,False,False,False,False,False,"complaints, production system, laboratory control system, Wyeth Pharmaceuticals, pre-license inspection, Wyeth BioPharma Division, materials system, quality systems, eNSpect assignment #204656, facilities and equipment, adverse events, Center for Biologics Evaluation, recall procedures, drug substance manufacturing, Andover, MA, FEI: 1222181, regulatory compliance",17,86,https://drive.google.com/file/d/1bd6opFB-tWSz8WtcYiZph5WOtGko_bLm/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:05
117_2_BLA 125742-0_08-22-2021_Inspection Related_Inspect.pdf,PDF,Biologics License Application (BLA) 125742-0 Inspection-Related Documents,2021-08-22,Regulatory Submission,,,False,False,False,False,False,"Pharmaceutical Manufacturing, Clinical Trials, BLA 125742-0, FOIA (Freedom of Information Act), Regulatory Submission, Efficacy Data, CBER (Center for Biologics Evaluation and Research), Adverse Events, Drug Approval Process, Compliance, Biologics License Application, FDA Inspection, Quality Assurance, Regulatory Affairs, Safety Data, Vaccine Development, Pharmaceutical Development",17,3,https://drive.google.com/file/d/16-QUAVo-2QbnlGj2BPZaRzPIDA1znKve/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:09
119_Courtesy Copy_BLA 125742-0_Real World Evidence BLA Memo - COMIRNATY.pdf,PDF,Real World Evidence BLA Memorandum,2021-05-18,memo,"Yun Lu, PhD, Ramachandra Naik, PhD, Richard Forshee, PhD",,False,True,False,False,False,"BLA 125742, FOIA document, Pharmaceutical clinical trials, Regulatory submission, Post-authorization studies, Intramuscular injection, FDA review, Real-world evidence, COMIRNATY, Vaccine safety, Epidemiology, COVID-19 vaccine, Protocol, Biologics evaluation, Biostatistics, Pharmacovigilance plan, Vaccine product information, Vaccine effectiveness",18,7,https://drive.google.com/file/d/1CQfXog_xzndUygpA0-k10kuGnY-IymPw/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:13
"109_Courtesy Copy_2_BLA 125742-0_CMC Review Memo, August 21, 2021 - COMIRNATY.pdf",PDF,CMC Review Memo for BLA 125742-0 (COMIRNATY),2021-08-21,memo,"Xiao Wang, Anissa Cheung, Keith Peden, Robin Levis, Jerry Weir, Ramachandra Naik, Michael Smith, Laura Gottschalk",,False,False,False,False,False,"product-characterization, bla-125742, cmc-review, regulatory-submission, covid-19-vaccine, ovrr-department, analytical-methods, stability-data, manufacturing-process, drug-substance, comirnaty, process-validation, good-manufacturing-practice, clinical-trial-material, fda-review, pfizer-biontech, quality-attributes",17,63,https://drive.google.com/file/d/1G6TJDhhH_IHSzW8Fn7XICJgdkJHl9sld/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:20
111_BLA 125742-0_08-21-2021_Telecon_Advice.pdf,PDF,Teleconference Advice on BLA 125742/0,2021-08-21,email,"Naik, Ramachandra, Harkins Tull, Elisa, Smith, Michael (CBER), Gottschalk, Laura, Boyce, Donna, Devlin, Carmel M",,False,False,False,False,False,"post-marketing-commitments, bla-125742, regulatory-submission, safety-efficacy-review, quality-compliance, package-insert, pharmaceutical-development, fda-communication, data-exchange, clinical-trial-data, us-based, teleconference-meeting, regulatory-affairs, email-correspondence, vaccine-approval-process, eua-fact-sheets, pfizer-vaccine",17,1,https://drive.google.com/file/d/1pkm9joFpQeLykGgKXF-vVuIrkFjTU5Wf/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:23
110_1_Courtesy Copy_BLA 125742-0_Analytical Method Review Memo - COMIRNATY.pdf,PDF,Analytical Method Review Memo - COMIRNATY,2021-08-20,memo,"Emnet Yitbarek, Kori Francis, Hsiaoling Wang, Tao Pan, Esmeralda Alvarado-Facundo, Muhammad Shahabuddin, Anil Choudhary, Karla Garcia, James Kenney, Simleen Kaur, Maryna Eichelberger, Mary A. Malarkey",,False,False,False,False,False,"analytical methods, BLA 125742, quality control, drug product, lot release, BioNTech, OCBQ, COMIRNATY, FDA, COVID-19 vaccine, SARS-CoV-2, drug substance, lipid nanoparticle, regulatory compliance, method validation, Pfizer, DBSQC",17,31,https://drive.google.com/file/d/1HqITlHkMTsYZ_NzvUOtSUxWIDNOgnyo9/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:29
108_BLA 125742-0_08-21-2021_Inspection Related_Inspect.pdf,PDF,"Review Memorandum - BioNTech Manufacturing GmbH in partnership with Pfizer, Inc.: to provide for review of the responses to the 483 Inspectional Observations issued during the July 19 - 23, 2021, Pre-License Inspection (PLI) of Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC (referred to as Pfizer Andover; FEI: 1222181)"",","2021-08-21"",",document,,,False,False,False,False,False,"2021, FOIA-document, needs-review",3,29,https://drive.google.com/file/d/1x8zoJZ8dPjSSLVhZHbnuAmNjKFMjgEyh/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:34
107A_1_BLA 125742-0_08-20-2021_Telecon_Labeling via FAX_e.pdf,PDF,Comments regarding inclusion of draft carton and container labels in a single amendment,2021-08-18,email,"Gottschalk, Laura, Harkins Tull, Elisa, Smith, Michael (CBER), Naik, Ramachandra, Devlin, Carmel M, Aghajani Memar, Neda",,False,False,False,False,False,"pharmaceutical-regulatory-affairs, covid-19-vaccine, vaccine-distribution, regulatory-compliance, vaccine-efficacy, fda-communications, comirnaty-vaccine, regulatory-review, pharmaceutical-quality, carton-and-container-labels, product-labeling, clinical-trial-data, vaccine-safety, vaccine-development, fda-submission, vaccine-manufacturing, vaccine-approval-process",17,2,https://drive.google.com/file/d/1BHGF6OQTqzaD_mcY6tzkMcAnTdiZWIpg/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:38
115_1_BLA 125742-0_08-21-2021_Telecon_Labeling via FAX_e.pdf,PDF,Final Draft Labels: Carton and Containers,2021-08-21,email,"Gottschalk, Laura, Harkins Tull, Elisa, Devlin, Carmel M, Aghajani Memar, Neda, Smith, Michael (CBER), Naik, Ramachandra",,False,False,False,False,False,"BLA 125742, quality control, FOIA document, clinical trial data, biologics, product packaging, CBER review, regulatory project management, carton and container labels, drug labeling, vaccine development, regulatory compliance, FDA approval, pharmaceutical manufacturing, teleconference, Pfizer, regulatory submission",17,1,https://drive.google.com/file/d/1bP_u5m_SpzV4WtHv-0AJ_-I04xCyZwBi/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:41
107_1_BLA 125742-0_08-20-2021_Telecon_Labeling via FAX_e.pdf,PDF,"Comment regarding vial labels for COMIRNATY (COVID-19 Vaccine, mRNA)",2021-08-20,email,"Gottschalk, Laura, Harkins Tull, Elisa, Devlin, Carmel M, Aghajani Memar, Neda, Smith, Michael (CBER), Naik, Ramachandra",,False,False,False,False,False,"FDA CBER, Carton Labels, Clinical Trial, Diluent Information, COMIRNATY, Labeling, Artwork Revision, Regulatory Submission, FOIA Document, Compliance, Vaccine Identification, Vial Labels, Quality Assurance, BLA 125742/0, Regulatory Project Management, COVID-19 Vaccine, Pharmaceutical Development",17,3,https://drive.google.com/file/d/1GCMBvKA7rTw8S4Mgi1pLi9xtQmo3VEr9/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:45
125742-0_20219005.P0.pdf,PDF,Electronic Protocol Signature Page,2021-08-18,protocol,(b) (6),,False,True,False,False,False,"vaccine dosage, Pharmacia & Upjohn Company LLC, stability data, manufacturing site, lot release, FDA submission, electronic signature, Kalamazoo, Michigan, COVID-19 vaccine, clinical trial protocol, mRNA vaccine, fill information, Protocol, BioNTech Manufacturing GmbH, product components, virus verification, vaccine storage, regulatory compliance",18,17,https://drive.google.com/file/d/1aN7y6drZ39v9pWbfH1eL-gKYEF_6R3nJ/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:50
125742-0_20219002.P0.pdf,PDF,Electronic Protocol Signature Page,2021-08-16,protocol,(b) (6),,False,True,False,False,False,"Pharmacia & Upjohn Company LLC, stability data, manufacturing site, lot release, FDA submission, electronic signature, STN 125742-0, COMIRNATY, Kalamazoo, Michigan, COVID-19 vaccine, clinical trial protocol, Protocol, BioNTech Manufacturing GmbH, vaccine components, electronic protocol, virus verification, BNT162b2, regulatory compliance",18,18,https://drive.google.com/file/d/14KpXZkYWyh78RvUlYwTPO50m7saOrzRa/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:54
125742-0_20219001.P0.pdf,PDF,Electronic Protocol Signature Page,2021-08-16,protocol,(b) (6),,False,True,False,False,False,"nucleoside-modified mRNA vaccine, Pharmacia & Upjohn Company LLC, stability data, manufacturing site, lot release, FDA submission, electronic signature, COMIRNATY, Kalamazoo, Michigan, COVID-19 vaccine, clinical trial protocol, fill information, product information, Protocol, BioNTech Manufacturing GmbH, virus verification, BNT162b2, regulatory compliance",18,18,https://drive.google.com/file/d/1__rKmiQy0tLhPymfoVzGevN7V3hxaVHL/view?usp=drivesdk,pd-production-110123,2025-08-12 00:58:58
125742-0_20219003.PC1.pdf,PDF,Electronic Protocol Signature Page for COVID-19 mRNA Vaccine,2021-08-18,protocol,(b) (6),,False,True,False,False,False,"Pharmacia & Upjohn Company LLC, quality control, vaccine distribution, lot release, storage conditions, FDA submission, electronic signature, COVID-19 vaccine, clinical trial protocol, mRNA vaccine, dose information, vaccine stability, BioNTech Manufacturing GmbH, United States, Protocol, vaccine identification, vaccine manufacturing, regulatory compliance",18,17,https://drive.google.com/file/d/11IkeCGNQ4CiSvIxxKHTvDuIazZTSexNW/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:02
124_BLA 125742-0_08-23-2021_Memo_Committee Memo_SBRA.pdf,PDF,"Summary Basis for Regulatory Action"",","2021-08-23"",",document,,,False,False,False,False,False,"2021, FOIA-document, needs-review",3,31,https://drive.google.com/file/d/1Kcw8P8Uwr50Kr0Kc_KhqTJ4fkOt65pfj/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:08
"121_Courtesy Copy_BLA 125742-0_Employee-Officer List Memo, August 22, 2021 - COMIRNATY.pdf",PDF,"EMPLOYEE/OFFICER LIST MEMO"",","2021-08-22"",",document,,,False,False,False,False,False,"2021, FOIA-document, needs-review",3,1,https://drive.google.com/file/d/1fYZS-ajmzvdvs7JBf5-ii7uCBIzkn3R_/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:12
125742-0_20219001.PC1.pdf,PDF,"Electronic Protocol Signature Page for COVID-19 Vaccine, mRNA",2021-08-18,protocol,(b) (6),,False,True,False,False,False,"Pharmacia & Upjohn Company LLC, quality control, lot release, storage conditions, FDA submission, electronic signature, COMIRNATY, product information, COVID-19 vaccine, clinical trial protocol, mRNA vaccine, regulatory compliance, Kalamazoo, Michigan, BioNTech Manufacturing GmbH, Protocol, dosage information, virus verification, manufacturing details",18,18,https://drive.google.com/file/d/1494pzLzKPHgu6eBDwQ1uwj5_pTKFtwvB/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:16
125742-0_20219004.P0.pdf,PDF,Electronic Protocol Signature Page,2021-08-18,protocol,(b) (6),,False,True,False,False,False,"Pharmacia & Upjohn Company LLC, vaccine manufacturing, vaccine storage conditions, quality control, lot release, FDA submission, electronic signature, vaccine fill information, Kalamazoo, Michigan, COVID-19 vaccine, clinical trial protocol, mRNA vaccine, Protocol, BioNTech Manufacturing GmbH, vaccine dosage, vaccine identification, virus verification, regulatory compliance",18,18,https://drive.google.com/file/d/1Z3V4T1HBzHPjju7970U2A21kpQpJScz1/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:20
122_BLA 125742-0_08-22-2021_Telecon_Labeling via FAX_e.pdf,PDF,Final Draft Label: Package Insert,2021-08-22,email,"Gottschalk, Laura, Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Smith, Michael (CBER), Naik, Ramachandra",,False,False,False,False,False,"biologics-license-application, safety-efficacy-data, regulatory-compliance, package-insert, labeling, regulatory-review, pharmaceutical-quality, pfizer-pharmaceutical, clinical-trial-data, august-2021, vaccine-development, fda-submission, regulatory-project-management, teleconference, foia-document, adverse-event-reporting, cber-office-of-vaccines",17,1,https://drive.google.com/file/d/1kSufHDWt3QdMMrkTYPobUygJCCRg4GRM/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:24
125742-0_20219003.P0.pdf,PDF,Electronic Protocol Signature Page,2021-08-16,protocol,(b) (6),,False,True,False,False,False,"Pharmacia & Upjohn Company LLC, stability data, FOIA document, lot release, FDA submission, electronic signature, COMIRNATY, COVID-19 vaccine, clinical trial protocol, regulatory compliance, Protocol, BioNTech Manufacturing GmbH, Kalamazoo, MI, vaccine components, virus verification, BNT162b2, nucleoside modified mRNA vaccine, manufacturing details",18,17,https://drive.google.com/file/d/1U4VGuOEL1ekoN6hkTr7C075AijN1EqNT/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:29
120_Courtesy Copy_BLA 125742-0_CBER CMC BLA Review Memo - COMIRNATY.pdf,PDF,CBER CMC BLA Review Memo - COMIRNATY,2022-01-16,memo,"Donald Ertel, Laura Fontan, Alifiya Ghadiali, Kathleen R. Jones, Nicole Li, Gregory Price",,False,False,False,False,False,"BLA 125742, COVID-19 mRNA vaccine, FOIA document, OCBQ/DMPQ, drug product, quality compliance, COMIRNATY, regulatory submission, Pfizer Puurs, drug substance, CBER CMC review, Pfizer Kalamazoo, FDA approval, facilities and equipment, Pfizer Andover, executed batch records, pharmaceutical/clinical trial",17,124,https://drive.google.com/file/d/1Rx1lS3tJIY9okFsYTZEa0uD0oYPDMNul/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:34
"123_Courtesy Copy_BLA 125742-0_August 23, 2021 Approval Letter - Comirnaty.pdf",PDF,BLA 125742/0 Approval Letter - Comirnaty,2021-08-23,Approval Letter,Amit Patel,,False,True,False,False,False,"Manufacturing Locations, Sterile Filtration, Stability Dating, Puurs, Belgium, Pharmaceutical Quality, Clinical Trials (NCT04368728, NCT04380701), FDA Approval, Protocol, Regulatory Compliance, BioNTech Manufacturing GmbH, Vaccine Formulation, Comirnaty, Pfizer Inc., Andover, MA, Kalamazoo, MI, COVID-19 Vaccine, Biologics License, BLA Submission",18,11,https://drive.google.com/file/d/1oQoylBdvHrCMMQNR2166Lz5FuacHoUJO/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:38
125742-0_20219002.PC1.pdf,PDF,Electronic Protocol Signature Page,2021-08-18,protocol,(b) (6),,False,True,False,False,False,"Pharmacia & Upjohn Company LLC, vaccine storage conditions, quality control, lot release, electronic submissions gateway, FDA submission, electronic signature, Kalamazoo, Michigan, COVID-19 vaccine, clinical trial protocol, mRNA vaccine, Protocol, virus verification, BioNTech Manufacturing GmbH, vaccine dosage, vaccine identification, vaccine manufacturing, regulatory compliance",18,18,https://drive.google.com/file/d/1q7x5NGm_g_eTPXSTcL36DajYwbfVrjk5/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:42
125742-0_20219006.PC1.pdf,PDF,"COVID-19 Vaccine, mRNA Electronic Protocol",2021-08-19,protocol,(b) (6),,False,True,False,False,False,"Pharmacia & Upjohn Company LLC, quality control, stability testing, vaccine manufacturing, lot release, vaccine storage conditions, FDA submission, electronic signature, COMIRNATY, Kalamazoo, Michigan, COVID-19 vaccine, clinical trial protocol, mRNA vaccine, Protocol, BioNTech Manufacturing GmbH, vaccine dosage, virus verification, regulatory compliance",18,18,https://drive.google.com/file/d/19afIrQUlj05lvfwE7g5Jb1GZQUGZj7kb/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:46
125742-0_20219006.P0.pdf,PDF,Electronic Protocol Signature Page,2021-08-18,protocol,(b) (6),,False,True,False,False,False,"Pharmacia & Upjohn Company LLC, stability data, manufacturing site, lot release, FDA submission, electronic signature, COMIRNATY, Kalamazoo, Michigan, COVID-19 vaccine, clinical trial protocol, mRNA vaccine, vaccine development, Protocol, BioNTech Manufacturing GmbH, dosage information, virus verification, BNT162b2, regulatory compliance",18,18,https://drive.google.com/file/d/11Roqi2dwVfMIhkkuMg94JCIDKBIs744m/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:50
125742-0_20219009.P0.pdf,PDF,Electronic Protocol for COVID-19 mRNA Vaccine (COMIRNATY),2021-10-01,protocol,(b) (6),,False,True,False,False,False,"stability, quality control, lot release, BioNTech, Kalamazoo, clinical trial, COMIRNATY, FDA, COVID-19 vaccine, mRNA vaccine, Protocol, vaccine components, electronic protocol, vaccine storage, Pharmacia & Upjohn, BNT162b2, manufacturing, regulatory submission",18,17,https://drive.google.com/file/d/1a0CX7R56FSY3A_T8pVE7lRpCLg2AKqHI/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:54
125742-0_20219008.P0.pdf,PDF,Electronic Protocol for COVID-19 mRNA Vaccine Lot FH8027,2021-10-01,protocol,(b) (6),,False,True,False,False,False,"stability, quality control, lot release, BioNTech, Kalamazoo, clinical trial, COMIRNATY, FDA, COVID-19 vaccine, mRNA vaccine, Protocol, virus verification, electronic protocol, sample submission, Pharmacia & Upjohn, BNT162b2, manufacturing, regulatory submission",18,17,https://drive.google.com/file/d/1HKv75m3uGsle-SH7-iXPraBC2U9caAPr/view?usp=drivesdk,pd-production-110123,2025-08-12 00:59:59
125742-0_20219007.P0.pdf,PDF,"Electronic Protocol Submission for COVID-19 Vaccine, mRNA",2021-08,protocol,(b) (6),,False,False,False,False,False,"stability data, quality control, licensing action, Pharmacia Upjohn Company LLC, lot release, December 2021 expiration, FDA submission, COVID-19 vaccine, mRNA vaccine, Pfizer-BioNTech manufacturing, United States, vaccine components, clinical trial phase, electronic protocol submission, July 2021 manufacturing, virus verification, regulatory compliance",17,18,https://drive.google.com/file/d/1CWJvGA366xVrkWzMkhT1oB-8VC8R3lTB/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:03
125742_S111_M1_356h.pdf,PDF,"Letter to Appoint Additional US Agents for COVID-19 mRNA Vaccine (BNT162, PF-07302048)",2021-09-16,letter,"Ruben.Rizzi@biontech.de, Amit Patel, Amitkumar.Patel@pfizer.com",M1,False,False,False,False,False,"covid-19-vaccine, clinical-trials, compliance, pf-07302048, croatia-testing, chesterfield-missouri, puurs-belgium, safety-data, dublin-ireland, bnt162, comirnaty, quality-control, efficacy-data, adverse-events, regulatory-affairs, fda-submission, manufacturing",17,7,https://drive.google.com/file/d/1xSrbu_uXrsIn6IN9W3qKgVgyNPfke8BA/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:12
125742_S112_M1_cover.pdf,PDF,Correction to Previously Submitted Documents for COMIRNATY (COVID-19 mRNA Vaccine) BLA,2021-09-17,letter,"Marion Gruber, Ph.D., Amit Patel, Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D., Captain Michael Smith, Ph.D.",M1,False,False,False,False,False,"biologics-license-application, covid-19-vaccine, regulatory-compliance, manufacturing-process, drug-substance, global-product-development, quality-control, pfizer, biontech, clinical-trial-data, safety-efficacy, regulatory-affairs, fda-submission, adverse-events, silver-spring, confidential-information, new-hampshire",17,2,https://drive.google.com/file/d/1-vnUaPiJPzthGQNIu4t5VhGrF3JLTgAL/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:16
125742_S112_S2_M3_32s2_control-critical-steps-manuf-process.pdf,PDF,Control of Critical Steps and Intermediates Manufacturing Process for BNT162b2 Drug Substance,2021-05-12,report,,M3,False,False,False,False,False,"vaccine production, quality control, FOIA document, Andover, pharmaceutical development, in-process testing, quality attributes, Pfizer, manufacturing process, FDA, regulatory compliance, drug substance, process characterization, risk assessment, BNT162b2, critical process parameters, clinical trials",17,2,https://drive.google.com/file/d/151_yIjTPfJRcEjCn6ZbY3EmLxZGhfY6L/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:20
125742_S11_M1_cover.pdf,PDF,Response to FDA's 25 June 2021 Information Request Regarding a Request for the Lot Release Protocol (LRP) Template and for Samples and Reagents,2021-07-09,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D., Emnet Yitbarek",M1,False,True,False,False,False,"product-characterization, bnt162-pf-07302048, regulatory-submission, biologics-license-application, covid-19-vaccine, global-regulatory-affairs, clinical-trial-materials, pfizer-inc, collegeville-pennsylvania, samples-and-reagents, quality-control, fda-information-request, silver-spring-maryland, Protocol, vaccine-development, biotech-company, confidential-information, lot-release-protocol",18,2,https://drive.google.com/file/d/19jSBRHdgYobuiChL-F9zEJintXvG2VK_/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:24
125742_S111_M1_cover.pdf,PDF,Change in Sponsor Authorized Representatives for BLA 125742 (COVID-19 mRNA Vaccine),2021-09-17,letter,"Marion Gruber, Ph.D., Adrienne Stafford, Rich Pelt, Amit Patel, Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D., Captain Michael Smith, Ph.D.",M1,False,False,False,False,False,"regulatory-submission, bla-125742, cmc-regulatory-affairs, covid-19-vaccine, safety-efficacy-data, compliance-quality, new-york-location, north-carolina-location, pfizer-vaccines, biologics-license-application, fda-cber, clinical-trial-data, maryland-location, vaccine-development, sars-cov-2, mrna-technology, sponsor-authorized-representatives",17,2,https://drive.google.com/file/d/1UTL63_J60gEJzyxtbnpA7vDbVPhiuXVC/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:29
125742_S116_M1_lab-1448-1-0.pdf,PDF,"HIGHLIGHTS OF PRESCRIBING INFORMATION FOR COMIRNATY (COVID-19 VACCINE, mRNA)",2021-08,prescribing information,,M1,False,False,False,False,False,"dosage and administration, mrna vaccine, covid-19 vaccine, adverse reactions, contraindications, warnings and precautions, comirnaty, regulatory compliance, safety data, intramuscular injection, vaccine indications, sars-cov-2, immunization, efficacy data, prescribing information, fda approval, clinical trials",17,20,https://drive.google.com/file/d/1SkrMbByu8XxeQNo--ujHG64_cJi3XtNl/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:33
125742_S11_M1_response-25jun2021-cmc.pdf,PDF,Response to 25Jun2021 FDA IR Re: LRP template for STN 125742/0,2021-07-09,response,Emnet Yitbarek,M1,False,True,False,False,False,"drug-product, biologics-license-application, covid-19-vaccine, clinical-trials, pharmaceutical-manufacturing, pf-07302048, regulatory-compliance, drug-substance, reference-materials, bnt162, quality-control, Protocol, assays, vaccine-development, fda-submission, foia-document, acceptance-criteria, lot-release-protocol",18,16,https://drive.google.com/file/d/1oSwsvXdcwV4qpx1rAu2fM-GIBLLGCp40/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:37
125742_S111_M1_letter-of-authorization.pdf,PDF,Letter of Authorization to Appoint US Agent,2021-09-09,letter,"Dr. Sierk Poetting, Dr. Oliver Hennig, Martin Lang, Jan Kürschner, Dr. Gruber, Adrienne Stafford, Rich Pelt, Amit Patel, Paul Rohlfing, Elisa Harkins",M1,False,False,False,False,False,"manufacturing-facility, clinical-trials, pfizer-inc, authorization-letter, fda-submission, collegeville-pennsylvania, new-york-city, vaccine-research-and-review, global-regulatory-compliance, biontech-manufacturing, sanford-north-carolina, cber-division, vaccine-development, regulatory-affairs, vaccine-approval, us-agent-appointment, contact-information",17,2,https://drive.google.com/file/d/137vEouPwVxnYL46dyNitVeN7-A1wpFAF/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:41
125742_S11_M3_32r_21y513c2401-coa.pdf,PDF,Certificate of Analysis for Pfizer Drug Substance 21Y513C2401,2021-02-09,Certificate of Analysis,(b) (6),M3,False,False,False,False,False,"analytical-testing, fda-regulatory, pharmaceutical-manufacturing, drug-substance, endotoxin, confidential, identity-confirmation, rna-based-product, safety-testing, quality-control, pfizer, clinical-trial-material, certificate-of-analysis, active-pharmaceutical-ingredient, lot-number, 2021, bioburden",17,1,https://drive.google.com/file/d/1EhVBLcv5PC-Vin9Xda2k38GJPVeOCnur/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:44
125742_S11_M3_32r_21y513c2301-coa.pdf,PDF,Certificate of Analysis,2021-02-10,report,(b) (6),M3,False,False,False,False,False,"confidential-report, identity, fda, rna-sequence, drug-substance, endotoxin, pharmaceutical-sciences, quality-control, pfizer, integrity, certificate-of-analysis, clinical-trial, active-pharmaceutical-ingredient, lot-number, registered-tests, bioburden, acceptance-criteria",17,1,https://drive.google.com/file/d/135j0XcTQmu8EPgpFwdJStpm5jJMCx_T1/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:48
125742_S11_M3_32r_21y513c2501-coa.pdf,PDF,Certificate of Analysis for Pfizer Drug Substance Active Pharmaceutical Ingredient 21Y513C2501,2021-02-09,Certificate of Analysis,(b) (6),M3,False,False,False,False,False,"analytical-testing, stability, quality-assurance, regulatory-compliance, drug-substance, pharmaceutical-development, endotoxin, rna-based-product, quality-control, pfizer, clinical-trial-material, certificate-of-analysis, fda-submission, active-pharmaceutical-ingredient, lot-number, bioburden, manufacturing",17,1,https://drive.google.com/file/d/1KXgwtHRhcRGTkQ-qkl9mYGHmvR5LI0wP/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:51
125742_S11_M3_32r_677159p-1g-a-010-coa.pdf,PDF,Pharmaceutical Sciences Reference Standard Certificate,2021-07-01,certificate,"Authorized By, Primary Contact",M3,False,True,False,False,False,"clinical-trial-materials, fda-regulatory, expiration-date, hygroscopic-material, single-use-aliquot, worldwide-research-and-development, long-term-storage, short-term-storage, occupational-exposure-band, report-creation-date, compound-identification, quality-control, vialing-protocol, Protocol, pharmaceutical-reference-standard, storage-conditions, pfizer-confidential, authorized-personnel",18,1,https://drive.google.com/file/d/1enhabtxzpcAMJag_7MttSz-_P4EWBKzz/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:54
125742_S11_M3_32r_677100p-1g-a-010-coa.pdf,PDF,Pharmaceutical Sciences Reference Standard Certificate,2021-07-07,certificate,"Authorized By, Primary Contact",M3,False,True,False,False,False,"drug identifier, storage conditions, pharmaceutical, FOIA, clinical trial, Pfizer, quality, FDA, certificate, Protocol, efficacy, safety, occupational exposure, expiration date, purity, adverse events, reference standard, regulatory",18,1,https://drive.google.com/file/d/1oY5ItUk9rsdH6lybW94WrBjuqUqXQ8G5/view?usp=drivesdk,pd-production-110123,2025-08-12 01:00:57
125742_S11_M3_32r_pf-07302048-dp-rm-coa.pdf,PDF,Pharmaceutical Sciences Reference Standard Certificate,2021-07-07,certificate,Rebekah Ward,M3,False,False,False,False,False,"fda-regulatory, worldwide-research-and-development, long-term-storage, expiration-date, quality-compliance, pf-07302048, lot-reevaluation, rna-content, confidential, occupational-exposure-band, fluorescence-assay, pfizer, data-reporting, united-states, clinical-trial, analytical-testing, pharmaceutical-reference-standard",17,1,https://drive.google.com/file/d/1FoAb3NhuHRd5A0rF8kMciRaOTcqYjK5o/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:00
125742_S11_M3_32r_fc3181-coa.pdf,PDF,Certificate of Analysis,2021-06,Certificate,,M3,False,False,False,False,False,"Pharmaceutical Manufacturing, Lipid Nanoparticles, Analytical Methods, Certificate of Analysis, Proprietary Documentation, Kalamazoo, Michigan, COVID-19 Vaccine, Subsidiary of Pfizer Inc., Pharmacia & Upjohn Company, Regulatory Compliance, GMP Manufacturing, Pfizer-BioNTech Vaccine, Quality Control, Sterility, FDA EUA, RNA Integrity, Lot Release Testing",17,2,https://drive.google.com/file/d/1V3blK-fh5o-2o2TK7aVpL_fKJ7Y5mPkf/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:04
125742_S15_M1_cover.pdf,PDF,Response to FDA's Information Request Regarding Lot Release Protocol and Sample Handling for COVID-19 mRNA Vaccine,2021-07-20,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,True,False,False,False,"covid-19-vaccine, fda-interaction, compliance, clinical-development, vaccine-efficacy, collegeville-pa, silver-spring-md, adverse-events, sample-handling, Protocol, vaccine-safety, pfizer-global-regulatory, regulatory-affairs, biontechpfizer-partnership, bla-submission, mrna-vaccine, product-quality, lot-release-protocol",18,2,https://drive.google.com/file/d/1J7IvheOMwoM934loCb9KK636ULz-kbHI/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:08
125742_S15_M3_32r_comirnaty-lot-release-16jul2021.pdf,PDF,Comirnaty Lot Release Protocol,2021-07-20,protocol,"Sample Custodian, Prepared By, Approved By",M3,False,True,False,False,False,"biologics-evaluation, regulatory-submission, electronic-protocol, batch-release, fda, product-information, silver-spring-md, comirnaty, quality-control, pfizer, vaccine, Protocol, clinical-trial, analytical-testing, covid-19, stability-testing, lot-release, manufacturing",18,6,https://drive.google.com/file/d/1AbwT7rDM757BsU8HAU6S66QKQlNw7wO6/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:11
125742_S11_M3_32r_677365-1g-a-010-coa.pdf,PDF,Pharmaceutical Sciences Reference Standard Certificate,2021-07-07,certificate,"Authorized By, Primary Contact",M3,False,True,False,False,False,"clinical-trial-materials, fda-regulatory, hygroscopic-material, long-term-storage, purity-testing, short-term-storage, report-creation, occupational-exposure-band, pfizer-r-and-d, quality-control, foia-release, vialing-protocol, compound-677365, Protocol, pharmaceutical-reference-standard, storage-conditions, confidential-document, authorized-personnel",18,1,https://drive.google.com/file/d/1bhsdB8V1efsQuYWzOoVivuwQRq5pHmdf/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:14
125742_S17_M1_cover.pdf,PDF,Response to FDA's Information Request Regarding the Validation of RNA Integrity by the Capillary Gel Electrophoresis (CGE) Method,2021-07-23,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"bnt162-pf-07302048, biologics-license-application, covid-19-vaccine, global-regulatory-affairs, pfizer-inc, regulatory-compliance, rna-integrity, biotech-development, pharmaceutical-manufacturing, information-request-response, us-based-operations, quality-control, product-registration, capillary-gel-electrophoresis, fda-submission, vaccine-research, clinical-data-analysis",17,2,https://drive.google.com/file/d/1DRc6I8gZ_u8-eldEqSfY6eMdDMapSaTN/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:18
125742_S11_M3_32r_677315o-1g-a-010-coa.pdf,PDF,Pharmaceutical Sciences Reference Standard Certificate,2021-05-13,certificate,Authorized By,M3,False,False,False,False,False,"clinical-trial-materials, long-term-storage, hygroscopic-material, short-term-storage, lot-reevaluation, regulatory-compliance, occupational-exposure-band, quality-control, pfizer, fda-regulation, compound-identification, analytical-testing, pharmaceutical-reference-standard, storage-conditions, stability-testing, confidential-document, authorized-personnel",17,1,https://drive.google.com/file/d/1x0F_trpxV4q2vj1x8fbGN4Ch5JWpRtcq/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:22
125742_S11_M3_32r_fd0809-coa.pdf,PDF,Certificate of Analysis,2021-06,Certificate,,M3,False,False,False,False,False,"Lipid Nanoparticle Characterization, Pharmaceutical Manufacturing, Appearance and Particulates, Certificate of Analysis, Proprietary Documentation, RNA Content, Kalamazoo, Michigan, COVID-19 Vaccine, Subvisible Particles, Date of Manufacture, Regulatory Compliance, Pfizer-BioNTech Vaccine, Quality Assurance, Expiration Date, FDA EUA, Sterility Testing, Lot Release Testing",17,2,https://drive.google.com/file/d/1DFAg182O6Z2zwkbRsXQBt0EJIx7YQaER/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:25
125742_S11_M3_32r_fc3184-coa.pdf,PDF,Certificate of Analysis,2021-06,Certificate,,M3,False,False,False,False,False,"Pharmaceutical Manufacturing, Lipid Nanoparticles, Certificate of Analysis, Proprietary Documentation, Analytical Testing, RNA Content, COVID-19 Vaccine, Kalamazoo, Michigan, Lot Release, Pharmacia & Upjohn Company, Subsidiary of Pfizer, Regulatory Compliance, Pfizer-BioNTech Vaccine, Quality Control, Sterility, FDA EUA, GMP Conditions",17,2,https://drive.google.com/file/d/17XptErFIAEYXP1yLEU18k3malJ_YN3Ex/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:28
125742_S15_M1_response-16jul2021-lrp-samples.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Response to 16July2021 FDA Queries",2021-07-20,response,,M1,False,True,False,False,False,"PF-07302048, quality control, stability data, FOIA document, pharmaceutical development, lot release protocol, freeze-thaw cycles, clinical trial, reference standards, COVID-19 vaccine, CBER, BNT162, drug substance, Protocol, FDA queries, BLA 125742/0, Pfizer, regulatory submission",18,2,https://drive.google.com/file/d/1TP5JBcFKbQ-9TCVJgO27XqFmbVjqNusX/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:32
125742_S19_M1_response-02jul2021.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Response to 02 Jul 2021 FDA queries - CMC information and categorical exclusion for an environment analysis",2021-07-02,response,,M1,False,False,False,True,False,"bla-125742, regulatory-submission, covid-19-vaccine, pharmaceutical-industry, pf-07302048, manufacturing-process, Exclusion, safety-data, fda-queries, bnt162, quality-control, efficacy-data, pfizer, environmental-analysis, clinical-trial, cmc-information, drug-development, confidential-document",18,45,https://drive.google.com/file/d/1qbqJYXJ7X3dCWGmByrFDwOKvMUApJL8r/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:38
125742_S19_M1_cover.pdf,PDF,Response to FDA's Information Request Regarding CMC Information and Categorical Exclusion for an Environmental Analysis,2021-07-28,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,True,False,"regulatory-submission, compliance-quality, biologics-license-application, covid-19-vaccine, global-regulatory-affairs, office-of-vaccines-research-and-review, pf-07302048, Exclusion, collegeville-pa, center-for-biologics-evaluation-and-research, silver-spring-md, bnt162, fda-information-request, clinical-trial-data, safety-efficacy, vaccine-development, environmental-analysis, cmc-information",18,2,https://drive.google.com/file/d/1jFSJ3ufyUFKzr-uzfUlBdpIqTyOrCxJD/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:43
125742_S17_M1_reponse-09jul2021.pdf,PDF,Response to 09 Jul 2021 FDA queries - RNA Integrity by capillary gel electrophoresis,2021-07-21,response,,M1,False,False,False,False,False,"bla-125742, drug-product, regulatory-submission, covid-19-vaccine, pharmaceutical-clinical-trial, mrna-technology, pf-07302048, rna-integrity, lipid-nanoparticle, drug-substance, fda-queries, bnt162, quality-control, validation, capillary-gel-electrophoresis, quantitation-limit, confidential",17,6,https://drive.google.com/file/d/1mTL11nL989gbRxlG01BLXoYJvReNhh5J/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:47
125742_S1_M1_financial-cert-summary.pdf,PDF,Financial Certification and Disclosure Summary for BNT162b2 Clinical Trials,2021-04-29,report,(b) (6),M1,False,True,False,False,False,"clinical-trials, covid-19-vaccine, investigator-payments, regulatory-compliance, transparency, fda-regulations, financial-disclosure, safety-data, Protocol, efficacy-data, argentina, pfizer, data-reporting, clinical-study-agreement, adverse-events, bnt162b2, phase-1-2-3-trials, protocol-c4591001",18,4,https://drive.google.com/file/d/1GZ-_wjSFPtYaYsyh120guefU3SfQTlYH/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:50
125742_S1_M1_1.9.2_ped-studies-deferral-req.pdf,PDF,"Deferral Request for Pediatric Studies of COVID-19 Vaccine (BNT162, PF-07302048)",2021-04-02,Regulatory Submission,BioNTech,M1,False,False,False,False,False,"Clinical Trials, BioNTech, Pfizer, Regulatory Submission, Efficacy Data, FDA, IND, Immunogenicity, Adverse Events, Infants, Regulatory Compliance, Adolescents, Children, Pediatric Studies, Safety Data, COVID-19 Vaccine, Deferral Request",17,3,https://drive.google.com/file/d/1Bvy6gxHln6VtqPdgc32-qiU6T7ETKmGG/view?usp=drivesdk,pd-production-110123,2025-08-12 01:01:56
125742_S1_M1_financial-cert-3455.pdf,PDF,DISCLOSURE: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS,2021-03-31,form,Pfizer Inc.,M1,False,True,False,False,False,"Protocol, data-collection, financial-interests, regulatory-compliance, public-reporting-burden, omb-control-number, safety-data, clinical-trial-disclosure, clinical-investigators, fda-regulation, pharmaceutical-company, bnt162b2-vaccine, data-reporting, adverse-events, efficacy-data, bla-submission, paperwork-reduction-act, healthcare-department",18,18,https://drive.google.com/file/d/17GeAza1kS9pqOg3W1Q4zDBfBFj2CjBoL/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:01
125742_S26_M1_andover-483-response.pdf,PDF,Pfizer Andover Response to the FORM FDA 483 PAI BLA 125742 (COVID-19 mRNA Vaccine),2021-08-02,response,,M1,False,False,False,False,False,"andover-facility, bla-125742, fda-regulatory, drug-product, clinical-trials, covid-19-vaccine, batch-release, deviation-investigation, critical-quality-attributes, manufacturing-process, drug-substance, regulatory-compliance, confidential-information, stability-testing, quality-assurance, data-review, product-quality",17,36,https://drive.google.com/file/d/1eFmDgvh6K_i-6jw0EMt9cAwzPhAyzQml/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:05
125742_S1_M1_1.9.4_ipsp-agreed.pdf,PDF,"Agreed Initial Pediatric Study Plan (iPSP) for COVID-19 Vaccine (BNT162, PF-07302048)",2021-04-02,protocol,,M1,False,False,False,False,False,"PF-07302048, FDA regulatory submission, IND 019736, pediatric population, diagnosis methods, disease epidemiology, COVID-19 vaccine, clinical trial protocol, BNT162, pediatric study plan, vaccine development, SARS-CoV-2, active immunization, safety and efficacy data, treatment strategies, Pfizer confidential, regulatory compliance",17,23,https://drive.google.com/file/d/1AjZcwzgOxpu9Hh0KdQFJULWsjAhzD-dw/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:10
125742_S25_M1_response-26jul2021.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Response to 26 Jul 2021 FDA queries",2021-07-26,response,,M1,False,False,False,False,False,"vaccine-identification, bla-125742, covid-19-vaccine, regulatory-compliance, pharmaceutical-development, safety-data, equipment, efficacy-data, adverse-events, quality-control, data-response, united-states, fda-submission, clinical-trial, foia-document, manufacturing, pfizer-confidential",17,32,https://drive.google.com/file/d/1qHshYMfdffn5sfUeKZ_vSJGAlLv40SWD/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:15
125742_S22_M1_cover.pdf,PDF,Response to FDA's 16July2021 Information Request Regarding Sterility and Endotoxin Methods,2021-07-30,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"bnt162-pf-07302048, office-of-vaccines-research-and-review, global-regulatory-affairs, covid-19-vaccine, biologics-license-application, compliance, pfizer-inc, collegeville-pa, center-for-biologics-evaluation-and-research, silver-spring-md, quality-control, clinical-trial-response, vaccine-development, fda-submission, sterility-testing, pharmaceutical-regulatory, endotoxin-testing",17,2,https://drive.google.com/file/d/1OexkZJnh22faZFiKFGf6iFG0n7bOTuqi/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:19
125742_S25_M1_cover.pdf,PDF,Response to FDA 26 July 2021 Information Request Regarding Manufacturing and Equipment,2021-07-30,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"regulatory-submission, bla-125742, biologics-license-application, covid-19-vaccine, pfizer-global-regulatory-affairs, clinical-development, quality-compliance, product-development, collegeville-pa, center-for-biologics-evaluation-and-research, silver-spring-md, manufacturing-equipment, safety-data, fda-information-request, efficacy-data, adverse-events, vaccine-research-and-review",17,2,https://drive.google.com/file/d/1gPKR-YBfvdl1t0D6HtND8WGOhCtCNJg3/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:23
125742_S22_M1_response-16jul2021.pdf,PDF,Response to 16Jul 2021 FDA queries - Sterility and Endotoxin,2021-07-29,response,,M1,False,False,False,False,False,"bnt162-pf-07302048, biologics-license-application, covid-19-vaccine, pharmaceutical-clinical-trial, puurs-kzo-testing-facilities, quality-control-assurance, positive-product-control-recovery, manufacturing-process-validation, bacterial-endotoxin-verification, analytical-testing-methods, visual-inspection-growth, regulatory-submission-response, sterility-testing, fda-regulatory-compliance, product-lot-identification, pfizer-confidential, endotoxin-testing",17,2,https://drive.google.com/file/d/1_e9JvBgce7JltH0T9mHBhz9KhPBkaWxW/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:26
125742_S26_M1_fda-bnt-cl.pdf,PDF,Pfizer-BioNTech COVID-19 Vaccine Clinical Trial Data Submission,2021,report,"(b) (6), (b) (6), (b) (6), (b) (6), (b) (6)",M1,False,False,False,False,False,"immunogenicity-data, safety-efficacy-data, pharmaceutical-industry, regulatory-compliance, adverse-events-reporting, regulatory-approval-process, clinical-trial-protocols, medical-countermeasures, clinical-trial-data, public-health-emergency, cber-review-process, vaccine-development, fda-submission, data-analysis-and-reporting, vaccine-manufacturing, pfizer-biontech-covid-19-vaccine, phase-1-2-3-trials",17,2,https://drive.google.com/file/d/1-AzurD3LTD8tp3d8ykTpXr6n7tSfBdTc/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:29
125742_S2_M2_drug-product-description-composition-drug-prod.pdf,PDF,Description and Composition of the BNT162b2 Drug Product,2021-05-12,report,,M2,False,False,False,False,False,"drug product description, FDA submission, cryoprotectant, clinical trial, drug composition, multi-dose vial, lipid nanoparticles, quality standards, intramuscular injection, vaccine development, COVID-19, dose information, excipient composition, pharmaceutical manufacturing, BNT162b2, Pfizer, regulatory compliance",17,2,https://drive.google.com/file/d/1tOxgnNu9l91wd10kDp-Y43PQjsDP_U_u/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:33
125742_S2_M2_drug-product-reference-stand-or-materials.pdf,PDF,BNT162b2 Drug Product Reference Standards or Materials,2021-05-12,report,,M2,False,False,False,False,False,"analytical methods, quality control, drug product, lipid components, qualification, pharmaceutical development, compliance, reference standards, FDA, emergency use authorization, COVID-19, release and stability testing, vaccine, clinical trial materials, BNT162b2, Pfizer, regulatory submission",17,1,https://drive.google.com/file/d/1oOckqqCkCZg4CARgo63cIfB4QBAgz75w/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:36
125742_S26_M1_cover.pdf,PDF,Response to FORM FDA 483 for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-08-02,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D., John Eltermann, R.Ph., Kathleen Jones",M1,False,False,False,False,False,"andover-manufacturing-facility, vaccine-identification, safety-and-efficacy, covid-19-vaccine, global-regulatory-lead, regulatory-compliance, response-to-483-form, clinical-trial-data, product-registration, biologic-license-application, massachusetts-location, fda-inspection, regulatory-affairs, vaccine-development, bla-submission, confidential-information, pfizer-global-development",17,2,https://drive.google.com/file/d/1QeZvA5LJUI4OpOLiOAHzaY9a2AaP5xvb/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:40
125742_S2_M3_32a2_adventitious-agents-andover.pdf,PDF,BNT162b2 3.2.A.2. Adventitious Agents Safety Evaluation [Andover],2021-05-12,report,,M3,False,False,False,False,False,"raw material sourcing, safety evaluation, quality control, TSE/BSE risk management, FDA submission, Andover facility, transmissible spongiform encephalopathy, adventitious agent control program, vaccine development, drug substance, non-viral agents, animal-derived materials, clinical trials, adventitious agents, BNT162b2, Pfizer, regulatory compliance",17,6,https://drive.google.com/file/d/1yWvzolnq42AKjqclZuE4i-qClmrStMbF/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:44
125742_S2_M2_drug-product-stability.pdf,PDF,BNT162b2 Drug Product Stability,2021-05-12,report,,M2,False,True,False,False,False,"long-term storage, shelf life, quality control, stability data, pfizer confidential, pharmaceutical development, product documentation, thermal stress testing, accelerated storage, photostability, regulatory compliance, Protocol, bnt162b2 vaccine, drug product stability, vaccine manufacturing, clinical trials, fda approval, regulatory submission",18,23,https://drive.google.com/file/d/14EW4ElnsMKWYrjdwIYiI2ZqBZSO5iOfo/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:47
125742_S2_M2_appendices-adv-agen-safe-val.pdf,PDF,Adventitious Agents Safety Evaluation for BNT162b2,2021-05-12,report,,M2,False,False,False,False,False,"safety evaluation, sterility testing, FOIA document, clinical trial, Kalamazoo facility, FDA, vaccine development, CBER, non-viral agents, TSE/BSE risk, quality assurance, viral safety, raw materials, adventitious agents, BNT162b2, Pfizer, regulatory compliance",17,3,https://drive.google.com/file/d/1U9sxWspeLJEYcUvhmTADXwNTlz1Lh397/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:52
125742_S2_M2_introduction.pdf,PDF,BNT162b2 2.3 Introduction,2021-05-12,report,,M2,False,False,False,False,False,"process-risk-assessment, drug-product, critical-quality-attributes, control-strategy, regulatory-compliance, drug-substance, confidential, common-technical-document, quality-control, pfizer, chemistry-manufacturing-controls, good-manufacturing-practice, vaccine-development, fda-submission, analytical-testing, clinical-trial, bnt162b2",17,10,https://drive.google.com/file/d/10qWovaGMGBcsstdSvLgYe9SrNOqyIJGd/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:55
125742_S2_M3_32a3_excipient-information-structure-alc-0159.pdf,PDF,BNT162b2 3.2.A.3.1.2 Structure [ALC-0159],2021-05-12,report,,M3,False,False,False,False,False,"clinical-trial-documentation, pharmaceutical-excipient, molecular-structure, regulatory-compliance, drug-product-characterization, pfizer-confidential, polydispersity, analytical-data, quality-control, cmc-section-3.2.a, freedom-of-information-act, bnt162b2-vaccine, vaccine-development, fda-submission, vaccine-safety, excipient-information, chemical-composition",17,1,https://drive.google.com/file/d/1Nzj1zz8qwWLtaoJe_6s3cwxJfhUmj5Jf/view?usp=drivesdk,pd-production-110123,2025-08-12 01:02:59
125742_S2_M3_32a3_excipient-information-excipients-alc-0159.pdf,PDF,BNT162b2 3.2.A.3 Excipients [ALC -0159],2020-10-24,report,,M3,False,False,False,False,False,"BNT162b2 vaccine, pharmaceutical excipient, acetamide derivative, clinical trial documentation, FOIA document, quality control, FDA submission, drug formulation, chemical composition, vaccine development, regulatory compliance, Pfizer confidential, COVID-19 vaccine, drug delivery system, polyethylene glycol, phase 3 clinical trial, safety information",17,1,https://drive.google.com/file/d/184QA1Rad_irHXh7fZF3u__xl7n7k3CPx/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:03
125742_S2_M3_32p1_description-and-composition.pdf,PDF,Description and Composition of the BNT162b2 Drug Product,2021-05-12,report,,M3,False,False,False,False,False,"BNT162b2 vaccine, FOIA document, clinical trial documentation, drug product description, FDA compliance, lipid nanoparticles, multi-dose vial, quality standards, intramuscular injection, dose preparation, Pfizer confidential, buffer components, sterile dispersion, pharmaceutical composition, excipient information, cryoprotectant, regulatory submission",17,2,https://drive.google.com/file/d/1wFT51PCZ0GTJ90UvEUaRHLXDfEuzi163/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:09
125742_S2_M3_32a2_adventitious-agents-kalamazoo.pdf,PDF,BNT162b2 3.2.A.2. Adventitious Agents Safety Evaluation [Kalamazoo],2021-05-12,report,,M3,False,False,False,False,False,"raw material sourcing, safety evaluation, quality control, TSE/BSE risk management, clinical trial documentation, PFIZER confidential, Kalamazoo, FDA submission, transmissible spongiform encephalopathy, adventitious agent control program, COVID-19 vaccine, animal-derived materials, virus contamination prevention, pharmaceutical manufacturing, adventitious agents, BNT162b2, regulatory compliance",17,4,https://drive.google.com/file/d/1n1nR2dHpAF6Ti7MsGsJkyIz_guShKMl2/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:13
125742_S2_M3_32a2_adventitious-agents-puurs.pdf,PDF,BNT162b2 3.2.A.2. Adventitious Agents Safety Evaluation [Puurs],2020-10-24,report,,M3,False,False,False,False,False,"raw material sourcing, safety evaluation, bovine spongiform encephalopathy, quality control, FOIA document, clinical trial documentation, transmissible spongiform encephalopathy, non-viral adventitious agents, COVID-19 vaccine, animal-derived materials, Pfizer confidential, viral safety, pharmaceutical manufacturing, Puurs manufacturing site, adventitious agents, BNT162b2, regulatory compliance",17,4,https://drive.google.com/file/d/10ozY-DlV1bb_K4u15xoyGbDDD8O-WRKr/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:17
125742_S2_M3_32a3_excipient-information-nomenclature-alc-0315.pdf,PDF,Nomenclature of ALC-0315 Excipient,2021-05-12,report,,M3,False,False,False,False,False,"drug-identification, technical-documentation, compliance, chemical-structure, regulatory-aspects, pharmaceutical-development, nomenclature, safety-data, quality-control, cas-registry-number, efficacy-data, fda-submission, clinical-trial, excipient-information, bnt162b2, iupac-name, pfizer-confidential",17,1,https://drive.google.com/file/d/1gaig0WMSCDwISVeGG2qQgj_BlTKeeSrT/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:20
125742_S2_M3_32a3_excipient-information-excipients-alc-0315.pdf,PDF,BNT162b2 Excipient Information: ALC-0315,2020-10-24,report,,M3,False,False,False,False,False,"drug-identification, chemical-composition, clinical-trial-documentation, pharmaceutical-excipient, vaccine-adjuvant, manufacturing-process, safety-information, fda-regulatory-submission, regulatory-approval, phase-3-clinical-trial, compliance-documentation, quality-control, novel-excipient, vaccine-formulation, bnt162b2-vaccine, vaccine-development, pfizer-confidential",17,1,https://drive.google.com/file/d/1GU1JyTVL8beXj0764tM68GxY-od9Nd4S/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:24
125742_S2_M3_32a3_excipient-information-structure-alc-0315.pdf,PDF,Structure of Excipient ALC-0315,2021-05-12,report,,M3,False,False,False,False,False,"lipid-nanoparticle, pharmaceutical, chemical-structure, fda-submission, regulatory-compliance, drug-delivery, safety-data, molecular-formula, chirality, quality-control, pfizer, excipient, clinical-trial, vaccine-development, confidential, bnt162b2, molecular-weight",17,1,https://drive.google.com/file/d/1GpFSHcwTesO5BeqHvNWTVBXgq6AStQjX/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:27
125742_S2_M3_32a3_excipient-information-nomenclature-alc-0159.pdf,PDF,Nomenclature of ALC-0159 Excipient,2020-10-24,report,,M3,False,False,False,False,False,"quality control, polymer, chemical composition, drug product, pharmaceutical development, confidential, clinical trial, CAS registry number, FDA, nomenclature, safety data, vaccine, ALC-0159, excipient information, BNT162b2, Pfizer, regulatory submission",17,1,https://drive.google.com/file/d/1kUlfOzhDkq_lirCmdfkaqhbAyczGYCww/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:30
125742_S2_M3_32p4_excipients-human-animal.pdf,PDF,Excipients of Human or Animal Origin for BNT162b2 Drug Product,2020-10-24,report,,M3,False,False,False,False,False,"pharmaceutical manufacturing, safety assessment, quality control, drug product, confidential document, FDA submission, FOIA request, human origin, vaccine development, regulatory compliance, data transparency, excipients, animal origin, pharmaceutical industry, BNT162b2, Pfizer, clinical trials",17,1,https://drive.google.com/file/d/1tGKHB4BRI9NTXgRdMrDvSi2vUuyLDl_S/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:34
125742_S2_M3_32p52_analytical-procedure-cap-gel-electro.pdf,PDF,Analytical Procedures Capillary Gel Electrophoresis,2020-10-24,protocol,,M3,False,False,False,False,False,"quality control, regulatory approval, capillary gel electrophoresis, fda, pharmaceutical development, submission, clinical trial, biopharmaceutical, technical protocol, safety data, pfizer, vaccine, adverse events, confidential, efficacy data, bnt162b2, analytical procedures",17,1,https://drive.google.com/file/d/1o6fdSfibE_mKh6Y3nonwfZSBeT56wVdM/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:38
125742_S2_M3_32p3_batch-formula.pdf,PDF,BNT162b2 3.2.P.3.2 Batch Formula,2021-05-12,report,,M3,False,False,False,False,False,"quality control, pharmacopeia, drug product, batch formula, fda, pharmaceutical, unit formula, batch size, clinical trial, in-house specification, foia, pfizer, vaccine, excipients, confidential, bnt162b2, regulatory submission",17,1,https://drive.google.com/file/d/1L7ADMVAauyumv1Q-f6JuHXcvtYnRuZ7X/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:41
125742_S2_M3_32p4_novel-excipients.pdf,PDF,BNT162b2 3.2.P.4.6 Novel Excipients (Non-Compendial),2021-05-12,report,,M3,False,False,False,False,False,"safety-overview, clinical-trials, compliance, vaccine-composition, drug-product-manufacturing, pharmaceutical-development, alc-0315, lipid-excipients, quality-control, pfizer, bnt162b2-vaccine, novel-excipients, fda-submission, regulatory-affairs, toxicology-data, alc-0159, confidential-document",17,1,https://drive.google.com/file/d/1hvTPylHPgj7GqUj8jdd69VnXT_yQK6tA/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:44
125742_S2_M3_32p3_control-critical-steps-in-process-mon-control-overview.pdf,PDF,Control of Critical Steps and Intermediates In-Process Monitoring and Control – Overview,2021-05-12,report,,M3,False,False,False,False,False,"fill-and-finish, technical-documentation, pharmaceutical-manufacturing, critical-quality-attributes, regulatory-compliance, product-integrity, process-parameters, drug-product-formulation, quality-control, bnt162b2-vaccine, fda-submission, manufacturing-process-overview, clinical-trial, in-process-monitoring, process-risk-assessment, quality-assurance, pfizer-confidential",17,1,https://drive.google.com/file/d/18umxTVYqjNEH8oMqwOB3864CMayysvhp/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:48
125742_S2_M3_32p3_manufacturers.pdf,PDF,BNT162b2 Drug Product Manufacturer Information,2021-05-12,report,"Pharmacia & Upjohn Company LLC, Pfizer Manufacturing Belgium NV, Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC, Pfizer Inc., Pfizer Ireland Pharmaceuticals, Hospira Zagreb Ltd., SGS Lab Simon SA",M3,False,False,False,False,False,"bulk-formulation, fill-and-finish, regulatory-compliance, drug-product-manufacturing, stability-testing, primary-packaging, quality-control, pfizer, release-testing, secondary-packaging, fda-submission, sterility-testing, clinical-trial, 2021, bnt162b2, global-manufacturing, lnp-production",17,1,https://drive.google.com/file/d/1tKt-nf6BQ2yRKilsVZL4eG29rjSWvBlT/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:51
125742_S2_M3_32p2_pharmaceutical-development-introduction.pdf,PDF,BNT162b2 3.2.P.2 Pharmaceutical Development Introduction,2021-05-12,report,,M3,False,False,False,False,False,"pharmaceutical manufacturing, FOIA document, mRNA technology, drug product, pharmaceutical development, FDA submission, quality attributes, process risk assessment, process characterization, regulatory compliance, vaccine development, COVID-19, control strategy, analytical method evolution, BNT162b2, Pfizer, clinical trials",17,4,https://drive.google.com/file/d/1hksytUyD_xrUshw3yEgDAYBC1kG8bTtz/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:55
125742_S2_M3_32p52_analytical-procedure-subvis-particulate-matter.pdf,PDF,Analytical Procedures for Subvisible Particulate Matter in BNT162b2 Drug Product,2021-05-12,protocol,,M3,False,False,False,False,False,"safety assessment, quality control, drug product characterization, BNT162b2 drug product, subvisible particulate matter, FOIA document, product release testing, clinical trial, regulatory submission, vaccine development, PFIZER CONFIDENTIAL, USP <787>, particle analysis, Ph. Eur. 2.9.19, analytical procedure, pharmaceutical R&D, FDA compliance",17,1,https://drive.google.com/file/d/1YvdcbgAsZnVD2HWiU8rXrlpFy8OioGBi/view?usp=drivesdk,pd-production-110123,2025-08-12 01:03:59
125742_S2_M3_32p53_validation-analytical-procedure-rt-pcr.pdf,PDF,Validation of Analytical Procedures Reverse Transcription -Polymerase Chain Reaction (RT -PCR),2020-10-24,report,,M3,False,False,False,False,False,"regulatory-compliance, protocol-development, safety-data, phase-3-clinical-trial, reverse-transcription-pcr, analytical-procedure-validation, efficacy-data, adverse-events, laboratory-testing, fda-submission, pharmaceutical-clinical-trials, data-analysis, covid-19, bnt162b2, quality-assurance, mrna-vaccine, pfizer-confidential",17,1,https://drive.google.com/file/d/1pq8wBf0ruMHXA6jShvWArnCokj6TPqiH/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:02
125742_S2_M3_32p52_analytical-procedure-overview.pdf,PDF,BNT162b2 3.2.P.5.2 Analytical Procedures Overview,2021-05-12,report,,M3,False,False,False,False,False,"quality control, compliance, drug development, pharmaceutical, submission, clinical trial, FDA, analytical procedures, report, vaccine, safety, technical documentation, method validation, regulatory affairs, BNT162b2, data analysis, standard operating procedures",17,1,https://drive.google.com/file/d/1oFCkldGL18pZFW4yZD-9VpOk8iBjoWAr/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:06
125742_S2_M3_32p53_validation-analytical-procedure-cap-gel-electro.pdf,PDF,Validation of Analytical Procedures Capillary Gel Electrophoresis,2020-10-24,report,,M3,False,False,False,False,False,"safety assessment, quality control, vaccine research, scientific research, capillary gel electrophoresis, FOIA document, FDA submission, pharmaceutical development, analytical procedure validation, clinical trial, adverse event monitoring, PFIZER CONFIDENTIAL, efficacy evaluation, technical documentation, BNT162b2, data analysis, regulatory compliance",17,1,https://drive.google.com/file/d/1fiQZsYUINI784j8ZNjBdZcmhIA3tJ_pP/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:09
125742_S2_M3_32p52_analytical-procedure-osmometry.pdf,PDF,Analytical Procedure for Osmometry of BNT162b2 Drug Product,2020-12-18,protocol,,M3,False,False,False,False,False,"freezing point depression, quality control, drug product, drug development, pharmaceutical, FOIA, clinical trial, USP <785>, FDA, PFIZER CONFIDENTIAL, vaccine, osmometry, Ph.Eur.2.2.35, BNT162b2, analytical procedure, data analysis, regulatory compliance",17,1,https://drive.google.com/file/d/14U78ztDuxYd-MZpUVspZoO-2IJ8Z0ePy/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:13
125742_S2_M3_32p52_analytical-procedure-endotoxin.pdf,PDF,Analytical Procedure for Endotoxin Testing of BNT162b2 Drug Product,2021-05-12,protocol,,M3,False,False,False,False,False,"jp-4-01, clinical-trial-documentation, pharmaceutical-clinical-trial, pharmaceutical-manufacturing, regulatory-compliance, pfizer-confidential, safety-testing, drug-product-quality, analytical-procedure, quality-control, ph-eur-2-6-14, limulus-amebocyte-lysate, bnt162b2-vaccine, vaccine-development, fda-submission, endotoxin-testing, usp-85",17,1,https://drive.google.com/file/d/1XhmdVLi4egQHJkYl3KX1uZMRoYJ1FRYZ/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:18
125742_S2_M3_32p52_analytical-procedure-rt-pcr.pdf,PDF,Analytical Procedures for Reverse Transcription-Polymerase Chain Reaction (RT-PCR) of BNT162b2,2021-05-12,protocol,,M3,False,False,False,False,False,"safety assessment, quality control, pharmaceutical research, biotechnology, reverse transcription-polymerase chain reaction, fda, confidential document, clinical trial, adverse event monitoring, vaccine development, pfizer, rt-pcr, efficacy evaluation, bnt162b2, analytical procedures, data analysis, regulatory submission",17,1,https://drive.google.com/file/d/1UOjo7nyIBnljBAkz70e3emzDJ4E0ty2f/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:21
125742_S2_M3_32p5_batch-analyses.pdf,PDF,BNT162b2 3.2.P.5.4. Batch Analyses,2020-11,report,,M3,False,False,False,False,False,"stability testing, drug product, regulatory submission, Pfizer Puurs, FDA, vaccine development, safety data, LNP, process performance qualification, Polymun Scientific, emergency supply, Pfizer Kalamazoo, batch analysis, nonclinical toxicology, BNT162b2, Pfizer, clinical trials",17,55,https://drive.google.com/file/d/1oq9qa3QGhUnr2ihQWrampfhTMWJrgNQc/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:27
125742_S2_M3_32p8_stability-data-photostability.pdf,PDF,BNT162b2 Stability Data - Photostability,2021-05-12,report,,M3,False,False,False,False,False,"ich-photostability-testing, product-quality-control, vaccine-development-research, drug-product-characterization, appearance-and-physical-properties, chemical-composition-analysis, lipid-nanoparticle-analysis, fda-regulatory-submission, light-exposure-effects, clinical-trial-process-validation, analytical-testing-methods, bnt162b2-vaccine, pharmaceutical-stability-data, rna-encapsulation-integrity, biologic-activity-evaluation, stability-under-storage-conditions, pfizer-confidential",17,2,https://drive.google.com/file/d/1mPQasbchiAwAyx4ZKd4EJoORxWoNqxsM/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:31
125742_S2_M3_32p8_postapproval-stability.pdf,PDF,BNT162b2 Post-Approval Stability Protocol and Stability Commitment,2020-10-24,protocol,,M3,False,True,False,False,False,"drug product, RNA encapsulation, sterility, container closure integrity, post-approval stability, ICH stability studies, endotoxin, quality attributes, pharmaceutical development, lipid nanoparticle, analytical procedures, FDA, Protocol, commercial stability program, long-term storage conditions, BNT162b2, HPLC-CAD, regulatory compliance",18,1,https://drive.google.com/file/d/1HEUYHQT3teDSLMYTo3nxxeCMvpL63Hu-/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:34
125742_S2_M3_32p8_stability-data-long-term.pdf,PDF,BNT162b2 3.2.P.8.3 Stability Data Long Term,2020-11,report,Pfizer,M3,False,False,False,False,False,"covid-19-vaccine, emergency-supply-lots, fda-submission, drug-product-characterization, regulatory-compliance, pharmaceutical-development, product-quality-attributes, pharmaceutical-supply-chain, quality-control, clinical-trial-data, stability-indicating-methods, pharmaceutical-stability-data, analytical-testing, vaccine-manufacturing, storage-conditions, bnt162b2, long-term-stability",17,42,https://drive.google.com/file/d/1fXl4uKjR38H6oxc3MXaD6SsH2tLcWWz5/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:41
125742_S2_M3_32p53_validation-analytical-procedures-overview.pdf,PDF,Validation of Analytical Procedures Overview for BNT162b2 Drug Product,2021-05-12,report,,M3,False,False,False,False,False,"ICH Q2(R1) guidelines, BNT162b2 drug product, FDA submission, quantitative analytical methods, pharmaceutical development, precision, accuracy, specificity, linearity, pharmaceutical quality control, clinical trial materials, robustness and range evaluation, Pfizer confidential, release and stability testing, product identity, potency, purity, safety, compendial and non-compendial methods, method validation reports, analytical procedures validation, microbiological testing, regulatory compliance",17,1,https://drive.google.com/file/d/1N_pO6_RT4dSLZE6ziI3C3kdC0fh603Bw/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:45
125742_S2_M3_32p8_stability-data-accelerated.pdf,PDF,BNT162b2 3.2.P.8.3. Stability Data - Accelerated,2020-12-31,report,,M3,False,False,False,False,False,"pharmaceutical-data, regulatory-submission, emergency-supply, clinical-trials, pharmaceutical-manufacturing, data-tables, drug-product-characterization, fda-approval-process, product-batches, quality-control, bnt162b2-vaccine, vaccine-development, temperature-monitoring, analytical-testing, accelerated-stability-studies, storage-conditions, stability-testing",17,67,https://drive.google.com/file/d/1lHl5Ua0VRblhtsBOJMuXmm6G-NOt8C7D/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:53
125742_S2_M3_32p5_specifications.pdf,PDF,BNT162b2 Drug Product Specification,2021-05-12,Specification,,M3,False,False,False,False,False,"regulatory-submission, compliance-quality, lipid-nanoparticles, pharmaceutical-specification, drug-product-characterization, analytical-procedures, clinical-trial-drug, rna-encapsulation, adventitious-agents, potency-testing, bnt162b2-vaccine, fda-review, quality-attributes, vaccine-development, stability-testing, acceptance-criteria, pfizer-confidential",17,2,https://drive.google.com/file/d/1R_O-yAjG4IRStOI4F5RWtNRzfmo23Q3O/view?usp=drivesdk,pd-production-110123,2025-08-12 01:04:57
125742_S2_M3_32s2_control-critical-steps-manuf-process.pdf,PDF,Control of Critical Steps and Intermediates Manufacturing Process for BNT162b2 Drug Substance,2021-05-12,report,,M3,False,False,False,False,False,"BNT162b2 vaccine, quality control, FDA submission, Andover facility, in-process testing, ICH guidelines, quality attributes, Pfizer, manufacturing process, COVID-19 vaccine, risk assessment, drug substance, process development, regulatory compliance, pharmaceutical production, critical process parameters, clinical trials",17,2,https://drive.google.com/file/d/1wBfl7ovvVD8RPn2TPl1pc2QpdVKBo9pX/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:00
125742_S2_M3_32r_reg-info-lot-release-documentation-package.pdf,PDF,Lot Release Documentation Package for COMIRNATY (COVID-19 mRNA Vaccine BNT162b2),2021-05-10,Regulatory submission,Sample Custodian,M3,False,True,False,False,False,"Manufacturing site, Regulatory submission, Certificate of Analysis, COMIRNATY, Lot release documentation, FDA, COVID-19 vaccine, CBER, Kalamazoo, Michigan, Protocol, Pfizer Global Supply, Compliance, Quality control, Regulatory approval, Batch information, BNT162b2, Stability data, Electronic submission",18,6,https://drive.google.com/file/d/1fsV3n9dIGYKKUAQxYu8XT9x3A_ALEnco/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:06
125742_S2_M3_32p8_stability-summary.pdf,PDF,BNT162b2 3.2.P.8.1. Stability Summary and Conclusion,2021-05-12,report,,M3,False,True,False,False,False,"regulatory-submission, drug-product, clinical-trials, long-term-storage, vaccine-research, accelerated-testing, stability-summary, pharmaceutical-development, photostability, quality-control, foia-document, fda-approval, shelf-life, Protocol, bnt162b2, thermal-stress, pfizer-confidential, confidential-document",18,25,https://drive.google.com/file/d/1J1ad9xOkrJlrQSWaNi0AG21-4gklX_Mu/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:10
125742_S2_M3_32s2_manufacturer.pdf,PDF,Manufacturer(s) for BNT162b2 Drug Substance,2021-05-10,report,Pfizer,M3,False,False,False,False,False,"stability testing, Andover, GMP, Chesterfield, pharmaceutical, Wyeth Pharmaceuticals, release testing, clinical trial, FOIA, production, FDA, quality, manufacturer, drug substance, BNT162b2, Pfizer, regulatory",17,1,https://drive.google.com/file/d/1WCAeMxGghNg--_WLplVkp2kU5ggKPREN/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:14
125742_S2_M3_32r_reg-info-manufacturing-schedules.pdf,PDF,BNT162b2 3.2.R Manufacturing Schedules,2021-05-12,report,,M3,False,False,False,False,False,"regulatory information, production timeline, facility operations, confidential document, quality compliance, FDA submission, Kalamazoo facility, clinical trial, FOIA request, routine production, COVID-19 vaccine, Puurs facility, manufacturing schedules, pandemic supplies, pharmaceutical production, vaccine development, BNT162b2",17,1,https://drive.google.com/file/d/1_Lf2KZvq_nDN2OJjEnwNEyRgzYttsOiX/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:18
125742_S2_M3_32p8_stability-data-thermal-stress-cycling.pdf,PDF,BNT162b2 3.2.P.8.3. Stability Data Thermal –Stress and Cycling,2020-12-31,report,,M3,False,False,False,False,False,"stability data, quality control, drug product, cycling, FDA compliance, storage conditions, lot release, pharmaceutical development, regulatory submission, adverse event monitoring, product characterization, pharmaceutical quality, thermal stress, emergency supply, BNT162b2, accelerated stability, clinical trials",17,32,https://drive.google.com/file/d/1KIypIqAny72IhUHgoMTcboY1tf8ALoYq/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:24
125742_S2_M3_32s4_validation-analyt-procedure-overview.pdf,PDF,Validation of Analytical Procedures Overview for BNT162b2 Drug Substance,2021-05-12,report,,M3,False,False,False,False,False,"FOIA document release, non-compendial and compendial methods, clinical trial documentation, FDA regulatory compliance, Pfizer confidential document, pharmaceutical development, data integrity, analytical procedure validation, vaccine composition and identity, analytical method suitability, pharmaceutical quality control, product characterization, COVID-19 vaccine, quality assurance, BNT162b2 drug substance, drug substance purity and safety, regulatory submission",17,1,https://drive.google.com/file/d/1blaXaTEI9qBZW_ZyPHN5XM-7oNzXc8Zp/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:28
125742_S34_M1_response-03aug2021.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Response to 03 August 2021 FDA queries",2021-08-06,response,,M1,False,False,False,False,False,"bla-125742, regulatory-submission, manufacturing-sites, covid-19-vaccine, clinical-trials, biological-attributes, pf-07302048, compliance, confidential, pharmaceutical-development, physicochemical-attributes, fda-queries, bnt162, quality-control, pfizer, data-analysis, shipping-performance",17,14,https://drive.google.com/file/d/1mznC629rQ_7OE08j0c1LHqCSKExo3H2E/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:32
125742_S2_M3_32s4_specification.pdf,PDF,BNT162b2 Drug Substance Specification,2021-05-10,specification,,M3,False,False,False,False,False,"fda-regulatory, stability-studies, bacterial-endotoxin, product-related-impurities, pharmaceutical-specification, drug-substance-quality, analytical-procedures, clinical-trial-drug, process-related-impurities, pharmaceutical-development, quality-control, rna-concentration-integrity, bnt162b2-vaccine, identity-purity-safety, bioburden, acceptance-criteria, pfizer-confidential",17,1,https://drive.google.com/file/d/1UMyWZXL7YFxQ1DPFOIvj38ijrSGoL_07/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:35
125742_S2_M3_32s4_analytical-procedure-overview.pdf,PDF,Analytical Procedures Overview for BNT162b2 Drug Substance,2021-05-12,report,,M3,False,False,False,False,False,"quality control, FDA submission, pharmaceutical development, clinical trial, Pfizer, analytical procedures, drug substance, COVID-19, vaccine, standard operating procedures, efficacy, safety, data reporting, method validation, BNT162b2, manufacturing, regulatory compliance",17,1,https://drive.google.com/file/d/1doh_1jyIynVUXtEUp_U9c-CNR9W8Hscr/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:39
125742_S30_M1_response-26jul2021.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Follow-up Response to 26 Jul 2021 FDA Query #10",2021-07-26,response,Laura Gottschalk,M1,False,False,False,False,False,"BLA 125742, product manufacturing, quality control, partial response, clinical trial data, FDA compliance, CBER/OVRR, drug substance contact items, autoclave sterilization, COVID-19 vaccine, heat penetration studies, supporting documents, PFIZER CONFIDENTIAL, vaccine development, validation summary report, FDA query response, regulatory submission",17,1,https://drive.google.com/file/d/1xIYkUIrJKPbwROHsAi46tjp2db2xGFvk/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:43
125742_S34_M3_32a3_excipient-information-nomenclature-alc-0315.pdf,PDF,Nomenclature of ALC-0315 Excipient,2021-08-06,report,,M3,False,False,False,False,False,"IUPAC-name, excipient-safety, regulatory-compliance, drug-product-characterization, CAS-number, pharmaceutical-development, ALC-0315, Pfizer-confidential, nomenclature, formulation-development, quality-control, chemistry-manufacturing-controls, clinical-trial, vaccine-composition, FDA-submission, excipient-information, BNT162b2",17,1,https://drive.google.com/file/d/1mAYBXu9JaiqclQycBkEMUJl3obvRxjCr/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:47
125742_S34_M1_cover.pdf,PDF,Response to FDA's 03 August 2021 Information Request Regarding CMC-related Comments and Requests for Additional Information,2021-08-06,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"bnt162-pf-07302048, biologics-license-application, covid-19-vaccine, safety-and-efficacy, pfizer-global-regulatory-affairs, us-regulatory-agencies, fda-information-request, clinical-trial-data, vaccine-registration, vaccine-quality-control, regulatory-affairs, cmc-related-comments, vaccine-development, vaccine-manufacturing, pharmaceutical-compliance, vaccine-approval-process, vaccine-product-development",17,2,https://drive.google.com/file/d/1gXjnaDJHQXcymDcezYPe7cT75uwat8GG/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:50
125742_S30_M1_cover.pdf,PDF,Response to FDA's 26 July 2021 IR Comments Regarding Manufacturing and Equipment,2021-08-03,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"document-confidentiality, bnt162-pf-07302048, regulatory-submission, biologics-license-application, covid-19-vaccine, global-regulatory-affairs, pfizer-inc, quality-compliance, biotech-development, vaccine-efficacy, collegeville-pennsylvania, us-regulatory, manufacturing-equipment, fda-information-request, clinical-trial-data, vaccine-safety, silver-spring-maryland",17,2,https://drive.google.com/file/d/1VMr3gifxWb9_wP92yYVWx-JKhcbor3gW/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:54
125742_S35_M1_cover.pdf,PDF,Response to FDA's 04Aug 2021 IR Comments Regarding Potency Assay for Determination of IVE by Flow Cytometry,2021-08-06,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"bnt162-pf-07302048, regulatory-submission, immunogenicity, covid-19-vaccine, fda-interaction, potency-assay, biologics-license-application, global-regulatory-affairs, collegeville-pa, silver-spring-md, vaccine-compliance, vaccine-quality-control, clinical-trial-data, vaccine-development, flow-cytometry, confidential-information, vaccine-research-and-review",17,2,https://drive.google.com/file/d/1EVFUUiiXBpdZOh3zHVQIklAWCf8P81F7/view?usp=drivesdk,pd-production-110123,2025-08-12 01:05:58
125742_S35_M1_response-04aug2021.pdf,PDF,Response to 04 Aug 2021 FDA IR - Regarding potency assay for determination of IVE by flow cytometry,2021-08-06,response,,M1,False,False,False,False,False,"regulatory-submission, covid-19-vaccine, fda-interaction, potency-assay, pf-07302048, technical-documentation, bla125742, pharmaceutical-development, confidential, bnt162, quality-control, validation-report, pfizer, in-vitro-expression, data-analysis, clinical-trial, flow-cytometry",17,3,https://drive.google.com/file/d/1RJn6vFGK0QOpsGPiTOOweLThDDDyVaUP/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:02
125742_S36_M1_cover.pdf,PDF,Response to FDA's 02 August 2021 Information Request Regarding Validation of Assay Methods and Lot Release,2021-08-09,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"BLA 125742, BNT162/PF-07302048, Vaccine Efficacy, Vaccine Compliance, FDA Information Request, COVID-19 mRNA Vaccine, SARS-CoV-2, Lot Release, Regulatory Submission, Vaccine Safety, Collegeville, PA, Silver Spring, MD, Biologics License Application, Vaccine Quality, Vaccine Development, Assay Methods Validation, Pfizer Global Regulatory Affairs",17,2,https://drive.google.com/file/d/1TU-HW-Zo1cqH52wa727ernPoAgVlxUz-/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:06
125742_S37_M1_cover.pdf,PDF,Response to FDA's 05August 2021 Information Request Regarding the Saline Diluent,2021-08-09,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"BLA 125742, BNT162/PF-07302048, Vaccine Efficacy, Vaccine Approval, Clinical Trials, Pharmaceutical Compliance, FDA Information Request, COVID-19 mRNA Vaccine, SARS-CoV-2, Regulatory Submission, Collegeville, PA, Silver Spring, MD, Biologics License Application, Saline Diluent, Vaccine Development, Vaccine Safety, Pfizer Global Regulatory Affairs",17,2,https://drive.google.com/file/d/1ATEkyCR-_P30DVoW0EW_CVjhmnbbCBNx/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:10
125742_S40_M1_cover.pdf,PDF,Response to FDA's 06August 2021 IR Comments Regarding Two Drug Product (DP) Documents,2021-08-10,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"Drug Product (DP) Documents, Biologics License Application (BLA), FDA Information Request (IR), Clinical Trials, Pfizer Global Regulatory Affairs, Assay Validation, Pharmaceutical Compliance, COVID-19 mRNA Vaccine, Regulatory Submission, Lot Release, Collegeville, PA, Silver Spring, MD, Regulatory Affairs, Quality Control, Vaccine Safety and Efficacy, Vaccine Development, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1BK6vA_-rQo07CQEo3bX-qe1HOxwm_8x2/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:14
125742_S40_M1_response-06aug2021.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Response to 06Aug 2021 FDA IR Regarding two drug product (DP) documents",2021-08-10,response,,M1,False,False,False,False,False,"bla-125742, puurs-facility, regulatory-submission, covid-19-vaccine, compliance, pf-07302048, batch-size, lnp-production, pharmaceutical-development, manufacturing-process-development, bnt162, process-validation, fda-information-request, clinical-trial-data, quality-control, bulk-drug-product-formulation, drug-product-documents",17,1,https://drive.google.com/file/d/1UArkFwJu9P3nE7MWJOcwhXVbY6eoqzZj/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:18
125742_S36_M1_response-02aug2021.pdf,PDF,Response to 02 Aug 2021 FDA IR–Assay Methods and Lot release,2021-08-09,response,,M1,False,True,False,False,False,"drug-product, biologics-license-application, covid-19-vaccine, lipid-nanoparticles, clinical-trials, pf-07302048, regulatory-compliance, assay-validation, drug-substance, dynamic-light-scattering, pharmaceutical-development, response-to-information-request, vaccine-characterization, bnt162, quality-control, Protocol, fda-submission, confidential",18,8,https://drive.google.com/file/d/1fr5s5nkzF369vRNZdJEDA2Mc6Oj8uvJ1/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:23
125742_S37_M1_response-05aug2021.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Response to 05 Aug 2021 FDA IR – Diluent",2021-08-05,response,,M1,False,False,False,False,False,"bla-125742, diluent, covid-19-vaccine, pf-07302048, regulatory-compliance, confidential, pharmaceutical-development, reconstitution, bnt162, container-closure, quality-control, product-labeling, dosage-instructions, united-states, fda-submission, clinical-trial, saline-solution",17,6,https://drive.google.com/file/d/1rYAVjcNX8Z5xSmn67CxfA0MU65jmGCp3/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:26
125742_S42_M1_cover.pdf,PDF,Response to FDA's 04 August 2021 Information Request Regarding the Lot Release Protocol Template,2021-08-11,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,True,False,False,False,"bnt162-pf-07302048, biologics-license-application, covid-19-vaccine, pfizer-inc, quality-compliance, clinical-development, vaccine-efficacy, collegeville-pa, silver-spring-md, information-request-response, global-product-development, adverse-events, Protocol, biotech-partnership, vaccine-safety, regulatory-affairs, fda-submission, lot-release-protocol",18,2,https://drive.google.com/file/d/1TTdIKXR1vU9JB5Me_5gRKLPdRdhxC1LR/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:30
125742_S42_M3_32r_comirnaty-lot-release-template.pdf,PDF,Comirnaty Lot Release Template,2021-08-11,form,,M3,False,True,False,False,False,"regulatory-submission, cber, electronic-protocol, biologics, fda, silver-spring-md, safety-data, comirnaty, quality-control, efficacy-data, vaccine, adverse-events, virus-verification, Protocol, clinical-trial, authorized-official, lot-release, manufacturing",18,12,https://drive.google.com/file/d/172OVfGIgbp_WtyC2v19ft3keSu_5oGid/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:34
125742_S44_M1_cover.pdf,PDF,Response to FDA 10August 2021 Testing Related Information Request,2021-08-11,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ram achandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"regulatory-submission, biologics-license-application, covid-19-vaccine, global-regulatory-affairs, pfizer-inc, pf-07302048, biotech-development, assay-validation, clinical-trials, vaccine-efficacy, quality-compliance, pharmaceutical-industry, bnt162, fda-information-request, vaccine-safety, united-states, lot-release",17,2,https://drive.google.com/file/d/1nM8ECNHrg5R7fkUrg47F1T5DD_0qF9hT/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:38
125742_S43_M1_cover.pdf,PDF,Response to FDA's 05 August 2021 Information Request Regarding Facilities,2021-08-11,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"BLA 125742, Clinical Trials, BioNTech, FDA Center for Biologics Evaluation and Research, FDA Information Request, COVID-19 mRNA Vaccine, SARS-CoV-2, Compliance, Facilities, Regulatory Affairs, Biologics License Application, Global Product Development, Manufacturing, Vaccine Research and Review, Vaccine Development, Pfizer, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/15NPhId6_WKXrsCr5CR0tTYWnu4wmKaCO/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:42
125742_S43_M3_32p3_manufacturers.pdf,PDF,BNT162b2 Manufacturer(s),2021-08-11,report,"Pfizer Inc., Pfizer Manufacturing Belgium NV, Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC, Hospira Zagreb Ltd., SGS Lab Simon SA",M3,False,False,False,False,False,"BNT162b2 vaccine, drug product manufacturing, quality control, stability testing, sterility testing, FOIA document, release testing, clinical trial, FDA, Belgium, Croatia, packaging, United States, fill and finish, pharmaceutical industry, Pfizer, regulatory submission",17,2,https://drive.google.com/file/d/1HPTjeYU24_afGB1F5manf7iPmOOXv-6h/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:46
125742_S43_M1_response-05aug2021.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Response to 05 Aug 2021 FDA IR-Facilities Questions",2021-08-05,response,,M1,False,False,False,False,False,"facilities-questions, regulatory-submission, drug-product, biologics-license-application, covid-19-vaccine, quality-compliance, pf-07302048, pharmaceutical-manufacturing, drug-substance, pfizer-andover, safety-data, bnt162, fda-information-request, efficacy-data, pfizer-kalamazoo, clinical-trial, pfizer-chesterfield",17,24,https://drive.google.com/file/d/1LuIUVDwvtdGoH_AmLEXj9A0ZfIAz0qKG/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:51
125742_S42_M1_response-04aug2021.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Response to 04Aug 2021 FDA IR–Lot Release Protocol (LRP) Template",2021-08-11,protocol,,M1,False,True,False,False,False,"BLA 125742, FDA response, PF-07302048, quality control, BioNTech, sterility, lot release protocol, clinical trial, Pfizer, bacterial endotoxin, COVID-19 vaccine, BNT162, Protocol, lipid analysis, RNA integrity, data reporting, drug product testing, regulatory submission",18,4,https://drive.google.com/file/d/1NwE8Twxg2L36-pAaiiom-WlrroFLws0E/view?usp=drivesdk,pd-production-110123,2025-08-12 01:06:56
125742_S47_M1_response-11aug2021.pdf,PDF,Response to 11Aug 2021 FDA IR1 - Diluent,2021-08-13,response,,M1,False,False,False,False,False,"diluent, covid-19-vaccine, clinical-trials, pf-07302048, regulatory-compliance, pharmaceutical-development, sodium-chloride-injection, safety-data, bnt162, adverse-events, blA-125742, efficacy-data, quality-control, united-states, fda-submission, manufacturing, vaccine-administration",17,8,https://drive.google.com/file/d/1gV0FuQC65-asTY20GV1SXWWGJPR5MTk2/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:00
125742_S50_M1_cover.pdf,PDF,"Response to FDA 13 August 2021 Information Request Regarding Test Methods, the lot release process, and Lot Release Protocol (LRP) Template",2021-08-16,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D., Paul Rohlfing",M1,False,True,False,False,False,"biologics-license-application, clinical-trials, pf-07302048, fda-submission, collegeville-pa, test-methods, silver-spring-md, safety-data, global-product-development, bnt162, quality-control, efficacy-data, Protocol, biotech-pharma-collaboration, regulatory-affairs, vaccine-development, covid-19, lot-release",18,2,https://drive.google.com/file/d/1e6l23Ipcgpj85vbWOZS2yqmUzL1Vesj8/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:03
125742_S47_M1_cover.pdf,PDF,Response to FDA Information Request Regarding the Saline Diluent,2021-08-13,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"biologics-license-application, clinical-trials, fda-interaction, covid-19-vaccine, vaccine-efficacy-data, vaccine-adverse-events, saline-diluent, collegeville-pa, silver-spring-md, vaccine-compliance, container-closure, vaccine-quality-control, pfizer-global-regulatory, regulatory-affairs, vaccine-development, vaccine-safety-data, bla-submission",17,2,https://drive.google.com/file/d/1SEtrMQvmK6ePitcZ0Rh-14sV8Wxulaw8/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:08
125742_S44_M1_response-10aug2021.pdf,PDF,Response to FDA Information Request on PF-07302048 Drug Product Testing,2021-08-11,response,,M1,False,False,False,False,False,"drug-product, established-limits, covid-19-vaccine, clinical-trials, pharmaceutical-manufacturing, pf-07302048, regulatory-compliance, dynamic-light-scattering, response-to-information-request, bnt162, quality-control, size-and-polydispersity-measurement, vaccine-development, fda-submission, data-analysis, vaccine-formulation, confidential-document",17,1,https://drive.google.com/file/d/1C8cZvWQEuZX25OKxrBG8BdMw1eLBJLqc/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:11
125742_S48_M1_response-06aug2021.pdf,PDF,Response to 06 Aug 2021 FDA 3 Questions on Measurement of Endotoxin Procedures,2021-08-13,response,,M1,False,False,False,False,False,"lal-procedure, biologics-license-application, covid-19-vaccine, pf-07302048, regulatory-compliance, pharmaceutical-development, pre-clinical-studies, immunotoxicity-evaluation, bnt162, quality-control, clinical-trial-data, endotoxin-measurement, literature-references, fda-submission, vaccine-manufacturing, safety-assessment, pfizer-confidential",17,6,https://drive.google.com/file/d/1ePyn9jJTgEhqOck1mmFQG3vKdw83BhlA/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:15
125742_S48_M1_cover.pdf,PDF,Response to FDA 06August 2021 Information Request Regarding Measurement of Endotoxins,2021-08-13,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"safety-evaluation, bnt162-pf-07302048, lal-procedure, biologics-license-application, covid-19-vaccine, global-regulatory-affairs, pfizer-inc, regulatory-compliance, biotech-development, us-based-operations, vaccine-quality-control, clinical-trial-data, endotoxin-measurement, product-registration, fda-submission, vaccine-manufacturing, information-request-response",17,2,https://drive.google.com/file/d/1s4CEdgcOkRp621lkMnQAnOWCy5__qpuy/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:21
125742_S47_M3_32p3_manufacturer-diluent.pdf,PDF,Manufacturer(s) - [DILUENT] for BNT162b2 Vaccine,2021-08-13,report,"Fresenius -Kabi USA  LLC, Hospira, Inc, Pfizer Healthcare India Pvt. Ltd.",M3,False,False,False,False,False,"sodium chloride solution, BNT162b2 vaccine, quality control, vaccine distribution, FOIA document, FDA compliance, Hospira subsidiary, testing and release, pharmaceutical supply chain, vaccine development, Pfizer confidential, diluent manufacturing, pharmaceutical production, vial sizes, clinical trial materials, India manufacturing site, regulatory submission",17,1,https://drive.google.com/file/d/1K35Xw4vwtS1Xzrkwoz2VpvOSUu1V8JYX/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:24
125742_S50_M1_response-13aug2021.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Response to 13Aug 2021 FDA queries",2021-08-16,response,,M1,False,True,False,False,False,"BLA 125742, Lot release protocol, Vaccine efficacy, Pharmaceutical manufacturing, Regulatory submission, RNA integrity assay, Capillary gel electrophoresis, Vaccine safety, COVID-19 vaccine, CBER, Protocol, Pfizer Kalamazoo, FDA queries, Sample submission, Clinical trial data, Quality control, Regulatory compliance, Vaccine development",18,8,https://drive.google.com/file/d/1t00XYJSq3w8hsPsqiJ5Q2SGH1aIK4dSI/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:28
125742_S55_M1_cover.pdf,PDF,BLA 125742 COVID-19 mRNA Vaccine (BNT162/PF-07302048) CMC Amendment Regarding 9-Month Shelf Life Extension,2021-08-17,letter,"Marion Gruber, Ph.D., Elisa Harkins",M1,False,False,False,False,False,"BLA 125742, Shelf Life Extension, Stability Data, Lipid Nanoparticle Characterization, CBER Review, Vaccine Approval, RNA Content and Integrity, Global Regulatory Affairs, Pharmaceutical Quality, COVID-19 mRNA Vaccine, Collegeville, PA, CMC Amendment, Vaccine Formulation, Pfizer Inc., FDA Regulatory Submission, Vaccine Development, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1JbAO1EmNQ6UiYy_SboS-rUj6O1htyPNI/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:32
125742_S55_M2_32p8_stability-data-accelerated.pdf,PDF,BNT162b2 3.2.P.8.3. Stability Data Accelerated,2020-12-01,report,,M2,False,False,False,False,False,"bnt162b2-covid-19-vaccine, polymun-vaccine-manufacturing, vaccine-lot-numbers, accelerated-stability-testing, fda-approval-process, temperature-storage-conditions, vaccine-production-and-supply-chain, clinical-trial-protocols, regulatory-submission-documentation, pharmaceutical-quality-assurance, vaccine-quality-control, vaccine-stability-over-time, pharmaceutical-stability-data, data-analysis-and-reporting, kalamazoo-and-puurs-manufacturing-sites, pfizer-vaccine-development, phase-3-clinical-trial-data",17,108,https://drive.google.com/file/d/1sNxXxMAGkLVwuRitffKMBcYJ8hQcJMO4/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:37
125742_S53_M1_cover.pdf,PDF,Response to FDA's 13August 2021 Information Request from the DMPQ Team Regarding Facilities,2021-08-17,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"BLA 125742, Vaccines, Clinical Trials, BioNTech, FDA Information Request, COVID-19 mRNA Vaccine, SARS-CoV-2, Silver Spring, MD, Collegeville, PA, Compliance, Facilities, Regulatory Affairs, Biologics License Application, Global Product Development, DMPQ Team, Pfizer, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1PeM9SiDOumTHRwPu1ykGZpmKYAK2liGn/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:41
125742_S53_M1_response-13aug2021.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Response to 13 Aug 2021 FDA queries – Drug Substance",2021-08-13,response,,M1,False,False,False,False,False,"bla-125742, regulatory-submission, clinical-trials, covid-19-vaccine, microbiological-testing, pf-07302048, cold-storage, freeze-thaw, drug-substance, compliance, fda-queries, bnt162, pfizer, water-quality, automated-control, andover, quality-testing",17,20,https://drive.google.com/file/d/1wFZXLO_HfO4tcYEVNN1U89wGowQSG6Vk/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:46
125742_S50_M3_32r_comirnaty-lot-release-template.pdf,PDF,Comirnaty Lot Release Template,2021-08-16,report,,M3,False,False,False,False,False,"manufacturing-site, drug-product, covid-19-vaccine, lipid-identity, regulatory-compliance, vaccine-efficacy, drug-substance, pharmaceutical-development, rna-sequence-identity, comirnaty, quality-control, lal-test, clinical-trial-data, vaccine-safety, fda-submission, lot-release, kalamazoo-michigan",17,12,https://drive.google.com/file/d/1ZTDlxqo_1BN-OTLWOyEqEAWzEneyUZl2/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:50
125742_S55_M2_drug-product-stability.pdf,PDF,BNT162b2 Drug Product Stability,2020-11-20,report,,M2,False,True,False,False,False,"regulatory-submission, clinical-trials, long-term-storage, stability-data, pharmaceutical-manufacturing, accelerated-testing, drug-product-stability, photostability, quality-control, pfizer, fda-approval, shelf-life, Protocol, vaccine-development, stability-protocol, bnt162b2, thermal-stress, confidential-document",18,28,https://drive.google.com/file/d/19ypH92lgWQQk0Yjx8vfhV7qye4iGFnyB/view?usp=drivesdk,pd-production-110123,2025-08-12 01:07:55
125742_S55_M2_introduction.pdf,PDF,Introduction to Quality Overall Summary – 9 Month Expiry Extension,2021-08-17,report,,M2,False,True,False,False,False,"BLA 125742, CMC information, quality control, shelf life extension, LNP characterization, global distribution, FDA, COVID-19 vaccine, clinical trial material, PPQ lots, Protocol, emergency supply, in vitro expression, RNA integrity, drug product stability, BNT162b2, Pfizer, regulatory submission",18,3,https://drive.google.com/file/d/1yLXsYmBs4xsg3aIjh7slyahe36z28b9Y/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:00
125742_S55_M3_32p8_stability-summary.pdf,PDF,BNT162b2 3.2.P.8.1. Stability Summary and Conclusion,2021-08-17,report,,M3,False,True,False,False,False,"regulatory-submission, drug-product, clinical-trials, long-term-storage, confidential, stability-summary, photostability, quality-control, pfizer, fda-approval, shelf-life, foia-document, vaccine-development, Protocol, data-analysis, accelerated-storage, bnt162b2, thermal-stress",18,30,https://drive.google.com/file/d/1zXbckvTkODuBkNTPHR0QseGtNYJCDMTR/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:06
125742_S56_M1_cover.pdf,PDF,Commitment to Implement an Additional Endotoxin Method,2021-08-17,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"office-of-vaccines-research-and-review, biologics-license-application, clinical-trials, covid-19-vaccine, pfizer-inc, pf-07302048, collegeville-pa, center-for-biologics-evaluation-and-research, silver-spring-md, information-request, global-product-development, bnt162, quality-control, regulatory-affairs, fda-submission, vaccine-development, endotoxin-testing",17,2,https://drive.google.com/file/d/1ye_xJnQmT6eATXhkkLsm5XlD2oOC2qSm/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:09
125742_S55_M3_32p8_stability-data-long-term.pdf,PDF,BNT162b2 3.2.P.8.3 Stability Data Long Term,2020-12-31,report,,M3,False,False,False,False,False,"product-characterization, regulatory-submission, manufacturing-sites, process-performance-qualification, clinical-trial-drug-product, fda-approval-process, long-term-stability-studies, compliance-with-regulations, analytical-testing-methods, bnt162b2-vaccine, quality-control-data, pharmaceutical-stability-data, vaccine-development, adverse-event-monitoring, storage-conditions, supply-chain-logistics, pfizer-confidential",17,60,https://drive.google.com/file/d/1vwukl-aZUndoj9clK2HKvtQUICwiyA03/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:18
125742_S57_M3_32p3_manufacturer-diluent.pdf,PDF,BNT162b2 Diluent Manufacturer Information,2021-08-17,report,"Fresenius -Kabi USA, LLC, Hospira, Inc, Pfizer Inc.",M3,False,False,False,False,False,"product-release, sodium-chloride, regulatory-compliance, pharmaceutical-production, diluent-manufacturing, safety-data, product-testing, quality-control, efficacy-data, adverse-events, subsidiary-company, foia-document, vaccine-development, fda-submission, clinical-trial, bnt162b2, us-manufacturing",17,1,https://drive.google.com/file/d/1cLJFrHu7CHklc2yKaX_FKdPOk-E8ktlM/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:22
125742_S57_M1_response-16aug2021.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742.0 Response to 16Aug 2021 FDA IR–STN 125742.0 IR RE Diluent Suppliers",2021-08-17,response,,M1,False,False,False,False,False,"bla-125742, covid-19-vaccine, official-action-indicated, regulatory-compliance, container-closure-system, pharmaceutical, safety-data, geographic-location, quality-control, efficacy-data, adverse-events, pfizer, warning-letter, fda-submission, clinical-trial, diluent-suppliers, manufacturing",17,2,https://drive.google.com/file/d/1knA2zV2Sj-GZkcF1AtNSBbK62z9vaQaa/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:26
125742_S5_M1_cover.pdf,PDF,Response to FDA 20May 2021 Information Request Regarding Manufacturing Schedules and COVID-19 Precautions,2021-05-24,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"regulatory-submission, covid-19-precautions, bla-125742, covid-19-vaccine, biologics-license-application, pfizer-global-regulatory-affairs, biontech-and-pfizer, safety-and-efficacy, quality-compliance, belgium-travel-guidelines, manufacturing-schedules, manufacturing-facilities, fda-information-request, regulatory-affairs-vaccines, clinical-trial-data, vaccine-development, visitor-entry-requirements",17,2,https://drive.google.com/file/d/18Xydpt00ghlJxDyjR7frfT5efjxapeUR/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:30
125742_S59_M1_cover.pdf,PDF,Pfizer Global Regulatory Affairs Submission for COVID-19 mRNA Vaccine BLA,2021-08-18,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D., John Eltermann, R.Ph., Kathleen Jones, Christian Lynch",M1,False,False,False,False,False,"andover-facility, vaccine-efficacy-safety, biologics-license-application, covid-19-vaccine, fda-interaction, regulatory-documentation, regulatory-compliance, manufacturing-quality, vaccine-authorization, form-483-response, clinical-trial-data, product-registration, regulatory-affairs, vaccine-development, bla-submission, confidential-information, pfizer-global-development",17,2,https://drive.google.com/file/d/1qj7-KgZqCIkZxa7jLzWqc3wwWljEXySM/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:34
125742_S5_M1_response-20-may-2021-facilities.pdf,PDF,"COVID-19 Vaccine (BNT162, PF-07302048) BLA 125742/0 Module 1.11.1 Response to 20 May 2021 FDA IR–Manufacturing Schedules & Precautions",2021-05-20,response,,M1,False,False,False,False,False,"bla-125742, drug-product, lipid-nanoparticle, covid-19-vaccine, pf-07302048, regulatory-compliance, drug-substance, puurs-belgium, bnt162, manufacturing-schedule, pfizer, fill-finish, wyeth-biopharma, production-timeline, fda-submission, andover-ma, kalamazoo-mi",17,8,https://drive.google.com/file/d/1wJanseKDF0YdEPNvhFnLqnoMWxk0B-dU/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:38
125742_S56_M1_response-13aug2021.pdf,PDF,Response to 13Aug 2021 FDA Commitment to Implement an Endotoxin Method on Drug Product,2021-08-17,response,,M1,False,False,False,False,False,"method-transfer, drug-product, biologics-license-application, covid-19-vaccine, clinical-trials, pharmaceutical-manufacturing, pf-07302048, method-verification, lot-release-testing, regulatory-compliance, cber, bnt162, quality-control, pfizer, vaccine-development, fda-submission, endotoxin-testing",17,1,https://drive.google.com/file/d/1BWhsuaEYinfDw11zyIMguEDdMPlFZPQY/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:42
125742_S59_M1_response-17aug2021.pdf,PDF,Pfizer Andover Response to the FORM FDA 483 PAI BLA 125742 (COVID-19 mRNA Vaccine),2021-08-17,response,,M1,False,False,False,False,False,"andover-facility, fda-regulatory, drug-product, covid-19-vaccine, batch-release, deviation-investigation, confidential-commercial-information, drug-substance, form-fda-483, pre-approval-inspection, pharmaceutical-response, blA-125742, clinical-trial, stability-testing, quality-assurance, mrna-vaccine, product-quality",17,36,https://drive.google.com/file/d/1K52SgRvpjpjhxzwaDibzQAqeMo2XUglu/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:46
125742_S57_M1_cover.pdf,PDF,Response to FDA 16August 2021 Information Request Regarding Diluent Suppliers,2021-08-17,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"bnt162-pf-07302048, biologics-license-application, covid-19-vaccine, clinical-trials, quality-compliance, pfizer-inc, biotech-partnerships, manufacturing-process, regulatory-approval, safety-data, global-product-development, adverse-events, efficacy-data, regulatory-affairs, fda-submission, vaccine-development, diluent-suppliers",17,2,https://drive.google.com/file/d/1R1wZi0ulZwtMlx0R2Msl3tAHnuWBOkNH/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:50
125742_S61_M1_response-17aug2021.pdf,PDF,Response to 17 Aug 2021 FDA queries – Shelf-life and date of manufacture,2021-08-19,response,,M1,False,False,False,False,False,"regulatory-submission, drug-product, covid-19-vaccine, fda-response, stability-data, kalamazoo-manufacturing, module-2, supporting-documentation, puurs-manufacturing, undiluted-product, literature-references, shelf-life, bnt162b2-vaccine, module-3, clinical-trial, manufacturing-date, pfizer-confidential",17,2,https://drive.google.com/file/d/14kSK1lfKM7kM-nD43p86HvCR99rJWEPv/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:54
125742_S63_M1_cover.pdf,PDF,Response to FDA 18August 2021 Information Request: DBSQC Comments,2021-08-19,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,True,False,False,False,"regulatory-submission, biologics-license-application, covid-19-vaccine, global-regulatory-affairs, pfizer-inc, pf-07302048, biotech-development, safety-and-efficacy, collegeville-pa, clinical-data, silver-spring-md, lot-release-process, information-request-response, bnt162, quality-control, Protocol, fda-review, endotoxin-testing",18,2,https://drive.google.com/file/d/1E5f6UNIX6Fn3wrz326uuIVQDgRr3t1y4/view?usp=drivesdk,pd-production-110123,2025-08-12 01:08:58
125742_S80_M1_cover.pdf,PDF,Pfizer BLA 125742 Submission Cover Letter,2021-08-24,cover letter,"Marion Gruber, Ph.D., Amit Patel, Ramachandra S. Naik, Ph.D., Laura Gottschalk, Ph.D., Captain Michael Smith, Ph.D.",M1,False,False,False,False,False,"BLA 125742, Vaccines, Clinical Trials, FDA, Efficacy Data, CBER, Cover Letter, Pharmaceutical, Adverse Events, Submission, Compliance, Regulatory Affairs, Quality Assurance, United States, Safety Data, Pfizer, Biologics",17,2,https://drive.google.com/file/d/1keodckcfTwExxmeOiJf21aZdNn4NJvFh/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:01
125742_S63_M1_response-18aug2021.pdf,PDF,Response to 18 August 2021 Information Request: DBSQC Comments,2021-08-19,response,,M1,False,True,False,False,False,"pharmaceutical/clinical trials, FOIA document, PF-07302048, quality control, lot release protocol, endotoxin test, Pfizer, FDA, COVID-19 vaccine, CBER, BNT162, DBSQC, Protocol, robustness studies, BLA 125742/0, method validation, CGE integrity test, regulatory submission",18,2,https://drive.google.com/file/d/1xuLXY4Gu8aHoGR_VRrDYWIadGZkaQQEf/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:05
125742_S61_M1_cover.pdf,PDF,Response to FDA 17 August 2021 Information Request Regarding Shelf Life and Date of Manufacture,2021-08-19,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"FOIA document, Biologics License Application (BLA), shelf life, date of manufacture, product development, FDA submission, Pfizer Global Regulatory Affairs, clinical trial, confidential information, Center for Biologics Evaluation and Research (CBER), COVID-19 vaccine, safety data, pharmaceutical regulatory affairs, trade secret, efficacy data, Office of Vaccines Research and Review, BNT162/PF-07302048",17,2,https://drive.google.com/file/d/1wNOO5i5rf3kFvW5AOJCIjfmkz58KHK-v/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:08
125742_S60_M1_cover.pdf,PDF,Response to FDA 17 August 2021 Information Request Regarding Drug Substance and Drug Product for COVID-19 mRNA Vaccine (BNT162/PF-07302048),2021-08-19,letter,"Marion Gruber, Ph.D., Elisa Harkins, Ramachandra S. Naik, Ph.D., Michael Smith, Ph.D., Laura Gottschalk, Ph.D.",M1,False,False,False,False,False,"bnt162-pf-07302048, regulatory-submission, drug-product, covid-19-vaccine, biologics-license-application, global-regulatory-affairs, clinical-development, compliance, pfizer-inc, drug-substance, collegeville-pa, silver-spring-md, safety-data, quality-control, fda-information-request, efficacy-data, vaccine-manufacturing",17,2,https://drive.google.com/file/d/1MPSXk1mQsV8489o07NJ8MgVyaO_eX6dv/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:13
125742_S60_M1_response-17aug2021.pdf,PDF,Response to 17Aug 2021 FDA queries - Drug Substance,2021-08-18,response,,M1,False,False,False,False,False,"bla-125742, regulatory-submission, kalamazoo, covid-19-vaccine, compliance, pf-07302048, manufacturing-process, drug-substance, process-parameters, safety-data, fda-queries, bnt162, process-validation, quality-control, efficacy-data, clinical-trial, puurs",17,3,https://drive.google.com/file/d/1m0CiPk8LQZGI-GmydvrLJOaC3s4pFD-0/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:16
125742_S60_M3_32s2_control-critical-steps-manuf-process.pdf,PDF,Control of Critical Steps and Intermediates Manufacturing Process for BNT162b2 Drug Substance,2021-08-18,report,,M3,False,False,False,False,False,"regulatory-submission, clinical-trials, technical-documentation, in-process-testing, pharmaceutical-manufacturing, manufacturing-process, drug-substance, fda-regulations, process-validation, process-characterization, pfizer, quality-control, vaccine-development, quality-attributes, quality-risk-management, bnt162b2, critical-process-parameters",17,2,https://drive.google.com/file/d/1evLPTvobErcUehUaoeci-lgM2wHr9OqR/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:20
127_Courtesy Copy_BLA 125742-0_CBER Sentinel Program Sufficiency Memo - COMIRNATY.pdf,PDF,CBER Sentinel Program Sufficiency Memo: BNT162b2 (COVID-19 Vaccine) /STN 125742,2019-01-29,memo,"Joyce Obidi, Hui-Lee Wong",,False,False,False,False,False,"FOIA document, vaccine efficacy, BNT162b2 COVID-19 vaccine, Centers for Medicare and Medicaid (CMS), COMIRNATY vaccine, myocarditis and pericarditis, FDAAA post-market requirement, regulatory compliance, Biologics Effectiveness and Safety (BEST) Initiative, vaccine safety data, FDA approval, VRBPAC advisory committee, adverse event reporting, Harvard Pilgrim Health Care Institute, post-authorization safety monitoring, pharmaceutical clinical trial, CBER Sentinel Program",17,7,https://drive.google.com/file/d/19iNrTuCOHx6QxQtuXCLe9ibS2nl6UepR/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:24
128_BLA 125742-0_08-30-2021_Telecon_Other (1).pdf,PDF,Response to DBSQC IR RE testing related limits for established and polydispersity index,2021-08-30,email,"Wang, Hsiaoling, Smith, Michael (CBER), Naik, Ramachandra, Gottschalk, Laura, Sutkowski, Elizabeth M., Eichelberger, Maryna, Pan, Tao, Francis, Kori",,False,False,False,False,False,"BLA 125742, FOIA document, Polydispersity index, Data review, FDA regulatory, Pharmaceutical/clinical trial, August 2021, Teleconference, CBER department, Compliance, Submission, Vaccine/drug characterization, Quality control, DLS test memo, Amendment 41, Established limits, Response to IR",17,1,https://drive.google.com/file/d/1ckdlRapZfayRvud3OsjuBbZmiwxf1npU/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:28
"131_Courtesy Copy_BLA 125742-0_Clinical Review Memo, August 23, 2021 - COMIRNATY.pdf",PDF,Clinical Review Memo for BLA 125742-0 (COMIRNATY),2021-08-23,Memo,"Susan Wollersheim, MD, Ann Schwartz, MD, Lucia Lee, M.D., Maria Allende, M.D.",,False,False,False,False,False,"Clinical Review, BLA 125742-0, COMIRNATY, Regulatory Submission, FDA Approval, SARS-CoV-2, Efficacy Data, DVRPA/OVRR, Adverse Events, BioNTech Manufacturing GmbH, Vaccine Formulation, Biologics License Application, Pfizer Inc., Safety Data, COVID-19 Vaccine, Intramuscular Injection, Pharmacologic Class",17,107,https://drive.google.com/file/d/12tpnl6qnGhNZl8UQlaV0Xkl7S3XjCXH8/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:34
125_BLA 125742-0_08-23-2021_Memo_Committee Memo_Toxico.pdf,PDF,"Toxicology Review of COVID-19 Vaccine (BNT162, PF-07302048)",2021-08-23,memo,"Nabil Al Humadi, Martin Green, Kirk Prutzman, Ramachandra Naik, Michael Smith",,False,True,False,False,False,"regulatory-submission, ovrr-dvrpa-division, covid-19-vaccine, clinical-trials, pf-07302048, safety-data, bnt162, Protocol, fda-review, preclinical-studies, biotech-company, toxicology-review, adult-population, reproductive-toxicity, original-submission, immunization, germany-location, repeated-dose-toxicity",18,124,https://drive.google.com/file/d/1Db-T1S7BSQFdsA3JwxmvUx4HATR8QzYd/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:39
132_BLA 125742-0_09-13-2021_Memo_Committee Memo_Review (1).pdf,PDF,BioNTech Manufacturing GmbH's COMIRNATY BLA Documentation Review Memo,2022-04-14,memo,"Mike Smith, Lei Huang, Iryna Zubkova, Marie Anderson, Deb Thompson, Xiao Wang, Ram Naik, Laura Gottschalk",,False,True,False,True,False,"Safety and efficacy data, Regulatory submission, CBER information requests, Exclusion, Manufacturing facilities, Clinical trial data, Environmental assessment, COVID-19 vaccine, Pharmacovigilance, RNA integrity validation, COMIRNATY, Protocol, Sterility and endotoxin testing, BLA 125742/0, Puurs, Belgium, Lot release protocol, PREA deferred studies, BioNTech Manufacturing GmbH, FDA regulatory review",19,11,https://drive.google.com/file/d/1hxg1RCZkupO_Vo2h4YE-3ttuXkx5ST--/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:43
133_Courtesy Copy_BLA 125742-0_Benefit-Risk Assessment Review Memo - COMIRNATY.pdf,PDF,Benefit-Risk Assessment Review Memo - COMIRNATY,2021-09-13,memo,"Ramachandra Naik, Hong Yang, Patrick Funk, Osman N. Yogurtcu, Richard Forshee",,False,False,False,False,False,"FOIA document, Pfizer vaccine, BLA 125742/0, FDA review, clinical trial, COMIRNATY, benefit-risk assessment, safety data, CBER, scenario analysis, modeling, age 16-17, DHHS, efficacy data, adverse events, data analysis, regulatory submission",17,40,https://drive.google.com/file/d/1DBYF4iBUJK6lwMUVTbJXBzkYRugU0dyY/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:48
129_BLA 125742-0_08-30-2021_Telecon_Other.pdf,PDF,Teleconference on Revised 483 Responses for Andover Site,2021-08-30,email,"Jones, Kathleen (CBER), Smith, Michael (CBER), Peters, Lori, Fontan, Laura, Price, Gregory, Lynch, Christian, Emerson, Debra, Eltermann, John, Renshaw, Carolyn, Allen, Ekaterina, Naik, Ramachandra, Gottschalk, Laura, Sutkowski, Elizabeth M.",,False,False,False,False,False,"regulatory-submission, andover-site, pharmaceutical-manufacturing, dmpq-team, safety-data, fda-communication, site-inspection, quality-control, efficacy-data, cber-division, clinical-trial-compliance, adverse-events, vaccine-development, pfizer-biontech, teleconference, 483-response, data-review",17,1,https://drive.google.com/file/d/11W27I2G322SLOmBajRkqTGjfWDx4XdDK/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:53
"135_Courtesy Copy_BLA 125742-0_November 8, 2021_Summary Basis for Regulatory Action - COMIRNATY.pdf",PDF,"Summary Basis for Regulatory Action"",","2021-11-08"",",document,,,False,False,False,False,False,"2021, FOIA-document, needs-review",3,30,https://drive.google.com/file/d/1WmyBQngygRSdXLiSQlrK9ynV3QvTWFbG/view?usp=drivesdk,pd-production-110123,2025-08-12 01:09:58
15_BLA 125742-0_07-02-2021_Telecon_Information Reques.pdf,PDF,COMIRNATY (COVID-19 mRNA Vaccine) BLA Submission - CMC Information Request,2021-07-02,Telecon/Information Request,"Naik, Ramachandra, Harkins Tull, Elisa, Gottschalk, Laura, Smith, Michael (CBER), Aghajani Memar, Neda, Devlin, Carmel M",,False,False,False,True,False,"CMC Information Request, Process Parameters, Kalamazoo, Puurs, Drug Substance, COMIRNATY, Exclusion, FDA Regulatory, CBER, Lipid Nanoparticle (LNP), Process Performance Attributes, Endotoxin, Manufacturing Process, COVID-19 Vaccine, Drug Product, Pfizer, Bioburden, BLA Submission",18,4,https://drive.google.com/file/d/1Z4VAaDpWhOKXEbTeJ5DuO7jFReggyJfu/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:03
21_BLA 125742-0_07-15-2021_Letter_Filing Notification.pdf,PDF,Filing Notification for BLA 125742/0 for COVID-19 mRNA Vaccine,2021-07-15,Letter,"M. Smith, R. Naik, L. Gottschalk, K. Prutzman, E. Sutkowski, D. Dickerson, S. Wollershiem, A. Schwartz, D. Thompson, H. Chun, X. Wang, A. Cheung, N. Al-humadi, M. Anderson, L. McVittie, Elisa Harkins",,False,False,False,False,False,"Biologics License Application (BLA), PDUFA VI, Pharmaceutical Regulation, Expedited Review, Priority Review, Good Review Management Principles, Filing Notification, COVID-19 mRNA Vaccine, Silver Spring, MD, Collegeville, PA, Regulatory Compliance, BioNTech Manufacturing GmbH, Pfizer Inc., FDA Submission, CBER Electronic Repository, Vaccine Development, Clinical Trial Data",17,3,https://drive.google.com/file/d/1ry7JwxsChB68nwNHH7T08XNAR0UO0n8b/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:07
18_BLA 125742-0_07-09-2021_Telecon_Information Reques.pdf,PDF,Information Request Regarding Validation of RNA Integrity by Capillary Gel Electrophoresis (CGE) Method,2021-07-09,Email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"BNT162b2 vaccine, FOIA document, Biologics License Application (BLA), Capillary gel electrophoresis (CGE) method, FDA-CBER communication, Center for Biologics Evaluation and Research (CBER), RNA integrity validation, Clinical trial data, Analytical method validation, Quantification limit, Quality assurance, Assay range evaluation, FDA information request, Vaccine research and development, Regulatory compliance, Pfizer, Pharmaceutical development",17,2,https://drive.google.com/file/d/1K9n0wYlmBf6YjqIOxXe14M5fo58xF27U/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:11
1_IND_19736_185_23-Feb-2021_KERRY_KERRY__RO_.pdf,PDF,Periodic Safety Report Review Checklist,2021-02-23,report,"Kerry Welsh, Ramachandra Naik",,False,False,False,False,False,"office-of-biostatistics-and-epidemiology, fact-sheet-updates, clinical-trials, pharmacovigilance, periodic-safety-report, covid-19-vaccine, ind-19736, worldwide-distribution, division-of-epidemiology, signal-evaluation, safety-data-management, adverse-events, vaccine-development, fda-submission, regulatory-affairs, pfizer-biontech, labeling-changes",17,2,https://drive.google.com/file/d/1i8X8JPrFhEZibF1ycuLXCSVQ-yhFmZ3z/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:15
1_BLA 125742-0_05-13-2021_Letter_Acknowledgement Let.pdf,PDF,Acknowledgement Letter for BioNTech Manufacturing GmbH's COVID-19 mRNA Vaccine BLA,2021-05-13,letter,"Elisa Harkins, CAPT Mike Smith",,False,False,False,False,False,"CBER Secure Email, Biologics License Application (BLA), Vaccine Approval Process, Regulatory Submissions, COVID-19 mRNA Vaccine, Vaccine Safety and Efficacy, Collegeville, PA, BioNTech Manufacturing GmbH, FDCA Section 506, FDAAA Title VIII, Vaccine Indication: Prevention of COVID-19, FDA Acknowledgement Letter, Electronic Submissions Gateway (ESG), Regulatory Project Management, Clinical Trial Data, Fast Track Product, Section 351(a) of the Public Health Service Act",17,2,https://drive.google.com/file/d/1sVmPGiImEyl9OlGJKZT591M2PzzXhuL4/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:19
134_Courtesy Copy_BLA 125742-0_Toxicology Review - COMIRNATY.pdf,PDF,Toxicology Review - COMIRNATY,2018-08-31,report,"Nabil Al-Humadi, Martin Green, Ramachandra Naik, Michael Smith",,False,True,False,False,False,"regulatory-submission, covid-19-vaccine, prophylactic-immunization, pf-07302048, biotech-rna-pharmaceuticals, ovrr-dvrpa, experimental-design, safety-data, stability-study, bnt162, comirnaty, adult-population, Protocol, fda-review, toxicology-study, clinical-trial, reproductive-toxicity, repeated-dose-toxicity",18,125,https://drive.google.com/file/d/16zNyXkrDWDzClGsl6WZVzD8HmWC8-Uva/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:26
"137_BLA_125742_Endotoxin release tests lots FD7220, FE3592, FF2587.pdf",PDF,"Endotoxin Release Tests for Lots FD7220, FE3592, FF2587",2021-08-18,report,"James L. Kenney, Nadine S. Kaelber",,False,False,False,False,False,"regulatory-compliance, good-manufacturing-practices, lot-numbers, safety-data, drug-product-quality, adverse-events, efficacy-data, cber-division, quality-control, hhs-department, endotoxin-release-testing, fda-submission, pharmaceutical-clinical-trials, vaccine-development, freedom-of-information-act, lot-release, us-government",17,6,https://drive.google.com/file/d/14Cdhu5y3zfEqti9zHMZl1L1Y3DZSIljY/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:30
136_BLA_125742_RNAcontent_InSupportTesting.pdf,PDF,Total RNA Content Determination for COMIRNATY® Final Container Lots for BLA In-Support Testing,2021-09-23,Memorandum,"Anil Choudhary, Muhammad Shahabuddin, Maryna Eichelberger, Mary A. Malarkey, Laura Gottschalk, Michael Smith, Ramachandra Naik",,False,False,False,False,False,"Fluorescence Assay, Encapsulation Percentage, DBSQC Laboratory, Quality Specifications, CBER Division, OCBQ Department, RNA Content Determination, COMIRNATY, Regulatory Submission, Biologics Quality Control, Lot Release Testing, Analytical Methodology, FDA Compliance, COVID-19 Vaccine, Pharmaceutical Development, Clinical Trial Support, BLA Submission",17,2,https://drive.google.com/file/d/1WSnr1az3vzfVFnuh3NTkiWRKV-PV1vNM/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:34
"138_BLA_125742_STN125742 release test (pH) lots FD7220, FE3592, FF2587.pdf",PDF,"Release Test (pH) Lots FD7220, FE3592, FF2587",2021,report,,,False,False,False,False,False,"BLA 125742, release test, quality control, compliance, pharmaceutical, FOIA, clinical trial, lots FD7220, FDA, safety data, CBER, lots FE3592, pH, lots FF2587, drug development, efficacy data, regulatory submission",17,7,https://drive.google.com/file/d/1sd7IWsEXGwusA6_qtsCopVIXUcymQv2G/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:39
25_1_BLA 125742-0_07-16-2021_Telecon_Information Reques.pdf,PDF,Lot Release Protocol Template and Drug Substance Handling Instructions,2021-07-16,Email,"Gottschalk, Laura, Harkins, Elisa, Aghajani Memar, Neda, Devlin, Carmel, Naik, Ramachandra, Smith, Michael, Rohlfing, Paul",,False,True,False,False,False,"Vaccine Characterization, Assay Acceptance Criteria, CBER Review, Drug Substance Handling, Pfizer Vaccine Development, Pharmaceutical Quality, COVID-19 mRNA Vaccine, Compliance Documentation, Lot Release Protocol, Protocol, Aliquot Preparation, Biologics License Application, Teleconference Information Request, Regulatory Project Management, FDA Regulatory Submission, Vaccine Stability, Clinical Trial Materials, Freeze-Thaw Cycles",18,2,https://drive.google.com/file/d/10aGGO0KGKw6V_bUtOvVVV8WFhWzfNnNq/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:42
26_2_BLA 125742-0_07-16-2021_Telecon_Information Reques.pdf,PDF,Information Request for Sterility and Endotoxin Methods,2021-07-16,email,"Gottschalk, Laura, Harkins, Elisa, Aghajani Memar, Neda, Devlin, Carmel, Naik, Ramachandra, Smith, Michael, Rohlfing, Paul",,False,False,False,False,False,"cber-office-of-vaccines, biologics-license-application, pharmaceutical-manufacturing, regulatory-compliance, lot-release-testing, pfizer-pharmaceutical, july-2021, information-request, data-submission, quality-control-methods, clinical-trial-data, fda-regulatory-review, laboratory-testing, vaccine-development, sterility-testing, product-verification, endotoxin-testing",17,1,https://drive.google.com/file/d/1GuJ-di-HgfKOz7dUyLR3VdNeoc-ac2dG/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:46
27_BLA 125742-0_07-19-2021_Telecon_Advice.pdf,PDF,BLA STN 125742/0 – COMIRNATY - COVID -19 mRNA Vaccine - Issuance of BLA license number in advance of approval,2021-07-19,email,"Naik, Ramachandra, Harkins Tull, Elisa, Gottschalk, Laura, Smith, Michael (CBER), Aghajani Memar, Neda, Devlin, Carmel M, Rohlfing, Paul",,False,False,False,False,False,"Public health emergency, Pfizer-BioNTech, Center for Biologics Evaluation and Research, Vaccine research and review, License number issuance, Teleconference advice, Regulatory communication, COMIRNATY, BLA submission, Vaccine safety and efficacy, Pharmaceutical development, COVID-19 vaccine, Vaccine labeling, Clinical trial data, Regulatory compliance, FDA approval process, Biologic License Application",17,1,https://drive.google.com/file/d/1oguGk4FDZVST_gBYGCSz1ddx5HDWQTPS/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:50
40_2_BLA 125742-0_08-03-2021_Telecon_Information Reques.pdf,PDF,CMC-related questions for COMIRNATY (COVID-19 mRNA Vaccine),2021-08-03,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Rohlfing, Paul, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"COVID-19 mRNA vaccine, FOIA document, Regulatory affairs, Analytical methods, Regulatory submission, Lipid ALC-0315, Pharmaceutical/clinical trial, CMC-related questions, COMIRNATY vaccine, Shipping performance qualification, Process validation, Pfizer manufacturing sites, FDA communication, Quality control, Compliance, Drug substance, Drug product",17,3,https://drive.google.com/file/d/1ao1fYcW2NAUI7bN90bFb994pKtn9GAN6/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:54
2_IND_19736_214_03-Mar-2021_KERRY_KERRY__RO_ .pdf,PDF,Periodic Safety Report Review Checklist,2021-03-03,report,"Kerry Welsh, Ramachandra Naik",,False,False,False,False,False,"office-of-biostatistics-and-epidemiology, regulatory-submission, anaphylaxis, covid-19-vaccine, ind-19736, periodic-safety-report, safety-signals, label-updates, us-distribution, division-of-epidemiology, worldwide-distribution, hypersentivity-reactions, diarrhea, fda-review, pfizer-biontech, adverse-events, clinical-safety-data-management",17,2,https://drive.google.com/file/d/1IaI_sulHtukYgUKv-QqVennx53eySgDe/view?usp=drivesdk,pd-production-110123,2025-08-12 01:10:58
32_1_BLA 125742-0_07-26-2021_Telecon_Information Reques.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) Manufacturing and Equipment Information Request",2021-07-26,Telecon,"Gottschalk, Laura, Harkins Tull, Elisa, Naik, Ramachandra, Smith, Michael (CBER), Devlin, Carmel M, Aghajani Memar, Neda, Rohlfing, Paul",,False,False,False,False,False,"Shipping Validation, Hold Time Studies, Regulatory Approval, Drug Substance, COMIRNATY, Quality Control, Equipment, FOIA Request, Teleconference, Endotoxin, FDA Submission, Sterility, Manufacturing, COVID-19 Vaccine, Pfizer, Bioburden, Drug Product",17,4,https://drive.google.com/file/d/1MnrUPCk4z_dt-nj73lydTiy8VdoAcUqk/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:02
3_BLA 125742-0_05-20-2021_Telecon_Information Reques.pdf,PDF,Information Request for BLA 125742/0 Facilities,2021-05-20,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"Manufacturing schedule, Pharmacia & Upjohn Company LLC, Pfizer Manufacturing Belgium NV, Lipid nanoparticle formulation, Visitor entry requirements, Upstream and downstream operations, Fill/finish operations, Facility inspection, COVID-19 vaccine, Production capacity, Teleconference, BLA 125742/0, Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC, FDA information request, BNT162b2, Regulatory compliance, COVID-19 precautions",17,2,https://drive.google.com/file/d/13HwelazFnzHgSUjby2drK5YONdDCBvhD/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:06
43A_STN 125742.0 4AUG21 LRP FU IR 2.pdf,PDF,Electronic Protocol Signature Page,2021-08-04,form,Sample Custodian,,False,True,False,False,False,"clinical-trial-protocol, lot-testing, biologics-evaluation, electronic-protocol, manufacturing-details, regulatory-compliance, product-information, vaccine-or-drug-product, electronic-submissions-gateway, sample-status, quality-control, Protocol, silver-spring-maryland, virus-verification, fda-submission, authorized-official, lot-release, phase-unspecified",18,6,https://drive.google.com/file/d/1_dANhfb4UaZg5IB7gANyEXstxk4G88vI/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:10
42_1_BLA 125742-0_08-04-2021_Telecon_Information Reques.pdf,PDF,Comments on LRP template submitted to STN 125742/0.14 on 7/20,2021-08-04,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Rohlfing, Paul, Naik, Ramachandra, Gottschalk, Laura",,False,True,False,False,False,"BLA 125742, FOIA document, Pharmaceutical clinical trial, RNA encapsulation and content, Lipid analysis, Regulatory submission, Quality control testing, Pfizer, August 2021, Electronic protocol, Lot release protocol (LRP), Bacterial endotoxin, CBER (Center for Biologics Evaluation and Research), Protocol, In vitro expression, FDA review and comments, RNA integrity, Identity of encoded RNA sequence",18,3,https://drive.google.com/file/d/1lBDrfSK1QgxLudKWyyolQgLch-YmK4S1/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:15
33_1_BLA 125742-0_07-27-2021_Telecon_Information Reques.pdf,PDF,Information Request for Assessment of Vaccine Effectiveness,2021-07-27,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"vaccine-effectiveness, bla-125742, confidence-intervals, cber, time-periods, vaccine-efficacy, regulatory-review, placebo-crossover, information-request, division-of-vaccines, unblinding, vaccine-safety, pfizer-biontech, fda-submission, data-analysis, clinical-trial, statistical-methods",17,2,https://drive.google.com/file/d/1MoTx00WqDH66rJjVHMnXOMioKztS_RuU/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:18
39_2_BLA 125742-0_08-02-2021_Telecon_Information Reques.pdf,PDF,Questions regarding validation of assay methods and lot release,2021-08-02,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Rohlfing, Paul, Naik, Ramachandra, Gottschalk, Laura",,False,True,False,False,False,"Container content, Lot release testing, FOIA document, Pharmaceutical clinical trials, Vaccine development, Assay validation, Accuracy and precision, Pfizer, Capillary gel electrophoresis (CGE), Dynamic light scattering (DLS), CBER (Center for Biologics Evaluation and Research), Protocol, Submission and approval, Integrity assay, Quality control, FDA regulatory review, Regulatory compliance, COMIRNATY (COVID-19 Vaccine, mRNA)",18,3,https://drive.google.com/file/d/1QcNV9KfozxWKqX2WNBgyNyzbITyDCrFK/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:23
3_IND_19736_243_19-Mar-2021_KERRY_KERRY__RO_ .pdf,PDF,Periodic Safety Report Review Checklist,2021-03-19,report,"Kerry J. Welsh, Ramachandra Naik",,False,False,False,False,False,"epidemiology division, clinical trial data, product labeling changes, global drug distribution, adverse event monitoring, medical officer guidance, COVID-19 vaccine, periodic safety report, safety data reporting, cumulative dose distribution, data management compliance, vaccine safety, safety signal evaluation, biostatistics and epidemiology, FDA regulatory review, Pfizer-BioNTech vaccine, regulatory submission",17,2,https://drive.google.com/file/d/1847lnzuLAVlFnGgFLWrI4QUZ0aN_XrWh/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:26
53_2_BLA 125742-0_08-06-2021_Telecon_Information Reques.pdf,PDF,Telecon Information Request,2021-08-06,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"LAL procedures, Division of Vaccines and Related Products Applications, FOIA document, Pharmaceutical clinical trial, Biologics License Application (BLA), Endotoxin-like activity, Specification establishment, Lot release testing, Technical scientific terms, Endotoxin measurement, STN 125742.0, Center for Biologics Evaluation & Research (CBER), Compliance and quality control, FDA regulatory review, Data request, Pfizer, Drug product quality",17,2,https://drive.google.com/file/d/15TNvS_JiIYPquNMD9qFoMo9UNKwI_Toh/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:30
49_BLA 125742-0_08-06-2021_Letter_UNII Code Notificat.pdf,PDF,UNIQUE INGREDIENT IDENTIFIER (UNII) CODE ASSIGNMENT,2021-08-06,letter,"Elisa Harkins, CAPT Mike Smith, Ph.D.",,False,False,False,False,False,"pharmaceutical/clinical trials, FOIA document, drug listing, Center for Biologics Evaluation and Research, establishment registration, Regulatory Project Manager, UNII code assignment, COVID-19 vaccine, mRNA vaccine, drug substance, BioNTech Manufacturing GmbH, FDA approval, Pfizer Inc., excipients, Substance Registration System (SRS), Division of Vaccines and Related Product Applications, regulatory compliance",17,3,https://drive.google.com/file/d/1NWM_GebVQQegfNFyzQlDVijIq5f0myrq/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:33
54_BLA 125742-0_08-09-2021_Inspection Related_Inspect.pdf.pdf,PDF,Inspection Waiver for Pre-License Inspections of COVID-19 Vaccine Manufacturing and Testing Facilities,2021-08-09,memo,"Kathleen R. Jones, Laura Fontan, Gregory Price, CDR Donald Ertel, Nicole Li, Michael Smith, Laura Gottschalk, Carolyn Renshaw, Iryna Zubkova",,False,False,False,False,False,"grange-castle-ireland, zagreb-croatia, biologics-license-application, covid-19-vaccine, regulatory-compliance, chesterfield-missouri, fda-inspection-waiver, manufacturing-facilities, pre-license-inspection, comirnaty, cber-division-of-manufacturing-and-product-quality, testing-facilities, wavre-belgium, surveillance-inspection, bnt162b2, quality-assurance, kalamazoo-michigan",17,5,https://drive.google.com/file/d/1QYZSpudH_heSOL4QknFZCdQpypIWO97X/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:38
52_1_BLA 125742-0_08-06-2021_Telecon_Information Reques.pdf,PDF,Teleconference Information Request,2021-08-06,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"regulatory-submission, response-deadline, biologics-license-application, compliance, batch-size, drug-product-manufacturing, pfizer-puurs, lipid-nanoparticle-production, fda-communication, process-validation, quality-control, clinical-trial-data, cber-division-of-vaccines, vaccine-development, software-update, data-request, bulk-drug-product-formulation",17,2,https://drive.google.com/file/d/1hMSNkOLqo7ue6dnvRTEVFfSAaKi7EkVK/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:42
47_1_BLA 125742-0_08-05-2021_Telecon_Information Reques.pdf,PDF,Teleconference Information Request for BLA 125742-0,2021-08-05,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Rohlfing, Paul, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"container-closure-information, regulatory-submission, biologics-license-application, safety-efficacy-data, cber, quality-compliance, pharmaceutical-development, information-request, division-of-vaccines-and-related-products-applications, clinical-trial-data, pfizer, august-2021, fda-review, vaccine-diluent, teleconference, foia-document, reconstitution-instructions",17,2,https://drive.google.com/file/d/10s8rzk7_KuXqZbTtF_AjUExHgJqHYIhI/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:45
55_BLA 125742-0_08-09-2021_Telecon_Advice.pdf,PDF,Teleconference Advice Regarding Validation of Assay Methods and Lot Release for BLA 125742-0,2021-08-09,email,"Naik, Ramachandra, Rohlfing, Paul, Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Gottschalk, Laura",,False,True,False,False,False,"Pharmaceutical Manufacturing, Vaccine Efficacy, FDA Regulatory Advice, CBER Guidance, BLA 125742-0, Pharmaceutical Quality, Assay Validation, Regulatory Submission, Teleconference, Protocol, Vaccine Lot Release, Adverse Event Monitoring, COVID-19 Pandemic, Regulatory Compliance, Public Health Considerations, Clinical Trial Data, Vaccine Safety, Pfizer-BioNTech COVID-19 Vaccine",18,5,https://drive.google.com/file/d/1xwESejWYIYpxvOWQljwMRWOygJpSloO8/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:49
58_2_BLA 125742-0_08-10-2021_Telecon_Information Reques.pdf,PDF,Testing related Information Request for STN 125742.0,2021-08-10,email,"Smith, Michael (CBER), Aghajani Memar, Neda, Harkins Tull, Elisa, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"Division of Vaccines and Related Products Applications, FOIA document, Pharmaceutical clinical trial, Dynamic light scattering, Information request, Biologics License Application (BLA), Size and polydispersity index measurement, Data analysis, PF-07302048 drug product, Center for Biologics Evaluation and Research (CBER), mRNA lipid nanoparticle (LNP), Teleconference, Compliance, Quality control, FDA regulatory review, Established limits, Office of Vaccines Research and Review",17,2,https://drive.google.com/file/d/1w4LEBi3qTr8NiYlEKNZ6ia-zbf9alNhH/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:53
51_Courtesy Copy_BLA 125742-0_Pharmacovigilance Plan Review Memo - COMIRNATY.pdf,PDF,Pharmacovigilance Plan Review Memo - COMIRNATY,2021-05-18,memo,"Deborah L. Thompson, Ramachandra Naik, Manette Niu, Narayan Nair",,False,True,False,False,False,"vaccine-safety-monitoring, regulatory-submission, clinical-trials, pharmacovigilance, OVRR, COMIRNATY, immunization, CBER, FDA-review, post-marketing-surveillance, adverse-events, COVID-19-vaccine, Protocol, DE, vaccine-composition, BNT162b2, OBE, BLA-125742",18,33,https://drive.google.com/file/d/1u8c6flInK1vY-r5J_dch4BRglgSoqoO4/view?usp=drivesdk,pd-production-110123,2025-08-12 01:11:56
45_BLA 125742-0_08-05-2021_Telecon_Advice.pdf,PDF,"Proper Name for COVID-19 Vaccine, mRNA",2021-08-05,email,"Gottschalk, Laura, Harkins Tull, Elisa, Naik, Ramachandra, Smith, Michael (CBER), Devlin, Carmel M, Aghajani Memar, Neda",,False,False,False,False,False,"cber, biologics-license-application, covid-19-vaccine, proper-name, pharmaceutical-industry, regulatory-compliance, regulatory-approval, safety-data, fda-communication, adverse-events, pfizer, efficacy-data, quality-control, vaccine-development, clinical-trial, united-states, mrna-vaccine",17,1,https://drive.google.com/file/d/1_eFnxnl0EuBAjCZw0lQ9fZrqKsc6KAxj/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:00
46_2_BLA 125742-0_08-05-2021_Telecon_Information Reques.pdf,PDF,Teleconference Information Request for BLA 125742-0,2021-08-05,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Rohlfing, Paul, Naik, Ramachandra, Gottschalk, Laura",,False,True,False,False,False,"Analytical testing, BNT162b2 vaccine, FOIA document, Product-dedicated equipment, Regulatory submission, BLA 125742-0, Pharmaceutical/clinical trial, Facilities information request, Quality compliance, Microbial control, Cleaning validation, Protocol, FDA communication, Visual inspection, Pfizer Chesterfield, Hold time validation, Environmental monitoring, Pfizer Andover",18,5,https://drive.google.com/file/d/1QIfAQQGXphF2sM_1cPhReya9_WTP7Eff/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:05
4_IND_19736_289_27-Apr-2021_DEBORAH_DEBORAH__RC_.pdf,PDF,Periodic Safety Report Review Checklist,2021-04-27,report,"Ramachandra Naik, Deborah Thompson",,False,False,False,False,False,"Pfizer-BioNTech, labeling changes, epidemiology, FDA review, safety signals, clinical trial, product distribution, regulatory actions, COVID-19 vaccine, periodic safety report, safety data management, hepatic events, reference safety information, biostatistics, adverse events, vaccine stress-related responses, regulatory submission",17,2,https://drive.google.com/file/d/1lNWuBfA0aTuqS3Zuzj8EljRRLBfkVgZh/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:08
44_3_BLA 125742-0_08-04-2021_Telecon_Information Reques.pdf,PDF,Telecon Information Request for BLA 125742-0,2021-08-04,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"potency-assay, regulatory-compliance, pharmaceutical-manufacturing, information-request, pfizer-vaccine, quality-control, clinical-trial-data, cber-division, teleconference, fda-review, bnt162b2-construct, flow-cytometry, data-analysis, bla-submission, vaccine-development, reproducibility, in-vitro-expression",17,2,https://drive.google.com/file/d/1ACcCibM7jnArVSyRP56twsZX1dIldcty/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:12
68_5_BLA 125742-0_08-13-2021_Telecon_Information Reques.pdf,PDF,"Requests and instructions regarding test methods, the lot release process, and the lot release protocol template",2021-08-13,email,"Smith, Michael (CBER), Aghajani Memar, Neda, Rohlfing, Paul, Naik, Ramachandra, Gottschalk, Laura, Harkins Tull, Elisa, Devlin, Carmel M",,False,True,False,False,False,"protocol-template, product-submission, biologics-license-application, product-release, regulatory-compliance, manufacturing-process, test-methods, pfizer-pharmaceutical, lot-release-process, information-request, cber-division-of-vaccines, Protocol, clinical-trial-data, fda-regulatory-review, vaccine-development, data-requirements, scientific-communication, quality-assurance",18,2,https://drive.google.com/file/d/12mUEyu751nMVumB9gDM3u-oiOl-n0iYl/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:16
"64_Courtesy Copy_BLA 125742-0_Bioresearch Monitoring Discipline Review Memo, August 13, 2021 - COMIRNATY.pdf",PDF,Bioresearch Monitoring (BIMO) Discipline Review Memo,2021-08-13,memo,"Haecin Chun, Dennis Cato, Carrie Mampilly, Mary A. Malarkey, Ramachandra Naik, Susan Wollersheim, Ann Schwartz, Michael Smith, Laura Gottschalk",,False,True,False,False,False,"FOIA document, Adult population, Safety, tolerability, immunogenicity, efficacy, Pharmaceutical clinical trials, Compliance program 7348.811, COMIRNATY, Bioresearch Monitoring (BIMO), Domestic and international clinical sites, Phase 1/2/3 study, COVID-19 vaccine, Protocol, Pediatric population, Emergency Use Authorization (EUA), Study protocol C4591001, BLA 125742/0, Regulatory review and approval, Inspection program, FDA compliance",18,3,https://drive.google.com/file/d/1pyoA8KKrz-SgGVRfXvGL8V8FfTVM42IX/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:20
62_BLA 125742-0_08-12-2021_Memo_Committee Memo_Requir.pdf,PDF,CMC Review Memorandum,2021-08-12,memo,"Anissa Cheung, Jerry Weir, Ramachandra Naik, Michael Smith, Laura Gottschalk, Kathleen Jones",,False,False,False,False,False,"cmc-review, drug-product, covid-19-vaccine, deviation-investigation, critical-quality-attributes, pf-07302048, regulatory-compliance, andover-ma, drug-substance, stability-testing, bnt162, wyeth-biopharma, fda-submission, clinical-trial, pre-license-inspection, quality-assurance, product-quality",17,2,https://drive.google.com/file/d/1K-m02i_Ki1x4mzzTwfNoq5rNxrvqFjZ9/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:24
61_BLA 125742-0_08-11-2021_Telecon_Other.pdf,PDF,"Teleconference Summary for BLA 125742/0 - COVID-19 Vaccine, mRNA (COMIRNATY)"",","2021-08-11"",",document,,,False,True,False,False,False,"Protocol, 2021, FOIA-document, needs-review",4,3,https://drive.google.com/file/d/1hQwyT-PRZJfBn5oz7x-r2ncC82bIjWQf/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:28
65_BLA 125742-0_08-13-2021_Memo_Request For Complianc.pdf,PDF,Request for Compliance Check BLA STN 125742/0,2021-08-13,memo,"Zubkova, Iryna, DeCiero, Daniel, Peters, Lori, Naik, Ramachandra, Smith, Michael (CBER), Gottschalk, Laura, Ertel, Donald",,False,False,False,False,False,"COVID-19 mRNA vaccine, compliance check, FOIA document, drug product, COMIRNATY, regulatory submission, Wyeth BioPharma, SARS-CoV-2, drug substance, release and stability testing, inspection waiver, FDA approval, Pfizer Inc., manufacturing facilities, BLA 125742/0, immunization, pharmaceutical/clinical trial",17,4,https://drive.google.com/file/d/1AQ6PwHENVeRZheLb9_lwANCLNZxAuK2h/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:32
6_IND_19736_366_24-Jun-2021_DEBORAH_DEBORAH__RO_.pdf,PDF,Periodic Safety Report Review Checklist,2021-06-24,report,"Ramachandra Naik, Deborah Thompson",,False,False,False,False,False,"labeling changes, US market, worldwide distribution, dose distribution, epidemiology, FDA review, safety signals, PSUR, regulatory submission, PAER, periodic safety report, adverse events, vaccine safety, biostatistics, BNT162b2, E2C guidance, Pfizer-BioNTech COVID-19 Vaccine",17,2,https://drive.google.com/file/d/1SVkIHk48JnrIru7Wlbt90mQdgRkOQTak/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:35
60_BLA 125742-0_08-11-2021_Telecon_Information Reques.pdf,PDF,Telecon Information Request for BLA 125742-0,2021-08-11,email,"Smith, Michael (CBER), Aghajani Memar, Neda, Harkins Tull, Elisa, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,False,False,False,False,"clinical-trial-materials, shipping-procedures, covid-19-vaccine, biologics-license-application, pharmaceutical-quality-control, regulatory-compliance, regulatory-review, sterile-saline-solution, cber-division-of-vaccines, vaccine-vial-sizes, fda-information-request, fda-submission, vaccine-approval, diluent-information, pfizer-vaccine-development, vaccine-distribution-logistics, manufacturing-information",17,2,https://drive.google.com/file/d/11tERPjdn2Uz46ZfRANRHPzThcFV639n7/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:39
5_IND_19736_335_19-May-2021_DEBORAH_DEBORAH__RC_.pdf,PDF,Periodic Safety Report Review Checklist,2021-05-19,report,"Deborah Thompson, Ramachandra Naik",,False,False,False,False,False,"Pfizer-BioNTech, product labeling, compliance, epidemiology, signal detection, clinical trial, FDA, periodic safety report, safety data, risk assessment, vaccine, adverse events, biostatistics, data review, BNT162b2, emergency use authorization, regulatory submission",17,2,https://drive.google.com/file/d/1HSQzRM1GL_Qo6DhJNMwrXz_Njgy-o8E7/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:43
68A_5_BLA 125742-0_08-13-2021_Telecon_Information Reques.pdf,PDF,Teleconference Information Request for BLA 125742-0,2021-08-13,memo,Joseph Quander,,False,True,False,False,False,"rna-integrity-assay, eua-lots, biologics-license-application, pharmaceutical-manufacturing, regulatory-compliance, total-rna, fda-cber, expedited-review, coefficient-of-determination, quality-control, clinical-trial-data, silver-spring-maryland, Protocol, in-vitro-expression-assay, vaccine-development, encapsulated-rna, sample-submission, lot-release-protocol",18,4,https://drive.google.com/file/d/1R29TiH2BpRbsvGEKatYY0Ur7jqdhNU3m/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:46
68B_5_BLA 125742-0_08-13-2021_Telecon_Information Reques.pdf,PDF,Teleconference Information Request for BLA 125742-0,2021-08-13,memo,Joseph Quander,,False,True,False,False,False,"rna-integrity-assay, eua-lots, biologics-license-application, sample-shipment, pharmaceutical-manufacturing, regulatory-compliance, total-rna, fda-cber, expedited-review, coefficient-of-determination, quality-control, clinical-trial-data, silver-spring-maryland, Protocol, in-vitro-expression-assay, vaccine-development, encapsulated-rna, lot-release-protocol",18,4,https://drive.google.com/file/d/16OIu94AA9BsYumCkk5K0r3rqrKifDiir/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:50
66_4_BLA 125742-0_08-13-2021_Telecon_Information Reques.pdf,PDF,Teleconference Information Request for BLA 125742-0,2021-08-13,email,"Smith, Michael (CBER), Aghajani Memar, Neda, Rohlfing, Paul, Naik, Ramachandra, Gottschalk, Laura, Harkins Tull, Elisa, Devlin, Carmel M",,False,False,False,False,False,"FOIA document, Pharmaceutical clinical trial, Computer system validation, Water quality monitoring, Equipment qualification, Regulatory submission, BLA 125742-0, Product contact equipment, Compressed air and nitrogen utilities, Pfizer Andover facility, Cleaning validation, CBER (Center for Biologics Evaluation and Research), Teleconference, BNT162b2 drug substance, Pfizer Puurs and Kalamazoo facilities, FDA information request, DMPQ (Division of Manufacturing and Product Quality)",17,3,https://drive.google.com/file/d/1DP-4forOWRowFxHo8a5SjZbfxnt3YaFe/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:54
89_1_BLA 125742-0_08-18-2021_Telecon_Information Reques.pdf,PDF,"COMIRNATY (COVID-19 Vaccine, mRNA) BLA 125742/0 Teleconference Information Request",2021-08-18,Email,"Smith, Michael (CBER), Harkins Tull, Elisa, Rohlfing, Paul, Naik, Ramachandra, Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M",,False,True,False,False,False,"Vaccine Approval, Vaccine Efficacy, Clinical Trials, Endotoxin Testing, CGE Integrity Test, CBER Division, COMIRNATY, Vaccine Compliance, FDA Regulatory, Pfizer Submissions, Teleconference, Protocol, Lot Release Protocol, Quality Assurance, BLA 125742/0, COVID-19 Vaccine, Vaccine Safety, Information Request",18,2,https://drive.google.com/file/d/1vy5LfnQ8kOBFynjCwxisOP5oIIy07SZp/view?usp=drivesdk,pd-production-110123,2025-08-12 01:12:58
81_1_BLA 125742-0_08-17-2021_Telecon_Information Reques.pdf,PDF,Information Request on Drug Substance Manufacturing Process Validation,2021-08-17,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Naik, Ramachandra, Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M, Rohlfing, Paul",,False,False,False,False,False,"BLA 125742, clinical trial data, critical process parameters, Andover, Secaucus, Kalamazoo, Puurs, vaccine development, CBER, data submission, pharmaceutical manufacturing, drug substance manufacturing, FDA information request, drug product quality, Pfizer, process validation, regulatory compliance",17,2,https://drive.google.com/file/d/1lQohZSLU6SWHXSFaevpj0wyCZ3r7TGQ8/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:02
75_1_BLA 125742-0_08-16-2021_Telecon_Information Reques.pdf,PDF,"Teleconference Summary for BLA 125742/0 - COVID-19 Vaccine, mRNA (COMIRNATY)",2021-08-16,teleconference summary,"Maryna Eichelberger, Mary Malarkey, Ramachandra Naik, Michael Smith, Paul Rohlfing, Rich Pelt, Roger Nosal, Brian Picard, Andrew Nelson, Donna Boyce, Carmel Devlin, Lavinia Lewis, Meg Ruesch, Dave Cirelli",,False,True,False,False,False,"pfizer-biontech-partnership, bla-125742, lal-procedure, covid-19-vaccine, teleconference-summary, clinical-development, information-request, comirnaty, quality-control, lot-release-protocol, fda-regulatory-review, Protocol, regulatory-affairs, analytical-testing, vaccine-manufacturing, vaccine-approval, product-quality, endotoxin-testing",18,2,https://drive.google.com/file/d/1rkGrc6UZp9iVN63W-1XT7SLlj_srzxJC/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:06
84_BLA 125742-0_08-18-2021_Memo_Committee Memo_Review.pdf,PDF,Review of Lot Release Protocol (LRP) Template for COVID-19 mRNA Vaccine,2021-08-18,memo,"Marie J. Anderson, Maryna Eichelberger, Mary A. Malarkey, Ramachandra Naik, Michael Smith, Laura Gottschalk",,False,True,False,False,False,"BLA 125742, Lot release protocol, OVRR, OCBQ, Regulatory submission, FDA review, COMIRNATY, COVID-19 vaccine, mRNA vaccine, CBER, Quality control, Compliance, BioNTech Manufacturing GmbH, Clinical trial data, Silver Spring, MD, Protocol, DVRPA, DBSQC",18,3,https://drive.google.com/file/d/1HYIi2tXHBnSmmrtdHptNvPBNu_GWEbZD/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:10
85_Courtesy Copy_BLA 125742-0_Statistical Review -- COMIRNATY.pdf,PDF,"Statistical Review of COMIRNATY (COVID-19 Vaccine, mRNA)",2021-05-18,report,"Ramachandra Naik, Xiao Wang, Mike Smith, Laura Gottschalk, Xinyu Tang, Lei Huang, Tsai-Lien Lin, John A. Scott",,False,False,False,False,False,"ovrr, covid-19-vaccine, virus-neutralization-assay, linearity, fda-submission, division-of-biostatistics, priority-review, regulatory-approval, statistical-review, precision, comirnaty, biontech-manufacturing, pfizer, limits-of-quantitation, original-bla, intramuscular-injection, clinical-trial",17,11,https://drive.google.com/file/d/1dtqhN_7ydA4dSKwnxnaKr3jTEYBiY9D1/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:14
7_IND_19736_409_26-Jul-2021_DEBORAH_DEBORAH__RO_.pdf,PDF,Periodic Safety Report Review Checklist,2021-07-26,report,"Ramachandra Naik, Deborah Thompson",,False,False,False,False,False,"PBRER, dose distribution, epidemiology, FDA review, PSUR, PAER, regulatory submission, periodic safety report, pericarditis, risk assessment, myocarditis, PADER, adverse events, vaccine safety, BNT162b2, data analysis, Pfizer-BioNTech COVID-19 Vaccine",17,2,https://drive.google.com/file/d/1qcFP-W4ellXRC8ooqY26lfbq5QB6o682/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:17
83_BLA 125742-0_08-17-2021_Telecon_Other.pdf,PDF,"Teleconference Summary for BLA 125742/0 (COVID-19 Vaccine, mRNA (COMIRNATY))",2021-08-17,teleconference summary,"Ekaterina Allen, Anissa Cheung, John Eltermann, Debra Emerson, Kathleen Jones, Christian Lynch, Ramachandra Naik, Lori Peters, Carolyn Renshaw, Michael Smith, Paul Rohlfing, Adrienne Stafford, Andrew Nelson, Elisa Harkins Tull, Meg Ruesch, Dave Cirelli, Amy Lovasko",,False,False,False,False,False,"regulatory-submission, covid-19-vaccine, fda-regulatory-affairs, teleconference-summary, software-controls, bla-125742-0, pfizer-inc, pharmaceutical-quality, active-immunization, comirnaty, manufacturing-site-inspection, biontech-manufacturing, data-integrity, august-2021, sars-cov-2, vaccine-development, clinical-trial-application",17,4,https://drive.google.com/file/d/1RgYJWXd_iDZVZJuDA4eg2kdtAg3GNLVy/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:22
73_2_BLA 125742-0_08-16-2021_Telecon_Information Reques.pdf,PDF,Information Request Regarding Diluent Suppliers,2021-08-16,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Naik, Ramachandra, Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M, Rohlfing, Paul",,False,False,False,False,False,"regulatory-communication, clinical-trial-materials, biologics-license-application, vaccine-manufacturing, quality-compliance, vaccine-supply-chain, pfizer-healthcare-india, pharmaceutical-development, information-request, drug-product-quality, cber-division-of-vaccines, fda-regulatory-review, official-action-indicated, warning-letter, diluent-suppliers, vaccine-approval-process, vaccine-formulation",17,2,https://drive.google.com/file/d/1qyVb5CX0cKzTI5EBmVvzi3MiiDCZA1_l/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:26
74_3_BLA 125742-0_08-16-2021_Telecon_Information Reques.pdf,PDF,Submission of CMC information to support extension of shelf life of BNT162b2 to 9 months,2021-08-16,email,"Naik, Ramachandra, Harkins Tull, Elisa, Gottschalk, Laura, Smith, Michael (CBER), Rohlfing, Paul, Aghajani Memar, Neda, Boyce, Donna",,False,False,False,False,False,"shelf-life-extension, regulatory-submission, pfizer-corporation, biologics-license-application, regulatory-compliance, drug-product-characterization, pharmaceutical-quality, eua-amendment, clinical-trial-data, cber-division, august-2021, bnt162b2-vaccine, fda-review, vaccine-development, vaccine-stability, cmc-information, vaccine-approval-process",17,1,https://drive.google.com/file/d/1Tge_k3pRo6cIW6rjunS3uW-7-JtN28Yf/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:30
86_BLA 125742-0_08-18-2021_Telecon_Advice.pdf,PDF,Teleconference Advice on Drug Substance (DS) for BLA 125742-0,2021-08-18,email,"Smith, Michael (CBER), Rohlfing, Paul, Naik, Ramachandra, Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M, Harkins Tull, Elisa",,False,False,False,False,False,"Technical Discussions, Andover Manufacturing Site, Vaccine Approval, FDA Regulatory Advice, Quality Compliance, BLA 125742-0, Manufacturing Process Development, Proven Acceptance Range (PAR), Regulatory Submission, Teleconference, Process Characterization, Confidential Information, Pharmaceutical Development, Drug Substance (DS), Clinical Trial Data, CBER Review Team, Pfizer Vaccine",17,4,https://drive.google.com/file/d/19nzOVDJIffji0Rl8tTNyVNOtLAPL4md5/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:34
87_3_BLA 125742-0_08-18-2021_Telecon_Information Reques.pdf,PDF,Teleconference Information Request,2021-08-18,email,"Smith, Michael (CBER), Rohlfing, Paul, Gottschalk, Laura, Naik, Ramachandra, Aghajani Memar, Neda, Harkins Tull, Elisa, Devlin, Carmel M",,False,False,False,False,False,"annual-report-submission, real-time-data-reporting, pharmaceutical-quality-control, date-of-manufacture, drug-product-shelf-life, cber-review-team, stn-125742.0, regulatory-compliance, fda-regulatory-submission, batch-updates, product-correspondence, expiry-dating-period-extension, data-analysis-and-reporting, vaccine-manufacturing, foia-document, clinical-trial-stability-data, pfizer-vaccine-development",17,3,https://drive.google.com/file/d/1l84WMaM3s35eOQmynQ4fxYKmacUIud4M/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:38
79_3_BLA 125742-0_08-17-2021_Telecon_Information Reques.pdf,PDF,Information Request Regarding Shelf Life and Date of Manufacture,2021-08-17,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Naik, Ramachandra, Gottschalk, Laura, Aghajani Memar, Neda, Devlin, Carmel M",,False,False,False,False,False,"vaccines, biologics, compliance, date_of_manufacture, data_submission, clinical_trial, product_labeling, pharmaceutical_development, communication, information_request, stability_data, FDA_CBER, drug_product, quality_control, regulatory_review, shelf_life, product_lifecycle",17,2,https://drive.google.com/file/d/1WVo2mrCGBkEUrDrRpv95xrM0FuZ7X3an/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:42
94_Courtesy Copy_1_BLA 125742-0_Statistical Review-COMIRNATY.pdf,PDF,"Statistical Review of BLA 125742/0 for COMIRNATY (COVID-19 Vaccine, mRNA)",2022-01-16,report,"Ramachandra Naik, Ann Schwartz, Susan Wollersheim, Michael Smith, Laura Gottschalk, Ye Yang, Lei Huang, Tsai-Lien Lin, John Scott",,False,True,False,False,False,"bla-125742, clinical-trial-c4591001, regulatory-submission, covid-19-vaccine, good-clinical-practices, dvrpa-ovrr, division-of-biostatistics, vaccine-efficacy, pdufa-goal-date, biontechmanufacturing-pfizer, active-immunization, statistical-review, comirnaty, intramuscular-injection, Protocol, data-integrity, vaccine-safety, fda-review",18,16,https://drive.google.com/file/d/1W35vsUK8ykVXelM_m3xHLY1qNKbNWbso/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:46
95_BLA 125742-0_08-19-2021_Memo_Compliance Check Acce.pdf,PDF,Memo - Compliance Check Acceptance,2021-08-19,memo,"DeCiero, Daniel, Zubkova, Iryna, Peters, Lori, Naik, Ramachandra, Smith, Michael (CBER), Gottschalk, Laura, Ertel, Donald, Sausville, Robert, Anderson, Maria (CBER), Mendoza, Melissa, Malarkey, Mary",,False,False,False,False,False,"regulatory-submission, approval-process, fill-and-finish, covid-19-vaccine, bla-application, pharmaceutical-industry, fda-compliance-check, manufacturing-facilities, comirnaty, drug-substance-testing, packaging, drug-product-testing, clinical-trial-data, geographic-locations, regulatory-affairs, inspection-history, quality-assurance",17,7,https://drive.google.com/file/d/1Iwprz0n6HPeaf0l0yPYFGlq-SPRCYGg5/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:50
8_1_BLA 125742-0_06-25-2021_Telecon_Information Reques.pdf,PDF,Information Request for Lot Release Protocol Template and Samples & Reagents,2021-06-25,email,"Smith, Michael (CBER), Harkins Tull, Elisa, Aghajani Memar, Neda, Devlin, Carmel M, Naik, Ramachandra, Gottschalk, Laura",,False,True,False,False,False,"COVID-19 mRNA vaccine, Lot release protocol, FOIA document, Pharmaceutical clinical trial, Analytical testing, Drug substance and product samples, Assay controls and reagents, Information request, FDA regulatory, Potency assay, Submission and review, CBER, Protocol, Compliance, Regulatory documentation, Quality control, Drug product characterization, Pfizer",18,4,https://drive.google.com/file/d/1KazvtYPCoHib6nAryGezbmOthDDAQces/view?usp=drivesdk,pd-production-110123,2025-08-12 01:13:54
92_BLA 125742-0_08-19-2021_Inspection Related_Inspect.pdf,PDF,Establishment Inspection Report for Pfizer Manufacturing Belgium NV,2021-07-02,report,LF,,False,False,False,False,False,"bla-125742, covid-19-vaccine, production-system, materials-system, facilities-and-equipment, drug-product-manufacturing, comirnaty-vaccine, regulatory-compliance, puurs-belgium, recall-procedures, packaging-and-labeling, laboratory-controls, fda-inspection, vaccine-development, pre-license-inspection, quality-systems, pfizer-manufacturing",17,79,https://drive.google.com/file/d/16h5RKCGOCISsxtp_t2oKTa7mbalFaIVr/view?usp=drivesdk,pd-production-110123,2025-08-12 01:14:01
93_Courtesy Copy_2_BLA 125742-0_Statistical Review - COMIRNATY.pdf,PDF,"Statistical Review of BLA 125742/0 for COMIRNATY (COVID-19 Vaccine, mRNA)",2022-01-16,report,"Ramachandra Naik, Ann Schwartz, Susan Wollersheim, Mike Smith, Laura Gottschalk, Lei Huang, Tsai-Lien Lin, John A. Scott",,False,True,False,False,False,"bla-125742, regulatory-submission, good-clinical-practices, covid-19-vaccine, clinical-trials, dvrpa-ovrr, statistical-review, safety-data, comirnaty, biontech-pfizer, efficacy-data, data-integrity, dosing-regimen, fda-review, Protocol, adverse-events, intended-population, vaccine-formulation",18,26,https://drive.google.com/file/d/1RATQJPh127xe1rpvycffM6JlBW7BViXc/view?usp=drivesdk,pd-production-110123,2025-08-12 01:14:04
8_IND_19736_453_26-Aug-2021_DEBORAH_DEBORAH__RO_.pdf,PDF,Periodic Safety Report Review Checklist,2021-08-26,report,"Deborah Thompson, Laura Gottschalk",,False,False,False,False,False,"regulatory-submission, covid-19-vaccine, pharmacovigilance, periodic-safety-report, immune-thrombocytopenia, nephrotic-syndrome, safety-data, thrombocytopenia, pericarditis, myocarditis, thrombosis, fda-review, pfizer-biontech, adverse-events, erythema-multiforme, glomerulonephritis, healthcare-professional-communication",17,2,https://drive.google.com/file/d/1R13oxPgHo0S3prYTrU2zjh-lE4191ZR3/view?usp=drivesdk,pd-production-110123,2025-08-12 01:14:07
99_BLA 125742-0_08-20-2021_Memo_Committee Memo_Labeli.pdf,PDF,Review of BioNTech Manufacturing GmbH - BLS 125742/0 COVID-19 mRNA Vaccine (nucleoside modified) - COMIRNATY® Carton and Container Labeling,2021-08-20,Memo,"Daphne D. Stewart, CSO, Tim D. Nelle, Ph.D., CAPT U.S. Public Health Service",,False,False,False,False,False,"National Drug Code, Compliance with 21 CFR Regulations, CBER Checklists, Fresenius Kabi, FDA Regulatory Review, Product Identifier, COMIRNATY, Diluent Sodium Chloride Injection, Carton and Container Labeling, DVRPA/OVRR, Kalamazoo, MI, Drug Supply Chain Security Act, Regulatory Management Support Branch, Hospira, COVID-19 Vaccine, Puurs, Belgium, BLA Submission",17,31,https://drive.google.com/file/d/1JG0FEYjrhYXrOI5TAeRnKOU3P3OFp_l5/view?usp=drivesdk,pd-production-110123,2025-08-12 01:14:12
9_IND_19736_491_29-Sep-2021_DEBORAH_DEBORAH__RO_ The Summary Monthly Safety Report has been reviewed. No furthe.pdf,PDF,Periodic Safety Report Review Checklist,2021-09-29,report,"Deborah Thompson, Laura Gottschalk",,False,False,False,False,False,"bnt162b2-covid-19-vaccine, regulatory-submission, periodic-safety-report, safety-signals, epidemiology, us-distribution, worldwide-distribution, compliance, clinical-trial-safety, pfizer, fda-review, adverse-events, regulatory-actions, labeling-changes, immunocompromised-patients, biostatistics, data-review",17,2,https://drive.google.com/file/d/1Hm6oImCu7Onbs8rjsQ2hkYFK7FRYZtJ2/view?usp=drivesdk,pd-production-110123,2025-08-12 01:14:15
FDA-CBER-2021-5683-1150835-1200874_Slipsheet.pdf,PDF,Drug Master Files Withheld from FOIA Request,2021,FOIA document,,,False,False,True,False,False,"Adverse events, Bates numbering, Data redaction, Safety data, Regulatory submission, Drug identification, FOIA request, FDA, Efficacy data, CBER, Exemption, Clinical trials, FOIA Exemption 4, Drug Master Files, Pharmaceutical regulatory, Vaccine development, Regulatory compliance, Pharmaceutical development",18,1,https://drive.google.com/file/d/19ySRqAlITk1-sEqB6Iq_1AR82EjqSnfv/view?usp=drivesdk,pd-production-110123,2025-08-12 01:14:18
STN 124742_Courtesy Copy_Pfizer-BioNTech Comirnaty STN 125742 COVID-19 Vaccine Lot Notifications (2021).pdf,PDF,Report on Action Taken on COVID-19 Vaccine Lot Submissions,2021-08-23,report,"Christopher Nagra, John A. Eltermann, Peter Marks",,False,False,False,False,False,"Pfizer-BioNTech Comirnaty, Center for Biologics Evaluation and Research, vaccine distribution, clinical trial data, vaccine efficacy, public health, vaccine quality control, adverse event monitoring, FOIA request, Kalamazoo, Michigan, COVID-19 vaccine, vaccine lot numbers, vaccine lot release, FDA approval, vaccine safety, pharmaceutical manufacturing, regulatory compliance",17,9,https://drive.google.com/file/d/14EMwqzFPeupZgtFb9Rw_ISCodXiIAAMy/view?usp=drivesdk,pd-production-110123,2025-08-12 01:14:21
BATES-93_tv.xpt,XPT,BATES-93 tv,undated,statistical-data,,,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1jFBuLcbzsjAZztC7JDPikfHi7csMzKA9/view?usp=drivesdk,pd-production-111721,2025-08-12 01:14:22
5.2-listing-of-clinical-sites-and-cvs-pages-1-41.pdf,PDF,Listing of Clinical Sites and CVs,2021,report,,,False,False,False,False,False,"clinical sites, compliance, pharmaceutical, curriculum vitae, clinical research, clinical trial, FDA, data management, CBER, safety data, quality assurance, United States, adverse events, efficacy data, drug development, medical professionals, regulatory submission",17,41,https://drive.google.com/file/d/1LlMwYbvf42YBDwmSjJLwzj-dR2k_wUBl/view?usp=drivesdk,pd-production-111721,2025-08-12 01:14:28
5.2-tabular-listing.pdf,PDF,Tabular Listing of FDA CBER Submissions,2021,report,,,False,False,False,False,False,"submission process, compliance reporting, pharmaceutical regulatory, regulatory approval, medical research, public health, government records, tabular listing, vaccine development, safety data, data management, quality assurance, FDA CBER submissions, efficacy data, adverse events, drug identifiers, clinical trials",17,12,https://drive.google.com/file/d/1Y7xEf-OHO9M3b2PWlBtTVPk2g-nrOhtf/view?usp=drivesdk,pd-production-111721,2025-08-12 01:14:31
5.3.6-postmarketing-experience.pdf,PDF,Cumulative Analysis of Post-authorization Adverse Event Reports,2021-04-30,report,Worldwide Safety Pfizer,,False,False,False,False,False,"post-authorization adverse events, CONFIDENTIAL, PF-07302048, pharmacovigilance, cumulative analysis, medication error, US, regulatory submission, FDA, report, vaccine, adverse events of special interest, BNT162b2, safety database, Pfizer, data analysis, clinical trials",17,38,https://drive.google.com/file/d/14y6IalEy6RAoJwdHWuHmoOmJ_FlCyzTP/view?usp=drivesdk,pd-production-111721,2025-08-12 01:14:35
BATES-92_adc19ef-ve-cov-7pd2-wo-eval-sas.txt,TXT,adc19ef-ve-cov-7pd2-wo-eval.sas,2021-03-22,SAS program,WUY169,,False,False,False,False,False,"pharmaceutical research, data quality, SAS programming, CDISC, ADAM, clinical trial, statistical analysis, data management, data processing, COVID-19, vaccine, efficacy, safety, data visualization, adverse events, data analysis, regulatory submission",17,3,https://drive.google.com/file/d/1NwWLwDs0BEKaoBy4hn8Ea4lZ60jdQQ56/view?usp=drivesdk,pd-production-111721,2025-08-12 01:14:38
Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-B.pdf,PDF,Pfizer CV Wolf,2020-07-15,CV,Thomas Wolf,,False,False,False,False,False,"C4591001, compliance, electronic signature, clinical trial, CV, quality, FDA, ETMF, document management, United States, efficacy, safety, electronic record, data, adverse events, Pfizer, regulatory",17,124,https://drive.google.com/file/d/1z7vM1UvUCsmd1xZzmIYS8KkfefYS7RqI/view?usp=drivesdk,pd-production-120121,2025-08-12 01:14:43
Pages-42-289-Section-5.2-listing-clinical-sites-cvs_Part-A.pdf,PDF,Clinical Site CVs for COVID-19 Vaccine Trial,2020-11-06,report,,,False,False,False,False,False,"pharmaceutical development, geographic diversity, trial enrollment, clinical trial, regulatory submission, FDA, COVID-19 vaccine, safety data, global clinical sites, clinical site information, investigator CVs, ETMF (electronic trial master file), data management, quality assurance, efficacy data, adverse events, regulatory compliance",17,124,https://drive.google.com/file/d/1sbDZ-bC7uf92XOby3eIGOfKtPitEwiWc/view?usp=drivesdk,pd-production-120121,2025-08-12 01:14:51
FDA-CBER-2021-5683-0595465-0595943-125742_S1_M5_bnt162-01-S-D-vs.xpt,XPT,FDA-CBER-2021-5683-0595465-0595943-125742 S1 M5 bnt162-01-S-D-vs,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1yyYXpMdRRb-ArjzlpbOe95mSacfmhQiN/view?usp=drivesdk,pd-production-120122,2025-08-12 01:14:53
FDA-CBER-2021-5683-0594977-0595464-125742_S1_M5_bnt162-01-S-D-suppvs.xpt,XPT,FDA-CBER-2021-5683-0594977-0595464-125742 S1 M5 bnt162-01-S-D-suppvs,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1YVzzhplJlXlAGwBau4LzYsqs-BsP7JMa/view?usp=drivesdk,pd-production-120122,2025-08-12 01:14:54
FDA-CBER-2021-5683-0633945-0634074-125742_S1_M5_bnt162-01-S-D-adva.xpt,XPT,FDA-CBER-2021-5683-0633945-0634074-125742 S1 M5 bnt162-01-S-D-adva,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1hxprBnQBsiWsoaaXqG2eh0mip-IFsdRM/view?usp=drivesdk,pd-production-120122,2025-08-12 01:14:55
FDA-CBER-2021-5683-0633790-0633944-125742_S1_M5_bnt162-01-S-D-adcevd.xpt,XPT,FDA-CBER-2021-5683-0633790-0633944-125742 S1 M5 bnt162-01-S-D-adcevd,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1nKmWFwyXO6MxRDyuoZbL7Gzyd9YvUOl_/view?usp=drivesdk,pd-production-120122,2025-08-12 01:14:57
FDA-CBER-2021-5683-0623311-0633789-125742_S1_M5_c4591001-S-D-vs.xpt,XPT,FDA-CBER-2021-5683-0623311-0633789-125742 S1 M5 c4591001-S-D-vs,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/18Axn4iv9zUH9bPGPkRKb32J3rT5EBlY5/view?usp=drivesdk,pd-production-120122,2025-08-12 01:15:03
FDA-CBER-2021-5683-0650114-0650115-125742_S1_M5_c4591001-S-D-ts.xpt,XPT,FDA-CBER-2021-5683-0650114-0650115-125742 S1 M5 c4591001-S-D-ts,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1XCKds-fn3XR4xzxVkOfRIE8X_3s-_HRu/view?usp=drivesdk,pd-production-120122,2025-08-12 01:15:04
FDA-CBER-2021-5683-0616659-0623310-125742_S1_M5_c4591001-S-D-sv.xpt,XPT,FDA-CBER-2021-5683-0616659-0623310-125742 S1 M5 c4591001-S-D-sv,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1Dc8HXGg92eF6gq5ABBeo_jjQvBjSdvo-/view?usp=drivesdk,pd-production-120122,2025-08-12 01:15:07
FDA-CBER-2021-5683-0634075-0650113-125742_S1_M5_c4591001-S-D-suppex.xpt,XPT,FDA-CBER-2021-5683-0634075-0650113-125742 S1 M5 c4591001-S-D-suppex,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1-GX5v_ZpO5bFd5wpNhrbJ20UyF02TZ4T/view?usp=drivesdk,pd-production-120122,2025-08-12 01:15:11
FDA-CBER-2021-5683-0600620-0616658-125742_S1_M5_c4591001-S-D-suppec.xpt,XPT,FDA-CBER-2021-5683-0600620-0616658-125742 S1 M5 c4591001-S-D-suppec,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1IjVp1xoLhhm0eS-5PDDtQuo7ElrS4Lay/view?usp=drivesdk,pd-production-120122,2025-08-12 01:15:16
FDA-CBER-2021-5683-0595944-0600619-125742_S1_M5_c4591001-S-D-se.xpt,XPT,FDA-CBER-2021-5683-0595944-0600619-125742 S1 M5 c4591001-S-D-se,undated,statistical-data,,M5,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/10IPOCHwS8TNv5AQBJsRxrPfoRcVBB_yy/view?usp=drivesdk,pd-production-120122,2025-08-12 01:15:19
signed-F21-5683-CBER-Dec-13-2021-Response-Letter.pdf,PDF,FDA FOIA Response Letter,2021-12-13,letter,"Aaron Siri, Courtney Enlow",,False,False,True,False,False,"pharmaceutical-data, personal-privacy, medical-professionals, clinical-trials, fda-response, regulatory-compliance, safety-data, data-redaction, foia-request, efficacy-data, trade-secrets, public-health, vaccine-development, adverse-events, northern-district-of-texas, sas-files, Exemption, data-file-formats",18,2,https://drive.google.com/file/d/18zrZU_57XcqopKDkunyzhV_yn0yh918s/view?usp=drivesdk,pd-production-121321,2025-08-12 01:15:22
STN-125742_0_0-Section-2.5-Clinical-Overview.pdf,PDF,BNT162b2 2.5 Clinical Overview,2021-04-30,report,,,False,False,False,False,False,"clinical pharmacology, immunogenicity, biopharmaceutical studies, fda, therapeutic context, clinical development, efficacy endpoints, formulation development, clinical overview, vaccine product information, safety data, bnt162b2 vaccine, covid-19, ethical considerations, adverse events, proposed indication, regulatory submission",17,334,https://drive.google.com/file/d/14el1RPUVdkUGERte5JcNsR3XUN4krNwt/view?usp=drivesdk,pd-production-121321,2025-08-12 01:15:27
BATES-FDA-CBER-2021-5683-0002372_adc19ef-ve-cov-7pd2-eval-sas.txt,TXT,adc19ef-ve-cov-7pd2-eval.sas,2021-03-22,SAS program,WUY169,,False,False,False,False,False,"statistical programming, population analysis, data quality, SAS programming, CDISC, clinical trial, vaccine evaluation, unblinded analysis, FDA, data management, safety data, COVID-19, data visualization, efficacy data, adverse events, data analysis, regulatory submission",17,2,https://drive.google.com/file/d/1Wpk1qEGNb9WeW2uDsIIEbH2N3PnPUrH9/view?usp=drivesdk,pd-production-121321,2025-08-12 01:15:31
BATES-FDA-CBER-2021-5683-0002376_relrec.xpt,XPT,BATES-FDA-CBER-2021-5683-0002376 relrec,undated,statistical-data,,,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1fjsCVeti_huJOPBCXRPw3VkLCvl6g0VE/view?usp=drivesdk,pd-production-121321,2025-08-12 01:15:32
STN-125742_0_0-Section-2.7.4-summary-clin-safety.pdf,PDF,BNT162b2 2.7.4 Summary of Clinical Safety,2021-05-05,report,,,False,False,False,False,False,"safety-evaluation, immunogenicity, pharmaceutical-research, phase-3-study, regulatory-compliance, data-analysis, phase-1-study, adverse-events, efficacy, vaccine-development, fda-submission, participant-data, clinical-trial, phase-2-study, bnt162b2, united-states, confidential-document",17,344,https://drive.google.com/file/d/1FYQpIQksIDWmUOP6tOOwHsyEx7mVkyXd/view?usp=drivesdk,pd-production-121321,2025-08-12 01:15:38
BATES-FDA-CBER-2021-5683-0002379_te.xpt,XPT,BATES-FDA-CBER-2021-5683-0002379 te,undated,statistical-data,,,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1PnrWcZ4q1c7cb4gfOaeTuso-dEndAPIX/view?usp=drivesdk,pd-production-121321,2025-08-12 01:15:39
CRFs-for-site-1055.pdf,PDF,Clinical Research Forms for Site 1055,2021-03-29,Clinical Trial Forms,pfe.levissc,,True,True,False,True,False,"Exclusion, clinical trial, regulatory compliance, data quality, pharmaceutical, cohort selection, inclusion/exclusion criteria, phase 2/3 study, CRF, subject data, informed consent, Diablo Clinical Research, visit date, FDA, vaccine development, Protocol, c4591001, site 1055, demography, data collection",20,2030,https://drive.google.com/file/d/1lQh09PEDIiyQp2IWCVPbpFtk2yU_NSLH/view?usp=drivesdk,pd-production-121321,2025-08-12 01:15:51
BATES-FDA-CBER-2021-5683-0002380_ti.xpt,XPT,BATES-FDA-CBER-2021-5683-0002380 ti,undated,statistical-data,,,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/1umzpTlagizjYbSTRYSVaU5o8KdQbRAiy/view?usp=drivesdk,pd-production-121321,2025-08-12 01:15:52
BATES-FDA-CBER-2021-5683-0002378_ta.xpt,XPT,BATES-FDA-CBER-2021-5683-0002378 ta,undated,statistical-data,,,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/14J8LIA-lCTYkwMEHkjDcqpd2K01883zS/view?usp=drivesdk,pd-production-121321,2025-08-12 01:15:53
STN-125742_0_0-Section-2.7.3-Summary-of-Clinical-Efficacy.pdf,PDF,BNT162b2 2.7.3 Summary of Clinical Efficacy,2021-04-30,report,,,False,False,False,False,False,"phase-1-2-3-study, global-distribution, pharmaceutical-research, regulatory-compliance, immunogenicity-evaluation, safety-profile, clinical-endpoints, data-summary, adverse-events, efficacy-analysis, vaccine-development, fda-submission, clinical-trial, covid-19, bnt162b2, statistical-methods, confidential-document",17,182,https://drive.google.com/file/d/1U5chSGUjLiXJx0orJ96tLRk9Whlq3rgn/view?usp=drivesdk,pd-production-121321,2025-08-12 01:16:02
BATES-FDA-CBER-2021-5683-0002374_adc19ef-ve-sev-cov-7pd2-wo-eval-sas.txt,TXT,adc19ef-ve-sev-cov-7pd2-wo-eval.sas,2021-03-22,SAS program,WUY169,,False,False,False,False,False,"data quality, SAS programming, CDISC, ADAM, clinical trial, statistical analysis, phase 2, FDA, data processing, COVID-19, vaccine, efficacy, safety, data visualization, adverse events, data analysis, regulatory",17,3,https://drive.google.com/file/d/1sfdqq4KtvaUaxKkUWMaoJmk7nnaQsc3R/view?usp=drivesdk,pd-production-121321,2025-08-12 01:16:05
BATES-FDA-CBER-2021-5683-0002375_addv-sas.txt,TXT,Create addv dataset,2021-03-09,SAS program,XIONGR03,,False,True,False,False,False,"data standardization, data transformation, data quality, ADAM, SAS programming, clinical trial, unblinded analysis, FDA, data management, data processing, safety data, data integration, Protocol, dataset creation, efficacy data, adverse events, SDTM, regulatory submission",18,1,https://drive.google.com/file/d/1NWweRkN5_Y3LzhtnToOLIHlW_nCraqIi/view?usp=drivesdk,pd-production-121321,2025-08-12 01:16:07
BATES-FDA-CBER-2021-5683-0002373_adc19ef-ve-sev-cov-7pd2-eval-sas.txt,TXT,adc19ef-ve-sev-cov-7pd2-eval,2021-03-22,SAS program,WUY169,,False,False,False,False,False,"safety-evaluation, pharmaceutical-research, regulatory-compliance, vaccine-efficacy, data-visualization, clinical-trial, data-quality, sas-programming, statistical-analysis, adverse-events, data-management, data-reporting, data-processing, fda-submission, data-analysis, covid-19, unblinded-study",17,2,https://drive.google.com/file/d/1G3AyYetEJNELhVaxvgJ5mJuol3cYCPJW/view?usp=drivesdk,pd-production-121321,2025-08-12 01:16:10
BATES-FDA-CBER-2021-5683-0002377_supppr.xpt,XPT,BATES-FDA-CBER-2021-5683-0002377 supppr,undated,statistical-data,,,False,False,False,False,False,"statistical-data, xpt-file, clinical-data, data-file",4,0,https://drive.google.com/file/d/15_52b3A_1dkwDQPdOkKnf9zjs3xj8nDC/view?usp=drivesdk,pd-production-121321,2025-08-12 01:16:11
Supplemental-Index-12-22-21.pdf,PDF,License Action Recommendation Documents for Submissions and FDA Communication,2021-12-20,memo,"DICKERSON, DAVID, SMITH, MICHAEL, NAIK, RAMACHANDRA, JONECKIS, CHRISTOPHER, GOTTSCHALK, LAURA, ELEKWACHI, OLUCHI",,False,True,False,True,False,"regulatory-submission, clinical-trial-c4591001, pediatric-studies, Exclusion, comirnaty-vaccine, confidential-information, rna-integrity-validation, bla-filing, rolling-review, manufacturing-facility-puurs-belgium, lot-release-protocol, bnt162-vaccine, myocarditis-pericarditis-safety, Protocol, official-use-only, license-action-recommendation, fda-communication, proprietary-name-acceptance, filing-checklist",19,17,https://drive.google.com/file/d/1YC-eF_Njno-RZWyr1EBXwV9ibL9EAuuM/view?usp=drivesdk,pd-production-122221,2025-08-12 01:16:16
CRFs-for-site-1081.pdf,PDF,Clinical Research Forms for Site 1081,2021-03-29,Clinical Trial Forms,pfe.levissc,,True,True,False,True,False,"Exclusion, clinical trial, phase 2/3, confidential, regulatory compliance, data quality, inclusion/exclusion criteria, CRF, audit trail, subject enrollment, informed consent, visit date, FDA, Protocol, Sterling Research Group, vaccine, c4591001, eCRF, data management, demography",20,3380,https://drive.google.com/file/d/1-lB6ASkLn2oPOmoRIXd65B3WVGR9wsUw/view?usp=drivesdk,pd-production-123021,2025-08-12 01:16:27
